The 27th World Congress on
Controversies in Obstetrics,
Gynecology & Infertility (COGI)
All About Women’s Health

In partnership with Reproductive BioMedicine Online (RBMO)

Paris, France
November 21-23, 2019

Congress Program

www.cogi-congress.org • cogi@congressmed.com
The only oil-based contrast agent indicated for HSG

The 27th World Congress on Controversies in Obstetrics, Gynecology & Infertility (COGI)
Paris, France • November 21-23, 2019

MEET US ON BOOTH 4-5

INFERTILITY EVALUATION

TUBAL IMAGING

UTERINE IMAGING

ENDORSED BY INTERNATIONAL CLINICAL PRACTICE GUIDELINES 10-13

NICE

ASRM

CFAS

FIGO

SPC is available on the Guerbet booth 4-5 and through scanning the QR code (page: our products - Lipiodol® Ultra Fluid). Indications may vary from country to country. Countries in which HSG indication is registered: USA, Canada, Argentina, UK, Ireland, The Netherlands, Denmark, Turkey, South-Africa, Japan, Taiwan, Thailand, Australia & New Zealand. For complete information, please refer to country’s local SPC. L’indication HSG du Lipiodol® Ultra Fluide n’est pas enregistrée en France.


Visit our website: guerbet-womenhealthcare.com
# Table of Contents

Welcome letter  
General information  
Scientific program  
Abstracts  
Industry
# Timetable

## Thursday, November 21, 2019

<table>
<thead>
<tr>
<th>Time</th>
<th>Hall A</th>
<th>Hall B</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00-15:00</td>
<td>The Best of RBMO 2018-2019</td>
<td></td>
</tr>
<tr>
<td>15:00-16:15</td>
<td>Interventions that Matter in Pregnancy Maintenance: A PreIS School Academy Session</td>
<td></td>
</tr>
<tr>
<td>16:15-16:45</td>
<td>Industry Supported Session</td>
<td>Laser Course</td>
</tr>
<tr>
<td>16:45-18:30</td>
<td>Hot Controversies in Infertility Treatments</td>
<td></td>
</tr>
<tr>
<td>18:30-19:30</td>
<td>Opening Session: Nobel Prize Laureate Robert G. Edwards Annual Lecture</td>
<td>Networking Reception</td>
</tr>
<tr>
<td>19:30-20:15</td>
<td>Best Abstract Awards Ceremony</td>
<td></td>
</tr>
</tbody>
</table>

## Friday, November 22, 2019

<table>
<thead>
<tr>
<th>Time</th>
<th>Hall A</th>
<th>Hall B</th>
<th>Hall C</th>
<th>Hall D</th>
<th>Hall E</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30-10:00</td>
<td>Infertility/Art/IVF</td>
<td>Infertility/Art/IVF II</td>
<td>Gynecology</td>
<td>FetoMaternal Medicine</td>
<td>Oral Presentations</td>
</tr>
<tr>
<td>08:30-10:00</td>
<td>AMH vs AFC…AND THE WINNER IS…….?</td>
<td>Screening of the Man for Infertility</td>
<td>HPV</td>
<td>Pregnancy Support and NIPT</td>
<td>Oral Presentations 01 - Diagnostic Procedure/Gynecological Oncology/FetoMaternal Medicine</td>
</tr>
<tr>
<td>10:00-10:20</td>
<td>Coffee break, visit exhibition and poster viewing</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:20-11:50</td>
<td>PCOS/PCO</td>
<td>Add-On Treatments</td>
<td>Industry Supported Session</td>
<td>Industry Supported Session</td>
<td>Oral Presentations 02 - FetoMaternal Medicine</td>
</tr>
<tr>
<td>11:50-12:10</td>
<td>Break</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:10-13:40</td>
<td>Industry Supported Session</td>
<td>Laboratory Work</td>
<td>Vulvo-Vaginal Atrophy</td>
<td>Multiple Pregnancies</td>
<td>Oral Presentations 03 - Infertility/Art/IVF</td>
</tr>
<tr>
<td>13:40-14:30</td>
<td>Lunch break, visit exhibition and poster viewing</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30-16:30</td>
<td>Stimulation, Oocytes and Embryos</td>
<td>Implantation Models</td>
<td>Breast Cancer</td>
<td>Preterm Delivery</td>
<td>Oral Presentations 04 - FetoMaternal Medicine</td>
</tr>
<tr>
<td>16:30-16:50</td>
<td>Coffee break, visit exhibition and poster viewing</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## Saturday, November 23, 2019

<table>
<thead>
<tr>
<th>Time</th>
<th>Hall A</th>
<th>Hall B</th>
<th>Hall C</th>
<th>Hall D</th>
<th>Hall E</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30-10:00</td>
<td>Infertility/Art/IVF</td>
<td>Infertility/Art/IVF II</td>
<td>Gynecology</td>
<td>FetoMaternal Medicine</td>
<td>Oral Presentations</td>
</tr>
<tr>
<td>08:30-10:00</td>
<td>PGT-A</td>
<td>Fertility Preservation</td>
<td>Prediction of Menopause and Risk Factors</td>
<td>Pregnancy Management</td>
<td>Oral Presentations 06 - FetoMaternal Medicine</td>
</tr>
<tr>
<td>10:00-10:20</td>
<td>Coffee break, visit exhibition and poster viewing</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:20-11:50</td>
<td>Industry Supported Session</td>
<td>Diagnosis of Infertility</td>
<td>Uterine Anomalies; Gyno-Oncology</td>
<td>Diabetes</td>
<td>Oral Presentations 07 - Infertility/Art/IVF/Gynecology</td>
</tr>
<tr>
<td>11:50-12:10</td>
<td>Break</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:10-13:40</td>
<td>Q &amp; A</td>
<td>Q &amp; A in Hall A</td>
<td>Advances in Hormonal Treatment</td>
<td>Caesarean Section</td>
<td>Oral Presentations 08 - Other</td>
</tr>
<tr>
<td>13:40-14:30</td>
<td>Lunch break, visit exhibition and poster viewing</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30-16:30</td>
<td>Hi-Tech IVF: Artificial Gamete and Embryos</td>
<td>What’s New in POI Research I</td>
<td>Prevention of Menopausal Symptoms</td>
<td>Intrapartum and Children Follow Up</td>
<td>Oral Presentations 09 - Infertility/Art/IV/Other</td>
</tr>
<tr>
<td>16:30-16:50</td>
<td>Coffee break, visit exhibition and poster viewing</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:50-18:20</td>
<td>Freeze All</td>
<td>What’s New in POI Research II</td>
<td>Perimenopausal Contraception</td>
<td>Labor</td>
<td>Oral Presentations 10 - Gynecology</td>
</tr>
</tbody>
</table>
Dear Colleagues,

COGI and RBMO are delighted to welcome you to the magnificent city of Paris and to the 27th World Congress on Controversies in Obstetrics, Gynecology and Infertility.

World renowned leaders in the field of Ob/Gyn and infertility, will review advances, breakthroughs and controversies in the field via round table discussions, debates, and lectures. Highlights of the program include the “Robert G. Edwards Nobel Prize Laureate” lecture, cutting edge “countercurrent” lectures by leading experts “who think differently”, an inspiring fetomaternaledge program, sessions on early prenatal diagnosis, pregnancy support, age-related risks, nutrition, the epidemic of multiple pregnancies, HPV, menopause, and more. As always, there will be ample time during every session for speaker-audience discussions.

We would like to thank our industry supporters for their investment in COGI. Without this continued support, we would not be able to offer such a high level of knowledge to be shared with a truly international delegation.

We look forward to thought-provoking debates, enjoyable discussions and an overall exchange of knowledge. We wish you an excellent congress experience.

Looking forward to welcoming you in 2020, to Berlin where the COGI experience will continue.

Sincerely,

COGI Congress Co-Chairpersons

Zion Ben Rafael
Israel

Bart C.J.M. Fauser
Netherlands

Rene Frydman
France
VENUE
MARRIOTT HOTEL
Paris Marriott Rive Gauche Hotel & Conference Center
17, Boulevard Saint Jacques
75014 Paris – France

LANGUAGE
The official language of the congress is English.

REGISTRATION AND FACULTY DESK OPENING HOURS
Thursday, November 21  12:30-20:00
Friday, November 22  07:30-18:30
Saturday, November 23  08:00-18:30

CONGRESS ADMISSION – NAME BADGE
Admission to the scientific sessions, exhibition area and congress-related events is by badge only. All participants are kindly requested to carry their personal badge received upon registration at all times while at the congress.

EXHIBITION OPENING HOURS
Thursday, November 21  19:30-20:15
Friday, November 22  09:30-17:00
Saturday, November 23  09:30-17:00

E-POSTERS
All the posters are presented in electronic format. The e-Posters are located on Level 0 and will be open to all participants on Thursday, Friday and Saturday during the exhibition hours.

INTERNET
Wireless internet is complimentary in all congress areas.
Network: COGI2019
Password: COGI2019

CERTIFICATE OF ATTENDANCE (non-CME/CPD)
Certificates of attendance will be available for all participants and may be collected at the Registration Desk on Saturday, November 23.

CME ACCREDITATION
The 27th COGI Congress has been accredited by the European Accreditation Council for Continued Medical Education (EACCME®) for a maximum of 21 CME credits (ECMEC®s).
To receive your CME accreditation certificate, please visit the congress website after the congress and complete the online form. Your certificate will be sent to you approximately 30 days after completion of the survey.

REFRESHMENTS
The networking reception will be held on Thursday, November 21 at 19:30 in the exhibition area on Level 0. Coffee/tea and lunch will be served in the exhibition area on Friday, November 22 and Saturday, November 23, during the official catering breaks.

SPEAKERS’ PREVIEW ROOM
All invited speakers and oral presenters are asked to upload their presentations at the speakers’ preview room (Scene G and H on Level 0 adjacent to the exhibition area) at least 2 hours before the start of their session. The room will be open during the following hours:
Thursday, November 21  13:00-19:00
Friday, November 22  07:30-18:00
Saturday, November 23  08:00-18:00
CLOAKROOM
The cloakroom is located on Level 0 behind the e-Posters (Scene D)
Thursday, November 21   13:30–20:30
Friday, November 22    07:30–18:30
Saturday, November 23   08:00-18:30

SAFETY AND SECURITY
Please do not leave any bags or other personal belongings unattended at any time, whether inside or outside the session halls.

LIABILITY AND INSURANCE
The COGI Congress secretariat and the organizers cannot accept liability for personal accidents, or loss or damage to private property of participants, either during or directly arising from the 27th COGI Congress. Participants are advised to make their own arrangements with respect to health and travel insurance.

RECORDING POLICY
Recording (photographic, video and audio) of the session is strictly prohibited.

SOCIAL MEDIA
Follow COGI social media pages for the latest updates, key date reminders, and discussions with colleagues and experts from around the world.

Download CongressMed to access COGI 2019!

After installing the app, you can:
- Access CongressMed by clicking on the respective tile and pressing "Install"
- Access the event program and speakers list
- Create your own daily schedule that will guide your through the day
- Stay informed and receive the latest messages and news
- Chat with other attendees
- Take notes during sessions

How to download:
The easiest way to download our mobile app is to scan one of these barcodes.
You can also search for ‘CongressMed’ in the Apple App Store or Google Play Store.
Scientific Program
### THURSDAY, NOVEMBER 21

#### PLENARY SESSIONS | HALL A

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Chairpersons</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>14:00-15:00</strong></td>
<td><strong>THE BEST OF RBMO 2018-2019</strong></td>
<td><strong>Bart Fauser, Netherlands</strong></td>
<td><strong>HALL A</strong></td>
</tr>
<tr>
<td></td>
<td>Capsule</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>The three best papers published in RBMO in 2018 are presented in this session</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>14:00-14:20</strong></td>
<td>An evidence-based scoring system for prioritizing mosaic aneuploid embryos following preimplantation genetic screening</td>
<td><strong>Francesca Grati, Italy</strong></td>
<td></td>
</tr>
<tr>
<td><strong>14:20-14:40</strong></td>
<td>Predicting live birth for poor ovarian responders: The PROsPeR concept</td>
<td><strong>Philippe Lehert, Australia</strong></td>
<td></td>
</tr>
<tr>
<td><strong>14:40-15:00</strong></td>
<td>The impact of antenatal Bisphenol: An exposure on male reproductive function at 20–22 years of age</td>
<td><strong>Roger J. Hart, Australia</strong></td>
<td></td>
</tr>
<tr>
<td><strong>15:00-16:15</strong></td>
<td><strong>INTERVENTIONS THAT MATTER IN PREGNANCY MAINTENANCE</strong></td>
<td><strong>Gian Carlo Di Renzo, Italy</strong></td>
<td><strong>HALL A</strong></td>
</tr>
<tr>
<td></td>
<td>Capsule</td>
<td><strong>Kypros Nicolaides, UK</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Prevention of repeated abortion and preterm birth: Any similarities?</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>15:00-15:25</strong></td>
<td>What do we know about preventing threatened abortion and recurrent miscarriage?</td>
<td><strong>Adam Devall, UK</strong></td>
<td></td>
</tr>
<tr>
<td><strong>15:25-15:50</strong></td>
<td>Is “Aspirin” valuable only for preventing preeclampsia or also for preterm birth?</td>
<td><strong>Kypros Nicolaides, UK</strong></td>
<td></td>
</tr>
<tr>
<td><strong>15:50-16:15</strong></td>
<td>Cannabis in pregnancy</td>
<td><strong>Michael Dor, Israel</strong></td>
<td></td>
</tr>
<tr>
<td><strong>16:15-16:45</strong></td>
<td><strong>INDUSTRY SUPPORTED SESSION</strong></td>
<td></td>
<td><strong>HALL A</strong></td>
</tr>
<tr>
<td></td>
<td>See Page 178</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>16:45-18:30</strong></td>
<td><strong>HOT CONTROVERSIES IN INFERTILITY TREATMENTS</strong></td>
<td><strong>Rene Frydman, France</strong></td>
<td><strong>HALL A</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Zion Ben Rafael, Israel</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Bart Fauser, Netherlands</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Capsule</td>
<td>Reproduction is a delicate balancing act. A viable embryo must interact with a receptive endometrium. A small window of opportunity during which the embryo orchestrates its attachment and fate exists. Insight to this process could improve implantation rates and pregnancy success overall. For simplicity, the coordination of the process has been historically attributed to estrogen, progesterone and to embryo quality. Is it that simple?</td>
<td></td>
</tr>
<tr>
<td><strong>16:45-17:15</strong></td>
<td>Is it the embryo or the endometrium? Pregnancy: Embryo-led maternal adaptive response. PIF determining regulatory role</td>
<td><strong>Eytan Barnea, USA</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Capsule</td>
<td>Human embryo genome editing holds great promise to cure several diseases and avoid the necessity of discarding embryos. In addition, whole chromosome editing may rescue aneuploid embryos from patients of advanced maternal age. However, recent events have hampered progress in the field, with many calling for a global moratorium on both research and clinical development. How far should we go with this?</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>------------------------------------------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:15-17:45</td>
<td><strong>Human embryo gene editing</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Nathan Treff, USA</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Capsule</td>
<td>The microbiome is a big unknown, the &quot;elephant in the room&quot; of reproductive health. What do we know? What do we have to know?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:45-18:15</td>
<td><strong>Reproductive tract microbiome and its relevance to pregnancy outcome and neonatal/post-natal development</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Jerome Strauss, USA</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Capsule</td>
<td>2020 will mark the launching of the international cervical cancer elimination campaign. The role of the health care providers will be examined</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:15-18:30</td>
<td><strong>Milestones towards cervical cancer elimination</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Xavier Bosch, Spain</em></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>18:30-19:30</td>
<td><strong>OPENING SESSION</strong></td>
</tr>
<tr>
<td>Capsule</td>
<td>PCOS is a life-long reproductive disorder, which is extremely prevalent but is often underdiagnosed, in part because of its heterogeneity, and due to the existence of various phenotypes. Although there remain large gaps in our knowledge base, the transition of PCOS from adolescence to menopause and beyond will be discussed.</td>
</tr>
<tr>
<td>Chairpersons</td>
<td><em>Zion Ben Rafael, Israel</em></td>
</tr>
<tr>
<td></td>
<td><em>Bart Fauser, Netherlands</em></td>
</tr>
<tr>
<td></td>
<td><em>Rene Frydman, France</em></td>
</tr>
<tr>
<td>18:30-19:15</td>
<td><strong>Nobel prize laureate Robert G. Edwards annual lecture</strong></td>
</tr>
<tr>
<td></td>
<td>PCO/PCOS, before during and after reproductive life</td>
</tr>
<tr>
<td></td>
<td><em>Roger A. Lobo, USA</em></td>
</tr>
<tr>
<td>19:15-19:30</td>
<td>Best Abstract Award Ceremony</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>19:30-20:15</td>
<td><strong>NETWORKING RECEPTION</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:00-18:00</td>
<td><strong>LASER COURSE</strong></td>
</tr>
<tr>
<td></td>
<td><em>See page 177</em></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>HALL A</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>HALL B</strong></td>
</tr>
</tbody>
</table>


### FRIDAY, NOVEMBER 22

#### INFERTILITY/ART/IVF | HALL A

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Chairpersons</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30-10:00</td>
<td>AMH vs AFC…AND THE WINNER IS……?</td>
<td>Scott Nelson, UK Nick Macklon, UK</td>
</tr>
<tr>
<td></td>
<td>Capsule</td>
<td>Are we still debating on the role of AMH in the diagnosis and treatment of infertility?</td>
</tr>
<tr>
<td>08:30-09:15</td>
<td>Debate: Is AMH a good predictor for success in IVF cycles?</td>
<td>Antonio La Marca, Italy</td>
</tr>
<tr>
<td></td>
<td>Pro: Antonio La Marca, Italy</td>
<td>Joop Laven, Netherlands</td>
</tr>
<tr>
<td></td>
<td>08:30-09:00</td>
<td>Discussion</td>
</tr>
<tr>
<td>09:15-10:00</td>
<td>Debate: Are we really misinforming young women on their reproductive potential by using AMH and AFC testing?</td>
<td>Edgardo Somigliana, Italy</td>
</tr>
<tr>
<td></td>
<td>Yes: Edgardo Somigliana, Italy</td>
<td>Antonio La Marca, Italy</td>
</tr>
<tr>
<td></td>
<td>09:15-10:00</td>
<td>Discussion</td>
</tr>
<tr>
<td>10:00-10:20</td>
<td>COFFEE BREAK, VISIT THE EXHIBITION AND POSTER VIEWING</td>
<td></td>
</tr>
<tr>
<td>10:20-11:50</td>
<td>PCOS/PCO</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Capsule</td>
<td>PCOS is considered the most common endocrine disorder in reproductive age. However, the prevalence (6.5-17.8%), as well as the long-term risks, vary widely with the diagnostic tests and criteria. Should we change the criteria?</td>
</tr>
<tr>
<td></td>
<td>Chairpersons</td>
<td>Roger A. Lobo, USA Zion Ben Rafael, Israel</td>
</tr>
<tr>
<td>10:20-11:05</td>
<td>Debate: Androgens are the villain in PCOS</td>
<td>Joop Laven, Netherlands</td>
</tr>
<tr>
<td></td>
<td>Con: Joop Laven, Netherlands</td>
<td>Jerome Strauss, USA</td>
</tr>
<tr>
<td></td>
<td>Pro: Jerome Strauss, USA</td>
<td>Discussion</td>
</tr>
<tr>
<td>11:05-11:50</td>
<td>Debate: We must screen PCOS cases for the presence of the metabolic syndrome</td>
<td>Bart Fauser, Netherlands</td>
</tr>
<tr>
<td></td>
<td>11:05-11:50</td>
<td>Philippe Bouchard, France</td>
</tr>
<tr>
<td></td>
<td>11:05-11:50</td>
<td>Discussion</td>
</tr>
<tr>
<td>11:50-12:10</td>
<td>BREAK</td>
<td></td>
</tr>
<tr>
<td>12:10-13:40</td>
<td>INDUSTRY SUPPORTED SESSION</td>
<td></td>
</tr>
<tr>
<td></td>
<td>See page 179</td>
<td></td>
</tr>
<tr>
<td>13:40-14:30</td>
<td>LUNCH BREAK, VISIT THE EXHIBITION AND POSTER VIEWING</td>
<td></td>
</tr>
<tr>
<td>14:30-16:30</td>
<td>STIMULATION, OOCYTES AND EMBRYOS</td>
<td>HALL A</td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>Capsule</td>
<td>Stimulation, the first step in IVF, has never been in consensus</td>
<td></td>
</tr>
</tbody>
</table>
| **Chairpersons** | **Victor Gomel, Canada**  
**Scott Nelson, UK** | |
| 14:30-15:00 | **Debate: Ovarian stimulation: More or Less?**  
Less is more: **Geeta Nargund, UK**  
No! New twists in ovarian stimulation: More is better: **Dominique de Ziegler, France** | |
| 14:30 | 14:40 | 14:50 |
| 15:00-15:20 | GnRH agonists and IVF: The end ... or not?  
**Joelle Belaisch Allart, France** | |
| 15:20-15:40 | The numbers of small (2-5 and 6-9 mmm) follicles are inversely correlated in both normal women and in PCOS: What is the missing link?  
**Sophie Catteau-Jonard, France** | |
| 15:40-16:30 | COGI SPECIAL COUNTERCURRENT SYMPOSIA | |
| Capsule | The next stage in improving the result, is understanding what’s wrong with what we’re doing | |
| 15:40-16:05 | RCTs may not be the answer to all outstanding questions in IVF  
**Bart Fauser, Netherlands** | |
| 16:05-16:30 | Repeated implantation failure: An iatrogenic phenomenon which leads to many unnecessary activities  
**Zion Ben Rafael, Israel** | |
| 16:30-16:50 | COFFEE BREAK, VISIT THE EXHIBITION AND POSTER VIEWING | EXHIBITION AREA |
| 16:50-18:20 | ADENOMYOSIS AND ENDOMETRIOSIS | HALL A |
| Capsule | The concept that uterine adenomyosis and pelvic endometriosis as well as endometriotic lesions at distant sites of the body share a common pathophysiology with endometriosis was promoted almost a decade ago. What is the current thinking? | |
| **Chairpersons** | **Marie-Madeline Dolmans, Belgium**  
**Philippe Descamps, France**  
**Aleksandar Stefanović, Serbia** | |
| 16:50-17:10 | Adenomyosis and deep endometriosis: Two linked diseases?  
**Jacques Donnez, Belgium** | |
| 17:10-17:45 | **Debate: The endometrioma and the ovarian reserve: The challenge of the surgeon**  
To operate first: **Herve Fernandez, France**  
ART before operation: **Edgardo Somigliana, Italy** | |
| 17:10 | 17:25 | 17:40 |
| 17:45-18:20 | **Debate: Deep-endometriosis should be operated prior to ART**  
Pro for surgery first: **Olivier Donnez, Belgium**  
Cons for IVF first (against surgery): **Pietro Santulli, France** | |
| 17:45 | 18:00 | 18:15 |

**Recorded sessions**
FRIDAY, NOVEMBER 22

INFERTILITY/ART/IVF  |  HALL B

<table>
<thead>
<tr>
<th>08:30-10:00</th>
<th>SCREENING OF THE MAN FOR INFERTILITY</th>
<th>HALL B</th>
</tr>
</thead>
<tbody>
<tr>
<td>Capsule</td>
<td>Have we neglected the treatment of male infertility? Can better screening improve the overall results?</td>
<td></td>
</tr>
</tbody>
</table>

Chairpersons: Christopher Barratt, UK  
Christopher De Jonge, USA  
Giuseppe Tritto, France

| 08:30-08:35 | Introduction | Christopher Barratt, UK |
| 08:35-09:00 | Screening of the man for infertility; Why its necessary (canary in the coal mine) | Michael Eisenberg, USA |
| 09:00-09:25 | The Male Reproductive Health initiative | Christopher De Jonge, USA |
| 09:25-09:50 | Use of Social Media platforms to inform the public about male reproductive health issues | Allan Pacey, UK |
| 09:50-10:00 | Discussion |

10:00-10:20  COFFEE BREAK, VISIT THE EXHIBITION AND POSTER VIEWING  EXHIBITION AREA

<table>
<thead>
<tr>
<th>10:20-11:50</th>
<th>ADD-ON TREATMENTS</th>
<th>HALL B</th>
</tr>
</thead>
<tbody>
<tr>
<td>Capsule</td>
<td>Add-on treatments: The best solution to keep patients from quitting the program?</td>
<td></td>
</tr>
</tbody>
</table>

Chairpersons: Anja Pinborg, Denmark  
Ben Mol, Australia

<table>
<thead>
<tr>
<th>10:20-11:05</th>
<th>Debate: Standard IVF vs Add-on IVF - What if the patient is willing to pay for add-ons?</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:20</td>
<td>Con: Joyce Harper, UK</td>
</tr>
<tr>
<td>10:35</td>
<td>Pro: Simon Fishel, UK</td>
</tr>
<tr>
<td>10:50</td>
<td>Discussion</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>11:05-11:30</th>
<th>ICSI does not increase the cumulative live birth rate in non-male factor infertility</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:30-11:50</td>
<td>Is there a relationship between the time to ICSI and the reproductive outcomes?</td>
</tr>
</tbody>
</table>

11:50-12:10  BREAK

<table>
<thead>
<tr>
<th>12:10-13:40</th>
<th>LABORATORY WORK</th>
<th>HALL B</th>
</tr>
</thead>
<tbody>
<tr>
<td>Capsule</td>
<td>Basic issues in lab work are still controversial</td>
<td></td>
</tr>
</tbody>
</table>

Chairperson: Mina Popovic, Belgium

<table>
<thead>
<tr>
<th>12:10-12:30</th>
<th>IVF and the lab: Which culture medium to use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Aafke van Montfoort, Netherlands</td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
</tr>
<tr>
<td>---------------</td>
<td>----------------------------------------------------------------------</td>
</tr>
<tr>
<td>12:30-13:15</td>
<td><strong>Debate:</strong> Still room for embryo morphological evaluation?</td>
</tr>
<tr>
<td>12:30</td>
<td>Yes: in favor: Luca Gianaroli, Italy</td>
</tr>
<tr>
<td>12:45</td>
<td>No: against: Marine Poulain, France</td>
</tr>
<tr>
<td>13:00</td>
<td>Discussion</td>
</tr>
<tr>
<td>13:15-13:40</td>
<td>The secret lives of human embryos exposed through time-lapse. An analysis of over 300 SET cycles Diana Stein, Israel</td>
</tr>
<tr>
<td>13:40-14:30</td>
<td><strong>LUNCH BREAK, VISIT THE EXHIBITION AND POSTER VIEWING</strong></td>
</tr>
<tr>
<td>14:30-14:50</td>
<td>IMPLANTATION MODELS</td>
</tr>
<tr>
<td></td>
<td>Capsule: IVF failure is mainly due to embryonal or endometrial reasons?</td>
</tr>
<tr>
<td></td>
<td>Chairpersons: Nick Macklon, UK</td>
</tr>
<tr>
<td></td>
<td>Simon Fishel, UK</td>
</tr>
<tr>
<td></td>
<td>14:30-14:50</td>
</tr>
<tr>
<td></td>
<td>14:50-15:15</td>
</tr>
<tr>
<td></td>
<td>15:15-15:40</td>
</tr>
<tr>
<td>15:40-16:30</td>
<td><strong>SPECIAL COGI COUNTERCURRENT LECTURES</strong></td>
</tr>
<tr>
<td>15:40-16:05</td>
<td>Can IVF influence human evolution? Hans Ivar Hanevik, Norway</td>
</tr>
<tr>
<td>16:05-16:30</td>
<td>Endometrial receptivity testing: Can the most reliable test stand up? Samuel Dos Santos Ribeiro, Belgium</td>
</tr>
<tr>
<td>16:30-16:50</td>
<td><strong>COFFEE BREAK, VISIT THE EXHIBITION AND POSTER VIEWING</strong></td>
</tr>
<tr>
<td>16:50-17:15</td>
<td>BLASTOCYSTS</td>
</tr>
<tr>
<td></td>
<td>Capsule: Single euploid, morphologically intact blastocyst seems like the holy grail of IVF. So why we are still debating?</td>
</tr>
<tr>
<td></td>
<td>Chairpersons: Laura Rienzi, Italy</td>
</tr>
<tr>
<td></td>
<td>Scott Nelson, UK</td>
</tr>
<tr>
<td>16:50-17:15</td>
<td>Chromosomal mosaicism in human blastocysts: The ultimate challenge of preimplantation genetic testing? Mina Popovic, Belgium</td>
</tr>
<tr>
<td>17:15-17:35</td>
<td>Prevalence of XXY karyotypes in human blastocysts: Multicenter data from 7549 trophectoderm biopsies obtained during preimplantation genetic testing cycles in IVF Laura Rienzi, Italy</td>
</tr>
<tr>
<td>17:35-18:20</td>
<td><strong>Debate:</strong> Blastocyst-stage embryo transfer for all</td>
</tr>
<tr>
<td>17:35</td>
<td>Yes: Samir Hamamah, France</td>
</tr>
<tr>
<td>17:50</td>
<td>No: Amelia Rodriguez-Aranda, Spain</td>
</tr>
<tr>
<td>18:05</td>
<td>Discussion</td>
</tr>
</tbody>
</table>
**FRIDAY, NOVEMBER 22**

**GYNECOLOGY | HALL C**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>08:30-10:00</strong></td>
<td><strong>HPV</strong></td>
</tr>
<tr>
<td>Capsule</td>
<td>As the cervical cancer elimination campaign takes shape, several initiatives are being considered in practical contexts. The session will explore some of them and specifically the role of the gynecologists</td>
</tr>
<tr>
<td>Chairperson</td>
<td>Xavier Bosch, Spain</td>
</tr>
<tr>
<td>Panelists</td>
<td>Mario Poljak, Slovenia</td>
</tr>
<tr>
<td></td>
<td>Maaike Bleeker, Netherlands</td>
</tr>
<tr>
<td></td>
<td>Pier Luigi Lopalco, Italy</td>
</tr>
<tr>
<td></td>
<td>Kevin Pollock, UK</td>
</tr>
<tr>
<td></td>
<td>- General frame on cervical cancer elimination</td>
</tr>
<tr>
<td></td>
<td>- Female HPV vaccine acceptance. Vaccination achievements</td>
</tr>
<tr>
<td></td>
<td>- Vaccination crisis</td>
</tr>
<tr>
<td></td>
<td>- Safety of the vaccines and the Cochrane dispute</td>
</tr>
<tr>
<td></td>
<td>- Male vaccination. Expected penetrance and impact</td>
</tr>
<tr>
<td></td>
<td>- Vaccinating women in screening ages (25-45+)</td>
</tr>
<tr>
<td></td>
<td>- Transition to HPV primary screening in Europe</td>
</tr>
<tr>
<td></td>
<td>- Self-sampling initiatives in Europe and in developing countries</td>
</tr>
<tr>
<td></td>
<td>- HPV testing technology. Validation of tests</td>
</tr>
<tr>
<td></td>
<td>- Questions from the audience</td>
</tr>
</tbody>
</table>

| **10:00-10:20** | **COFFEE BREAK, VISIT THE EXHIBITION AND POSTER VIEWING**              |

<table>
<thead>
<tr>
<th><strong>10:20-11:50</strong></th>
<th><strong>INDUSTRY SUPPORTED SESSION</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>See page 178</td>
<td></td>
</tr>
</tbody>
</table>

| **11:50-12:10** | **BREAK**                     |

<table>
<thead>
<tr>
<th><strong>12:10-13:40</strong></th>
<th><strong>VULVO-VAGINAL ATROPHY/ GSM</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Capsule</td>
<td>Laser treatment for vulvo-vaginal atrophy, a transit relief or paradigm shift?</td>
</tr>
<tr>
<td>Chairpersons</td>
<td>Santiago Palacios, Spain</td>
</tr>
<tr>
<td></td>
<td>Alessandra Graziottin, Italy</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>12:10-12:55</strong></th>
<th>Debate: Do we need RCTs for laser in VVA/GSM or are observational data enough?</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:10</td>
<td>For RCTs: Santiago Palacios, Spain</td>
</tr>
<tr>
<td>12:25</td>
<td>For observational/registry data: Marco Gambacciani, Italy</td>
</tr>
<tr>
<td>12:40</td>
<td>Discussion</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>12:55-13:20</strong></th>
<th>Can lasers reduce overactive bladder symptoms?</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:20-13:40</td>
<td>VVA – Do we need to change nomenclature to GSM?</td>
</tr>
<tr>
<td>13:40-14:30</td>
<td>LUNCH BREAK, VISIT THE EXHIBITION AND POSTER VIEWING</td>
</tr>
</tbody>
</table>

**EXHIBITION AREA**
### 14:30-16:30  BREAST CANCER  

**Capsule**  
**Breast cancer epidemic and hormonal replacement: What is the relationship?**

**Chairpersons**  
**Herjan Coelingh Bennink, Netherlands**  
**Nicholas Panay, UK**

**14:30-14:55**  
**Can HRT be individualized to reduce the incidence of breast cancer?**  
**Mark Brincat, Malta**

**14:55-15:15**  
**Prescribing Contraception and HRT in BRCA carriers**  
**Anne Gompel, France**

**15:15-16:00**  
**Debate: Does HRT increase the risk of breast cancer?**

- **Yes:** **Serge Rozenberg, Belgium**
- **No:** **Mark Brincat, Malta**

**Discussion**

**16:00-16:30**  
**Special countercurrent lecture:**  
**Treatment of advanced breast cancer with high dose estrogens**  
**Herjan Coelingh Bennink, Netherlands**

### 16:30-16:50  COFFEE BREAK, VISIT THE EXHIBITION AND POSTER VIEWING  

**EXHIBITION AREA**

### 16:50-17:55  PERIMENOPAUSAL SIDE EFFECTS AND MANAGEMENT  

**Capsule**  
**Perimenopausal and menopausal side effect**

**Chairpersons**  
**Ann Gompel, France**  
**Alessandra Graziottin, Italy**

**16:50-17:10**  
**Hot flushes, peripheral or central nervous system?**  
**Mark Brincat, Malta**

**17:10-17:35**  
**Update on isoflavones in menopause**  
**Christian Egarter, Austria**

**17:35-17:55**  
**Endometriosis in the menopause**  
**Marco Gambacciani, Italy**
### FRIDAY, NOVEMBER 22

#### FETOMATERNAL MEDICINE | HALL D

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Chairpersons</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30-10:00</td>
<td>PREGNANCY SUPPORT AND NIPT</td>
<td><strong>HALL D</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Chairpersons</strong></td>
<td>Patrick Rozenberg, France</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Gian Carlo Di Renzo, Italy</td>
</tr>
<tr>
<td>08:30-08:55</td>
<td>PROBIOTICS AND PREGNANCY SUPPORT</td>
<td></td>
</tr>
<tr>
<td></td>
<td>The role of probiotics and <em>Lactobacillus reuteri</em> during pregnancy: What is the evidence?</td>
<td>Flavia Indrio, Italy</td>
</tr>
<tr>
<td>08:55-09:15</td>
<td></td>
<td>How do different cfDNA tests compare? Should we expand the scope of cfDNA testing beyond common trisomies?</td>
</tr>
<tr>
<td>09:15-09:35</td>
<td>NIPT</td>
<td></td>
</tr>
<tr>
<td></td>
<td>NIPT: What the physician should know about the test?</td>
<td>Francois Vialard, France</td>
</tr>
<tr>
<td>09:35-10:00</td>
<td></td>
<td>NIPT for everyone?</td>
</tr>
<tr>
<td>10:00-10:20</td>
<td>COFFEE BREAK, VISIT THE EXHIBITION AND POSTER VIEWING</td>
<td><strong>EXHIBITION AREA</strong></td>
</tr>
<tr>
<td>10:20-11:50</td>
<td>INDUSTRY SUPPORTED SESSION</td>
<td><strong>HALL D</strong></td>
</tr>
<tr>
<td>11:50-12:10</td>
<td>BREAK</td>
<td></td>
</tr>
<tr>
<td>12:10-13:40</td>
<td>MULTIPLE PREGNANCIES</td>
<td><strong>HALL D</strong></td>
</tr>
<tr>
<td></td>
<td>Capsule</td>
<td>Twins remain a high-risk pregnancy despite all monitoring capabilities</td>
</tr>
<tr>
<td></td>
<td><strong>Chairpersons</strong></td>
<td>Gerard Visser, Netherlands</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Patrick Rozenberg, France</td>
</tr>
<tr>
<td>12:10-13:35</td>
<td></td>
<td>Assessment of fetal growth in twins</td>
</tr>
<tr>
<td>12:35-13:20</td>
<td>Debate: Should we recommend fetal reduction from twins to singleton</td>
<td>Yariv Yogev, Israel</td>
</tr>
<tr>
<td></td>
<td>12:10 Pro-</td>
<td>Gerard Visser, Netherlands</td>
</tr>
<tr>
<td></td>
<td>12:25 Con-</td>
<td>Discussion</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Asma Khalil, UK</td>
</tr>
<tr>
<td>13:20-13:40</td>
<td>How to avoid stillbirth in twins</td>
<td></td>
</tr>
<tr>
<td>13:40-14:30</td>
<td>LUNCH BREAK, VISIT THE EXHIBITION AND POSTER VIEWING</td>
<td><strong>EXHIBITION AREA</strong></td>
</tr>
</tbody>
</table>
## Preterm Delivery

### Capsule: Are we advancing in the diagnosis and management of preterm birth?

**Chairpersons**
- Asma Khalil, UK
- Ariel Many, Israel
- Francois Vialard, France

### 14:30-14:50

**Prediction of preterm birth: Cervical length and biomarkers**

Patrick Rozenberg, France

### 14:50-15:15

**Late preterm delivery: Do we underestimate the problem?**

Yariv Yogeve, Israel

### 15:15-15:35

**Controversies about the secondary prevention of spontaneous preterm birth**

Franz Bahlmann, Germany

### 15:35-16:00

**What is the evidence that any tocolytics work?**

Ben Mol, Australia

### 16:00-16:30

**Special countercurrent lecture:**

Placental microbiome: What do we know, what should we know?

Jerome Strauss, USA

---

## Endoscopy During Pregnancy by SLS: The Society of Laparoendoscopic Surgeons

### Capsule: Laparoscopy and pregnancy: An update by SLS

**Chairpersons**
- Jessica Ybanez-Morano, USA
- Thiers Soares Raymundo, USA

### 16:50-17:20

**Laparoscopic cerclage**

Thiers Soares Raymundo, Brazil

### 17:20-17:50

**Laparoscopy and pregnancy: The fundamentals**

Jessica Ybanez-Morano, USA

### 17:50-18:20

**Laparoscopic interventions for infertility**

Stefano Landi, Italy
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30-10:00</td>
<td>ORAL PRESENTATIONS 01 – DIAGNOSTIC PROCEDURE/GYNECOLOGICAL ONCOLOGY/FETOMATERNAL MEDICINE</td>
<td>DIAGNOSTIC PROCEDURES</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chairperson</td>
<td>Alessandra Graziottin, Italy</td>
<td></td>
</tr>
<tr>
<td>08:30-08:37</td>
<td>OP1-101</td>
<td>The diagnostic accuracy of 3-dimensional saline infusion transvaginal ultrasound (3-D SIS) Compared with combined laparoscopic - hysteroscopic procedure in the distinction between septate and bicornuate uteri</td>
<td>Ebrahimi Mahbod, Iran</td>
</tr>
<tr>
<td>08:37-08:44</td>
<td>OP1-102</td>
<td>Value of vaginal fetal fibronectin and cervical interleukin-8 in predicting premature birth</td>
<td>Dat Do Tuan, Vietnam</td>
</tr>
<tr>
<td>08:44-08:51</td>
<td>OP1-103</td>
<td>Management of endometriosis in women at reproductive age: Systematic review and critical appraisal of current guidelines including 2018 Spanish Fertility Society endometriosis clinical guideline</td>
<td>Maria Carrera, Spain</td>
</tr>
<tr>
<td>08:51-08:58</td>
<td>OP1-104</td>
<td>MTHFR in a large infertile cohort of more than 2500 patients: Incidence, effect of treatment and impact on other systems</td>
<td>Arthur Clement, France</td>
</tr>
<tr>
<td>08:58-09:05</td>
<td>OP1-105</td>
<td>Treatment for MTHFR (methylenetetrahydrofolate reductase) C677T mutations carriers with 5 methylene tetrahydrofolate (5MTHF) improves their ART outcomes</td>
<td>Patrice Clement, France</td>
</tr>
<tr>
<td></td>
<td>GYNECOLOGICAL ONCOLOGY</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:05-09:12</td>
<td>OP1-106</td>
<td>Cyclical versus continuous oral progestin monotherapy in endometrial hyperplasia without atypia</td>
<td>Hui Men Selina Chin, Singapore</td>
</tr>
<tr>
<td>09:12-09:19</td>
<td>OP1-107</td>
<td>Cytoreductive surgery and hyperthermic intaperitoneal chemotherapy in an adolescent patient with a recurrent uterine leiomyosacroma as peritoneal sarcomatosis</td>
<td>Payam Katebi Kashi, USA</td>
</tr>
<tr>
<td>09:19-09:26</td>
<td>OP1-108</td>
<td>Evaluation of gynecologic cancer awareness and cancer worry in women</td>
<td>Dilek Coskuner Potur, Turkey</td>
</tr>
<tr>
<td>09:26-09:33</td>
<td>OP1-109</td>
<td>A systematic review with meta-analysis of NRF2 as a prognostic marker for breast cancer survival</td>
<td>Micaela Almeida, Portugal</td>
</tr>
<tr>
<td>09:33-09:40</td>
<td>OP1-110</td>
<td>Cytotoxicity of soursop leaves (annona muricata) against hela cervical cancer cells</td>
<td>Fona Qorina, Indonesia</td>
</tr>
</tbody>
</table>
## FETOMATERNAL MEDICINE

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:40-09:47</td>
<td>OP1-111</td>
<td>A rare case of atypical hemolytic uremic syndrome following medical termination of pregnancy</td>
<td>Umme Farwa Shah, UK</td>
<td></td>
</tr>
<tr>
<td>09:47-09:54</td>
<td>OP1-112</td>
<td>Prevent mother-to-child transmission (PMTCT) programs and enhancement of maternal healthcare infrastructure to improve early detection of maternal syphilis in Shanghai, China</td>
<td>Li Du, China</td>
<td></td>
</tr>
</tbody>
</table>

### 10:00-10:20 COFFEE BREAK, VISIT THE EXHIBITION AND POSTER VIEWING EXHIBITION AREA

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:20-11:50</td>
<td>ORAL PRESENTATIONS 02 – FETOMATERNAL MEDICINE HALL E</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:27-10:34</td>
<td>OP1-202</td>
<td>Group a streptococcal (GAS) infections in obstetrics and gynecology</td>
<td>Arthur Zaltz, Canada</td>
<td></td>
</tr>
<tr>
<td>10:34-10:41</td>
<td>OP1-203</td>
<td>Clinical safety and efficacy of dinoprostone gel for cervical ripening in a pregnant women not in labor</td>
<td>Julienne Katrina Beltran, Philippines</td>
<td></td>
</tr>
<tr>
<td>10:41-10:48</td>
<td>OP1-204</td>
<td>Relationship between success and failure rates of SMUCS with antepartum, intrapartum and postpartum factors in atomic uterine cases at Dr. Soetomo Hospital Surabaya during 2012-2017</td>
<td>Tizar Dwi Satyoputro, Indonesia</td>
<td></td>
</tr>
<tr>
<td>10:48-10:55</td>
<td>OP1-205</td>
<td>Correlation of timing of delivery and maternal and fetal outcomes among women with severe preeclampsia: A descriptive cross-sectional study</td>
<td>Maria Margarita Sayao-Manuel, Philippines</td>
<td></td>
</tr>
<tr>
<td>10:55-11:02</td>
<td>OP1-206</td>
<td>Laparoscopic surgery in pregnancy after the second trimester: A case series</td>
<td>Alexandra Wisentaner, UK</td>
<td></td>
</tr>
<tr>
<td>11:02-11:09</td>
<td>OP1-207</td>
<td>Risk factors for severe perineal tears among first versus repeat vaginal delivery</td>
<td>Danit Aviv, Israel</td>
<td></td>
</tr>
<tr>
<td>11:09-11:16</td>
<td>OP1-208</td>
<td>Prevalence, risk factors and aetiologies of postpartum pyrexia in the Douala General Hospital, Cameroon</td>
<td>Ngunyi Yannick Lechedem, Cameroon</td>
<td></td>
</tr>
<tr>
<td>11:16-11:23</td>
<td>OP1-209</td>
<td>Self-reported health outcomes of donor conceived and spontaneously conceived adults</td>
<td>Damian Adams, Australia</td>
<td></td>
</tr>
</tbody>
</table>
# FRIDAY, NOVEMBER 22

## 11:23-11:30
**OP1-210**  
Anteroposterior renal pelvic diameter on ultrasound among male and female Filipino fetuses at 24 to 28 weeks age of gestation: A comparative study  
*Cathy Bernabe-Hisanan, Philippines*

## 11:30-11:37
**OP1-211**  
Glycated haemoglobin and risk for large for gestational age neonates in gestational diabetes pregnancies  
*Carolina Carneiro, Portugal*

## 11:37-11:44
**OP1-212**  
Oxytocin use in grand multipara with dysfunctional labor and one previous cesarean section results in high rate of normal deliveries  
*Yara Naser, Israel*

## 11:50-12:10  
**BREAK**

## 12:10-13:40  
**ORAL PRESENTATIONS 03 - INFERTILITY/ART/IVF**  
**HALL E**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Author</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:10-12:19</td>
<td>Does IVF/ICSI condemn you to a caesarean section? A local population-based study</td>
<td>Maria Petra Agius</td>
<td>Malta</td>
</tr>
<tr>
<td>12:19-12:28</td>
<td>Opinions of French women on surrogate pregnancy and ethical aspects</td>
<td>Souhail Alouini</td>
<td>France</td>
</tr>
<tr>
<td>12:28-12:37</td>
<td>GSTT1 and GSTM1 deletion is a risk factor for infertility in women</td>
<td>Maria Manuel Casteloiro Alves</td>
<td>Portugal</td>
</tr>
<tr>
<td>12:37-12:46</td>
<td>Day-6 frozen-thawed blastocysts transfer on day-5 compared with day-6: Catching up with the window of implantation – A retrospective study</td>
<td>Asaf Bilgory</td>
<td>Israel</td>
</tr>
<tr>
<td>12:46-12:55</td>
<td>Are babies born through ART at higher risk of anomalies – A population-based study</td>
<td>Eleanor Brincat</td>
<td>Malta</td>
</tr>
<tr>
<td>12:55-13:04</td>
<td>Evaluation of age, AMH and AFC as predictors of ovarian response to treatment in IVF cycles</td>
<td>Olivia Anne Cassar</td>
<td>Malta</td>
</tr>
</tbody>
</table>
### ORAL PRESENTATIONS 04 – FETOMATERNAL MEDICINE

**Chairpersons**

<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:30-14:38</td>
<td>Phaleria macrocarpa’s extracts inhibits autophagy probably through MDA in huvec cell culture</td>
<td>Leo Simanjuntak, Indonesia</td>
<td></td>
</tr>
<tr>
<td>14:38-14:46</td>
<td>A multi-centre analysis of the incidence of second stage (fully dilated) caesarean sections</td>
<td>Asad Rahim, UK</td>
<td></td>
</tr>
<tr>
<td>14:46-14:54</td>
<td>Of pregnancies complicated with small for gestation age babies at term, what proportions have placental findings with implications for future pregnancies or neonatal outcomes</td>
<td>Roberto Orefice, Australia</td>
<td></td>
</tr>
<tr>
<td>14:54-15:02</td>
<td>Positive pregnancy outcome in women with phenylketonuria is possible!</td>
<td>Zhao Xuan Tan, UK</td>
<td></td>
</tr>
<tr>
<td>15:02-15:10</td>
<td>Case of heterotopic pregnancy (ovarian and intrauterine) in a 30-year-old patient</td>
<td>Gene Afzelia Austria, Philippines</td>
<td></td>
</tr>
<tr>
<td>15:10-15:18</td>
<td>Management of a paraganglioma in pregnancy</td>
<td>Payam Katebi Kashi, USA</td>
<td></td>
</tr>
<tr>
<td>15:18-15:26</td>
<td>Predictive value for spontaneous preterm birth in women presenting with preterm labor: Comparison of placental alpha microglobulin-1 and fetal fibronectin according to the cervical length</td>
<td>Woo Jeng Kim, South Korea</td>
<td></td>
</tr>
</tbody>
</table>
### FRIDAY, NOVEMBER 22

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 15:26-15:34   | OP1-408  
Evaluation of efficiency of myomectomy during cesarean section  
**Vafa Huseynzade**, Azerbaijan |
| 15:34-15:42   | OP1-409  
Obstetric performance of huge babies (>4800gm)  
**Linda Harel**, Israel |
| 15:42-15:50   | OP1-410  
Can pravastatin / l-arginine therapy improve placental perfusion and umbilical artery vascular resistance in singleton pregnancies?  
**Aleksandar Jurisic**, Serbia |
| 15:50-15:58   | OP1-411  
Vaginal microorganism and its influence in pre-term delivery  
**Sara Bernardes da Cunha**, Portugal |
| 15:58-16:06   | OP1-412  
Is 3D omniview ultrasound helpful for diagnosis of fetal cleft palate?  
**Zaklina Jurisic**, Serbia |
| 16:06-16:14   | OP1-413  
Is induction of labour at term a safe and effective strategy to reduce the risk of stillbirth in South Asian origin mothers?  
**William Stobie**, Australia |
| 16:14-16:22   | OP1-414  
Risk factors analysis and different outcomes in peripartum cardiomyopathy (PPCM) patients with and without hypertensive disorders in Hasan Sadikin General Hospital, Bandung, West Java, Indonesia  
**Saskia Soraya**, Indonesia |
| 16:22-16:30   | OP1-415  
Cause and consequence of fever in pregnant women: A retrospective study in a gynecological emergency department  
**Charles Egloff**, France |
| 16:30-16:50   | COFFEE BREAK, VISIT THE EXHIBITION AND POSTER VIEWING  
EXHIBITION AREA |
<table>
<thead>
<tr>
<th>16:50-18:20</th>
<th>ORAL PRESENTATIONS 05 - GYNECOLOGY</th>
<th>HALL E</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Chairperson</strong></td>
<td>Mordechai Ben David, Israel</td>
<td></td>
</tr>
</tbody>
</table>
| 16:50-16:58 | **OP1-501** | The effect of simulation method on knowledge, critical thinking and clinical decision-making level of nursing students for the management of pregnancy with preeclampsia  
Ayse Akalin, Turkey | |
| 16:58-17:06 | **OP1-502** | Medical or surgical method in treatment of symptomatic uterine myoma  
Athar Rasekh Jahromi, Iran | |
| 17:06-17:14 | **OP1-503** | Laser therapy of condylomata acuminate  
Urska Bizjak-Ogrinc, Slovenia | |
| 17:14-17:22 | **OP1-504** | The management of gynecological hemorrhages - Hypogastric artery ligation technique  
Petru Chitulea, Romania | |
| 17:22-17:30 | **OP1-505** | Fertility and conception in a patient with virilizing adrenocortical carcinoma: A case report  
Michael Dayrit, Philippines | |
| 17:30-17:38 | **OP1-506** | Myomatous erythrocytosis syndrome: A case series  
Glaiza De Guzman, Philippines | |
| 17:38-17:46 | **OP1-507** | Laparoscopic cornual excision (wedge resection) or laparoscopic cornuostomy and removal of ectopic pregnancy to preserve uterus for future pregnancies? That is the question  
Mahmoud Rahimi, Australia | |
| 17:46-17:54 | **OP1-508** | Pracau protocol: New protocol for chronic pelvic pain syndrome  
Ernesto Delgado Cidranes, Spain | |
| 17:54-18:04 | **OP1-509** | Serum proprotein convertase subtilisin-kexin type 9 (PCSK-9) levels in patients with normal and over-weight / obesic polycystic over syndrome  
Sinem Eldem, Turkey | |
| 18:04-18:12 | **OP1-510** | Laser treatment for genitourinary syndrome of menopause. Is there any evidence?  
Ivan Fistonic, Croatia | |
| 18:12-18:20 | **OP1-511** | Non-ablative laser treatment of lichen sclerosus et atrophicus – Comparison with topical corticosteroid therapy  
Sabina Sencar, Slovenia | |
# SATURDAY, NOVEMBER 23

## INFERTILITY/ART/IVF | HALL A

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30-10:00</td>
<td>PGT-A</td>
<td>HALL A</td>
</tr>
<tr>
<td>Capsule</td>
<td>Is PGS useful or harmful?</td>
<td></td>
</tr>
<tr>
<td>Chairpersons</td>
<td>Simon Fishel, UK, Gerald Schatten, USA</td>
<td></td>
</tr>
<tr>
<td>08:30-09:00</td>
<td>PGT-A for advanced maternal age and repeated abortion: Useful or harmful?</td>
<td>HALL A</td>
</tr>
<tr>
<td>Nathan Treff, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:00-09:30</td>
<td>RCT of PGT for aneuploidy by microarray of polar body in advance maternal age. Any advantage?</td>
<td>HALL A</td>
</tr>
<tr>
<td>The Esteem Study, Luca Gianaroli, Italy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:30-10:00</td>
<td>PGD/PGT-A without embryo biopsy, is this the answer?</td>
<td>HALL A</td>
</tr>
<tr>
<td>Samir Hamamah, France</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00-10:20</td>
<td>COFFEE BREAK, VISIT THE EXHIBITION AND POSTER VIEWING</td>
<td>EXHIBITION AREA</td>
</tr>
<tr>
<td>10:20-11:50</td>
<td>INDUSTRY SUPPORTED SESSION See page 180</td>
<td>HALL A</td>
</tr>
<tr>
<td>11:50-12:10</td>
<td>BREAK</td>
<td></td>
</tr>
<tr>
<td>12:10-13:40</td>
<td>QUESTIONS AND ANSWERS FROM HALL A AND B</td>
<td>HALL A</td>
</tr>
<tr>
<td>Chairpersons</td>
<td>Zion Ben Rafael, Israel, Rene Frydman, France, Bart Fauser, Netherlands</td>
<td></td>
</tr>
<tr>
<td>Discussants</td>
<td>Nick Macklon, UK, Edgardo Somigliana, Italy, Samir Hamamah, France, Joop Laven, Netherlands, Simon Fishel, Laura Rienzi, Italy</td>
<td></td>
</tr>
<tr>
<td>• In which selected patient populations is PGS/PGT-A proven beneficial?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Freeze all embryos strategies in IVF for all?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Duo stim? Why bother?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Embryo selection with highest implantation potential: Tell me how?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• ERA test: Who can it benefit?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Natural and natural/mild cycles, are they the same? Are we misleading each other?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Is Machine Learning beginning to improve IVF outcomes. What can we expect in the future?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• What is the best measure of IVF outcome from clinical, patients, healthcare system?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Is SET possible for all? If not, what is the percentage of SET we should strive for?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Should it be age dependent?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• LH or hCG: Which is more important for ovarian stimulation?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:40-14:30</td>
<td>LUNCH BREAK, VISIT THE EXHIBITION AND POSTER VIEWING</td>
<td>EXHIBITION AREA</td>
</tr>
</tbody>
</table>
### 14:30-16:30  
**HI-TECH IVF: ARTIFICIAL GAMETE AND EMBRYOS**  
**HALL A**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:30-14:55</td>
<td>Artificial ovary</td>
<td>Marie Madeleine Dolmans</td>
<td>Belgium</td>
</tr>
<tr>
<td>14:55-15:15</td>
<td>Conception versus manufacturing: ART Prospects with artificial gametes and assembled embryos</td>
<td>Gerald Schatten</td>
<td>USA</td>
</tr>
<tr>
<td>15:15-15:40</td>
<td>Self-organization of the human embryo in the absence of maternal tissues</td>
<td>Matteo Mole</td>
<td>UK</td>
</tr>
<tr>
<td>15:40-16:00</td>
<td>Expanding PGT to polygenic risk</td>
<td>Nathan Treff</td>
<td>USA</td>
</tr>
<tr>
<td>16:00-16:30</td>
<td>Special countercurrent lecture: Are we overusing IVF?</td>
<td>Fulco van der Veen</td>
<td>Netherlands</td>
</tr>
</tbody>
</table>

### 16:30-16:50  
**COFFEE BREAK, VISIT THE EXHIBITION AND POSTER VIEWING**  
**EXHIBITION AREA**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:50-17:20</td>
<td>Debate: Freeze only strategy for all?</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Con: Ben Mol, Australia</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pro: Anja Pinborg, Denmark</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:20-18:00</td>
<td>Debate: Should we measure progesterone on the day of a frozen embryo transfer?</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>No: Annalisa Racca, Belgium</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Yes: Elena Labarta, Spain</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:00-18:20</td>
<td>Comparing fresh and frozen embryo transfers in IVF: Cost effectiveness analysis</td>
<td>Ben Mol</td>
<td>Australia</td>
</tr>
</tbody>
</table>

*Recorded sessions*
**SATURDAY, NOVEMBER 23**

### INFERTILITY/ART/IVF | HALL B

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30-10:00</td>
<td>Capsule FERTILITY PRESERVATION</td>
<td>With so many methods of fertility preservation, do they all offer similar probabilities?</td>
</tr>
<tr>
<td></td>
<td>Chairpersons</td>
<td>Jacques Donnez, Belgium, Michael Grynberg, France</td>
</tr>
<tr>
<td>08:30-08:50</td>
<td>How many eggs do we need for preserving fertility?</td>
<td>Nathalie Sermondade, France</td>
</tr>
<tr>
<td>08:50-09:15</td>
<td>Oocytes or ovarian cortex cryopreservation for fertility preservation</td>
<td>Jean-Philippe Wolf, France</td>
</tr>
<tr>
<td>09:15-09:35</td>
<td>The place of IVM for fertility preservation</td>
<td>Michael Grynberg, France</td>
</tr>
<tr>
<td>09:35-10:00</td>
<td>Ovarian tissue cryopreservation and transplantation: Still experimental?</td>
<td>Marie-Madeline Dolmans, Belgium</td>
</tr>
</tbody>
</table>

**10:00-10:20 COFFEE BREAK, VISIT THE EXHIBITION AND POSTER VIEWING** EXHIBITION AREA

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:20-12:00</td>
<td>Capsule DIAGNOSIS OF INFERTILITY</td>
<td>Why should we keep doing HSG? Uterine transplantation, what kind of results can be expected?</td>
</tr>
<tr>
<td></td>
<td>Chairpersons</td>
<td>Rene Frydman, France, Katarina Jeremic, Serbia</td>
</tr>
<tr>
<td>10:20-10:40</td>
<td>Uterine transplantation – The French experience</td>
<td>Jean Marc Ayoubi, France</td>
</tr>
<tr>
<td>10:40-11:00</td>
<td>Failure in IVF. What’s next? A multidisciplinary approach</td>
<td>Rene Frydman, France</td>
</tr>
<tr>
<td>11:00-11:40</td>
<td>Debate: Hysterosalpingogram how?</td>
<td>Traditional oil-based HSG exploiting its therapeutic advantage: Ben Mol, Australia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ecosy is a good alternative: Marc Even, France</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Discussion</td>
</tr>
<tr>
<td>11:40-12:00</td>
<td>Biomarkers of ovarian response</td>
<td>Scott Nelson, UK</td>
</tr>
</tbody>
</table>

**12:00-12:10 BREAK**

**12:10-13:40 GO TO HALL A – QUESTIONS AND ANSWERS SESSION**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:40-14:30</td>
<td>LUNCH BREAK, VISIT THE EXHIBITION AND POSTER VIEWING</td>
<td>Exhibition Area</td>
</tr>
</tbody>
</table>
### WHAT’S NEW IN POI RESEARCH – I

**Capsule**
Can POI patients have any chance for normal fertility?

**Chairpersons**
Lisa Webber, UK  
Nicholas Panay, UK

**14:30-14:50**
Genetics of menopause
Joop Laven, Netherlands

**14:50-15:20**
Genetics of POI. Novel links with DNA repair/cancer genes
Micheline Misrahi, France

**15:20-15:40**
Fertility and management of Turner syndrome
Sophie Christin-Maitre, France

**15:40-16:00**
Stem cells in and out the ovaries: Promises for POI
Gabriel Livera, France

**16:00-16:30**
Special countercurrent lecture: Vaginal Lactobacilli: Key to successful human reproduction and future antibiotic resistant therapy
Gary Ventolini, USA

### COFFEE BREAK, VISIT THE EXHIBITION AND POSTER VIEWING

### WHAT’S NEW IN POI RESEARCH – II

**Capsule**
Can POI patients have any chance for normal fertility?

**Chairpersons**
Roger A. Lobo, USA  
Micheline Misrahi, France

**16:50-17:10**
Can we reliably predict POI using AMH?
Bart Fauser, Netherlands

**17:10-17:35**
Regulation of physiological reproductive lifespan and female fertility
Grant Montgomery, Australia

**17:35-17:55**
Developing new guidelines from a POI registry
Nicholas Panay, UK

**17:55-18:20**
The long-term health risks of POI
Lisa Webber, UK
### GYNECOLOGY | HALL C

#### 08:30-10:00 PREDICTION OF MENOPAUSE AND RISK FACTORS

**Capsule**

Can we predict and prevent menopausal complications and side effects?

**Chairpersons**

Nicholas Panay, UK  
Christian Egarter, Austria

**08:30-09:00**

Is there an increased CVD risk in PCOS women?  
Roger A. Lobo, USA

**09:00-09:30**

Does anti-Müllerian hormone predict menopause in the general population? Results of a prospective ongoing cohort study  
Joop Laven, Netherlands

**09:30-10:00**

Cardiovascular impact of progestins in women  
Christian Egarter, Austria

#### 10:00-10:20 COFFEE BREAK, VISIT THE EXHIBITION AND POSTER VIEWING

#### 10:20-11:50 UTERINE ANOMALIES; GYNE-ONCOLOGY

**Capsule**

Counselling on protection of fertility became a standard of care

**Chairpersons**

Ludwig Kiesel, Germany  
Alessandra Graziottin, Italy

**10:20-10:45**

Symmetric and non-symmetric uterine anomalies  
Leila Adamyan, Russia

**10:45-11:05**

Counseling young women with uterovaginal anomalies  
George Creatsas, Greece

**11:05-11:30**

Protecting reproductive potential in (gynecological) cervical cancer  
Pierluigi Benedetti Pancini, Italy

**11:30-11:50**

Protecting reproductive potential in ovarian cancer  
Catherine Uzan, France

#### 11:50-12:10 BREAK

#### 12:10-13:40 ADVANCES IN HORMONAL TREATMENT

**Capsule**

What is the ideal SERMs and SPRMs

**Chairpersons**

Mark Brincat, Malta  
George Creatsas, Greece

**12:10-12:40**

New progestogens / SPRMS: What are the possibilities?  
Christian Egarter, Austria

**12:40-13:10**

New SERMS / TSECS: Can they be an HRT substitute?  
Santiago Palacios, Spain

**13:10-13:40**

Targeting HRT: From indication to personalization  
Marco Gambacciani, Italy

#### 13:40-14:30 LUNCH BREAK, VISIT THE EXHIBITION AND POSTER VIEWING
### PREVENTION OF MENOPAUSAL SYMPTOMS

#### Capsule
Are we back to consensus in HRT?

**Chairpersons**
- **Santiago Palacios**, Spain
- **Serge Rozenberg**, Belgium

**14:30-14:55**
Should we use HRT for “prevention” in postmenopausal women
- **Roger A. Lobo**, USA

**14:55-15:15**
How to overcome hormone resistance in women with breast cancer?
- **Ludwig Kiesel**, Germany

**15:15-16:00**
Debate: Should androgens be routinely offered to optimize quality of life in menopause?
- **For**: **Alessandra Graziottin**, Italy
- **Against**: **Lydia Marie-Scemama**, France
  **Discussion**

**15:30-16:30**
Special countercurrent lecture:
Testosterone: The need for a new consensus
- **Nicholas Panay**, UK

### COFFEE BREAK, VISIT THE EXHIBITION AND POSTER VIEWING

### PERIMENOPAUSAL CONTRACEPTION

#### Capsule
Oral contraception until menopause?

**Chairpersons**
- **Mark Brincat**, Malta
- **Bari Kaplan**, Israel

**16:50-17:10**
Perimenopausal contraception: What are the current options?
- **Christian Egarter**, Austria

**17:10-17:35**
What are the future contraceptive possibilities?
- **Philippe Bouchard**, France

**17:35-17:55**
Minimizing cardiovascular risks of perimenopausal contraception
- **Lydia Marie-Scemama**, France

**17:55-18:20**
Optimizing psychosexual health with perimenopausal contraception
- **Alessandra Graziottin**, Italy
# SATURDAY, NOVEMBER 23

## FETOMATERNAL MEDICINE  |  HALL D

### 08:30-10:00  PREGNANCY MANAGEMENT  |  HALL D

<table>
<thead>
<tr>
<th>Capsule</th>
<th>Basic aspects of labour management are still in debate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chairpersons</td>
<td>Florence Bretelle, France  Mattheos Fraidakis, Greece</td>
</tr>
<tr>
<td><strong>08:30-09:00</strong></td>
<td><strong>08:30-09:00</strong></td>
</tr>
<tr>
<td>Debate: Betamethasone after 35 weeks of gestation?</td>
<td>Pro: Yariv Yogev, Israel  Con: Gerard Visser, Netherlands  Discussion</td>
</tr>
<tr>
<td>French recommendations on PTL</td>
<td>Florence Bretelle, France</td>
</tr>
<tr>
<td>Should we be advising our patients to take a hike? Physical activity in pregnancy: 2019 update</td>
<td>Milena Forte, Canada</td>
</tr>
<tr>
<td>A new perspective on high order cesarean deliveries up to number eleven</td>
<td>Mirra Manevich-Mazor, Israel</td>
</tr>
</tbody>
</table>

### 10:00-10:20  COFFEE BREAK, VISIT THE EXHIBITION AND POSTER VIEWING  |  EXHIBITION AREA

### 10:20-11:50  DIABETES  |  HALL D

<table>
<thead>
<tr>
<th>Capsule</th>
<th>The controversies relating to the definition and management of GDM are not abated</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chairpersons</td>
<td>Gerard Visser, Netherlands  Susana Santo, Portugal</td>
</tr>
<tr>
<td><strong>10:20-11:00</strong></td>
<td><strong>10:20-11:00</strong></td>
</tr>
<tr>
<td>Controversies in the management of GDM</td>
<td>Yariv Yogev, Israel</td>
</tr>
<tr>
<td>Women with gestational diabetes should be delivered at 38 weeks</td>
<td>Diogo Ayres-de-Campos, Portugal</td>
</tr>
<tr>
<td>Assessing the risks for shoulder dystocia</td>
<td>Ariel Many, Israel</td>
</tr>
</tbody>
</table>

### 11:50-12:10  BREAK

### 12:10-13:40  CAESEREAN SECTION  |  HALL D

<table>
<thead>
<tr>
<th>Capsule</th>
<th>The technique and the consequences of CS remains in debate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chairpersons</td>
<td>Bari Kaplan, Israel  Diogo Ayres-de-Campos, Portugal</td>
</tr>
<tr>
<td><strong>12:10-12:30</strong></td>
<td><strong>12:10-12:30</strong></td>
</tr>
<tr>
<td>Controversies around C-section techniques</td>
<td>Susana Santo, Portugal</td>
</tr>
<tr>
<td>Time</td>
<td>Topic</td>
</tr>
<tr>
<td>--------------</td>
<td>----------------------------------------------------------------------</td>
</tr>
<tr>
<td>12:30-12:55</td>
<td>Why do niches (CS defects) form? Are they a problem?</td>
</tr>
<tr>
<td>13:15-13:40</td>
<td>What is the optimal ‘decision to incision’ interval in cesarean section?</td>
</tr>
</tbody>
</table>

**13:40-14:30**  
**LUNCH BREAK, VISIT THE EXHIBITION AND POSTER VIEWING**  
**EXHIBITION AREA**

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker, Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:30-16:30</td>
<td>INTRAPARTUM AND CHILDREN FOLLOW UP</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Capsule</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Is ART pregnancy high risk?</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chairpersons</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dan Farine, Canada</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Gerard Visser, Netherlands</td>
<td></td>
</tr>
<tr>
<td>14:30-14:55</td>
<td>Child health after ART</td>
<td>Anja Pinborg, Denmark</td>
</tr>
<tr>
<td>14:55-15:15</td>
<td>Pregnancy in advance maternal age</td>
<td>Dan Farine, Canada</td>
</tr>
<tr>
<td>15:15-15:35</td>
<td>How to promote vaginal breech delivery</td>
<td>Maria Afonso, Portugal</td>
</tr>
<tr>
<td>15:35-16:00</td>
<td>Conservative management of intrapartum hypoxia</td>
<td>Susana Santo, Portugal</td>
</tr>
<tr>
<td>16:00-16:30</td>
<td>Special countercurrent lecture: All women in labor should be continuously monitored with CTG and fully mobile</td>
<td>Diogo Ayres-de-Campos, Portugal</td>
</tr>
</tbody>
</table>

**16:30-16:50**  
**COFFEE BREAK, VISIT THE EXHIBITION AND POSTER VIEWING**  
**EXHIBITION AREA**

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker, Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:50-18:20</td>
<td>LABOR</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Capsule</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Still controversies over delivery practice!</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chairpersons</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dan Farine, Canada</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Patrick Rozenberg, France</td>
<td></td>
</tr>
<tr>
<td>16:50-17:25</td>
<td>Debate: Should we use the partogram?</td>
<td></td>
</tr>
<tr>
<td></td>
<td>FIGO guidelines say yes: Gerad Visser, Netherlands</td>
<td></td>
</tr>
<tr>
<td></td>
<td>WHO guidelines say no: Dan Farine, Canada</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>17:25-18:00</td>
<td>Debate: Should all women be induced at 39 weeks?</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pro: Ariel Many, Israel</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Con: Gerard Visser, Netherlands</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>18:00-18:20</td>
<td>Outpatient induction of labor for all?</td>
<td>Maria Afonso, Portugal</td>
</tr>
</tbody>
</table>
## SATURDAY, NOVEMBER 23

### ORAL PRESENTATIONS  |  HALL E

<table>
<thead>
<tr>
<th>08:30-10:00</th>
<th>ORAL PRESENTATIONS 06 - FETOMATERNAL MEDICINE</th>
<th>HALL E</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chairpersons</td>
<td>Linda Harel, Israel</td>
<td>Arthur Clement, France</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>08:30-08:37</th>
<th>OP2-601</th>
<th>Labor induction in patients with a single prior caesarean section</th>
<th>Paul Funel, France</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:37-08:44</td>
<td>OP2-602</td>
<td>Which factors may influence women’s satisfaction and preferences in future mode of delivery?</td>
<td>Ana Rita Sarabando, Portugal</td>
</tr>
<tr>
<td>-------------</td>
<td>---------</td>
<td>-------------------------------------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>08:44-08:51</td>
<td>OP2-603</td>
<td>The effect of cervical cerclage on pregnancy outcome in women following electrosurgical conization</td>
<td>Jihyun Park, South Korea</td>
</tr>
<tr>
<td>-------------</td>
<td>---------</td>
<td>-------------------------------------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>08:51-08:58</td>
<td>OP2-604</td>
<td>Effects on preventing mother-to-child transmission of syphilis and syphilis associated adverse pregnant outcomes: A longitudinal study from 2001 to 2015 in Shanghai, China</td>
<td>Mao Hongfang, China</td>
</tr>
<tr>
<td>-------------</td>
<td>---------</td>
<td>-------------------------------------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>08:58-09:05</td>
<td>OP2-605</td>
<td>Predictive factors for successful vaginal delivery after a trial of external cephalic version</td>
<td>Asaf Bilgory, Israel</td>
</tr>
<tr>
<td>-------------</td>
<td>---------</td>
<td>-------------------------------------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>09:05-09:12</td>
<td>OP2-606</td>
<td>Previous history of gestational alloimmune liver disease: How to prevent</td>
<td>Maria Pulido Valente, Portugal</td>
</tr>
<tr>
<td>-------------</td>
<td>---------</td>
<td>-------------------------------------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>09:12-09:19</td>
<td>OP2-607</td>
<td>All options by cholecalciferol treatment of threatening miscarriage</td>
<td>Margarita Bakleicheva, Russia</td>
</tr>
<tr>
<td>-------------</td>
<td>---------</td>
<td>-------------------------------------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>09:19-09:26</td>
<td>OP2-608</td>
<td>Accuracy of the ultrasound fetal weight estimation before vaginal birth after a caesarian (VBAC) according to the maternal body mass index (BMI)</td>
<td>Ons Kaabia, Tunisia</td>
</tr>
<tr>
<td>-------------</td>
<td>---------</td>
<td>-------------------------------------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>09:26-09:33</td>
<td>OP2-609</td>
<td>Predictors of gestational diabetes risk in the first trimester of pregnancy</td>
<td>Aleksandra Epishkina-Minina, Russia</td>
</tr>
<tr>
<td>-------------</td>
<td>---------</td>
<td>-------------------------------------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>09:33-09:40</td>
<td>OP2-610</td>
<td>Effects of progesterone on preterm premature rupture of membrane treatment model</td>
<td>Soon-Cheol Hong, South Korea</td>
</tr>
<tr>
<td>-------------</td>
<td>---------</td>
<td>-------------------------------------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>09:40-09:47</td>
<td>OP2-611</td>
<td>Diagnosis and management of placenta previa and low placental implantation</td>
<td>Souhail Alouini, France</td>
</tr>
<tr>
<td>-------------</td>
<td>---------</td>
<td>-------------------------------------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>09:47-09:54</td>
<td>OP2-612</td>
<td>The effect of anesthesia maintenance with propofol and sevoflurane to cortisol, SFLT-1 and MDA level in severe preeclamptic patient underwent sectio cesarean</td>
<td>Theresia Monica Rahardjo, Indonesia</td>
</tr>
</tbody>
</table>

### 10:00-10:20  
**COFFEE BREAK, VISIT THE EXHIBITION AND POSTER VIEWING  | EXHIBITION AREA**
<table>
<thead>
<tr>
<th>10:20-11:50</th>
<th>ORAL PRESENTATIONS 07 - INFERTILITY/ART/IVF/GYNECOLOGY</th>
<th>HALL E</th>
</tr>
</thead>
</table>
| **Chairpersons** | Nathalie Sermondade, France  
Mark Brincat, Malta | |
| **ART/IVF/INFERTILITY** | | |
| 10:20-10:27 | OP2-701  
Is letrozole the answer to PCOS women who fail to ovulate with clomiphene citrate and with gonadotropins  
Shalini Gainder, India | |
| 10:27-10:34 | OP2-702  
The role of FSH to AMH ratio in predicting the number of oocyte retrieved or cycle cancellation with low prognosis patients undergoing ICSI cycle  
Ilay Gozukara, Turkey | |
| 10:34-10:41 | OP2-703  
Evolution of the sexual behaviour et dysfunctions in women in infertile couples  
Ons Kaabia, Tunisia | |
| 10:41-10:48 | OP2-704  
A study of 2,013 donor-conceived people  
Wendy Kramer, USA | |
| 10:48-10:55 | OP2-705  
Clinical and communication challenges of European and Latin American embryologists, nurses, and laboratory specialists involved in fertility care  
Laura Rienzi, Italy | |
| 10:55-11:02 | OP2-706  
Synergistic effect of obesity with polycystic ovarian syndrome on endothelial dysfunction. Role of insulin resistance  
Mardia Lopez-Alarcon, Mexico | |
| 11:02-11:09 | OP2-707  
Retroperitoneal ectopic pregnancy: A case report from Hanoi Obstetrics and Gynecology Hospital  
Toan Nguyen, Vietnam | |
| 11:09-11:16 | OP2-708  
Results of TRA after meteroplasty by uterus in T shape  
Cerrillo Maria, Spain | |
| 11:16-11:23 | OP2-709  
Leptin expression on midluteal endometrial tissue of macaca nemestrina after controlled ovarian hyperstimulation: Glandular, stromal and luminal analysis  
Adriana Viola Miranda, Indonesia | |
### SATURDAY, NOVEMBER 23

#### GYNECOLOGY

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:23-11:30</td>
<td>OP2-710 Do not forget ectopic pregnancy even with negative pregnancy test! A deceptive time bomb</td>
</tr>
<tr>
<td>11:30-11:37</td>
<td>OP2-711 Relationship between prolactin and dopamine receptor expression and progression of genital endometriosis</td>
</tr>
<tr>
<td>11:37--11:44</td>
<td>OP2-712 Sheehan’s syndrome in a patient presenting with organizing hematoma of the maxillary sinus</td>
</tr>
</tbody>
</table>

#### ORAL PRESENTATIONS 08 - OTHER

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:10-12:17</td>
<td>OP2-801 Outcomes of pregnancy of unknown location using serum BHCG and ultrasound in a district general hospital in United Kingdom</td>
</tr>
<tr>
<td>12:17-12:24</td>
<td>OP2-802 Five year incidence of osteoporosis among Macao adult women and its risk factors - Results from Macao follow up study 2011</td>
</tr>
<tr>
<td>12:24-12:31</td>
<td>OP2-803 The impacts on maternal age and perinatal outcomes since the birth policy shifts: Population-based analysis</td>
</tr>
<tr>
<td>12:31-12:38</td>
<td>OP2-804 Human overpopulation as the greatest challenge for gynecology in the 21st century</td>
</tr>
<tr>
<td>12:38-12:45</td>
<td>OP2-805 A case report on Hamman’s syndrome</td>
</tr>
<tr>
<td>12:45-12:52</td>
<td>OP2-806 Changes in intervertebral discs with the menopause and HRT</td>
</tr>
<tr>
<td>12:52-12:59</td>
<td>OP2-807 Patient-centred or patient-friendly: What of them is the most relevant standard value in assisted reproduction treatments?</td>
</tr>
<tr>
<td>Time</td>
<td>Presentation</td>
</tr>
<tr>
<td>---------------</td>
<td>--------------</td>
</tr>
<tr>
<td>12:59-13:06</td>
<td>OP2-808</td>
</tr>
<tr>
<td>13:06-13:13</td>
<td>OP2-809</td>
</tr>
<tr>
<td>13:13-13:20</td>
<td>OP2-810</td>
</tr>
<tr>
<td>13:20-13:27</td>
<td>OP2-811</td>
</tr>
<tr>
<td>13:27-13:34</td>
<td>OP2-812</td>
</tr>
<tr>
<td>13:40-14:30</td>
<td>LUNCH BREAK</td>
</tr>
<tr>
<td>14:30-14:38</td>
<td>OP2-901</td>
</tr>
<tr>
<td>14:38-14:46</td>
<td>OP2-902</td>
</tr>
<tr>
<td>14:46-14:54</td>
<td>OP2-903</td>
</tr>
<tr>
<td>14:54-15:02</td>
<td>OP2-904</td>
</tr>
<tr>
<td>15:02-15:10</td>
<td>OP2-905</td>
</tr>
<tr>
<td>15:10-15:18</td>
<td>OP2-906</td>
</tr>
<tr>
<td>15:18-15:26</td>
<td>OP2-907</td>
</tr>
</tbody>
</table>
## SATURDAY, NOVEMBER 23

### HPV

<table>
<thead>
<tr>
<th>Time</th>
<th>OP2-908</th>
<th>Ilya Olkov, Russia</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:26-15:34</td>
<td>Health saving technologies in XXI century – Basic concepts of HPV-associated diseases control in Russian Federation</td>
<td></td>
</tr>
<tr>
<td>15:34-15:42</td>
<td>OP2-909 Urinary HPV DNA testing as a tool for cervical cancer screening in France: An update of the CAPU3 study</td>
<td>Caroline Lefeuvre, France</td>
</tr>
<tr>
<td>15:42-15:50</td>
<td>OP2-910 International HPV awareness day in Russia on March 4, 2019 - Global Russian action for cervical cancer prevention</td>
<td>Ilya Olkov, Russia</td>
</tr>
</tbody>
</table>

### OTHER

<table>
<thead>
<tr>
<th>Time</th>
<th>OP2-911</th>
<th>Giuseppe Tritto, France</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:50-15:58</td>
<td>Bionanotechnologies in men’s health medicine the sperm nanobiosomes (male reproduction, contraception, STD and ageing)</td>
<td></td>
</tr>
<tr>
<td>15:58-16:06</td>
<td>OP2-912 Impact of revised management policies on the efficiency of gynecologic operating room processes in a tertiary training hospital</td>
<td>Glaiza De Guzman, Philippines</td>
</tr>
<tr>
<td>16:06-16:18</td>
<td>OP2-913 Matrix regeneration of the human testis in male infertility testis regenerative matrix (TREM) bioexpansion in testis insufficiency syndrome (TIS) testis expandable biosurgery and microsurgery (TEBS and TEMS) in male infertility based on autologous regenerative stem cells</td>
<td>Giuseppe Tritto, France</td>
</tr>
<tr>
<td>16:18-16:30</td>
<td>OP2-914 Modifying the caesarean - Seven years on</td>
<td>Chris Tsitlakidis, UK</td>
</tr>
<tr>
<td>16:30-16:50</td>
<td>COFFEE BREAK, VISIT THE EXHIBITION AND POSTER VIEWING</td>
<td>EXHIBITION AREA</td>
</tr>
</tbody>
</table>

---
<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:50-16:58</td>
<td>Determination of serum endocan levels which is inflammatory marker in patients with premature ovaryan failure</td>
<td>Melike Guler, Turkey</td>
</tr>
<tr>
<td>16:58-17:06</td>
<td>A rare case of ovarian metastasis of esthesioneuroblasotma, a sinonasal cavity malignancy: A case report</td>
<td>Maria Margarita Franchesca Lojo, Philippines</td>
</tr>
<tr>
<td>17:06-17:14</td>
<td>Epidermoid clitoral cyst: A rare cause of clitoromegaly</td>
<td>Matilde Martins, Portugal</td>
</tr>
<tr>
<td>17:14-17:22</td>
<td>Surgical or medical treatment for ectopic pregnancy in unusual locations? That is the question</td>
<td>Mahmoud Rahimi, Australia</td>
</tr>
<tr>
<td>17:22-17:30</td>
<td>Hysteroscopic repair of cesarean scar defect in women with abnormal uterine bleeding: A prospective study</td>
<td>Nguyen Ha, Vietnam</td>
</tr>
<tr>
<td>17:30-17:38</td>
<td>Russian first HPV primary screening program in the Republic of Bashkortostan in action</td>
<td>Ilya Olkov, Russia</td>
</tr>
<tr>
<td>17:38-17:46</td>
<td>GLIA cells number and BDNF expression in endometriosis mice with and without lipopolysaccharide (LPS) exposure</td>
<td>Daniel Yoseph Pardomuan, Indonesia</td>
</tr>
<tr>
<td>17:46-17:54</td>
<td>Surgical or non-surgical treatment of uterine fibroids? That’s the question</td>
<td>Mahmoud Rahimi, Australia</td>
</tr>
<tr>
<td>17:54-18:02</td>
<td>Infertile PCOS patients treatment with optimal results and decrease the rate of OHSS</td>
<td>Athar Rasekh Jahromi, Iran</td>
</tr>
<tr>
<td>18:02-18:10</td>
<td>Determining the relationship between married women’s attitudes towards fertility and family planning and their intention to use contraceptive methods and affecting factors</td>
<td>Asli Sis Celik, Turkey</td>
</tr>
<tr>
<td>18:10-18:18</td>
<td>Postpartum sexual dysfunction - A prospective study</td>
<td>Diana Natacha Sousa, Portugal</td>
</tr>
<tr>
<td>Paper Number</td>
<td>Title</td>
<td>Presenter, Location</td>
</tr>
<tr>
<td>--------------</td>
<td>----------------------------------------------------------------------</td>
<td>--------------------------------------------</td>
</tr>
<tr>
<td>P001</td>
<td>Heterotopic pregnancy after intra-cytoplasmatic sperm injection: When identifying an intrauterine pregnancy is not enough</td>
<td>Carolina Costa Gomes, Portugal</td>
</tr>
<tr>
<td>P002</td>
<td>Ovarian and endometrium platelet-rich plasma (PRP) therapy in reproductive medicine</td>
<td>Menildo Giovanni, Italy</td>
</tr>
<tr>
<td>P003</td>
<td>Endometrial thickness as a determinant of frozen embryo transfer outcomes</td>
<td>Bethany Goulson, UK</td>
</tr>
<tr>
<td>P004</td>
<td>Exposure to propyl gallate hamper calcium hoemostasis and induced mitochondria dysfunction of testis, leading to male infertility</td>
<td>Jiyeon Ham, South Korea</td>
</tr>
<tr>
<td>P005</td>
<td>Function of LIN28A/WNT/Β-CATENIN in regulating premature ovarian failure</td>
<td>Chen Jing, Hong Kong, China</td>
</tr>
<tr>
<td>P006</td>
<td>The association between progesterone levels on the day of oocyte maturation day and systemic inflammatory markers of complete blood count for fresh in vitro fertilization cycles</td>
<td>Jieun Kang, South Korea</td>
</tr>
<tr>
<td>P007</td>
<td>Use of follitropin delta in controlled ovarian stimulation for in vitro fertilization in high responder patients: Case-control study</td>
<td>Carerra Maria, Spain</td>
</tr>
<tr>
<td>P008</td>
<td>Efficacy of ICSI in overcoming fertility problems in men with auto immune reactivity to sperm (anti sperm antibody: ASA)</td>
<td>Dashti Maryam, Bahrain</td>
</tr>
<tr>
<td>P009</td>
<td>Endometrial scratching and analysis uterine natural killer (UNK) improve pregnancy rate in infertile women with previous IVF failure</td>
<td>Giovanni Menaldo, Italy</td>
</tr>
<tr>
<td>P010</td>
<td>Aromatase inhibitors (letrozole) versus clomiphene citrate as ovulation induction agents in patients with polycystic ovarian syndrome, and their role on ultrasonographic markers of endometrial receptivity</td>
<td>Judith Marie Milford, Malta</td>
</tr>
<tr>
<td>P011</td>
<td>Toxic effects of ochratoxin a on Sertoli and Leydig cells causing male infertility in mice</td>
<td>Hahyun Park, South Korea</td>
</tr>
<tr>
<td>P012</td>
<td>Hormonal treatment prior to testicular sperm extraction (TESE) improves ICSI outcomes</td>
<td>Mario Alfonso Patron Vazquez, Mexico</td>
</tr>
<tr>
<td>P013</td>
<td>Conception factors in unexplained infertility patients</td>
<td>Bauyté Raminta, Lithuania</td>
</tr>
<tr>
<td>P014</td>
<td>Mediator in the embryo-endometrium cross-talk: Granulocyte colony-stimulating factor in infertility</td>
<td>Chris Andrea Robert, USA</td>
</tr>
<tr>
<td>P015</td>
<td>Ovarian stimulation in low responders classified as group I AND II according to the Poseidon system</td>
<td>Jesus Arnulfo Roiz Castro, Mexico</td>
</tr>
<tr>
<td>P016</td>
<td>Distinguishing between cornual and eccentrically located intrauterine pregnancy after intrauterine insemination - A case report study</td>
<td>Rita Salgueiro Neto, Portugal</td>
</tr>
<tr>
<td>P017</td>
<td>Quantitative analysis of the SHLA-G protein in seminal plasma</td>
<td>Andreas Schallmoser, Germany</td>
</tr>
<tr>
<td>P018</td>
<td>A case of live birth after embryo transfer with significant fluid in endometrial cavity</td>
<td>Shayna Siew, Singapore</td>
</tr>
<tr>
<td>P019</td>
<td>Controlled ovarian stimulation in breast cancer patients: Does receptor status make a difference?</td>
<td>Stephanie Sii, Australia</td>
</tr>
<tr>
<td>P020</td>
<td>Endometrial volume and adjusted endometrial volume assessment of endometrial receptivity in assisted reproductive technology cycles</td>
<td>Renato Silva Martins, Portugal</td>
</tr>
<tr>
<td>P021</td>
<td>Outcome of ICSI-ET cycles in women presenting with low anti- Mullerian hormone in Southern India</td>
<td>Dhodapkar Sneha Badwe, India</td>
</tr>
<tr>
<td>P022</td>
<td>Evaluation of clinical &amp; embryological factors influencing pregnancy outcomes in the first frozen blastocyst transfer: A retrospective study, in IVF Hung Vuong</td>
<td>Thanh Thuy Tran, Vietnam</td>
</tr>
<tr>
<td>P023</td>
<td>Comparison of live birth rates between frozen single and double embryo transfer following a failed fresh single blastocyst transfer</td>
<td>Wong Ker YL, Singapore</td>
</tr>
<tr>
<td>P024</td>
<td>Effect of jogyeongbohyeoldan (JBD) on the restoration of ovarian function in aged female mice</td>
<td>Jeongeun Yoo, South Korea</td>
</tr>
</tbody>
</table>
### DIAGNOSTIC PROCEDURES

<table>
<thead>
<tr>
<th>Paper ID</th>
<th>Title</th>
<th>Authors</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>P025</td>
<td>Correspondence between ultrasound finding, hysteroscopy and histological results in premenopausal women</td>
<td>Augusto Brandao</td>
<td>Brazil</td>
</tr>
<tr>
<td>P026</td>
<td>Bysteroscopic management of cesarean scar ectopic pregnancy: A case report</td>
<td>Brás Ana Filipa</td>
<td>Portugal</td>
</tr>
<tr>
<td>P027</td>
<td>Comparison between operative hysteroscopy and histopathological findings</td>
<td>Matilde Martins</td>
<td>Portugal</td>
</tr>
<tr>
<td>P028</td>
<td>Uterine bleeding in postmenopausal women – The role of hysteroscopy</td>
<td>Diana Natacha Sousa</td>
<td>Portugal</td>
</tr>
</tbody>
</table>

### FETOMATERNAL MEDICINE

<table>
<thead>
<tr>
<th>Paper ID</th>
<th>Title</th>
<th>Authors</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>P029</td>
<td>Do cervical intraepithelial neoplasia (CIN) and human papilloma virus (HPV) infection predispose to uterine tachysystole when double balloon catheter (DBC) is considered for cervical ripening? Case report</td>
<td>Shady Abd Elmoneim</td>
<td>UK</td>
</tr>
<tr>
<td>P030</td>
<td>Anencephalus - First trimester detection</td>
<td>Nurije Aliji</td>
<td>Republic of North Macedonia</td>
</tr>
<tr>
<td>P031</td>
<td>Peripartum cardiomyopathy after cesarean section in women with pre-eclampsia related to more severe outcome: Case series</td>
<td>Suryawan Aloysius</td>
<td>Indonesia</td>
</tr>
<tr>
<td>P032</td>
<td>Prospective non invasive study of the endothelial function by uterine artery doppler flow velocimetry</td>
<td>Elefterios Anastasakis</td>
<td>Greece</td>
</tr>
<tr>
<td>P033</td>
<td>Why 40 is not the new 207 Pregnancy and obstetrical outcomes in women of advanced maternal age</td>
<td>Anita Barisic</td>
<td>Croatia</td>
</tr>
<tr>
<td>P034</td>
<td>The childbirth experience questionnaire (CEQ) - Validation of its use in a Danish-speaking population of new mothers stimulated with oxytocin during labour</td>
<td>Sidsel Boie</td>
<td>Denmark</td>
</tr>
<tr>
<td>P035</td>
<td>Factors associated with successful vaginal birth after induction of labor in women with a previous cesarean section</td>
<td>Ana Catarina Borges</td>
<td>Portugal</td>
</tr>
<tr>
<td>P036</td>
<td>Conservative management of early-onset preeclampsia with severe features: Maternal and perinatal results and assessment of causes for early delivery</td>
<td>Augusto Brandao</td>
<td>Brazil</td>
</tr>
<tr>
<td>P037</td>
<td>Pharmacological treatment of gestational diabetes</td>
<td>Carolina Carneiro</td>
<td>Portugal</td>
</tr>
<tr>
<td>P038</td>
<td>An unusual cause of acute abdominal pain in a pregnant didelphic uterus - A case report</td>
<td>Olivia Anne Cassar</td>
<td>Malta</td>
</tr>
<tr>
<td>P039</td>
<td>Chromosomal associations and genomic instability in idiopathic recurrent pregnancy loss(RPL)</td>
<td>Abhik Chakraborty</td>
<td>India</td>
</tr>
<tr>
<td>P040</td>
<td>Incidence of asymptomatic bacteriuria in a local pregnant population</td>
<td>Cassandra Cheong</td>
<td>Singapore</td>
</tr>
<tr>
<td>P041</td>
<td>Fetal pulmonary venous flow impedance in pregnancies with placental insufficiency-Related oligohydramnios</td>
<td>Hyunjin Cho</td>
<td>South Korea</td>
</tr>
<tr>
<td>P042</td>
<td>Usefulness of fetal pulmonary venous impedance to predict low birth weight infants</td>
<td>Hyunjin Cho</td>
<td>South Korea</td>
</tr>
<tr>
<td>P043</td>
<td>Anaemia during pregnancy in South Africa: Establishing the cause</td>
<td>Vino Dorsamy</td>
<td>South Africa</td>
</tr>
<tr>
<td>P044</td>
<td>Antenatal diagnosis of absence of septum pellucidum</td>
<td>Charles Egloff</td>
<td>France</td>
</tr>
<tr>
<td>P045</td>
<td>Curraro syndrome - A pre and post natal diagnosis correlation: Case report and literature review</td>
<td>Catarina Ferreira</td>
<td>Portugal</td>
</tr>
<tr>
<td>P046</td>
<td>Iodine supplementation during pregnancy and neonatal outcomes</td>
<td>Maria Flores Casteleiro</td>
<td>Portugal</td>
</tr>
<tr>
<td>P047</td>
<td>Chorionicity in twin pregnancies – Obstetric and neonatal impacts at the moment of delivery</td>
<td>Maria Flores Casteleiro</td>
<td>Portugal</td>
</tr>
<tr>
<td>ID</td>
<td>Title</td>
<td>Author(s)</td>
<td>Country</td>
</tr>
<tr>
<td>------</td>
<td>----------------------------------------------------------------------</td>
<td>----------------------------</td>
<td>---------------</td>
</tr>
<tr>
<td>P048</td>
<td>Microrna analysis of desidua derived mesenchymal stem cells from preeclampsia patient</td>
<td>Tuba Gunel, Turkey</td>
<td></td>
</tr>
<tr>
<td>P049</td>
<td>Determining preterm labour through cervical biometrics and fetal fibronectin</td>
<td>Elitsa Gyokova, Bulgaria</td>
<td></td>
</tr>
<tr>
<td>P050</td>
<td>Implications of extreme weight loss due to hyperemesis in pregnancy</td>
<td>Nandini Halder, UK</td>
<td></td>
</tr>
<tr>
<td>P051</td>
<td>Efficiency of exographic examination of fetoplacentar system in women with uterine scar after myomectomy</td>
<td>Yashar Hasanov, Azerbaijan</td>
<td></td>
</tr>
<tr>
<td>P052</td>
<td>Pregnancy of uncertain viability: Is prediction better than strategy?</td>
<td>Helga Consiglio, Malta</td>
<td></td>
</tr>
<tr>
<td>P053</td>
<td>Perinatal mortality and morbidity in Finnish twins</td>
<td>Riina Jernman, Finland</td>
<td></td>
</tr>
<tr>
<td>P054</td>
<td>Incidental myomectomy at time of vaginal delivery contributing to postpartum hemorrhage: A case report</td>
<td>Payam Katebi Kashi, USA</td>
<td></td>
</tr>
<tr>
<td>P055</td>
<td>Determining preterm labour through cervical biometrics and fetal fibronectin</td>
<td>Elitsa Gyokova, Bulgaria</td>
<td></td>
</tr>
<tr>
<td>P056</td>
<td>The efficacy of third-generation cephalosporin plus metronidazole versus third-generation cephalosporin plus clarithromycin in neonatal outcomes and oxidative stress markers for women with preterm premature rupture of membranes</td>
<td>Jong Woon Kim, South Korea</td>
<td></td>
</tr>
<tr>
<td>P057</td>
<td>Challenges in the diagnosis and screening for toxoplasma gondii during pregnancy: Results from a reference center in Brazil</td>
<td>Cesar Rodrigues Larissa Cynthia, Brazil</td>
<td>Brazil</td>
</tr>
<tr>
<td>P058</td>
<td>Association of the development of surgical site infection and post-operative oral antibiotics in low risk term pregnancies who underwent cesarean section in a low resource country hospital</td>
<td>Carla Lenice Lee, Philippines</td>
<td></td>
</tr>
<tr>
<td>P059</td>
<td>High placental growth factor levels in women with suspected or with confirmed preclampsia do not associate with bronchopulmonary dysplasia development in preterm neonates</td>
<td>Vanessa Marcha, Netherlands</td>
<td></td>
</tr>
<tr>
<td>P060</td>
<td>Unruptured third trimester ovarian pregnancy: A case report</td>
<td>Alexis Martinez, Philippines</td>
<td></td>
</tr>
<tr>
<td>P061</td>
<td>Claude-Bernard-Horner’s syndrome during labour</td>
<td>Ana Maria Munoz Ledesma, Spain</td>
<td>Spain</td>
</tr>
<tr>
<td>P062</td>
<td>Knowledge, attitude and practices of obstetricians and gynecologists on non–invasive prenatal testing in a private tertiary hospital in a low resource income country</td>
<td>Kristel Danica Panes, Philippines</td>
<td>Philippines</td>
</tr>
<tr>
<td>P063</td>
<td>Antibody microarray analysis of amniotic fluid proteins associated with subsequent ruptured membranes after clinically indicated amniocentesis in women with preterm labor</td>
<td>Ye Hyon Park, South Korea</td>
<td></td>
</tr>
<tr>
<td>P064</td>
<td>Pessary insertion in preterm twin gestation in the Philippines: A case report</td>
<td>Koleen Pasamba, Philippines</td>
<td></td>
</tr>
<tr>
<td>P065</td>
<td>Maternal mortality in Mexico 2010-2018</td>
<td>Francisco Javier Posadas Robledo, Mexico</td>
<td>Mexico</td>
</tr>
<tr>
<td>P066</td>
<td>Congenital x-linked intestinal pseudo-obstruction</td>
<td>Carolina Rueda, Spain</td>
<td></td>
</tr>
<tr>
<td>P067</td>
<td>Dandy-Walker malformation: The importance of prenatal diagnosis. A case report</td>
<td>Carolina Rueda, Spain</td>
<td></td>
</tr>
<tr>
<td>P068</td>
<td>Pregnant and newborn with restricted fetal growth - 5-year experience in a tertiary hospital</td>
<td>Rita Salgueiro Neto, Portugal</td>
<td></td>
</tr>
<tr>
<td>P069</td>
<td>The role of TNF-α gene polymorphisms in preterm delivery</td>
<td>Agnieszka Seremak-Mrozikiewicz, Poland</td>
<td>Poland</td>
</tr>
<tr>
<td>P070</td>
<td>The establishment of a score system for vaginal delivery of twin pregnancy</td>
<td>Nan Shen, China</td>
<td></td>
</tr>
<tr>
<td>P071</td>
<td>The relationship between high vaginal swab cultures and preterm birth in women with cervical cerclage</td>
<td>Emilia Shingleton, UK</td>
<td></td>
</tr>
<tr>
<td>P072</td>
<td>The use of levobupivacaine with or without ketorolac in post cesarean pain management: A randomized double-blinded control trial</td>
<td>Artitaya Singwongsa, Thailand</td>
<td>Thailand</td>
</tr>
<tr>
<td>P073</td>
<td>Delayed diagnosis of gestational diabetes mellitus in pregnant women with macrosomia at late pregnancy</td>
<td>Jeenah Sohn, South Korea</td>
<td></td>
</tr>
<tr>
<td>P074</td>
<td>Antibiotic prophylaxis for preterm premature rupture of membrane based on their microbiology pattern and antibiotic susceptibility test: Is it appropriate?</td>
<td>Saskia Medinawati Soraya, Indonesia</td>
<td></td>
</tr>
<tr>
<td>P075</td>
<td>Prenatal CF-DNA screening for down syndrome and other chromosomal abnormalities in unselected pregnancies in Slovenia</td>
<td>Darija Mateja Strah, Slovenia</td>
<td></td>
</tr>
<tr>
<td>P076</td>
<td>Total antioxidant capacity level comparation between spontaneous abortion and normal pregnancy</td>
<td>Alfonsoz Zeus Suryawan, Indonesia</td>
<td></td>
</tr>
<tr>
<td>P077</td>
<td>Three cases of recurrent pregnancy loss complicated by complex chromosomal rearrangements</td>
<td>Koichi Takakuwa, Japan</td>
<td></td>
</tr>
<tr>
<td>P078</td>
<td>Management of a rare case of non-immune hydrops and congenital chylothorax with diffuse lung disease</td>
<td>Yin Ru Tan, Singapore</td>
<td></td>
</tr>
<tr>
<td>P079</td>
<td>Caffeine content in newborn hair correlates with maternal dietary intake</td>
<td>Lauri Uusitalo, Finland</td>
<td></td>
</tr>
<tr>
<td>P080</td>
<td>Preconceptional training for women with varicose veins</td>
<td>Mishshenko Valentyna, Ukraine</td>
<td></td>
</tr>
<tr>
<td>P081</td>
<td>Anticoagulant treatment in women with recurrent miscarriages with inherited thrombophilia</td>
<td>Rita Vasconcelos, Portugal</td>
<td></td>
</tr>
<tr>
<td>P082</td>
<td>Type of conception in twin pregnancies - Obstetric and neonatal impacts at the moment of delivery</td>
<td>Rita Vasconcelos, Portugal</td>
<td></td>
</tr>
<tr>
<td>P083</td>
<td>D vitamin deficiency among Danish pregnant women - A need for an increased supplementation in pregnancy?</td>
<td>Anna Louise Vestergaard, Denmark</td>
<td></td>
</tr>
<tr>
<td>P084</td>
<td>Biometric data: Biparietal diameter, head circumference, abdominal circumference, femur length in our population (Portugal)</td>
<td>Flavia Vicente, Portugal</td>
<td></td>
</tr>
<tr>
<td>P085</td>
<td>Fetal growth curves in the second trimester- Are there differences in the different regions?</td>
<td>Flavia Vicente, Portugal</td>
<td></td>
</tr>
<tr>
<td>P086</td>
<td>Labor patterns in women undergoing vaginal birth after cesarean delivery in Shanghai</td>
<td>China Li Wenxian, China</td>
<td></td>
</tr>
<tr>
<td>P087</td>
<td>Pathomorphological afterbirth peculiarities in early form of intrauterine fetus growth restriction</td>
<td>Tetiana Yaremchuk, Ukraine</td>
<td></td>
</tr>
<tr>
<td>P088</td>
<td>Pregnancy outcomes in women with asymptomatic bacteriuria</td>
<td>Tatiana Zefirova, Russia</td>
<td></td>
</tr>
<tr>
<td>P089</td>
<td>Expression of genetic markers of endothelial pathology in pregnant women</td>
<td>Tatiana Zefirova, Russia</td>
<td></td>
</tr>
<tr>
<td>P090</td>
<td>Distribution of naturally-occurring IGG isotypes to HCG and its subunits in patients with ovarian cyst</td>
<td>Nino Chikadze, Georgia</td>
<td></td>
</tr>
<tr>
<td>P091</td>
<td>Routine follow-up in women conservatively treated for endometrial hyperplasia must be recommended</td>
<td>Clara Faarby Maarup, Denmark</td>
<td></td>
</tr>
<tr>
<td>P092</td>
<td>Association of CYP19A1 gene RS2414098 single nucleotide polymorphism with the risk of endometrial cancer</td>
<td>Russhania Gabilullina, Russia</td>
<td></td>
</tr>
<tr>
<td>P093</td>
<td>Is there any relation between miRNAs and ovarian cyst to become ovarian cancer?</td>
<td>Ece Gumusoglu, Turkey</td>
<td></td>
</tr>
<tr>
<td>P094</td>
<td>Reduction of bone mineral density and risk of osteoporosis in gynecologic cancer patients</td>
<td>Yong Il Ji, South Korea</td>
<td></td>
</tr>
<tr>
<td>P095</td>
<td>CDK12 regulates gene expression of DNMT1 &amp; ERBB3 by altering transcription of MIR-152</td>
<td>Jaroslav Klat, Czech Republic</td>
<td></td>
</tr>
<tr>
<td>P096</td>
<td>Outcomes of surgical management of endometrial hyperplasia without atypia</td>
<td>Shi Hui Lee, Singapore</td>
<td></td>
</tr>
<tr>
<td>P097</td>
<td>Management of ovarian teratomas associated with autoimmune encephalitis: A case report and review of the literature</td>
<td>Christopher Michael Mayer, USA</td>
<td></td>
</tr>
<tr>
<td>P098</td>
<td>Which ultrasound features of the endometrium are predictive of malignancy in post-menopausal bleeding?</td>
<td>Michele Montanaro Gauci, Malta</td>
<td></td>
</tr>
<tr>
<td>P099</td>
<td>Out-patient endometrial sampling in the investigation of post-menopausal bleeding: how useful is it?</td>
<td>Michele Montanaro Gauci, Malta</td>
<td></td>
</tr>
</tbody>
</table>
P100 Endometrial polyps and post-menopausal bleeding  
Michele Montanaro Gauci, Malta

P101 Clinical algorithm for investigation of post menopausal bleeding  
Michele Montanaro Gauci, Malta

P102 Incidence of high grade cervical intraepithelial neoplasia in women with normal and abnormal pap smears: A-3 year follow up in Thammasat University Hospital  
Awassada Punyashthira, Thailand

P103 Radiofrequency ablation (RFA) limits in the emergency haemostasis in bleeding tumours of the uterine cervix  
Maria-Manuela Ravas, Romania

P104 Case report – Anaplastic large cell lymphoma in women with breast implants  
Anna Salvador, Brazil

P105 The effect of octreotide in postoperative lymphocele in gynecologic cancer patients  
Seunghyuk Shim, South Korea

---

**GYNECOLOGY**

P106 Endometrial E-cadherin expression in women with reproductive dysfunctions  
Natalia Aganezova, Russia

P107 Endometrial leukemia inhibitory factor expression in women with reproductive dysfunctions  
Natalia Aganezova, Russia

P108 Ovarian teratoma causing recurrent syncope and anti-N-methyl-D-aspartate receptor encephalitis  
Marrwah Ahmadzai, Australia

P109 Preeclampsia: Updates in definitions and guidelines  
Ayse Akalin, Turkey

P110 The relationship of ovarian reserve and autoimmune thyroid disease in women of reproductive age  
Elena Andreeva, Russia

P111 Metabolic disorders and therapeutic options for polycystic ovary syndrome with concomitant thyroid pathology  
Elena Andreeva, Russia

P112 Higher serum levels of vitamin D are associated with lower blood glucose levels  
Tania Andriolli, Brazil

P113 Molecular changes in uterine leiomyomas in myomectomy patients  
Anna Ayravainen, Finland

P114 The curious case of a deviant mole: A case of an invasive mole metastatic to the ovary  
Julienne Katrina Beltran, Philippines

P115 Pelvic floor dysfunction after vaginal delivery: A prospective study  
Ana Catarina Borges, Portugal

P116 Myo-inositol effects on metabolic and hormonal parameters and body composition in women with polycystic ovary syndrome  
Galina Chernukha, Russia

P117 Why are we admitting women with acute abnormal bleeding? – One-year experience  
Carolina Costa Gomes, Portugal

P118 A rare case of thoracic diaphragmatic endometriosis invading the liver and lower lobe of lungs  
Azal El Adwan, UK

P119 Effects of flexible extended regimens of oral contraceptives on the vaginal environment  
Rushania Gabidullina, Russia

P120 Pelvic inflammatory disease as atypical presentation of rectal cancer  
Rita Gomes, Portugal

P121 Preserving the uterus in an infertile woman with complex atypical endometrial hyperplasia  
Rita Gomes, Portugal

P122 Treatment of patient with uterine fibroid using focused ultrasound surgery - Clinical case  
Yoana Ivanova, Bulgaria

P123 Pseudoaneurysm of the uterine artery after abdominal bilateral salpingo-oophorectomy caused by tubo-ovarian abscess  
Dahye Ju, South Korea

P124 Climacteric syndrome with psychoemotional load in women  
Nigar Kamilova, Azerbaijan

P125 Pseudoaneurysm: An unusual cause of secondary postpartum haemorrhage  
Whui Whui Lim, Singapore
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>P126</td>
<td>Venous thromboembolisms following laparoscopic hysterectomy for benign disease in a Danish cohort</td>
<td>Hanneh L Mengu</td>
<td>Denmark</td>
</tr>
<tr>
<td>P127</td>
<td>Pregnancy after hysterectomy: A case report from Hanoi Obstetrics and Gynecology Hospital and literature review</td>
<td>Toan Nguyen</td>
<td>Vietnam</td>
</tr>
<tr>
<td>P128</td>
<td>Results of hormonal and ultrasound examination in chronic salpingo-oophoritis</td>
<td>Nigar Kamilova</td>
<td>Azerbaijan</td>
</tr>
<tr>
<td>P129</td>
<td>Calcium and vitamin D intakes from dietary sources and physical activity women in peri-and post-menopause</td>
<td>Dragica Odalovic Markovic</td>
<td>Serbia</td>
</tr>
<tr>
<td>P130</td>
<td>Hysteroscopic isthmoplasty as treatment for abnormal uterine bleeding, pelvic pain and secondary infertility - Brief review from a case report</td>
<td>Maria Prat Om</td>
<td>Spain</td>
</tr>
<tr>
<td>P131</td>
<td>Physiotherapeutic approach of dyspareunia in women with chronic pelvic pain: Comparison between two techniques. A randomized clinical trial</td>
<td>Ana Carolina Rosa-E-Silva</td>
<td>Brazil</td>
</tr>
<tr>
<td>P132</td>
<td>Women with chronic pelvic pain have worse pelvic floor muscle performance</td>
<td>Ana Carolina Rosa-E-Silva</td>
<td>Brazil</td>
</tr>
<tr>
<td>P133</td>
<td>Ashi acupuncture and local anesthetic injection have similar efficacy in the treatment of abdominal myofascial pain syndrome in women: a randomized clinical trial</td>
<td>Julio Rosa-E-Silva</td>
<td>Brazil</td>
</tr>
<tr>
<td>P134</td>
<td>Effect of diazepam on facilitating the placement of devices during tubal sterilization procedure by hysteroscopy: A randomized controlled trial</td>
<td>Julio Rosa-E-Silva</td>
<td>Brazil</td>
</tr>
<tr>
<td>P135</td>
<td>Hysteroscopic surgery for submucosal fibroids performed in consideration of the myoma pseudocapsule</td>
<td>Juichiro Saito</td>
<td>Japan</td>
</tr>
<tr>
<td>P136</td>
<td>The management of patients with premature ovarian failure</td>
<td>Zinaida Sarbu</td>
<td>Moldova</td>
</tr>
<tr>
<td>P137</td>
<td>Photodynamic therapy of chronic endometritis in infertility</td>
<td>Klara Serebrennikova</td>
<td>Russia</td>
</tr>
<tr>
<td>P138</td>
<td>A rare case of perineal scar endometriosis extending up to the internal anal sphincter</td>
<td>Umme Farwa Shah</td>
<td>UK</td>
</tr>
<tr>
<td>P139</td>
<td>Uterine necrosis following selective embolization for postpartum hemorrhage: Report of four cases and review of literature</td>
<td>Yeun Joo Shin</td>
<td>South Korea</td>
</tr>
<tr>
<td>P140</td>
<td>Controversial outcome in two different GTD with same sonographic image: A case report</td>
<td>Dragutin Sretenovic</td>
<td>Serbia</td>
</tr>
<tr>
<td>P141</td>
<td>Leiomyosarcoma in pregnancy – Incidental finding of leiomyosarcoma during caesarean section</td>
<td>Toon Wen Tang</td>
<td>Singapore</td>
</tr>
<tr>
<td>P142</td>
<td>Method of surgical treatment of prolapse of the anterior pelvic floor with titanium implant</td>
<td>Iuliia Tarasenko</td>
<td>Russia</td>
</tr>
<tr>
<td>P143</td>
<td>Transvaginal surgical prevention for posthysterectomy prolapse of vaginal dome in patients with complete uterine prolapse</td>
<td>Iuliia Tarasenko</td>
<td>Russia</td>
</tr>
<tr>
<td>P144</td>
<td>A rare case of genital tuberculosis presenting as a vulvovaginal ulcer in a 12 year old female</td>
<td>Kara Angelique Valles</td>
<td>Philippines</td>
</tr>
<tr>
<td>P145</td>
<td>Unicornuate uterus with functional rudimentary horn: Diagnostic problems</td>
<td>Nataliya Veresnyuk</td>
<td>Ukraine</td>
</tr>
<tr>
<td>P146</td>
<td>Outcomes of two patients with strumae ovarii in dermoid tumours</td>
<td>Wanxuan Wang</td>
<td>Singapore</td>
</tr>
<tr>
<td>P147</td>
<td>Possibilities of application of interferon Alpha-2β in combined treatment of patients with genital endometriosis</td>
<td>Maria Yarmolinskaya</td>
<td>Russia</td>
</tr>
<tr>
<td>P148</td>
<td>The role of neurokinin B in the pathophysiological mechanisms of vasomotor symptoms and sleep disorders in postmenopausal women</td>
<td>Svetlana Yureneva</td>
<td>Russia</td>
</tr>
<tr>
<td>P149</td>
<td>Study on the mechanism of lysyl oxidases family in endometrial fibrosis after injury</td>
<td>Lan-Mei Zhang</td>
<td>China</td>
</tr>
<tr>
<td>P150</td>
<td>Y – Graft application in the repair of pelvic floor functional disease of department of gynecology study</td>
<td>Yudi Zhang</td>
<td>China</td>
</tr>
</tbody>
</table>
### HPV

<table>
<thead>
<tr>
<th>Paper ID</th>
<th>Title</th>
<th>Authors</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>P151</td>
<td>P16/Ki67 expression and the applicability through different ages</td>
<td>Sara Bernardes Da Cunha</td>
<td>Portugal</td>
</tr>
<tr>
<td>P152</td>
<td>Medical providers’ attitude toward HPV vaccination, Israel, 2017</td>
<td>Haneen Jeries-Ghantous</td>
<td>Israel</td>
</tr>
<tr>
<td>P153</td>
<td>Prevalence of high-risk HPV and its distribution in cervical pre-cancerous lesions among 35-64 years old women who received cervical cancer screening in Beijing</td>
<td>Wang Jiandong</td>
<td>China</td>
</tr>
</tbody>
</table>

### OTHER

<table>
<thead>
<tr>
<th>Paper ID</th>
<th>Title</th>
<th>Authors</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>P154</td>
<td>Significant pubic symphysis diastasis following kiwi cup delivery: Report of a severe case</td>
<td>Marrwah Ahmadzai</td>
<td>Australia</td>
</tr>
<tr>
<td>P155</td>
<td>Evaluation of the utilization of thromboprophylaxis in out-patient pregnant women at SQUH</td>
<td>Rahma Al-Haddabi</td>
<td>Oman</td>
</tr>
<tr>
<td>P156</td>
<td>A case of necrotising fascitis post-emergency caesarean section: A rare complication of a common procedure</td>
<td>Kawthar Barkat</td>
<td>Australia</td>
</tr>
<tr>
<td>P157</td>
<td>Preimplantation genetic diagnosis (PGD) for Duchenne Muscular Dystrophy (DMD) using multiplex nested PCR: A single medical center experience and evolution along sixteen years</td>
<td>Asaf Bilgory</td>
<td>Israel</td>
</tr>
<tr>
<td>P158</td>
<td>A pilot study of HCG point of care testing: Thinking outside the lab</td>
<td>Azal El Adwan</td>
<td>UK</td>
</tr>
<tr>
<td>P159</td>
<td>Unexpected appendicular malignancy in a transgender man on exogenous testosterone supplementation</td>
<td>Nandini Halder</td>
<td>UK</td>
</tr>
<tr>
<td>P160</td>
<td>Aplasia cutis congenita hereditary form - Case report</td>
<td>Yoana Ivanova</td>
<td>Bulgaria</td>
</tr>
<tr>
<td>P161</td>
<td>Persistent rise of BHCG after complete surgical treatment of ectopic pregnancy - Case report and review of literature</td>
<td>Neeraja Jampana</td>
<td>UK</td>
</tr>
<tr>
<td>P162</td>
<td>Secondary postpartum hemorrhage: Incidence, etiologies and clinical courses in the setting of high cesarean delivery rate</td>
<td>Deeonngkij Kittiyi</td>
<td>Thailand</td>
</tr>
<tr>
<td>P163</td>
<td>The prognosis of pregnancy in patients with recurrent abortion whose chromosomes show “46,XX/45,X mosaicism”</td>
<td>Taro Nonaka</td>
<td>Japan</td>
</tr>
<tr>
<td>P164</td>
<td>Elastography and electromyography assessment of the pelvic floor muscle after deep electromagnetic field stimulation: A randomized, placebo-controlled study</td>
<td>Kuba Ptaszkowski</td>
<td>Poland</td>
</tr>
<tr>
<td>P165</td>
<td>Reducing cardiovascular risks with the combined oral contraceptive pill: Can we improve our general practice services?</td>
<td>Devyani Shete</td>
<td>UK</td>
</tr>
<tr>
<td>P166</td>
<td>Measuring the cerebellum – A growth curve in a specific population</td>
<td>Flávia Vicente</td>
<td>Portugal</td>
</tr>
<tr>
<td>P167</td>
<td>Interoperator variability in fetal ultrasound measurements in a Portuguese prenatal diagnosis center</td>
<td>Flávia Vicente</td>
<td>Portugal</td>
</tr>
<tr>
<td>P168</td>
<td>Inherited thrombophilia in pregnant patients: Relationship between thrombophilia and early pregnancy loss</td>
<td>Diana Voicu</td>
<td>Romania</td>
</tr>
</tbody>
</table>
Abstracts
INVITED SPEAKER ABSTRACTS

THE DOMINANT EMBRYO ROLE IN MAMMALIAN REPRODUCTION
Eytan R. Barnea, MD FACOG

Reproduction is an active/interactive act. From spawning by fish until mammalian reproduction. In water sperm penetrates the egg leading to zygote formation and further until adult fish develops. Intrabody fertilization from insects, to bird laying eggs to develop outside the body until hatching. In marsupials intrabody fertilization is followed by migration of the embryo to the pouch until delivery. In mammals the entire reproduction is intrabody and the conceptus stays there until delivery. Throughout evolution, the sperm has a primary active role while the egg is silent until fertilization has occurred. Post-fertilization, the situation changes dramatically since the fertilized egg takes the leading role. The cells start dividing and are in a search of a site to implant. In marsupials where implantation period is short and the embryo gets into the pouch, in mammals it is from start from conception until delivery. This clearly indicates that implantation is an aggressive act. As nature taught us, implantation preferentially occurs in the maternal endometrium. However, it can implant elsewhere as well: in the tube, ovary, abdominal cavity even under the spleen. Pregnancy was reported (extremely rarely) even without a uterus. Therefore, the zygote in this instance takes the leading role where the maternal system ie. endometrium becomes a more receptive environment that is conditioned by the presence of the viable embryo. ART techniques have taught us that conditioning of the maternal environment by hormones is not sufficient, since embryo viability signaling must be present for implantation to occur. What makes the embryo the dominant player in the embryo maternal equation? Embryo-driven signaling emitted by the viable embryo MUST occur from the earliest stages of development starting from the first step of post-fertilization. This is necessary since the maternal environment needs to adapt to the incoming embryo though a process of priming. This is evidenced by the normal fertilization where the process takes a 5-7 days for implantation take place, while in ART/IVF following embryo transfer a similar time is required. This indicates that embryo signaling must be present in both circumstances. What required for maternal recognition of pregnancy is a viable embryo that emits specific signaling (not found outside pregnancy). Such signal effect must be both local and systemic, integrated to create tolerance, preserved antipathogen activity and maternal preference for the incoming embryo. Once pregnancy occurs, it is followed by maternal adaptation to pregnancy. Our focus has been to identify embryo-specific compounds that enable initiating and maintaining an effective embryo maternal interaction from recognition to adaptation to successful reproduction. To support the embryo-driven premise we present that PIF (the Preimplantation Factor) through autotrophic and protective effect aids the embryo development precisely at recognition (2cell onward) to adaptation and, when necessary in reducing adverse environment. As for the endometrium it helps in priming, implantation and post-implantation and protecting against pregnancy loss. As for immune system it promotes immune homeostasis. Overall data supports the embryo-driven dominance in maternal responsive hypothesis.

SCREENING OF THE MAN FOR INFERTILITY
Christopher Barratt, UK

Introduction to session
Approximately 1 in 20 young men today have sperm counts low enough to impair fertility, whereas this may not have been the case historically. The cause(s) of such a decline in male reproductive health is unknown, despite it being a global health issue. Concomitantly, little progress has been made in answering fundamental questions in andrology or in developing new diagnostic tools or alternative management strategies to ICSI in infertile men. We advocate formulation of a detailed roadmap for male reproductive health to facilitate development of a research agenda that highlights the present unmet needs and key unanswered questions, and seeks to deliver effective funding and investment to address them. This vision we term ‘a Male Reproductive Health Ecosystem’.

GnRH AGONISTS AND IVF: THE END... OR NOT?
Joelle Belaisch Allart, Tania Ghomashi, Irene Grefenstette, Negar Khalorpour, Jean marc Mayenga Yacien Belaid et Olivier Kulski.
Centre Hospitaller des 4 Villes rue Charles Lauer 92210 Saint Cloud France

In many congresses devoted to Assisted Reproductive Technologies (ART), the use of long GnRH agonist protocols for pituitary desensitization and prevention of premature LH discharge is presented as an antiquated attitude, totally outdated, and only the use of antagonist, modern technique, is advocated. Paradoxically in the same congresses during the presentations that are not devoted to the stimulation of ovulation or in the published articles it is amusing to discover in the paragraph “material and methods” that the agonists are still very used! GnRH analogues are criticized for being a “non-friendly” stimulation because the number of subcutaneous injections would be infinitely higher than with an antagonist forgetting that if one uses the nasal route (whose efficiency equal to the way subcutaneous is demonstrated) the number of days with subcutaneous injections of gonadotropins is exactly the same for agonists and antagonists. We forget too much that in the public centers we are kindly requested by the administration and by the anesthesiologists not to use the operating room at the weekend and to program our oocytes retrievals from Monday to Friday, which is infinitely easier with agonist protocols than with antagonists. It is also forgotten that as far as women have normal response to ovarian stimulation, the pregnancy rates remains better, not always significantly, this is true, with the agonist analogues, as Lambalk’s meta-analysis has just shown (1) : « In a general IVF population, GnRH antagonists are associated with lower ongoing pregnancy rates when compared to long protocol agonists, but also with lower OHSS rates. Within this population, antagonist treatment prevents one case of OHSS in 40 patients but results in one less ongoing pregnancy out of every 28 women treated. Thus, standard use of the long GnRH agonist treatment is perhaps still the approach of choice for prevention of premature luteinization, “. It is certain that the antagonists protocols have for them a lower hyperstimulation rate, it is certain that there is any interest in using them for women with polycystic ovaries or women whose ovaries respond too well to gonadotropins, but for other women to date, it has not been demonstrated that antagonistic protocols are preferable either in terms of pregnancy rate or in terms of comfort.In conclusion the long agonist protocol is not dead! Lambalk CB,Banga F, Huyme J, Tolfager M, Pinborg A, Veen R, van der Veen F, va Wely M. GnRH antagonist versus long agonist protocols in IVF: a systematic review and meta-analysis accounting for patient type. Hum Reprod Update 207;23:560-570.
IVF is a multi-stages procedure with many variables that can each succeed or fail with no real good explanation. The term repeated implantation failure (RIF) is a misnomer, since not every failure is due to implantation or to one reason only. Furthermore, implantation failure is common, so even after 3 failures the chances for success are still very good. Patients need to persevere after failure not to change course by using all kinds of common unproven add-ons procedures. With the professional revelation of the true results of almost all add-ons, comes the negative attention in the lay media and not surprising the first couple suing over “worthless unproven extras” that was registered in England. Add-ons offers to so called “RIF” a costly “better way” to reach better results after few failures. Repeated failure, is also the preferred group to recruit patients to research studies, randomized or not, to prove that a certain add-on is effective. But what is RIF? Does it exist? Treatment protocol, lab work, quality of gametes and embryo, quality of endometrium, women age, and luteal support, all constantly changing, hence we can rephrase the famous Greek expression as follows “No women can have the same IVF treatment cycle twice… for it is not the same women and it is not the same IVF cycle”. If RIF does not exist what are the consequences on the studies that are based on them? Different authors have selected different definition. The more commons published definitions, are failure to achieve an ultrasonographically detectable pregnancy in women less than 40 years with at least 3 -4 ET or up to 4-10 good quality embryos, or 4 blastocyst or even after two failed cycles, or after 2 ET. The fact that know society have stepped in to the challenge to define RIF is interesting. The different definitions are usually not explained in the publication. However, some used the presumed maximal implantation rate (IR) per embryo in optimal situation like oocyte donation and natural conception that are claimed to reach 40%. However, extrapolation of large data base like the ESHRE registry encompassing all European countries show substantially lower IR 17.7%. (H.R. 2017 Cahilaz-Jorge ESHRE registry 2013), so 3-4 failure should be very common and probably does not require any change in plan in the next cycle, certainly not of os tested procedures. Using a mathematical model, Somigliana et al (RBMO, 2017) have shown that assuming 30% implantation rate, the cumulative chances of pregnancy after 3 or 6 cycles was 59% and 79%, respectively, consequently, the false-positive rate of a diagnosis of RIF after 3 or 6 failed cycles is 75% and 51%, respectively attesting to the fact that no change in treatments or addition to the treatment should be offered. That said, the results of the study and control groups after 3-4 ET should not be much different than the preceding cycle. But this is not the case. control groups of so-called RIF, inexplicably tend to present very low results even after 1-2 failures compared to the study group. Undoubtedly, every failure is stressful for the patient and care givers. The majority of failed IVF do not need re-evaluation of their clinical diagnosis and status since they probably had gone through comprehensive evaluation and go through minor changes and accommodation after every cycle. Patients who are exposed to endless lay-press stories and publication fear that they have been misdiagnosed or mistreated, while physician who are in constant competition in this highly privatized sector fear that the failure will result in drop-out, so both side are ready to grasp in subsequent cycles, every new procedure or protocols, that might be offered even if not proven. We will discuss all of these common add-on’s solutions like PGS, endometrial scratching, freeze only, assisted hatching, and newly launched ERA test, all of which are used in an effort to increase success, but actually all of them are unproven and some were also suggested to have damaging effect.

PREVENTION OF SPONTANEOUS PRETERM BIRTH: GUIDELINES FOR CLINICAL PRACTICE BASED ON THE FRENCH COLLEGE OF GYNAECOLOGISTS AND OBSTETRICIANS (CGOF)


In France, 60,000 neonates are born preterm every year (7.4%), half of them after the spontaneous onset of labor. Among preventable risk factors of spontaneous prematurity, only cessation of smoking is associated with decreased prematurity (level of evidence [LE]1). It is therefore recommended (Grade A). Routine screening and treatment of vaginal bacteriosis is not recommended in the general population (Grade A). The only population for which vaginal progesterone is recommended is that comprising asymptomatic women with singleton pregnancies, no history of preterm delivery, and a short cervix at 16-24 weeks of gestation (Grade B). A history- indicated cerclage is not recommended for women with only a history of conization (Grade C), uterine malformation (professional consensus), isolated history of preterm delivery (Grade B), or twin pregnancies for primary (Grade B) or secondary (Grade C) prevention of preterm birth. A history-indicated cerclage is recommended for a singleton pregnancy with a history of at least 3 late miscarriages or preterm deliveries (Grade A).

Ultrasound cervical length screening is recommended between 16 and 22 weeks for women with a singleton previously delivered before 34 weeks gestation, so that cerclage can be offered if cervical length <25mm before 24 weeks (Grade C). A cervical pessary is not recommended for the prevention of preterm birth in a general population of asymptomatic women with twin pregnancies (Grade A) or in populations of asymptomatic women with a short cervix (professional consensus). Although the implementation of universal screening by transvaginal ultrasound for cervical length at 18-24 weeks of gestation in women with a singleton gestation and no history of preterm birth can be considered by individual practitioners, this screening cannot be universally recommended. In cases of preterm labor, (i) it is not possible to recommend any one of the several methods (ultrasound of the cervical length, vaginal examination, or fetal fibronectin assay) over any other to predict preterm birth (Grade B); (ii) routine antibiotic therapy is not recommended (Grade A); (iii) prolonged hospitalization (Grade B) and bed rest (Grade C) are not recommended. Compared with placebo, tocolytics are not associated with a reduction in neonatal mortality or morbidity (LE2) and maternal severe adverse effects may occur with all tocolytics (LE4). Ato西班 and nifedipine (Grade B), unlike beta-agonists (Grade C), can be used for tocolysis in spontaneous preterm labor without preterm premature rupture of membranes. Maintenance tocolysis is not recommended (Grade B). Antenatal corticosteroid administration is recommended for all women at risk of preterm delivery before 34 weeks of gestation (Grade A). After 34 weeks, the evidence is insufficiently consistent to justify recommending systematic antenatal corticosteroid treatment (Grade B), but a course of this treatment might be indicated in clinical situations associated with high risk of severe respiratory distress syndrome, mainly in cases of planned cesarean delivery (Grade C). Repeated courses of antenatal
corticosteroids are not recommended (Grade A). Rescue courses are not recommended (Professional consensus). Magnesium sulfate administration is recommended for women at high risk of imminent preterm birth before 32 weeks (Grade A). Cesareans are not recommended for fetuses in vertex presentation (professional consensus). Both planned vaginal and elective cesarean delivery are possible for breech presentations (professional consensus). Delayed cord clamping may be considered if the neonatal or maternal state allows (professional consensus).

THE NUMBERS OF 2-5 AND 6-9-MM OVARIAN FOLLICLES ARE INVERSELY CORRELATED IN BOTH NORMAL WOMEN AND IN POLYCYSTIC OVARY SYNDROME PATIENTS: WHAT IS THE MISSING LINK?

Catherine-Jonard S, Peigné M, Robin G, Dumont A, Pigny P, Dewailly D

What is known already and objective: Previous reports described a direct negative correlation between the number of small antral follicles (2-5 mm) and large antral follicle (6-9 mm) during the early follicular phase (cycle Days 2-5) in normal and PCOS women. Numerous factors, that could be either intrinsic to the ovary or secondary to metabolic influence and/or gonadotropin regulation, might account for this. Is the negative correlation between the numbers of 2-5 and 6-9 mm follicles influenced by ovarian and/or metabolic parameter(s) in young control women and in patients with polycystic ovarian syndrome (PCOS)? Study design, materials and methods: Six hundred and thirty-nine patients with PCOS according to Rotterdam Criteria and 157 control women were recruited in this retrospective cross-sectional study from January 2009 to January 2016. Data were obtained from a database of clinical, hormonal and ultrasound (U/S) features recorded consecutively in a single reproductive medicine center. Univariate correlations between the various parameters were analysed by the Spearman's correlation test. All variables significantly related to the 2-5 and/or 6-9 mm follicle numbers were included in a principal component analysis (PCA) in order to structure the data and to obtain collections of uncorrelated variables, called principal components (PC), which are linear combinations of the original variables. Results: By univariate analysis, we describe an strongly independent negative correlation between the 2-5 and 6-9 mm follicle numbers, both in populations. In PCOS women, this relationship is preserved and amplified. Many other variables were correlated to the 2-5 and/or 6-9 mm follicle numbers and to each other. By PCA, these relationships were gathered into four independent PCs in each population. In both groups, the 2-5 and 6-9 mm follicle numbers correlated strongly and inversely to the other variables tested, only serum oestradiol level correlated weakly to this PC in the control group. Two other uncorrelated PCs gathered relationships between variables linked to the metabolic status and the gonadotropin regulation both in control and PCOS women. Lastly, a fourth PC included relationships which linked to ovarian ageing in controls and to follicle dysregulation in patients with PCOS. Discussion: In PCOS women, the negative relationship between the 2-5 and 6-9 mm follicle numbers is preserved and amplified, probably due to 2-5 mm follicular excess, but this does not seem to play a role in the follicular arrest leading to oligo-anovulation. None of the classical hormones implicated in the follicular growth (AMH, FSH, LH, E2, TT) and no parameter of the metabolic status (BMI, WC, Insulin) seem to be involved in this phenomenon. We hypothesize that the oocyte is involved in the equilibrium between both follicle numbers through factor(s) that still need to be identified. Our study confirmed that the negative correlation between numbers of follicles sized 2-5 and 6-9 mm was stronger in PCOS than in young control women and was not linked to any ovarian or metabolic parameter.

FERTILITY AND MANAGEMENT OF PATIENTS WITH TURNER SYNDROME

Bruno Donadille1, Valérie Bernard1, Mariana Nedelcu1, Sophie Christin-Maitre1,2

1Hôpital Saint-Antoine, APHP, Center for Rare Diseases 2 UMR S933, Sorbonne University, Paris, France

Tumor syndrome (TS) is a rare condition associated with a complete or partial loss of one X chromosome. It affects 1/2500 female newborns. Most women with TS (95%) have primary ovarian insufficiency (POI), defined as an amenorrhea or severe oligo-menorrhea with an FSH level higher than 25 IU/L and low serum estradiol level, occurring before the age of 40. Therefore, most women with TS desiring a pregnancy will need assisted reproductive technologies (ART) with oocyte donation (OD). Few studies have evaluated the rate of natural pregnancies in TS patients. It ranges from 4 to 7% of TS patients. In our study, including 480 TS patients, 27 women (5.6%) had a total of 52 pregnancies, with 30 full-term delivey two for 18 women. The two predictive factors which correlated with occurrence of spontaneous natural pregnancy were described a direct negative correlation between the number of small antral follicles (2-5 mm) and large antral follicle (6-9 mm) during the early follicular phase (cycle Days 2-5) in normal and PCOS women. In controls and to follicle dysregulation in patients with PCOS. The overall rate of PHD is around 30 to 50% of pregnancies with TS. When a patient with TS is desiring a pregnancy, a multidisciplinary screening is mandatory before initiating the pregnancy. It includes blood pressure measurements and biological testing evaluating thyroid, liver functions as well as glycaemia. An aortic MRI should be performed within the 2 years before the beginning of the pregnancy. It should evaluate the aortic diameters at the level of the aortic cusps, Valsalva sinuses, supra-aortic ridge and proximal ascending aorta. All diameters should be indexed to the body surface area. Pregnancy should be avoided in case of pregnancies with TS. When a patient with TS is desiring a pregnancy, a multidisciplinary screening is mandatory before initiating the pregnancy. It includes blood pressure measurements and biological testing evaluating thyroid, liver functions as well as glycaemia. An aortic MRI should be performed within the 2 years before the beginning of the pregnancy. It should evaluate the aortic diameters at the level of the aortic cusps, Valsalva sinuses, supra-aortic ridge and proximal ascending aorta. All diameters should be indexed to the body surface area. Pregnancy should be avoided in case of an ascending indexed aortic diameter > 25 mm/m² alone or between 20 and 25 mm/m² with associated risk factors for dissection. Those factors are the presence of a bicuspid aortic valve, an aortic coarctation and an uncontrolled hypertension. Heart echography should be performed during each trimester and even one to two months after the delivery. In order to make the pregnancy safe, identification of high-risk patients of cardiovascular events should be performed. Hypertension and pre-eclampsia prevention may benefit from beta-blockers and aspirin, respectively. Collaborations between endocrinologists, cardiologists and obstetricians are mandatory during pregnancy and even in the post-partum period in TS patients. Patients should be referred to reference centers of rare diseases. Counseling them about the risks of pregnancy, screening them and spreading the international guidelines to physicians taking care of patients with TS are the three pillars of a safe pregnancy.
TREATMENT OF ADVANCED BREAST CANCER WITH HIGH DOSE ESTROGENS
Herjan JT Coelighn Bennink
Pantarhei Oncology, Zeist, the Netherlands

Estrogens are known to stimulate the growth of existing estrogen-receptor positive BC, but estrogens are also an effective treatment of BC under special conditions. This contradictory knowledge is known as the “estrogen paradox.” The data summarised in this presentation demonstrate that high-dose estrogens is an effective treatment of advanced breast cancer after the occurrence of resistance to endocrine anti-estrogen treatment. Essential for efficacy is an extended period of estrogen deprivation before the tumour is subjected to estrogen treatment (the “gap hypothesis”). However, high-dose estrogens (HDE) have been abandoned for BC treatment because of cardiovascular side-effects. High dose estrol (HDE) may be a new treatment option for patients with advanced breast cancer, since this fetal estrogen has less interference with liver function and is expected to be less harmful for the CV system, whereas data from non-clinical and clinical studies suggest anti-breast tumor effects. A phase IB/IIA, dose-escalation, safety and proof of concept study with high doses of E4 has been performed in Germany in postmenopausal patients with advanced ER+/HER- breast cancer. The study has been completed clinically and the preliminary anti-tumor and quality of life results will be presented, confirming the “Dual Efficacy” concept of high dose E4 in advanced breast cancer.

COUNSELING WOMEN WITH UTEROVAGINAL ANOMALIES
George Creatsas, MD FACS, FRCOG, FACOG, Greece

Uterovaginal anomalies have a prevalence of 1 in 4000 females and are usually found as a clinical feature of the Mayer-Rokitansky-Küster-Hauser syndrome. Primary amenorrhea during adolescence is the prominent symptom. Diagnosis is confirmed by the ultrasonography, the gynecological examination under anesthesia and the laparoscopy. An intravenous pyelography is also suggested to exclude urogenital anomalies, which coincide in 40% of the cases. The management of the patients, along with the proper psychological support and reassurance, includes the creation of a neovagina during adolescence to offer them the opportunity for a normal sexual life. Several, non-surgical and surgical techniques, have been proposed for the creation of a neovagina as the Creatsas vaginoplasty, the Frank method and its modification by Ingram, the McIndoe operation, the Wiliam’s vaginoplasty, the Vechielli procedure and its laparoscopic modification and others. Following the appropriate consultation, the fertility preservation is the main goal in case that the uterus or part of this is present. Otherwise the surrogate uterus or the uterine transplantation are proposed. Creatsas vaginoplasty is a simple, fast and safe technique that has been applied around the world in 304 cases over the last 28 years, providing excellent results in the vast majority of the patients. The technique (video presentation) last no more than 20 minutes and the mean hospital stay is approximately 4 days. The relative results (case reports) are included in this presentation. The above should be proposed to the patient by expert colleagues mainly in Pediatric and Adolescent Gynecological Centers following a careful explanation, usually in front of the parent(s).

THE MALE REPRODUCTIVE HEALTH INITIATIVE (MRHI)
Christopher J. De Jonge, Ph.D., HCLD
Director, Andrology Program, University of Minnesota Medical Center; Adjunct Professor; Department of Urology, University of Minnesota, Minneapolis, MN USA

Male reproductive health is globally in crisis and worsening in the virtual absence of effective healthcare policies, research funding, societal awareness and education. Evidence of a significant gender gap in healthcare policies and initiatives demonstrates the urgent and critical need for global gender-inclusive healthcare strategies. Men on average live sicker and have a shorter life expectancy as compared to women. Contributing factors include reluctance of men to seek health care advice and treatment and, in general, unhealthy lifestyle factors. Social norms can play a positive role in help-seeking if, for example, a partner or family member suggests that the man have a routine physical exam and he sees other men doing the same. The disparity in life expectancy between male and female has tremendous impact not only on the family and community but also the economy. In the US, many hundreds of billions of dollars are spent by federal, non-federal and employer-supported health plans to support male chronic disease. Effecting change in male attitude from reluctance to active and regular participation in health care seeking would likely result in lower morbidity and mortality and, as a consequence, a very substantial monetary savings to national and global economies. Economics is not the only benefit to come from men more actively seeking health care. For couples experiencing infertility, the male factors in to 40% of the cause of infertility yet very often he lacks a current health and lifestyle profile much less a reproductive health profile. Absence of early diagnosis and treatment for a reproductive health issue or comorbidity can result not only in greater health care cost but, importantly, often places the burden of infertility treatment solely upon the woman. Thus, men’s health extends beyond just the individual; men’s health is very much a women’s health issue and a baby-bom health concern as well. Teenage and young adult men typically have limited reproductive health care needs that require medical attention. However, a portent of potentially significant male reproductive health issues is the global decline in sperm counts. In parallel with sperm count decline is an equally unsettling and persisting upward trend in male reproductive system abnormalities, such as cryptorchidism, germ cell tumors and onset of puberty. Associated significant health conditions include diabetes mellitus, metabolic disorders and cardiovascular disease. There is an increasing trend of couples delaying family-building until later in life and advanced paternal age at time of conception is causing significant concern. Danish birth and death registry data show a correlation between increased paternal age (>40) and 1) increased risk of < 5-year-old child mortality, and 2) greater risk to < 15 years old adolescent children of developing acute lymphoblastic leukemia. Moreover, Arslan and colleagues investigated three pre-industrial western populations and found evidence for a transgenerational paternal age effect on both decreased offspring survival and decreased ability of surviving offspring to reproduce. They concluded that paterally driven de novo single nucleotide mutations “reduce offspring fitness across populations and time periods”. The parallel between reduced offspring reproductive health and globally declining sperm count may not be coincidental. It could be reflective of a mutually related reproductive epidemic. Evidence is accumulating that paternal lifestyle is driving transgenerational genomic imprinting and epigenetic alterations. The sperm epigenome is uniquely complex and susceptible to environmentally-associated modification in part because there are developmental points of susceptibility, i.e., paternal embryonic development, spermatogenesis and...
offspring early embryonic development. Paternal age, smoking, obesity and other life factors, such as pollution, have been implicated as influencing the development and wellness of offspring. Paternal obesity is associated with increased body fat in prepubertal offspring, increased risk of offspring developing metabolic syndrome spectrum disorder and, on a molecular level, influences the methylation pattern of specific loci of imprinting genes in offspring.\(^6\) Cigarette smoking is considered to be a male fertility risk factor. Smoking has perhaps its greatest negative impact on genome integrity where a majority of publications report some level of smoking related damage to the genome, e.g., increased DNA fragmentation and aneuploidy. Furthermore, paternal preconception smoking significantly increases cancer risk in offspring. In vitro fertilization (IVF) is a multi-billion-dollar global industry responsible for the birth of millions of babies that otherwise might not have been born. Male infertility, which is diagnosed in approximately 40% of couples, is associated with impaired DNA methylation patterns. In more severe forms of male infertility, e.g., obstructive and non-obstructive azoospermia, the technique of intracytoplasmic sperm injection (ICSI) is used to inject into the oocyte a single spermatozoon judged by the ICSI operator as ‘alive and well’. Alarming, there is an association between IVF-ICSI and imprinting disorders in offspring, such as Beckwith–Wiedemann and Angelman syndromes. Approximately 25% of males in an infertile couple do not undergo a male reproduction evaluation. Complicating matters is almost 20–30% of men evaluated for (in)fertility will have no definitive diagnosis. A recent case-control study reported an association between aberrant methylation of imprinted genes and idiopathic infertility. However, no follow-up on offspring born has been reported. Therefore, the possibility exists that an unknown percentage of children born to fathers without a fertility diagnosis may have occult paternally transmitted imprinting errors – and these children may in turn transmit the errors to their future offspring. The increasing use of ART-ICSI has digitized the diagnostic role of semen analysis, i.e., sperm presence/absence. Significantly, an ICSI-all approach to IVF removes the couple-shared burden of infertility treatment and places it solely on the woman. As a consequence, she becomes potentially and unnecessarily exposed to greater health and emotional risk. An additional impact of ICSI has, in many ways, lessened the need to investigate sperm function and requirements for fertilization; thus diminishing funding in these basic research areas. This is significant because enhancing that knowledge affords better opportunities for developing male infertility diagnostic tools and therapeutic interventions. These critically essential elements should serve to invigorate funding agencies and policy makers to refocus allocation of funds to stimulate and support significantly greater investigation into male reproductive health.

**Summary:** Numerous scientific reports provide evidence for a growing global crisis in male reproductive health that is linked to overall health. Further, emerging data demonstrate that the reproductive health of the father impacts the wellness of offspring and grand-offspring. These male-borne health issues, largely unknown by the general population, are increasing at an alarming rate and demand urgent action. Given the link between reproductive and somatic health, a new male preventive health care paradigm is proposed for early teens and young adults, embraced by payors, and that combines an annual physical with a reproductive health exam, including semen analysis, to ensure routine medical examination during a medically vulnerable period due to infrequent health seeking by those age groups. To secure the proposed paradigm shift requires the demand not only from men but society as a whole. Men, their families and society, by in large, are naïve to men but society as a whole. Men, their families and society, proposed paradigm shift requires the demand not only from including semen analysis, to ensure routine medical health and emotional risk. An additional impact of ICSI has, in many ways, lessened the need to investigate sperm function and requirements for fertilization; thus diminishing funding in these basic research areas. This is significant because enhancing that knowledge affords better opportunities for developing male infertility diagnostic tools and therapeutic interventions. These critically essential elements should serve to invigorate funding agencies and policy makers to refocus allocation of funds to stimulate and support significantly greater investigation into male reproductive health.

**OVARIAN STIMULATION: MORE IS BETTER**

D. de Ziegler, P. Pirtea, C. Tran, M. Poulain, JM Ayoubi
Dept of Ob-Gyn and reproductive sciences, Hôpital Foch – Université de Paris Ouest

Ovarian stimulation (OS) has been linked to Assisted Reproductive Technologies (ART) practically from inception. Today, 40 years into the history of ART, OS stands as the single most effective measure ever undertaken for enhancing the yield of ART. Originally however, fears existed that OS might provide excessive responses and cause ovarian hyperstimulation syndrome (OHSS), a dreadful complication – at times fatal – of ART. The hazard that was believed to influence the risk of OHSS was the multiple follicle ovulation induced by OS. The logical defense against the risk of OHSS was therefore to reduce the number of follicles stimulated by mending OS protocols used in ART. This approach led to the concept of mild ovarian stimulation protocols, which held its supporter for a time. Things have changed however, when it was discovered that OHSS is not directly related to the number of follicles stimulated by OS, but rather to an effect of hCG – used for triggering ovulation – on ovarian follicles. The proper defense against OHSS logically became to revert to no-hCG ART protocols. The latter was made possible by triggering ovulation with GnRH-a in antagonist protocols. GnRH-a triggering was recognized to alter the luteal phase so that this approach became intimately associated with freeze all and deferred embryo transfer (ET) protocols. Globally, antagonist protocols with GnRH-a trigger and freeze all plus deferred ET have practically eradicated OHSS. The advent of PGTA led to realize that large fractions of embryos are aneuploid particularly, in the older population. This has put the emphasis on the importance of getting enough embryos for making up for the losses to aneuploidy – discarded embryos or lack of pregnancy – and optimizing the number of embryos obtained. When simply looking at fresh pregnancy rates there have been reports indicating that the optimal number of embryos obtained is of approximately 15. On the contrary, when cumulative outcome is looked at – the proper modern-day metric – ART results continue to increase when >15 embryos are harvested. There is ample evidence today indicating that oocyte quality is not harmed by the amounts of gonadotropin used and/or number of oocytes harvested. In this context therefore, the vanishing risk of OHSS and evidence that cumulative pregnancy rates increase pregnancy chances favor heftier OS protocol for retrieving more oocytes.
WHAT DO WE KNOW ABOUT PREVENTING THREATENED ABORTION AND RECURRENT MISCARRIAGE?
Adam Devall, UK

Background: Progesterone, produced by the corpus luteum in the ovary, helps to prepare the endometrium for implantation of the embryo, and thus is an essential hormone for a successful pregnancy. Evidence from several controlled clinical trials suggested a benefit from progesterone therapy, but with insufficient certainty due to the size of the trials and their methodological weaknesses. This prompted The National Institute for Health and Care Excellence (NICE) in the UK (clinical guideline 154 on “Ectopic Pregnancy and Miscarriage”) to call for a definitive trial to answer this question. Objectives: The PRISM study was designed to test the hypothesis that in women with vaginal bleeding in the first 12 weeks of pregnancy, vaginal progesterone (400mg pessaries, twice daily), started as soon as possible after the identification of an intrauterine gestation sac and continued to 18 weeks of gestation increases live births ≥34 completed weeks of pregnancy by at least 5% compared with placebo. In addition, an economic evaluation was conducted alongside the trial to assess the relative cost-effectiveness of progesterone compared with placebo. Design: The PRISM trial was a randomised, double blind, placebo-controlled, multi-centre study. Setting: The study was conducted in hospital settings across the United Kingdom (48 sites) between 2015-2018. Participants: Participants were women who presented with early pregnancy bleeding that had started within the preceding 4 days and were in the first 12 weeks of pregnancy, with an intrauterine gestation sac visible on ultrasoundography. Participants were aged between 16 and 39 years at randomisation and gave informed consent. Interventions: Each participant in the PRISM trial received either progesterone or placebo pessaries, at a dose of 400mg, twice daily, administered vaginally from the day of randomisation until 16 completed weeks of gestation. Main outcome measures: The primary outcome measure was live birth ≥34 completed weeks of gestation. The secondary outcome measures included: ongoing pregnancy at 12 weeks, miscarriage, gestation at delivery, neonatal survival at 28 days of life, congenital anomalies and resource use. Methods: Participants were randomised online in a 1:1 ratio via a secure internet facility through an Integrated Trial Management System. Minimisation was implemented for age (>35, >35 years), Body Mass Index (BMI) (<30, ≥30), fetal heart activity (present, absent) gestation at presentation by date of last menstrual bleed (≥42 days, >42 days), and amount of bleeding (PBAC [Pictorial Bleeding Assessment Chart] score 5; ≥5). Data were collected at three points of outcome assessment after randomisation, up to 28 days after birth. The primary analysis was by intention to treat (ITT). A within-trial cost-effectiveness analysis was conducted from the NHS and Personal Social Services perspective based on the main clinical outcome of the trial. Results: A total of 4153 women, from 48 hospitals in the UK, received either progesterone (2079 women) or placebo (2074 women). The follow-up rate for the primary outcome was 97.2% (4038 of 4153 women). The live birth rate was 75% (1513 of 2025 women) in the progesterone group and 72% (1459 of 2013 women) in the placebo group (relative rate [RR], 1.03; 95% confidence interval [CI], 1.00 to 1.07; p=0.08). A significant subgroup effect (interaction test p=0.007) was identified for pre-specified subgroups by the number of previous miscarriages: none (74% versus 75%, RR 0.99; 95% CI, 0.95 to 1.04; p=0.72); one or two previous miscarriages (76% versus 72%, RR 1.05; 95% CI, 1.00,1.12; p=0.07); and three or more previous miscarriages (72% versus 57%, RR 1.28; 95% CI, 1.08,1.51; p=0.004), thus demonstrating a biological gradient in the effect by the increasing number of previous miscarriages. A significant post-hoc subgroup effect (interaction test p=0.01) was found when we grouped all women with any number of previous miscarriage(s) (75% in the progesterone group versus 70% in the placebo group, RR 1.09; 95% CI, 1.03,1.15; p=0.003). There were no significant differences in adverse events. For secondary outcomes, there was evidence that progesterone may increase the rate of ongoing pregnancy at 12 weeks (83% versus 80%; relative risk 1.04, 95%CI: 1.01 to 1.07; p=0.01). There was no evidence of a difference in the safety outcomes. Conclusions: Progesterone therapy in the first trimester of pregnancy did not result in a significantly higher rate of live births among women with threatened miscarriage overall. However, an increase in live births was observed in the subgroup of women with early pregnancy bleeding and a history of previous miscarriages.

FIBROIDS AND UPA: HOW TO EXPLAIN THE GOOD AND BAD RESPONDERS
MM Dolmans, MD, PhD
Head of the Gynaecology Research Laboratory, Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain; Cliniques Universitaires Saint Luc, Gynecology Department, Brussels, Belgium

Introduction: Uterine fibroids (also called myomas or leiomyomas) are the most commonly found benign uterine tumors in women of reproductive age, found in 20-25% of women. Patients often present with a variety of symptoms, including pelvic pain, pressure, dysmenorrhoea, anaemia due to heavy bleeding, reduced quality of life and infertility. Treatment often depends on the patient’s age and her desire to preserve her fertility. Radical surgery like hysterectomy should be avoided where possible in patients who wish to preserve their fertility, and other surgical and non-surgical approaches, such as myomectomy or laparotomy or laparoscopy, uterine artery embolization under radiological or ultrasound control should be considered when possible (1). Progesterone, however, is known to play a key role in promoting myoma growth, hence modulating the progesterone pathway may prove to be an effective medical approach, which is why the use of selective progesterone receptor modulators (SPRM’s) may be a viable option to consider. SPRM’s are becoming increasingly available and several studies (PEARL I, PEARL II, PEARL III and PEARL IV) have shown them to be both safe and highly effective when used both short and long term. Recent reports have shown that short-term use of UPA results in bleeding control in approximately 90% of cases, which was achieved within 5-7 days compared to 21 days with GnRH agonists. This decrease in bleeding also results in a very important improvement in hemoglobin levels, which in turn controls anaemia. Estradiol levels also remained at mid-follicular levels, avoiding the menopausal symptoms often seen with GnRH agonists. Furthermore 80% of patients showed a significant reduction (>25%) in fibroid volume (good responders). Hence the other 20% do not respond to the treatment and fibroid volume remains unchanged (bad responders). The reasons why this occurs are discussed from a physiopathological point of view. Tissue micro-arrays and immunohistochemical studies, as well as gene expression analysis and PCR arrays were done in both groups (good and bad responders) in order to understand why (2). Moving forward, we should consider that UPA has a valid place in the future. Hum Reprod Update. 2016;22:665-686.

OVARIAN TISSUE CRYOPRESERVATION AND TRANSPLANTATION: STILL EXPERIMENTAL?

MM Dolmans, MD, PhD
Head of the Gynecology Research Laboratory, Institut de Recherche Experimenterale et Clinique (IREC), Université Catholique de Louvain; Cliniques Universitaires Saint Luc, Gynecology Department, Brussels, Belgium

Available options for fertility preservation in cancer patients include embryo cryopreservation, oocyte cryopreservation and ovarian tissue cryopreservation. However, cryopreservation of ovarian tissue is the only option for prepubertal girls and women who cannot delay the start of chemotherapy (no time for ovarian stimulation). Orthotopic reimplantation of frozen-thawed ovarian tissue has indeed proved successful, yielding over 130 published live births worldwide and pregnancy rates of around 40% (1). Techniques of ovarian tissue transplantation will be presented. Restoration of ovarian function, evidenced by follicular development and estradiol secretion, occurs in 95% of cases. It takes around 3.5 to 5 months for grafts to start functioning post-transplantation. Pregnancies are achieved naturally in 50% of cases. Graft activity usually persists for 2.5 to 4 years but can reach 7 years if the patient is young (<25 years). Graft activity usually persists for 2.5 years. Graft activity usually persists for 2.5 years.

References:

THE ARTIFICIAL OVARY

MM Dolmans, MD, PhD
Head of the Gynecology Research Laboratory, Institut de Recherche Experimenterale et Clinique (IREC), Université Catholique de Louvain; Cliniques Universitaires Saint Luc, Gynecology Department, Brussels, Belgium

A concern that must be addressed in case of frozen-thawed ovarian tissue transplantation is the risk of reimplanting malignant cells together with the grafted tissue, especially in patients with leukemia (1), which is the most common hematological cancer in women under 20 years of age. The risk is particularly high in women with acute leukemia and cannot be completely eliminated, even if the biopsy destined for cryopreservation is taken from patients in complete remission (2). One alternative to avoid reimplanting malignant cells is to obtain mature oocytes by means of the so-called transplantable artificial ovary. Isolation of primordial follicles from cryopreserved ovarian tissue and their transfer onto a scaffold to create this artificial organ will serve to eliminate the risk of transmission of malignant cells (3,4). Recent developments in the follicle isolation technique with GMP grade enzymes and involving washing the follicles three times (5), have proved successful, making this option applicable to leukemic patients (6). Growing antral follicles were observed after autografting primordial follicles inside a fibrin scaffold in a mouse model (7) and after xenografting human primordial follicles in mice with severe combined immunodeficiency (8). The different steps necessary to create an artificial ovary will be revised (8).

References:
medical diseases in men. European investigators have linked impaired semen quality to a nearly higher risk of testis cancer in men in the years following an infertility evaluation, a finding later confirmed in US studies. In addition to cancer, longitudinal studies suggest that men diagnosed with infertility had a higher incidence of diabetes, hypertension, and heart disease. Moreover, earlier and higher rates of inpatient hospitalization have been reported in men with lower semen quality in a dose dependent fashion. In addition, several groups have also demonstrated higher overall mortality rates among infertile men with impaired semen parameters in both Europe and the US. Select comorbid conditions (e.g. obesity, smoking) are known to impact male fertility and health; however, the etiology of the association remains unknown. Data suggests genetic, in utero, and hormonal factors may contribute. The findings suggest an opportunity to positively affect men’s health. If infertility is confirmed as an early marker of chronic disease, screening practices could be adjusted, as they are for patients with a family history of malignancy.

THE PARTOGRAM – SHOULD WE USE IT?
Dan Farine, MD, Canada

In 1955 Emanuel Friedman defined labor in a quantitative manner, thereby providing standardization and facilitating precise mathematical derivation of normal and abnormal labor progression (1). When evaluating the progression of labor according to the Friedman curves, based on the analysis of labor in fifty primigravid parturients, the active phase of the first stage of labor begins at 4 cm (2). More than fifty years later, Zheng et al systematically analyzed contemporary labor data to examine the labor patterns in a large, modern obstetric population in the United States. Their rationale for the need to redefine labor patterns emerged from the changes in the laboring population and current obstetrical practices. On the one hand, increasing maternal age and fetal weights make labor more challenging today. On the other hand, higher rates of labor induction, oxytocin use and epidural anesthesia, intervene with normal labor, potentially altering its rate of progression. In an attempt to examine if Friedman’s curves accurately define labor today, they reviewed labor and delivery information from 12 clinical centers within 19 hospitals in the USA from 2002 to 2008 (3). Their analysis of 62,415 women demonstrated that for both nulliparous and multiparous women at four cm, it could take more than six hours to progress to five cm, whereas at five cm, it may take more than three hours to progress to six cm. Only after six cm did multiparous women show faster labor progression than nulliparous women. Additionally, at six cm or more, almost all women who had had a vaginal delivery with normal neonatal outcomes achieved a 95th percentile of first stage of labor of more than two hours. This was particularly true for multiparous women. This data suggests that the active phase of the first stage of labor may only begin at six cm, and not at four, as proposed by Friedman, since only 50% of the women entered it by four cm (3). For this reason, no appreciable change in dilation for four hours may be normal in early labor but is probably abnormal after six cm. Therefore, the authors concluded that the term arrest of labor probably should not be used in laboring women who are only six cm dilated, or less. The results of this impactful study were partly supported by an older study with somewhat different results than those initially presented by Friedman. Peisner and Rosen in 1986 examined the labors of 1060 nulliparous and 639 multiparous women. In both of these populations less than 50% of labors became active by the time the cervix dilated to four cm. By five cm, 74% of labors were active. However, when procted and arrested labors were eliminated, 60% of the patients had reached the latent-active transition by four cm and 89% did so by five cm. The authors concluded that once a parturient has reached five cm of dilation, she should be in the active phase of labor (2). When evaluating the study of Zhang et al (3), it is important to acknowledge several potential selection biases in the study design. Firstly, women who had a cesarean delivery in labor were excluded from the cesarean analysis. Some of these cases may have been due to dysfunctional labor and labor dystocia. Their exclusion may have, therefore, resulted in an increase in dilation rate in residual study cases (4). Secondly, women whose cervix was more than cm dilated at admission were also excluded. If these cases were reflective of more rapid labors, their exclusion may contribute to a slower overall appearance of cervical dilatation (4,5). Lastly, nearly half of the parturients included in study received oxytocin for labor augmentation, potentially altering the natural course and rate of labor progression (3). Due to these limitations some have questioned the validity of the newly proposed labor curves and there is controversy surrounding this new six cm definition of active labor (4–8). Over the last several decades cesarean deliveries have been increasing in rate worldwide. In an effort to halt the increasing rate of cesarean delivery, the American College of Obstetricians and Gynecologists (ACOG) and The Society for Maternal-Fetal Medicine responded to the new labor curves proposed with workshop recommendations and an Obstetric Care Consensus statement on safe prevention of the primary CD in 2014 (9). The hope was that by avoiding the possible erroneous diagnosis of arrest of dilation at six cm and thereby preventing cesarean deliveries performed for this indication, the rates of primary cesareans may decrease. Several recent studies have evaluated the implementation of the new labor guidelines. Rosemberg et al, in their retrospective study, assessed the incidence of cesarean sections performed in a single academic medical center in the United States before and after the change in guidelines (10). Their analysis of 7,845 women over a four-year time period showed that there were no significant decreases in the rates of cesarean deliveries performed for arrest of dilation or in the rates of overall cesarean delivery rates. Additionally, there were no significant changes in the rates of cesarean deliveries for arrest of dilation at more than six cm or less than six cm. The results of this study differ substantially from those of Thuillier et al. In their retrospective cohort study at a university referral hospital in France, the rates of primary cesarean deliveries in laboring women with a singleton term gestation were compared over two 1-year time periods - from March 2013 to February 2014 (preguideline) and from June 2014 to May 2015 (postguideline). The analysis of 3,283 and 3,068 women in the before and after periods respectively, demonstrated a decrease in the global cesarean delivery rate from 9.4% in the preguideline to 6.9% in the postguideline period (odds ratio, 0.71; 95% confidence interval, 0.59-0.85; P < .01). The cesarean delivery rate for arrest of first-stage labor decreased by 50%, from 1.8% to 0.9% (odds ratio, 0.51; 95% confidence interval, 0.31-0.81; P < .01) but was significant only among nulliparous women (11). An additional recent study evaluated this very question of the effect of guideline change on rates of term singleton primary cesarean deliveries in three community hospitals in the USA over two six months’ time periods. Their results are in agreement with Thuillier et al, as they too demonstrated reduction in the rate of primary cesarean deliveries from 27.9% to 19.7% (odds ratio, 0.63, 95% confidence interval 0.46-0.88) in 434 women identified in the preguideline period and 401 women in the postguideline period (12). Due to the recent change in the definition of active labor and the slow and gradual process of adoption of new guidelines in daily medical practice, there is scarcity of information available regarding the effects of this change on maternal and neonatal outcomes. A secondary analysis of
WHAT DO WE KNOW ABOUT UTERINE RUPTURE?
Dan Farine, MD, Canada

There is abundant data on uterine rupture that is the basis for counselling and current guidelines. However, the basis for data is quite shaky. There are 24 large retrospective studies on uterine rupture. In 19 uterine rupture and dehiscence are lumped together making analysis of one vs. the other impossible. In 5 articles the database used distinguished between the two. We looked at our own data in which the database distinguishes between the two diagnoses. We then reviewed all these charts individually and were surprised to find that there was no accurate diagnosis in about half the cases.

Most common obstetrical outcomes miscoded as Uterine Dehiscence or Uterine Rupture during the study period (1988-2017)

<table>
<thead>
<tr>
<th>Obstetrical Outcomes</th>
<th>Coded as Dehiscence (n)</th>
<th>Coded as Uterine Rupture (n)</th>
<th>Total (n)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Uterine extensions during repeat cesarian sections</td>
<td>17</td>
<td>0</td>
<td>17</td>
</tr>
<tr>
<td>Other tears of birth canal</td>
<td>24</td>
<td>0</td>
<td>24</td>
</tr>
<tr>
<td>No evidence of Dehiscence/Rupture</td>
<td>29</td>
<td>1</td>
<td>30</td>
</tr>
<tr>
<td>Confirmed Uterine Dehiscence</td>
<td>69</td>
<td>4</td>
<td>73</td>
</tr>
<tr>
<td>Confirmed Uterine Rupture</td>
<td>6</td>
<td>24</td>
<td>30</td>
</tr>
<tr>
<td>Total</td>
<td>145</td>
<td>29</td>
<td>174</td>
</tr>
</tbody>
</table>

Table 5 – Uterine Dehiscence and Rupture and modes of Delivery identified during t

Is there anything magical about the 30 rule?
• 30 minutes rule was developed by consensus
• most fetuses with abnormal tracings are not acidotic and can wait for longer than 30 minutes
• if a fetus is becoming compromised, 30 minutes may be a long time

What are the recommendations re decision to delivery interval for urgent CS?
• UK: 30 minutes (RCOG, AAGB, RCM 1998)
• US: 30 minutes (ACOG, 2002)
• Canada: SOGC Guidelines (SOGC 2000)
• Germany: 20 minutes from decision to delivery

SOGC VBAC Guidelines 2005:
• For a safe labour after Caesarean section, the woman should deliver in a hospital where a timely Caesarean section is available. The woman and her health care provider must be aware of the hospital resources and the availability of obstetric, anesthetic, obstetrical, and newborn resuscitation personnel to deal effectively with obstetrical emergencies. Problems may occur suddenly and unexpectedly even in patients thought to be at low risk. Hospitals must always be ready to respond to such emergencies.”

SOGC L&D Attendance Guidelines 2000:
• Timing of emergency Caesarean section: “It is the hospital’s responsibility to ensure adequate operating room time, as well as nursing, anaesthetic, obstetrical, and newborn resuscitation personnel to deal effectively with obstetrical emergencies. Problems may occur suddenly and unexpectedly even in patients thought to be at low risk. Hospitals must always be ready to respond to such emergencies.”

Table 5 – Uterine Dehiscence and Rupture and modes of Delivery identified during t

<table>
<thead>
<tr>
<th>Obstetrical Outcomes</th>
<th>Coded as Dehiscence (n)</th>
<th>Coded as Uterine Rupture (n)</th>
<th>Total (n)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Uterine extensions during repeat cesarian sections</td>
<td>17</td>
<td>0</td>
<td>17</td>
</tr>
<tr>
<td>Other tears of birth canal</td>
<td>24</td>
<td>0</td>
<td>24</td>
</tr>
<tr>
<td>No evidence of Dehiscence/Rupture</td>
<td>29</td>
<td>1</td>
<td>30</td>
</tr>
<tr>
<td>Confirmed Uterine Dehiscence</td>
<td>69</td>
<td>4</td>
<td>73</td>
</tr>
<tr>
<td>Confirmed Uterine Rupture</td>
<td>6</td>
<td>24</td>
<td>30</td>
</tr>
<tr>
<td>Total</td>
<td>145</td>
<td>29</td>
<td>174</td>
</tr>
</tbody>
</table>
CARE WE RELIABLY PREDICT POI USING AMH
Bart CJM Fauser, MD, PhD, FRCOG
Em. Professor of Reproductive Medicine, University of Utrecht,
Utrecht, The Netherlands

Premature ovarian sufficiency (POI) is a devastating clinical condition, with many short and long term health implications. Historically diagnosis is made on the basis of cycle history (i.e. the presence of amenorrhea for 3, 6 or 12 months) complemented with hormone assays (i.e. serum FSH above 25 or 40 IUL in one or 2 occasions). Estrogens concentrations are low, as well as the number of ovarian follicles assessed by ultrasound but these is not part of the diagnostic criteria. In more recent years the assessment of anti-Mullerian hormone (AMH) concentrations in blood has been demonstrated to be a reliable marker for the number of early antral developing follicles. The number of growing follicles is in turn related to the pool of resting primordial follicles and could therefore be used as marker for ovarian reserve. This has proven to be useful under various clinical conditions, and the question at hand is can AMH be used as an early marker to diagnose POI. Why would an early diagnosis of imminent POI be relevant? As clinician I have seen quite a few young women with a positive family history of POI and they want to know whether they are indeed at risk themselves. In addition, women with signs of estrogen deficiency may want to know why this is and what implications are for future health. This especially holds true for young cancer survivors where sometimes potentially gonadotoxic chemotherapy or radiation is applied. Early POI diagnosis may have implications regarding fertility potential and the need to cryopreserve own oocytes or use donated oocytes. Hormone replacement therapy may be considered in the light of osteoporosis prevention and long-term cardiometabolic health risks. Remarkably few studies have appeared over the years to assess whether indeed AMH is capable of predicting POI. Ideally, you would need a prospective follow-up design to answer this question, and this kind of studies have only been performed in cancer patients. Under those circumstances, it could indeed be demonstrated

RCTS MAY NOT BE THE ANSWERE TO ALL OUTSTANDING QUESTIONS IN INFERTILITY
Bart CJM Fauser, MD, PhD, FRCOG
Em. Professor of Reproductive Medicine, University of Utrecht,
Utrecht, The Netherlands

Beyond any doubt evidence based medicine (EBM) and the related emphasis on properly designed and sufficiently powered randomized controlled trials (RCTs) has revolutionized the way medicine is practiced today. Like in other areas in medicine, also in infertility many newly designed strategies have failed to pass the scrutiny of well designed studies and have therefore been abandoned. In infertility, a heated and fears debate has recently taken place regarding the use and misuse of IVF ‘add on’ interventions, and doctors working in the private sector have been accused of exploiting the needs of desperate patients because the proper proof for beneficial effects are often lacking. Overall, performing RCTs is still considered the gold standard for evaluating novel interventions. However, RCTs by definition represent the science of the average of (more or less heterogeneous) groups, and does not take into account potential individual response differences. Often RCTs show no difference between both interventions in both groups, but this does not rule out the possibility that interventions might be useful in subgroups. In addition, performing useful RCTs are not without difficulties: a) it is shown that in order to demonstrate a clinically useful increase in pregnancy rates, large sample size studies (involving > 1000 individuals) are needed. b) By definition it is difficult, costly and time consuming to perform such studies. Therefore average duration between design and the actual execution and publication of such a study is often at least 5 years. c) Once the results of such studies are finally published, conclusions drawn may be questioned because used technologies are considered to be outdated. In the current era of personalized medicine, other validated and scientifically sound research strategies - like prospective cohort follow studies and subsequent multi-variate prediction analyses - where a heterogeneous cohort of patients undergo a single intervention, may be consider as a valid alternative strategy. Under those circumstances it is not the intervention but rather the patient which is considered the primary variable of interest. Such an initiative would radically differ from current evidence-based research orthodoxy. The opportunities for generating large cohorts offered by increasing consolidation in the IVF market are enhanced by the maturing of techniques of big data analysis.

SHOULD WE BE ADVISING OUR PATIENTS TO TAKE A HIKE? PHYSICAL ACTIVITY IN PREGNANCY: 2019 UPDATE
Milena Forte, Canada

The 2019 Canadian Physical Activity Guidelines in Pregnancy guidelines represent a foundational shift in how we view exercise in the prenatal period. These guidelines strengthen the recommendation that most women can safely exercise throughout pregnancy, and also position prenatal physical activity as a therapy that can reduce pregnancy complications and optimize health across the lifespan of two generations. Adverse pregnancy outcomes such as gestational diabetes (GDM) and hypertensive disorders of pregnancy (HDP) have increased over past decades. These outcomes are associated with an increased risk of developing cardiovascular disease (CVD). Moderate intensity prenatal exercise (600 MET-min/week which = 140 minutes of brisk
TARGETING HRT: FROM INDICATION TO PERSONALIZATION

Marco Gambacciani
The Italian Menopause Society Recommendations
Department of Obstetrics and Gynecology, University of Pisa, Via Roma 67, 56100 Pisa, Italy

During the past decade the risks and benefits balance of hormone replacement therapy (HRT) in menopause has been thoroughly reassessed especially when considering the cardiovascular risk. The term HRT is usually referred to all hormone therapy, orally, transdermal or vaginally administered, as well as the estradiol and progestin combination therapies, both in sequential or continuous scheme, estrogen-progestin-androgenic compounds (Tibolone), estrogen combinations with SERMs (called Tissue Selective Estrogen Complex, TSEC). Menopause is not a disease and does not require treatment, but some women may be affected by hormonal decline and therefore need a replacement. HRT should be considered as part of a fully integrated clinical-therapeutic assessment that must also include advice for a correct lifestyle, diet, physical exercise, to enable the woman to regain or maintain good health and well-being. HRT should not be recommended in the absence of a clear indication such as the presence of vasomotor symptoms or vaginal dryness. HRT remains the most effective therapy for the treatment of climacteric symptoms, from vasomotor symptoms to menopausal genitourinary syndrome. Other climacteric symptoms such as muscle-joint pain, changes in mood, changes in the sleep-wake rhythm, changes in sexual behavior and quality of life (QoL) may improve with HRT. The relationship between the benefits and risks of HRT is not absolute and univocal but varies according to the selection of women, the starting time, the dose and type of HRT selected. HRT includes a wide variety of compounds: estrogens, progestins, estrogen-progestin combinations, Tibolone, TSEC. All these compounds, with different dosages and routes of administration, show benefits, but above all very different potential risks. Consequently, an absolute "class effect" cannot be quantified for HRT. Assuming a class effect is inappropriate and will certainly generate confusion between clinicians and the population. In general, there is no ideal dosage or product suitable for all women at any age. Each combination can have unique characteristics that can be used appropriately. The numerous products available allow a dynamic customization of the therapy, modifying the dosage, the choice of progestin and the route of administration based on the characteristics, objectives and preferences of the women to guarantee the most efficacy with maximum safety. HRT can be performed using different dosages, according to the woman's clinical conditions. By standard doses we mean the administration of 2 mg 17β estradiol orally or equivalent doses of other estrogenic preparations. Other dosages are currently in use and are reported as low or ultra-low dose, to be adjusted according to the clinical needs and age of the woman. In general, it is good practice to reduce the hormonal dosage with the woman's age. Dosages lower than those used in past years show good efficacy on clinical symptoms and maintain beneficial preventive effects, with an undoubtedly better risk profile. The fundamental principle is to treat symptomatic women. Systemic HRT is essentially indicated for symptomatic women under the age of 60, or in any case within 10 years of menopause, after excluding the presence of contraindications. The selection of symptomatic patients in the immediate postmenopausal, or perimenopausal, period is essential to maintain the effect of endogenous estrogens, which only early on can be guaranteed. In fact, the presence of menopausal symptoms is related to a greater endocrine-metabolic risk that conditions a more focused and rational clinical use profile. The majority of postmenopausal women can use HRT. The risk / benefit ratio is certainly more favorable in symptomatic women who start HRT under the age of 60 and in any case within 10 years of menopause, in which the certain benefits in terms of symptoms and quality of life (QoL) may improve with HRT. The changes in the sleep-wake rhythm, changes in sexual behavior and quality of life far exceed the possible hypothetical risks. Observational clinical studies show that transdermal therapy does not cause any increase in venous thromboembolism or stroke in the general population. In subjects at higher risk (e.g. with genetic thrombophilia). Low dose vaginal estrogen administration for the GSM treatment is safe and free of any potential severe adverse events. HRT must be evaluated with the specialist, case by case. Therefore, HRT must be personalized according to the individual characteristics of the woman, her personal and family history, the results of suitable clinical and laboratory analyses, the preferences and expectations, as well as the predominant symptoms. The gynecologist should assess the most appropriate type of HRT (dosage, drug composition, pattern, route of administration and duration of use) to achieve the treatment goals, with a periodic reassessment of changes in women's health, benefits and risks over time.
LASER THERAPY FOR THE FUNCTIONAL VAGINAL RESTORATION: THE RESULTS OF LONG-TERM EFFICACY OF VAGINAL ERBIUM LASER IN PROSPECTIVE STUDIES ON GENITOURINARY SYNDROME OF MENOPAUSE

Marco Gambacciani
for the Italian Vaginal Erbium Laser Academy
Department of Obstetrics and Gynecology, Pisa University Hospital, Via Roma 67, 56100 Pisa

Laser therapy has a therapeutic role for different medical conditions and most recently has gained interest as a non-hormonal treatment for genitourinary syndrome of menopause (GSM) and non-invasive option for stress urinary incontinence (SUI). Several therapeutic options are available to alleviate GSM symptoms, including hormonal and non-hormonal products. Both microablative fractional CO2 laser and the non-ablative vaginal Er: YAG laser (VEL) induce morphological changes of vaginal tissues, and from available, non-randomized clinical trials data alleviate the symptoms of dryness and dyspareunia. In a multicentric, prospective study performed on an outpatient basis using an erbium laser (XS Fotona Smooth™, Fotona, Ljubljana, Slovenia) postmenopausal women (PMW, n = 676, mean age 54.3±3.9 years) were treated with 3 Renovalea applications every 30 days. Symptoms were assessed before and after 4, 12 and 24 weeks from the last VEL treatment, using The Female Sexual Function Index (FSFI) and the Female Sexual Distress Scale-Revised (FSDS-R). In addition, in 205 PMW symptoms were assessed up to 24 months, using the visual analog scale (VAS) and the vaginal health index score (VHIS). Stress Urinary Incontinence (SUI) was evaluated with the International Consultation on Incontinence Questionnaire-Unrinary Incontinence Short Form (ICIQ-UI SF). A standardized 1-hour pad test was conducted by having the patient perform a set of activities with 300 ml saline in the bladder. A positive 1-hour Pad test was defined as >1g leakage. We considered mild incontinence if the Pad test reached < 10g; moderate incontinence >10 < 20g; severe incontinence >20g. Objective improvement after treatment was defined by a > 50% decrease in the follow-up. Patients suffering from SUI were treated with the Incontiitalize procedure. The procedures were performed without anesthesia or drug use before or after the intervention. Results: The FSFI total score from basal values of 15.5 ± 4.2 reached 28.5 ± 2.5 and after the second VEL treatment, (p<0.001). We observed a significant (p = 0.001) improvement in each specific domain FSFI scores at the end of treatment compared to baseline. The FSDDS-R from basal values of 29.5 ± 1.5 dropped to 10.5± 1.5 after the first and second VEL treatment (p<0.001). The results were maintained up to the 24th week of observation. In the long-term follow-up VEL treatment significantly improved VHIS, as well as vaginal dryness and dyspareunia scores (p<0.01) up to the 12 months after the last VEL treatment, while the values were similar to the baseline after 18 and 24 months. In 114 PMW suffering from mild-moderate SUI, VEL treatment significantly (p<0.01) improved ICIQ-SF score, up to the 12 month of observation. Overall significant improvements in the pad weights were noted in the follow-up visits (p<0.0001). In particular, women with mild SUI (n=68) showed 100% improvement in all patients at 6 months and 60% (n=40) after 12 months. Among patients who had moderate SUI (n=34), 80% of the patient (n=27) exhibited improvement at 6 months and 38% (n=17) at 12 months. Finally, women with severe SUI (n=12), 58.3% of patients (n=7) exhibited improvement at 6 months and 16.7% of the patients (n=2) at 12 months. No serious adverse events were recorded during the study. VEL was well tolerated with less than 3% of patients discontinuing treatment due to adverse events. During our observation period, 174 (84.9 %) PMW asked to repeat VEL procedure for GSM, and 96 patients (69.6%) for the treatment of SUI. Conclusion: Albeit not randomized, this large, multicentric, prospective study confirms that VEL is effective, safe and well accepted for the treatment of GSM and SUI, leading to a significant and long lasting decrease in the distress associated with impaired sexual function with an improvement of satisfaction with sexual life in PMW suffering from GSM. VEL was repeatedly reported to improve GSM, SUI as well as vaginal prolapse. Being a non-ablative procedure VEL is suitable for multiple treatments repeated over time. Although large randomized trials have not been reported to date, existing evidences suggest that VEL can be offered as a safe and efficacious alternative to HRT for GSM. As for SUI is concerned a randomized sham-controlled trial confirms that VEL can effectively suggested as well as a first step treatment of mild-moderate SUI before surgical procedures. Further properly sized, randomized studies are needed to evaluate the laser treatments in comparison with other therapies, as well as to assess the duration of the therapeutic effects and the safety of repeated applications. Active research is evaluating both an automated robotic probe for VEL treatments, as well as an Erbium-Yag intraurethral probe for the treatment of severe and Type III SUI.

RCT OF PGT FOR ANEUPLOIDY BY MICROARRAY OF POLAR BODY IN ADVANCE MATERNAL AGE. ANY ADVANTAGE? THE ESTEEM STUDY

L. Gianaroli, MD, FRCOG

Chromosome abnormalities in gametes and embryos are one of the main causes of prolonged time to pregnancy, implantation failure and miscarriage in assisted reproduction treatments. Reproductive medicine specialists have been investigating techniques to detect them before embryo transfer with the aim to improve the outcome of assisted reproduction cycles. In 2009, the European Society for Human Reproduction and Embryology (ESHRE), started a pilot study in two centers to investigate whether zygote chromosomal status could be accurately predicted by array comparative genomic hybridization (aCGH) analysis of both polar bodies (PBs). This technique still needed validation for Preimplantation Genetic Testing for Aneuploidy (PGT-A) back then. Based on the high degree of concordance (94%) between the chromosome analysis of PBs and those from the resulting fertilized oocytes, the ESHRE Study into the Evaluation of oocyte Euploidy by Microarray analysis (ESTEEM) was launched. The first aim of the study was to evaluate whether preimplantation genetic testing for aneuploidy by comprehensive chromosome screening (CCS) of the first and second PB to select embryos for transfer increased the likelihood of a live birth within 1 year in advanced maternal age (AMA) women (36-40 years) planning an ICSI cycle compared to ICSI without chromosome analysis. ESTEEM was a multinational, multicentre, pragmatic, randomized clinical trial with intention-to-treat analysis. It involved 9 European ART Centers. Of 396 women enrolled between June 2012 and December 2016, 205 were allocated to CCS of the first and second PB (study group) as part of their ICSI treatment cycle, and 191 were allocated to ICSI treatment without chromosome testing (control group). Block randomization was performed stratified for centre and age group. Participants and clinicians were blinded at the time of enrolment until the day after intervention. Results obtained show that the cumulative live birth rate at one year of follow-up is not substantially increased by PGT-A on PBs of oocytes harvested after ovarian stimulation for ICSI in AMA patients. However, the clinical outcome demonstrated that although in both study arms 24% of patients had one live birth, this was consequent to significantly fewer ETs.
The aim of this study was to devise an evidence-based scoring system for prioritizing mosaic aneuploid embryos for transfer. Through a retrospective analysis of all sequential cytogenetic and molecular results on chorionic villi samples (n = 72,472) and products of conception (n = 3806) analysed at a single centre, the likelihood of 4 adverse outcomes associated with mosaic aneuploid trophoblast were evaluated. A composite score was obtained for each individual mosaic aneuploidy after assignment of an individual risk score based on the incidence/likelihood of each adverse outcome. The higher the composite score, the lower the priority for transfer. Due to the paucity of prospective studies on the actual transfer of mosaic aneuploid embryos, we suggest using this evidence-based scoring system to provide a useful tool for clinicians, embryologists and patients.

**SHOULD ANDROGENS BE ROUTINELY OFFERED TO OPTIMIZE QUALITY OF LIFE IN MENOPAUSE?**

**DEBATE - PRO**

**Alessandra Graziottin, MD, SOGC (Hon)**

Director, Center of Gynecology and Medical Sexology, H. San Raffaele Resnati, Milan, Italy

President, Alessandra Graziottin Foundation for the cure and care of pain in women NPO

---

YES, androgens – testosterone and/or dehydroepiandrosterone, DHEA – should be routinely offered to women after the menopause. Exceptions include current major contraindications (such as hormone-dependent cancers). Offered means to explain to every consulting woman why androgens are key for many aspects of women’s health, far beyond sexuality.

**Well informed women** should then make their own choice and give their written consensus to the androgen treatment, systemic and/or local, vulvo-vaginal, when interested.

The information offered to women should include a concise summary of:

- **androgen’s physiology.** Only a few women and a minority of physicians know that:
  - androgens plasmatic levels are far higher than estrogens in women’s body, particularly in the first part of the menstrual cycle (estrogens levels are higher only during pregnancy; progesterone levels are higher than testosterone both in the luteal phase and in pregnancy);
  - androgens plasmatic levels peak around 20 years of age. Their adrenal and ovarian production is then gradually reduced with age (with the exception of women affected with Polycystic Ovary Syndrome, PCOS). At the age of 50, women have lost on average 50% of their testosterone and up to 60-70% of their DHEA, with subtle and yet pervasive consequences: why not replace them?
  - after the menopause, the ovarian exhaustion and the progressively reduced adrenal androgen production deprive women of a substantial component of their biological energy;
  - **androgen’s role in women’s body,** highlighting their specific action on:
    - the brain: androgens stimulate neuroplasticity, having a trophic role both as testosterone and through the aromatization to estradiol. The prominent effect is on the dopaminergic system, with increased activity and performance level of the seeking-appetitive-lust system, with a specific impact on sex drive, the motor system, and the memory system, the latter in simergy with the colinergic neurons. Androgens reduce the neuroinflammation, thus preventing/reducing the most powerful common denominator of depression, cognitive impairment leading to Alzheimer, and motor impairment contributing to Parkinson’s disease;
    - the muscles: in synergy with appropirial physical exercise, androgens contribute to maintain an optimal muscle mass, strength and performance, thus contrasting sarcopenia, an otherwise powerful contributor to frailty in the elderly;
    - the bones: they promote the activity of the osteoblasts and reduce the activity of the osteoclasts, thus contributing to a net bone calcium balance;
    - the immune system: whilst estrogens’ fluctuations and then loss are powerful triggers of mastcells’ degranulation, contributing to increased local and systemic inflammation, androgens down-regulate the hyperactive immune system, with an overall better balance, reducing the vulnerability to inflammatory and autoimmune diseases;
    - the hematopoietic system: androgens are useful to prevent and cure the anemia of the elderly (whilst erytrocytosis, with increased red-cells count and increased hemoglobin, is a contraindication);
    - the gut brain and microbiota, which are emerging contributors non only of bowels pathologies, such as the irritable bowel syndrome (IBS), but also of neurological diseases, such as the Parkinson’s disease;
    - the vulvar and vaginal tissues, with a specific trophic and pro-sexual effect;
    - the pelvic floor trophism;
    - the bladder function;
  - **reasons of persisting androgen neglect in the clinical practice.** Three major facts, rooted in clinical mistakes, have shadowed the role of androgens for women’s health:
    - the use of different units to measure sexual hormones (picograms for estradiol, nanograms for testosterone, micrograms for DHEA and DHEA-S) has generated for decades the wrong idea that estradiol is quantitatively the most abundant sexual hormone in women. This idea, shared by physicians and lay people alike, has marginalized the role of androgens, particularly after the menopause, with a dramatic reduction of vital energy and longevity in health for women;
    - when testosterone patches where investigated, they were studied just to prove that women’s sexuality could be improved (in fact with a limited benefit, from 1 to 2 sexual encounter/month), with a total neglect of the many advantages testosterone could have offered to prevent/reduce the risk of cognitive impairment, Parkinson’s disease, sarcopenia, osteopenia/osteoporosis, to modulate/reduce the progression of autoimmune diseases, to improve the anemia of the elderly, the bladder function and the
pelvic floor tonus (the bladder wall and the elevator ani are extremely rich of androgen receptors in women);

3. lack of long prospective clinical trials on systemic DHEA, and ideologically distorted analysis of a few small studies, have marginalized the huge health impact that is clinically evident when well-tailored androgens and estrogens treatments are carried out in the long term, in synergy with appropriate healthy lifestyles.

Forty years of Author’s clinical experience show that well informed women are far most interested to continue androgens therapy when they experience the many health-related systemic benefits they can enjoy, in the short and long term. As many women say: «A smarter sexuality is just the flower in the buttonhole of a more rewarding sense of regained vital energy, physical and mental». Treatment options include testosterone (with vulvovaginal creams, gel or other routes of administration) and/or DHEA ([oral, at different dosages, and vaginal (prasterone)]). Conclusion: YES, androgens should be routinely offered to postmenopausal women, with the exception of the minority who present major contraindications. In synergy with estrogens and healthy lifestyles, androgens are women’s best friends, from puberty to old age. In the clinical practice, a clear explanation of pros and cons, including the lack of “pro-androgens” guidelines in women, should be given. A signed consensus to androgen treatment should be reported in the clinical record. The goal of androgen treatment is to optimize women’s vital energy, overall health and quality of life – including couple’s sexuality, if welcomed — after the menopause and beyond.

OPTIMIZING PSYCHOSEXUAL HEALTH WITH PERIMENOPAUSAL CONTRACEPTION: A CLINICAL PERSPECTIVE
Alessandra Graziottin, MD, SOGC (Hon)
Director, Center of Gynecology and Medical Sexology, H. San Raffaele Resnati, Milan, Italy President, Alessandra Graziottin Foundation for the cure and care of pain in women - NPO

Women’s psychosexual health may be deeply threatened by the perimenopausal transition. The impact on the couple’s relationship can be significant, requiring new adjustments, or disrupting, leading to the separation of the partners. Women’s sexual identity, function and relationship may be variably disrupting, leading to the separation of the partners. Women’s relationship can be significant, requiring new adjustments, or the perimenopausal transition. The impact on the psychological, physical and relationship well being, of dopamine in the brain; diabetes, for its complex metabolic, vascular and nervous consequences; obesity, for the associated increased sistemic and brain inflammation and involution of the vulvar tissue with dramatic and underestimated specific sexual consequences.

➢ Conoid dependent, including, but not limited to: iron-deficient anemia (IDA), more frequent if the woman suffers from functional or submucosal myoma/dependent heavy menstrual bleeding (HMB). This is an underestimated cause of low sexual drive, as iron is key also to maintain appropriate levels of dopamine in the brain: diabetes, for its complex metabolic, vascular and nervous consequences; obesity, for the associated increased sistemic and brain inflammation and involution of the vulvar tissue with dramatic and underappreciated specific sexual consequences.

➢ Lifestyle dependent: pro-inflamatory or hypercaloric diet and alcohol use (above 1-2 glasses/week), physical inactivity and chronic sleep shortage may further affect the physical and emotional well being, contributing to impair the whole sexual response in the perimenopausal years.

Women at higher risk of premature ovarian failure (POF) and, consequently, of an earlier perimenopausal transition include women with a family history of POF; with autoimmune diseases such as celiac disease, thyroiditis, reumathoid arthritis, when the dysfunctional immune system may attack the ovary after a first organ; survivors of chemotherapy, total body or pelvic radiotherapy. The risk should be considered when early and still “vague” or occasional perimenopausal symptoms and/or sexual dysfunctions, worsening of the premenstrual syndrome and/or changes in the body shape are reported in the clinical consultation.

The optimal approach to perimenopausal sexual complaints requires a detailed clinical history (medical, besides psychosexual), accurate physical examinations and exams, including hormones levels (on the 3rd-or 4th day from the beginning of the cycle). The first recommendation is to improve life-styles, and to encourage the woman to assume full responsibility in changing her daily life for the better, in synergy with appropriate medical advice. 30-45’ of daily brisk walking help to steam-off the negative emotions and recharge limbid vital energy that may boost sexual drive.

Sexual dissatisfaction and sexual dysfunctions are the result of a multifactorial etiology; this is why sexual dysfunctions cannot be addressed with a single pill.
This said, a well tailored contraception (oral, or with contraceptive ring or patches) can reduce psychosexual symptoms through:

- Normalization/stabilization of the plasmatic levels of estradiol and progesterone, which translates into a significant reduction of all the menstrual and premenopausal symptoms due to the otherwise increased fluctuations of estradiol and progesterone. Estradiol containing pills are the most appropriate for premenopausal women.

- Reduction of the hormone-free interval (HFI), from 7 to 4, 2 days, or eliminating the HFI for two-three months or more, according to the woman preferences, maintains constant hormonal levels of estradiol and progesterone, thus eliminating the increased inflammation, and related symptoms, associated with periods. The parallel reduction/exclusion of the menstrual bleeding will also reduce IDA, thus contributing to an improvement of the sense of vital energy, overall well-being and sex drive.

**Clinical note:** When the blood sample indicates a significant reduction of free testosterone and/or DHEA, it is clinically appropriate to replace those hormones, as they are the most important biological fuel of sex drive, in association with the prescribed pill. As no guidelines address this specific association, a detailed signed consensus should be reported in the medical record. This Author’s experience, with thousands of patients treated over the years, with ongoing follow-ups, includes topical testosterone, either propionate or of vegetal origin, to be applied daily (a fingertip) to the vulva and inside the vagina, with a gentle massage on the upper part of the vagina, to improve the vaginal and urethral wellbeing and potentiate the sexual response. DHEA (10 or 25 mg, 1 capsule in the morning after breakfast) contributes the re-enhance the biological basis of well being, perceived sense of vital energy and sex drive. If the woman is nulliparous or had only cesarean deliveries, she is likely to have an increasing hyperactive pelvic floor, with recurrent candida and coital pain at the entrance of the vagina. A specific physiotherapy, with BioFeedBack, should be recommended to relax the hyperactive pelvic floor, in perfect synergy with the pharmacologic therapy and lifestyle changes. This multimodal, comprehensive approach, were Hormonal Contraception is given in association with androgens, when indicated, empowers the physician ability to address the complex scenario of psychosexual issues before and across the menopause. To optimize the impact, coexisting male sexual problems, either lifelong such as premature ejaculation, or acquired, such as the erectile dysfunction, should be diagnosed and treated in parallel, the give the couple a new boost, if welcomed. The presentation will address the key biological contributors to sexual dysfunctions in the premenopause, the role of a well tailored contraceptive choice, and the value of adding androgens, when clinically indicated.

**CAN IVF INFLUENCE HUMAN EVOLUTION?**

Hans Ivar Hanevik, Norway

As all other animal species, humans are influenced by evolution. We change. In large, well-studied human populations, some recent changes in physiology and behavior were due to evolutionary effects [1]. The most common mechanism of evolution is natural selection, where selection pressures are applied on available phenotypes. All the necessary requirements for natural selection are present in IVF cases, and in this talk I argue that IVF influences human evolution. Natural selection also occurs in non-assisted human reproduction of course, but selection pressures in IVF are very different compared to the natural situation. Take for example the sprinter spermatozoon that wins the race in IVF. This spermatozoon swims very short distances compared to the long-distance specialist that fertilizes the oocyte in nature. ICSI is an extreme variant of this, where the spermatozoon barely has to move at all. The ICSI spermatozoon also avoids the hassle of finding its way to the oocyte by a probably chemotactic mechanism. This and other examples concerning the systematically different selection pressures that are applied on oocytes, embryos and even couples wanting to conceive in IVF programs compared to the natural situation, suggest that IVF influences human evolution. If so, this is another case of cultural and technological advances inducing changes in the human genome. A previous, well-known example of such gene-culture co-evolution is the relationship between lactase expression and milk consumption in human populations. In comparison, the evolutionary implications of systematically different selection pressures in IVF could be even more influential, as evolutionary theory underlines that selection works through differential reproductive success and not through differential survival. The purpose of this talk is not to judge or impose a set of norms on IVF, but rather to draw attention to the fact that IVF is not just a treatment for infertility, but also a technological intervention at the point in a human life cycle where natural selection operates at its strongest. Although IVF is a great medical achievement, it circumvents the systematically different selection pressures that are applied on oocytes, embryos in IVF and even couples wanting to conceive. It also increases the reproductive fitness of sub fertile couples by technologically removing several naturally occurring selective barriers and by altering other such barriers. In accordance with the basic principle of evolution, the subsequent generations will thus be genetically and epigenetically adapted to an environment in which reproduction is increasingly dependent on technological intervention.


**DEBATE: STANDARD IVF VS ADD-ON IVF - WHAT IF THE PATIENT IS WILLING TO PAY FOR ADD-ONS?**

Joyce Harper, UK

It is estimated that the assisted reproductive technologies (ART) industry is worth almost $27 billion. In some countries ART cycles are publically funded but in others, such as the UK, there is very limited funding. Globally the cost of ART varies enormously and one that can double the price is adjunct treatments. An adjunct is defined as any technique that is a variation or add-on from the standard IVF cycle (Harper et al., 2017). The majority of add-ons claim to increase live birth rate (LB), but these claims should be backed up by robust randomised controlled trial (RCT). In an RCT, patients are randomly allocated into a control or treatment group, and the primary outcome needs to show a significant improvement in the live birth rate. These studies need to be adequately powered, ideally with at least 200 patients per arm. The Human Fertilisation and Embryology Authority have analysed the RCT’s for a list of adjuncts and rated them according to a traffic light system. Assisted hatching, intrauterine culture, preimplantation genetic testing for aneuploidy (PGT-A) (using cleavage stage biopsy) and reproductive immunology tests and treatments get a red light, meaning that there is no evidence that they will improve live birth. All of the other adjuncts are rated amber which means there is limited evidence but not enough to routinely offer the treatment. Infertile patients will often try any form of treatment if they feel that it gives them even a slight chance of improving their chance of success. They may feel guilty or a failure if they have not given it their best shot. If their physician recommends a treatment, they will probably do it, at any price.
THE IMPACT OF ANTENATAL BISPHENOL A EXPOSURE ON MALE REPRODUCTIVE FUNCTION AT 20–22 YEARS OF AGE
Roger J. Hart, Australia

Bisphenol A (BPA) is an ubiquitous chemical suspected to possess oestrogenic hormonal activities. Male population studies suggest a negative impact on testicular function. As Sertoli cell proliferation occurs during fetal or early postnatal life, it is speculated that oestrogenic environmental exposures may influence mature testicular function. Among 705 Western Australian (Raine) Cohort men aged 20–22 years, 404 underwent testicular ultrasound examination (149 who had maternal serum available), and/or 365 provided semen (136 had maternal serum) and/or 609 serum samples for sex steroids, gonadotrophins and inhibin B analysis (244 had maternal serum). Maternal serum collected at 18- and 34-weeks gestation was pooled and assayed for concentrations of total BPA (free plus conjugated) as an estimate of antenatal exposure. Testicular volume was calculated by ultrasonography, and semen analysis performed. Serum luteinising hormone, follicular stimulating hormone and inhibin B were measured by immunassay while testosterone, oestradiol, oestrone and BPA were measured by liquid chromatography-mass spectrometry (LC-MS). In most (89%) maternal serum samples BPA levels were detectable. After adjustment for maternal smoking, abstinence and varicocele; sperm concentration and motility were significantly positively correlated to maternal serum BPA (r=0.18 p=0.04 for both), no other associations of maternal serum BPA with testicular function were observed.

THE ROLE OF PROBIOTICS AND LACTOBACILLUS REUTERI DURING PREGNANCY: WHAT IS THE EVIDENCE?
Flavia Indrio, Italy

During the course of a normal pregnancy, several deep and dynamic physiological changes occur in the mother. Some of the endocrine and immune changes induced by pregnancy increase the susceptibility of the mother to various infections, including those of the oral cavity. During pregnancy, there is a reduction of antimicrobial activity of peripheral neutrophils, essential components of the innate immune defenses of the periodontal tissues. This could be related to the well-documented increase in gingival inflammation observed during pregnancy. One of the main changes in the immune system during pregnancy is the partial mitigation of the immune responses that are mediated by the mother’s cells, as 50% of the antigens in the cells of the fetus are derived from the father, and these cells are chronically exposed to the mother’s immune system. Several complex physiological changes are therefore induced during pregnancy in order to prevent immune rejection in the mother’s body of her fetus. Researches have shown that pregnant women are exposed to a higher risk of gingival alterations. The increased susceptibility to infections in the oral cavity can occur due to pH decrease and, consequently, the salivary buffer capacity decreases during pregnancy, which, along with the change of dietary and oral hygiene habits, contributes to bacterial growth and increases the risk of caries. Among the changes most frequently cited in the literature in pregnant women are gingivitis, periodontitis and pyogenic granuloma. The early identification and treatment of gingivitis and periodontitis in pregnant women is crucial when you consider the existent high prevalence of periodontal disease and that periodontal disease is not influenced by pregnancy. Previous analyses of microbiological culture have demonstrated that changes in estrogen and progesterone associated with pregnancy have an effect on the composition of the subgingival microbiota, which was also confirmed by more recent studies. The role of probiotic supplementation during pregnancy will be discussed.

VVA – DO WE NEED TO CHANGE NOMENCLATURE TO GSM?
Bari Kaplan, Israel

After menopause, the ovaries cease to produce significant amounts of Estrogen. Since estrogen receptors are present in the vagina, urethra, bladder trigone and the pelvic floor, the lack of estrogen leads to atrophy of these structures which is manifested by a marked thinning of the epithelium, a reduction in blood supply, a loss of glycogen, more parabasal cells, high nuclear/cytoplasmatic ratio, inflammatory exudate. These changes cause an increase in the pH of the vagina, making it more alkaline, which in turn leads to alterations in the vaginal microbiome. Other changes include a loss of labial and vulvar fullness, pallor of urethral and vaginal epithelium and decreased vaginal moisture. This condition is known as Vulvo-Vaginal Atrophy (VVA) of menopause or as Urogenital Atrophy of menopause. In the same way that the hypoestrogenic state during the menopause impacts the skeletal system by causing a reduction in bone mass, microarchitectural distortion and resulting in osteoporosis, this hypoestrogenic state leads to vulvo-vaginal atrophy which results in vaginal dryness, pruritus, dyspareunia, dysuria, and urinary urgency. Unlike vasomotor symptoms, which abate over time, vaginal atrophy can be progressive and is unlikely to resolve on its own. The International Society for the Study of Women’s Sexual Health (ISSWSH) and the North American Menopause Society (NAMS) have endorsed a new term for these symptoms – Genito-Urinary Symptoms of Menopause (GSM) replacing the old name Vulvo-vaginal atrophy. They define vulvo-vaginal atrophy (VVA) as the appearance of the vulva and vagina after the menopause, irrespective of associated symptoms. Similarly, Atrophic vaginitis reflects inflammation or infection of the vagina. Neither of these terms describe the urinary symptoms associated with the menopause. Furthermore, they state that labels such as "Atrophy" may have negative connotation to patients whilst other patients may prefer not to use the word vagina. The authors compare the use of GSM to the term "testo-dysfunction", replacing the emotionally charged term: "impotence" or having to say "penis." We believe that the new term GSM should not come to replace the term Vulvo-vaginal atrophy, rather, the two terms describe separate phenomenon. Much like osteoporosis is a condition manifested by increase fracture risk, vulvo vaginal atrophy is a condition manifested by increased genito urinary symptoms

ASSESSMENT OF FETAL GROWTH IN TWINS
Asma Khalil, UK

The risk of fetal growth restriction (FGR) is increased in twin pregnancies, particularly in monochorionic twins. Although twins and singletons have similar growth patterns in the second trimester, in the third trimester growth velocity in twins is found to be consistently less than in singletons, again with the differences most pronounced and noted earlier in
The stillbirth rate in the UK remains one of the highest in Europe. This has prompted the UK government to set a target in 2016 of reducing stillbirths by 20% by 2020 and 50% by 2030. In the past 30 years, the twin birth rate has risen worldwide, due largely to the increasingly widespread use of assisted reproduction techniques and delayed childbirth resulting in advanced maternal age at conception. Approximately one third of twin pregnancies result from assisted reproduction, hence the practice of single embryo transfer now being advocated in many countries. Twin pregnancies are associated with a thirteen-fold increase in the rate of stillbirths in monochorionic, and a five-fold increase in dichorionic, twins compared with singleton pregnancies. Although multiple pregnancies comprise only 1.6% of all births in England and Wales, they represent around 20% of preterm births, 6% of stillbirths, 18% of neonatal mortality and 10% of all NHS maternity litigation claims in respect of stillbirth. Moreover, the risk of cerebral palsy is six times higher in multiple pregnancy than in singletons. In 2018 MBRRACE published its report focusing on perinatal deaths in the UK in 2016. While disappointing that the rate of stillbirths in singletons remained static, the report described a significant fall in the rate of stillbirths and neonatal deaths in twin pregnancies. In fact, the stillbirth rate was almost halved from 11.07 (95% CI, 9.78 to 12.47) per 1,000 births in 2014 to 6.16 (95% CI, 5.20 to 7.24) in 2016 (Table 1, Figure 1). The neonatal mortality rate in twins also fell significantly from 7.81 (95% CI, 6.73 to 9.01) to 5.34 (95% CI, 4.47 to 6.36) per 1,000 live births. What might account for this impressive reduction, can it be maintained, and are there any lessons that can be applied to singleton pregnancies to try to effect a similar reduction? A number of national and international guidelines which focused on twin pregnancies have been published in the last few years, such as the National Institute for Health and Care Excellence (NICE) guideline and quality standards, the International Society of Ultrasound in Obstetrics and Gynecology (ISUOG) guideline and the Royal College of Obstetricians and Gynaecologists (RCOG) Green-top Guideline on the management of monochorionic twin pregnancy. This was followed by extensive efforts to improve awareness and training of healthcare professionals. Monochorionic twin pregnancies generate management dilemmas for clinicians and are associated with significantly higher perinatal mortality and morbidity. Monochorionicity-related complications include twin-to-twin transfusion syndrome (TTTS), selective fetal growth restriction (sFGR), twin anaemia polycythaemia sequence (TAPS) and twin reversed arterial perfusion sequence (TRAP). Over the past 5 years there have been a number of key improvements in the diagnosis, monitoring, management and fetal therapy for complex monochorionic twins. Whether this reported decline in perinatal mortality in twins can be replicated in singleton pregnancies is as yet unknown. However, one would imagine that initiatives such as focused efforts on implementation of evidence-based guidelines, education and training, might also be effective in singletons. One third of stillbirths in singletons occur after 36 weeks’ gestation and up to two thirds after 34 weeks; if these at-risk fetuses could be identified and delivered appropriately, many of these stillbirths could potentially be avoided. Over half of stillbirths are related to impaired fetal growth secondary to placental dysfunction. Until recently, two thirds of stillbirths were considered ‘unexplained’ and therefore thought to be unavoidable. Using a new classification system, however, it has been demonstrated that 43% of stillborn babies were growth restricted. Therefore, a policy of screening for fetal growth restriction, and tailored antenatal surveillance and intervention, could potentially prevent a significant proportion of stillbirths.

HOW TO AVOID STILLBIRTH IN TWINS
Asma Khalil, UK

The stillbirth rate in the UK remains one of the highest in Europe. This has prompted the UK government to set a target in 2016 of reducing stillbirths by 20% by 2020 and 50% by 2030. In the past 30 years, the twin birth rate has risen worldwide, due largely to the increasingly widespread use of assisted reproduction techniques and delayed childbirth resulting in advanced maternal age at conception. Approximately one third of twin pregnancies result from assisted reproduction,
therapy in case of treatment significantly changed the prognosis of patients progressing to endocrine development of new targeted therapies for MBC treatment. Mechanisms causing remains an important challenge. The improved knowledge of to ET still mutated ABC (SOLAR-1 trial), who had relapsed or months vs 5.7 months). In summary, endocrine treatment is a progressed during or after previous endocrine therapy (11.0 months in the palbociclib-fulvestrant group and 3.8 months in the placebo-fulvestrant group. Enhanced signaling through pathway is often upregulated in MBC and promotes ER resistance to endocrine therapy in HR+ breast cancer. This PI3K/AKT/mTOR pathway is also an important mechanism of resistance and disease progression during therapy. The treatment of this group of patients is one of the most important research fields over the last years. Primary endocrine resistance is defined as a relapse within 2 years of adjuvant endocrine treatment (ET) or a progression within the first six month of first-line ET for MBC, whereas secondary endocrine resistance is defined as a relapse within the first 2 years of adjuvant ET or within 12 months after concluding adjuvant ET or a progression of disease after 6 month of ET for MBC. Mechanisms of resistance to endocrine therapy are known to occur at several levels, including the deregulation of several components of the ER/PgR pathway, changed regulation of signaling molecules of the cell cycle or cell survival and the activation of escape pathways that can initiate cell proliferation. Patients can experience resistance during treatment with all endocrine drug classes. Resistance mechanisms can occur De novo or acquired by up-regulation of alternative signaling pathways. One of the most investigated mechanism of ET-resistance is through affecting ER constitutive ligand independent transcriotional activity. ER-α mutations are rarely found in primary tumors but are enriched in tumor biopsies from patients, who underwent endocrine treatment with an Aromatase inhibitor (AI). They can lead to resistance to ET and the transition to an endocrine resistant phenotype that needs to be addressed by alternative therapeutic strategies. CDK4 and CDK6 are enzymes, which promote cell cycle progression from G1 to S phase by interacting with D-type cyclins, are potential targets for anti-cancer therapy. Development of CDK 4/6 inhibitors has changed the therapeutic management of HR+ metastatic breast cancer (palbociclib, ribociclib, and abemaciclib). The use of CDK 4/6 inhibitors in combination with specific endocrine therapies improves progression free survival (PFS) and quality of life as it has been shown in the PALOMA-3 trial in endocrine-therapist resistant patients (9.2 months in the palbociclib-fulvestrant group and 3.8 months in the placebo-fulvestrant group. Enhanced signaling through PI3K/AKT/mTOR pathway is also an important mechanism of resistance to endocrine therapy in HR+ breast cancer. This pathway is often upregulated in MBC and promotes ER transcriptional activity, thereby leading to anti-estrogens resistance and tumor cell growth. Drugs targeting this pathway have shown to increase PFS in MBC. In up to 40% of HR+, Her2- BC PI3K4 mutations can be found. The addition of everolimus (Inhibitor of the mTOR pathway) to an AI enhances the PFS (6.9 months vs 2.8 month. Therefore, the combination of everolimus and exemestane remains a reasonable second- or third-line therapy after progression on endocrine therapy (BOLERO-2 trial). Very recently, it could be shown that PI3K inhibitors can also increase the prolongation of progression-free survival among patients with PI3KCA-mutated ABC (SOLAR-1 trial), who had relapsed or progressed during or after previous endocrine therapy (11.0 months vs 5.7 months). In summary, endocrine treatment is a mainstay for HR+HER2- MBC and resistance to ET still remains an important challenge. The improved understanding of mechanisms causing hormone resistance has allowed the development of new targeted therapies for MBC treatment. CDK4/6 inhibitors combined with endocrine agents have changed the prognosis of patients progressing to endocrine treatment but the resistance to endocrine therapies remains one of the major causes of breast cancer mortality. In women, who are diagnosed with MBC, 50% will develop endocrine resistance and disease progression during therapy. The treatment of this group of patients is one of the most important research fields over the last years. Primary endocrine resistance is defined as a relapse within 2 years of adjuvant endocrine treatment (ET) or a progression within the first six month of first-line ET for MBC, whereas secondary endocrine resistance is defined as a relapse within the first 2 years of adjuvant ET or within 12 months after concluding adjuvant ET or a progression of disease after 6 month of ET for MBC. Mechanisms of resistance to endocrine therapy are known to occur at several levels, including the deregulation of several components of the ER/PgR pathway, changed regulation of signaling molecules of the cell cycle or cell survival and the activation of escape pathways that can initiate cell proliferation. Patients can experience resistance during treatment with all endocrine drug classes. Resistance mechanisms can occur De novo or acquired by up-regulation of alternative signaling pathways. One of the most investigated mechanism of ET-resistance is through affecting ER constitutive ligand independent transcriotional activity. ER-α mutations are rarely found in primary tumors but are enriched in tumor biopsies from patients, who underwent endocrine treatment with an Aromatase inhibitor (AI). They can lead to resistance to ET and the transition to an endocrine resistant phenotype that needs to be addressed by alternative therapeutic strategies. CDK4 and CDK6 are enzymes, which promote cell cycle progression from G1 to S phase by interacting with D-type cyclins, are potential targets for anti-cancer therapy. Development of CDK 4/6 inhibitors has changed the therapeutic management of HR+ metastatic breast cancer (palbociclib, ribociclib, and abemaciclib). The use of CDK 4/6 inhibitors in combination with specific endocrine therapies improves progression free survival (PFS) and quality of life as it has been shown in the PALOMA-3 trial in endocrine-therapist resistant patients (9.2 months in the palbociclib-fulvestrant group and 3.8 months in the placebo-fulvestrant group. Enhanced signaling through PI3K/AKT/mTOR pathway is also an important mechanism of resistance to endocrine therapy in HR+ breast cancer. This pathway is often upregulated in MBC and promotes ER transcriptional activity, thereby leading to anti-estrogens resistance and tumor cell growth. Drugs targeting this pathway have shown to increase PFS in MBC. In up to 40% of HR+, Her2- BC PI3K4 mutations can be found. The addition of everolimus (Inhibitor of the mTOR pathway) to an AI enhances the PFS (6.9 months vs 2.8 month. Therefore, the combination of everolimus and exemestane remains a reasonable second- or third-line therapy after progression on endocrine therapy (BOLERO-2 trial). Very recently, it could be shown that PI3K inhibitors can also increase the prolongation of progression-free survival among patients with PI3KCA-mutated ABC (SOLAR-1 trial), who had relapsed or progressed during or after previous endocrine therapy (11.0 months vs 5.7 months). In summary, endocrine treatment is a mainstay for HR+HER2- MBC and resistance to ET still remains an important challenge. The improved understanding of mechanisms causing hormone resistance has allowed the development of new targeted therapies for MBC treatment. CDK4/6 inhibitors combined with endocrine agents have changed the prognosis of patients progressing to endocrine treatment but the resistance to endocrine therapies remains one of the major causes of breast cancer mortality. In women, who are diagnosed with MBC, 50% will develop endocrine resistance and disease progression during therapy. The treatment of this group of patients is one of the most important research fields over the last years.

P113K inhibitors (apelinib) can be suggested as second-line therapy in combination with fulvestrant or exemestane. P113K inhibitors are especially recommended for patients with P113KCA mutations, before chemotherapy should be initiated. In the future studies should focus on the identification of new resistance and response biomarkers to endocrine targeted patients benefiting most from currently available therapy options. Furthermore, mechanisms behind the resistance to CDK4/6 and mTOR inhibitors have to be elucidated and treatment options after progression on these drugs analyzed.

 SHOULD WE MEASURE PROGESTERONE ON THE DAY OF A FROZEN EMBRYO TRANSFER? YES Elena Labarta, Spain

The administration of exogenous progesterone (P) is needed for the luteal phase support in artificial endometrial preparation cycles with hormone replacement therapy (HRT) for embryo transfer. By promoting endometrial maturation, it is essential for the embryo implantation process. The transformation of the endometrium from a proliferative to a receptive state depends on an adequate exposure to P, which prepares the uterus for implantation and the maintenance of pregnancy. Progesterone also has non-hormonal actions such as allowing immune tolerance during pregnancy, especially affecting the synthesis of cytokines and the function of Natural Killers cells. Low exposure to P at the time of implantation or during early pregnancy may result in an implantation failure or spontaneous miscarriage. Surprisingly, there is no individualization in the best route, dose or time of exogenous P administration, as published studies do not demonstrate that there is a clearly superior protocol. There are different administration routes of P such as vaginal, subcutaneous, intramuscular, oral or rectal. Until now, the vaginal route has been the most used in Europe. It has been shown that although serum P levels appear to be lower after vaginal than intramuscular administration, vaginal route results in an adequate secretary transformation and reduced pregnancy rates. This discrepancy suggests that the bioactivity of vaginal P in the uterus is higher, due to the effect of the first step of the uterus. For this reason, no measurement of serum P levels have been conducted to analyse if the absorption was adequate. The best context to analyse the net impact of exogenous P is the artificial cycle, in which there is no endogenous production, in comparison with the stimulated or natural cycle. In this scenario, recent studies have suggested that serum P levels have a correlation with the success rate in artificial cycles when using the vaginal route. The only published prospective study analysing this topic was carried out in oocyte donation cycles performed in our centre (Labarta et al., 2017), showing that there is a serum P threshold (9.2 ng/ml) below which ongoing pregnancy rates significantly decrease (32.7% vs 52.8%, p=0.016). These results have been confirmed and validated in a large prospective study of almost 1200 unscreened patients undergoing an embryo transfer in an artificial cycle, regardless the origin of the oocytes and after adjusting for any confounding factors (Labarta et al., ESHRE 2019). In summary, after analysing more than 1400 artificial cycles with the same luteal phase support, we can conclude that we have found the critical threshold of serum P on the day of ET, which is around 9ng/ml. Before these two studies, some clinicians were measuring serum P on the luteal phase but the decision making on when to increase exogenous P was doctor dependent, as the threshold was not clearly established. The advantage of our studies is that we were absolutely blind to the results of serum P and no modifications of exogenous P were done, being this the best way to analyse its impact. Once demonstrated that the results can be extrapolated to the general infertile population, our new research is focused on...
GENETICS OF MENOPAUSE

Joep S.E. Laven1, Jenny A. Visser2, Andre G. Uitterlinden3, Wilbert P Vermeij4, Jan H.J. Hoeijmakers4

1 Division of Reproductive Medicine, Department of Obstetrics and Gynaecology, Erasmus Medical Centre, Rotterdam, The Netherlands
2 Division of Endocrinology, Department of Internal Medicine, Erasmus Medical Centre, Rotterdam, The Netherlands
3 Human Genotyping Facility, Department of Internal Medicine, Erasmus Medical Centre, Rotterdam, The Netherlands
4 Department of Molecular Genetics, Erasmus Medical Centre, Rotterdam, The Netherlands

Menopause is defined as the permanent cessation of ovulation and hence menstruation due to ovarian failure. The median age of menopause is 51 years. However, early menopause might occur at 40 years of age whereas late menopause might happen as late as 62 years of age. Menopause is also a highly heritable condition. Genetic variants are known to contribute to about 50% of the variation in age at menopause.

Several genetic studies have tried to unravel this genetic background making use of different genetic techniques in population studies as well as in animal models. Genome wide linkage studies have only identified a limited amount of genetic variants that seem to be associated with menopause. Population based studies as well as animal research into the genetic background of POI has identified several genetic variants that seem to be associated with primary ovarian insufficiency. However, a lot of these studies suffer from methodological flaws since results are generally not replicated in different independent samples and most of these studies are underpowered. Hence results are conflicting. Recent genome wide association studies (GWAS) have identified numerous, over 220, genetic variants that are associated with menopause. The majority of identified genetic variants seem to be mainly involved in DNA repair and DNA maintenance. Another cohort of genetic variants are important in mitochondrial function as well as in immune systems.

Biological as well as epidemiological data seem to indicate that reproductive performance, age at menopause and longevity are interlinked through common genetic factors involved in DNA repair and DNA maintenance. In case these systems fail cell death and accelerated loss of function occurs which is generally referred to as ageing. Consequently, ageing of the soma as a result of inefficient DNA repair appears also to be responsible for failure to reproduce and the subsequent occurrence of menopause. In this way reproductive performance might be strongly linked to the physical condition of the soma and may be a very good predictor for general health in later life.

PREDICTING LIVE BIRTH FOR POOR OVARIAN RESPONDERS: THE PROsPeR CONCEPT

Philippe Lehet, Australia

Our objective was the development of the first specific tool of live birth prediction for Poor Ovarian responders treated with recombinant human FSH. Two continuous models were developed separately for patients with/without first ART experience and were synthesized by the simplified Poor Responder Outcome Prediction (PROsPeR) model using only three variables: AMH, Age and previous (if exiting) number of oocytes. The best discrimination was found compared with other models (AUCROC=0.84 [79-88]). This model was discriminative was directly applicable for any center under some simple calculation. Specific to PGR, PROsPeR constitutes the best compromise between precision and simplicity, and is suitable for routine practice.

COMPLEX ENDOMETRIAL ORGANOIDS TO MODEL EMBRYO IMPLANTATION

Emma Lucas, UK

Problem statement: The establishment of a successful pregnancy depends on closely and co-ordinated development of the endometrium in order to promote implantation and invasion by developmentally competent embryos, as well the ability to recognise and dispose of those embryos with limited developmental potential, for example aneuploid or otherwise compromised embryos. Failures in this quality control process are thought to underlie reproductive disorders such as recurrent pregnancy loss and implantation failure. Although animal models can provide useful information about early pregnancy which cannot be obtained in human, these models are limited by distinct differences in the timing and regulation of implantation processes. Further, while existing in vitro models of monolayer endometrial cell cultures allow the study of discrete cellular responses to hormonal and biochemical signals, they lack the structural and functional complexity of the in vivo situation and therefore preclude analysis of interactions between the different compartments of the tissue. Therefore we are striving to develop a complex three-dimensional co-culture system comprising the major cell types of endometrial tissue in order to develop higher resolution studies of the processes of decidualization and implantation.

Methods: Dissociation of timed luteal phase endometrial tissue into single cell suspensions was performed by mechanical and enzymatic processing. Using a complex medium containing growth factors and inhibitors designed to induce glandular organoid formation, endometrial epithelial cell clumps were first expanded in matrigel, then passaged and cultured in collagen hydrogel to induce formation of epithelial organoids. By modifying the culture media, stromal cells can be included in the hydrogel cultures to form a supporting matrix around the epithelial organoids. Organoids and co-cultures allow the study of discrete cellular responses to hormonal and biochemical signals, they lack the structural and functional complexity of the in vivo situation and therefore preclude analysis of interactions between the different compartments of the tissue. Therefore we are striving to develop a complex three-dimensional co-culture system comprising the major cell types of endometrial tissue in order to develop higher resolution studies of the processes of decidualization and implantation.

Results: To identify stromal-epithelial interactions, the minimal medium required for differentiation when cocultured with stromal cells was determined by systematically removing components of the medium and measuring expression of glandular differentiation genes. The established minimal medium maintained gland organoid differentiation to similar levels to when stimulated in the complex medium only when cocultured with stromal cells. In monocyte culture, organoids failed to differentiate in this medium due to dependence on a complex cocktail of growth factors and inhibitors. Single cell RNA sequencing of a decidual time course of organoids in both monocyte culture and in co-culture with stromal cells differentiated in minimal medium was performed. All undifferentiated organoids clustered regardless of stromal cell coculture. However, upon exposure of deciduogenic cues, organoids from monocyte culture and coculture diverged. By day 4, monocyte organoids expressed stress genes (BIRC3),
whereas organoids in coculture expressed differentiation genes (PAEP and SPP1), suggesting the stromal interactions rescued differentiation of the organoids in the minimal medium. **Conclusion:** Endometrial cells can be propagated and differentiated in our three-dimensional co-culture system, and display transcriptional and morphological similarities to the human endometrium. Our minimal medium has been able to demonstrate that stromal cells influence epithelial gland differentiation and that our coculture system can be utilised to model epithelial-stromal interactions of the endometrium. Our ongoing work aims to exploit the system to develop patient- and disease-specific models using research embryos to study the complex interactions of embryo and endometrium at implantation.

**A NEW PERSPECTIVE ON HIGH ORDER CESAREAN DELIVERIES UP TO NUMBER ELEVEN**

Mirra Manevich-Mazor, Ronit Silber, Bari Kaplan, Linda Harel Mayanei Hayeshua Medical Center, Bnei Brak, Israel

**Introduction:** As Cesarean Delivery (CD) rate is constantly on the rise, an ongoing debate deliberates how many repeat CDs are safe and how to counsel women regarding their family planning choices. It is customary to counsel women against additional pregnancies after their third CD. In this study, the authors aim to elucidate whether this is a prudent clinical strategy by evaluating and comparing the maternal and neonatal outcomes of women undergoing repeat cesareans, up to CD number 11. **Materials & methods:** In this single-center retrospective study, between the years 2012 and 2018, women who underwent a third CD were compared to patients undergoing repeat CDs up to their eleventh. Comparison of both maternal and neonatal outcomes was performed. Maternal outcomes evaluated included uterine rupture/dehiscence, adjacent organ damage (bladder and bowel), placentaion, excessive bleeding, operation time, ICU admission and hospitalization length. Neonatal outcomes evaluated were Apgar scores, cord pH, birth weight and NICU admission. A statistical analysis was performed to assess the relative risk posed to the mother or newborn with each additional CD. **Results:** A total of 483 women undergoing 564 CDs (147 3rd CDs, 260 5th CDs, 99 6th CDs, 36 7th CDs, 11 8th CDs, 6 9th CDs, 3 10th CDs and 2 11th CDs) were included in this study. Following outcome stratification and comparison, no statistically significant differences were found in either maternal or neonatal major outcomes between the groups. Only 3 cases of uterine rupture were observed, 2 cases during 5th CD, and 1 case during 6th CD. The statistically significant differences included thin lower uterine segment and use of hemostatic agents. There were 3 urgent hysterectomies performed altogether in the high order cesarean group. There was a trend to higher blood loss in the 3rd CD group. The mean maternal age was 34.8 years (SD 3.9), mean gestational age 38+0 (IQR 37.6-38.9) and average birth weight 3065 grams (SD 506 grams) were without significant differences between the groups, except a trend towards an older maternal age in higher CDs. Moreover, the incidence of gestational diabetes, hypertension, obesity and other maternal diseases was highest in the third CD group, the rate reducing with each additional CD. We also conducted a gross analysis of CDs between the years 2008 to 2019. During this time frame 2,483 additional CD. We also conducted a gross analysis of CDs between the years 2008 to 2019. During this time frame 2,483 additional CD. There was one case of maternal death during this period, from an amniotic fluid embolism. We discuss tubal sterilization with our repeat CD patients, and if they are interested in further fertility, we offer them a conditional informed consent for tubal sterilization. The surgeon decides whether to put the consent form into effect and proceed with tubal sterilization during surgery. **Conclusions:** Based on our data, there is no definite number of CDs a woman may undergo safely, rather this should be discussed individually based on the findings during surgery. Some women heal spectacularly with lower uterine segment intact, and no significant adhesions found even on their 10th CD. Also, there is a clear trend among patients who reach the high order cesareans, as being generally healthier relative to their earlier CD counterparts. Thus, it seems that patients with comorbidities are less likely to heal well enough for, or desire, additional pregnancies.

**NO TREATMENT BEFORE IFV IS NEEDED FOR INTRAMURAL SMALLER THAN 3 CM FIBROIDOS**

Roberto Marci

Dpt. Of Morphology Surgery and Experimental Medicine- University of Ferrara-I Hirslanden Clinic-Geneva-CH

Uterine fibroids (UFs) are monoclonal benign tumors consisting of smooth muscle cells and connective tissue that develop in the uterine wall. Although the etiology is largely unknown, leiomyomas are estrogen- and progesterone-dependent tumors characterized by an increased and disorganized proliferation of smooth muscle cells with overproduction of extracellular matrix (ECM). UFs seem to have an increased sensitivity to sex steroid hormones which is associated with a higher expression of estrogen receptor-α (ER-α) and progesterone receptor (PR) when compared to the normal myometrium. Furthermore, in the luteal phase while normal myometrial cells undergo apoptosis, UFs show increased activity and proliferation, which may promote cell proliferation and grows in response to progesterone (which typically has a suppressive effect on the myometrium). UFs represent one of the most common pelvic tumors. Symptoms associated with myomas depend on numerous factors such as number, volume and location. Generally, they cause heavy and prolonged menstrual bleeding that could lead to severe anemia in patients with UFs. Other symptoms are swelling and pelvic pain. In addition, UFs may alter female reproductive function, causing infertility, abortions and pregnancy complications. Although benign, leiomyomas may have serious consequences, requiring medical and/or surgical treatment. Annually, among women aged 15-54, UFs-related treatments account for 42 per 10,000 hospitalizations and in most of the cases the hospital stay is accompanied by some type of surgical procedure (hysterectomy, myomectomy). To date, despite the available data concerning the management of fibroids are scarce. At present, in fact, there are only few published randomized trials that have compared different therapies for UFs and data on long-term outcomes (quality of life, fertility, recurrence of symptoms, complications) are still inadequate. Current management strategies include both surgical and medical options, depending on severity of symptoms, tumor number, location and size, patient’s age and fertility preservation wishes. Furthermore, current available treatments for UFs to preserve fertility are not capable yet to control symptoms and progression of the disease and have not been proven to be effective in the long term or are associated with high risk of post-operative complications and...
relapse of the disease. Treatments that offer long term resolution are often invasive and burdened by considerable costs related to surgery and hospitalization. Nowadays, UFs represent the most common indication for hysterectomy (2/3 of all hysterectomies are performed for this indication) and one of the main causes of the total health care cost in gynecological departments. Uterus-sparing surgical approaches include hysteroscopic myomectomy for small submucosal fibroids, laparoscopic or laparotomy myomectomy (depending on fibroids’ location and size), laparoscopic cryomyolysis and thermo-coagulation and laparoscopic occlusion of the uterine arteries. Other minimal invasive but non surgical alternatives are uterine artery embolization (UAE), vaginal occlusion of uterine arteries and high frequency magnetic resonance-guided focused ultrasound (MGrFUS). Gynecologists generally considered medical treatments (oral contraceptives, levonorgestrel intrauterine devices, GnRH agonists/antagonists, Ulipristal acetate) as preoperative adjuvants mainly because of their inability to fully resolve UFs-related symptoms and their heavy side effects that limit their long-term use. However, depending on volume/location a conservative/medical treatment may represent a valuable option before IVF.

MINIMIZING CARDIOVASCULAR RISKS OF PERIMENOPAUSAL CONTRACEPTION

Lydia Marié-Scemama, France

Dealing with the approach of menopause after 40 women are entering a new phase - not to be confused with the onset of old age, as in the past. Cardiovascular risks increase with age. Contributing factors are: obesity, smoking, lack of exercise, metabolic diseases, stress or a history of pathologic pregnancies i.e. toxemia or eclampsia. QOL factors. The ongoing need for contraception. Changes in the household: children are grownup, couple experience renewed interest in sexual activity or are dealing with separation and life with a new partner. Perimenopausal contraception is often complicated to administer. « Primum non nocere » Pills or IUD? Certain countries today are against prescribing COC after the age of 35 even in the case of non-smokers. Other countries, such as France, prescribe it. Estrogens and blood circulation: Even in women presenting no cardio-vascular pathologies, synthetic estrogens, present in the majority of COC’s, have a negative effect on the cardiovascular system: arterial and venous. Advantages of prescribing COC with natural estradiol or progestogens only? Best approach for women at risk ie. history of coronary disease, stroke, VTE and high blood pressure (HBP).

WHY DO NICHES (CS DEFECTS) FORM? ARE THEY A PROBLEM?

Ben W. Mol
Professor of Obstetrics and Gynaecology, NHMRC Practitioner fellow, Department of Obstetrics and Gynaecology Monash University & Monash Medical Centre, Australia

Caesarean section (CS) rates are rising globally. In the UK the CS rate increased from 12% to 29% between 1990 and 2008. In the United States, one in three women delivered by CS in 2011, whereas in China the rates have even risen from 2% in 1985 to 36-58% in 2010. The strongest increase was seen in Brazil from 15% in 1970 to even 80% in the private sector in 2004. This increasing CS rate has stimulated an interest in the potential long-term morbidity of CS scars. The etiology of niche related postmenstrual spotting and pain has not been fully elucidated. They are thought to be caused by retention of menstrual blood in a niche, which is intermittently expelled after the majority of the menstruation has ceased. Blood can also accumulate, if fibrotic tissue in the myometrium at the site of the caesarean scar may impair normal contractions and as a consequence the drainage of menstrual flow. Additionally, newly formed fragile vessels in the niche may also attribute to the accumulation of blood or fluid in the niche or uterine cavity due to a constant low production of in situ leakage of blood and fluid. This is supported by the presence of free blood cells in the endometrial stroma, suggesting recent haemorrhage and hysteroscopic evaluations where small vessels in the majority of patients are seen. In this presentation, I will discuss why do niches (CS defects) form, and whether and why they are a problem.

THERE SHOULD NOT BE A FREEZE ONLY STRATEGY FOR ALL

Ben W. Mol
Professor of Obstetrics and Gynaecology, NHMRC Practitioner fellow, Department of Obstetrics and Gynaecology Monash University & Monash Medical Centre, Australia

Since its successful introduction in 1978, in-vitro fertilization (IVF) has traditionally been performed using fresh embryo transfer. In the first decades of IVF, ovarian hyperstimulation allowed the development and transfer of multiple embryos. As IVF technology improved, the number of multiple pregnancies increased, leading to a gradual reduction in the number of embryos transferred. Embryo freezing was performed to allow subsequent transfer if the fresh cycle was unsuccessful. Small randomized trials suggested that freezing all embryos in a fresh IVF cycle followed by thawed frozen transfer in subsequent cycles might improve pregnancy rates. Also, it has been suggested that pregnancies occurring after frozen embryo transfer are associated with fewer complications (e.g. lower rates of antepartum hemorrhage) and better neonatal outcomes, including higher birth weight and lower risk of perinatal mortality. Frozen embryo transfer has become increasingly common, with the number of frozen cycles increasing in many countries. I will discuss studies comparing the effectiveness of a freeze-only and subsequent frozen embryo transfer strategy to conventional fresh embryo transfer (with remaining embryos frozen) in infertile women.

TRADITIONAL OIL-BASED HSG EXPLOITING ITS THERAPEUTIC ADVANTAGE

Ben W. Mol
Professor of Obstetrics and Gynaecology, NHMRC Practitioner fellow, Department of Obstetrics and Gynaecology Monash University & Monash Medical Centre, Australia

Infertility defined as the inability to conceive within 1 year of unprotected intercourse is one of life’s great misfortunes, which affects 1 out of 6 couples trying to get pregnant. Testing for tubal patency is part of the basic fertility work-up, and still in many hospitals hysterosalpingography (HSG) is used. We recently showed in our landmark trial published in the New England Journal of Medicine that in infertile women undergoing HSG tubal flushing with oil-based contrast medium (Lipiodol®) resulted in more ongoing pregnancies than with the use of water-based contrast medium (Telebrix Hyster®) (Dreyer et al, 2017). I will discuss the latest evidence of the use of tubal flushing in infertility.

WHAT IS THE EVIDENCE THAT ANY TOCOLYTI CS WORK?

Ben W. Mol
Professor of Obstetrics and Gynaecology, NHMRC Practitioner fellow, Department of Obstetrics and Gynaecology Monash University & Monash Medical Centre, Australia

Worldwide, the calcium channel blocker nifedipine is used to treat threatened preterm labour, but sound evidence to support this practice is lacking. Nifedipine is not registered for use in pregnancy, and its manufacturer, Bayer, does not want to take any responsibility for its use in pregnancy. There is a possibility that this widely practiced management, which is advocated in State guidelines, could even be harmful. Case reports have described fetal death after maternal hypotension following administration of Nifedipine (Van Veen 2005). A large cohort study confirmed more hypotension after tocolysis with nifedine as compared at the oxytocin antagonist atosiban (De Heus 2009). More importantly, a recent randomised clinical trial directly comparing nifedipine to atosiban in women with threatened preterm labour (510 women) showed the composite neonatal outcome to be comparable (14% versus 15%, RR 0·91, 95% CI 0·61–1·37), while the perinatal mortality rate was doubled after nifedine (16% versus 7% (RR 2·20, 95% CI 0·91–5·3) (Van Vliet 2016). In view of the frequent clinical problem and the use of barely evaluated tocolytic drug nifedipine, that might be either beneficial or harmful for the children involved, there is a need for randomised clinical trials on the subject. 

van Veen AJ et al. Severe hypotension and fetal death due to tocolysis with nifedipine. BJOG. 2005;112:509-10.

SELF-ORGANISATION OF THE HUMAN EMBRYO IN THE ABSENCE OF MATERNAL TISSUE

Matteo A. Molè, Tim Coorens, Marta N. Shahbazi, Antonia Weberling, Lucy Richardson, Abbie Drinkwater, Najma Syed, Stephanie Engley, Philip Snell, Leila Christie, Kay Elder, Alison Campbell, Simon Fishel, Roser Vento-Tormo, Sam Behjati & Magdalena Zernicka-Goetz

1 Mammalian Embryo and Stem Cell Group, University of Cambridge, Department of Physiology, Development and Neuroscience, Downing Street, Cambridge CB2 3EZ, UK.
2 Wellcome Sanger Institute, Cambridge, Hinxton, CB10 1SA, UK.
3 Herts & Essex Fertility Centre, Bishops College, Cheshunt, Herts, EN8 9XP, UK.
4 Bourn Hall, Bourn, Cambridge, CB2 0QQ, UK.
5 CARE Fertility Group, John Webster House, 6 Lawrence Drive, Nottingham Business Park, Nottingham, NG8 6PZ, UK.
6 School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Byrom Street, Liverpool, L3 3AF, UK.
7 Cambridge University Hospital NHS Foundation Trust, Cambridge, CB2 0QQ, UK.
8 Department of Paediatrics, University of Cambridge, Cambridge, CB2 0QQ, UK.

Human embryogenesis follows a series of coordinated and conserved cell fate specification events. Upon implantation on day 7, the three cell lineages forming the human blastocyst – the embryonic epiblast and the two extra-embryonic tissues hypoblast and trophoderm – undergo major developmental changes. This time period represents one of the major causes of pre-clinical miscarriages due to failure of the embryo to progress through development. Despite its key importance, we lack major understanding of the molecular and cellular mechanisms governing this essential stage. Using our recently developed method to culture human embryos beyond implantation (Deglincerti et al., 2016; Shahbazi et al., 2016) in combination with single cell RNA sequencing, we have constructed a molecular map of the human pre-gastrulation embryo at day 9 and day 11 of development. Through this analysis, we were able to identify a subset of hypoblast cells that expressed BMP, WNT and NODAL antagonists, reminiscent of factors secreted by the anterior-visceral endoderm of pre-gastrulation mouse embryos. Their unequal distribution within the embryo, enriched at one end, suggests that these cells may constitute a localised signalling centre for symmetry breaking and specification of the anterior-posterior axis of the human embryo. Furthermore, we unveiled key signalling interactions between epiblast and hypoblast cells. As human embryos develop beyond day 7, epiblast cells undergo a pluripotent stage transition, and upregulate the expression of fibroblast growth factor (FGF) ligands, which act both in an autocrine and a paracrine manner. We found that FGF signalling is required to preserve both epiblast and hypoblast cells beyond the blastocyst stage. Our study provides the first map of cell types and cellular interactions of the pre-gastrulation human embryo.

References:

REGULATION OF PHYSIOLOGICAL REPRODUCTIVE LIFESPAN AND FEMALE FERTILITY

Grant W. Montgomery, Australia
Institute for Molecular Biosciences, The University of Queensland, Brisbane, Queensland, Australia.

Variation in reproductive lifespan and female fertility have implications for individual health, population size and ageing. Fertility declines well before general signs of menopause and is also adversely affected by common reproductive diseases, including polycystic ovarian syndrome (PCOS) and endometriosis. There is substantial genetic variation for common traits associated with reproductive lifespan and for common diseases influencing female fertility. Progress in high-throughput sequencing and genome-wide association studies (GWAS) have transformed our understanding of common genetic risk factors for complex traits and diseases influencing reproductive lifespan and fertility. The data emerging from GWAS demonstrate the utility of genetics to explain epidemiological observations, revealing shared biological pathways linking puberty timing, fertility, reproductive ageing and health outcomes. The observations also identify unique genetic risk factors specific to different reproductive diseases impacting on female fertility. Sequencing in patients with primary ovarian insufficiency (POI) have identified mutations in a large number of genes while GWAS have revealed shared genetic risk factors for POI and ovarian ageing. Studies on age at menopause implicate DNA damage/repair genes with implications for follicle health and ageing. In addition to the discovery of individual genes and pathways, the increasingly powerful studies on common genetic risk factors help interpret the underlying relationships and direction of causation in the regulation of reproductive lifespan, fertility and related traits.
DEBATE: OVARIAN STIMULATION MORE OR LESS?
LESS IS MORE
Geeta Nargund, UK
Lead consultant for Reproductive Medicine, St George’s University Hospital and Medical Director, Create Fertility, London

Not every woman undergoing IVF requires ovarian stimulation. However, controlled ovarian stimulation to achieve multiple follicle development is an integral part of IVF treatment for most women. There is an on-going debate about optimising short and long-term health outcomes for women and babies in IVF. There is an urgent need to reduce the cost and burden of IVF treatment for women. The conventional IVF protocols can be complex, aggressive and unfriendly with treatment lasting up to 4 weeks and involving pituitary downregulation followed by higher doses of daily stimulation. As a result, many women experience considerable discomfort. Milder stimulation approaches fit within women’s menstrual cycles and are associated with less physical and emotional burden and drop-outs from treatment. The primary aim of mild stimulation is to provide a more physiological approach with the collection of fewer but mature oocytes of higher quality. Studies have shown that this method may be beneficial for oocyte/embryo quality and endometrial receptivity. The effect of high stimulation on intrafollicular and endometrial physiology and potential epigenetic errors in oocytes and embryos is already known. The adverse effects of high response and high oestradiol levels on adverse perinatal outcomes are extensively studied. Knowing the lower biological efficiency of oocytes with conventional stimulation protocols and in the context of improved laboratory performance, the need for collecting many oocytes per cycle will be debated. The efficiency of mild stimulation in normal and high responders including cumulative live birth rates will be discussed. The use of high stimulation for IVF in poor responders will be questioned in the light of recent ASRM recommendation to use mild stimulation protocols in such women. There has been a societal field change in the need for and availability of IVF to an increasing spectrum of healthy women including same sex couples, single women, as well as for women requesting egg freezing and those who wish to donate eggs. These women are not infertile yet frequently exposed to high stimulation and its associated burden of treatment. Inequality of IVF provision is also affected by high drug costs making IVF available only to the very affluent in treatment. Inequality of IVF provision is also affected by high drug costs making IVF available only to the very affluent in treatment. Inequality of IVF provision is also affected by high drug costs making IVF available only to the very affluent in treatment. 

As a result, many women experience considerable discomfort. Milder stimulation approaches fit within women’s menstrual cycles and are associated with less physical and emotional burden and drop-outs from treatment. The primary aim of mild stimulation is to provide a more physiological approach with the collection of fewer but mature oocytes of higher quality. Studies have shown that this method may be beneficial for oocyte/embryo quality and endometrial receptivity. The effect of high stimulation on intrafollicular and endometrial physiology and potential epigenetic errors in oocytes and embryos is already known. The adverse effects of high response and high oestradiol levels on adverse perinatal outcomes are extensively studied. Knowing the lower biological efficiency of oocytes with conventional stimulation protocols and in the context of improved laboratory performance, the need for collecting many oocytes per cycle will be debated. The efficiency of mild stimulation in normal and high responders including cumulative live birth rates will be discussed. The use of high stimulation for IVF in poor responders will be questioned in the light of recent ASRM recommendation to use mild stimulation protocols in such women. There has been a societal field change in the need for and availability of IVF to an increasing spectrum of healthy women including same sex couples, single women, as well as for women requesting egg freezing and those who wish to donate eggs. These women are not infertile yet frequently exposed to high stimulation and its associated burden of treatment. Inequality of IVF provision is also affected by high drug costs making IVF available only to the very affluent in many countries. I will also demonstrate that aggressive ovarian stimulation to collect a large number of oocytes with an aim to "freeze all embryos (FAE) is neither a solution for all women nor in line with delivering a safe and successful IVF-ET cycle of treatment. The concept of FAE lacks proper evaluation in "public healthcare" settings. The overwhelming evidence for safety, reduced cost and burden of treatment combined with its efficiency in achieving equivalent success rates make mild stimulation for IVF a better approach for women undergoing IVF treatment.

DEVELOPING NEW GUIDELINES FROM A POI REGISTRY
Nick Panay, UK

Context: Premature ovarian insufficiency (POI) remains poorly understood and under researched. Guidelines from ESHRE, IMS, EMAS and NICE UK have been developed using data largely from observational and short term RCTs. The POI registry https://poiregistry.net was developed at Imperial College London (ICL), UK using a British Research Council grant to collect national/international data in an effort to avoid fragmented research, improve our understanding of this important disease and to inform new guidelines.

Objective: Retrospective and prospective registry analysis of women with POI to update evidence-based management guidelines for POI. Methods: Data collected on women diagnosed with POI < 40 years were entered onto an online registry using the semantic web. The data were extracted and analysed at ICL by patient ages, etiology, ethnicity, time to diagnosis, symptom profile and bone mineral density (BMD). Results: More than 60 centres have registered to enter data globally. Many centres are in the UK but also include investigators in Australia, Canada, Chile, Italy, Russia, Spain and South Africa. Retrospective (legacy) data have been entered for 484 women and prospective data for 343 women with POI thus far. A further 400 patients have been entered into a Chinese translation of the registry at Beijing O & G Hospital, Capital Medical University and will be uploaded. Data include demographics, diagnosis, presentation, management, fertility and health outcomes e.g. Bone Mineral Density(BMD). Delay to diagnosis is associated with progressively lower BMD. Collaborative work is planned to facilitate biobanking for genetic and biomarker analyses. These data will be used to revise and update guidelines on perspective of the "deficit model". This proposes that the public are in some way deficient in key information and that if only this were rectified, and their knowledge gap filled by the provision of more information, their attitude, belief or behaviour would automatically change as a consequence. This is what happens through traditional media outlets (e.g. TV, Radio, Newspapers, etc) as well as the traditional lecture style of presentation: the flow of information is from the expert to the audience. However, we now know that the communication of science and medical information to the public is more complex than this and that generally this approach does not work (although professionals usually feel very comfortable in doing it!). Today, it is generally considered that models involving "consultation" or "engagement", where the public are active participants in regular dialogue and debate, are better able to influence opinion and behaviour. Thus, the very nature of social media platforms (e.g. Facebook, Twitter, Instagram, YouTube) which offer the opportunity for two-way dialogue have a significant advantage. Unfortunately, studies on how social media is better able to communicate information about male reproductive health are limited, but we do know that men would generally like more information (and medical professionals and online sources are their preference). This is supported by data from the recent Wellcome Trust Global Monitor Report 2018 which show across 140 countries that the majority of people have an interest in learning more about science and healthcare and, moreover, there is a high degree of trust in the information given by scientists and health professionals. Therefore, there is much that scientists and healthcare professionals can do in this space. However, would-be social media users should be aware that there are country and age-specific preferences in social media use. Therefore, it is important to work out in advance the optimal social media platform(s) to be used to reach the target audience.

USE OF SOCIAL MEDIA PLATFORMS TO INFORM THE PUBLIC ABOUT MALE REPRODUCTIVE HEALTH ISSUES
Allan Pacey, UK
Academic Unit of Reproductive and Developmental Medicine, Department of Oncology and Metabolism, The University of Sheffield, Level 4, The Jessop Wing, Sheffield, South Yorkshire, S10 2SF, United Kingdom

The communication of science and healthcare messages has changed enormously in the last 25 years. Whilst this has largely been helped by the technological development and accessibility of the internet (>4 billion) and the number of social media users (>3 billion), there has also been critical shifts in our understanding of how such topics are best communicated. Historically, the communication of science and healthcare messages has been carried out from the

Event: 27th World Congress on Controversies in Obstetrics, Gynecology & Infertility (COGI)

Location: Paris, France

Date: November 21-23, 2019
The first international consensus statement on the use of testosterone in the treatment of women, led by the International Menopause Society (IMS), has been published in four leading international medical journals: Climacteric; Maturitas; The Journal of Sexual Medicine; and The Journal of Clinical Endocrinology and Metabolism. The advice has been developed by nine leading medical organisations including The International Menopause Society; The International Society for Sexual Medicine; The Federation Latinoamericana de Sociedades de Climaterio y Menopausia; The American College of Obstetricians and Gynecologists, The North American Menopause Society, The European Menopause and Andropause Society; The International Society for the Study of Women’s Sexual Health, The Royal College of Obstetricians and Gynaecologists and The Endocrine Society, and endorsed by several additional Societies. It follows years of debate regarding testosterone therapy for women and, for the first time, provides agreement from experts about the known benefits and potential risks of testosterone therapy for premenopausal and postmenopausal women. The consensus specifically states that testosterone can be effective at improving sexual wellbeing for postmenopausal women with hypoactive sexual desire dysfunction (HSDD). Benefits include improved sexual desire, function and pleasure, together with reduced concerns and distress about sex. There are insufficient data to support the use of testosterone for the treatment of any other symptom or clinical condition, or for disease prevention. The international panel is calling on industry, researchers and funding organisations to recognise the need for further research into testosterone therapy for menopausal women and the development and licensing of products indicated specifically for women. Translated versions of the consensus statement will be available on the International Menopause Society website. Visit https://www.imsociety.org to find out more [Link to further information].

**WE NEED RANDOMIZED CONTROL TRIAL FOR VULVO-VAGINAL LASER**

*Santiago Palacios, Spain*
Director of the Instituto Palacios de Salud y Medicina de la Mujer, Madrid
www.institutopalacios.com

We must clearly increase the number of randomized and controlled group clinical studies, for many reasons, which I will discuss:

1. The first and obvious one is that there are very few studies, and also with a small and short number of patients.
2. One of the main problems that exist today is the lack of protocols for the different indications and for the different characteristics of the patients. In addition, there are no comparisons between the use of CO2 or erbium lasers, and even the indications and specifications are according to the type of laser in particular. Today it is mandatory to know in detail, the possibilities of power, energy, creep pixel density and number of pulses your laser has. However, there are no specifications on how to identify each patient, depending on age or response characteristics. And what is worse is that what is published with another brand of laser device, does not work for yours.
3. Another key point for which more RCTs are needed is that we do not know which of the vulvo-vaginal laser option is better than other options. Let’s take the example of vulvo-vaginal atrophy. What is better?
   - Use laser or radiofrequency
   - Use laser or local estrogens
   - Use in combination

Only with RCT will it be possible to answer.

4. Another question that arises and can be answered with future studies, is whether it would be good to apply before or after lasers, PRP or local estrogens or other products, to try to improve the fibroblasts of the lamina propria or to maintain and improve its collagen production. That is, can we achieve better results if we somehow increase the capacity of fibroblasts?
5. Of course you cannot talk about other indications such as lichen sclerosus or fissures etc., without proper studies.
6. I will mention other fundamental questions that must be answered, and the only way would be with RCT Is its long-term use safe?
Why are there NO responders?
Subgroups of best responders, for example for stress urinary incontinence?

I do not want to conclude without mentioning that the results that exist are optimistic, but to understand and improve future perspectives we must answer the questions. In the same way that we do not know with certainty, the containdications or the number of sessions needed in a person who does not respond, there will surely be new possibilities in the future, since you can use the laser to prevent vulvovaginal atrophy or urinary incontinence.

I think it is time for clinical research and answering the questions of the clinicians

**NEW SERMs/TSEC**

*Santiago Palacios, Spain*
Director of the Instituto Palacios de Salud y Medicina de la Mujer, Madrid
www.institutopalacios.com

SERMs are compounds with a molecular structure different from that of steroids. They share their selective binding to estrogen receptors (ER) with steroids and produce an estrogen agonist or antagonist effect depending on the target cell and hormonal environment. They have been developed with the aim of producing specific positive estrogenic effects on some target tissues, but with negative or neutral estrogenic effects on other tissues. They were first known as anti-estrogens and developed for the treatment of breast cancer.

Today, the four-best known SERMs are tamoxifen, raloxifene, bazedoxifene and ospemifene, tamoxifen currently being used in the prevention and treatment of breast cancer, both raloxifene and bazedoxifene for the treatment of osteoporosis, and ospemifene for dyspareunia or vulvovaginal atrophy. Therefore, the main aim of the pharmacological development of SERMs is to increase the benefit/risk ratio compared to estrogen therapy in the prevention and treatment of several highly prevalent, chronic, postmenopausal diseases that are associated with this state of estrogen. There is an estrogenic agonist effect that may be beneficial either on the bone or on the vagina and which appears to be an effect dependent on the greater or lesser potency of the SERM (in postmenopausal women). The SERMs assessed appear to have antiestrogenic or neutral effects on the breast; tamoxifen, raloxifene, and lasofoxifene have shown antiestrogenic effects in clinical trials; and bazedoxifene and...
ospemifene have shown antiestrogenic effects in preclinical trials but appear to be neutral in clinical trials to date. Most SERMs have been associated with a slightly increased risk of venous thromboembolism (VTE). The cardiovascular and cardiometabolic effects of SERMs in clinical trials appear to be positive or neutral. The adverse effects of tamoxifen, relative to other SERMs, on the endometrium are well documented. We currently have extensive experience concerning the risks and benefits of SERMs. Therefore, we know the benefits that are ideally required of a SERM, such as those that help in the prevention and treatment of osteoporosis, those that help in the primary and secondary prevention of breast cancer and those that may represent added cardiovascular benefits. A new SERM, Ospemifene belongs to the family of triphenylethylenes. It is a biologically active metabolite of toremiphene (desamino-hydroxy-toremiphene). Ospemifene has been assessed for the treatment of postmenopausal women with vulvovaginal atrophy in two 12-week phase 3 trials, two long-term safety extension trials, and one 52-week safety and efficacy trial. Compared to placebo, ospemifene (30 and 60 mg) significantly increased the percentage of surface cells and decreased the percentage of parabasal cells (improved maturation rate) at weeks 4 and 12. A significantly greater reduction in vaginal pH was also observed in the ospemifene group compared to the placebo group at weeks 4 and 12 for both doses of ospemifene. After 12 weeks of treatment, ospemifene (30 and 60 mg) significantly decreased the vaginal dryness symptoms rating compared to placebo. Also, 60 mg ospemifene significantly reduced the symptom rating of the women who reported dyspareunia as the major symptom in comparison to placebo. We can conclude that it is the first non-hormonal oral alternative for vulvovaginal atrophy. It is a selective estrogen receptor modulator (SERM) that selectively exerts agonistic effects on vaginal tissue. 60 mg ospemifene has been shown to reduce symptoms of dyspareunia and vaginal dryness significantly compared to placebo and to be safe at 52 weeks. Now, thanks to ospemifene, we can add treatment of dyspareunia and vulvovaginal atrophy. We also know the possible side effects to be avoided: the risk of endometrial cancer with tamoxifen, and venous thrombosis and the possible increase in hot flushes with all SERMs. In the short term, it does not seem realistic to expect a SERM to be able to meet all requirements. But each SERM that appears provides more information on efficacy and safety. A new approach to hormone therapy is to combine an estrogen with a SERM in order to achieve all the positive effects of estrogens and even increase them and avoid their negative effects by using a SERM, and this combination is called the Tissue Selective Estrogen Complex (TSEC). The purpose is to decrease hot flushes, prevent and treat vulvovaginal atrophy, and prevent bone loss, without stimulating the breast or endometrium. Bazedoxifene in combination with conjugated estrogens in doses of 0.45 or 0.625 mg significantly reduces vasomotor symptoms, improves vaginal symptoms, and increases bone mineral density in the lumbar spine and hip. It is clear that this is a promising treatment for both vasomotor symptoms and the prevention of osteoporosis. Meanwhile, the rapid developments in the molecular biology of the ER activation cascade, together with advances in genomics and chemistry and proteomics, makes us optimistic about the future of different estrogen modulators in the medium term.

**CHROMOSOMAL MOSAICISM IN HUMAN BLASTOCYSTS: THE ULTIMATE CHALLENGE OF PREIMPLANTATION GENETIC TESTING?**

Mina Popovic, Belgium

Human preimplantation embryos are inherently prone to chromosomal instability. As such, preimplantation genetic testing for aneuploidies (PGT-A) has become widely implemented in conjunction with assisted reproduction, with an aim to improve embryo selection. At present, blastocyst culture followed by trophectoderm (TE) biopsy of 5-10 cells and next generation sequencing (NGS) have become the preferred techniques for embryo screening. However, higher sensitivity has led to an increase in reports of embryo mosaicism, chromosomally distinct cells within a single TE biopsy. This has raised substantial controversy surrounding the diagnostic accuracy of PGT-A, as the presence of mosaicism may ultimately undermine the principle strategy of improved embryo selection. As the biological significance of chromosomal mosaicism remains uncertain, mosaic embryos are often classified as clinically unsuitable. To define the distribution and prevalence of mosaicism in human blastocysts, we used NGS to evaluate the ICM and multiple TE biopsies obtained from the same embryo (n=58). We evaluated blastocysts with an unknown genetic profile, as well as those previously diagnosed as abnormal or mosaic following PGT-A. Overall, we uncover chromosomal mosaicism in up to 38% of the embryos analysed, suggesting that human blastocysts harbour a higher rate of chromosomal heterogeneity than anticipated. Nevertheless, we reveal high sensitivity in the context of PGT-A, as uniform abnormalities in the ICM were accurately diagnosed within the TE in 91% of cases. However, strikingly, a normal ICM was detected in 23% of embryos for which at least one TE sample revealed a mosaic chromosomal aberration. Moreover, we could not confirm the original mosaic diagnosis in 50% of the pretested embryos. Therefore, attesting to low diagnostic specificity, a considerable proportion of viable blastocysts are potentially being classified as clinically unsuitable, ensuing the diagnosis of mosaicism. The transfer of mosaic blastocysts, however, continues to raise an uncomfortable uncertainty. Current reports suggest that mosaic embryos may lead to healthy live births, but also result in poorer clinical outcomes compared to euploid blastocysts. To assess the fate of euploid, chromosomally abnormal and mosaic blastocysts during peri-implantation development (n=80), we developed an optimised system for the extended in vitro culture of human embryos up to 12 days post fertilisation (dpf). We compared original TE biopsy profiles to both culture outcomes and the chromosomal status of the embryos during later development. Viable day 12 outgrowths were predominantly generated from euploid blastocysts and those diagnosed with trisomies, duplications or mosaic aberrations. Conversely, monosomies, deletions and more complex chromosomal constitutions, significantly impaired in vitro development to 12 dpf. Nine outgrowths were further separated into two or more portions corresponding to ICM and TE-derived lineages. When compared to the original biopsy, we determined 100% concordance for uniform numerical aneuploidies, both in whole outgrowths, as well as ICM and TE-derived portions. However, uniform structural variants were not always confirmed later in development. Furthermore, 58% of embryos originally diagnosed with chromosomal mosaicism remained viable at 12 dpf, of which 71% presented with euploid profiles in both embryonic lineages. Overall, our findings support the high clinical predictive value of PGT-A for diagnosing uniform abnormalities, as well as euploid chromosomal constitutions. However, while excluding mosaic embryos may result in an improved clinical pregnancy rate per transfer for the ART centre, it may do so at the expense of the individual patient.
To preclude the inadvertent classification of viable embryos as clinically unsuitable, mosaic blastocysts may be considered as a third diagnostic category in PGT-A. Yet, it must be acknowledged that a portion of mosaic blastocysts will inevitably lead to negative clinical outcomes. While further outcomes data may contribute to individual treatment strategies, at present, the potential risks must be carefully weighed against the possibility of discarding viable embryos. Nevertheless, greater standardisation amongst clinics will be paramount for achieving consistency and substantiating relevant findings. As our understanding of blastocyst mosaicism continues to advance, clinical management and counselling strategies must also concomitantly improve. Diligently informing patients about the risks, challenges and limitations of PGT-A remains our utmost responsibility.

ENDOMETRIAL RECEPTIVITY TESTING: CAN THE MOST RELIABLE TEST STAND UP?
Samuel Santos-Ribeiro, Belgium

ART have developed vastly since the first live birth following IVF in 1978. This multidirectional improvement led to the optimisation of ovarian stimulation and to a better assessment of embryo quality, ultimately causing a steady increase of live birth delivery rates until the late 1990s. Despite that, live birth rates have remained relatively low and, since the year 2000, rather stagnant. Many authors have postulated whether the supraphysiologic milieu of hormones produced during ovarian stimulation (OS) may affect endometrial receptivity (ER) and hinder both pregnancy rates and neonatal outcomes. More specifically, the abnormal production of progesterone (P) during the later stages of the follicular phase (late-follicular/early secretory) and elevated progesterone, LFEFP) has been associated with both an abnormal endometrial gene expression and an atypical epigenetic profile in the luteal phase. This has led many fertility centers to change their clinical practice and to measure serum P levels on the day of hCG administration, adopting a freeze-all strategy whenever LFEFP occurs. Nonetheless, the everyday use of a universal LFEFP threshold as an ART outcome predictor has proven to be harder than originally expected, owing mostly to the fact that a) excessive P production is frequently encountered in good-prognosis women with an otherwise healthy multi-follicular response and b) it seems to be non-linearly related with pregnancy outcomes. Furthermore, the universal use of the threshold of >1.50 ng/mL for LFEFP on the day of hCG administration (which is the most frequently used cut-off to define LFEFP in daily clinical practice) has been challenged by previous studies which have proposed that the detrimental effect of circulating P may be already set into motion below this arbitrary cut-off. Many investigators have attempted to enhance the predictive capacity of this single P measurement by using ratios such as P-to-follicle, P-to-oocyte and P-to-estradiol. However, such indexes have failed to perform superiorly, thus limiting their routine clinical use, an observation that may have led some to propose clinicians to disregard endocrine monitoring of P during OS altogether. The knowledge that OS hinders ER has led to multiple efforts to adequately assess the endometrium prior to embryo transfer. These research groups stem from many scientific fields, including immunology, histology, endocrinology, microbiology, proteomics and genomics. Amongst these, the most notable was the development of customized microarrays that analyse the transcriptomic signature of freshly biopsied secretory endometria have recently been developed. By analysing the endometrium’s expression profile, these microarrays can accurately discriminate between receptive and non-receptive uteri. Although this innovative approach has an enormous potential, its use as a decision-making tool during ART has been hampered thus far by two factors: a) criticism stating that the increased pregnancy rates following the diagnostic biopsy may be due to the effect of endometrial scratching, and b) a biopsy during the secretory phase induces endometrial injury which, although temporary, effectively precludes the transfer of an embryo during that same window of implantation. During this lecture we will review the increasing evidence around the role of the endometrium during IVF and evaluate the existing evidence around the current tests available to diagnose ER abnormalities.

FREEZE ONLY STRATEGY FOR ALL?
Anja Pinborg, Denmark

Due to improved freezing techniques including vitrification and blastocyst transfer the number of freezing embryo transfer (FET) cycles is still increasing and has in the US exceeded the number of fresh cycles, while in Europe one third of the cycles are FET. Growing clinical evidence supporting the justification of further implementation of the freeze-all strategy in standard ART care has emerged in recent years as pregnancy and live birth rates appear to be steadily approaching those seen in fresh cycles. Further benefit of the freeze-all strategy maintains with the possibility of adapting to the full “OHSS-free” strategy enabled by use of GnRH agonist trigger in the FET cycles, practically eliminating the risk ovarian hyperstimulation syndrome (OHSS) in FET cycles. Recent large Asian randomized controlled trials have shown benefit of a freeze-all strategy in women with PCOS and high responders, while there are controversies into whether this strategy is beneficial for patients with an ovarian reserve within the normal or lower range. Recent large retrospective cohort studies from Australia and the US show no benefit from freeze-all except from patients with a high ovarian response. Another aspect is the time to pregnancy or livebirth which is crucial for our patients, however patient’s attitudes seem to be positive towards a freeze-all strategy, if there is a risk of OHSS and if the information on a possible postponed embryo transfer is provided timely at the start of the stimulation and explained as a strategy to escape the high risk for the women. Women are more reluctant towards a freeze-all strategy while men are less likely to accept health risks on their female partners. With the current knowledge there seem to be no indication for freeze-all to all rather there should be specified indications for a freeze-all strategy which should include strict transfer postponement criteria in case of an ovarian hyper response herein patients with more than 15 oocytes at OPU and more than 16 follicles of ≥11 mm at the day of ovulation trigger. In case of cycle segmentation du to risk of OHSS ovulation trigger should be performed with a GnRH agonist to avoid OHSS. Other indications for freeze-all are endometrial pathology, day 6-culture, PGT and hydrosalpinges. Time to pregnancy and live birth is crucial to patients and whether to transfer in the cycle immediate after the stimulated cycle or whether to postpone two cycles are being discussed. Recent retrospective studies in artificial cycle FET have showed no difference in success rates in immediate FET versus postponed FET, but literature is still lacking in modified natural cycle or natural cycle IVF. Moreover, research on the optimal FET cycle is urgently needed. Although babies born after FET have a lower risk of preterm birth, low birth weight and being small-for-gestational age, recent studies have shown that FET babies are more likely to be large-for-gestational age and prepgestational hypertension and preeclampsia is more frequent in FET pregnancies. This seems to be most pronounced in artificial cycle FET programmed with estradiol and progesteron. Altered maternal vascular health in early pregnancy and increased risk of preeclampsia and macrosomia has been shown in pregnancies with absence of a corpus luteum. To conclude Freeze-all for all
should not be the future IVF strategy rather GnRH agonist trigger and cycle segmention should be performed in women at a high risk of developing OHSS and by the other indications listed above. Hence, eliminating the risk of OHSS and keeping the same live birth and cumulative live birth rates.

References
frozen/thawed embryos from a single ovarian stimulation and oocyte collection. Other studies demonstrated that, despite the plateau reached for fresh live birth rates between 10 and 15 oocytes, cumulative live birth rates may continue to increase with the number of oocytes harvested, indicating that higher oocyte yields lead to an increased likelihood of cumulative live birth. Female age constituting a major oocyte quality factor, it has also been recently suggested that larger oocyte yields would be more beneficial in younger women, with an increase in cumulative live birth rate per additional oocyte being lower in the older age groups. Nevertheless, those results were obtained with fresh oocytes, and the generalization to frozen oocytes can be questioned. Indeed, although this strategy has strongly increased in recent years, little evidence about the outcomes of oocyte vitrification cycles is available in the literature. In particular, reports about using vitrified oocytes in cancer patients are scarce with limited long-term follow-up data, emphasizing that the competence of oocytes retrieved in this context remains poorly known. This situation may be further compounded when there is a very limited time frame available, as often occurs in cancer situations, limiting the possibility to repeat the fertility preservation procedures in order to reach optimal cryopreserved oocyte numbers. In those cases, a combination of techniques could be proposed as an option to improve fertility preservation effectiveness by increasing the total number of cryopreserved gametes. In total, in a context of growing interest and demand in fertility preservation, it is crucial for reproductive medicine providers to be conscious of success rates and limits of oocyte freezing procedures, in order to provide women with proper and reliable counselling.

**gSEQ FOR PGT-A**
Noora Sirkkanen
Chief Technology Officer, Reprocare Genetics Scandinavia

Preimplantation Genetic Testing for Aneuploidy (PGT-A) has demonstrated clinical benefit in multiple randomized controlled trials. Contemporary methods of PGT-A involve next generation sequencing (NGS) with whole genome amplification (WGA). We have developed a new method of PGT-A that overcomes limitations of WGA based strategies. gSEQ not only evaluates chromosome copy number, including mosaicism, and segmental aneuploidy, but also provides genotype information through proprietary machine learning algorithms. The additional feature of genotyping data analyses improves PGT-A accuracy through allele-ratio assessment and allows for detection of contamination, triploidy, and relatedness, as well as independent confirmation of aneuploidy predictions. gSEQ provides increased sample processing throughput without compromising accuracy and at a cost significantly lower than WGA-based commercial PGT-A kits.

**LAPAROSCOPIC CERCLAGE**
Thiers Soares Raymundo, USA

With the advance of laparoscopic surgery, several minimally invasive cervical cerclage techniques have been described and the outcome of those has been promising. Experts suggest that a transabdominal cerclage is warranted in women with a prior failed transvaginal cerclage and those with cervical or anatomical issues precluding a transvaginal cerclage placement. It is usually placed between 12 and 14 weeks gestational age, after the prenatal screening window, based solely on prior adverse obstetric outcomes. Given the morbidity associated with multiple preterm deliveries, substantial efforts were made to incorporate ultrasound technology to identify women at highest risk earlier in their obstetric history. The minimally invasive approach can be done by laparoscopy or robotic. The suture material is a standard non-absorbable, braided polyester Mersilene tape which is also used for transvaginal cerclage. Cesarean section is necessary for the delivery after an abdominal cerclage.

**REPRODUCTIVE TRACT MICROBIOME AND ITS RELEVANCE TO PREGNANCY OUTCOME AND NEONATAL/POST-NATAL DEVELOPMENT**
Jerome F. Strauss, III, USA
Departments of Obstetrics and Gynecology, Virginia Commonwealth University School of Medicine and Perelman School of Medicine, University of Pennsylvania

Advances in nucleic acid sequencing technology and bioinformatics have made it possible to interrogate the microbiota of various human cavities and organs, including the reproductive tract and reproductive tissues. Although pathogenic microbes and dysbiotic states have long been implicated in infertility and adverse pregnancy outcomes, the comprehensive characterization of the microbial communities and the presence of virulence factors in specific taxa residing in the reproductive tract was not possible until recently. Although still very much in the descriptive phase of research, investigators have attempted to characterize the vaginal, endometrial and placental microbiota and the potential contribution of microbiota from other body sites such as the oral cavity to the reproductive tract microbiome. Of particular interest has been the potential role of the microbiome in establishing a pregnancy, risk of viral infection such as HSV-2 and HIV, preterm birth, and neonatal physiology. This presentation will focus on the most studied reproductive tract microbiota, the vaginal microbiome. Although there is little doubt that pathogenic microorganisms can populate the upper reproductive tract and placenta, reports that a microbiota exists in the normal placenta and possibly the endometrium are confounded by low biomass and the potential for spurious observations due to contamination from microbial DNA at the time of collection of samples or in reagents used to process the samples. Studies of the vaginal microbiome in pregnant women have, in general, provided consistent observations that include that the vaginal microbiome becomes less complex as pregnancy advances, characterized by a lactobacillus-dominated flora. In pregnancies that are complicated by spontaneous preterm birth, the vaginal microbiota contains taxa associated with bacterial vaginosis/vaginal dysbiosis including Gardnerella, BVAB1, Sneathia amni, TM7-H1 and Mobiluncus among others. In our hands, the vaginal microbiota examined at 20 weeks of gestation can predict risk of spontaneous preterm birth (1). The vaginal microbial communities that populate the vagina are shaped by complex environmental factors including race/ethnicity (2), number of partners, nutrition, including vitamin D status, smoking, hygiene practices, medications and the host genome. For example, we have found that the vaginal microbiota of African-American women is significantly different than that of women of European ancestry. We have also found that vitamin D status affects vaginal microbial communities with low vitamin D associated with dysbiosis (3). Genetic variants in host anti-microbial peptide genes (e.g., defensins) also appear to play a role. Importantly, the identification of microbial taxa in the vagina is not sufficient to implicate a particular microorganism in a pathologic process. For example, sequencing the microbial genomes of isolates of Gardnerella revealed virulence factors in some isolated that promote cytolysis and biofilm formation, indicating that all Gardnerella isolates are not necessarily pathogenic. Thus, characterization of the microbiota using standard methods based on 16s RNA sequencing may not be sufficient to identify drivers of adverse reproductive outcomes. The in-
depth characterization of the reproductive tract microbiome and reproductive outcomes may yield insight into ways in which dysbiotic states can predict the need for interventions and the type of intervention that will be most effective.


DEBATE: ANDROGENS ARE THE VILLAIN IN PCOS PRO
Jerome F. Strauss, III, USA
Departments of Obstetrics and Gynecology
Virginia Commonwealth University School of Medicine and Perelman School of Medicine, University of Pennsylvania

Hyperandrogenism/hyperandrogenemia are cardinal features of polycystic ovary syndrome (PCOS) that figure into most commonly employed diagnostic criteria. The androgen excess is of ovarian origin, although the adrenal cortex may also contribute in some women with a PCOS diagnosis. Genome-wide association studies (GWAS) have identified a number of loci associated with PCOS in different populations. At least two of these loci (HFCGR and DENND1A) are associated with or implicated in increased theca cell androgen production. The bioactivity of androgens in the circulation is influenced by sex hormone binding globulin (SHBG) levels that determine the free fraction of testosterone, and SHBG production by the liver is suppressed by androgens in addition to insulin. There is evidence that elevated androgens influence weight gain and alter carbohydrate metabolism in women, features frequently associated with PCOS. Androgens have also been implicated in granulosa cell abnormalities in follicles of PCOS animal models, and neuroendocrine changes leading to altered gonadotropin secretion. Elevated testosterone levels have been discovered in female rhesus monkeys who exhibit PCOS-like characteristics. Additionally, intrauterine androgen exposure results in a PCOS-like phenotype in exposed female offspring in animal models. Drugs that increase ovarian androgen levels in rodent models (e.g., letrazole) produce a PCOS-like phenotype. Collectively, these observations suggest that androgens are major contributors to the PCOS phenotype, and possibly the pathogenesis of PCOS.

PLACENTAL MICROBIOME: WHAT DO WE KNOW, WHAT SHOULD WE KNOW?
Jerome F. Strauss, III, USA
Departments of Obstetrics and Gynecology, Virginia Commonwealth University School of Medicine and Perelman School of Medicine, University of Pennsylvania

A report by Aagaard and colleagues published in 2014 claiming that the normal human placenta harbors a unique microbiota based on bacterial DNA sequences, with taxa most closely related to those in the oral cavity, opened up a new universe of thinking about the potential role of microbes in pregnancy outcome and fetal and neonatal health. While there have been subsequent publications consistent with the conclusions of Aagaard et al., including reports of a microbiome in amniotic fluid, there have also been recent reports from at least 4 different groups that fail to identify a microbiome in the normal and preterm placenta, and conclude that positive findings noted above are most likely the result of contamination at the time of collection, or microbial DNA contamination in the laboratory or reagents used for microbiome analysis. Furthermore, placental microbiome skeptics point to the existence of germ-free animals that would presumably not be possible to generate if the placenta and amniotic fluid were populated by microbes. Although there is little doubt that pathogenic microorganisms can populate the upper reproductive tract and placenta and or fetal membranes, proving that this is a normal phenomenon is challenging due to the low biomass and multiple opportunities for specimen contamination, detectable by the highly sensitive nucleic acid sequencing methods employed in microbiome research. Consequently, investigators have recently proposed that rigorous controls be carried out to identify sources of possible contamination and to confirm the presence of a microbiota by methods beyond the sequencing of 16s rRNA including culture, quantitative PCR, metatranscriptomics, and fluorescence in situ hybridization (1).

Although, some investigators who hold to the notion that there is a placental microbiome have employed confirmatory methods and claimed success, a critical evaluation of the published findings leaves this and other investigators unconvinced by the existing data (2). Consequently, it seems fruitless to speculate at this time about the role of the placental microbiome in pregnancy beyond the investigation of microorganisms known to infect or pass through the placenta including Listeria, Plasmodia, Treponema, Toxoplasma and viruses. The evolving story of the placental microbiome, whether it exists or not, is a cautionary tale about the application of new and highly sensitive technology, and in particular the problem/challenges of low biomass.


ICSI DOES NOT INCREASE THE CUMULATIVE LIVE BIRTH RATE IN NON-MALE FACTOR INFERTILITY
Elizabeth A. Sullivan, Australia

Background: Intracytoplasmic sperm injection (ICSI) is a technique developed to achieve fertilization for male factor infertility. There has been an increased use of ICSI for all causes of infertility. In Australia, the use of ICSI has increased from 57.8% in 2005 to 69.4% in 2016. Internationally, ICSI accounted for 66.5% of non-donor aspiration cycles in 2011 which was a marginal decline from 67.4% of non-donor...
proposed national guidelines developed with all national gynecologic societies (FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY under the aegis of CNGOF) and endorsed by INCa (French National Institute of Cancer). The PubMed database was searched for English and French language articles, between 2005 and 2017, according to predefined search equations. I will present conclusions of those guidelines with practical day life examples. Main conclusions of those national guidelines are here summarized. Young patients with stage IA EOC willing to conceive should be informed that conservative treatment (contralateral ovary and salpinx, uterus) is possible (Grade C), associated with a 6% to 13% recurrence risk (Grade C) on the remaining ovary. This conservative surgical treatment includes adnexectomy, peritoneal and lymph node staging for all subtypes, and additional endometrial curettage for endometriosis and mucinous subtypes (Grade C). In case of positive staging conservative treatment is not possible. In case of mucinous EOC with an infiltrative pattern, lymph node staging is not necessary. Multidisciplinary analysis (including oncologists and reproductive medicine specialists) of the risk-benefit balance for a conservative surgery is recommended and must rely on a complete final pathology report (Grade C). No recommendation on bilateral adnexectomy and uterine conservation to allow pregnancy using egg donation can be provided in case of low-grade stage IA EOC, in the absence of data. Bilateral adnexectomy and uterine conservation to allow pregnancy using egg donation can be offered in case of serous, mucinous or endometrioid high-grade FIGO stage IA or low-grade FIGO stage IC1 or IC2 EOC (Grade C). Preservation of the uterus and contralateral ovary and fallopian tube can be discussed with a specialized rare ovarian tumors multidisciplinary staff in case of clear cell stage I EOC.

ARE WE OVERUSING IVF?  
Fulco van der Veen, Netherlands

Louise Brown, the first IVF baby was born 25 July 1978. She was immediately called Superbabe by the media since her mother, Lesley, was sterile after several attempts of tubal surgery and would never have conceived, had it not been for the groundbreaking pioneering work of Edwards and Steptoe. Things have changed since then. The use of IVF is no longer restricted to tubal blockage, but has expanded to male infertility, unexplained infertility, age related infertility, anovulation and endometriosis; in fact, to infertility in the broadest sense. It may be initiated as primary treatment or as treatment of last resort. This has led –over time- to a steady increase of the number of treatment cycles worldwide. The evidence generated by RCTs underpinning these “newer” indications is weak to absent, which in itself is worrying if one adheres to the principles of evidence-based medicine but does not answer the question whether current practice is based on overuse. To answer this question, one needs to go back to what actually constitutes the disease unexplained infertility. In other words, what kind of patients are we treating with IVF and is this really effective? If the answer to the latter would be negative, then we would have a clinical practice based on overuse. The basic facts on unexplained infertility are the following. First, in couples attempting to become pregnant a new chance to conceive arises every month again, second, each couple has a ~ constant monthly chance to conceive but between couples’ chances vary widely and third, the most fertile couples conceive first, leaving progressively less fertile couples in the pool of not (yet) pregnant couples. This means, that over time, the population of our patients changes from a heterogeneous group to a more homogenous group with an ever-increasing worse prognosis. This implies that the

aspiration cycles in 2010. Cycle-based statistics show that there is no difference in pregnancy rates between ICSI and IVF in couples with non-male factor infertility. Evidence indicates that ICSI is associated with an increased risk of adverse perinatal outcomes. This presentation is based on a recently published paper which investigates if ICSI results in a similar cumulative live birth rate compared with IVF for couples with non-male factor infertility1. Methods: A population-based cohort of 16716 women who had their first ever stimulated cycle with fertilisation performed for at least one oocyte by either IVF or ICSI between July 2009 and June 2015 in Victoria, Australia was evaluated retrospectively. Demographic, treatment characteristics and resulting outcome data were obtained from the Victorian Assisted Reproductive Treatment Authority. Data items in the VARTA dataset were collected from all fertility clinics in Victoria. Causes of infertility were classified by the patient’s treating clinician. The pregnancy and birth outcomes following IVF or ICSI were recorded for the first oocyte retrieval (fresh stimulated cycle or associated thaw cycles) until 30 June 2018, or until a live birth was achieved, or until all embryos from the first oocyte retrieval had been used. The primary outcome was the cumulative live birth rate, which was defined as live deliveries (at least one live birth) per woman from the first oocyte retrieval. A discrete-time survival model was used to evaluate the cumulative live birth rate following IVF and ICSI. The adjustment was made for year of treatment in which fertilisation occurred, the woman’s and male partner’s age at first stimulated cycle, parity, and the number of oocytes retrieved in the first stimulated cycle. Main results and the role of chance: A total of 5809 women undergoing IVF and 10084 women undergoing ICSI had 9213 and 15292 embryo transfers, resulting in 2162 and 3605 live deliveries, respectively. In the study period, the proportion of women undergoing ICSI increased from 52.6% in 2009 to 68.0% in 2015. For couples with a known cause of infertility, non-male factor infertility (female factor only or unexplained infertility) was reported for 64.5% in the IVF group and 40.0% in the ICSI group (p<0.001). About one fifth of the women (19.3% of the IVF group vs. 17.6% of the ICSI group) had 3 or more cycles to a live birth. The cumulative live birth rate was 37.2% for IVF and 35.7% for ICSI. The overall likelihood of a live birth for women undergoing ICSI was not significantly different from a heterogeneous group with variable prognoses (95% confidence interval: 0.93–1.06). Among couples with non-male factor infertility, ICSI resulted in a similar cumulative live birth rate compared with IVF (AHR 1.00, 95% CI 0.90–1.12). This was consistent across all causes of infertility. Conclusions: This population-based study found ICSI resulted in a lower fertilisation rate per oocyte retrieved and a similar cumulative live birth rate compared to conventional IVF. These data suggest that ICSI offers no advantage over conventional IVF in terms of live birth rate for couples with non-male factor infertility.  


PROTECTING REPRODUCTIVE POTENTIAL IN OVARIAN CANCER
Catherine Uzan, France

The objective of this lecture is to present the methods and strategies of fertility preservation in young women with stage I epithelial ovarian cancer (EOC), in order to propose recommendations for clinical practice. French experts

were collected from all fertility clinics in Victoria. Causes of infertility were classified by the patient’s treating clinician. The pregnancy and birth outcomes following IVF or ICSI were recorded for the first oocyte retrieval (fresh stimulated cycle or associated thaw cycles) until 30 June 2018, or until a live birth was achieved, or until all embryos from the first oocyte retrieval had been used. The primary outcome was the cumulative live birth rate, which was defined as live deliveries (at least one live birth) per woman from the first oocyte retrieval. A discrete-time survival model was used to evaluate the cumulative live birth rate following IVF and ICSI. The adjustment was made for year of treatment in which fertilisation occurred, the woman’s and male partner’s age at first stimulated cycle, parity, and the number of oocytes retrieved in the first stimulated cycle. Main results and the role of chance: A total of 5809 women undergoing IVF and 10084 women undergoing ICSI had 9213 and 15292 embryo transfers, resulting in 2162 and 3605 live deliveries, respectively. In the study period, the proportion of women undergoing ICSI increased from 52.6% in 2009 to 68.0% in 2015. For couples with a known cause of infertility, non-male factor infertility (female factor only or unexplained infertility) was reported for 64.5% in the IVF group and 40.0% in the ICSI group (p<0.001). About one fifth of the women (19.3% of the IVF group vs. 17.6% of the ICSI group) had 3 or more cycles to a live birth. The cumulative live birth rate was 37.2% for IVF and 35.7% for ICSI. The overall likelihood of a live birth for women undergoing ICSI was not significantly different from a heterogeneous group with variable prognoses (95% confidence interval: 0.93–1.06). Among couples with non-male factor infertility, ICSI resulted in a similar cumulative live birth rate compared with IVF (AHR 1.00, 95% CI 0.90–1.12). This was consistent across all causes of infertility. Conclusions: This population-based study found ICSI resulted in a lower fertilisation rate per oocyte retrieved and a similar cumulative live birth rate compared to conventional IVF. These data suggest that ICSI offers no advantage over conventional IVF in terms of live birth rate for couples with non-male factor infertility.  


PROTECTING REPRODUCTIVE POTENTIAL IN OVARIAN CANCER
Catherine Uzan, France

The objective of this lecture is to present the methods and strategies of fertility preservation in young women with stage I epithelial ovarian cancer (EOC), in order to propose recommendations for clinical practice. French experts
prognostic profile of the couples we see, and treat is of paramount importance and this in turn means that we cannot apply IVF in couples with unexplained infertility without first determining their actual prognosis on natural conception. Models that are able to do so currently exist and have been validated. These models will be presented. To prevent oversite this is not enough; obviously, we need to compare the prognosis on natural conception with the prognosis on conception after IVF in the same couple. The first data are now available based upon a cohort study and a subgroup analysis performed in a network meta-analysis comparing IVF with expectant management. The data of both studies show that IVF only contributes to an increase in live birth rate in couples with a poor prognosis on natural conception. So, the conclusion must be that current knowledge shows that indiscriminate use of IVF, ie IVF in any couple with unexplained infertility, leads by definition to overuse of the intervention. This misuse of IVF is easily reduced by selective use of IVF, ie IVF in couples after careful assessment of their prognosis after IVF relative to their chances after extended natural conception at various time points. Edwards and Steptoe would not have seen it otherwise.

IVF AND THE LAB: WHICH CULTURE MEDIUM TO USE?
Aafke P.A. van Montfoort
Dept. of Obstetrics and Gynaecology GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands

Which culture medium to use? An easy question to ask, but difficult to answer. In vivo, the embryo obtains its nutrients from the oviduct and uterine fluid, the composition of which is partly determined by the mothers nutrition. In vitro, the embryo is dependent on the composition of the culture medium where the embryo is put in. At present there are several dozens of embryo culture media commercially available on the market. Most of these are physiological saline solutions to which components are added based on either one of two principles; ‘let the embryo choose’ in which the optimal concentration for blastocyst development of each component is based on simplex optimization or ‘back to nature’ in which the formulation of the medium is based on the components and its concentration in the oviduct and uterine fluid. The latter evolved into a so-called ‘sequential culture system’. After three days of culture, the embryo is transferred to a medium of a different composition. This is assumed to better reflect the changing composition of the embryo would be exposed to on its way through the fallopian tube and the uterus. Even though the composition of most media is based on only a few similar principles, all media differ in their components and/or concentration of components. In general, the media contain salts (ions), energy sources (glucose, pyruvate and/or lactate), proteins (like albumin) and amino acids, however the exact composition is not disclosed by the manufacturers for commercial reasons. Studies analysing known predefined components in commercially available media showed that the concentrations varied considerably. Besides, next to these known components, there are also many unknown and undisclosed components, as followed from protein analyses of eight commercial culture media. The variation in composition and the undisclosed components create the first obstacle in selecting a single best medium. To compare all media available would require a very complex randomized controlled trial (RCT). Several RCT’s comparing two or three media have been performed. However, through the relative scarcity of trials in comparison to the number of possible comparisons, the superiority of one or a few media above others cannot be determined. Another issue to consider when discussing about which culture medium is the best, is which outcome parameter should be taken. Some trials use embryo or blastocyst quality, while others focus on pregnancy, or, may be even better, live birth rates. In recent years however, several publications showed, in both animal and human, that the composition of the culture medium can affect perinatal and postnatal health outcomes. Birth weight for instance, which is considered indicative for future health based on the Developmental Origins of Health and Diseases concept, was found to be altered when comparing newborns who as an embryo were cultured in two different media. Furthermore, postnatal weight and child development have been reported to be different according to the culture medium used. Although more research is needed to confirm postnatal culture medium effects, an “offspring health” parameter might be more appropriate as an outcome measure to determine which medium to use. However, waiting until adulthood before a culture medium can be properly evaluated is not an option. This urges for more research in defining an early proxy for health at later ages, such as birthweight or (epigenetic) biomarkers.

Finally, it is important to realize that it is not only the culture medium on its own that determines IVF success rates. During culture, also pH, temperature, air quality, dishes, mineral oil and many other factors and probably the interactions between all these factors and culture medium affect the IVF success rate of an IVF clinic. The best culture medium might therefore be different for every clinic. In conclusion, a definite answer on which culture medium to use cannot be given at present. More large, multicentre, maybe even multinational randomized trials are needed, and more attention should be given to follow-up of IVF progeny.

ORGANOIDS FROM HEALTHY AND DISEASED ENDOMETRIUM AS INNOVATIVE RESEARCH TOOLS IN REPRODUCTIVE BIOLOGY
Hugo Vankelecom
Department of Development and Regeneration, Cluster of Stem Cell and Developmental Biology, Unit of Stem Cell Research (Lab. Tissue Plasticity in Health and Disease), KU Leuven (University of Leuven), Leuven, Belgium

The endometrium is the first contact site of the embryo and crucial for human reproduction. Knowledge on the cellular and molecular mechanisms underlying the tissue’s monthly remodeling and its embryo receptivity remains poor, as well as on how these processes go awry in endometriosis pathology. This limited understanding is primarily due to a lack of reliable and robust research models. Organoid technology provides an innovative tool to grow mini-tissues in culture. We established 3D organoid models from both healthy and diseased endometrium which reproduce key features of the original epithelial tissue. In addition, the organoids show long-term expansion capacity while remaining genomically, transcriptomically and functionally stable. Endometriosis-derived organoids phenocopy physiological responses to reproductive hormones and mimic the menstrual cycle ‘in the dish’. Organoids from endometriosis and endometrial cancer recapitulate characteristics of the patients’ diseased tissue and faithfully capture the clinical heterogeneity. Regarding endometriosis, little is known on its pathogenesis and on the underlying causes of its prominently associated infertility. Endometriosis-derived organoids can help to decode these burning issues. Taken together, the established organoid

7 Zandstra H, et al. Hum Reprod.2018 Sep 1;33(9):1645-1656
models provide powerful and innovative tools to study multiple aspects of reproductive biology including endometrium receptivity and infertility. Moreover, organoids have potential as (personalized) drug screening platform.

VAGINAL LACTOBACILLI: KEY TO SUCCESSFUL HUMAN REPRODUCTION AND FUTURE ANTIBIOTIC RESISTANT THERAPY
Gary Ventolini, USA

New molecular technique investigations have enabled in-depth study of vaginal microbiome including Lactobacilli. Healthier childbearing age women worldwide have vaginal microbiome mostly dominated by L. crispatus and L. jensenii; although L. gasseri and L. iners may also be present. A stable and healthier vaginal and endometrial microbiome are necessary for successful assisted reproductive techniques including IUI and IVF. Although less important for embryonic cryopreservation and frozen ET since less dependents from variations of estrogen levels. Consequently, a compatibility between the upper and lower genital tract microbiomes is expected. Pathological modification of the uterine microbiome is associated with poor reproductive outcomes in spontaneous pregnancies and IVF patients. For instance, chronic endometritis has been linked with recurrent implantation failure and pregnancy loss in almost half of infertile patients. Additionally, bacterial contamination of the endometrium has been proposed as new factor in the establishment of endometriosis. Therefore, intravaginal and endometrial microbiome are responsible for maintaining a healthy milieu to allow riskless human reproduction, from conception to delivery. Lactobacilli maintain a healthy ecological vaginal milieu by producing lactic and organic acids, hydrogen peroxide, hydroxyl radicals, bacteriocins, bio surfactants, arginine deaminases, and biofilm. Recently, we reported that vaginal Lactobacilli products knockdown biofilms produced by Gardnerella vaginalis in vitro; and by Pseudomonas aeruginosa in vivo and in vivo since these products prevented sepsis in murine models of thermal injury and dorsal excision. We predict soon the utilization of Lactobacilli products to assisting/taking care of not only Bacterial Vaginosis microbes but most importantly antibiotic resistant bacteria.

NIPT : WHAT THE PHYSICIAN SHOULD KNOW ABOUT THE TEST?
Francois Vialard, France

NIPT (non-invasive prenatal testing) is based on free fetal DNA (ffDNA) (1) in maternal blood (2) with a trophoblastic origin (3) with a high quantity variation between women. These 3 points originate few results interpretation problems that need to be considered for interpretation. Initially, NIPT was done for fetal sex diagnosis and secondly for RhD identification. In these contexts, the DNA sequence is absent in the mother. Its identification gives the opportunity to perform a fetal diagnosis without any invasive procedure for confirmation. At the opposite, to study DNA sequences, with a maternal and fetal origins, give us the opportunity to perform a screening test associates, when positive, to invasive procedure for confirmation. The main discussion is to implement or not this technology for everyone, and to define the diseases that need to be screened. Furthermore, as the ffDNA is trophoblastic originated, what is the positive predictive value (PPV) for test not based on fetal DNA ? Focusing on Down syndrome screening, PPV was very high, and limitations are based on ffDNA origin. Discordance between trophoblast and fetus is a well-known mechanism, frequently identified in prenatal diagnosis. Furthermore, to focus on Down syndrome allows to miss syndromes previously identified using invasive procedure. NIPT for Down syndrome only screens the number of chromosome 21. It isn't a low-resolution whole genome analysis like conventional karyotype. According to that, why not to propose a larger NIPT to screen to most frequent syndromes ? But which syndromes are going to be screened ; the most frequent, those which a full genetic penetrance, those with a homogeneous genetic defect ? This question is still on debate, but if the region 22q11.2 seems to be the most relevant, many cautions exist.

CAN LASERS REDUCE OVERACTIVE BLADDER SYMPTOMS?
Zdenko Vizintin
Fotona, Stegne 7, 1000 Ljubljana, Slovenia

Problem statement: The purpose of this lecture is to report about studies in which new laser treatment was used for therapy of overactive bladder (OAB) symptoms. Methods: In last few years four clinical studies were published in which the authors were assessing the efficacy and safety of non-ablative Erbium YAG laser for the treatment of the overactive bladder symptoms. In all of these studies the OABSS score was used as a measurement tool for efficacy. In two studies the comparison of laser treatment with surgery and with standard medications (anticholinergics and beta 3 adrenoceptor agonists) were performed. Patients received between one and three laser treatment sessions (one session in Tien study, two sessions on Lin study and three sessions in Oku studies) and were follow up between 3 months and 1 year. Adverse effects were observed at every follow-up and in one of the studies patients were interviewed about their satisfaction with the results. Results: In all four studies 165 (35, 30, 50, 50) female patients were treated with non-ablative ErYAG laser and in two studies with comparison to surgery and medicaments additional 100 patients were included in control groups. Patients were assessed with OABSS questionnaire. The OABSS scores significantly improved in all four studies (from 8.16 to 3.76; from 4.1 to 2.7; from 8.2 to 6.1). At 6 months follow up the improvement of symptoms in the laser groups was still significant. The adverse effects were all mild and transient. Majority of interviewed patients were satisfied with the treatment and the outcome. Conclusions: Non-ablative ErYAG laser therapy for overactive bladder (OAB) symptoms demonstrated significant improvement of the OABSS score. This laser therapy seems to be a promising option for OAB patients not willing to perform long term medication therapy. However more studies with larger number of patients and longer follow-up are needed for better understanding and stronger evidence of this new treatment option.

THE LONG-TERM HEALTH RISKS OF POI
Lisa Webber, UK

Premature ovarian insufficiency (POI) affects 1% of women of reproductive age. As well as being a cause of infertility, POI has long term health consequences for affected women. Untreated POI is associated with reduced life expectancy and increased risk of cardiovascular disease and osteoporosis. There is a suggestion that POI is a condition of premature aging Quality of life is adversely affected and there may be a detrimental effect on cognition. Hormone replacement therapy (HRT) is recommended to reduce the long-term risks of POI, but the evidence is limited and the populations studied are often of mixed aetiology. Compliance with HRT may be poor, probably for a number of reasons, but including misunderstanding the risks and benefits of treatment and possibly lack of acceptance of the diagnosis.

THE LONG-TERM HEALTH RISKS OF POI
Lisa Webber, UK

Premature ovarian insufficiency (POI) affects 1% of women of reproductive age. As well as being a cause of infertility, POI has long term health consequences for affected women. Untreated POI is associated with reduced life expectancy and increased risk of cardiovascular disease and osteoporosis. There is a suggestion that POI is a condition of premature aging Quality of life is adversely affected and there may be a detrimental effect on cognition. Hormone replacement therapy (HRT) is recommended to reduce the long-term risks of POI, but the evidence is limited and the populations studied are often of mixed aetiology. Compliance with HRT may be poor, probably for a number of reasons, but including misunderstanding the risks and benefits of treatment and possibly lack of acceptance of the diagnosis.
THE FUNDAMENTALS OF LAPAROSCOPIC SURGERY DURING PREGNANCY
Jessica Ybanez-Morano, MD, MPH, FACOG, CPE
President, SLS (Society for Laparoendoscopic Surgeons)
Medical Director for Women’s Services, Department of Obstetrics and Gynecology, Canton, Ohio, USA

The safety of laparoscopic surgery during pregnancy remains debated, despite the well-established benefit of minimally invasive surgery (MIS) in nonpregnant patients. Non-obstetrical-related surgery during pregnancy is not rare, occurring in 1-2% of all pregnant women. In the United States, non-obstetric surgery is performed in 1:200 to 1:500 of pregnant women annually. This presentation focuses on the current guidelines and recommendations to optimize maternal and fetal outcomes using laparoscopic and minimally invasive surgical (MIS) techniques in the operative care of gravid patients. We will review diagnostic workup, patient selection, patient positioning, port placement, insufflation pressure, intraoperative monitoring and other perioperative/postoperative care. Operative laparoscopy during pregnancy should minimize fetal risk without diminishing the safety and quality outcomes for the mother. This presentation will provide guidance and recommendations to help surgeons in the laparoscopic surgical care of the gravid patient.
**Problem statement:** The prevalence of congenital uterine anomalies is reported to be about 5-14% in different patient populations. Septate uterus (the most common uterine anomaly) and bicornuate uterus are found to be associated with the risk of subfertility and adverse reproductive outcomes. Accurate diagnosis of these two types of uterine anomalies is mandatory, where the patients may benefit from specific therapeutic modalities. Although laparoscopy performed concurrently with hysteroscopy has been considered as the gold standard in confirmation of diagnosis of uterine anomalies, this procedure is associated with the complications of surgery and anesthesia. Three-dimensional saline infusion transvaginal ultrasound (3-D SIS) is a fast-evaluating, relatively cost-effective, and minimal invasive imaging technique with considerable ability to depict congenital uterine anomalies. In this study, main objective was first to evaluate the accuracy of this modality in the evaluation of uterine contour and cavity, and second, to analysis the level of agreement in the results between this method and combined diagnostic laparoscopy/hysteroscopy as a gold standard. **Methods:** In this double-blind prospective study, 100 reproductive age (30.19 ± 2.31) women with history of spontaneous abortion(s) (57%) or candidate for assisted reproductive technology procedures (43%) and a suspected diagnosis of congenital uterine anomalies by hysterosalpingography were enrolled. The patients underwent (3-D SIS) and hysteroscopy with laparoscopy to establish the final diagnosis. The findings of two procedures were compared. **Results:** The accuracy, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of (3-D SIS) in diagnosis of uterine anomalies were 98.6, 100, 96.77, 97.66, 100%, respectively. The accuracy, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) in the differentiation of septate uterus from bicornuate uterus were 100%. **Conclusion:** There is a close correlation between the findings of (3-D SIS) and laparoscopy performed concurrently with hysteroscopy for the diagnosis of congenital uterine anomalies. (Three-D SIS) could be considered as an accurate and minimal invasive diagnostic procedure to assess uterine contour and cavity. This modality have the potential to become the gold standard in distinction between septate and bicornuate uteri.

**OP1-102**

**VALUE OF VAGINAL FETAL FIBRONECTIN AND CERVICAL INTERLEUKIN-8 IN PREDICTING PREMATURITY BIRTH**

**Problems statement:** Premature birth is a major problem of medicine in general as well as obstetrics in particular. According to a WHO study, there are approximately 15 million premature babies are born annually. In clinical practice, due to unclear symptoms, the diagnosis of preterm labor remains challenging. If doctors could diagnose sooner, preterm births would be treated earlier and more effective. **Objectives:** This study was undertaken to determine the value of fetal fibronectin (FFN) in vaginal mucus and interleukin-8 (IL-8) in cervical mucus to predict preterm labor. **Methods:** From 2016-2018, 146 pregnancy women with preterm labor symptoms were screened at 28-32 weeks of gestation for FFN and IL-8 in vaginal and cervical mucus. **Results:** IL-8 and FFN test showed high value in predicting for premature birth before 37 weeks, 34 weeks, within 7 days and 14 days. Among them, predicting for premature birth before 34 weeks showed highest value (OR=14.7 with IL-8 test and OR=21.4 with FFN test). Combination of FFN probe with cervical length ultrasonography increased predictive value of premature birth, especially premature birth before 34 weeks (OR = 32.1). Another combination of IL-8 and FFN probe test increased diagnosing value of premature birth before 34 weeks (OR = 25.1). Especially when combining FFN negative with IL-8 in low-risk pregnant group, there are no pregnant woman delivered prematurely within 14 days. **Conclusions:** FFN in vaginal mucus and IL-8 in cervical mucus had high value in predict preterm, especially when we combine them together.

**OP1-103**

**MANAGEMENT OF ENDOMETRIOSIS IN WOMEN AT REPRODUCTIVE AGE: SYSTEMATIC REVIEW AND CRITICAL APPRAISAL OF CURRENT GUIDELINES INCLUDING 2018 SPANISH FERTILITY SOCIETY ENDOMETRIOSIS GUIDELINES**

**Problems statement:** The main scope of Clinical Practice Guidelines is to resume the available evidence so undesirable clinical practice variation can be reduced. Former appraisals have found important methodological differences among Endometriosis Guidelines, many of them scoring below the desirable average. Two reviewers (JAD, MC) performed a systematic research at PubMed/MEDLINE and EMBASE from 2008 to 2019. Inclusion criteria: Endometriosis Guidelines in English, French and Spanish. Two reviewers (JAD, MC) assessed guidelines quality except the Spanish guideline, assessed by four independent reviewers (GB, JLL, RM, EPB). The assessment of methodological quality was performed with the Appraisal of Guidelines for Research and Evaluation II (AGREE II) scale, a fully validated assessment instrument containing 23 items grouped into 6 domains. Each item is evaluated with a seven-point Likert scale score, between 1 (strongly disagree) and 7 (strongly agree), for each item. As former appraisals, a guideline score was calculated by summation of domains and standardised. Guidelines were then categorised as high quality between 67-100%, moderate 34-66% and low 0-33%. **Results:** Search strategy identified 584 references. Finally 10 National and International Guidelines were included in the review (by chronological order). Spanish Fertility Society(SEF,2018), Korean Society of Endometriosis(2018), Collège National des Gynécologues et Obstétriciens Français(CNGOF,2018), National Institute for Health and Care Excellence(NICE,2017), National German Guideline(S2k,2014), European Society of Human Reproduction and Embryology(EHRE,2013), World Endometriosis Society Metchpelier Consensus(WES,2013), Spanish Health Ministry(2013), Australasian Certificate of Reproductive Endocrinology and Infertility Consensus Expert Panel on Trial Evidence(ACCEPT,2012), American Society of Reproductive Medicine(ASRM,2012), and Society of Obstetricians and Gynaecologists of Canada(SOGC,2018). After Guidelines AGREE-II appraisal, scoring remained as follows: NICE-2017: 152.5 points(95%), SEF-2018: 126.5(78%), ESHRE-2013: 104(65%), S2k-2014: 103(64%), CNGOF-2018: 98(61%), WES-2013: 92.5(57%), ACCEPT-2012: 81.5(51%), Koreea-2018: 81(50%), Spanish Health M.-73.5(46%), SOGC-
patients were wild type for both c677CT and c1298AC (84.3% of patients was significantly higher than among wild type patients before starting a new ART attempt. 5MTHF by-pass the problems linked to MTHFR impaired activity. Homocysteine levels were measured before and after treatment. Results: 2503 patients were included and screened for c677CT and c1298AC. 198 mutation(s) carriers had their homocysteine levels measured before and after treatment: competitive immunoassay using direct, chemiluminescent technology. 15.7% of the patients were wild type for both c677CT and c1298AC (84.3% of the patients were carrying at least one of the two mutations). 51.8% of patients were carrying the c677CT mutation (44.3% in a heterozygous and 10.9% in a homozygous state); 49.8% of patients were carrying the c1298AC mutation (41.4% in a heterozygous and 8.4% in a homozygous state). The average level of homocysteine among homozygous and heterozygous patients was significantly higher than among wild type patients (respectively 18.4 and 12.2 vs 7.9 μmol/L, p=0.0003 and p=0.01). After treatment, the level of homocysteine significantly decreased both in homozygous and heterozygous patients (10.5 and 9.8 μmol/L respectively, p=0.05). Following the treatment, we obtained 18 pregnancies out of 30 cycles including 14 ongoing pregnancies (ongoing pregnancies rate per cycle 47 %). Conclusion: Treating MTHFR mutations carriers with 5MTHF decreases their homocysteine levels and improves their ART outcomes. Infertile patients with ART cycle failures should be tested for MTHFR mutations and their homocysteine levels should be measured. Indeed, the affected patients could benefit from a treatment available allowing to by-pass the problems linked to MTHFR impaired activity and thus decreasing oxidative stress and improving their ART outcomes.

Cyclical versus Continuous Oral Progestin Monotherapy in Endometrial Hyperplasia without Atypia

Hui Men Selina Chin, Shi Hui Lee, Charissa Shu Ying Goh, Manisha Mathur, Timothy Yong Kuei Lim, Felicia Hui Xian Chin Obstetrics and Gynaecology, KK Women's and Children's Hospital, Singapore

Problem statement: The use of progestins in endometrial hyperplasia (EH) holds a popular choice after the Levonorgestrel intrauterine device, mostly due to patient preference and in some cases structural uterine abnormalities. We present a comparative audit of the effectiveness of cyclical (21 days per month) versus continuous oral progestin regimens, including Norethisterone acetate (NorE) and Medroxyprogesterone acetate (MPA). We illustrate that cyclical oral progestin monotherapy produces similar remission rates to continuous oral progestin monotherapy for EH without atypia. Methods: This was a single-centre, retrospective audit. 119 cases were diagnosed with EH without atypia by endometrial biopsy and received either NorE or MPA monotherapy from April 2015 and December 2016. Patient notes and electronic patient records were reviewed for information on age, menopause status, parity, body mass index (BMI), Tamoxifen use, co-morbidities, method of histological sampling (dilatation and curettage [D&C] versus bedside endometrial sampling [ESI]), type, dose, and duration of medical treatment given, subsequent histology reports, and length of follow-up. The objective was to compare the duration of treatment and regression rates for EH without atypia after treatment with cyclical versus continuous progestin monotherapy. Results: 90 cases had complete data and were included for analysis. Cases that were lost to follow-up or declined repeat endometrial biopsy were excluded. 45 cases received cyclical progestin monotherapy (all of which received progestin for 21 days per month). The remaining 45 cases had continuous oral progestin monotherapy. The patients were comparable in age, BMI, menopause status, Tamoxifen use, co-morbidities, method of endometrial biopsy, daily progestin dose, and duration of follow up.
The average durations for cyclical versus continuous monotherapy were similar at 4.93 months and 3.04 months respectively (p=0.09). The median time to progression for cyclical versus continuous oral progestins were 97.8% and 65.5% respectively (p=0.18). The regression rates for cyclical versus continuous oral progestins monotherapy were similar at 4.93 months and 3.04 months respectively (p=0.18), suggesting no difference between the two.

**Conclusion:** There seems to be no difference between cyclical versus continuous oral progestin monotherapy in achieving remission of EH without atypia. Larger studies are warranted to confirm these results.

---

**Problem statement:** Peritoneal sarcomatosis (PS) from uterine leiomyosarcoma (ULMS) has no effective treatment and poor prognosis.

**Methods:** A 17-year-old presented with an abdominal mass, 2.4 x 2 cm left lower quadrant mass and 0.9 cm posterior to the right hepatic lobe (Figure 1 A,B). It was determined that a complete CRS. Results: The patient underwent hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin 84 mg and doxorubicin 25 mg at 42 degrees C over one hour. The final pathology confirmed resected tumors to be ULMS. The patient tolerated the procedure well and is currently receiving additional treatment with gemcitabine and docetaxel.

**Conclusion:** There is no standard of care treatment for PS. CRS/HiPEC could be an option analagous to its use for peritoneal carcinomatosis form appendiceal, colorectal, gastric, and ovarian cancers. A worldwide study is underway to determine the effectiveness of CRS/HiPEC in PS from ULMS.

---

**Problem statement:** This study was conducted in order to evaluate gynecologic cancer awareness and cancer worry in women presenting at the gynecology polyclinic and to determine the relationship between those variables. **Method:** This cross sectional, descriptive, and correlational study was conducted in the gynecology polyclinics of the Woman and Child Disease Training and Research Hospital in Istanbul, Turkey between February 2018 and February 2019. The sample of the study consisted of 403 women between the ages of 20 and 65. Data was collected using an Introductory Information Form, the Cancer Worry Scale (CWS), and the Gynecological Cancer Awareness Scale (GCAS). **Results:** The mean age of the women participating in the study was 36.45 ± 10.69, and it was determined that 65.5% were married, 28.5% were high school graduates, 68% were unemployed, and 71% were worried about cancer. The GCAS mean total score of the participants was 156.55±22.14 while their CWS mean total score was 16.32±4.59. When the GCAS scores of those who worried about cancer and those who did not were compared, no statistically significant difference could be found (p=0.05), while an advanced difference in cancer worry was found between those two groups (p=0.001). When the GCAS and CWS scores of the women with and without a history of cancer in their family were compared, the groups were found to be similar (p=0.05). A positive, weak, and advanced significant relationship between the Gynecologic Cancer Risk Awareness sub dimension scores and Cancer Worry Scale total scores was found (r=0.13, p=0.001). Nor significant relationship between GCAS and CWS total scores could be found.

**Conclusion:** Almost three quarters of the women experienced cancer worry despite gynecologic cancer awareness and cancer worry being on moderate levels. Those who had fear of cancer had higher cancer worry. However, cancer worry was found not to affect Gynecologic Cancer Awareness. It is suggested that health professionals working in the field of women’s health should increase the gynecologic cancer awareness of women and refer them for the necessary routine scans for early diagnosis.

**Problem statement:** A systematic review with meta-analysis of NRF2 as a prognostic marker for breast cancer survival.

**Conclusion:** There is no standard of care treatment for PS. CRS/HiPEC could be an option analagous to its use for peritoneal carcinomatosis form appendiceal, colorectal, gastric, and ovarian cancers. A worldwide study is underway to determine the effectiveness of CRS/HiPEC in PS from ULMS.
Problem statement: Nuclear factor E2-related factor 2 (NRF2), is a transcription factor that plays a major role on the regulation of intracellular antioxidant response. The effect of NRF2 overexpression in many malignancies is still unclear and recent meta-analysis correlated the overexpression of this transcription factor with poor prognosis in a variety of human cancers. However, the effect of NRF2 overexpression in breast cancer is still unclear. Thus, the main goal of this work was to clarify the role of NRF2 expression in survival of breast cancer patients by performing a systematic review according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) statement followed by a meta-analysis. Methods: The electronic search was conducted in PubMed, Scopus, SciELO, Web of Science and Embase between November of 2017 and September of 2018. To be included, studies should evaluated NRF2 expression in breast cancer tissue; through immunohistochemistry and/or mRNA and had to report 1 or more of the following outcomes: overall survival (OS), disease-free survival (DFS). Results: For the meta-analysis, 7 studies were included and NRF2 expression was correlated with OS and DFS. It was observed that compared to patients with low NRF2 expression, patients with NRF2 overexpression had poorer OS (p-value = 0.000) and poorer DFS (p-value = 0.027). These results suggest that tumours that overexpress NRF2 have a more aggressive behaviour. Conclusion: Thus, NRF2 expression could be a marker for the prognostic of breast cancer patients and it would be done to find a new treatment that will improve treatment efficacy for patients with NRF2 overexpression. Conflict of Interest: The authors declare that they have no conflict of interest.

Problem statement: Cervical cancer is a cancer with highest prevalence and the leading cause of women’s death worldwide. Current treatments available for cervical cancer are chemotherapy, radiation, surgery, and nuclear therapy. Unfortunately, these treatments still have several limitations due to serious side effects, development of resistance, and very expensive price. Therefore, it is necessary to develop effective and low-cost therapy to treat cervical cancer. One of which is by utilizing natural sources available in Indonesia such as soursop leaves which has been used in folk medicine as treatment for various diseases, including cancer. However, studies about its cytotoxicity against cervical cancer are still limited. The aim of this research is to analyze the potency of A. muricata leaves extracts originated from Indonesia as a novel alternative treatment for cervical cancer. Methods: This study is an experimental study conducted in Department of Chemistry, Faculty of Medicine, University of Indonesia using HeLa cervical cancer cells. Leaves of A. muricata, originating from Serpong, Tangerang, Java, Indonesia were ground and macerated in three solvents with various polarity consist of ethanol (polar), ethyl acetate (semipolar) and hexane (non-polar). Then, the extracts were diluted into 8 various concentrations. Triplo mechanism is also applied in this study to increase accuracy of the results. Cytotoxicity of A. muricata leaves extracts against HeLa cervical cancer cells were determined by MTT assay and shown by IC50 value. Data was analysed using analysis of variance (ANOVA). Statistical significance level was established at p<0.05. Results: The results showed that three extracts of A. muricata have strong cytotoxicity against cervical HeLa cells. The highest cytotoxic activity was shown by ethanolic extract with an IC50 of 35.51 µg/mL, followed by ethyl acetate (IC50 5.91 µg/mL), and hexane (IC50 8.39 µg/mL). Based on statistical analysis, there is no significant difference between IC50 of three extracts A. muricata (p = 0.055). Conclusion: A. muricata leaves extracts are potential to be developed as a novel alternative therapy for cervical cancer. Keywords: Annona muricata, Cytotoxicity, HeLa cervical cancer cells, Soursop leaves. Abbreviations Used MT: (3-[4,5-Dimethylthiazol-2-yl]-2,5-Diphenyltetrazolium Bromide); IC50: Inhibition Concentration 50%; HeLa: Henrietta Lack. Disclosure of Interest: The authors declare no conflict of interest.
infrastructure could bring about an early detection of maternal syphilis. **Methods:** Detection of maternal syphilis was initiated in 2001 and then scaled-up in 2011 along with enhancing antenatal healthcare infrastructure. The initial 5-years of municipal and national PMTCT policies were respectively defined as “Exploring Period” (2002–2006) and “Comprehensive Period” (2011–2015). Demographic and gestational weeks (GW) of syphilis screening and diagnosis were analyzed to identify the factors affecting early detection. Patients: All of the pregnant women during the two periods were included. Interventions: Shanghai initiated the municipal PMTCT program in 2001, which was a joint effort among local health facilities for delivery and sexually transmitted infection treatment. Since 2011, it has been intensified and upgraded, enhancing secured central government budget, quality assured laboratory for syphilis screening and diagnosis, and comprehensive training and supervision for capacity building in all maternity health facilities. **Results:** The amount of maternal syphilis screening increased from 83,718 in 2002 to 243,432 in 2015. Of the 1,894,062 screened pregnant women, 1,528 and 2,714 participants were diagnosed with maternal syphilis respectively. The average age was 28.36 years and non-resident accounted for 71.1%. In comprehensive periods, more women received early syphilis screening (14.0% vs. 10.8%) and diagnosis (13.3% vs. 7.3%) within 12 GWs. Significantly, the proportion of early detection sustained growth during 2011-2015 rather than years in exploring period. Multivariate analysis revealed a higher possibility for infected women in comprehensive period to be diagnosed within 16GWs (OR = 2.76), but those who were non-resident and unemployed were less likely to receive early detection. **Conclusion:** Early detection of maternal syphilis has been remarkably improved. More emphasis is required on developing pro-vulnerable policies and implementing tailored education on syphilis prevention.

**OP2-201**

PREGNANCY COMPLICATIONS AND ITS MANAGEMENT: AN EXPERIENCE AT DISTRICT HOSPITAL OF NEPAL

Manohar Joshi1,2

1Department of General Practice and Emergency Medicine, Universal College of Medical Sciences, Bhairahawa, Nepal  
2Emergency, Bhim Hospital, Bhairahawa, Nepal

**Problem statement:** Pregnancy Complications and its management: Experience at District Hospital of Nepal. **Methods:** The descriptive, observational, retrospective study of the obstetric cases having complications before, during and immediate thereafter at Bhim Hospital, Bhairahawa, Nepal in a period of one year (FY 2012-2013). Except the abortion, live birth are included in the study. **Results:** Out of 1594 pregnant women admitted in the hospital, 1280 cases gave the live births. 264 cases were admitted due to abortion complications; either induced abortion 119 cases (45%) spontaneous abortions 145 cases (55%). The complications observed were 288 numbers (22.5%). Most frequent complication is prolonged second stage of labor is 105 number (36.4%) then retained placenta 53 cases (18.4%) followed by mal-positions mainly breech 49 (17.1%), cervical tear 25 cases (8.6%), immediate postpartum hemorrhage 19 cases (6.6%), third degree tear 8 cases (2.7%). Cesarean sections were done for limited time, only 26 cases. Total obstetric cases at that time is 168 cases. Main indications for operative delivery were mal-positions 8 cases (30%) and spontaneous rupture of membrane (SRM) 6 cases (25%) followed by previous CS and CPD 7 cases (29%), eclampsia and severe eclampsia 5 cases (20%). The Cesarean rate is 7%. There is no maternal mortality during this study period. **Conclusions:** This study shows that every pregnancy is not risk free. Health staff must work like a watch dog 24 hours a day to recognize promptly and manage the complications promptly. This study will help to manage resources and also to have training to the staff. Common complications come commonly and general practitioners in Nepal are quite competent to manage those complications occurring in pregnancy even such resource constraint setting. **Disclosure of Interest:** Manohar Joshi Shareholder of: none, Grant/ Research support from: none, Consultant for: none, Employee of: none, Paid Instructor for: none, Speakers Bureau for: none, Other: none

**OP1-202**

GROUP A STREPTOCOCCAL (GAS) INFECTIONS IN OBSTETRICS AND GYNECOLOGY

Arthur Zaltz

Obstetrics and Gynecology, Sunnybrook Health Sciences Centre, Toronto, Canada

**Problem:** Group A Streptococcal Sepsis in Obstetrics and Gynecology; an uncommon but re-emerging disease. **Methods:** A series of cases resulting in serious morbidity and mortality were reviewed. **Results:** Clinical findings that could have resulted in earlier intervention and diminished morbidity were not recognized. **Conclusion:** This oral presentation will discuss strategies to identify and appropriately manage GAS sepsis. **No Disclosures**

**OP1-203**

CLINICAL SAFETY AND EFFICACY OF DINOPROSTONE GEL FOR CERVICAL RIPENING IN A PREGNANT WOMEN NOT IN LABOR

Julienne Katrina Beltran, Ramon Gonzalez

Obstetrics & Gynecology, University of Santo Tomas Hospital, Metro Manila, Philippines

**Problem statement:** To determine the safety of dinoprostone gel and clinical efficacy for cervical ripening among women for labor induction with a Bishop score of less than 9. **Methods:**

**Results:** A median of 1 dinoprostone gel was used per woman. No significant differences based on parity were detected for the outcomes of dinoprostone dosage and mode of delivery, although in terms of relative proportion, more multiparous women gave birth normally (69% vs. 57%, P = 0.226). There was, however, evidence of increased induction success among women who have given birth previously (94% vs 79%, P = 0.022). The success group generally had higher Bishop scores (i.e. success group had predominantly Bishop 4 and up scores) and higher ages of gestation, more than 50% term patients. There was insufficient evidence to demonstrate a difference between the AOG groups. The duration from labor induction to active phase of labor was shorter for those with BS 4 (median 240 versus 265 minutes), while the duration from labor induction to termination of pregnancy was shorter for BS 4 points (478 mins vs 510 mins). However, these were not statistically significant. Similarly, the duration from Dinoprostone insertion to active phase of labor was shorter for those with BS 4 (median 420 versus 502.5 minutes). The duration from Dinoprostone insertion to termination of pregnancy was also shorter for BS 4 points (685 mins vs 835 mins). However, these were not statistically significant. The median time from labor induction to active phase was 260 minutes (95% CI: 210 to 360 minutes) and from labor induction to termination was 490 minutes (95% CI: 434 to 590 minutes). The median interval from dinoprostone insertion to active labor and termination of pregnancy were 480 and 820 minutes, respectively. Labor was successfully induced in 83%. No adverse events were noted. **Conclusion:** The use of dinoprostone gel is safe. No adverse events have been reported. Induction success was at 83.03%. Vaginal delivery was achieved by 66.67% of the population. Significantly higher induction success and higher vaginal delivery rates were seen for parous group.
**OP1-204 RELATIONSHIP BETWEEN SUCCESS AND FAILURE RATES OF SMUCS WITH ANTEPARTUM, INTRAPARTUM AND POSTPARTUM FACTORS IN ATOMIC UTERINE CASES AT DR. SOETOMO HOSPITAL SURABAYA DURING 2012-2017**

**Tizar Dwi Satyaputra, Mawarke Nareswari, Cininta Imadha Marcianora, Agus Sulistyono**

1 Obstetric and Gynecology Department, Faculty of Medicine Airlangga University, Surabaya, Indonesia
2 Obstetric and Gynecology Department, Dr. Soetomo Hospital Surabaya, Surabaya, Indonesia

**Objective:** To analyze the relationship between success and failure rates of surabaya-method uterine compression suture (SMUCS) with antepartum, intrapartum and postpartum in atomic uterine cases at dr. Soetomo hospital Surabaya Methods: This is an observational analytic study with case-control design. Subjects of this study were post-labor patients who had undergone SMUCS during 2012-2017 period. Secondary data was obtained from medical record to determine antepartum (age, parity, obesity, multiple pregnancy and maternal comorbidities, such as Diabetes-Mellitus, hypertension-in-pregnancy, heart disease in pregnancy, anemia, jaundice-of-pregnancy, SLE and infection), intrapartum (mode-of-delivery, induction of labor) and postpartum factors (interval of time when uterine compression suture surabaya-method in atomic uterine after SC or postpartum vaginal delivery was performed). Two-step analysis using bivariate and multivariate logistic regression were performed for screening and determine the-strength between two variables, respectively. Results: From 278-patients approximately 192 patients met the inclusion criteria. There were 32 failures and 160 successful cases. Bivariate regression test indicated 7 variables were significant (p<0.05), including age, infection, anemia, hypertension-in-pregnancy, mode-of-delivery, induction of labor and interval of when to perform uterine compression. Multivariate regression for those 7 variables pointed only two were significant (p<0.05), i.e. anemia (p=0.016, OR=4.78 Cl:1.343 - 17.038) and time interval of when compression suture was performed. Longer duration of procedure delay related to failure rates at p<0.001; OR 6.75; Cl: 2.249 - 20.406 for over-than-two to 7-hours group and 20.406; Cl:2.781 - 232.893 for longer than 7-hour compare to less than one-hour. Conclusion: The failure of uterine compression suture surabaya-method were affected by anemia, delay of uterine compression 2-to-7-hours group and p<0.016; OR 25.45; CI:2.781 - 232.893 for over -than-two to 7-hours group. Multivariate regression for those 7 variables pointed only two were significant (p<0.05), i.e. anemia (p=0.016, OR=4.78 Cl:1.343 - 17.038) and time interval of when compression suture was performed. Longer duration of procedure delay related to failure rates at p<0.001; OR 6.75; Cl: 2.249 - 20.406 for over-than-two to 7-hours group and 20.406; Cl:2.781 - 232.893 for longer than 7-hour compare to less than one-hour. Conclusion: The failure of uterine compression suture surabaya-method were affected by anemia, delay of uterine compression 2-to-7-hours and delay for more-than 7-hours. Keywords: The failure of Uterine compression suture surabaya-method, uterine infection, antepartum factors, intrapartum factors, postpartum factors.

**Problem statement:** Does the timing of delivery after the maternal and fetal outcomes in women with severe preeclampsia? **Objective:** The primary objective of this study is to determine whether the timing of delivery significantly affects maternal and fetal and neonatal outcome in women with severe preeclampsia. **Methods:** This is a descriptive cross-sectional study with a retrospective chart review of women with severe preeclampsia at the East Avenue Medical Center, Quezon City, Philippines. The outcomes measured were timing of delivery, adverse maternal, fetal and neonatal outcomes. **Results:** 362 women with severe preeclampsia were included. The most common maternal outcomes recorded were pulmonary congestion (5.52%), blood transfusion (3.87%) secondary to anemia from blood loss, and HELLP syndrome (3.04%). Majority delivered either via spontaneous vaginal delivery (43.3%) or assisted vaginal delivery (30.94%), successfully, with only a 23.76% delivering via cesarean section. There is insufficient evidence showing an association of the timing of delivery with adverse maternal outcome. There is a significant association of the timing of delivery to neonatal adverse outcome. For patients in whom there was no maternal adverse event, a 50% probability of a neonatal adverse outcome occurs when the delivery is at 281 hours from admission. For babies born to mothers with a maternal adverse event before delivery, a 50% probability for a neonatal adverse outcome occurs if the baby was delivered at 24 hours from admission. For patients born to mothers who had a maternal adverse event during or after delivery, a 50% probability for a neonatal adverse outcome occurs if the baby was delivered at 21 hours from admission. Conclusion: We recommend a cut off time of 20 hours from the time of admission to delivery for women with severe preeclampsia already presenting with an adverse event. For women with severe preeclampsia presenting with no adverse maternal event, successful vaginal delivery can be achieved with no significant adverse maternal, fetal or neonatal outcome, as the 50% probability of a neonatal adverse outcome occurs when the delivery is at 281 hours from admission.

**OP1-205 LAPAROSCOPIC SURGERY IN PREGNANCY AFTER THE SECOND TRIMESTER: A CASE SERIES**

Alexandra Wisentanter, Nina Cooper, Dina Saleh, Manojkumar Nair, Wai Cheong Yoong
Obstetrics & Gynaecology and General Surgery, North Middlesex University Hospital, London, UK

**Problem statement:** Emergency surgery for non-obstetric indications occurs in 1-2% of pregnancies. Recent literature promotes a laparoscopic technique as a safe, feasible and optimal approach in managing the acute abdomen during pregnancy. However, concerns regarding trocar placement, the impact of insufflation pressures on utero-placental circulation and the limited exposure to these cases has prevented routine implementation of a laparoscopic approach. We present 6 cases of laparoscopic surgery in women during their second and third trimesters of pregnancy. **Method:** This was a single-centre, retrospective case series of 6 women undergoing non-obstetric emergency laparoscopic surgery after 12 weeks gestation at a busy District General Hospital in London from January 2012 - June 2019. Exclusion criteria included women undergoing an open approach or intraoperative conversion from laparoscopic to open surgery. **Result:** 6 cases of laparoscopic surgery for non-obstetric emergency indications were performed. 4 laparoscopic appendectomies were performed at 12, 20, 24 and 31 weeks gestation. 2 laparoscopic cholecystectomies were performed at 14 and 16 weeks. The median age of the women was 28 years. An open Hasson technique at the umbilicus was used for laparoscopic access in all patients. 4 cases adopted a four port technique, the remaining 2 cases used three ports. There were no post-operative complications and mean length of stay was 3 days. Median gestational age at delivery was 39.2 weeks. There were no cases of fetal loss. 3 patients had normal vaginal deliveries at term, 2 patients were lost to follow up and 1 patient’s pregnancy is still ongoing. **Conclusion:** A laparoscopic surgical approach is increasingly considered a safe and optimal approach for the management of surgical pathology in pregnancy, with preservation of the benefits of laparoscopic surgery through advancing gestational age. Our case series has demonstrated successful non-obstetric, emergency laparoscopic surgery, with good materno-fetal outcomes in the second and third trimesters of pregnancy. Locally, a laparoscopic approach is increasingly considered the optimal first-line approach in appropriate patients. Input from both general surgeons and obstetricians is vital and we advocate the use of the emergency multidisciplinary team approach to facilitate discussion and joint decision making.
**Problem statement:** severe perineal tear (3-4 degree) is a major complication of vaginal delivery (0.3%-6.3%). The aim of our study was to evaluate the difference of risk factors of severe perineal tear between first vaginal delivery (FVD) and repeat vaginal delivery (RVD).**Method:** Study included retrospective data of women who gave birth of singleton, vertex vaginal deliveries between 2005 to 2018. 247 women had severe perineal tears and were stratified according to FVD and RVD. Common Risk factors were calculated for each group. **Results:** 77,981 women included in the study. 55,787 (71.5%) were RVD and 22,194 (28.5%) were FVD including first vaginal birth after previous cesarean section (CS). 247 of those women (0.31%) had a severe perineal tear. Multilevel logistic regression analysis demonstrate a significant association between severe tears and FVD, increased birth weight, instrumental delivery, previous CS, episiotomy, episiotomy and gestational age and young age. Comparing risk factors between FVD and RVD showed that higher weight of newborn was found to be a significant risk factor among FVD (OR=3.12, 95% CI [2.18-4.47]), and RVD (OR=3.57, 95% CI [2.01-6.33]), Although high weight is a risk factor for both groups, among RVD weight of risk for severe tears is 3.7Kg, while among FVD is 3.3Kg, according to the median split. In addition, instrumental delivery was found to be another risk factor for both groups, specifically among RVD (OR=3.401, 95% CI [1.33-8.69]) in comparison with FVD (OR=2.50, 95% CI [1.71-3.83]). Young age was found to be a significant risk factor among both FVD (OR=0.85, 95% CI [0.30-2.39]) and RVD (OR=0.92, 95% CI [0.87-0.96]). Previous CS was found to predict severe tears among FVD (OR=1.91,95% CI [1.24-2.93]) but not among RVD (OR=0.85, 95% CI [0.30-2.39]). Finaly, episiotomy was found to be related to severe tears among FVD (OR=1.66, 95% CI [1.17-2.39]) but not among RVD (OR=0.85, 95% CI [0.30-2.39]). **Conclusion:** Birth weight, instrumental delivery and young age are significant risk factors in first and repeat vaginal delivery. While only in FVD a previous CS and episiotomy are significant risk factors in first and repeat vaginal delivery.
fetus. The APRPD measurements were obtained, and fetal sex was determined. At term, the APRPD were re-measured to validate that the subjects included were normal fetuses. Cross-sectional analytical study design was employed. Results: There was a significant difference in the APRPD between male and female fetuses with a p value of ≤ 0.05. The mean APRPD of male and female fetuses were 3.4 mm ± 1.1 mm and 2.9 mm ± 0.6 mm, respectively, with a mean difference of 0.49 mm. A cut-off of 4.5 mm for male and 3.5 mm for female fetuses may be considered in diagnosing urinary tract dilation at 24 to 28 weeks. Upon validation at term, a significant difference was also noted in the APRPD of male and female fetuses with a p value of ≤ 0.001. The mean APRPD of term male fetuses was 4.5 mm ± 0.7 mm and 3.8 ± 0.7 mm for female with a mean difference of 0.65 mm. Conclusion: Male fetuses have larger APRPD compared to female fetuses. Thus, it is worthwhile to establish sex specific cut offs in diagnosing urinary tract dilation. Moreover, a higher cut off value should be allowed for male fetuses while a lower threshold of suspicion should be considered in dealing with female fetuses. The cut-off values established in this study were 4.5 mm in male and 3.5 mm for female fetuses given this study population.

OP1-211
GLYCAED HAEMOGLOBIN AND RISK FOR LARGE FOR GESTATIONAL AGE NEONATES IN GESTATIONAL DIABETES PREGNANCIES
Carolina Carneiro1, Sara Bernardes Da Cunha1, Vânia Ferreira1, Cátia Rasteiro1, Célia Araújo1, Teresa Teles1
1Serviço de Ginecologia e Obstetrícia, Centro Hospitalar entre o Douro e Vouga, Santa Maria da Feira, Portugal
2Faculdade de Ciência da Saúde, Universidade da Beira Interior, Portugal

Problem statement: Gestational diabetes (GD) is associated with multiple maternal and neonatal complications such as large for gestational age (LGA), macrosomia, prematurity and hypertensive complications. Optimal glycemic control may allow to minimize them. Glycated hemoglobin’s (HbA1C) goal in GD, is usually defined as 6%. HbA1C assumes a secondary role in the assessment of glycemic control since it doesn’t allow to properly evaluate the postprandial glycemia described as more often associated with fetal macrosomia. In the era of the emergence of new surveillance markers for GD glycemic control, the current role of HbA1C is questioned. The aim of this study is to determine the HbA1C cutoff in identifying LGA in pregnant with GD.

Methods: A retrospective analysis of singleton pregnancies with GD with delivery in our hospital from April 2015-July 2019 was conducted. Pregnancy, delivery and newborn data were assessed. Receiver operating characteristic (ROC) curve used to determine the cut-off for HbA1C in identifying LGA and area under the curve (AUC) was computed. Using the cut-off value, sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), were computed with 95% CI.

Results: 538 cases were identified. 48 were excluded since no HbA1C evaluation were available. Pregnant with neonates with birth weight (BW) superior to percentile 90 (BWp90) had higher levels of HbA1C on 3rd trimester. ROC curve for HbA1C as a test for BWp90 revealed an AUC on the 3rd trimester of 0.709 (p=0.010), on the 2nd trimester, 0.68 (p=0.151) and on the 1st trimester 0.62 (p=0.406). On 3rd trimester the ROC curve coordinates indicated that the best HbA1C cutoff was 5.65 with sensitivity 38.5%, specificity 93.2%, PPV 14.3% and NPV 98.1%. Conclusion: HbA1C measurements on 3rd trimester performed better to detect LGA. These values reflect glycemic control in mid trimester, suggesting that glycemic values on mid trimester may be more decisive on risk of LGA. Although AUC was statistically significant, it was small. The ROC curve suggested 5.65 as a more appropriate cutoff in identifying LGA, but although specificity was high, sensitivity wasn’t acceptable. These results suggest that HbA1C alone is not a good indicator for LGA.

OP1-212
OXYTOCIN USE IN GRAND MULTIPARA WITH DYSFUNCTIONAL LABOR AND ONE PREVIOUS CESAREAN SECTION RESULTS IN HIGH RATE OF NORMAL DELIVERIES
Yara Naser, Yael Yekel, Yael Arbel, Roni Rozenberg, Mordechai Ben David
Department ofObgyn, Laniado Medical Center, Netanya, Israel

Problem statement: Dysfunctional labor is an indication for caesarean section. The aim of our study was to evaluate whether use of oxytocin in dysfunctional labor (DL) among grand multiparous (GMP) with one previous segment cesarean section (CS) decreases the rate for repeated cesarean section.

Patients and Methods: During the years 2005-2017, 88,820 women delivered at our institution. 10,618 (12%) were GMP (%2 deliveries) of whom 1168 (12%) had one previous CS. 1022 (87.5%) underwent spontaneous labor without augmentation and 146 (12.5%) had DL and needed oxytocin augmentation based on high risk protocol- in the range of 0.5 mU/min as starting dose, to maximum of 6 mU/min, after gradual increase of 3 mU/min every 20 min until the appearance of three regular contractions in 10 min. Results: In the GMP who got into spontaneous labor, 91.1% (911/1022) underwent repeat CS in the control group. Oxytocin use in DL among GMP with previous one cesarean section during labor, have decreased the rate of CS to be the same as the rate of spontaneous labor in the control group. The mean birth weight of GMP who got into spontaneous labor was 3.59 kg compared to 2.67 kg in the control group. The rate of NICU admission was also higher in the IVF/ICSI group being solely ‘IVF pregnancy’. Normal vaginal delivery was the commonest mode of delivery in the IVF/ICSI group compared to age-matched controls who conceived naturally during the same time period. Data was collected retrospectively. Results: The IVF/ICSI cohort consisted of 71 patients and these were compared to a total of 710 controls. Controls were stratified according to age into three groups (25–29 years, 30 – 34 years, and above 35 years). Antenatally, 77.46% of IVF/ICSI patients were found to have some obstetric complication, the most prevalent of which was gestational hypertension (23.95%). Of the controls, 22.25% of the patients developed an obstetric complication antenatally with gestational hypertension being the commonest in the above 35 age group. The mean gestational age at delivery was 37 weeks in the IVF/ICSI cohort and 39 weeks in the controls. Cesarean section (CS) was the commonest mode of delivery in the IVF/ICSI group (43.66%) and around 4% of patients had an elective CS with the indication being solely ‘IVF pregnancy’. Normal vaginal delivery was the most common mode of delivery in the control cohort (58.87%). The mean birth weight was 2.65kg in the IVF/ICSI group compared to 3.25kg in the natural conception group. The rate of NICU admission was also higher in the IVF/ICSI group being 18.31% compared to 2.67% in the controls. Conclusion: Even when the higher proportion of multiple gestations in the IVF group was accounted for, the CS rate was higher in our local population, and this reflects global trends (Helmerhorst et al., 2004). Possible reasons may be attributed to a more defensive attitude by the caring obstetrician, intensified parental anxiety. Even though clinician concern may be a factor in the decision to deliver by CS, an increased rate of NICU admission in IVF/ICSI babies might support this heightened concern. Conversely, the very mode of delivery may be a contributing factor to the increased NICU admission rates.
any functional enzymatic activity. A case-control study was performed. We found an increased risk of developing endometriosis associated with GSTT1 null genotype (OR 5.370; 95% CI 2.684-10.742; p<0.001) as well as GSTM1 null genotype (OR 2.549; 95% CI 1.301-4.998; p=0.009). We also observed an increased prevalence of polycystic ovary syndrome (PCOS) associated with deletion of GSTT1 (OR 4.890; 95% CI 2.621-9.122; p<0.001). We found an increased risk of premature ovarian failure associated with GSTT1 null genotype (OR 5.182; 95% CI 2.554-10.515; p<0.001) and verified an increased prevalence of tubal pathology in carriers of GSTT1 deletion (OR 6.693; 95% CI 3.385-13.233; p<0.001). A strong association of GSTT1 null genotype with female infertility, regardless of the cause was found (OR 5.300; 95% CI 3.238-6.875; p<0.001), as well as for GSTM1 null genotype (OR 1.620; 95% CI 1.067-2.459; p<0.001). The two-way combination of GSTT1 and GSTM1 null genotypes proved an increased susceptibility to infertility development in simultaneous carriers of the two deletions (OR 11.136; 95% CI 5.035-24.629; p<0.001). In conclusion, GSTT1 and GSTM1 null genotypes, alone or in association, are associated with increased susceptibility to infertility development in women.

Problem statement: Surrogate pregnancy is prohibited in France and in many other European countries. We aimed to investigate the opinions of French women on surrogate pregnancy before the revision of the Bioethics Laws. Methods: An anonymous questionnaire with 15 items was proposed to 200 women after delivery concerning their opinions about surrogacy. The study was conducted in the maternity department of the Regional Hospital Centre of Orleans. Results: 114 women (59%) stated that the surrogate pregnancy was ethically acceptable, 175 women (88.8%) stated that it should be legalized in France for infertility, refusal of adoption or homosexual couples' request. 65.5% of women of French origin, 34.8% from North Africa and 31.8% from Sub Saharan Africa stated that surrogacy was ethically acceptable (p<0.01). 64.6% of Catholic and 28.6% of Muslim women respectively (p<0.01). Among the reasons listed by participants in support of legalized surrogate pregnancy: its authorization in other countries (17%), generosity of the surrogate mother (37%), the importance of education of the child by the receiver couple (37%) and the fact that in many cases, the surrogate mother has no genetic bond with the child (24%). Reasons that women listed against legalization include unclear filiations (7%), religious prohibition (9.5%) and the psychological trauma of the surrogate mother and the child (26%). 50% of women thought that the surrogate mother should continue to have a relationship with the child. 137 participants (68.4%) believed the surrogate mother should have financial compensation. 82.8% of participants supported an age limit for the surrogate mother and 67.7% supported an age limit for the receiver couple. Conclusion: Most participants thought that surrogate pregnancy was ethically acceptable and was favorable to its legalization in France. Infertility was considered as the major reason for access to surrogacy. The authors report no conflict of interest.
OP1-305
ARE BABIES BORN THROUGH ART AT HIGHER RISK OF ANOMALIES – A POPULATION BASED STUDY

Eleanor Brincat, Maria-Petra Agius, Olivia-Anne Cassar
ART Clinic, Mater Dei Hospital, Malta

Problem statement: To compare the rate of congenital fetal anomalies in babies born through artificial reproductive techniques (ART) vs those born through spontaneous conception. Methods: A retrospective cohort study was done including 71 babies born through transfer of cleavage stage embryos by IVF/ICSI between January 2015 to June 2017 in Malta. The incidence of congenital anomalies was identified and compared with 710 naturally conceived infants born to age matched mothers (controls) through the same time period. Data was collected through the National Obstetric Information System database (NOIS). No PGD is allowed in Malta, and genetic testing on the couple and counselling for major genetic diseases is done prior to stimulation for IVF. Results: Out of the 71 babies born through ICSI, 6 (8.45%) had a congenital anomaly diagnosed at birth and 13 (18.31%) required NICPU admission. Of the 710 babies born through spontaneous conception, 34 (4.79%) were diagnosed with a congenital anomaly and 19 (2.68%) required NICPU admission. Average birth weight of 2.65kg in the ART group and 3.25kg in the control group. The incidence of multiple gestation in the ART group was higher than the control group (25% vs 2%). Average maternal age was 35 years in both the ART and naturally occurring pregnancy group while mean BMI was 26.48 in the study group and 25.07 in the control group with 6% being smokers in the control group and 3% in the ART group. Conclusion: Concerns about fetal outcomes of babies born through artificial reproductive techniques (ART) including In-Vitro Fertilisation (IVF) and Intracytoplasmic sperm injection (ICSI) have been studied with conflicting conclusions (Fauser et al., 2014; Lacamara et al., 2017). In this population-based study, babies born through ART had higher congenital anomaly rates than babies born through spontaneous conception, however rate of twinning was also higher in the ART group. Therefore, one can say that ART is associated with a higher incidence of congenital anomalies, however it does not necessarily prove direct causality. Single embryo transfer protocols could improve this outcome.

OP1-306
EVALUATION OF AGE, AMH AND AFC AS PREDICTORS OF OVARIAN RESPONSE TO TREATMENT IN IVF CYCLES

Olivia Anne Cassar1, Liberato Camilleri2, Paul Bezzina2, Mark Sant3
1Department of Health Sciences, University of Malta, Malta
2Department of Health Sciences, University of Malta, Malta
3Department of Obstetrics and Gynaecology, Mater Dei Hospital, Malta

Problem: Infertility is becoming an increasingly important branch of gynaecological practice as more and more women are postponing childbirth. One of the matters of great interest to both patients and clinicians alike is how the ovaries will respond to treatment during an IVF cycle. Ovarian reserve has long been recognised as one of the key players when it comes to response to treatment and a lot of effort is being put into trying to determine the best biomarker for it. The objective of this study was to identify which among age, anti-Mullerian hormone (AMH) and antral follicle count (AFC), performs best at predicting how the patients will respond to treatment during IVF treatment. Methods: This was a retrospective correlational non-experimental study, where 117 patients were assessed for age, AMH, and AFC. Data was collected for the number of oocytes retrieved at pick up, the dose of follicle stimulating hormone (FSH) used during stimulation, the duration of stimulation in days, as well as pregnancy rates. Regression analysis was applied to the data to try and determine which of the biomarkers was the strongest predictor of ovarian response. Results: Assessed separately, all three markers were useful at predicting the number of oocytes retrieved. Used collectively, however, AFC emerged as the strongest one (p-value 0.000). For the dose of FSH used, all markers used singly were significant, but used together, the predictive effect was less strong than for oocyte number. The markers were most useful at predicting how long stimulation would take, or which of the patients would get pregnant. This has significant implications when it comes to counselling women prior to the start of their treatment as all three biomarkers have become standard tests in the work up prior to IVF. Conclusion: All three markers were useful during an IVF cycle but in this study, AFC emerged as the strongest marker for prediction of ovarian response to treatment across the entire menstrual cycle.

OP1-307
CORRELATION BETWEEN SPERM DNA DEFECTS AND MUTATIONAL STATUS OF THE MTHFR GENE: IMPACT OF TREATMENT

Arthur Clement, Patrice Clement, Yves Menez, Eric Sedbon, Silvia Alvarez, Charles Brami, Laetitia Jacquesson, Edouard Amaury
IVF Unit, Laboratoire Clément, Paris, France

Problem statement: DNA fragmentation index (DFI) is involved in some AMP failures (Spano 2000, Saleh 2003). Anomalies in the decondensation of sperm DNA lead to early stage developmental failure and recurrent AMP failures (Junca, 2012). Polymorphisms of MTHFR increases the risk of male infertility (Gong, 2015). MTHFR gene is involved the one-carbon cycle (1-CC): it allows the synthesis of antioxidant molecules and improves the methylation of DNA, which plays a key role in epigenetic and fingerprint defects. 5-methyltetrahydrofolic acid (5MTHF) treatments allow to restore the activity of the cycle, as evidenced by the decrease in homocysteine after treatment. (Clement, 2018). Methods: The MTHFR gene mutation research was conducted by real-time PCR. Sperm DNA analysis is performed according to the SCSS (Sperm Chromatin Structure Assay) protocol. Men carrying the mutation were treated with 5MTHF 400 μg for a minimum of 3 months, and the variations of sperm DNA parameters (fragmentation and decondensation) were measured before and after treatment. Results: In our infertile population, 700 patients benefited from MTHFR gene mutation research and sperm DNA defects. The 677 polymorphism of the MTHFR gene is correlated with both fragmentation and decondensation of sperm DNA (p 0.05). The 1298 polymorphism of the MTHFR gene is correlated with fragmentation of sperm DNA (p 0.05) but not with decondensation. Among the patients who received treatment with 5MTHF, 68 had a search for spartic DNA abnormalities before and after treatment. The treatment resulted in a significant decrease in sperm DNA fragmentation (from 24.0 to 13.7%, p 0.05) and a non-significant decrease in decondensation (19.4 to 16.6%, NS). Conclusion: There is a correlation between sperm DNA and mutational status of the MTHFR gene. In order to prevent failures and improve ART outcomes, patients with high fragmentation or decondensation and patients with a mutation in the MTHFR gene could benefit from a search for isoforms of the gene and they could then be treated with 5MTHF to improve the parameters of their gametes and their fertility.

OP1-308
PROGESTIN-PRIMED OVARIAN STIMULATION (PPOS) PROTOCOL FOR IN VITRO FERTILIZATION, OOCYTE DONORS OR FERTILITY PRESERVATION SYSTEMATIC REVIEW AND META-ANALYSIS

Jose Antonio Dominguez1, Maria Carrera2, Jaime Dominguez3, Ana Ortiz4
1Reproduction Unit, Iera, Badajoz, Spain
2Reproduction Unit, Hospital Doce De Octubre, Madrid, Spain
Problem statement: Standard ovarian stimulation for IVF requires GnRH agonists or antagonists to prevent a premature LH surge. In recent years, several authors have suggested the safety and efficacy of different oral progestin preparations in preventing premature LH surges, thus reducing the amount of injections and the cost of treatment.

Methods: A systematic search of the literature was conducted in PubMed, EMBASE, Web of Science, and Cochrane databases. Search words employed were: “progestins”, “In Vitro Fertilization” “ovarian stimulation” and “progestin-primed”. RevMan 5.3 software was used for quality assessment of studies and statistical analysis. Results: Ten studies were included in the meta-analysis. Five of them were prospective (two Randomized Controlled Trials and three controlled studies) and five were retrospective studies. Due to methodological and clinical heterogeneity among studies, random effects model was used. There were no significant differences between the two protocols regarding number of recovered oocytes (mean difference (MD)=0.43, 95% CI:-1.10-0.22, N=1448, 8 studies); Metaphase II oocytes (MD=0.1, 95%CI:-0.80,0.67, N=1275, 5 studies) or follicles14 mm (MD=0.67, 95% CI -0.24,1.58, N=614, 3 studies). Stimulation length was higher in the PPOS group (MD=0.02,0.05 cut 0.23-0.83, N=2046, 10 studies) but differences in gonadotrophins consumption were not significant (MD=39.65 95% CI:-84.84,63.63, N=614, 4 studies). No differences were found regarding good quality embryos (MD=0.39, 95% CI -0.28,1.05, N=420, 2 studies) or cycle cancellation rates (OR: 1.36, 95% CI:0.67,2.75, N=486, 2 studies). Conclusions: According to the best available evidence, PPOS protocol is not inferior to the standard protocol with GnRH antagonists or antagonist in terms of stimulation efficacy, safety and clinical results. PPOS protocol may be convenient in certain subgroups of patients as oocyte donors, fertility preservation cycles or when freeze-all policy is the first choice as it may reduce costs and burden of treatment.

OP1-309 PREVENTIVE STRATEGIES FOR PREOVULATORY PROGESTERONE ELEVATION DURING OVAIRAN STIMULATION FOR IN VITRO FERTILIZATION

Emina Ejubovic1,2, Miro Kasum3, Malik Ejubovic4, Dinka Pavićić-Baldani5, Slavko Oresković6, Ivka Džaković7, Anida Kurtovic-Hmičij8
1Department of Gynecology and Obstetrics, Cantonal Hospital Zenica, Zenica, Bosnia and Herzegovina
2Sarajevo Medical School, Sarajevo School of Science and Technology, Sarajevo, Bosnia and Herzegovina
3Clinical Department of Obstetrics and Gynecology, Zagreb University Hospital Center, School of Medicine, University of Zagreb, Zagreb, Croatia
4Department of Internal diseases, Cantonal Hospital Zenica, Zenica, Bosnia and Herzegovina
5Department of Gynecology and Obstetrics, Sestre milosrdnice University Hospital Center Zagreb, Croatia
6Sarajevo Military Medical Center, Sarajevo, Bosnia and Herzegovina
7Department of Health Care of Women and Maternity of Sarajevo Canton, The Department of Health Care of Women and Maternity of Sarajevo Canton, Bosnia and Herzegovina

Problem statement: Elevated proovulatory serum progesterone (P) is frequently observed during the late follicular phase at the end of ovarian stimulation on the day of ovulation triggering with human chorionic gonadotropin (hCG) during the in vitro fertilization (IVF) cycle. The incidence of premature P rise varies widely from 35% to 85% with the definition, cut-off, systematic P, stimulation protocols and population characteristics. The purpose of this review is to present contemporary measures for preventing the preovulatory P elevation and its adverse effects on ovarian stimulation in IVF. Methods: Review article of the current scientific research on preventive strategies for preovulatory P elevation during ovarian stimulation for IVF. Results: The increase of preovulatory P is not fully understood in terms of its impact on pregnancy outcome after IVF. Some studies failed to establish a connection between the preovulatory P increase and pregnancy outcome, while, most other studies have found its adverse effects. It is now accepted that P prematurely opens the window of implantation and modifies endometrial receptivity, leading to defective implantation and decreased pregnancy rate. Current strategies include the use of mild stimulation protocols and early application of hCG for ovulation induction among good responders, as they are associated with lower estradiol levels, delay in the transfer of fresh embryos from 3rd to 5th day, and cryopreservation of all embryos with the embryo transfer (ET) in the natural cycle. An earlier hCG trigger, when follicles reach a diameter of 15-16 mm is associated with lower preovulatory P but not with better ongoing pregnancy rates. A better implantation rate and IVF outcome with day 5 as compared with day 3 single ET has been found; the selection of blastocyst transfer seems to be justified. The cryopreservation of all embryos and a subsequent transfer in a natural cycle has increased the success rates in IVF cycles. Conclusion: Further studies are needed to confirm the current preventive methods or enable the application of new strategies in order to lower or eliminate the detrimental effects of preovulatory P rise during ovarian stimulation in IVF. All the authors have nothing to disclose.

OP1-310 EFFECTS OF CONTROLLED OVARIAN HYPERSTIMULATION ON THE EXPRESSION OF ENDOMETRIAL TISSUE GLYCODELIN-A DURING MIDLUTEAL PHASE OF MACACA NEMESTRINA

Afif Rasyad1, Adriana Viola Miranda1, Karina Rahmaningrum1, Kusmardi Kusmardi2, Diah Kristianti2, Nurhuda Nurhuda3
1Undergraduate Program, Faculty of Medicine, University of Indonesia, Indonesia
2Department of Anatomical Pathology, Faculty of Medicine, University of Indonesia, Indonesia
3Department of Clinical Pathology, Faculty of Medicine, University of Indonesia, Indonesia
4Department of Biology, Faculty of Medicine, University of Indonesia, Indonesia

Problem statement: The success rate of IVF is still considered low, about 30% will result in birth. Numerous factors determine the success of IVF, one of those is endometrial receptivity. One of the crucial steps of IVF is the controlled ovarian hyperstimulation (COH), in which the protocol may decrease the receptivity of the endometrial tissue. The protocol will cause the body to release multiple follicles, reaching the superovulation state, and it can alter the expression of molecules such as glycodelin-A. Methods: Paraffin-embedded tissue blocks of Macaca nemestrina (macaques) uterus are used for this study. The subjects that are included consist of 15 female Macaca nemestrina, all on reproductive age of 8-10 years with history of birth. The subjects were then divided into four groups; control group (GnRH agonist with no recombinant follicle stimulating hormone (r-FSH)) and three intervention groups (with r-FSH of 30 IU, 50 IU and 70 IU). The tissues were retrieved 7 days after the stimulation and were embedded into paraffin blocks. Afterwards the tissues were stained using immunohistochemistry, and then the expression was determined by IHC profiler and counted semiquantitatively as H-score. Results: The result of one-way ANOVA shows that the differences of glycodelin-A expression in the endometrial glands (F (3,10) = 0.803, p = 0.520), stromal (F (3,11) = 0.915, p = 0.465), and the luminal parts of the tissue (F (3,8) = 0.991, p = 0.445) between the groups are insignificant. The insignificance of the differences may result from the indirect nature of relationship between FSH and glycodelin-A, since it is mediated by estrogen and progesteron. The result may also be explained by the 7-day interlude between the administration of GnRH and r-FSH and tissue retrieval, due to the latter half-life of only 24 hours. The limitation of our study is the low number of subjects due to the dwindling number of Macaca nemestrina in Indonesia. Conclusion: The glycodelin-A expression in endometrial tissues are not significantly affected by COH protocol, specifically the administration of r-FSH. Further study regarding the effect of estrogen and progesteron on glycodelin-A concentration is needed.
Problem statement: The etiopathogenesis of preeclampsia remains unclear but endothelial dysfunction is one of the leading theories. Increased oxidative stress and lipid peroxides and reduced antioxidants play important role in the pathophysiology of preeclampsia. Malondialdehyde (MDA) is the final product of lipid peroxidation, used as the oxidative stress marker. Autophagy plays an important role in the pathophysiology of preeclampsia as observed in the failure of trophoblast invasion and spiral artery remodelling. LC3-II is used as a typical marker of autophagy. Phaleria macrocarpa (Scheff.) Boerl also known as Mahkota Dewa in Indonesia is widely used as an anti-inflammation and antioxidant.

Methods: This study used HUVEC culture as an in vitro model and Phaleria macrocarpa’s extract, to determine the effects of Phaleria macrocarpa (Scheff.) Boerl extract on oxidative stress and autophagy in endothelial cells by measuring the MDA and LC3-II level in preeclampsia-induced HUVEC. Results: Phaleria macrocarpa’s extract reduce MDA level significantly at concentration 3.906 μg/mL and at 15.625 μg/mL reduce MDA level to normal level. There was no significant decrease in mean LC3-II levels between control and PE model and Phaleria macrocarpa’s extract at concentration more than 250 μg/mL needed to reduce LC3-II level in preeclampsia model to normal pregnancy level. MDA have strong positive correlation with LC3-II level in preeclampsia-induced HUVEC. Autophagy plays an important role in the pathophysiology of preeclampsia. Malondialdehyde (MDA) is the final product of lipid peroxidation, used as the oxidative stress marker. Thus, Phaleria macrocarpa’s extract might be used to overcome oxidative stress and autophagy in preeclampsia.

Disclosure of Interest: The authors whose names are listed above certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; stock ownership, or other equity interest; consultancies; expert testimony; royalties or patent licenses) or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.

Problem statement: Caesarean sections performed at full dilatation (FDCS) often involve disengagement of a deeply impacted fetal vertex and as such, can be the most challenging type of delivery for the obstetrician and can result in greater maternal morbidity. FDCS are becoming more commonplace, however data on incidence remains sparse and can sometimes be misleading if an individual maternity unit has a high elective or first-stage caesarean section rate. This study aims to collate data from multiple maternity units and propose alternative methods for representing the incidence of FDCS.

Methods: Data was collated from six maternity units in North-West London over twelve months. Total number of deliveries, numbers of fully dilated, first-stage and elective caesarean sections as well as spontaneous vaginal and assisted vaginal deliveries were recorded for all singleton pregnancies. Three indices were calculated using this data: (1) FDCS as a proportion of all births, (2) FDCS as a proportion of all labouring women [i.e. excluding elective caesarean sections] and, (3) FDCS as a proportion of all women who reach full dilatation [i.e. excluding all first-stage and elective caesarean sections]. Results: There was a total of 28,867 deliveries in North-West London over the twelve-month study period. This consisted of 15,469 spontaneous vaginal deliveries, 4,171 assisted vaginal (instrumental) births, 3,797 elective and 5,430 emergency caesarean sections. Of the emergency caesarean sections, four hundred and ninety-three were performed at full dilatation. This represented 1.7% of all births (range: 0.8 – 2.2%), 2.0% of all labouring women (range: 0.9 – 2.4%) and 2.5% of all women who reached full dilatation (range: 1.0 – 2.9%). Conclusion: To our knowledge, this is the first multi-centre analysis of the incidence of FDCS. Second-stage caesarean sections remain relatively common and therefore safe delivery of a deeply impacted fetal vertex should continue to be an essential component of obstetric practice. This study has suggested that by representing FDCS as a proportion of all labouring women or as a proportion of those who reach full dilatation, maternity units can better analyze how they manage the first and second stages of labour, respectively. Disclosure of interest: None declared

PO1-403
OF PREGNANCIES COMPPLICATED WITH SMALL FOR GESTATION AGE BABIES AT TERM, WHAT PROPORTIONS HAVE PLACENTAL FINDINGS WITH IMPLICATIONS FOR FUTURE PREGNANCIES OR NEONATAL OUTCOMES

Roberto Orefice1, Alison Kent2, Farah Sethna3, Jane Dahlstrom3
1Fetal Medicine Unit, Centenary Hospital for Women and Children, Canberra, Australia
2Department of Neonatology, The Canberra Hospital, Canberra, Australia
3Department of Anatomical Pathology, The Canberra Hospital, Canberra, Australia

Problem statement: To identify the proportion of term pregnancies complicated by SGA with placental findings that may have implications for future pregnancies or neonatal outcomes. Methods: A retrospective review between 2011-2015 of babies and placentas born at term with SGA. Histopathological findings were categorised as to whether they had a high recurrence rates or findings that may benefit from neonatal follow up. Under 50% of pregnancies complicated by SGA at term had a placental examination, resulting in a significant number of potential important clinical consequences being missed.

Disclosure of interest: None declared

PO1-404
POSITIVE PREGNANCY OUTCOME IN WOMEN WITH PHENYLKETONURIA IS POSSIBLE!

Zhao Xuan Tan1, Nandini Halder2, Roopam Goel2
1Obstetrics and Gynaecology, Glangwilli General Hospital, Hwyel Dda University Health Board, UK
2Obstetrics and Gynaecology, Glangwilli General Hospital, Hwyel Dda University Health Board, UK

Introduction: Phenylketonuria (PKU) is a rare autosomal recessive hereditary metabolic disorder with a prevalence of approximately 1: 10,700 newborns in Wales, UK. Case: 37-year-old G3 P+1 lady with congenital PKU, BMI of 38.8 kg/m2 is presently 27 weeks pregnant. She had a positive outcome in her last pregnancy following commendable effort from her clinicians combined with her compliance. Patient had optimised...
phenylalanine (PHE) levels with excellent adherence to PKU treatment prior to and throughout her last pregnancy. At 20 weeks gestation, tyrosine supplements were arranged due to low tyrosine levels 50μmol/L, she also developed hyperthyroidism in pregnancy. At 30 weeks, she was referred to Fetal Medicine Unit with suspected fetal growth restriction and was delivered by elective caesarean section at 37+5 weeks for the same reason. Baby was born with good apgars weighing 2.3kg with no intrapartum or immediate postnatal complication. Both were discharged home after day 2. Discussion: PKU is due to an inborn error of PHE metabolism caused by variants in the gene encoding phenylalanine hydroxylase (PAH) that converts PHE into a nonessential amino acid called tyrosine. This leads to toxic level of accumulation of PHE in the blood and brain with by-products phenylpyruvic acid and phenylthylamine, which are neurotoxic. High levels of PHE can cause irreversible intellectual disability, motor deficits, encephalitis, rash, seizures, developmental problems, aberrant behaviour and psychiatric symptoms. It has teratogenic effect on the developing fetus that can cause growth retardation, microcephaly, intellectual disabilities, birth defects including congenital heart defects or even fetal demise. Low PHE diet with PHE-free L-amino acid supplements are the cornerstones of PKU treatment. Conclusion: Family planning and preconception counselling are crucial to woman with PKU. Maintaining normal plasma PHE levels 300μmol/L from at least two weeks prior to conception and throughout pregnancy improves the chances of favourable obstetric outcome.

CASE OF HETEROTOPIC PREGNANCY (OVARIAN AND INTRAUTERINE) IN A 30-YEAR-OLD PATIENT

Gene Afzelia Austria
Department of Obstetrics and Gynecology, Veterans Memorial Medical Center, Quezon City, Philippines

Problem statement: Heterotopic pregnancy is the presence of simultaneous pregnancies in two different implantation sites. Oviduct is the most frequent location of extrauterine pregnancy coexisting with intrauterine pregnancy, and is followed by pregnancy in the ovary. Method: This is a 30 year old, Gravida 2 Para 1 (1001), with a chief complaint of severe abdominal pain. Low PHE diet with PHE-free L-amino acid supplements are the cornerstones of PKU treatment. Conclusion: Family planning and preconception counselling are crucial to woman with PKU. Maintaining normal plasma PHE levels 300μmol/L from at least two weeks prior to conception and throughout pregnancy improves the chances of favourable obstetric outcome.

MANAGEMENT OF A PARAGANGLIOMA IN PREGNANCY

Kelsey Simpson1, Payam Katebi Kashi2, Katherine Dengler3
1Department of Obstetrics and Gynecology, Walter Reed National Military Medical Center, Bethesda, USA
2Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Inova Fairfax Women’s Hospital, Falls Church, USA
3Department of Obstetrics and Gynecology, Division of Urogynecology, Walter Reed National Military Medical Center, Bethesda, USA

Problem statement: Paragangliomas are made of neural crest cells and arise from the extra-adrenal parasympathetic and sympathetic paraganglia. Catecholamine secreting tumors, including paragangliomas and pheochromocytomas, are very rare in pregnancy with less than 250 cases documented in the literature. Typically, paragangliomas are discovered during an evaluation of paroxysmal symptoms of flushing, tachycardia, severe headaches, and tremor, a workup of uncontrolled severe hypertension, or incidentally found on radiographic evaluation of an unrelated condition. Fractioned plasma and urine metanephrines, although not validated in pregnancy, are typically used to evaluate for catecholamine secreting tumors and would be significantly elevated. Definitive treatment for pheochromocytomas and paragangliomas is surgical resection. In pregnant patients, careful consideration must be applied to maternal and fetal well-being in regards to timing of this excision. Sparse literature is available regarding early diagnosis in pregnancy and conservative management with alpha and beta blockade throughout the duration of pregnancy. Case Report: Twenty-two year old primiparous patient at five weeks gestation with known chronic hypertension was diagnosed with a incidentally found 3.7cm retroperitoneal tumor concerning for pheochromocytoma versus paraganglioma. After evaluation and counseling, the patient decided upon conservative management with alpha and beta blockers throughout pregnancy. Results: Subsequent increases in her medication regimen of phenoxybenzaine and propranolol controlled symptoms of fatigue, lightheadedness, palpitations, and headaches. Surgical resection of her retroperitoneal mass was scheduled at time of planned primary cesarean section at 37 weeks gestation. The patient underwent an uncomplicated surgical procedure and postoperative course. Both her and the infant did very well. Conclusion: In this case, a paraganglioma was diagnosed early in pregnancy and conservatively managed with alpha antagonists and beta blockers. Although safe surgical resection has been documented in the second trimester for catecholamine secreting tumors, her resection was coordinated at time of cesarean section resultng in good outcomes for both the fetus and mother. Careful patient selection and informed consent is foremost when determining a health care plan for a patient with a paraganglioma in pregnancy and the collaboration of a multi-disciplinary team is paramount. Financial Disclosure: The authors declare that there is no conflict of interest to disclose.

PREDICTIVE VALUE FOR SPONTANEOUS PRETERM BIRTH IN WOMEN PRESENTING WITH PRETERM LABOR: COMPARISON OF PLACENTAL ALPHA MICROGLOBULIN-1 AND FETAL FIBRONECTIN ACCORDING TO THE CERVICAL LENGTH

Woo Jeng Kim1, Yoo Hyun Chung2, Jeong Ha Wise3
1Obstetrics and Gynecology, Seoul St Mary’s Hospital, Seoul, South Korea
2Obstetrics and Gynecology, Daejeon St Mary’s Hospital, Daejeon, South Korea
3Obstetrics and Gynecology, Eunpyeong St Mary’s Hospital, Seoul, South Korea

Problem statement: The purpose of this study was to compare the placental alpha microglobulin-1 (PAMG-1) and fetal fibronectin (FFN) for prediction of spontaneous preterm delivery among women with symptoms of preterm labor and to investigate the difference in predictive performance for both rapid bed side tests according to the cervical length. Methods: We conducted a retrospective cohort study on pregnant women with signs or symptoms suggestive of preterm labor between 22+0 and 33+6 weeks of gestation from April 2012 to December 2018
in the Seoul Saint Mary’s hospital. Singleton pregnant patients with clinically intact membranes and cervical dilatation less than 3cm were selected for chart review and included in the analysis. Positive predictive value (PPV), negative predictive value (NPV), sensitivity and specificity of PAMG-1 were compared with FFN for the prediction of spontaneous preterm birth (SPB) less than 37 weeks of gestation and delivery within 7 days of PAMG-1 and FFN testing. In addition, the test performances were compared according to the severity of cervical length shortening. **Results:** 589 women were included in the study cohort. The rate of SPB was 20.4% (120/589) and the rate of delivery within 7 days of testing was 5.1% (30/589). The detection rate of PAMG-1 and FFN were 6.5% (38/589) and 34.1% (201/589), respectively. The PPV for the prediction of SPB for PAMG-1 and FFN were 51.4% and 32.1%, respectively (P=0.028); the PPV for prediction of delivery within 7 days of testing for PAMG-1 and FFN were 23.7% and 9.5%, respectively (P=0.012). The results were analyzed according to the severity of cervical length shortening. The group with cervical length between 15 and 25 mm, the PPV of PAMG-1 was significantly higher in the prediction of SPB within 7 days of testing than that of FFN. **Disclosure:** No potential conflicts of interests.

**OP1-409**

**OBSTETRIC PERFORMANCE OF HUGE BABIES (4800GM)**

**Linda Harel**

Obstetrics and Gynecology, Myney Hayeshua Medical Center, Bnei Brak, Israel

**Problem statement:** Practically all huge babies have underestimated sonographic fetal weight. This study shows the outcome of 56 such babies born in Myney Hayeshuva Medical Center. **Methods:** This is a retrospective cohort. All information was gathered from patients’ electronic files between 2012 and 2018. **Results:** Fifty six huge babies (4800gm) were born in a six year period in Myney Hayeshuva Medical Center which composed approximately 1:1000 babies born. Patients were in their first to eighth delivery. One fifth of these babies were girls and the rest boys. Only 11 babies were delivered by Cesarean delivery, the rest vaginally. There were five documented cases of shoulder dystocia with two clavicular fractures and two cases of transient Erb’s Palsey. In all of the cases there was underestimation of the fetal weight prior to delivery. Seven cases of maternal diabetes mellitus and six cases of maternal morbid obesity were found. All of the cases (of multipartas) had documented previous maximal birth weight but 20.4% and 9.5% respectively. **Conclusion:** Huge babies are often born with minimal difficulty and very large babies almost always have underestimated fetal weight.
VAGINAL MICROORGANISM AND ITS INFLUENCE IN PRE-TERM DELIVERY
Sara Bernardes da Cunha¹, Patricia Gomes¹, Carolina Carneiro¹, Inês Reis¹, Cátia Rasteiro¹,², Augusto Pinto¹, Teresa Tittes¹
¹Obstetrics and Gynecology, Centro Hospitalar De Entre Douro E Vouga, Portugal
²Faculdade De Ciências Da Saúde, Universidade Da Beira Interior, Portugal

Problem statement: Preterm delivery (PTD), a leading cause of morbidity and mortality, occurs in 5-18% of pregnancies. Several studies reported an association between PTD and infection. However, the association remains controversial. The aim of this study was to evaluate the cases of threatened preterm labour (TPTL) of our unit and the association with vaginal exudates results.

Methods: Retrospective study of TPTL pregnancies admitted at our unit. Maternal age, cervical length, PTD history, cervical conization, gestational age at diagnosis and delivery, type delivery, Apgar score, birth weight and microbiological vaginal results – mycoplasma and microbiotic smear were assessed.

Results: We assessed 97 cases of TPTL. In 39 cases there was at least one positive vaginal smear. Mycoplasma was the most frequently agent identified (19 cases). When comparing the positivity of any microbiologic test with the gestational age (>1.5; p=0.13) and cervical length (>0.8; p=0.42) at diagnosis there were no differences. In individual analysis, women with positive mycoplasma test had inferior gestational age at diagnosis compared with women negative cases (t=2.2; p=0.50). The age of birth did not differ in function of mycoplasma smear result (t=3.52; p=0.72). In other hand a positive test to SGB, candida albicans and microbiological culture showed a lower mean age of birth (t=2.7; p=0.01; F=3.3; p=0.01; t=3.03; p=0.01), with no difference in the age of the diagnosis (t=1.14; p=0.15; t=1.62; p=0.3; t=0.4; p=0.96). In 81.4% the delivery occurred vaginally, in 11.9% the fifth minute Apgar score was equal or below 7. In 23%, foetal weight was below the tenth percentile. Conclusion: In our study, we found differences in the gestational age of TPTL diagnosis according to mycoplasma presence. The labour was earlier in women with positive microbiological vaginal smear. In the cases of TPTL we also find a foetal weight below the tenth percentile more often than in the normal population, that could be a marker of placental insufficiency. These findings reflect the multifactorial aetiology of PTD. More studies need to be made to find markers that can predict specific pathway of disease in TPTL. Treatment and costs implications were not assessed, but must be taken in consideration.

IS 3D OMNIVIEW ULTRASOUND HELPFUL FOR DIAGNOSIS OF FETAL CLEFT PALATE?
Zaklina Jurisic¹, Aleksandar Jurisic², Sladjana Mihajlovic³, Dejan Dinica⁴
¹Ultrasonography, Ob/Gyn Polyclinic Jurisic, Beograd, Serbia
²Ultrasonography, University of Belgrade Medical School, University Ob/Gyn Hospital Narodni Front, Beograd, Serbia
³Ob/Gyn, University of Belgrade Medical School, Clinical Center Dr Dragisa Mihajlovic, Beograd, Serbia
⁴Ob/Gyn, Clinical Center Zemun, Beograd, Serbia

Objectives: To analyse the diagnostic value of 3D Omniview Ultrasound in analysis of fetal face and diagnosis of cleft palate in second trimester of pregnancy. Methods: In this study 350 patients with normal pregnancy were included. Patients were scanned on GE E10 ultrasound with R6MC transabdominal probe. The analysis of fetal face in Omniview technique was performed from the volume obtained from fetal profile position. After obtaining fetal face image in surface rendering, the analysis was continued in Omniview mode. First plane represented frontal face section with retoronal triangle. In the second plane fetal lips, maxilla and palate were analysed. In the third plane fetal mandible was reconstructed. In 3 patients referred with suspected fetal cleft palate, we performed the same procedure. Results: In 350 patients we did not detect any abnormality of fetal face and we followed them up until delivery. No abnormality of fetal face was confirmed on delivery.

In 3 patients who were referred with suspicious fetal cleft we performed detailed analysis of fetal face in 3D surface rendering mode and also in 3D Omniview mode. Utilizing Omniview procedure, we confirmed unilateral cleft of lip and palate in two patients and bilateral cleft lip and palate in one patient. The defects were visible in retoronal triangle plane. The cleft lines were visible in the second Omniview plane. We compared Omniview technique with other relevant 3D diagnostic procedures like Reverse view and Flipping image. The advantage of Omniview procedure is that in this mode the anomaly can be evaluated in minimum two directions in order to increase the diagnostic accuracy. No other anomalies of fetal organs were detected on detailed ultrasound scan in second trimester. We performed genetic analysis in all patients with clefts and excluded chromosomal abnormalities in all of them. Detected anomalies were confirmed on delivery.

Conclusion: In 3D Omniview mode it is possible to analyse the morphology of fetal face and facial bones. Fetal nose, lips, maxilla and hard palate, and mandible can be visualized in separate planes. Abnormalities of fetal face development and unilateral and bilateral cleft lines can be confirmed in Omniview 3D technique.

IS INDUCTION OF LABOUR AT TERM A SAFE AND EFFECTIVE STRATEGY TO REDUCE THE RISK OF STILLBIRTH IN SOUTH ASIAN ORIGIN MOTHERS?
William Stobie, Emma O'Callaghan, Trent Hambleton
Department of Women's and Children's Health, St George Hospital, Sydney, Australia

Problem statement: There is an increasing awareness that ethnicity plays an important role in dictating a woman’s risk of stillbirth, independent of socioeconomic-status. South Asian origin mothers (SAOMs) have been identified as a higher risk group for term and late-term stillbirth in an Australian setting. This study suggests a potential approach to mitigate this risk by assessing the safety of a policy of induction of labour (IOL) as routine care for all undelivered SAOMs at 40 weeks gestation.

Methods: Retrospective cohort study of 1,017 SAOMs with singleton pregnancies who delivered by normal vaginal delivery, instrumental delivery or emergency caesarean section at a tertiary maternity hospital in Sydney, Australia between 2016 to 2018. SAOMs who delivered in 2018 were offered IOL at 40 weeks gestation (IOLT-group) as routine (n=394) and were compared to SAOMs who received routine care (RC-group) prior to implementation of the policy (2016-2017, n=623). Main outcome measures were stillbirth, gestational age, mode of birth, and 5 minute apgar scores, and special care nursery admission. Results: Of the 1,017 births, there were 2 stillbirths (0.3%) in the RC-group compared to 0 in the IOLT-group (p = 0.53). The IOLT-group had significantly more IOLs with vaginal prostaglandin (39.8% vs. 23.9%, p = 0.001). The IOLT-group delivered at earlier gestational ages than the RC-group with more full-term (39+0-40+6 weeks) births (66.5% vs. 53.6%, RR 1.24, 95% CI = 1.12-1.37, p = 0.001) and less late-term (41+0 to 41+6 weeks) births (0.3% vs. 12.0%, RR 0.021, 95% CI = 0.003-0.15, p = 0.001). The only neonatal or maternal outcomes which differed between the two groups was a higher 1 minute Apgar score in the IOLT-group (8.6 vs. 8.4, p = 0.004).

Conclusion: IOL at term is a safe strategy with similar modes of delivery and fewer late term deliveries. Although there were insufficient numbers to significantly assess the effects on the stillbirth rate, there were no stillbirths in the intervention group and two stillbirths in the routine care group. Nil disclosures of interest
Problem statement: Peripartum cardiomyopathy (PPCM) is a severe form of idiopathic cardiomyopathy, affecting previously healthy young women during late pregnancy or postpartum. The actual incidence of PPCM is highly reported across a variety of countries. The nonspecific symptoms and late diagnosis of PPCM might lead to its complications, which are similar to the complications of heart failure. West Java is the most populated province in Indonesia with high rates of pregnancy; Hasan Sadikin Hospital as the main referral hospital in West Java, this study is to analyze the obstetric outcome of PPCM with and without hypertensive disorders and factors associated with its prognosis. Methods: This study is a cross-sectional study with a retrospective quantitative approach to understand characteristics and delivery outcome of PPCM patients. Data were taken from PPCM registry in Cardiology Department, Hasan Sadikin Hospital. Subjects of this study are pregnant women around 22 - 40 weeks of pregnancy diagnosed with PPCM between 2014 and 2019. Patients had to fulfill diagnosis criteria of PPCM, had already undergone echocardiography done by Cardiology Department and treated by pregnancy termination either abdominally or vaginally. Results: A total of 103 patients were identified as having PPCM. Most cases were associated with comorbidities of 68 women diagnosed with pre-eclampsia. Weight, high BMI, hypertension in a previous pregnancy was the most influential risk factor for PPCM. With appropriate coordinated efforts to confirm that fever is associated with significant morbidity. We think antibiotics are often overprescribed. More studies are needed to be able to target patients at risk and study new antibiotics prescription when a patient consults for fever during pregnancy. We confirm that fever is associated with significant morbidity. The nonspecific symptoms and late diagnosis of PPCM might lead to its complications, which are similar to the complications of heart failure. Problem statement: Fever is a very common reason for emergency consultation during pregnancy, and presents significant maternal, obstetrical and fetal issue. The aim of this study was to determine etiology, maternal or fetal complications and antibiotics prescription when a patient consults for fever during pregnancy. Methods: This is a retrospective single center study that included all patients who presented fever to the gynecological emergency department from August 2016 to July 2017. Clinical features, laboratory findings, prescription and issue were collected from electronic medical records. Results: A total of 100 patients who had fever were included. The etiology was: common viral infections (36%), influenza (21%), unknown (14%), acute pyelonephritis (11%), acute viral gastroenteritis (8%), chorioamnionitis (5%), other (7%). Fever was objected during consultation on 45 patients (45%). Among these patients, 46.7% were hospitalized with a median of hospitalization stay 3 days (IQR 2.8) and 22.2% developed fetal or maternal complications. Probablistic antibiotics were delivered for 75.6% patients while only 31.1% got single bacterial infection. When etiology was uncertain, among 32 patients who had objectified fever, 59.3% have been treated with antibiotics against listeria. None was listeria, and they were all probably common viral infections. Conclusions: This is the first study to estimate prevalence of the main etiologies in cases of fever during pregnancy. We confirm that fever is associated with significant morbidity. More studies are needed to be able to target patients at risk and study new management of fever. The authors declare no conflict of interest.
before the training, after of the HFS applications and after one month of the HFS application to the students. **Results: **In the study, it was determined that simulation method for the management of preeclampsia were increased students' total point average of level of knowledge (p0.001), retention of knowledge (p0.001), critical thinking disposition (p0.05) and clinical decision making (p0.05). In the focus group interviews five theme were identified including the development of learning, the transfer of theoretical knowledge to clinical practice, gaining decision-making skill and self-confidence, preparation for professional role and recommendations. **Conclusion:** As a result of the research, it is suggested that to use the scenario-based HFS in training on management of preeclampsia and integrated into the undergraduate nursing education curriculum.

**OP1-502**

**MEDICAL OR SURGICAL METHOD IN TREATMENT OF SYMPTOMATIC UTERINE MYOMA**

Athar Rasekh Jahromi,1 Mahbod Ebrahimi,2 Mohammadali Nasseri,2 Mohammadali Nasseri Jahromi3

1Obstetrics and Gynecology, Jahrom University of medical sciences, Jahrom, Iran
2Obstetrics and Gynecology, Tehran University of medical sciences, Tehran, Iran
3Economy, Shiraz Azad University, Jahrom, Iran

**Problem statement:** uterine leiomyomata is a common and benign connective tissue tumor. The prevalence is 30% of all women. leiomyomas is the most important reason of abnormal uterine bleeding that is still a common indication for myomectomy or hysterectomy in the world. The aim of this study is Comparison of two groups of drugs in treatment of symptomatic uterine myoma and the need to use surgical procedure. **Method:** this is a comparative clinical trial on 48 women with symptomatic uterine leiomyomata accompanied vaginal bleeding referred to Dr. rasekh clinic, Iran. Diagnosis was performed based on clinical symptoms, pelvic examination and ultrasonography. patients randomly divided in two groups: 24 patients in control group treated with Dydrogesterone and 24 patients in case group gonadotropin- releasing hormone agonist(Triptorelin acetate) for 6 months. Data collection was performed via questionnaires and statistical analysis by SPSS 21. **Result:** There is no significant difference between mean size of the myoma before intervention in case and control groups. Mean myoma size is not significant difference in Dydrogesterone usage (control group) before and at the end of six months intervention. But the rate of increase myoma size is significant difference in Triptorelin acetate usage (case group) before the intervention 56.45 ± 5.84 and after intervention 50.06 ± 5.30 (p value≤.05) that represents a significant reduction of myoma size. Clinical bleeding symptoms improved in both groups which indicate response to treatment. **Conclusion:** Due to the complications of surgical procedures and the results of this research shows that there is a significant decrease in myoma size and response to treatment in Triptorelin acetate usage. Therefore, surgical procedure is not necessary. Medical therapy is recommended as the first choice of myoma treatment. **key words:** leiomyomas, Triptorelin acetate, Dydrogesterone, surgery.

**OP1-503**

**LASER THERAPY OF CONDYLOMA ACUMINATA**

Urška Bžjak-Ogrinc,1 Sabina Sencar,2 Ženko Vizintin3

1Juna Clinic, Ljubljana, Slovenia
2Fotona, Ljubljana, Slovenia

**Problem statement:** The purpose of this lecture is to report about efficacy and safety of the use of ablative Er:YAG laser for removal of external genital warts (EGW), also called condylomata acuminata (CA). **Methods:** This is a retrospective cohort study performed at Juna Clinic in Ljubljana, Slovenia. All patients older than 18 years that were clinically diagnosed with EGW and were treated with ablative Er:YAG laser between January 2012 and December 2017 were included in the study. Patients received between one and five treatments depending on the lesion extension. The interval between the treatments was two weeks and the lesion clearance was assessed at every visit. Topical anesthesia (EMLA) was applied to reduce the treatment discomfort. Follow-ups were performed at every visit and at 6 and 12 months. **Results:** A total of 140 female patients (mean age 40±13 years, range: 19–80) with EGW were found eligible to be included in this study. EGW have been present from 1 to 7 months, with a mean presence of 2.1±2.0 months. The majority of the warts were on the labia major some also on the mons pubis. The size of the lesions was 2-8 mm. 64% of the patients received only one and 21% two treatments. 81% of the patients showed complete clearance without recurrence. Among these, 90 patients were treated once, 17 twice, 23 of them 3-5 times. These 23 patients received multiple treatments due to extensive wart area, which could not be cleared with a single treatment. There were no adverse effects reported. **Conclusions:** Er:YAG laser removal of EGW is simple, quick and safe procedure, particularly suitable for large volume EGW or those that are located in anatomical sites difficult to access for other techniques. Recurrence rate in our study was 19%, a percentage comparable or even lower than observed with other treatment options.

**OP1-504**

**THE MANAGEMENT OF GYNECOLOGICAL HEMORRHAGES - HYPOGASTRIC ARTERY LIGATION TECHNIQUE**

Petru Chitulea, Gherai Rares

Obstetrics and Gynecology, Faculty of Medicine, Oradea, Romania

The historical background of ligation of the internal iliac artery for the control of haemorrhage is not clear. [1] Howard Kelly first pioneered ligation of the internal iliac (hypogastric) artery in the treatment of inoperative bleeding from cervical cancer prior to this technique being applicable to postpartum haemorrhage. [2] Later were designed and studied other types of vascular ligatures, used in obstetrical and gynecological hemorrhages, some of having as a departure Ligation of the Internal Iliac Artery, as well as the procedure Thoma Ionescu Triple Ligation (hypogastric artery, ovarian, uterosacral). In the early twentieth century, as a palliative treatment of massive cervical bleeding in cervical cancer, stage III, performed then by Tzitzikov (1979) for the control of severe postpartum hemorrhage. [8]

**OP1-505**

**FERTILITY AND CONCEPTION IN A PATIENT WITH VIRILIZING ADRENOCORTICAL CARCINOMA: A CASE REPORT**

Michael Dayrit, Irimna Lacsina-Gomez

Department of Obstetrics & Gynecology, Jose B. Lingad Memorial Regional Hospital, City of San Fernando, Philippines

**Problem:** Adrenocortical carcinoma is a rare virilizing tumor with an estimated incidence of 0.5–0.2 new cases per million annually. Its clinical evolution may include an initial phase of feminization, followed by masculinization, resulting from increased androgen levels. **Method:** A case of a virilizing adrenocortical carcinoma is reported in a 33-year-old nulligravid presenting with secondary amenorrhea for 9 months, along with 16-year history of infertility and manifestations of hirsutism and virilization. Dihydroepiandrosterone Sulfate (DHEA-S) and total testosterone were elevated and imaging revealed an adrenal androgen-secreting neoplasm. Laparoscopic adrenalectomy, right was done. **Result:** Postoperatively, there was resolution of hirsutism and virilizing features, menstrual cycles recurred, with decline of serum androgen levels to normal limits. The patient subsequently conceived and delivered to a live term cephalic baby boy via low transverse cesarean section for cephalopelvic disproportion. No fetomaternal complications were noted. **Conclusion:** Prognosis is excellent with surgical resection. However, its aggressive behavior and high recurrence rate warrants the need for adjuvant therapy and questions the feasibility of future pregnancy.
OP1-506
MYOMATOUS ERYTHROCYTOSIS SYNDROME: A CASE SERIES
Giza De Guzman, Eileen Manalo
Department of Obstetrics and Gynecology, University of the Philippines - Philippine General Hospital, Manila, Philippines

Problem/Objective: To report three cases of myomatous erythrocytosis syndrome. Methods: Design - Case series. Setting: Tertiary training hospital. Patients: Here, we present three cases of large leiomyomas with an incidental finding of isolated erythrocytosis on preoperative workup. Interventions: Two patients underwent total abdominal hysterectomy while one patient underwent a myomectomy. Main Outcome Measures: Histologic diagnosis and resolution of erythrocytosis. Results: Histologic examination confirmed the diagnosis of leiomyoma while serial complete blood count monitoring showed normalization of postoperative hemoglobin levels. Together with the finding of isolated erythrocytosis, the cases fulfilled the criteria of myomatous erythrocytosis syndrome. Conclusion: All three criteria were observed in the three cases described. To date, less than 40 cases have been reported worldwide. These are the first reported cases of myomatous erythrocytosis syndrome in the Philippines.

OP1-507
LAPAROSCOPIC CORNAL EXCISION (WEDGE RESECTION) OR LAPAROSCOPIC CORNUSTOMY AND REMOVAL OF ECTOPIC PREGNANCY TO PRESERVE UTERUS FOR FUTURE PREGNANCIES? THAT IS THE QUESTION
Mahmoud Rahimi
Gynaecology, Chatswood Medical Center, Chatswood Sydney, Australia

Laparoscopic surgery is currently the preferred treatment for ectopic pregnancy. Interstitial tubal pregnancy is rare and dangerous form of ectopic pregnancy which is usually treated by cornual resection or hysterec tomy. In 1995 the author developed a new laparoscopic approach for the treatment of interstitial ectopic pregnancy to preserve uterus in a young patient who desired to have more children in the future. By performing cornuostomy, removing the part of conception and applying endolocop the bleeding was controlled quickly without suturing. Since then and after publication of this approach the colleagues call it S procedure (Simple, Safe, and Swift). The pros and cons of different approaches of minimally invasive surgeries to preserve uterus will be discussed as well as controversies.

OP1-508
PRACAU PROTOCOL: NEW PROTOCOL FOR CHRONIC PELVIC PAIN SYNDROME
Ernesto Delgado Cidranes, Prof. Ernesto Delgado Cidranes MD, PhD, Prof. Zuramis Estrada Blanco MD
Pain Management / Urogynecology, Hospital La Milagrosa, Hospital Universitario Sureste, Madrid, Spain

Introduction: The prevalence of pelvic floor pain syndrome in women is about 4%. The use of a powerful tool like advanced three-dimensional ultrasound in the assessment, study, treatment and monitoring of painful pelvic pathology starts getting encouraging results. Knowing the behavior of the injured area in real time without surgery and without radiation exposure is very remarkable. Objective: To discuss the case of a 28 year old woman with intractable pudendal neuralgia. Description: 28 year old patient attends consultation related to untreatable diagnosed pelvic floor pain syndrome for 5 years. Poor response to specialized medical treatment, no pain relief with physiotherapy and rehabilitation. Go with intense pain in the right vulvo-vaginal area of 12 weeks duration and pain during sexual intercourse (dyspareunia). Evaluated by our interdisciplinary team approach and decided to make pudendal release by three-dimensional ultrasound vulvo-vaginal area. The new PRACAU Protocol (Pudendal Relief Alcock Canal Advanced Ultrasound) of our authorship was applied. It consists of a hydrodissection release using platelet-rich plasma (PRP) 10 ml and local anesthetic (levobupivacaine 0.125%). This treatment method is applied around the nerve to provide symp toms relief. Discussion: Consultations review showed an improvement of symptoms and signs immediately, comparative assessment score showed a positive development objective measure and valued through the strain rate. The interdisciplinary evaluation and use of advanced ultrasonic image techniques provide security and guaranteed ultrasound patients.

OP1-509
SERUM PROPROTEIN CONVERTASE SUBLITISIN-KEXIN TYPE 9 (PCSK-9) LEVELS IN PATIENTS WITH NORMAL AND OVER-WEIGHT/ OBESITY POLYCYSTIC OVER SYNDROME
Sinem Eldem, Yasemin Tasci
Reproductive Endocrinology Unit, Zekai Tahir Burak Education and Research Hospital, Ankara, Turkey

Objective: The aim of this study is to compare serum Proprotein Convertase Subtilisin-Kexin Tip 9 (PCSK9) levels between the polycystic ovary syndrome (PCOS) patients with normal weight and overweight/obese, also to investigate relationship between the PCSK9 levels. Framingham cardiovascular risk score and metabolic parameters. Material and methods: Between April 2017 and October 2017, 80 patients with PCOS between the ages 16-36 years who were admitted to the Reproductive Endocrinology Unit of Zekai Tahir Burak Education and Research Hospital were included in the study. Of a total of 80 participants, 40 patients with BMI 25 kg/m² were normal weight group and 40 patients with BMI ≥ 25 kg/m² were overweight/obese group. PCOS was defined in accordance to Rotterdam criteria. Anthropometric features of all cases were recorded. On days 2 and 3 of the menstruation, after the 12 hours hunger; fasting insulin, blood glucose levels, 75 gr oral glucose tolerance test (OGTT) and lipid parameters were measured. HOMA-IR was calculated. Serum PCSK9 level was measured by ELISA technique. Patients who are older than 30 years the 10 years Framingham cardiovascular risk score and for all patients 30 years Framingham cardiovascular risk score was calculated.

Results: Serum PCSK9 levels were significantly higher in PCOS patients whose BMI was 25 kg/m² (27.57 ng/ml) compare to BMI 25 kg/m² group (9.45 ng/ml) (p=0.009). There is no relationship between PCSK9 levels and 10 years Framingham score, fasting insulin, HOMA-IR, VLDL-K, HDL-K, triglyceride and total testosteron levels . There is positive correlation between PCSK9 and LDL-K, total cholesterol, 30 years Framingham risk score and anti-müllerian hormone (AMH). On the other hand, there is negative correlation between PCSK9 and fasting glucose and 75 gr OGGT.

Conclusion: With this prospective study according to correlation between serum PCSK9 levels and 30 years Framingham risk score, LDL and total cholesterol, PCSK9 can be used for cardiovascular risk marker in PCOS patients . According to the serum PCSK9 level detected in the reproductive period of PCOS patients PCSK9 antibodies can be used for the treatment of metabolic and reproductive diseases in PCOS.

OP1-510
LASER TREATMENT FOR GENITOURINARY SYNDROME OF MENOPAUSE. IS THERE ANY EVIDENCE?
Ivan Fistonic1, Nikola Fistionic2
1Ob/Gyn, Institute for Women’s Health, Zagreb, Croatia 2Ob/Gyn, University Hospital Merkur, Zagreb, Croatia

Noninvasive treatment is recommended as first line for urinary incontinence (UI) in women. However, surgical procedures are more likely to be implemented to cure UI but are associated with more adverse events. Less invasive operative mesh techniques are relatively effective, but not immune to complications such as bleeding, bladder perforation, urethral injury, infection, and the retention requiring mesh resection. In patients for whom the risks of anesthesia and surgery are too high, a minimally invasive approach is recommended and further research is needed in terms of more compliant, less invasive and low-cost methods for the treatment of stress UI and pelvic floor dysfunction. Contemporary scientific and technological breakthroughs have led to better clinical outcomes with minimally invasive procedures with shorter recovery times and lower implicated
costs. In this sense, recent evidence supports laser treatment as an effective and compliant intervention for stress UI. Although laser is an attractive novel, non-hormonal new technology for the treatment of the GSM, additional studies are needed to explore the long-term safety and efficacy of various laser therapies for genitourinary symptoms. PubMed database up to July 2018 derive only one patient-blinded randomized controlled laser sham trial for stress urinary incontinence using Er:YAG laser. Most of published evidence relies on short term follow-up (1-6 months). Three studies extended for 12-24 months (Er:YAG) and one to 36 months (CO2). Also, future studies need to be designed taking mentioned considerations into account, including the histological assessment performed immediately after treatment that will help compare morphology at baseline with changes in the vaginal architecture following laser procedure. Next studies should focus on the individual patient level in order to predict personal risk or benefit based on the decision of undergoing a given proposed procedure. Simultaneously, predictive systems may impact public health policies in terms of prevention. In spite of promising initial results, there is still need for long term consistent evidence analyzing laser efficacy and safety in the treatment of female UI.

OP-1-511
NON-ABLATIVE LASER TREATMENT OF LICHEN SCLEROSUS ET ALITIS: A COMPARISON WITH TOPICAL CORTICOSTEROID THERAPY
Sabina Sencar1, Urska Bizjak-Ogrinc2, Ždenko Vizinš1
1Juna Clinic, Ljubljana, Slovenia
2Fotona, Ljubljana, Slovenia

Problem statement: The purpose of this lecture is to report about randomized controlled trial in which new laser treatment was compared with corticosteroid therapy for lichen sclerosus (LS). Methods: 40 female patients with vulvar LS were randomized 1:1 into study (laser) group and control (topical corticosteroids) group. The laser group received three Nd:YAG laser treatments. Blinded evaluators evaluated biopsies and graded improvement on clinical photographs at baseline and 3 months. Patients graded the intensity of symptoms on 0-10 VAS scale at baseline and 1, 3 and 6 months follow-up. Patients also rated the tolerability of laser treatments and side effects were monitored. Results: All 20 patients from laser and 19 patients from control group completed the treatments and were followed up for 1, 3 and 6 months (laser group) and for 1 and 3 months (control). Laser treatment discomfort was on average 1.5/10 VAS. At 1 and 3 month follow up, patients in the laser group had significantly better improvement of LS symptoms (burning, itching, pain, dyspareunia), better patient satisfaction and better reduction of sclerosis than patients in the topical corticosteroid group. At 6 months follow up the improvement of symptoms in the laser group was still significant. The correct order of photographs (before/after treatment) was assigned significantly more often in the laser-treated patients compared to control group. The adverse effects were all mild and transient. Conclusions: Laser therapy for LS demonstrated minimal patient discomfort during the treatment, with no adverse effects, and better efficacy than the control group with significant improvement lasting up to 6 months. It is a promising option for patients not responding to topical corticosteroid therapy or patients wishing to reduce long-term corticosteroid maintenance use.

OP-2-601
LABOR INDUCTION IN PATIENTS WITH A SINGLE PRIOR CAESAREAN SECTION
Paul Funel, Linda Lassel, Maële Le Lou
Department of Gynecology Obstetrics and Human Reproduction, Rennes University Hospital, Rennes, France

Problem statement: Risks of Labor induction in patients with a single prior caesarean section are uterine rupture and fail of vaginal delivery. The aims of our study were to determine the vaginal delivery rate in patients with a single prior caesarean section who underwent labor induction in Rennes university Hospital between 2016 and 2018. Methods: It was a monocentric, retrospective study. All the patients with a single prior caesarean section who had labor induction between January 2016 et décembre 2018 were included in the study. We assessed fetal morbidity (pH7, Lactate 12, Apgar score after 10 minutes 5 or nécrotale réanimité admission) and maternal morbidity (uterine rupture, post partum hemorrhage (PPH), third degree or more perinéal trauma ). Results: A total of 125 patients with a single prior caesarean section underwent labor induction. Vaginal delivery rate was 91.2%. 87 patients (69.6%) had BISHOP score 6, vaginal delivery rate was 88.5%. 47 patients (37.6%) had a prior vaginal delivery, bail, after the single prior caesarean. Among them, vaginal delivery rate was 95.7%. There was four major neonatal complication (pH7) and seven major maternal complications (4 PPH1L and 3 third degree perinéal trauma). There was no uterine rupture. Conclusion: The vaginal delivery rate was 91.2% during labor induction in patients with a single prior caesarean section in our study. Fetal and maternal morbidity rate was low. It is therefore reasonable to propose labor induction, when needed, to patients with a single prior caesarean section.

OP-2-602
WHICH FACTORS MAY INFLUENCE WOMEN'S SATISFACTION AND PREFERENCES IN FUTURE MODE OF DELIVERY?
Ana Rita Sarabando1, Ana Catarina Borges1, Natacha Sousa2, Catarina Vieira1, Leonor Bivar1, Bárbara Ribeiro1, Joana Ignela1, Alexandra Miranda1,2,3, Paúlina Barbosa4, Margarida Cerqueira4, Isabel Reis1, Cristina Nogueira-Silva1,2,3
1Gynecology/obstetrics, Braga’s Hospital, Braga, Portugal
2School of Medicine, Minho University, Braga, Portugal
3Life and Health and Science Research Institute, Minho University, Braga, Portugal

Problem statement: Childbirth may have immediate and long-term positive or negative effects on women’s life. It can affect motherhood, health outcomes and future reproduction plans and deliveries. The aim of this study was to evaluate postpartum satisfaction and preferences on future delivery after a vaginal delivery (VD). Methods: Sub-analysis from an observational prospective study (MOODS: Maternal-neonatal Outcomes in Operative Vaginal Delivery Study) enrolled at Braga’s Hospital (tertiary center) from February to August 2018 (included singleton term pregnancies with operative vaginal deliveries and a random spontaneous vaginal delivery (SVD) sample in a 2:1 ratio). Demographics, obstetric, childbirth and puerperium history were analyzed. Women were asked about level of satisfaction and preference toward VD versus cesarean in 3 moments after childbirth: 24-hours, 3 and 12-months. Results: 216 women were recruited (122 women (57%) were solicited to answer after 24 hours, 3-months and 12-months, respectively. Concerning childbearing experience, 200 (89%) were very satisfied/satisfied after 24 hours, 121 (79%) after 3 months and 79 (76%) after 12 months. There were no differences between groups concerning age, marital or working status as well as obstetric history, with the exception of SVD and less postpartum pain being determinant factors for satisfaction in all survey timings (p<0.05). Multiparity (p=0.04) and previous VD (p=0.04) contributed to higher 24-hour satisfaction levels; absence of first grade laceration (p=0.02) and less puerperal complications (p=0.01) contributed to 3-months satisfaction levels; and less duration of second stage of labor to both (p<0.04), but none of them were present with statistical significance after 12 months. Regarding future delivery preferences, 182 (81%) at 24-hours, 122 (83%) after 3-months and 87 (84%) after 12-months would choose VD. Younger women were associated with VD preference across the 3 surveys (p<0.05) as well as less postpartum pain (p<0.05). At 24-hours after childbirth, less duration of second stage of labor (p=0.02), SVD (p=0.02) and absence or first grade laceration (p=0.04) were associated with a future vaginal delivery (VD). Conclusion: Less postpartum pain was significantly associated with postpartum satisfaction and VD preference from 24-hours till 12 months after birth. SVD was associated with higher satisfaction, as younger age was associated with desire of future VD. All other variables were not consistently associated with these outcomes over time.
**OP2-603**

THE EFFECT OF CERVICAL CERCLAGE ON PREGNANCY OUTCOME IN WOMEN FOLLOWING ELECTROSURGICAL CONIZATION

Jihyun Park, Jeong Ha Wie

1Department of Obstetrics and Gynecology, Seoul St. Mary's Hospital, College of Medicine, the Catholic University of Korea, Seoul, South Korea

2Department of Obstetrics and Gynecology, Eunpyeong St. Mary's Hospital, College of Medicine, the Catholic University of Korea, Seoul, South Korea

**Problem statement:** To determine the effect of cervical cerclage on perinatal outcomes in patients following electrosurgical conization.

**Methods:** This study was a retrospective cohort study. We analyzed the outcomes of 48 singleton pregnancies after electrosurgical conization of the cervix. The patients were divided into two groups according to early midtrimester cervical length and history of preterm birth. Pregnancy outcomes including rate of preterm birth were compared based on maternal risk for preterm birth.

**Results:** During the study period there were 48 deliveries of patients following a cervical conization. Cervical cerclage was placed in 20 deliveries and the rest (n = 28) served as the expectant group. The preterm delivery rate also was not significantly different between the expectant (10.7%) and cerclage group (30.3%) (p = 0.091). In high risk group, the preterm delivery rate also was not significantly different between the expectant (0%) and cerclage group (38.5%) (p = 0.044).

**Conclusion:** The cervical cerclage did not prevent preterm delivery in women following electrosurgical conization before pregnancy. High risk women for preterm birth, cerclage may be a risk factor for preterm birth.

**OP2-605**

PREDICTIVE FACTORS FOR SUCCESSFUL VAGINAL DELIVERY AFTER A TRIAL OF EXTERNAL CEPHALIC VERSION

Asaf Bilgory, Olena Minich, Maria Shvaikovsky, Genady Gurevich, Joseph B. Leasing, Ioana Olteanu

Department of Obstetrics and Gynecology, Mayanei Hayeshua Medical Center, Bnei Brak, Israel, affiliated with Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, Bnei Brak, Israel

**Problem statement:** Women after a successful external cephalic version (ECV) have a higher risk to deliver by a cesarean section (CS) compared with women who have a spontaneous vertex presentation. Our aim was to investigate what factors predict a vaginal delivery of a vertex presenting fetus after a trial of ECV.

**Materials and methods:** A retrospective cohort study of all women who underwent ECV and delivery in our center between 11/2011-12/2018. Women with known uterine or fetal malformations and women who delivered breech vaginally were excluded. Women who delivered vaginally were compared to women who delivered by a CS. Logistic regression was used for the multivariate analysis of the variables that were significantly associated with the type of delivery. Adverse neonatal and maternal outcomes were also assessed.

**Results:** Nine hundred forty-six women underwent both ECV and delivery in our center, 717 had a successful ECV (75.8%) and 663 (70.1%) delivered vaginally. Women who delivered vaginally were older, with higher parity, higher likelihood to have an unstable lie, transverse lie, and amniotic fluid index (AFI) 200 mm, lower likelihood to have AFI 80 mm, and higher estimated fetal weight in ultrasound. After adjustment in the multivariate analysis, parous women versus nulliparous women had an OR of 5.42 (95% CI [3.90-7.52] P<0.001), women with AFI 80 mm compared to AFI 200 had an OR of 0.21 (95% CI [0.12-0.37] P<0.001), and women with AFI 200 mm compared to AFI 200 had an OR of 1.74 (95% CI [1.03-2.92] P=0.037) to achieve vaginal delivery. Among women with successful ECV, induction of labor was not associated with higher likelihood to deliver vaginally regardless for the indication. The groups were not significantly different in week of ECV trial, fetal gender, placental location, and past CS.

**Conclusion:** Being parous and having AFI 200 mm are independent predictive factors for achieving vaginal delivery. As complications are scarce and success rates are high we advise all women without contraindication for a vaginal delivery to undergo a trial of ECV.

**OP2-604**

EFFECTS ON PREVENTING MOTHER-TO-CHILD TRANSMISSION OF SYPHILIS AND SYPHILIS ASSOCIATED ADVERSE PREGNANT OUTCOMES: A LONGITUDINAL STUDY FROM 2001 TO 2015 IN SHANGHAI, CHINA

Li Du, Liping Zhu, Rong Zhang, Houqiu Xu, Mao Hongfang

1Clinic Management, Shanghai Center for Women and Children’s Health, Shanghai, China

2Shanghai Jiading District Maternity and Child Health Care Hospital, Shanghai, China

**Problem statement:** This study aimed to delineate the longitudinal trend of maternal syphilis and burden of associated APOs in Shanghai from 2001 to 2015; and to evaluate the effects of preventing mother-to-child transmission (PMTCT) of syphilis in Shanghai with regard to service coverage and APOs averted.

**Methods:** PMTCT program of syphilis has been implemented since 2001. Municipal and national PMTCT surveillance data were used in analysis. By using WHO estimation model, the burden of associated APOs and APOs averted were estimated. The differences in access to antenatal care and PMTCT services between resident and non-resident pregnant women were analyzed.

**Results:** The sero-prevalence of maternal syphilis in Shanghai ranged from 0.20% to 0.38% during 2001-2015. The treatment rate varied from 69.8% to 96.8% and remained 83.66% in 2015. Under the PMTCT programs, 2163 APOs had been averted during the 15-year period, including 852 (39.4%) early fetal loss/stillbirth, 356 (16.4%) neonatal death, 190 (8.8%) prematurity or low birth weight, and 765 (35.4%) clinical evidence of congenital syphilis. Compared with the residents, the non-resident pregnant women had a higher prevalence of syphilis (1.2%, vs. 2.5%) and contributed to 81.7% of the syphilis associated APOs in 2015.

**Conclusion:** Screening of maternal syphilis has reached a full coverage both in residents and non-residents. Large numbers of APOs have been averted attributing to the PMTCT programs. More attentions should be paid to those vulnerable non-resident pregnant women and tailored interventions including health education, PMTCT promotion and point of care should be given to maximize the effects of PMTCT effects in Shanghai.

**OP2-606**

PREVIOUS HISTORY OF GESTATIONAL ALLOIMUNE LIVER DISEASE: HOW TO PREVENT

Maria Pulido Valente, Susana Santo, Cláudia Araújo, Teresa Loureiro, Rui Marques De Carvalho, Maria Afonso

Departamento De Obstetrícia, Ginecologia E Medicina Da Reprodução, Hospital Santa Maria, Centro Hospital Universitário Lisboa Norte, Medical Doctor, Lisboa, Portugal

**Introduction:** Gestational alloimmune liver disease (GALD) is a rare disease, which results from transplacental transfer of maternal IgG antibodies directed against a fetal hepatocyte antigen. Fetal liver injury causes disturbed fetal iron homeostasis, resulting in fetal iron overload. The risk of recurrence is very high (90%) and the antenatal diagnosis is not possible. Maternal treatment with intravenous immunoglobulin...
(IVIG) prevents the recurrence of GALD in subsequent pregnancies. **Case report:** 37-year-old Caucasian woman, healthy, gravida 5 para 1, with previous history of pregnancy termination at 23 weeks due to fetal hydrops and early fetal growth restriction. Autopsy diagnosis revealed GALD. The index pregnancy was monitored at Fetal Medicine Unit of Hospital de Santa María. Maternal IVIG infusion (Privigen®) 60mg was administered at 14,16 and 18 weeks and then given weekly until 36 weeks of pregnancy. There was no complication during the treatment which was done at inpatient-care and divided in 2 doses of 30mg/day in consecutive days. The anomaly ultrasound at 18 and 22 weeks were normal. At 25 weeks, the magnetic resonance imaging showed normal fetal liver and no signal of iron overload. Serial fetal growth assessment was performed showing appropriate fetal growth and normal biophysical profile and fetal doppler. At 37 weeks of gestation, an elective cesarean was performed and borne a male neonate weighing 3240g with Apgar scores of 5 and 9 at 1st and 5th minutes, respectively. Umbilical cord pH and lactate was normal. The neonate was admitted to NICU due to early respiratory distress syndrome and was discharged at the 8th day of life. Serial blood tests showed normal liver enzymes for 4 months of age. At the abdominal ultrasound did not reveal hepatic lesions. **Conclusion:** GALD is considered a leading cause of neonatal liver failure and is largely preventable with antepartum administration of maternal intravenous immunoglobulin.

OP2-607

ALL OPTIONS BY CHOLECALCIFEROL TREATMENT OF THREATENING MISCARRIAGE

Margarita Bakliecheva1, Olesia Bespalova1, Irina Kovaleva2, Maria Butenko3

1Pathology of Pregnancy, D.O.Ott Research Institute of Obstetrics, Gynecology and Reproductology, Saint-Petersburg, Russia
2Pathology of Pregnancy, Clinic “Ava-Peter”, Saint-Petersburg, Russia
3Obstetrics and Gynecology, Pavlov First Saint Petersburg State Medical University, Saint-Petersburg, Russia

**Problem statement:** Approximately 2 billion people are deficient in microelements, according to WHO resolution. Recent works emphasize the importance of non-classical roles of vitaminD in pregnancy, suggest important roles for the VDR(vitaminD-receptor) and VDR signaling pathways in the placenta. Placental trophoblasts express the VDR encoded by the CYP27B1 and CYP24A1 genes, produce and respond to 1,25(OH)2D. This vitamin induces decidualization, limits production of proinflammatory cytokines what can help in normalizing process of implantation in early pregnancy. **Methods:** The study included 120 pregnant women from 6-14 weeks of gestation with spontaneous presentation until delivery. The state of vitamin D was based on the concentration of 25(OH)D, determined by enzyme immunoassay in the mother’s serum. Serum concentrations of 25(OH)D: severe deficient 10 ng/ml, moderate deficient (10-30ng/ml), and normal status (30ng/ml). **Results.** In 1 trimester of gestation inside of 1 group were the biggest number of women with retrochorial haematoma (68.4%) and the lowest percentage of pulling pain(52,6%) among women with severe deficient of vitamin D and this is was conversely to group with normal state of vitamin D (7,1% and 92,8%). There were high negative correlation in group with threatening miscarriage between the norm of vitamin and 4 months of age of the vitamin D and BMI. Also there were negative correlation between the level of vitamin D and the size of retrochorial haematoma by ultrasound. In complex therapy, we used cholecalciferol 2000-4000 IU per day depends on baseline level of 25(OH)D in serum and there was a positive dynamics of the increasing the level of 25(OH)D in blood (by an average of 30-40%) after 6 weeks of treatment. **Conclusion:** Correction of vitamin D deficiency in pregnant women with a threatened miscarriage has been shown to be effective in treating and can be a perspective method in complex therapy of pregnancy loss.

OP2-608

ACCURACY OF THE ULTRASOUND FETAL WEIGHT ESTIMATION BEFORE VAGINAL BIRTH AFTER A CEASARIAN (VBAC) ACCORDING TO THE MATERNAL BODY MASS INDEX (BMI)

Ons Kaabia, Maria Jegham, Mouna Derwiche, Samir Hidar, Mohamed Bibi, Hédi Khairi

Gynecology and Obstetrics, Université de Sousse, Faculté de Médecine de Sousse, Hopital Farhat Hached, LR12ES03, 4000, Sousse, Tunisia; Tunisia

**Problem statement:** The ultrasound fetal weight estimation (UFWE) very often influences the obstetric management, especially after a caesarian section where fetal macrosomia is often used to refuse VBAC. But several parameters can influence this estimation among which maternal obesity. The aim of this study is to evaluate the accuracy of UFWE at the entrance to the delivery-room according to the BMI of the patients before VBAC. **Methods:** It is a prospective cohort study in VBAC candidates in labor at Farhat Hached Teaching Hospital Gynecology and Obstetrics Department in Sousse Tunisia from July 2017 to June 2018. We compared the accuracy of the UFWE versus the BW based on the maternal BMI. Our study population of 864 patients was divided into two groups based on BMI; Group 1: BMI Lower than 30 KG/m² (334 patients) and Group 2: BMI Greater than or equal to 30 KG/m² (330 patients)). For each group, the accuracy of the UFWE with respect to BW was calculated and then the precision values of each group were compared to see if the maternal BMI influences the ultrasound performance as well as its negative predictive value. **Results:** The median absolute difference between the UFWE and the BW was 287 [0-1250] grams. The median error percentage was 7% [0 to 38%], which was less than 10% in 72.5% of cases. There was a good correlation between the UFWE and the BW (R = 0.7). This correlation was stronger in less obese women (R = 0.78 versus R = 0.68, p = 0.03). A BMI<30kg / m2 significantly altered the performance of the ultrasound fetal weight estimation with an error percentage of 8.9% versus 7.4% in the BMI group. **Conclusion:** The UFWE in the delivery-room of remains limited with a margin of error greater than 10% in one-third of cases in the case of maternal obesity in patients candidate for VBAC.

OP2-609

PREDICTORS OF GESTATIONAL DIABETES RISK IN THE FIRST TRIMESTER OF PREGNANCY

Aleksandra Epishkina-Minina, Marina Khamoshina

Department of Obstetrics and Gynecology with a Course of Perinatology of Medical Institute, People's Friendship University of Russia (Rudn University), Moscow, Russia

**Problem statement:** Gestational diabetes mellitus (GDM) remains a serious medical and social problem of our time, which is far from the final solution. The high incidence of GDM-related obstetric complications and perinatal diseases that determine adverse pregnancy outcomes for the mother and newborn are largely associated with late diagnosis. **Materials and methods:** Prospective cohort study was provided in 2018 (January - September). All pregnant women satisfied inclusion criteria. In addition to the standard examination, serum iron and glycated...
hemoglobin (HbA1c) levels were determined in observed pregnant women. At the end of gestation, the study group included pregnant women with developed GDM (n=32), the control group included 61 women with physiological course of pregnancy and childbirth. Statistical processing of the data array was performed using the Statistics 8.0 software package. The binary logistic regression method was used to build the predictive model. Results: It was found that the predictors of the risk of GDM, suitable for its assessment in the first trimester of pregnancy, are the woman’s age, body mass index (BMI), levels of glucose, hCG, hPL in serum. A predictive model was developed: P = 1/(1 + e^-100), where z = -54.8 + 0.19*X1 + 0.89*X2 + 4.3*X3 + 5.92*X4 - 0.22*X5 - 0.17*X6, where P is the probability of developing GDM (%), X1 – age (years), X2 – the BMI (kg/m2), X3 – the level of glucose in serum (mmol/l), X4 – level of glycated hemoglobin (%), X5 – the concentration of hemoglobin in blood (g/l). Pregnant women with R ≥ 50% have a risk of developing GDM. Conclusion: The probability of verification of GDM in the modern population of healthy residents of Moscow optimal reproductive age is 9%. Risk shape women over 28.5 years who, at the time of registration BMI ≥ 24.4 kg/m2, and the determination in the first trimester HbA1c ≥ 4.85%, hemoglobin ≤ 109.5 g/l and serum iron ≤ 10.7 ng/ml. For the mathematical prediction in the first trimester of pregnancy can be used a mathematical model.
10 minutes after anesthesia was done (T3), were compared. **Result:** The level of cortisol, sFlt-1 and MDA in severe preeclamptic patient are lower in propofol maintenance than sevoflurane maintenance (p 0.05). **Conclusion:** Propofol maintenance has a greater capability to lower cortisol, sFlt-1 and MDA level in severe preeclamptic patient underwent SC than sevoflurane. **Key words:** preeclampsia, propofol, sevoflurane, cortisol, sFlt-1, MDA

**OP2-701**

**IN LETROZOLE THE ANSWER TO PCOS WOMEN WHO FAIL TO OVULATE WITH CLOMPHINE CITRATE AND WITH GONADOTROPINS**

Shalini Gainder1,2, Vanita Suri2

1 Obstetrics & Gynaecology, Additional Professor, Post Graduate Institute of Medical Education and Research, Chandigarh, India
2 Obstetrics & Gynaecology, Professor, Post Graduate Institute of Medical Education and Research, Chandigarh, India

**Problem statement:** To study the response of letrozole in women with PCOS related infertility who did not respond to 150 mg clomiphene citrate and gonadotropins. **Aim and objectives:** A prospective observational study was conducted in our institute on PCOS women not responding to clomiphene and gonadotropins of age group 20-35 years. The study population was given a trial of clomiphene citrate maximum 150 mg (3 cycles). In Clomiphene citrate resistant patients, gonadotropins (3-6 cycles) was given. Further if there was no ovulation, they were stimulated with 7.5 mg letrozole (2.5 mg TDS) and response was recorded as ovulation. **Results:** Of the total 42 women enrolled in the study, 18(42.86%) were clomiphene citrate resistant and 24(57.14%) did not ovulate with both clomiphene and gonadotropins. Some of these women were even given a trial of clomiphene + metformin and ovarian drilling but did not ovulate. Ovulation with letrozole was seen in 38(90.48%) of the women. However, 4 (9.52%) women did not ovulate with letrozole (7.5 mg) also. But conception with letrozole was seen in only 10 (26.31%) of the women who actually ovulated. **Conclusion:** Letrozole appears to be a suitable option in clomiphene and gonadotropin resistant PCOS women.

**OP1-702**

**THE ROLE OF FSH TO AMH RATIO IN PREDICTING THE NUMBER OF OOCYTE RETRIEVED OR CYCLE CANCELLATION WITH LOW PROGNOSIS PATIENTS UNDERGOING ICSI CYCLE**

İlay Gozukara1, Nafyeı Yılmaz1, M.Ufuk Ceran1, Ece Atalay2, İncı Kahyaoglu2, Cavidan Gülşen3, Yaprar Uşün2

1 Department of Obstetrics and Gynecology, Mustafa Kemal University, Antakya, Turkey
2 Obstetrics and Gynecology, Zekai Tahir Burak Women’s Health, Research and Education Hospital, Ankara, Turkey
3 Obstetrics and Gynecology, Baskent University, Konya, Turkey

**Problems:** The management of patients with poor ovarian response (POR) to exogenous gonadotropin stimulation is a challenging problem in ART cycles. Serum FSH positively and AMH negatively associated with POR. The aim of this study was to predict the number of oocyte retrieval and cycle cancellation with FSH/AMH ratio in low prognosis patients undergoing IVF-ICSI treatment. **Materials and Methods:** This retrospective study concern about fresh IVF-ICSI cycles was conducted in Zekai Tahir Burak Women’s Health Research and Education Hospital, between January 2015 and October 2018. All patients were included as ‘low prognosis patients’ in assisted reproductive technology according to the POSEIDON’s stratification. Women between 24 and 44 years were recruited and baseline demographics and fertility characteristics were collected. Basal serum AMH, E2, FSH levels and AFC were determined and FSH/AMH ratio was calculated. Number of retrieved total, MII, fertilised oocytes and embryos together with quality were also recorded. Correlation between FSH/AMH ratio and other parameters were analysed with Spearman rank R test. **Results:** In this study FSH/AMH ratio were strongly correlated with the number of oocytes retrieved (p 0.0001, r = -0.4 ) and cancelled cycle or absence of oocyte after oocyte pick-up (p 0.002, r = 0.3). This ratio performed well in predicting retrieved oocyte lesser than 5 with an AUC of 0.82 (95% confidence interval 0.71–0.92). A cut-off value of 11.36 predicted oocyte pick up less than 5 with a sensitivity of 80% and specificity of 57%. Moreover the optimal FSH/AMH cut-off value was 14.22 to predict cycle cancellation or absence of oocyte following OPU, providing sensitivity, 91%; specificity, 44% (AUC of 0.71; 95% confidence interval, 0.59-0.83). There were no any correlation between FSH/AMH ratio and clinical pregnancy (p 0.5). **Conclusion:** FSH/AMH ratio may be predictive for oocyte retrieval less than 5 and cycle cancellation in POR patients with simple ratio at the beginning of the cycle may help the clinician to notice accurate anticipation of gonadotropine stimulation treatment and correct counselling to the patient about cycle cancellation and expectation of retrieved oocyte.

**OP2-703**

**EVOLUTION OF THE SEXUAL BEHAVIOUR ET DYFUNCTIONS IN WOMEN IN INFERTILE COUPLES**

Ons Kaabia1, Khlaed Ben Ahmed2, Mouna Derwiche1, Samir Hida1, Mohamed Bibi3, Yousri El Kissi1, Hedi Khairi1

1 Gynecology and Obstetrics, Université de Sousse, Faculté de Médecine de Sousse, Hôpital Farhat Hached, LR12ES03, 4000, Sousse, Tunisia
2 Clinical Research Committee, Tunisian Society of Clinical Sexology, Tunisia

**Problem statement:** Infertility is currently a public health problem that is not life-threatening for the patients but which seriously affects their quality of life. The results of treatment options have steadily improved over the last decade, especially in terms of cumulative pregnancy and live birth rates. But what about the quality of life of patients? The main objective of this study is to evaluate the long-term (10 years) impact of infertility on female sex life. **Methods:** This is a prospective population-based analysis of 100 women from 100 voluntary infertile couples diagnosed and managed at the Reproductive Medicine Unit of the Obstetrics and Gynecology Department of CHU Farhat Hached Sousse. The study spanned a 10-year period from September 2009 to August 2018. The data were collected from 2 individual interviews spaced 10 years apart, during which the patient’s sexuality was assessed by the Arabian Sexual Function Index (ArFSFI) Arabic version of the FSFI. The data capture and analysis were performed with the SPSS 20 software. For the statistical study, we compared averages for 2 paired series by the student’s t-test after verifying the normality of the distribution. The level of significant threshold was 5% as the significance threshold. **Results:** The different scores of the 6 items of the ArFSFI score before treatment for infertility and after 10 years with no results show a non-significant difference in terms of desire disorders, arousal, dyspareunia, and satisfaction. On the other hand, there is a drop in lubrication and therefore objective excitation and an increase in female orgasm disorders with respectively p =0.049 and p= 0.019. **Conclusion:** The duration of infertility alters female sexuality essentially the objective excitation and the orgasm. **Conflicts of interest:** None

**OP2-704**

**A STUDY OF 2,013 DONOR-CONCEIVED PEOPLE**

Wendy Kramer

Research, Donor Sibling Registry, Nederland, USA

**Problem statement:** What are the experiences, desires, and needs of the donor-conceived community? **Methods:** In 2009 and again for three weeks in October of 2018 surveys with quantitative and qualitative questions were collected reporting on the experiences of being a donor-conceived person, including disclosure, terminology, anonymity, missing father/male figure, feelings about being donor-conceived, and curiosity about and contact with previously unknown genetic (donor) relatives. 1268 individuals responded to the survey designed for donor-conceived people raised in non-LGBTQ households (HET) (467 in 2009 and 801 in 2018). 745 individuals responded to the survey designed for donor-conceived people raised in LGBTQ households (LGBT) (287 in 2009 and 458 in 2018). 64% of LGBT and 74% of HET respondents were female. 14 LGBT and 69 HET respondents were conceived using an egg donor and
the balance were conceived with a sperm donor. **Results:** Disclosure: 69% of LGBT offspring and 32% of HET offspring indicate that they have "always known" about being donor conceived. In the HET families, over 50% of those under 18 have "always known." This number is considerably less for older cohorts. **Technique of the donor?** 67% of sperm donors were anonymous. **Conclusion:** "If your donor is anonymous, do you wish that your parent(s) would have used a willing-to-be-known or known donor?" 59% of LGBT offspring and 73% of HET offspring answered "Yes." **Conclusion:** The reproductive medicine industry can better serve the needs of the donor-offspring community by listening to their experiences, desire to know more about their origins, and desire to connect with their close relatives.

**OP2-705 CLINICAL AND COMMUNICATION CHALLENGES OF EUROPEAN AND LATIN AMERICAN EMBRYOLOGISTS, NURSES, AND LABORATORY SPECIALISTS INVOLVED IN FERTILITY CARE**

Sophie Pelouquin1, Laura Rienzi2, Christophe Blockeel3, Juan Antonio García Valasco4, Guy De Mesmaeker5, Patrice Lazure6, Fabiola Beligotti7, Suzanne Murray1

1Performance Improvement Research, AXDEV Group Inc., Brossard, Canada
2Clinica Valle Giulia, Genera Center for Reproductive Medicine, Rome, Italy
3Centre for Reproductive Medicine, University Hospital Brussels, Brussels, Belgium
4Department of Obstetrics and Gynecology, Rey Juan Carlos University, Madrid, Spain
5Global Medical Affairs, Reproductive Health, Ferring International Center SA, Saint-Priex, Switzerland

**Problem statement:** Multiple studies have focused on the challenges of patients undergoing assisted reproductive procedures. However, little is known about difficulties and challenges faced by healthcare providers practicing in fertility care. An international needs-assessment was conducted to identify the key challenges faced by these providers that could be addressed through continuing medical education and professional development activities. **Methods:** An ethics-approved study was conducted with fertility professionals (clinically practicing physicians, laboratory specialists and nurses) from 12 countries (n=535). A mixed-methods approach was used, consisting of semi-structured interviews (n=81) and an online survey (n=454). Presentation will focus on findings from participants in Europe (EU) (n=221; France, Germany, Italy, Spain, UK) and the Americas (AM) (n=137; Brazil, Canada, Mexico). Inclusion criteria for embryologists and nurses included a minimum of clinical time spent practicing in fertility clinics. **Results:** Two key laboratory tasks. **Results:** Triangulated analysis of qualitative and quantitative data identified challenges in four main areas related to: genetic testing and procedures; controlled ovarian stimulation (COS); luteal phase; and communication with patients. Regarding genetic testing, sub-optimal skills when performing embryo biopsies were identified among laboratory specialists (EU: 38%; AM: 46%) as well as sub-optimal knowledge of cases that would require pre-implantation genetic screening among physicians (EU: 31%; AM: 29%). Patients with estrogen-dependent cancer was identified as the most challenging profile to induce COS by physicians (EU: 46%; AM: 62%). Regarding the luteal phase, sub-optimal knowledge of abnormal microbiome composition was reported by physicians (EU: 40%; AM: 35%) and laboratory specialists (EU: 51%; AM: 46%). Finally, discussing treatment termination with the patient was reported as challenging by physicians (EU: 65%; AM: 56%) and nurses (EU: 62%; AM: 40%). **Conclusions:** Sub-optimal knowledge and skills were identified in four areas of fertility care. The patient communication challenges identified are aligned with findings from previous qualitative studies. This needs assessment provides improved specificity on the exact knowledge and skill-related challenges that professionals in fertility care experience, which could be addressed through professional development activities. **Disclosure of Interest:** This study was financially supported with education research funds from Ferring Pharmaceutical.

**OP2-706 SYNERGISTIC EFFECT OF OBESITY WITH POLYCYSTIC OVARIAN SYNDROME ON ENDOTHELIAL DYSFUNCTION ROLE OF INSULIN RESISTANCE**

Mardia Lopez-Alarcon1, Victor Saul Vital-Reyes2, Jose Vite-Bautista3, Aly Suegi Barradas-Vazquez4, Eduardo Almeida-Gutierrez2

1Unidad de Investigacion Medica en Nutricion, Instituto Mexicano Del Seguro Social, Mexico City, Mexico
2Biologia De La Reproduccion, Hospital De Gineco-Obstetricia 3, Mexico City, Mexico
3Hospital De Cardiologia, Instituto Mexicano Del Seguro Social, Mexico City, Mexico

**Problem statement:** Evidence informs early endothelial damage in women with polycystic ovary syndrome (PCOS) associated with hyperandrogenism but most of these studies do not consider the influence of obesity. This is relevant since obesity produces endometrial dysfunction, likely through the influence of insulin resistance, and also because it is highly frequent in women with PCOS. Asymmetric dimethyl arginine (ADMA) is considered a biomarker of endothelial damage found in clinical scenarios such as hypertension, cardiovascular disease and dyslipidemia whose pathophysiology include endothelial dysfunction. Endothelial damage is also evaluated by measuring the flux-mediated vasodilation with ultrasound. Thus, it seems necessary to disentangle the effect of hyperandrogenism, from that of obesity, on the risk for endothelial damage in women with PCOS. In this study we assessed associations between endometrial damage and PCOS adjusting by the presence of obesity and insulin resistance. **Methods:** A clinical cross-sectional study including women with and without PCOS (Rotterdam), with and without obesity (BMI ≥30) was conducted. Insulin sensitivity (hyperinsulinemic-euglycemic clamp), ADMA (Ultra high-performance chromatography), testosterone (MS-liquid chromatography), and flux-mediated vasodilation (FMVD) (ultrasound) were measured. Non-parametric statistics was used for comparisons. **Results:** Participants were stratified into four groups according with the combination of obesity and PCOS (Table 1). ADMA and testosterone were higher, and FMVD and M-value lower, in Obesity+PCOS compared to control (non-Obesity non-PCOS) group (p<0.01). This study present a high percentage presented endothelial damage (FMVD≤10), 21.3% Obesity+PCOS compared with 3.4% and 3.4% Obesity non-PCOS, non-Obesity PCOS and control groups respectively (X2, p=0.006). Likewise, 49% presented insulin resistance (M6.5, 31% Obesity+PCOS, compared with 6.6%, 6.6% and 4.5% in the other three groups respectively (X2, p<0.001). Logistic regression analysis demonstrated that the risk for endothelial damage was higher in women with combined obesity and PCOS as compared to control (OR: 6.5, 95%CI: 1.5, 28), as well as to the other two groups: Obesity non-PCOS (OR: 7.4, 95%CI: 1.2, 45), and non-Obesity PCOS (OR: 10.2, 95%CI: 1.7, 59). **Conclusion:** Our data suggests that PCOS induces endothelial damage independently of obesity. The combined effect of obesity and PCOS on the risk for endothelial damage in synergistic. No conflict of interest: Grant: CONACYT-SALUD-2017-1-239599

**OP2-707 RETROPERITONEAL ECTOPIC PREGNANCY: A CASE REPORT FROM HANOI OBSTETRICS AND GYNECOLOGY HOSPITAL**

Toan Nguyen1, Hai Nguyen1, An Nguyen2, Nga Pham2, Ha Nguyen1, Huynh Do1, Anh Nguyen1

1Department of Surgical Gynecology, Hanoi Obstetrics and Gynecology Hospital, Hanoi, Vietnam
2Department of Assisted Reproductive Technology and Andrology, Hanoi Obstetrics and Gynecology Hospital, Hanoi, Vietnam
Introduction: Retroperitoneal ectopic pregnancy (REP) is one of the rarest conditions of ectopic pregnancy. To date, there are merely 30 published cases available in English literature. An exceptional location of gestation with no symptoms makes a great challenge for clinicians to diagnose and can become a catastrophe for the patients. Case: We report a case of a 34-year-old woman with REP after fresh embryo transfer with a history of two previous salpingectomies via laparoscopy. 25 days after embryos transfer, her beta Human Chorionic Gonadotropin (βhCG) level was 8910 mIU/mL. Transvaginal ultrasound described a suspected heteroechoic mass next to the right ovary. Laparoscopic surgery was used to diagnose but we did not find embryonic location. The next day, an abdominal Magnetic Resonance Imaging (MRI) was performed showing a mass in the retroperitoneal space next to the right iliac artery. This mass was confirmed as a REP and was removed successfully via laparotomy. Histopathology of the removed gestation tissues showed an invasion of trophoblast cells into the lymphatic tissues. Results: The patient was discharged on day 4 of post-operation. Her βhCG level became normal 12 days after surgery. Conclusion: This study used paraffin-embedded tissue blocks of a previous study involving uterus of Macaca nemestrina (southern pig-tailed macaques). Subjects included in this study are 15 female macaques on reproductive age (8-10 years) with history of producing offspring. These macaques were divided into four groups in accordance to their COH protocols, which include administration of GnRH agonist and recombinant FSH (r-FSH) with dosages of 30 IU, 50 IU, 70 IU (intervention groups) and no r-FSH (control group). These stimulations were given for 14 days during midluteal phase. Endometrial tissues were retrieved on day 20-22 midluteal phase. Tissue staining was conducted using immunohistochemistry. Leptin expression was determined with IHC Profiler and counted semiquantitatively as H-score. Results: Differences of leptin expression in endometrial glands between intervention groups is insignificant as determined by one-way ANOVA (F(3, 10) = 0.464, p = 0.714). Similar results are also displayed in stromal (F(3, 11) = 1.033, p = 0.416) and luminal parts of the tissues (F(3, 9) = 1.059, p = 0.413). These insignificant differences may be explained by the indirect correlation between leptin and FSH, as the latter controls leptin expression by regulating the concentration of estrogen and progesterone. Other reason may be the 7-day interfuse between COH intervention and tissue retrieval, as r-FSH has a half-life of only 24 hour. A limitation of our study is the low number of subject due to restriction on Macaca nemestrina utilization for research in our country. Conclusion: Controlled ovarian hyperstimulation does not affect leptin expression in endometrial tissues significantly. Further research opportunity includes studying effects of estrogen and progesterone, as a result of COH, to leptin expression on endometrial tissues.
advised for tumour markers in view of suspected pelvic malignancy. While waiting for an MRI, US A&P (TAS) was done that concluded “Unable to determine if the mass is separate from the ovary”. βHCG reported as 61 U/L with remaining normal tumour markers. Patient collapsed in ward the following night and her Hb dropped from 93 to 49 g/L and a CT mesenteric angiogram was done to rule out active vessel bleeding! In view of the large volume haemoperitoneum the radiologist reported that the findings be regarded as ruptured ectopic pregnancy until proven otherwise even though βHCG is only marginally raised. Patient was taken to emergency theatre where a laparotomy revealed 3.5L blood in abdominal cavity with ruptured right tubal EP that was removed by salpingectomy. She was discharged home on Day 2 post-op with a Hb of 85 g/L and βHCG of 28 U/L that was reported as 1 U/L a week later. Conclusion: Over reliance on imaging at the expense of clinical judgment is an increasing issue in 21st century medicine that needs to be addressed. Ruptured EP is one of the commonest acute abdomen conditions for females of reproductive age. Negative urine test does not exclude pregnancy and slightly raised βHCG can be a common finding in ruptured EP.

OP2-711 RELATIONSHIP BETWEEN PROLACTIN AND Dopamine Receptor Expression and Progression of Genital Endometriosis
Maria Yarmolinskaya1, Elena Suslova1, Natalia Tkachenko2, Arsenii Molotkov2, Elena Netrova1, Tatiana Kleimenova3
1Department of Gynaecology of Reproduction, Scientific Research Institute of Obstetrics, Gynaecology and Reproductology Named After D.O.Ott, Saint Petersburg, Russia
2Department of Operative Gynaecology, Scientific Research Institute of Obstetrics, Gynaecology and Reproductology Named After D.O.Ott, Saint Petersburg, Russia
3Department of Pathomorphology, Scientific Research Institute of Obstetrics, Gynaecology and Reproductology Named After D.O.Ott, Saint Petersburg, Russia

Problem statement: The aim of the study was to investigate relationship between expression of prolactin (RPRL) and dopamine (DRD2) receptors and progression of genital endometriosis (GE). Methods: The study included 47 patients of reproductive age (23-42 years). The main group consisted of 35 women with GE of I-II degree according to R-APS classification. The diagnosis was stated during laparoscopy and confirmed by histological examination. The control group consisted of 12 women without gynecologic pathology. Levels of RPRL and DRD2 expression was assessed by immunohistochemical method using confocal microscopy in eutopic endometrium, eutopic endometrium and on peritoneum. Level of prolactin (PRL) in peripheral blood (PB) and in peritoneal fluid was investigated by immunochemiluminescent method. Statistica 10 program was used for statistical analysis. Results: Statistically significant increase in level of expression of RPRL in eutopic endometrium in patients with GE in comparison with this parameter in patients of the control group was observed. There was a significant decrease in expression of DRD2 in endometrioid heterotropies in comparison with controls. Negative correlation of expression level of DRD2 in endometrioid heterotropies with the level of PRL in PB of women with endometriosis was found. In the group of patients with GE of I-II degree, black foci were observed significantly more frequently compared with patients with GE of I-II degree. In patients with III degree of the disease red heterotropies (having high proliferative and angiogenic activity) reliably predominated which is consistent with pathophysiology of GE. Conclusion: Increased RPRL expression in endometriotic heterotropies indicates local increase in prolactin level which contributes to increase in proangiogenic potential, contributing to disease progression. However, decrease of expression of DRD2 in endometrioid heterotopy and its negative correlation with prolactin level in peripheral blood may contribute to spread of the disease and pathogenetically justifies the use of dopamine agonists as pathogenetic therapy of genital endometriosis.

OP2-712 SHEEHAN’S SYNDROME IN A PATIENT PRESENTING WITH ORGANIZING HEMATOMA OF THE MAXILLARY SINUS
Viktoria Ines Matibag, Ma. Cristina Pelaez-Crisologo
Department of Obstetrics and Gynecology, University of the Philippines - Philippine General Hospital, Manila, Philippines

Problem statement: Sheehan’s syndrome is a rare complication of post-partum hemorrhage that has decreased in incidence in the past decade due to better obstetrical practices, although still seen in developing countries. This is a case of a 31-year-old Gravida 1 Para 1 (1-0-0-0) with a 1-year history of enlarging maxillary sinus mass, where an incidental finding of an empty sella in an MRI with contrast was noted. The patient had amenorrhea of 15 years and received no medications for her undiagnosed Sheehan’s syndrome incurred during her first and only pregnancy. The patient’s cardiomyopathy and organizing hematoma may be rare complications of Sheehan’s syndrome. Methods: This is a case report. Results: In retrospect, the patient’s initial condition led to deleterious consequences. The postpartum hemorrhage caused Sheehan’s syndrome, causing undiagnosed, long-standing hypothyroidism, which led to dilated cardiomyopathy, then causing chronic passive congestion of the liver. Hepatic damage then caused an increased risk for bleeding, which may have contributed to the formation of an organizing hematoma. Conclusion: Patients, laymen, health practitioners, and traditional birth attendants should be informed of these complications. Treatment should be individualized and administered after diagnosing a patient with Sheehan’s syndrome to prevent complications such as adrenal insufficiency, hypothyroidism, infertility, and seen in this case, acute heart failure and possibly organizing hematoma.

OP2-801 OUTCOMES OF PREGNANCY OF UNKNOWN LOCATION USING SERUM BHCG AND ULTRASOUND IN A DISTRICT GENERAL HOSPITAL IN UNITED KINGDOM
Ananya Banerjee, Mojisola Oniah, Lesley Williams
Obstetrics and Gynecology, Hereford County Hospital, Hereford, UK

Problem statement: Pregnancy of unknown location (PUL) is defined as when the pregnancy test is positive but there are no signs of intrauterine pregnancy/ extraterine pregnancy via transvaginal ultrasonography (TVUS). It is not always possible to determine the location of the pregnancy in PUL since both miscarriage and ectopic pregnancy may resolve spontaneously without any treatment. A large number of studies have focussed on diagnosis and management of PUL but there are controversies on the approaches used to predict the outcome. Objectives: To study the BHCG trends and correlation with the initial scan findings in patients diagnosed with PUL, determine the final diagnosis and management. Methods: This was a retrospective study conducted in 50 patients diagnosed with PUL. Results: The mean age of patients was 27.52. PUL rate was 13.9%. Risk factors for ectopic pregnancy were identified in 12%. The initial BHCG level was 1500 in 44% of cases. The Bhcg levels at 48 hrs were: 66% rise in 22%, 35% rise in 12%, 50% drop in 18% and 13% decrease in 6%. Initial scan showed a gestational sac in 32%, anechoic area in 28%, adnexal mass in 6%; a thickened endometrium-14% and no adnexal mass/ intrauterine pregnancy in 8%. Final diagnosis: 14% - ectopic pregnancy, 32% - IUP and 52% failing PUL. 38% of failing PUL’s were managed expectantly. Bhcg level trends in 48 hrs for PULs eventually diagnosed as ectopic pregnancies.
were -35% increase in 50% and increase 35% in 16.66%. In IUP 66% rise was seen in 56.25% while 6.25% showed a 35% rise. In 24% patients BHCG was repeated 3 times. Conclusion: The BHCG ratio is one of the best predictors of outcome in PUL. PUL rates should be kept below 15% by use of skilled sonographers in i early pregnancy scanning to ensure appropriate diagnosis of PUL and decrease unnecessary monitoring and scans.

OP2-802
FIVE YEAR INCIDENCE OF OSTEOPOROSIS AMONG MACAO ADULT WOMEN AND ITS RISK FACTORS - RESULTS FROM MACAO FOLLOW UP STUDY 2011
Ken Gu
School of Health Science and Sports, Macao Polytechnic Institute, Macao, Macau China

Problem statement: Osteoporosis is a disease that human have lose bone strength. Women have higher risk than man especially after the menopause. Several diseases may also related to osteoporosis. Majority of Macao residents are Chinese, being an Asian is also a risk too. This report will use the sample of Macao women who participated a five year follow up study in Macao to present the incidence osteoporosis and try to explore its risk factors. Methods: In 2006, 3119 adults attended a whole region’s household randomized health survey in Macao. Data was collected by health assessment questionnaires and laboratory tests. In 2011, a phone follow up was conducted and 2395 people answered the questions. After excluding those who are males and had osteoporosis before 2006, a total of 899 cases were included for analysis. The osteoporosis was defined by answering “yes” for the questions “If a doctor had told you that you had osteoporosis?”. The SPSS17.0 was used for data analysis. Results: The five year self reported osteoporosis incidence was 7.8% in Macao women in 2011. Higher osteoporosis incidences were found in the women with diabetes, arthritis, kidney stone, anxiety, coronary heart disease, hypertension, or metabolic syndrome. These women also had lower education and took no soybean products. Women who developed osteoporosis, had higher mean values in age, BMI, SBP, DBP, Creatinine Urea, LDH in the baseline. In a logistic regression analysis with the osteoporosis status as dependent variable and significant variables listed above as independent variables, we found age and arthritis were significantly related to osteoporosis. Other variables became no significant. These variables seemed to be confounded by age. Conclusion: The osteoporosis incidence was 7.8% in Macao adult women. After adjusting effect from other related variables, Macao women with arthritis has a risk to develop osteoporosis 4.09 times (95%CI 3-5.12-1.75). Risk for each multiple births increased in “universal two children” ORadj=1.22 ,95% CI 1.07-1.40 .Risk for adverse pregnancy outcomes among multipara were not significant throughout the periods, despite multipara had higher adverse pregnancy rates than primipara. Conclusion: The proportion of multipara, women with younger or old age should been focused on for sharp increase. Additional, preterm birth and LBW should be highlighted for the increased risks over time.

OP2-804
HUMAN OVERPOPULATION AS THE GREATEST CHALLENGE FOR GYNECOLOGY IN THE 21ST CENTURY
Jan Gregus
Center for Outpatient Gynecology, Brno, Czech Republic
Center for Prenatal Diagnosis, Brno, Czech Republic

Problem statement: A significant part of the current, as well as future, global problems in the vein of environmental, healthcare, political, economic, and social issues, is directly linked to the size of human population. This report intends to show the gynecological audience how severe the problem of human overpopulation, which humankind is witnessing nowadays, really is, and that is linked with current gynecological problems. In particular, the global epidemic of unintended pregnancies and insufficient availability of family planning methods are discussed, notably in Sub-Saharan Africa where the problem of human overpopulation is (and will be) most severe. Methods: This report is based on data from United Nations (World Population Prospects – 2019 Revision), Population Reference Bureau (2016 World Population Data Sheet), FIGO’s Committee for Women’s Health and Human Rights (2017 Newsletter – Women’s Health Challenges), FIGO’s presentation on The Global Epidemic of Unintended Pregnancies, and World Healthcare Organization’s 2017 Sheet on Family Planning and Contraception. Results: In mid-2019, the world’s population reached 7.7 billion. Even though the fertility level is declining and population growth is slowing down, human population grows over 80 million people a year. According to the projections, the human population will keep growing, reaching 9.7 billion in 2050 and nearly 11 billion in 2100. The population growth is (and will be) most dramatic in Africa. With birth 15% of all pregnancies worldwide are unintended. Though contraceptive use has risen globally, it is still very low in Sub-Saharan Africa (28% in 2015), and availability of family planning methods worldwide still does not meet current global needs. Conclusion: The crucial problem of human overpopulation should become the greatest challenge for gynecology of the 21st century. The main reason is that the solution to gynecological problems, such as the epidemic of unintended pregnancies with all its consequences, overlaps with the solution to human overpopulation. In order to succeed, support of women’s rights, education, and empowerment worldwide are essential alongside a direct, systematic and global involvement of gynecologists and their organizations, with particular focus on Africa.
OP2-805
A CASE REPORT ON HAMMAN’S SYNDROME
Nikit Kadam
Department of Obstetrics and Gynaecology, Doncaster and Bassettlaw Teaching Hospitals, UK

Background: Hamman’s Syndrome is spontaneous pneumo-mediastinum and subcutaneous emphysema seen post-partum. It is a rare clinical entity seen in pregnancy and labour with crude incidence of 1 in 10000. There are over 200 reported cases of Hamman’s Syndrome in the literature so far. Case Description: A healthy 31 year old primigravida developed pneumo-mediastinum and emphysema following a normal vaginal delivery at 40 weeks and 4 days of gestation. She had an uneventful antenatal course. She was non-smoker with no significant past medical history. She presented in spontaneous labour. The total duration of labour was roughly 9 hours. The second stage of labour lasted for 1 hour and 45 mins. Roughly 10 hours after delivery she complained of chest tightness, shortness of breath and dysphagia. Her vital signs were stable, oxygen saturation being 97% on air. Heart sounds were normal. There was reduced air entry on the right side. On clinical examination crepitus was palpable at the base of the neck. Her investigations including ECG, arterial blood gases, Chest X-ray were normal. CTPA confirmed pneumo-mediastinum and subcutaneous emphysema. Her care was taken over by the surgeons who performed a CT Thorax and abdomen 48 hours after the initial CTPA. This ruled out Oesophageal rupture and reduction in pneumo-mediastinum. She was managed conservatively and discharged after 72 hours. An Oesophagogastrroduodenoscopy 3 month later was normal. Literature review: Hamman’s Syndrome is also called as ‘Macin’s Effect’. It was first reported in 1945. It is believed to be caused due to barotrauma which results in spontaneous rupture of alveoli in the second stage of labour. This leads to air leakage in the broncho-vascular connective tissue. Valsalva manoeuvre, screaming, coughing could be the triggering factors. The intra-alveolar pressure can be as high as 50mm of Hg. It is usually a benign condition but can lead to life threatening Cardiac tamponade. The differential diagnosis include Pulmonary Embolism, Oesophageal rupture, Rupture of Aortic aneurysm. CT is the gold standard investigation modality. The management is mainly conservative which comprises of analgesia, oxygen and reassurance. There is limited published evidence on recurrence and mode of delivery in subsequent pregnancies. There is no conflict of interest

OP2-806
CHANGES IN INTERVERTEBRAL DISCS WITH THE MENOPAUSE AND HRT
Joel Pollacco, Nicolas Felice, Yves Muscat-Baron, Mark Brinca Obstetrics and Gynaecology, Mater Dei Hospital, Malta

Problem statement: Vertebral fracture is a very common osteoporotic fracture, the cause of which can be mostly attributed to reduced bone density. Intervertebral discs are an integral part of the skeleton and are important in function. Therefore, reduced intervertebral disc height might predispose to fractures. Method: A Cross Sectional Study was done by recruiting women from a large bone densitometry registry. These were divided into categories according to whether they were pre-menopausal, untreated post-menopausal women or women on various post-menopausal treatments including HRT. Three inter-vertebral disc heights were measured between [T12 and L1 (D1), L1 and L2 (D2) and L2 and L3 (D3)]. A cohort of 1080 women were analysed. Results: HRT women had no significant changes compared to pre-menopausal women but highly significant improvement compared with strontium ranelate and particularly to women on bisphosphonates who had the lowest highly significant reduction in intervertebral disc height. In addition there was a significant reduction in disc height in pre-menopausal women with age, which accelerated in the immediate menopausal period (51-60 years). This was seen in every disc analysed. When disc heights were compared to T-scores, those women who were osteopenic and osteoporotic had lower disc heights than women with normal T-scores. Conclusion: Inter-vertebral disc heights present a new variable that impacts on bone integrity and incidence of osteoporotic bone fractures. Inter-vertebral discs are susceptible to osteoporosis at the time of the menopause just like other connective tissues including bone and skin. It is suggested that not all anti-osteoporotic agents have the same effect on inter-vertebral disc integrity and this might have to be borne in mind when considering the most suitable treatment according to the individual’s needs.

OP2-807
PATIENT-CENTRED OR PATIENT-FRIENDLY: WHAT OF THEM IS THE MOST RELEVANT STANDARD VALUE IN ASSISTED REPRODUCTION TREATMENTS?
Guillermo Quea1, Guillermo Quea2, María José Martínez Caniavate3, Gorka Barrenechea2,1
1Assisted Reproduction Unit, Reproducción Bilbao, Bilbao, Spain 2School of Medicine, Basque Country University, Bilbao, Spain

“Reproducción Bilbao”, a Fertility Centre in Bilbao, Spain certified in 2018 according to ISO 9001-2015 introduced recently a quality management system (QMS) to improve quality in our centre. There is no simple definition of quality improvement however, most definitions describe it as a systematic approach that uses specific techniques to improve quality. Within healthcare, there is no accepted definition of “quality” and has been identified six dimensions of healthcare quality. These state that healthcare must be: “safe, effective, patient-centred, timely, efficient and equitable”. Nevertheless, the question of what is quality in assisted reproduction techniques (ART) still remains. Is it just pregnancy rates? Or should we look at something else? To answer these questions, we focus on determining the most relevant standard value of success in ART, considering the whole treatment to improve our outcomes and the concepts of “patient-centred” and “patient-friendly” were introduced. “Patient-friendly” has been traditionally defined as the best possible outcome with greatest efficiency, using the most cost-effective and least invasive regimens. By the other hand, “patient-centred” establish a partnership between practitioners and patients to ensure care respects patients’ needs and preferences. According to these concepts, we focus all our efforts towards “patient-centred” care directing our activity to meet the needs of our patient and couples according to what was obtained in satisfaction survey such as: “Competence of clinic and staff, coordination and integration, continuity, physical comfort, emotional support, patient involvement and privacy” taking into account that our weaknesses or strengths related to system factors are directly related to human factors. The patient always the patient. What were the barriers to success in quality improvement? Basically four: “convincing people that there is a problem; the organisational context, culture of organization and capacities; tribalism and lack of staff engagement; convincing people that the solution chosen in the right one”.

OP2-808
SEXUAL PRACTICE IN PREGNANCY IN WOMEN OF LOW SOCIOECONOMIC STATUS IN A TERTIARY CARE HOSPITAL IN NORTHERN INDIA
Ananya Banerjee, Chanda Rai, Manisha Meena
1Obstetrics and Gynaecology, Hereford County Hospital, Hereford, UK 2Obstetrics and Gynaecology, VMMC and Safdarjung Hospital, New Delhi, India

Problem statement: Sex in pregnancy remains a rarely discussed topic in India because of social taboos and the embarrassment couples and clinicians face in discussing these issues. In view of hormonal changes both physical and psychological changes occur in a pregnant woman and it affects her sexual life. Aim: This study is an attempt to understand the attitude, knowledge and behaviour of pregnant women regarding their sexual practices, the fears they encounter, and ways to dispel these psychological issues. Materials and methods: A cross-sectional descriptive study was carried out in the department of Obstetrics & Gynecology at VMMC & Safdarjung Hospital, New Delhi, India.230 women were asked open ended questions about their sexual practice and variation in the different trimesters. Data was analysed by SPSS software. Results: Our
study showed that the frequency of sexual activities in the first, second and third trimester were 36.6%, 43.9% and 6.3% respectively thereby showing a decline in the third trimester. Around 9.8% women refrained from coitus throughout pregnancy. Vaginal intercourse remained the most common type of sexual activity in 75.6% of the population. 12.2% of the women indulged in oral sex, and 8.3% found sexual appeasement in masturbation and 3.9% of women had anal intercourse. The level of knowledge of the respondents was below average, the impact of the beliefs related to sexuality during pregnancy was weak. Love and intercourse increased by 31.2% of women and decreased by 38% of women and remained same in 30.7%. The factors prohibiting coitus included the risk of preterm labour, bleeding and chances of infection to the baby. Conclusion: Counselling for sexual health must be initiated by the health workers as it will help couples who are embarrassed to discuss these issues owing to the social and cultural norms. This will help to bridge the communication barrier and will be instrumental to a healthy sexual life during pregnancy.

OP2-809
STRESS AMONG PREGNANT WOMEN APPLYING FOR BIRTH PREPARATION TRAINING
Fatma Cosar Cetin
Nursing Department, Istanbul Medeniyet University, Istanbul, Turkey

Problem statement: Stress during pregnancy can contribute to adverse pregnancy outcomes such as low birth weight and preterm delivery. Therefore, measurement and follow up of psychological health in pregnant women is an important subject. The aim of this study was to evaluate the stress status of pregnant women applying for childbirth preparation education.

Methods: The descriptive study was carried out with pregnant women (n=106) who applied to the pregnant outpatient clinic of a maternity hospital and volunteered to participate in the study. Personal information form and Pregnancy Stress Rating Scale were used as data collection tools. Pregnancy Stress Rating Scale is developed by Chen (2015) identify pregnancy-related stress factors in pregnant women. It consists of 5 subdimensions (1) pregnancy, labor and delivery process stress, (2) infant care and changing family relationships stress, (3) mother role stress, (4) social support seeking stress, (5) physical change stress and 36 items. The score that can be obtained from the scale is in the range of 0-144 points. The higher stress scores indicates increased stress. In the analysis of the data; number, percentage, mean, standard deviation, independent samples t test and Anova analysis were used. Results: A total of 106 pregnant women admitted to the antenatal outpatient clinic were included in the study. The mean age of the pregnant women was 30.4±4.51, 64.2% were university graduates, 79.2% were in the first pregnancy, 44.3% were in the second trimester and 54.7% were in the third trimester. The mean score of Pregnancy Stress Rating Scale pregnant women was 64.01±19.10. Mean score of infant care-induced stress subscale 15.63±6.85, maternal role-induced stress mean score 15.85±5.15, pregnancy and childbirth stress mean score 13.12±3.84, physical appearance-induced stress mean score 11.46±4.77, lack of social support mean score 7.94±4.01. Stress scores of pregnant women in second trimester were higher than others (p=0.05). Training and spousal support did not affect stress score during pregnancy (p=0.05).

Conclusion: As a result, pregnant women experienced the most stress on the role of baby care and motherhood.
Key words: pregnancy, stress, childbirth, motherhood.

OP2-810
ORGAN-PRESERVING SURGERY FOR ABNORMAL INVASION PLACENTA
Roman G. Shmakov1, Mariva Pirogova2, Vladimir Chuprinin1, Vladimir Chuprinin2

1Institute of Obstetrics, FSBI National Medical Research Center for Obstetrics, Gynecology and Perinatology named after Academician V.I. Kulakov, Moscow, Russia
2General Surgery Department, FSBI National Medical Research Center for Obstetrics, Gynecology and Perinatology Named After Academician V.I. Kulakov, Moscow, Russia

Problem statement: Ph-negative myeloproliferative neoplasms (MPN) are a group of hematologic diseases that occur rare in reproductive age. However, in recent years there has been an increase in their frequency, including pregnancy. A high risk of thrombotic complications in vessels of various localization is one of the main features of MPN. During pregnancy this causes a pronounced degree of ingrowth of the placenta and trophoblast invasion. Methods: We analyzed 167 pregnancies in 95 women with MPN. The prospective group 1 included 82 women who were treated according to the developed algorithm. Retrospectively we have analyzed 76 pregnancies in 46 women (group 2) who did not receive a special treatment during pregnancy. Pregnancy outcomes, complications and neonatal health status were evaluated in both groups. The algorithm included cytoreductive therapy ( interferon alfa), antiplatelet drugs, low molecular weight heparin, platelet transfusion, vitamins of group B. Results: In the group 1 the rate of miscarriage was 3.3%: 2 cases of spontaneous abortion, 1 case - stillbirth (one fetus from twins). In group 2 miscarriages occurred in 76.3%: spontaneous abortion - 49 (64.5%) pregnancies, stillbirth - 9 (11.6%). Preterm labor were in 12 (13.2%) and 7 (9.2%)
pregnancies in 1 and 2 groups respectively. Full-term delivery occurred in 84.6% and 7.9% of cases in both groups (p=0.002). Pregnancy was uncomplicated in 25.8% and 15.4% cases in 1 and 2 groups. The most often pregnancy complication was anemia – in 51.7% and 38.5% cases. The health status and frequency of congenital malformations in children born to mothers with MPN did not differ from those in the healthy population. Conclusion: Pregnant women with Ph-negative MPN belong to a high-risk group on recurrent miscarriage. The development of a program for pregnancy planning and management in women with MPN led to a significant reduction in the frequency of congenital malformations in children born to the general population.

MPN belong to a high-risk group on recurrent miscarriage. The reduction of morbidity and mortality.


department of gynecology, anhui medical university, hefei, china
6biopsychiatric and artificial organs, anhui provincial engineering research center, anhui medical university, hefei, china

Problem statement: Endometriomas are common gynecological disease with major clinical manifestations of pain and infertility. Laparoscopic cystectomy of ovarian endometriomas (LCOE) is a widely used treatment but may affect ovarian reserve (OR). However, after LCOE, how OR changes and depends on which factors remains unclear.

Objectives: To evaluate OR change by serum anti-mullerian hormone (AMH) level and to find out the factors that may affect the changes 1, 3 and 6 months after LCOE.

Methods: A prospective longitudinal study from 2015-2017, 104 patients underwent LCOE, serum AMH level was measured preoperatively and at 1, 3 and 6 months postoperatively. Many factors were assessed to find the association with AMH level changes. Results: Preoperative AMH level significantly declined from 4.47 ± 2.88 ng/ml to 2.11 ± 1.88 ng/ml (P<0.0001), 1.96 ± 1.67 ng/ml (P<0.0001) and 1.97 ± 1.50 ng/ml (P<0.0001) at 1, 3 and 6 months respectively, respectively. The rate of reduction in AMH was unchanged during 6 months after surgery of 46.2 ± 39.3%, 48.7 ± 34.1% and 47.8 ± 35.9%, at 1, 3 and 6 months, respectively. Although most of the investigated factors were associated with AMH level changes in monovariant linear regression, multivariant regression analysis shown that only three of them were actually related including laterality of endometrioma, mean size of the endometrioma and preoperative serum AMH levels. Among these 3 contributing factors, the laterality factor of endometrioma appeared to have the greatest impact on the change in AMH levels. Conclusion: Serum AMH level declined significantly after laparoscopic cystectomy of endometriomas. This decreased level of AMH depends on laterality of endometriomas, mean size of the endometrioma and preoperative serum AMH levels and it can be predicted preoperatively.
mice were characterized by flow cytometry. Results: Compared with control group, women with RIF had decreased percentages of PMN-MDSCs (P 0.05), Chemokine receptors (CCR)5*PMN-MDSCs (P 0.01) and Treg cells (P 0.05). TCR ζ-chain expression of CD4+ and CD8+ T eff cells in PBM Cs from RIF patients was elevated as well, compared to that in control group (P 0.05). Chemokine ligand (CCL)5 and transforming growth factor (TGF)-β levels were significantly lower in the serum from RIF patients when compared to control (P 0.05). In mice PBM Cs, we found that PMN-MDSCs were in the low-dose group (P 0.05) and the high-dose group (P 0.01) was significantly reduced compared to the control group, meanwhile Treg cells (P 0.05) and Th2 cells (P 0.05) also showed a deletion in high-dose group. By analyzing endometrial single cell suspension, we detected decreases of PMN-MDSCs (P 0.05), mononuclear (Mo)-MDSCs (P 0.05) and increases of Th1 cells (P 0.05) in high-dose group. Conclusion: Impairment of PMN-MDSCs may be part of the pathogenesis of RIF and PDE5 inhibitor may affect embryo implantation by suppressing MDSCs.

OP2-903 EFFECTIVENESS OF HYSTEROSCOPY ISTHMOPLASTY IN SECONDARY INFERTILE PATIENTS DUE TO ISTHMOCELE

Chien Nguyen, Chien Nguyen Ngoc, Thuy Nguyen Bien, Huong To Minh, Hieu Ho Trung
IVF center, Vinmec International Hospital, Hanoi, Vietnam

Problem statement: Cesarean section is one of the most common surgical procedures performed worldwide especially in developing country like Vietnam, and one of its most serious consequences is the increasing number of secondary infertility due to isthmocele. There are several methods to solve this problem but none of them until now has demonstrated its effectiveness. Method: From January to August 2019, 20 patients with secondary infertility due to isthmocele were treated by hysteroscopy isthmoplasty in the first part of their cycle in Vinmec International Hospital, Hanoi, Vietnam by the same surgeons. After that 12 of them received frozen embryo transfer in the next cycle, adjunctive liquid aspiration was performed as needed. Embryos day 4 or day 5 was transferred in different grade of quality. We conducted a retrospective study to evaluate the effectiveness of this approach to treat this condition. Results: The majority of patients needed liquid aspiration form uterine cavity during the endometrium preparation (66%). All of them had an endometrium with more than 7mm in thickness, Doppler type II, triple line and without liquid inside before FET. Among those who received FET, 8 of them become pregnant after the first transfer (66%) and 4 of them failed to become pregnant (34%). Conclusion: Hysteroscopy isthmoplasty could be an effective method to manage secondary infertility due to this condition. Larger and randomized control trial study should be performed to evaluate this method more accurately.

OP2-904 THE INFLUENCE OF LEGAL AND TECHNOLOGICAL EVOLUTIONS ON PATIENTS' BEHAVIOUR USING DONOR EGGS: A BRITISH EXPERIENCE

Mona Rahmati, Shalaja Nair, Ajit Gill, Elena Linara-Demakakou, Trina Shah, Jinjun Wang, Tourandokht Arian-Schad, Sharon Walster, Nick Macklon, Kamal Ahuja
Reproductive Medicine, London Women's Clinic, London, UK

Problem statement: While treatment with egg donation is increasing in importance, sourcing donor eggs remains a challenge. The changing regulatory landscape together with advances in technology are likely to be impacting on the characteristics of egg donors, the way in which eggs are utilized and trends in cross border treatment. In this study we report how these changes have altered our practice over the past 13 years. Methods: This retrospective study reviews over 2000 treatment cycles using donor eggs from 2005 to 2018. The study focuses on the donor egg sources, frozen egg use, demographics of patients receiving treatment with donor eggs and pregnancy outcomes. Results: The 2012 legal changes in United Kingdom regarding egg donation and the creation of a local egg bank reversed the previous trend to seek cross border treatment for egg recipients. Since 2014, all our recipients have been treated with donor eggs from the nearby London Egg Bank. Moreover, the egg sharing programme providing eggs to 17% of the recipients in 2013 dropped to one case in 2018. The demand for treatment with the donor eggs appears stable among our patient population. Despite the permissive local legislation regarding the age limit for fertility treatment, the demand for treatment for recipients over 50 years old remains limited. The most striking change has been the growth in the use of frozen eggs. Comparable pregnancy outcomes are now achieved using frozen or fresh oocytes, and this has led to 95% of recipients now receiving treatment with frozen eggs compared with just 1% in 2013. Conclusions: Although limited to one centre, this descriptive study illustrates how legal and technological changes have resulted in remarkable change in the sourcing and profile of donors, and the way in which their eggs are being utilized in clinical practice.

OP2-905 THE ADVERSE EFFECT OF BODY MASS INDEX IN ASSISTED REPRODUCTION TREATMENTS AND PREGNANCY OUTCOMES

Diana Rodrigues-Martins, Carla Leal, Inês Nunes, Emídio Vale-Fernandes, Isabel Sousa-Pereira, Claudia Lourenço, Jorge Braga, Alexandre Morgado, Marcia Barreiro
Department of Obstetrics and Gynecology, Centro Materno Infantil Do Norte, Centro Hospitalar Universitário Do Porto, Portugal

Problem statement: There is compelling evidence about the negative impact of obesity in assisted reproduction treatments (ART), however the published studies lack attention on obstetrical outcomes such as related pregnancy complications and live birth rates. Methods: The present study aimed to evaluate the impact of body mass index (BMI) in ART cycles, and pregnancy outcomes after fertilization in vitro treatments (FIV), between 2014 and 2017 in our tertiary care center. Cycles with embryo transfer (n=471), a higher class of BMI was associated with lower fertilization (62.5% vs 80% vs 57%; P 0.05), and lower pregnancy rates (37% vs 38% vs 26%; P 0.05). On the other hand, the miscarriage rate among obese women was higher compared to those with normal BMI (30% vs 25% vs 26%; P 0.05). Eighty five of the 124 pregnancies were followed at our center (57 singletons and 28 twin pregnancies). Despite the high rate of at least one complication during pregnancy [30 (53%) of the singletons and 21 (75%) of the twin pregnancies, of which 40% and 80% demanded inpatient care, respectively], the global live birth rate was 99.3% (only one stillborn in a normal BMI range patient). There were no significant differences between BMI classes. Conclusion: Increasing prepregnancy BMI appears to progressively worsen the outcomes of ART treatments. A multidisciplinary management throughout gestation seems to be key to enhance pregnancy outcomes, however results were limited by the small sample size.

OP2-906 BIOPHYSICAL ULTRASONOGRAPHIC MARKERS ASSESSMENT OF ENDOMETRIAL RECIPROCY IN ASSISTED REPRODUCTIVE TECHNOLOGY CYCLES

Renato Silva Martins1,2, Antonia Helio Oliani1,2, Denise Vaz Oliani1,2, Jose Martinez De Oliveira1,2
1Unidade Medicina Reprodutiva, Centro Hospitalar Universitário Cova Da Beira Epe, Covilhã, Portugal

Problem statement: There is compelling evidence about the negative impact of obesity in assisted reproduction treatments (ART), however the published studies lack attention on obstetrical outcomes such as related pregnancy complications and live birth rates. Methods: The present study aimed to evaluate the impact of body mass index (BMI) in ART cycles, and pregnancy outcomes after fertilization in vitro treatments (FIV), between 2014 and 2017 in our tertiary care center. Cycles with embryo transfer (n=471), a higher class of BMI was associated with lower fertilization (62.5% vs 80% vs 57%; P 0.05), and lower pregnancy rates (37% vs 38% vs 26%; P 0.05). On the other hand, the miscarriage rate among obese women was higher compared to those with normal BMI (30% vs 25% vs 26%; P 0.05). Eighty five of the 124 pregnancies were followed at our center (57 singletons and 28 twin pregnancies). Despite the high rate of at least one complication during pregnancy [30 (53%) of the singletons and 21 (75%) of the twin pregnancies, of which 40% and 80% demanded inpatient care, respectively], the global live birth rate was 99.3% (only one stillborn in a normal BMI range patient). There were no significant differences between BMI classes. Conclusion: Increasing prepregnancy BMI appears to progressively worsen the outcomes of ART treatments. A multidisciplinary management throughout gestation seems to be key to enhance pregnancy outcomes, however results were limited by the small sample size.
Problem statement: Human implantation is a complex process requiring synchrony between a healthy embryo and a functionally competent or receptive endometrium. Ultrasound is a non-invasive technique that can assess changes in the endometrium during stimulated cycles in Assisted Reproductive Therapy (ART) cycles. The aim of this study is to correlate biophysical markers such as Endometrial pattern, endometrial thickness, endometrial volume and adjusted endometrial volume and Uterine Artery and SubEndometrial Resistance and Pulsatility Index with the ART cycle changes. Methods: Serial 2D transvaginal coloured power Doppler ultrasound performed in women on ART cycle to evaluate a pattern that better predicts implantation rates. 169 subjects on a prospective case control study were assessed. Biophysical ultrasound markers such as Endometrial pattern, endometrial thickness, endometrial volume and adjusted endometrial volume and Uterine Artery and SubEndometrial Resistance and Pulsatility Index was performed to all subjects at baseline (prior to ovarian controlled stimulation), at day 6, 8 and 10 of controlled ovarian stimulation, at trigger day and at embryo transfer day. Also the ratio of fluxometry parameters between SubEndometrial blood flow and uterine artery was measured. Results: No statistical difference was noted between the two groups in terms of demographics and ART procedures and scores. Endometrium Morphology also didn't show any difference between the two groups. Endometrial Thickness was significantly higher on the implantation group after Day 8 of controlled ovarian stimulation, but Endometrial Volume and Adjusted Endometrial Volume was significantly higher in the implantation group as soon as day 6 of ovarian controlled stimulation. Uterine Artery Resistance and Pulsatility Index showed statistical difference between the two groups (implantation versus non-implantation group). Also statistical significance was obtained between the two groups in terms of SubEndometrial vascularization. Ratio between SubEndometrial and Uterine Artery showed lower values of fluxometric parameters in all range for the SubEndometrial territory. Conclusions: Biophysical ultrasonographic markers may be a useful tool for clinicians in predicting endometrial receptivity enhancing elective embryo transfers in the same ART cycle. Keywords: Endometrial Receptivity, Assisted Reproductive Technology, Endometrial Volume, SubEndometrial blood flow, Uterine Artery Fluxometry, Embryo Implantation. The authors do not report any conflict of interest.

OP2-907
VITRIFICATION OF HUMAN OOCYTES: HOW TIMING BEFORE FREEZING AND AFTER THAWING AFFECT UTILIZATION EFFECTIVITY AND STATE OF THAWED OOCYTES
Olga Tepla1, Martin Golan2, Oleg Lunov2, Michala Frolíková3, Silviona Jirsova4, Katarinha Hortova5, Adela Minků6, Zinovij Topurko7, Irena Kratovilová8
1Centre of Assisted Reproduction, Department of Obstetrics and Gynecology of the First Faculty of Medicine and General Teaching Hospital, Plzeň, Czech Republic
2Department of Analysis of Functional Materials, Institute of Physics of the Czech Academy of Sciences, Na Slovance 2, Prague, Czech Republic
3Reproductive Biology, Biocev, Průmyslová 595, 252 50, Vestec, Czech Republic
4Centre of Assisted Reproduction, Isarcê M a.s., Prague, Czech Republic

Problem statement: Recent advances in oocytes vitrification have markedly improved the survival rate of mature oocytes after thawing. Despite the standard use of the vitrification it is not clear what is the exact impact of time before oocytes freezing and after thawing on the probability of success in oocytes fertilization. How are these factors correlate with thawed oocyte chromosomes organization and state of meiotic spindle. Methods: Maturated oocytes for statistical purposes were collected from donators (younger than 35 years, 317 oocytes, in the later prophase II or metaphase II. Oocytes were vitrified using media from Kitazato. The imaging was done with an Olympus IXplore SpiniSR10 (Olympus, Tokyo, Japan) confocal fluorescence microscope with a spinning disc and a super-resolution SIM module. Results: The average probability to fertilize vitrified oocytes after thawing was 61%. For time intervals before freezing - 4-7 hours and 7-10 hours the dispersion of the average probability was 5 % round average value. Time before freezing had similar impact on probability to fertilize vitrified oocytes after thawing as time between vitrification and fertilization. The average probability that collected oocytes will be after thawing utilized is 34%. Time before freezing plays more important role than time between thawing and ICSI. Oocytes frozen 4-7 hours after collection had grouped chromosomes after thawing and the average probability that these oocytes will be after thawing utilized was 27%. The average probability that collected oocytes would be after thawing utilized was 41% when oocytes were vitrified 7-10 hours after collection. These oocytes had separated chromosomes (formed meiotic spindle) after thawing. Conclusions: When oocytes were frozen at stage with formed meiotic spindle and separated chromosomes (typical for oocyte matured in metaphase II) more than 6 hours after retrieving the probability that this oocyte would be successfully utilized after its thawing was high. We showed that freezing of human oocytes before the meiotic spindle was formed lead to worse post-thaw conditions. Vitrification of the oocytes too early before final metaphase II maturation may disturb the crucial process of chromosome and spindle post thaw remodeling.
Problem statement: In France, since July 2019, cervical cancer screening is based on HPV testing on Pap smear for women aged 30 to 65, and cytological examination of a Pap smear for women aged 25 to 29. But screening coverage is unsatisfactory. Previous studies in our lab have shown that urinary HPV testing for high-risk HPV (HR-HPV) testing increases rates of compliance. In collaboration with the Cancer screening coordination center of the Pays de la Loire region, we conducted a study to offer urinary HPV testing for 13000 women aged 35 to 65 who don’t have regular cervical smear in order to increase the screening coverage in our department. 

Methods: 500 to 700 letters proposing an at-home urinary HPV testing are sent monthly. Women accepting to participate send their first-stream urine samples by mail to the Virology Laboratory in accordance with a three-rule secure packaging protocol as recommended in France. HR-HPV detection is performed using Anyplex II HPV28 Detection (Seegene®) that detects 19 HR-HPV genotypes. Patients with HR-HPV positive results are encouraged to perform a cervical smear as soon as possible to detect the presence of cervical lesions. 

Results: Between November 2016 and November 2018, 13355 letters were sent to women. After exclusion (past hysterectomy, recent smear or refusal), the participation rate is 15.4%. Out of the 1915 analyzed specimens, 1711 and 190 were negative and positive for at least 1 HR HPV respectively. HR-HPV others than HPV 16 or HPV 18 were mostly detected: HPV 53 (23.7%) and HPV 68 (14.2%). Invalid results occurred in only 14 samples (0.7%). Among the smears, 23 abnormal smears were observed and 6 high-grade cytological lesions after colposcopy and biopsy have been detected.

Conclusion: Because home HPV urinary testing is non-invasive and does not require medical attention, this method may be an alternative for women who are reluctant to use Pap smear. Furthermore, 89.5% of the HPV-positive women benefited from a Pap smear collected by a clinician during follow-up. So, the urinary HPV test could be an alternative to the usual screening by cervical smear thus extending screening coverage in our department.

OP2-911

BIONANOTECHNOLOGIES IN MEN’S HEALTH MEDICINE THE SPERM NANOBIOSOMES (MALE REPRODUCTION, CONTRACEPTION, STD AND AGEING)

Giuseppe Tritto1, Sujoy Guha2

1 WABT – World Academy of BioMedical Sciences and Technologies, Paris, France
2 Indian Institute of Technology and All India Institute of Medical Sciences, New Delhi, India

Synthetic Biology is a new Bio-Medical Field in which Convergence of BioInformatics, Genetic Engineering, BioCellomics, Bio-Nanonic... is raising new Strategic Technologies to sustain revolutionary approaches not only in the field of BioMedicine, but also a translational cascade effect on production of smart drugs from microorganisms, bioenergy production, bioremediation, biological threat detection and decontamination, programming cells for information processing, communication, gene regulation and cell therapies. These new futuristic potentialities of at-large scale applications raise complex problems of ethical knowledge management, implementation and transfer, involving not only the scientific communities but also the applied science policy-makers to drive the bioeconomy trends, the biosafety and biosecurity commitments for the environment, the protection of the human health as a primary asset of the global development. BioInformatics will play a new role, creating a parallel biodata synthetic knowledge for a responsible research for the benefit of humankind. The SynBionics or simply Synthetic Bionics Knowledge is progressively structuring as a new bio-science, based on the three pillars of Bio-Information, Bio-Innovation and Bio-Intelligence. SYNBIONICS, including Nano(Bio)Somes, is a unique term designed and proposed by Giuseppe TRITTO from WABT in 2011 to indicate the global processes to Engineering Life through Synthetic Biology. The First Operational Model of SynBionics Process in Vivo has been developed by a dual India–Europe Team of BioEngineers and Clinicians in the Field of Human Reproduction. An innovative BioDesign for self-generation and self-assembly of nano-liposomes in vivo (Nano-BioSomes) into the human reproductive tract has been engineered by the group of prof. S. Guha in the Weatherall Institute of Molecular Medicine in New Delhi, India, fitting the new bioconcepts and biosigns in SynBionics proposed by the group of BioMINT of prof. G. Tritto of WABT European Institute for Life (WEIL) in Europe. This new bio-nano-technological model in vitro and in vivo (BioNanoSpermGenSomes) opens highlights on advanced applications not only into reversible contraceptive methods for man, but also, beyond contraception, in local treatments of pathologies of the prostate, using nanoliposomes generated in vivo from sperm as carriers for drug delivery into the prostate, and as antimicrobial (including anti HIV) release from RISUG (and RISUGadv variant) contraceptive for male and female.

OP2-912

IMPACT OF REVISED MANAGEMENT POLICIES ON THE EFFICIENCY OF GYNECOLOGIC OPERATING ROOM PROCESSES IN A TERTIARY TRAINING HOSPITAL

Glaiza De Guzman1, Cecilia Llave2

1 Department of Obstetrics and Gynecology, University of the Philippines - Philippine General Hospital, Manila, Philippines
2 WABT – World Academy of BioMedical Sciences and Technologies

Background: A retrospective observational time motion study of elective gynecologic surgeries performed from January 2015 to December 2016 was conducted at the Operating Room Complex of a tertiary training hospital. There was a change from three operating suites with standard last stitch time in 2015 to only two out-patient departments by volunteers.

Conclusion: Reducing the incidence and cervical cancer–related mortality rates is crucial. In Russia we experience difficulties in reaching of the women invited for screening or vaccination. To cope with this situation national informational and educational campaign was developed. A part of this strategy was Russian Global action for celebration of International HPV Awareness Day. As a result of this campaign Russian regional programs for HPV screening and vaccination have been implemented.
with no cutoff times in 2016. This was due to the renovation of the Operating Room Complex. **Objective:** To determine the factors and problems affecting operating room processes. **Materials and methods:** Different time motion parameters such as induction time, length of induction, cutting time, last stitch time, total operating time, and number of packs were collected from the nurses’ documentation. Average values from two different time periods were compared and analyzed. **Results:** Results showed no improvement with the revised policies implemented in 2016. With only two rooms, surgeons were able to cope with the number of patients by extending operating hours later through the day. Recurring problems on manpower and lack of resources were noted. **Conclusion:** There is a need to identify hindrance to efficient operating room utilization with the goal to decrease patient queue, improve patient as well as staff satisfaction, and increase financial revenue. Multi-disciplinary changes in practices, processes, and attitudes are timely for improvements in operating room utilization and consequently better patient-centric outcomes.

**OP2-913**

**MATRIX REGENERATION OF THE HUMAN TESTIS IN MALE INFERTILITY TESTIS REGENERATIVE MATRIX (TREM) BIOEXPANSION IN TESTIS INSUFFICIENCY SYNDROME (TIS) TESTIS EXPANDABLE BIOSURGERY AND MARSUROPTEDY (TEBMS AND TEMS) IN MALE INFERTILITY BASED ON AUTOLOGOUS REGENERATIVE STEM CELLS**

**Giuseppe Tritto**

**WABT – World Academy of Biomedical Sciences and Technologies, Paris, France**

In the last COGI Congresses in Paris (Paris, France, November 17-20, 2011, A6), in Hainain (Hainain, China, December 8-11, 2011, A27), in Singapore (Singapore, July 19-22, 2012), in Wien (November 30-December 2, 2017) innovative TREMS Technologies (TREMS – Technology for REproductive Medicine and Surgery) have been presented for MARS (Male Reproductive Surgery and MicroSurgery), Testis Expandable BioSurgery and MicroSurgery (TEBS and TEMS) based on Cell Technology (Reproductive Cellomics) and on natural autologous Nanosomes (SpemoSomes) designed for Testis Insufficiency Syndrome (TIS) in Male Infertility and in Andropause. The Testis Insufficiency (Impairment) Syndrome – TIS is defined on 3T Parameters: Temperature Increasing, measured by IR Technology; Testosterone Decreasing, measured with salivary test; Testis Function Impairing, measured by computer-assisted Dynamic Imaging Technology (Power Doppler Ultrasound and Raman Spectroscopy). A flagship multi-centric clinical trial is realized on 85 cases of TIS Syndrome to implement the procedure for Testis Matrix Regeneration using Autologous Mesenchimal Stem Cells with a follow-up of 1year and half. The TREM Expansion in TIS has been realized with the technique TAS (Testis Augmentation Surgery) using a vascularized island vaginals flap to enlarge the testis with the goal to transform the testis ovoid from Dixon Euclidean egg classes to Golden Egg standard. Trough the abinguinal incision a microprobe tunneling the interlobular spaces has been used to permit the injection of microplugs of samples of purified adipose regenerative stem cells extracted from the same fat tissue of the patient from the abdomen or from the scrotum. The samples of regenerative stem cells were activated before introduction into a special box delivering ultrasound cavitation multispectra low frequencies through a SHDB Cell System for 20 minutes. The volume of the testis and the blood level of testosterone are the basic parameters monitored during the period of follow-up. The volume of the testis increases of more than 20 per cent with a normalization of the ovoid into the Dixon categories and a real improvement of the power doppler parameters. The level of blood testosterone increases in a period of 6 months from a mean value of two measurements of 2.45 ±0.47 to 4.50 ±0.82 Th. New Advanced Expandable MicroSurgery Techniques like the Human Testis (TEMS) to enhance or repair or regenerate the Intertubular Matrix of the Human Testis through Autologous Mesenchimal Stem Cells (Cell Therapy) represent the first attempt to reverse the hypogonadic status of the male gonads. Clinically Evaluative Male Factor Restoration and Improvement and Social Economy Benefits are described comparing and addressing Human Reproduction and Family Welfare Policies in Western and Asian Countries.

**OP2-914**

**MODIFYING THE CAESAREAN, SEVEN YEARS ON**

**Chris Tsitlakidis**

**Obstetrics and Gynaecology, Pinderfields Hospital, MidYorkshire NHS Trust, Wakefield, UK**

**Dr Christos Tsitlakidis, Consultant Obs and Gynae, Pinderfields Hospital, MidYorkshire NHS Trust, UK**

**Problem statement:** Caesarean carries the legacy of an Emperor. It is the procedure that more than any other complicated by bleeding and infection. Modifying the procedure in several areas came out of necessity to respond to new challenges that appear over last decades. Are we learning as fast as Midwifery changing, we should move to Modern Obstetrics, supporting ideas old and new ones, till we find those that work. **Methods:** Retraction tapes. Large intrabdominal packs. A stage stitch onto the middle of lower segment. . Use of suction to drain amniotic fluid. Opening lower segment high and cutting slightly upwards laterally. Fetal pillow to disaggregation head. Kiwi cup for high or low head. Natural birth simulation and delay in delivery through tight incisions. Invite parental couple to observe, delivery straight to mother, delay cord clamp. Repair of lower segment in one of four appropriate ways, one applies additional compression, turnover to lower segment. Cleaning scar with normal saline and vaginal toilet with antiseptic. **Results:** The need for assistance was minimised. The procedure remained clean and dry. Bleeding was eliminated. The surgeon operated in a controlled and calm environment. Natural birth simulation achieved and resulted in an excellent parental perception. The risk of post natal infection was eradicated. **Conclusion:** Caesarean still remains a ferocious procedure that can claim lives The Modified version applied in 500 women who underwent elective and emergency procedures over last 7 years with excellent results. Should we do not recognize the challenges from a changing world, the furies could become the Nemesis of our practise. Key words: Modified Caesarean, post partum haemorrhage, Natural Birth Simulation, Revive Caesarean. Disclosure: No conflict of interest.

**Professional Biography**

Dr Christos Tsitlakidis has graduated from Hellenic Aristotle University School of Medicine. He is a Consultant Obstetrician and Gynaecologist in Pinderfields Hospital, MidYorkshire NHS Trust, United Kingdom. He has published more than 6 papers in reputed journals in UK and abroad and has been member of the ROCG. email: ctsitlakidis@yahoo.co.uk

**OP2-1001**

**DETERMINATION OF SERUM ENDOCAN LEVELS WHICH IS INFLAMMATORY MARKER IN PATIENTS WITH PREMATURITY OVARIAN FAILURE**

**Mellek Guler**

**Nafiye Yılmaz, Mahmut Kuntay Kokanalı, Vehbi Topçu**

**Gynecology, Dr. Zekai Tahir Burak Women’s Health Education and Research Hospital, Ankara, Turkey**

**Problem statement:** The aim of this study is to be establish endocan/ESM-1 (endothelial cell-specific molecule-1) which is a new inflammatory marker levels in idiopathic premature ovarian failure (POF) cases and reveal the relation between endocan and inflammatory process that is regarded as playing a role in etiology of this disease. **Methods:** This study was performed as a prospective case control study and approved by the Local Ethical Committee of the institution. The study group consisted of 34 women diagnosed with POF had a 46.XX karyotype and the control group consisted of 34 healthy women with normal fertility. Patients who had systemic and endocrine pathology and patients with BMI 30 were excluded from the study. Serum samples were taken from all participants and endocan levels were measured using ELISA method. **Results:** Patients with premature ovarian failure and healthy volunteers were matched for age, BMI, smoking rates to control group (p=0.05). Serum endocan level was significantly higher in POF group than control group.
(p=0.04) (114.94 pg/mL vs. 97.22 pg/mL). In study group endocan level was determined as 124.34 pg/mL. **Conclusions:** In most cases of premature ovarian failure the cause remains a mystery however the etiology of POF which is thought to be associated with ovarian inflammation and autoimmunity. As a result of our study, elevated serum endocan levels in the POF group support the presence of chronic inflammation and autoimmunity in etiology. We expect that serum endocan level is thought to be helpful in the diagnosis of POF and may be a guide for future studies. A larger number of studies are needed to understand how inflammatory processes play a role in the etiology of POF and to understand the mechanism of increased endocan levels.

OP2-1002

**A RARE CASE OF OVARIAN METASTASIS OF ESTHESIOEUSROBLASTOMA, A SINONASAL CAVITY MALIGNANCY: A CASE REPORT**

Maria Margarita Franchesca Lojo, Glaiza De Guzman, Valerie Quinto

Department of Obstetrics and Gynecology, Philippine General Hospital, Manila, Philippines

**Problem/objective:** To report a case of ovarian metastasis of esthesioneuroblastoma. **Methods:** Design. Case report. Setting. Tertiary training hospital. **Patient** A diagnosed case of esthesioneuroblastoma who presented with an acute abdomen three years after treatment of the primary tumor. **Intervention:** The patient underwent total abdominal hysterectomy with bilateral salpingo-oophorectomy and total staging operation for a postoperative diagnosis of ovarian new growth, probably malignant. **Main Outcome Measures:** Diagnosis of the ovarian metastasis through high index of suspicion, thorough clinical assessment, imaging through ultrasound, proper surgical operation and histologic examination. **Results:** Histologic examination confirmed the diagnosis of metastatic esthesioneuroblastoma to the ovary. Postoperatively, the patient tolerated the procedure well with resolution of abdominal symptoms. Due to the distant spread of the primary tumor, the disease was very aggressive and eventually recurred in the primary site. The patient eventually succumbed to the complications of the disease. **Conclusion:** Due to the rarity, unusual spread and aggressive character of esthesioneuroblastoma, a high index of suspicion should be made in all patients diagnosed with this disease. As of writing, there has only been one similar case report of ovarian metastasis of esthesioneuroblastoma. This is the first case report of metastatic esthesioneuroblastoma to the ovary in the Philippines.

OP2-1003

**EPIDERMOID CLITORAL CYST: A RARE CASE OF CLITOROMEGALY**

Matilde Martins, Sara Cunha, Inês Reis, Mak Foo, António Lanhoso, Cristina Costa, Teresa Teles

Department of Gynaecology and Obstetrics, Entre o Douro e Vouga Hospital Centre, Santa Maria da Feira, Portugal

**Problem statement:** Epidermoid cysts are slowly growing tumors that arise due to invagination of epidermis into dermis either spontaneously (rare) or following trauma caused by genital mutilation. While common locations are the face, scalp, neck and trunk, epidermoid cysts are rare on the clitoris, especially with no history of previous trauma. It is one of the rare causes of non-hormonal acquired clitoromegaly. Surgical removal of the cyst is the preferred treatment. Preserving the vasculature and nerve supply is of utmost importance in preserving sexual health. **Methods:** We performed a retrospective clinical case review. **Results:** 22-year-old healthy and sexually active woman was referred to our hospital with a 3-year history of painless and gradual clitoral enlargement. No trauma history. The physical examination showed a mobile, soft, non-fluctuant mass with 3 cm arising from the superior aspect of the clitoral region and covered by the clitoral hood. The remainder of the external genitalia and surrounding structures were normal. There were no virilizing signs and a complete hormonal evaluation showed no endocrinopathy. Soft tissue ultrasound showed a hyper echo homogenous lesion with 36x21mm suggestive of lipoma. Surgical intervention was undertaken and complete excision of cyst was achieved with preservation of the neurovascular bundle. There were no postoperative complications or scarring. Patient was discharged 6-hours after surgery. Histopathologic examination reported a 20 mm epidermoid cyst. At 2 months follow-up, the physical exam showed no residual cyst and intact clitoral anatomy. Sexual sensation was preserved. **Conclusion:** When clitoral hypertrophy is encountered, endocrinological causes should be ruled out in the first step. Subsequent malignant or benign clitoral lesions should be considered, such as epidermoid clitoral cysts. The major surgical goals include preservation of sensory function for future sexual health and restoration of normal anatomy. This can be achieved by preservation of the neurovascular bundle during dissection. Preoperative magnetic resonance imaging evaluation can help the surgeon conceptualize the anatomy and prevent neurovascular damage. **No conflict of interest to declare.**

OP2-1004

**SURGICAL OR MEDICAL TREATMENT FOR ECTOPIC PREGNANCY IN UNUSUAL LOCATIONS? THAT IS THE QUESTION**

Mahmoud Rahimi

Gynaecology, Chatswood Medical Center, Sydney, Australia

**Problem statement:** The most common case of Maternal Mortality and Morbidity in early weeks and months of pregnancy is due to Ectopic Pregnancy (EP). The incidence of EP has increased to 2 percent in recent decades. **Methods:** Sophisticated diagnostic tools for detecting EP in early stage, such as ultrasound, laparoscopy, and sensitive beta HCG test are the main factors in increasing the incidence of EP. But close to half of these chemically diagnosed EPs will settle by themselves later. Other factors that should be counted as the causes for the increased incidence of EP are; PID, previous EP, pelvic or tubal surgeries, pelvic adhesions, IVF. **Results:** Tubal Ampulla is the most common location for EP (Tubal Pregnancy). Any other location for EP is called unusual locations, even if it is a section of the fallopian tube i.e., interstitial or the fimbriae section of the tube. Other unusual locations are: cervix, abdominal cavity (Abdominal Pregnancy), or other organs (such as ovaries). **Conclusions:** Because of rarities of EP in unusual locations, young gynaecologists who might have less experience in treating these types of EPs would benefit from the more experienced colleagues and pioneer experts regarding how to approach and treat EPs in unusual locations in emergency and non-emergency cases. The author with close to 45-years experience in Obstetrics and Gynaecology working at big public and teaching hospitals in 3 different countries (developing & developed) had opportunity to treat hundreds of EPs in usual locations and few EPs in unusual locations as well as one term abdominal pregnancies, and to follow them up for a long period (in one case 10 years follow-up). The author has published and presented case reports of EPs in unusual locations at world congresses and AAGL journal. He will share his knowledge of this field with attendees at COGI 2019 in Paris.
OP2-1005
HYSTEROSCOPIC REPAIR OF CESAREAN SCAR DEFECT IN WOMEN WITH ABNORMAL UTERINE BLEEDING: A PROSPECTIVE STUDY

Nguyen Ha1, Thuy Nguyen2, Tri Nguyen2, Huynh Do2, Anh Nguyen2
1Department of Assisted Reproductive Technology and Andrology, Hanoi Obstetrics and Gynecology Hospital, Hanoi, Vietnam
2Department of Surgical Gynecology, Hanoi Obstetrics and Gynecology Hospital, Hanoi, Vietnam

Introduction: A Cesarean scar defect, also called an isthmocele, is one of the consequences of Cesarean section that may cause postmenstrual spotting and therefore, affects the quality of life. Objectives: To determine the safety and effectiveness of hysteroscopic repair of isthmocele to treat postmenstrual spotting. Methods: 34 patients with abnormal uterine bleeding who had an isthmocele with a residual myometrium of ≥3mm (measured during transvaginal ultrasound) were performed hysteroscopic repair of isthmocele using a step-wise approach: identification of relevant anatomy; resection of the cephalad edge of fibrosis; resection of the caudal edge of fibrosis; and ablation of the isthmocele base. Complications of surgery were observed and the symptoms of postmenstrual spotting were monitored for 6 months afterwards. Results: No complications of surgery such as bleeding, uterine perforation, infection were noted. 19 (55.9%) patients had resolution of their symptoms. Among the remaining cases, 9 (26.5%) patients had an improvement of symptoms with decreasing duration of postmenstrual spotting from 8.1 ±1.7 days to 4.3 ± 0.5 days (P = 0.05), whereas 6 (17.6%) patients did not obtain any relief. Conclusions: Our data supports that hysteroscopic isthmoplasty is safe and effective in treating isthmocele-related abnormal uterine bleeding.

OP2-1006
RUSSIAN FIRST HPV PRIMARY SCREENING PROGRAM IN THE REPUBLIC OF BASHKORTOSTAN IN ACTION

Ilya Olkov1, Ildar Minniakhmetov2, Rita Husainova2, Manna Melnikova2
1Health Care Department, Social Programs Development Foundation, Moscow, Russia
2Medical Genetics, Laboratory, Obstetrics and Gynecology Departments, Republican Medical Genetic Centre, Ufa, Russia

Problem statement: In the Republic of Bashkortostan more than 373 women a year develop cervical cancer and about 46% of this women die. Russian First HPV Primary Screening Program was initiated in April 2019 according to latest WHO, IARC and Russian Ministry of Health recommendations. 30,000 women of 30-39 years old were enrolled into screening program to be done within one year. This age group was chosen due to highest mortality rate. Samples were collected for HPV and cytology at same day of postmenstrual spotting. Experimental analysis with randomized post-test only control group at Airlangga University in February 2018-January 2019 using Mus musculus divided into 4 groups with total sample 32 (K1: placebo; K2: endometriosis; K3: LPS; K4: endometriosis+ LPS). Immunohistochemical examination to determine BDNF expression and HE staining to count glia cells. Results: Glia cells was significantly higher on K2 (7.0 ± 2.26), K3 (6.63 ± 1.68), and K4 (9.0 ± 1.6) compared to K1 (3.63 ±1.18), K2 higher than K3, K4 higher than K2 and K3, while BDNF expression significantly higher on K2 (9.38 ± 2.33), K3 (8.13 + 2.1), and K4 (11.25 ± 2.12) compared to K1 (5.5 ± 2.27), K2 higher than K3, K4 higher than K2 while K4 higher than K3. Conclusion: Glia cells number and BDNF expression in endometriosis models, LPS exposure, and endometriosis models given higher exposure to LPS than placebo. Glia cells and BDNF expression in the endometriosis given LPS was higher than endometriosis and LPS only. Keywords: Endometriosis, Glia Cells, BDNF, Lipopolysaccharide (LPS)

OP2-1008
SURGICAL OR NON-SURGICAL TREATMENT OF UTERINE FIBROIDS? THAT’S THE QUESTION

Mahmoud Rahimi
Gynecology, Chatswood Medical Center, Chatswood, Sydney, Australia

Problem statement: Uterine Artery Embolization (UAE) has been used primarily in the treatment of postpartum hemorrhage since the 1980s. In 1995 Jacques Henri Revina et al from France published their first results with a new application of UAE for treatment of symptomatic myoma. Their results were promising. Five years later in year 2000 they reported 12-cases of pregnancy after UAE of uterine myoma which was published in Fertility Sterility 2000, 73:1241-3. They claimed the results were promising. They believed it could be a major breakthrough in the management of myoma and could replace conventional medical and surgical treatments. Methods: Since these publications the application of UAE has increased not only in France but in medical centers all over the world where there are international radiologists and have facilities to perform this technique. Results: Nowadays international radiologists are using MRgFUS which uses Resonance Guided Focused Ultrasound as well as a minimally invasive non-surgical treatment for management of uterine myomas avoiding surgery and conserving the uterus to preserve patients’ future fertility. Conclusion: Controversies exist between gynecologists and interventional radiologists. Gynecologists who are expert in advanced laparoscopy surgery believe the gold standard treatment of uterine fibroids is laparoscopy myomectomy which
is a minimally invasive surgery. There are advantages and disadvantages in each mode of treatment. This will be the subject of discussion at the presentation of this paper at the 2019 COGI Congress Paris.

OP2-1009
INFERTILE PCOS PATIENTS TREATMENT WITH OPTIMAL RESULTS AND DECREASE THE RATE OF OHSS
Athar Rasekh Jahromi1, Mahbod Ebrahimi2, Mohammadadi Nasser Jahromi3
1Obstetrics and Gynecology, Jahrom University of medical sciences, Jahrom, Iran
2Obstetrics and Gynecology, Tehran University of medical sciences, Jahrom, Iran
3Economy, Shiraz Azad University, Jahrom, Iran

Problem statement: Polycystic ovary syndrome (PCOS) is one of the most common endocrinopathies affecting women in the reproductive age group, and is one of the most common causes of ovarian hyperstimulation syndrome (OHSS) in infertile patients. The aim of this study was decreased OHSS due to induction of ovulation with clomiphene citrate and then letrozole in comparison of letrozole and cabergolin and an optimal pregnancy rate. Material and methods: This is prospective clinical research from Dr.Rasekh infertility clinic,jahrom city, Iran. 64 infertile polycystic ovarian syndrome women were selected with 47 months infertility. The average age of them is 27.3 years (STD=5). The patients were divided into two groups: Group A; 36 patients (40%); initially tablet clomiphene citrate (from day 3 of menstrual cycle), then the second drug Letrozole was started from day 8 to 11 menstrual cycle. Group B; 28 patients (31.1%); initially tablet Letrozole (from day 3 of menstrual cycle), then the second drug cabergolin started from day 8 to 11 menstrual cycle. Pregnancy rate in group A, 8 (22%) and in group B; 6(21%). The patients were monitored for ovulation by transvaginal ultrasonographic folliculometry, with measurement of number and size of the follicles, as well as endometrial thickness. Human chorionic gonadotrophin (HCG) was injected intramuscularly when at least one mature follicle 18-22 mm diameter. Data was analyzed with SPSS version 21. Results: The rate of OHSS was similar in both groups nearly zero (p0.05). This means that both methods of treatment is minimal side effects with optimal result. Whilst in both methods has been favorite fertility rate. The goal of treatment which one of the two mentioned methods is to be used.

OP2-1010
DETERMINING THE RELATIONSHIP BETWEEN MARRIED WOMEN’S ATTITUDES TOWARDS FERTILITY AND FAMILY PLANNING AND THEIR INTENTION TO USE CONTRACEPTIVE METHODS AND AFFECTING FACTORS
Orsman Oner1, Asil Sis Celik1
1Department of Obstetrics and Gynecology Nursing, Ataturk University, Graduate School of Health Sciences, Erzurum, Turkey

Problem statement: The aim of this study is to determine the attitudes of married women towards fertility and family planning, their intention to use contraceptive methods, the affecting factors and the relationship between them. Methods: This descriptive and cross-sectional study was conducted between April 10, 2018 and July 22, 2019, in Family Health Centers located in the central districts of Ipekolu, Tusba and Edremit of Van Provincial Health Directorate. The sample size of the study was calculated according to the sampling formula used in cases where the number of people in the universe is known and it was understood that 598 people should be reached. In determining the sample; stratified sampling method was used for the number of people to be taken from family health centers. 610 women who applied to the relevant Family Health Centers between March 1 and April 30, 2019 and met the criteria for inclusion, were included in the study by simple random sampling method. In the data collection, “Personal Information Form”, “Women’s Fertility Attitude Scale”, “Family Planning Attitude Scale” and “Contraceptive Intention Scale” were used. Results: There was a statistically significant negative correlation between the total score means of the Women’s Fertility Attitude Scale and the Family Planning Attitude Scale and Contraceptive Intention Scale (0.260.4, p<0.01). On the other hand, it was determined that there was a weakly statistically significant positive correlation between the total score means of the Family Planning Attitude Scale and Contraceptive Intention Scale (0.260.4, p=0.01). According to some demographic and obstetric characteristics of women, the difference between the total score means of Fertility Attitude Scale, Family Planning Attitude Scale and Contraceptive Intention Scale were found to be statistically significant (p<0.05). Conclusion: As the positive attitudes of women towards fertility increased, their intention to use contraceptive methods decreased. As positive attitudes towards family planning increased, their intention to use contraceptive methods increased. Some demographic and obstetric characteristics of women affected their attitudes towards fertility and family planning and their intention to use contraceptive methods.

OP2-1011
POSTPARTUM SEXUAL DYSFUNCTION - A PROSPECTIVE STUDY
Diana Natacha Sousa1, Ana Catarina Borges1, Rita Sarabando1, Bárbara Ribeiro1, Leonor Bivar1, Ana Catarina Vieira1, Joana Igrela1, Alexandra Miranda2-3, Paula Barboza2, Margarida Queiruz2, Isabel Reis2, Cristina Nogueira-Silva2
1Gynecology/Obstetrics, Hospital De Braga, Braga, Portugal
2Gynecology/obstetrics, Escola De Medicina - Universidade Do Minho, Portugal
3Gynecology/obstetrics, IVCS/36’S, Portugal

Problem statement: Childbirth brings important changes to the general and sexual health of women. Some studies identified operative vaginal delivery (OVD) and perineal tears as risk factors for postpartum sexual dysfunction (SD). The aim of this study was to evaluate women’s postpartum sexual function and factors associated with SD. Methods: Observational prospective cohort study (MOODS: Maternal-neonatal Outcomes in Operative Vaginal Delivery Study) in Braga's Hospital, Portugal, since February to August, 2018, including women who had a vaginal delivery (operative and spontaneous vaginal delivery in a relation 2:1). Women were invited to answer the Female Sexual Function Index (FSFI) questionnaire, at 3 months and 1 year postpartum. SD was defined by FSFI score 26.55. Women who did not answer both questionnaires and did not resume sexual activity were excluded. Results: From 272 initially recruited women, 76 met the inclusion criteria. Mean age was 30.9±3.8 years and mostly were nulliparous (n=57.8%). The mode of delivery was spontaneous in 26 (34.7%) and OVD in 50 (65.3%) (Thierry’s spatus in 26 (52.0%); Kitz vacuum in 24 (48.0%).) An episiotomy was performed in 64 (85.3%) of the deliveries and 26 (34.0%) had some degree of perineal tear (1 case of grade III laceration). About 19% (n=14) of women had complications (dehiscence/infection) of the perineal sutures. Mean FSFI score at 3 months was 20.7±8.8 with 70% classified with SD and at 1 year follow-up the mean FSFI-score was 27.3±5.17 with 32 (42.7%) women with SD. At 3 months SD was significantly more frequent in women with history of OVD (p<0.001), episiotomy (p=0.012) and perineal tears ≥ grade II (p=0.016). At 1 year postpartum these differences were no longer observed, as the other evaluated factors (parity, type of injury, postpartum pain and complications). Conclusions: SD affects a great proportion of women after delivery and in early postpartum months the mode of delivery and perineal tears seem to play an important role. Although there was a reduction in frequency, prevalence of SD was still considerable (42%) at 1 year postpartum Nonetheless, no delivery factors evaluated seemed to influence this condition.
POSTER ABSTRACTS

ART/IVF

P001
HETEROTOPIC PREGNANCY AFTER INTRACYTOPLASMIC SPERM INJECTION: WHEN IDENTIFYING AN INTRAUTERINE PREGNANCY IS NOT ENOUGH
Carolina Costa Gomes, Sara Cunha, Flávia Vicente, Ana Paula Valentim, Luís Filipe Peixoto, Ana Casquilho
Departamento de Ginecologia, Obstetrícia e Reprodução Humana, Centro Hospitalar Universitário do Algarve, Faro, Portugal

Problem statement: Heterotopic pregnancy is a rare condition, consisting on simultaneous pregnancies in two implantation sites, mainly one intrauterine and one ectopic site. It is a potentially dangerous condition occurring in only 1 in 30,000 spontaneous pregnancies. Although rare in healthy general population, its incidence increases in women undergoing fertility treatments and those with risk factors for ectopic pregnancy. Therefore, with the introduction of Assisted Reproductive Techniques (ART), its overall incidence has risen. It is a difficult diagnosis to establish, as the identification of an intrauterine evolving pregnancy may tranquilize physicians and obviate further investigation, making diagnosis usually late and at an emergency setting. Methods: We present a case report and literature review. Case Report: A 28 year-old woman, undergoing ART for primary infertility (male factor), was submitted to ovulation induction and later intra-cytoplasmatic sperm injection and transference of two frozen embryos. She was admitted to the emergency department for pelvic pain, more intense at the right iliac fossa (RIF), with nausea. On physical examination, she demonstrated mucocutaneous pallor and pain at RIF compression, without peritoneal irritation signs. Serum levels of human chorionic gonadotrophin (hCG) were 13.000 mUI/mL. Transvaginal ultrasound revealed an intrauterine gestational sac with 15 mm and a vitelin vesicle, no embryo visible. Further sonographic examination demonstrated a right adnexal mass, with 13.4 mm and peripheral flow on color Doppler, suggestive of right tubal ectopic pregnancy. Explorative laparoscopy further supported heterotopic pregnancy diagnosis, with hemoperitoneum and a right fallopian tube mass, compatible with tubal pregnancy. Laparoscopic salpingectomy was performed, and the material sent to anatomical pathology examination. To our knowledge, at the time being, the intrauterine pregnancy is evolving.

Conclusion: In light of the growing ART and consequent increase in heterotopic pregnancy risk, all physicians should be aware of this diagnosis. A high index of suspicion is needed, and confirming an intrauterine pregnancy should not be enough to exclude a co-existing pregnancy. Timely diagnosis is imperative in order to result in less maternal morbidity and better obstetric outcomes.

P002
OVARIAN AND ENDOMETRIUM PLATELET-RICH PLASMA (PRP) THERAPY IN REPRODUCTIVE MEDICINE
Giovanni Menaldo, Alessia Giovannelli, Chiara Conti
Unità di Procreazione Assistita, Centro Clinico San Carlo di Torino, Torino, Italy

Platelet rich plasma (PRP) has been previously used with some success in various non-reproductive medical contexts because its relevant tissue regeneration processes. In this study we extended PRP application to reproductive medicine to overcome problem of patients with low (or absent) ovarian reserve and patients who cannot obtain adequate endometrial thickness for successful embryo transfer. In this study we evaluated the effectiveness of ovarian PRP injection, in order to rejuvenate and reactivate ovaries with the ultimate goal of indicating a possible correlation between this mode of treatment and reproductive effect in women with diminished ovarian reserve as determined by at least one prior IVF cycle canceled for poor follicular recruitment response. PRP application in endometrium has also been associated with increased progesterone receptor activity. Progesterone receptors are the main actors that help maintain a thick and healthy endometrial lining, which in turn, helps with embryo implantation. We have started offering ovarian and endometrium PRP applications for 122 patients between 32 and 47 years old: IVF failures, poor oocyte yields and POF (Premature Ovarian Failure) and patients who cannot obtain an adequate endometrial thickness. Ovarian PRP is programmed in 8-10 day of menstrual cycle while endometrial PRP application is administered approximately 48-96 h before embryo transfer. PRP was prepared from autologous blood using RegenACR kit according to manufacturer’s instructions and subsequently 1 cc of PRP was infused on ovaries using a thin needle under transvaginal ultrasound guidance and/or infused on the endometrium using Gynetics catheter. To verify action of this treatment we attach importance to presence of dominant follicle in 8-10 day of cycle; we also check the hormonal profile of FSH and E2 in 3rd day of menstrual cycle; after application of PRP, the endometrial thickness was satisfactory in all patients (8 mm), with endometrial three-layer pattern. The results of ovarian PRP are promising because 36% of these patients with previous IVF failures achieved pregnancy (41 women). In our experience, PRP treatments seems to have an important regenerative function. These results translates into several pregnancies, registered in all women with previous IVF failures who have never had a pregnancy before.

P003
ENDOMETRIAL THICKNESS AS A DETERMINANT OF FROZEN EMBRYO TRANSFER OUTCOMES
Bethany Goulson
Reproductive Medicine Department, Cambridge University Hospitals, UK

Problem statement: Frozen embryo transfer (FET) is an increasingly popular method of assisted reproductive technology (ART) due to advances in cryopreservation and more favourable outcomes when compared to fresh embryo transfer (ET). Endometrial thickness (EMT) has previously been investigated as a determinant of pregnancy rates following ART, with many studies suggesting unfavourable outcomes below a threshold of 7 -8mm. However, there are limited studies investigating the role of EMT in FET cycles specifically. Hence, here we determine the relationship between EMT and outcomes following FET. Methods: Data was retrospectively analysed from FET cycles at a single-centre over a one-year period. Seventy-five patients matched the inclusion criteria. Patients underwent a mix of GnRH agonist, GnRH antagonist and natural cycle protocols. Embryos were frozen on day 5 of development and EMT was assessed prior to implantation by transvaginal ultrasound. The relationship between EMT was compared to subsequent pregnancy rates, defined by a positive beta-HCG test result. Statistical analysis was performed via
ANOVA, with results of p<0.05 deemed to be significant. Results: The overall pregnancy rate following FET cycles was 47.3%. EMT ranged from 6.2 to 16mm, with an EMT mean of 9.4mm and median of 8.9mm. One-way ANOVA showed that EMT did not influence pregnancy outcomes (p=0.982). Two-way ANOVA demonstrated that factors including age of the patient (range 23 – 45 years old), size of ovarian follicles prior to oocyte retrieval (range 10 - 21mm) or stimulation protocol used also did not influence pregnancy rates significantly (p=0.432, p=0.472, p=0.791 respectively). Using both ≤7 or ≤8mm as a 'suboptimal' EMT threshold (as commonly used in the literature), there were no differences in outcomes between groups (p=0.56 and p=0.75 respectively). Conclusion: EMT does not influence FET pregnancy outcomes. Other factors frequently considered in ART such as age of the patient, size of ovarian follicles and stimulation protocol used also do not influence the relationship between EMT and FET outcomes. Further, there does not appear to be a minimum EMT below which pregnancy outcomes are undesirable. Therefore, this study concludes that EMT is not a useful clinical indicator of FET outcomes.

P004 
EXPOSURE TO PROPYL GALLATE HAMPER CALCIUM HOEMOSTASIS AND INDUCED MITOCHONDRIA DYSFUNCTION OF TESTIS, LEADING TO MALE INFERTILITY 
Jiyeon Ham1, Wonhyoung Park2, Hahyun Park1, Hyoched Bae1, Whasun Lim2, Gwonhwa Song1
1Department of Biotechnology, Korea University, Seoul, South Korea
2Department of Food and Nutrition, College of Science and Technology, Kookmin University, Seoul, South Korea

Problem statement: Propyl gallate (propyl 3,4,5-trihydroxybenzoate, PG), as one of synthetic phenolic antioxidants (SPAs), has been used for oil-containing foods to prevent acidification. In addition, its usage is widely extended to hair product, cosmetics and even anti-cancer agents. However, there are still concerns about PG as a possible reproductive toxicant. In our previous study, we already confirmed the cytotoxic effect of PG on human trophoblast cells which could involve in abnormal pregnancy. Plus, the function of PG as an estrogen antagonist was reported. Still, studies of PG on male reproductive toxicity are rare. Therefore, we determined whether PG induced male infertility, especially focused on testis. Methods: We used mouse testis cell lines (Leydig cells and Sertoli cells) to conduct various experiments about proliferation, cell cycle, mitochondrial function and calcium homeostasis which are crucial for testis. Further, we performed western blot analysis focused on endoplasmic reticulum (ER) stress, MAPK and PI3K/Akt signaling cascades. After that, using both cell lines and mouse testis tissue which treated PG about 4 weeks, we verified changes of mRNA expression about testicular function-related genes. Further, those mRNA expressions were confirmed in mouse testis tissue via In situ hybridization. Results: Our results revealed that PG induced testicular dysfunction in both Leydig and Sertoli cells through suppression of cell viability and steroidogenesis. These normal testis functions were destroyed by PG-induced mitochondrial dysfunction and calcium homeostasis dysregulation. Plus, PG dysregulated the expression of several genes related to function of testis and induced ER stress. In addition, we confirmed PG-induced mRNA expression changes about steroidogenic enzymes and hormone receptors in both cell lines and tissues. Further, based on the results of the qPCR analysis, we further confirmed PG-induced suppression of the mRNA expression of genes about testis functions by in situ hybridization. Conclusion: We demonstrated that PG induced testicular toxicity via hampering of mitochondrial or ER function and suppression of testicular function-related genes in mice. Interest: synthetic phenolic antioxidants, steroidogenesis, male infertility, ER stress, calcium homeostasis

P005 
FUNCTION OF LIN28A/WNT/B-CATENIN IN REGULATING PREMATURE OVARIAN FAILURE 
Jing Chen, Weimin Liu, Kai Fai Lee, Shu Blu Yeung
Obstetrics and Gynaecology, The University of Hong Kong, Hong Kong China

Problem statement: Infertility is a prevalence of disease that besets 15% of couples in childbearing age around the world. Premature ovarian failure (POF), defined as primary ovarian defect and characterized as cessation of menstruation or absent function of ovarian follicles in women under the age of 40, accounts for approximately 1% of infertility disease in women at childbearing age. The study on the specific mechanism of how premature ovarian failure occurs remained further exploration. Lin28 which contains two isoforms lin28a and lin28b, is mRNA binding protein and highly expressed in embryogenesis. In this study, we aim to investigate the function of lin28a in regulating premature ovarian failure. Methods: ICR female mice and Lin28a transgenic mice were used as mouse model. Immunohistochemical staining, western immunoblotting and qPCR were applied in this experiment. Results: The fertility rate of four-month old Lin28a transgenic mice was significantly reduced compared with wild type. The superovulation result by pregnant mare’s serum gonadotropin (PMSG) also showed that ovum secretion of lin28a transgenic mice was also markedly decreased. Besides, primordial follicular amounts were significantly declined, while secondary follicles were markedly increased in 4-month old lin28a transgenic mice compare with wild type. Akt/mTOR pathway was activated in lin28a transgenic mice. The expression of β-catenin, which is the downstream molecule of wnt signaling pathway, was significantly enhanced in the ovary of lin28a transgenic mice. Suppression wnt signaling pathway could inhibit Akt signaling activity. Conclusions: Overexpression of lin28a in oocyte can enhanced the activity of Akt/mTOR via upregulating wnt/β-catenin pathway, which may play a role in regulating premature ovarian failure.

P006 
THE ASSOCIATION BETWEEN PROGESTERONE LEVELS ON THE DAY OF OOCYTE MATURATION DAY AND SYSTEMIC INFAMMOTORY MARKERS OF COMPLETE BLOOD COUNT FOR FRESH IN VITRO FERTILIZATION CYCLES 
Jieun Kang, Yeon Soo Jung
Department of Obstetrics and Gynecology, Wonju Severance Christian Hospital, Yonsei University College of Medicine, Wonju, South Korea

Problem statement: In recent studies, it has been found that increased progesterone level on oocyte maturation day affect the quality of embryo and the endometrial receptivity. In addition, systemic inflammatory markers (neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR)) are also thought to affect premature ovarian failure or endometriosis. We evaluate the association between systemic inflammatory markers and increased progesterone levels on the day of maturation and
compare the outcome in fresh IVF cycles. **Methods:** A total of 307 women were included in this retrospective study, undergoing IVF procedures. Serum progesterone level on the day of human chorionic gonadotropin (hCG) trigger and Complete blood counts (neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR)) were analyzed. **Results:** 21 Patients showed increased serum progesterone level(1.5 ng/ml) on the day of hCG. Neutrophil count, Lymphocyte count were significantly correlated with progesterone levels on the day of hCG (P = 0.009, P = 0.001). NLR, PLR were not significantly different between patients with increased serum progesterone level(P = 0.470, P = 0.823). **Conclusion:** Neutrophil, Lymphocyte may have impact on increased serum progesterone level, whereas NLR and PLR do not seem to be valuable markers associated with increased progesterone level. Disclosure of Interest: Authors have no conflict of interests.

**P007**

**USE OF FOLLITROPIN DELTA IN CONTROLLED OVARIAN STIMULATION FOR IN VITRO FERTILIZATION IN HIGH RESPONDER PATIENTS: CASE-CONTROL STUDY**

Maria Carrera, Laura De La Fuente, Laura Marqueta, Magdalena Abad, Elisa Escalante, Nerea Ruiz, Alicia Vázquez, Pilar Moreno

**Methods:** We aim to explore the use of Follitropin Delta in controlled ovarian stimulation for In Vitro Fertilization (IVF) in high responder patients and compare it to Follitropin alfa, beta and biosimilar FSH preparations in terms of efficacy and security. **Methods:** Observational case-control study including first or second IVF cycles in high responder patients. For each Follitropin Delta patient included in the study, a matched control by age, weight, Antral Follicle Count (AFC) and Antibüllerman Hormone (AMH) level was also included. We retrospectively recorded all first or second high responder patients IVF cycles stimulated with Follitropin Delta from June of 2018 until March of 2019. High response criteria included: AMH ≥3.5 ng/ml, AFC ≥20 or high response on previous cycle. Basal characteristics included: age, weight, Body Mass Index (BMI), Follicle Stimulating Hormone (FSH), AMH, AFC, number of previous IVF cycles, indication for IVF and previous gestations. All cycle, efficacy and safety variables were recorded. **Results:** No differences were found among basal characteristics between the two groups. No significant differences were found between the two groups in terms of stimulation number, number of follicles the day of hCG, total and MII oocytes or cleavage stage embryos. No differences were found in terms of percentage of patients who needed GnRH agonist trigger or could not go to fresh embryo transfer. Mean number of good quality embryos was similar in both groups. Among the 71 patients who had embryos either fresh or frozen, cumulative pregnancy rates were 52.11%. No difference were found between the two groups, 51.4% of pregnancies in Follitropin Delta and 48.9% in the rest of follitropins group (p=0.33). **Conclusion:** Follitropin delta is an efficacious and safe option for controlled ovarian stimulation for IVF in high responder patients. The results of the study must be taken with caution due to the small sample size. Larger prospective studies in this particular subgroup of patients are needed.

**P008**

**EFFICACY OF ICSI IN OVERCOMING FERTILITY PROBLEMS IN MEN WITH AUTO IMMUNE REACTIVITY TO SPERM (ANTI SPERM ANTIBODY: ASA)**

Maryam Dashki

**Molecular Medicine, College of Medicine and Medical Sciences, Arabian Gulf University, Manama, Bahrain**

**Problem statement:** The aim of this study was to evaluate the efficacy of the technique of Intra-Cytoplasmic Sperm Injection (ICSI) in the treatment of infertile couples due to presence of Anti-Sperm Antibodies (ASA) in seminal fluid. **Methods:** This study illustrates a retrospective analysis of clinical and laboratory data from a ten year-period ICSI cycles. The prevalence of ASA was assessed in 1500 males attending IVF clinics in Bahrain over a period of 10 years. Majority of patients in the study were of 30-49 years age group with an average of 39± 9. The initial detection of sperm autoantibodies was made by visual microscopic observation of clumped spermatozoa associated with motility restriction and by mixed agglutinin reaction (MAR-IgG) test. The titre of ASA was determined by more laborious Tray Agglutination Test (TAT) using Terazaki plate, donor normal sperm and patient serum. Couples with male partner showing Azospermia/ severe Oligozoospermia or having a female fertility problem were excluded in this study. All female partners were found to have a normal hormonal profile. **Results:** 720 patients were selected as per inclusion criteria to proceed for treatment with ICSI. The hormonal profile of all patients were compared on admission without any significant difference. Anti -Sperm Antibodies were suspected in 96 primary infertility patients showing Normozoospermia (13.33%) and 24 secondary infertility patients showing Oligozoospermia due to reversed earlier vasectomy (3.33%). Confirmatory TAT results showed a minimum serum antibody titre at a dilution of 1/256 in primary infertility group and 1/512 in the secondary infertility group (p=0.001). In this study, ICSI outcomes in men exhibiting different levels ASA were similar to those of patients with normal semen parameters who had no sperm autoimmune reaction. The differences in Fertilization rate, cleavage rate, D5 blastocyst formation, as well as clinical pregnancy and miscarriage rates were not significant among all study groups. **Conclusion:** Our data indicates that ICSI is efficient in overcoming fertility problems encountered in men with sperm auto-antibodies. Presence of ASA in semen does not affect the outcomes of ICSI. Key words: ASA, MAR, IVF, ICSI. Disclosure: No conflict of interest

**P009**

**ENDOMETRIAL SCRATCHING AND ANALYSIS UTERINE NATURAL KILLER (UNK) IMPROVE PREGNANCY RATE IN INFERTILE WOMEN WITH PREVIOUS IVF FAILURE**

Giovanni Menaldo, Alessia Giovannelli, Chiara Conti, Sergio Serrano

**Unità Di Procreazione Assistita, Centro Clinico San Carlo Di Torino, Torino, Italy**

Endometrial immune reaction that occurs in women during the implant window is crucial for implantation. Under physiological conditions, uNK lymphocytes are not spontaneously cytotoxic. However, uNK cells are not the only ones in the endometrium: in a predominantly Th1 environment, dendritic cells and Treg cells can increase the uNK lymphocytes cytotoxicity and in turn they are able to recognize trophoblastic cells as non -self and reject them by inducing a missed implant and repeated abortions. When uNK lymphocytes are elevated, aggressive environment is produced in the endometrium causing implantation failure. An altered immune system can be closely linked to abortions or repeated failures of an embryonic implant so a balanced local immune biological reaction is necessary to allow the embryo adhesion phase. A total of 95 women with IVF failures was participated in this study. Endometrial tissue samples were obtained with a microcatheter Pipelle, performing endometrial scratching. Research of uNK lymphocytes was performed by histological examination. Immunohistochemical markers CD16 and CD56 reveal the possible presence of lymphocyte elements in the stroma of the endometrial mucosa. Instead, the morphological and immunohistochemical marker CD138 reveals the possible presence of plasma cells that can be evidence of endometritis. Endometrial biopsies were collected in proliferative phase. They were considered positive cases presence of a number of cells of CD 10 cells. CD16 and CD56 cell
abundance in proliferative endometrial tissue of women with reproductive failure has suggested they may play a role in this pathogenesis. Common treatment for women with abnormal endometrial NK cells numbers is use of corticosteroids and in addition in our lab we use biophotonic therapy; through a special device connected to computer, woman received spermatic biophotonic emission of her male partner, previously stored. The administration of spermatic biophotonic energy was carried out a few minutes before the embryotransfer and on culture medium in which there are incubated embryos obtained through ICSI et/ord PICSI. Pregnancy rate was significantly higher (28%) in the same group of patients with several previous IVF failures (control group). Performing this combined treatment with endometrial scratching in patients with diagnosis of infertility increased pregnancy rates.

P010
AROMATASE INHIBITORS (LETROZOLE) VERSUS CLOMIPHENE CITRATE AS OVULATION INDUCTION AGENTS IN PATIENTS WITH POLYCYSTIC OVARIAN SYNDROME, AND THEIR ROLE ON ULTRASONOGRAPHIC MARKERS OF ENDOMETRIAL RECEPTIVITY
Judith Marie Mifsud
Obstetrics and Gynaecology, Mater Dei Hospital, Msida, Malta

Problem statement: Polycystic ovary syndrome (PCOS) is associated with anovulatory infertility, recurrent miscarriages and poor implantation rates. Letrozole has now been suggested to be used first-line as pharmacological management of anovulatory infertility in PCOS women by the ESHRE guideline released in 2018. Uterine perfusion plays a role in endometrial receptivity and hence embryonic implantation. PCOS is linked with abnormal uterine blood flow. Measurement of endometrial vascularisation around the endometrial layer via Doppler ultrasonography has been found to be adequate for assessment of endometrial receptivity. Compared to Letrozole, the anti-oestrogen effects of CC on the endometrium have a negative impact on endometrial receptivity. Compared to Letrozole, the anti-oestrogen effects of Letrozole compared to CC, and an overall increased pregnancy rate. In case of female, Letrozole plays an important role in placental cells that caused abnormal fetal development, the decreased sperm counts or motility by OTA indicated spermatoxotoxicity in male. However, intracellular physiological mechanisms in testicular cells were still not elucidated. Therefore, to give evidence of detailed mechanisms of OTA, we investigated cytotoxic effects of OTA which can cause male infertility using two types of testicular cells in mice, Sertoli cells (TM4) and Leydig cells (TM3) in this study. Methods: A literature search identifying articles published over the past 10 years, which compared ultrasonographic features of endometrial receptivity including doppler changes following the use of CC versus Letrozole in PCOS women, revealed four studies with a total of 510 patients. The studies where all randomised controlled trials and used timed intercourse as the method of fertilisation.

<table>
<thead>
<tr>
<th>Study</th>
<th>Country</th>
<th>Treatment</th>
<th>Randomised controlled trial</th>
<th>Study</th>
</tr>
</thead>
<tbody>
<tr>
<td>Al-Obaidi (2019)</td>
<td>Iraq</td>
<td>5mgLE/ 100mg CC</td>
<td>Timed intercourse</td>
<td>Randomised non-blinded control trial</td>
</tr>
<tr>
<td>Baruah (2009)</td>
<td>India</td>
<td>2.5-5mg LE/ 50-100mg CC</td>
<td>Timed intercourse</td>
<td>Prospective non-blinded randomised controlled trial</td>
</tr>
<tr>
<td>Selim (2012)</td>
<td>Egypt</td>
<td>5mg LE/ 100mg CC</td>
<td>Timed intercourse</td>
<td>Prospective randomised trial</td>
</tr>
<tr>
<td>Wang (2019)</td>
<td>China</td>
<td>2.5mg LE/ 50mg CC</td>
<td>Timed intercourse</td>
<td>Randomised controlled trial</td>
</tr>
<tr>
<td>Total number of patients</td>
<td>510</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Results: There is an overall positive effect on endometrial thickness and sub-endometrial vascularity and improved pregnancy rates with the use of Letrozole compared to CC. All studies show statistically improved doppler indices and endometrial thickness with the use of Letrozole compared to CC, and an overall increased pregnancy rate. In case of female, Letrozole improves sonographic features of endometrial receptivity when compared to CC in anovulatory PCOS women, and improves pregnancy rates.

P011
TOXIC EFFECTS OF OCHRATOXIN A ON SERTOLI AND LEYDIG CELLS CAUSING MALE INFERTILITY IN MICE
Hahyun Park1, Jiyeon Ham1, Gunwoo Park2, Changwon Yang3, Whasun Lim3, Gwonhwa Song4
1Institute of Animal Molecular Biotechnology and Department of Biotechnology, College of Life Sciences and Biotechnology, Korea University, Seoul, South Korea
2Department of Food and Nutrition, Kookmin University, Seoul, South Korea

Problem statement: Environmental factors from agriculture and industrial society cause severe male infertility in recent days. Kind of mycotoxin, ochratoxin A (OTA) is a secondary metabolite produced by Penicillium and Aspergillus which lead contamination on foodstuffs. It’s toxic effects in various tissues showed respect to pathogenesis of diseases or malformation in main organs. In case of female, OTA plays an important role in placental cells that caused abnormal fetal development, the decreased sperm counts or motility by OTA indicated spermatoxotoxicity in male. However, intracellular physiological mechanisms in testicular cells were still not elucidated. Therefore, to give evidence of detailed mechanisms of OTA, we investigated cytotoxic effects of OTA which can cause male infertility using two types of testicular cells in mice, Sertoli cells (TM4) and Leydig cells (TM3) in this study. Methods: OTA incubated with those cells for 24-h and various experiments including proliferation assay, cell cycle assay and cytotoxic calcium analysis were performed to identify the reproductive toxicity of OTA. Phosphorylation of diverse signaling molecules related to cell survival and growth were analyzed using western blotting. Results: The results showed significant decrease in proliferation of TM3 and TM4 cells, those cells were arrested in sub-G1 phase of cell cycle by OTA. OTA treatment showed imbalanced calcium ion concentration between the cytosol and mitochondria. Also, expression pattern of main regulators in PI3K (AKT, P70S6K, and S6) and MAPK (ERK1/2 and JNK) pathways significantly altered in response to dose-dependent OTA exposure. And we used inhibitors of each pathways to identify complex correlation between signal proteins. They exerted synergistic effects of OTA on growth inhibition in TM3 and TM4 cells. Conclusion: Taken together, OTA exposure inhibited proliferation on TM3 and TM4 cells, following results about disruption of calcium ion homeostasis, early stage apoptosis and changes in cell proliferating signal molecules supported cytotoxic effects of OTA. Therefore, OTA contaminated products can lead to male infertility through incomplete sperm maturation with damaged testicular cells. Disclosure of interest: ochratoxin A, sertoli cells, leydig cells, male infertility
P012  HORMONAL TREATMENT PRIOR TO TESTICULAR SPERM EXTRACTION (TESE) IMPROVES ICSI OUTCOMES

Mario Alfonso Paton Vázquez, Sergio Alberto Davila Garza, Pedro Galache Vega, Jose Iram Queso Montoya
Fertility Center, IECF, Monterrey, Mexico

Problem statement: To analyze embryological and obstetric outcomes obtained with the use of testicular sperm in patients receiving or not hormonal treatment prior to extraction. Methods: Retrospective cohort study between January 2007 to December 2017. All male patients attending the IECF fertility center in Monterrey requiring TESE for ICSI were enrolled. Group 1 were patients with severe OAT and NOA who received recombinant follicle stimulating hormone (rFSH) 25 IU three times a week, or recombinant human chorionic gonadotropin (hCG) 250 mcg once a week for at least 6 weeks prior to TESE; and Group 2 were patients with obstructive azoospermia not receiving treatment. Results: A total of 211 cases were analyzed; Group 1 (n=118) had mean age of 38.2±6.9, while group 2 (n=93) had a mean age of 40.5±7.4. Women average age was 33.8±5.1 (Group 1) versus 34.2±4.8 years (Group 2). Mean FSH values for group 1 was 8.6±6.7 mIU/mL vs 3.3±2.5 for group 2. In group 1, 65% were patients with severe OAT and 35% with NOA. In total, 65% of the patients received rFSH and 35% received hCG. Testicular sperm was successfully retrieved in all cases including patients diagnosed with NOA. Fertilization rates were 48% vs 51% between groups. Cleavage rate for group 1 was 94% vs 85% for group 2; blastocyst yield was 74% for group 1 vs 65% for group 2. None of these parameters were significantly different. Pregnancy rate was 35/118 (30%) for group 1 and 34/93 (36%) for group 2. Clinical and ongoing pregnancy rates were 48% for group 1 and 79% for group 2. Live Birth rate was 48% group 1 versus 52% for group 2. Implantation rate was 16% for group 1 and 33% for group 2. Conclusion: Hormonal treatment of men with NOA and severe OAT prior to TESE equalize the reproductive performance when compared to OA. Future studies should compare men with NOA treated with hormones versus non-treated to show whether our findings of retrieving sperm in all cases of NOA is secondary to the pharmacological treatment. No relationships to disclose.

P013  CONCEPTION FACTORS IN UNEXPLAINED INFERTILITY PATIENTS

Brigita Vaigauskaitė1, Raminta Baušytė1,2, Diana Ramšauskaitė1,2, Rūta Navakauskiene1
1Department of Molecular Cell Biology, Institute of Biochemistry, Life Sciences Center, Vilnius University, Vilnius, Lithuania
2Centre of Obstetrics and Gynecology, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania
3Faculty of Medicine, Vilnius University, Vilnius, Lithuania

Problem statement: Unexplained infertility nowadays persists highly prevalent despite all the precise diagnostics and evaluations of the couples. In all these cases, the question remains – which factors are decisive for conception? Methods: A total of 129 couples diagnosed with unexplained infertility and received assisted reproductive technology (ART) during the period of 1 year (2018) were retrospectively studied at Vilnius University Santaros Clinics. Age, duration of infertility, type of infertility, body mass index, baselines of sex hormones, anti-Müllerian hormone (AMH) prior the treatment has been recorded, including the age and sperm analysis data of men. Results: Of the 129 couples, 19 (14.7%) underwent intracytoplasmic sperm injection (ICSI). The total pregnancy rate was 55.8%. There were no statistically significant differences between the women who conceived after ART in terms of age, comorbidities (hypotension, depression, etc.), body mass index. The baseline characteristics of the FSH, LH, estradiol and prolactin were similar in failed to conceive group (A group) and women who became pregnant (B group) although the duration of infertility was significantly shorter B group (5.3 yr. vs. 4.1 yr.; p=0,012). Comparing AMH levels, there were no significantly relevant difference between A and B groups (p=0,541) which suggests that lower AMH levels are not related to reduced infertility. Endometrium thickness at transfer day was 2.1 mm higher in B group (p=0,033). We did not find higher predicted probability of conceiving when comparing both groups in couples where men had higher sperm concentration (p=0,838), nor sperm motility (p=0,190). Conclusion: Altogether, unexplained infertility conception rate is high. The duration of infertility plays an important role in predicting conception before staring ART in unexplained infertility patients. Endometrium thickness remains a strong predictor of implantation and conceiving a clinical pregnancy. Further studies are necessary to reveal the progression criteria for conception in unexplained infertility couples. Conflict of Interest: None. Disclosure of Funding: None.

P014  MEDIATOR IN THE EMBRYO-ENDOMETRIUM CROSS-TALK: GRANULOCYTE COLONY-STIMULATING FACTOR IN INFERTILITY

Chris Andrea Robert, Mohammed K. Abbas, Abdul Rehman Z. Zaidi, Suyeewin Thiha, Bilal Haider Malik
Research, California Institute of Behavioral Neurosciences and Psychology, Fairfield, USA

Problem statement: Successful implantation requires a receptive endometrium and a good quality egg. The challenges a physician encounters with regard to those in assisted reproductive technology are obtaining good quality embryo, achieving optimal endometrial thickness (EMT), and subsequently implantation, which is denotive of a receptive endometrium. Granulocyte colony-stimulating factor (G-CSF) has been observed to be a biomarker of oocyte quality and has been shown to enhance EMT and implantation because of its immunological effects. Methods: A systematic search for all relevant articles on G-CSF in follicular fluid and its therapeutic benefit in thin endometrium and recurrent implantation failure was performed, and peer-reviewed, full-text articles related to humans were included in the study. Results: As a tool to determine the potentiality of oocyte, G-CSF shows promise with its predictability increasing in combination with morphological embryo scoring or interferukin 15. For the thin endometrium, G-CSF is especially useful in patients who are refractory to other treatment modalities. In recurrent implantation failure (RIF), G-CSF showed potential in a subset of patients with immunological deficiency lacking killer cell immunoglobulin-like receptor genes. This review highlights the various forms of usage of G-CSF and the effectiveness of G-CSF in infertility. Conclusion: G-CSF equips embryologists with a tool to determine the potentiality of oocyte and physicians with therapy for thin endometrium and RIF; ART, especially since the available treatment options are ineffective.
Eccentrically located intrauterine pregnancy that was presented to us clinical presentation, management, and outcome of a patient with embryo quality and development was evaluated on day 3 and/or ICSI, the fertilization was evaluated 17 -19 hrs later and the sectional, inferential analytical study.

Oocyte retrieval was performed transvaginally 35-36 hrs after hCG triggering was with hCG upon detection of the first 18mm follicle. 75 to 450UI. GnRH analogues were used for suppression and monotherapy or rFSHr / rLH combination therapy at doses between a combined protocols of FSH / LH versus FSH monotherapy for ovarian stimulation was performed with rhFSH analysis. Ovarian stimulation was with hCG and pregnancy outcome of the female partner associated with greater quantity of recovered oocytes for both patients ≥35 years with adequate parameters of ovarian reserve and a higher rate of blastocysts (34.1% VS 32.1%, P0.001). A greater number of embryos were obtained in patients of group 2 (monotherapy) (2 ± 0.58, P=0.047). The live birth rate was not higher in the comparative groups ([19/310(64.2%) VS 159/273(58.2%) P=0.003], 7.07 ± 1.9, VS 6.45 ±1.8 0.001). A greater amount of fertilized oocytes was found in group 2 ([199/310(64.2%) VS 159/273(58.2%) P=0.003), and a higher rate of blastocysts (34.1% VS 32.1%, P=0.001). A greater number of embryos were obtained in patients of group 1 (monotherapy) (2 ± 0.58, P=0.047). The live birth rate was not higher in the comparative groups ([114 / 45 (31.1%) VS 19 / 55(34.5%) P=0.2138). Conclusions: Monotherapy with FSH was associated with greater quantity of recovered oocytes for both patients ≥35 years with adequate parameters of ovarian reserve and 35 years with deficient parameters of ovarian reserve. The addition of LH to the FSH stimulation protocols for poor responders was inefficient in improving outcome.

Objective: To compare the ovarian response between the use of a combined protocols of FSH / LH versus FSH monotherapy protocol in the subgroups I and II of low-responders using the POSEIDON classification criteria. Design: Retrospective, cross-sectional, inferential analytical study. Material and methods: Data from 101 stimulation cycles of low-responders classified as group I or II using the POSEIDON criteria, who participated in IVF/ICSI procedures between August 2014 and December 2018 were analyzed. Ovarian stimulation was performed with rhFSH monotherapy or rFSH / rLH combination therapy at doses between 75 to 450UI. GnRH analogues were used for suppression and triggering was with hCG upon detection of the first 18mm follicle. Oocyte retrieval was performed transvaginally 35-36 hrs after hCG administration. The oocytes were inseminated by conventional IVF or ICSI, the fertilization was evaluated 17-19 hrs later and the embryo quality and development was evaluated on day 3 and/or day 5. Results: A total of 46 (45.54%) patients formed group I and 55 (54.46%) were in Group II. Patient’s age was significantly different lower in the POSEIDON GI (31.04 ±3.48, VS 37.45 ±2.22 P=0.01). Furthermore, group I, had lower total doses requirement for ovarian stimulation (2290.49 ±830.23, VS 2704.55 ±785.92, P=0.01). The number of recovered and mature oocytes in group 1 POSEIDON was higher compared to the other group (7.07 ± 1.9, VS 6.45 ±1.8 0.001). A greater amount of fertilized oocytes was found in group 2 ([119/310(64.2%) VS 159/273(58.2%) P=0.003), and a higher rate of blastocysts (34.1% VS 32.1%, P=0.001). A greater number of embryos were obtained in patients of group 1 (monotherapy) (2 ± 0.58, P=0.047). The live birth rate was not higher in the comparative groups ([114 / 45 (31.1%) VS 19 / 55(34.5%) P=0.2138). Conclusions: Monotherapy with FSH was associated with greater quantity of recovered oocytes for both patients ≥35 years with adequate parameters of ovarian reserve and 35 years with deficient parameters of ovarian reserve. The addition of LH to the FSH stimulation protocols for poor responders was inefficient in improving outcome.

Objective: To compare the ovarian response between the use of a combined protocols of FSH / LH versus FSH monotherapy protocol in the subgroups I and II of low-responders using the POSEIDON classification criteria. Design: Retrospective, cross-sectional, inferential analytical study. Material and methods: Data from 101 stimulation cycles of low-responders classified as group I or II using the POSEIDON criteria, who participated in IVF/ICSI procedures between August 2014 and December 2018 were analyzed. Ovarian stimulation was performed with rhFSH monotherapy or rFSH / rLH combination therapy at doses between 75 to 450UI. GnRH analogues were used for suppression and triggering was with hCG upon detection of the first 18mm follicle. Oocyte retrieval was performed transvaginally 35-36 hrs after hCG administration. The oocytes were inseminated by conventional IVF or ICSI, the fertilization was evaluated 17-19 hrs later and the embryo quality and development was evaluated on day 3 and/or day 5. Results: A total of 46 (45.54%) patients formed group I and 55 (54.46%) were in Group II. Patient’s age was significantly different lower in the POSEIDON GI (31.04 ±3.48, VS 37.45 ±2.22 P=0.01). Furthermore, group I, had lower total doses requirement for ovarian stimulation (2290.49 ±830.23, VS 2704.55 ±785.92, P=0.01). The number of recovered and mature oocytes in group 1 POSEIDON was higher compared to the other group (7.07 ± 1.9, VS 6.45 ±1.8 0.001). A greater amount of fertilized oocytes was found in group 2 ([119/310(64.2%) VS 159/273(58.2%) P=0.003), and a higher rate of blastocysts (34.1% VS 32.1%, P=0.001). A greater number of embryos were obtained in patients of group 1 (monotherapy) (2 ± 0.58, P=0.047). The live birth rate was not higher in the comparative groups ([114 / 45 (31.1%) VS 19 / 55(34.5%) P=0.2138). Conclusions: Monotherapy with FSH was associated with greater quantity of recovered oocytes for both patients ≥35 years with adequate parameters of ovarian reserve and 35 years with deficient parameters of ovarian reserve. The addition of LH to the FSH stimulation protocols for poor responders was inefficient in improving outcome.

Problem statement: Eccentrically located intrauterine gestational sac can be misinterpreted as cornual pregnancy on ultrasound evaluation. To distinguish between these two, sonographic criteria can be applied: empty uterine cavity, sac 1 cm from the most lateral edge of the uterine cavity and a thin myometrial layer surrounding the sac. The more frequent use of assisted reproductive technologies, including ovulation induction, intrauterine insemination (IUI), in vitro fertilization (IVF), and intracytoplasmic sperm injection (ICSI), leads to a rise in ectopic pregnancy. Methods: We describe the clinical presentation, management, and outcome of a patient with eccentrically located intrauterine pregnancy that was presented to us with the suspicion of cornual pregnancy. Results: A 36-year-old, nullipara, presented with mild abdominal pain and spotting since three days, 4 weeks after IUI. Referred to the emergency for ultrasound suspicion of cornual pregnancy. General physical examination was normal. Pelvic examination revealed bulky uterus without any adnexal pathology. Clinical features were suggestive of either ectopic pregnancy or threatened abortion. Transvaginal sonography was performed but it could not differentiate whether it is eccentrically located intrauterine gestational sac or cornual pregnancy. β-hCG levels were 95,000 IU/ml. We performed a weekly ultrasound surveillance and observed complaints disappearance, gestational sac implanted near the right tubal orifice and embryo with cardiac activity. Conclusion: Although ultrasound imaging has made great improvement over the last decades, diagnosing a cornual pregnancy remains challenging. The use of other imaging modalities, such as magnetic resonance imaging and three-dimensional ultrasound seem to be promising in the diagnosis. However, the higher cost and lower availability of these technologies make them most appropriate for cases in which two-dimensional ultrasound scans are inconclusive. We draw your attention to the necessary balance between surveillance of a potentially life-threatening situation and timely attitudes that can end a life in its early stages.
Stephanie Siew\textsuperscript{1}, Shuling Liu\textsuperscript{2}
\textsuperscript{1}Department of Obstetrics and Gynaecology, KK Women’s and Children’s Hospital, Singapore
\textsuperscript{2}Department of Reproductive Medicine, KK Women’s and Children’s Hospital, Singapore

Introduction: Endometrial cavity fluid (ECF) present during embryo transfer (ET) has been associated with lower clinical pregnancy rates due to failure of implantation. It occurs at an incidence of 2.9%-8.2\textsuperscript{1,2}. Many gynaecologists will choose to abandon the cycle if ECF was detected before ET. Etiologies include tubal infertility, hydrosalpinges, polycystic ovarian disease and uterine infections\textsuperscript{3}. Case Presentation: We present a case of successful implantation despite significant ECF at ET. She was a 28 year old lady with a history of a laparotomy bowel resection at 4-months of age. Initial subfertility investigations showed 6cm endometriotic cyst, adenomyosis and blocked right fallopian tube. There was no hydrosalpinx. Her ovarian reserves were normal and her husband had terozoospermia. She declined surgery for endometriotic cyst and was keen for IVF. ET during fresh cycle was cancelled due to high risk of ovarian hyperstimulation syndrome. She was scheduled for a natural thaw cycle but ultrasound before ET showed significant ECF (Figure 1). Despite counseling about the lower chance of pregnancy, the couple was keen to proceed with the ET. She had a successful implantation, and later delivered at full term via normal vaginal delivery.

Discussion and Conclusion: ECF has been associated with poorer ART outcomes. ECF can be quantified by measuring the anterior-posterior diameter of fluid seen within the uterine cavity on ultrasound. A large retrospective controlled study showed no significant difference between patients with ECF 1. Although our patient had a significant ECF of This was a rare case of a successful pregnancy and subsequent live birth despite multiple factors not favoring this outcome. Hence, it is still plausible to consider and proceed with ET even in the presence of significant ECF after adequate counseling and discussion with the couple.

Figure 1 Ultrasound scan showing significant ECF prior to ET

Discussion and Conclusion: ECF has been associated with poorer ART outcomes. ECF can be quantified by measuring the anterior-posterior diameter of fluid seen within the uterine cavity on ultrasound. A large retrospective controlled study showed no significant difference between patients with ECF 1. Although our patient had a significant ECF of This was a rare case of a successful pregnancy and subsequent live birth despite multiple factors not favoring this outcome. Hence, it is still plausible to consider and proceed with ET even in the presence of significant ECF after adequate counseling and discussion with the couple.
OUTCOME OF ICSI-ET CYCLES IN WOMEN PRESENTING WITH LOW ANTI-MULLERIAN HORMONE IN SOUTHERN INDIA
Dr Sneha Badwe Dhodapkar, Soumyaaroop Dash, Sebanti Dash, Sindyu Bhair, Uma S, RT
Reproductive Medicine, Srishti Hospital, Puducherry, India

Problem statement: Anti-Mullerian Hormone (AMH); a proven marker of ovarian reserve, is known as the most reliable predictor of ovarian responsiveness to various controlled ovarian stimulation. Its role as a predictor of clinical pregnancy in assisted reproductive techniques (ART) is debatable. Our study aimed to analyze the outcome of Intra-Cytoplasmic Sperm Injection Embryo Transfer (ICSI-ET) cycles in women with low circulating AMH and factors affecting their probability of conception. Methods: We performed a retrospective analysis of details of 136 women with low circulating AMH (AMH<2.19ng/ml) levels who had undergone ICSI – ET cycles for a period of 6 months (January - June 2019). Results: In our study, of the 136 women with low circulating AMH, 91 (66.9%) were with AMH in the range of 1 ng/ml-2.19ng/ml and remaining 45 (33.1%) were with less than 1ng/ml. Most women, 61(44.9%) were more than 35 years of age, 46(33.8%) were between 30-34 years, and, 29(21.3%) were below 30 years. Clinically positive pregnancy was observed in 54/136 (39.7%) women. More than half of the women (51.6%) with positive pregnancy outcome had AMH in the range of 1.0ng/ml-2.19ng/ml, whereas only 15.6% women with AMH 1ng/ml were clinically positive. The observed difference was statistically significant (p-value<0.01). On further analysis, it was observed that more than half of the women (55.2%) with age less than 30 years had positive pregnancy outcome whereas it decreased to 47.8% in the age group 30-34 years. The recorded clinical pregnancy in women 35 years was only 26.2%. The difference in the clinical pregnancy rate amongst these groups was observed to be statistically significant (p-value- 0.01). Conclusion: Circulating low AMH is significantly associated with reduced chances of positive outcomes in ICSI-ET cycles. The chances of achieving pregnancy are good at young age but, significantly reduced with advanced chronological age. Thus, levels of circulating AMH plays a vital role in predicting the chances of pregnancy in women of advanced age groups.

EVALUATION OF CLINICAL & EMBRYOLOGICAL FACTORS INFLUENCING PREGNANCY OUTCOMES IN THE FIRST FROZEN BLASTOCYST TRANSFER: A RETROSPECTIVE STUDY, IN IVF HUNG VUONG
Thanh Thuy Tran, Vy Phuong Nguyen, Thai Loc Ly, Diem Tuyen Hoang
IVF Hung Vuong, Hung Vuong Hospital, Ho Chi Minh, Vietnam

Problem statement: At present, blastocyst transfer is an efficient embryo transfer method associated with satisfactory pregnancy outcomes, and performing blastocyst transfer may have benefits. The aim of this study was to investigate which factors contribute to the incidence of clinical pregnancy rate (CPR) in the first frozen blastocysts transfer. Methods: In this study, we analyzed the data from 342 women who were subjected to the first frozen blastocyst transfer registered from Jan 2017 - Dec 2018 at the IVF Hung Vuong, Ho Chi Minh city, Viet Nam. Baseline data and pregnancy outcomes were collected. We performed a retrospective analysis of clinical and embryological factors that potentially influence the outcome of the first frozen blastocyst transfer. Results: The outcome of 342 cycles in our analysis was the clinical pregnancy rate and ongoing pregnancy rates after the first frozen blastocysts transfer was 52.3 % and 38.3 %. Age, type of infertility, IVF indications, AMH, ovarian stimulation response (numbers of follicles, oocytes and mature oocytes), endometrial thickness, embryo transfer distance) were similar in the success and failure groups. The study recorded fertilization rate and blastocyst rate in the success were higher in failure group but not significantly different (p>0.05). The number of blastocyst in first transfer (single versus double) resulted in a significantly higher CPR [40.7% versus 52.7%]; odds ratio (OR) 1.63, 95% confidence interval (CI) 1.02–2.62). Similarly, No. of good quality blastocyst transfer resulted in a significantly [OR 2.19, 95% CI (1.41 - 3.41)] higher CPR compared with the group without good blastocyst transfer. As expected, the multiple pregnancy rate was significantly lower for single blastocyst transfer compared with double blastocyst transfer [OR 4.63 CI (1.61 - 13.35)]. Conclusion: The number and the good quality of the blastocyst transferred significantly influences clinical pregnancy rate in the first transfer. In general, consideration should be given to the transfer of blastocyst stage embryos. Limiting the number of transferred embryos can be reduced the multiple pregnancy rate.

COMPARISON OF LIVE BIRTH RATES BETWEEN FROZEN SINGLE AND DOUBLE EMBRYO TRANSFER FOLLOWING A FAILED FRESH SINGLE BLASTOCYST TRANSFER
Ker Yi Wong1, Tse Yeun Tan2, Heng Hao Tan
1Obstetrics & Gynecology, KK Women’s and Children’s Hospital, Singapore
2Reproductive Medicine, KK Women’s and Children’s Hospital, Singapore

Problem statement: In clinical practice, after a failed fresh single blastocyst transfer (SBT), both clinicians and the women may choose to transfer two embryos in the thaw cycle. This retrospective study aims to evaluate whether livebirth rates differ between a frozen single embryo transfer (SET) and a frozen double embryo transfer (DET) after a failed fresh SBT in a tertiary hospital in Singapore. Methods: Women who have undergone fresh SBT from 2014 to 2018 were recruited from the Reproductive Medicine Department database in KK Women’s and Children’s Hospital in Singapore. Women were excluded if they had only one available embryo for fresh transfer or if outcome data was missing. The primary outcome was livebirth rate. Analysis was done using Stata/IC 11.0. Results: A total of 535 women who had a SBT in a fresh cycle were included. The mean age was 33.8 years old. The average number of oocytes retrieved and number of embryos frozen were 14.8 and 5.2 respectively. The livebirth rate, inclusive of both singleton and twins, was 36.9%. Out of the 327 women who did not achieve a live birth in the fresh cycle, 204 underwent a thaw cycle. Five women had compulsory SET (cSET), 115 chose elective SET (eSET) and 72 chose DET. The majority of transfers in the thaw cycle was blastocyst transfer. The livebirth rates for cSET, eSET and DET were 40%, 24.3% and 36.1% respectively, which were significantly different, even after excluding non-blastocyst transfers in the thaw cycle. There were six twin livebirths in the DET group while there were none in the cSET and eSET groups. Conclusion: In clinical practice, a woman may opt for DET in her thaw cycle after a failed fresh SET cycle. From this study, a frozen DET is associated with significantly higher livebirth rate than a frozen SET but also significantly higher rate of twin births. Success rates and risks of higher order pregnancies have to be balanced when deciding whether to transfer a single or double embryo in a thaw cycle after a failed fresh single embryo transfer.

EFFECT OF JOGYEONBOHYEOELDAN (JBD) ON THE RESTORATION OF OVARIAN FUNCTION IN AGED FEMALE MICE
Jeongeun Yoo1, Chae-Hak Lim1, Bo Sun Joo2
1Department of Obstetrics and Gynecology, College of Korean Medicine, Daejeon University, Daejeon, South Korea
2Infertility Institute, Pohang Women’s Hospital, Pohang, South Korea

Problem statement: Ovarian aging remains a representative unmet demand of infertility treatment. Jogyeonbohyeoeldan (JBD) is an oriental herbal medicine used to improve female fertility. This study investigated whether JBD restores ovarian function and simulates gene expression related to activation of primordial
follcle, ovarian stem cells and angiogenesis in aged female mice. **Methods:** C57BL/6 female mice aged 12 months (natural ovarian aging, NOA) were administered every day with JBD of 15 mg/kg (n=7) and 30 mg/kg (n=7) of body weight for 4 weeks using oral zoned needle. The control group (n=7) was treated with normal saline. After final treatment of JBD, ovaries were collected, and follicle counts were evaluated by histological study and ovarian mRNA expressions of genes related to PI3K/mTOR (4E-BP1, S6K1, RPS6) and Hippo (MST1, LATS1) signaling pathway for the activation of primordial follicle and ovarian stem cells, and angiogenesis (VEGF, Vifafatin, and SDF-1α) were evaluated by quantitative real-time PCR. In the second experiment, NOA and premature ovarian failure (POF) mice were treated with JBD in the same manner as above, (n=7 each), and they were superovulated with PMSG and hCG, followed by mated with male mice. Zygotes were retrieved and cultured for 4 days, and numbers of zygotes and embryo development rate to blastocyst in both NOA and POF mice compared to the control group (P<0.05). **Conclusion:** These results show that JBD can restore ovarian aging and improve ovarian function and oocyte quality in aged mice. Also, this study suggests that JBD can activate PI3K/mTOR and Hippo signaling, ovarian stem cells, and ovarian angiogenesis. There are no conflicts of interest.

**P025**

**DIAGNOSTIC PROCEDURES**

CORRESPONDENCE BETWEEN ULTRASOUND FINDING, HYSTEROSCOPY AND HISTOLOGICAL RESULTS IN PREMENOPAUSAL WOMEN

Augusto Brandao, Carlos Henrique Mascarenhas, Livia Salvador, Anna Dias Salvador, Claudia Lourdes Laranjeira, Salua Call, Marcia Salvador Geo, Rívia Lamaita, Fernanda Menicucci, Jaqueline Dezordi

Gynecological Surgery, Rede De Saúde Mater Dei, Belo Horizonte, Brazil

**Problem statement:** Hysterectomy is a common procedure performed by gynecologists due to its diagnoses and therapeutic capacity and low rates of complications. In premenopausal women it is usually indicated after an abnormal ultrasound result suggesting submucous fibroids or polyps or in patients with severe abnormal uterine bleeding. Although ultrasound (US) has a good accuracy in predicting structural lesions, hysterectomy might be necessary for accomplishing adequate diagnosis and its capacity of imaging the interior of the uterine cavity while performing the procedure makes it far more accurate than curettage or any other available method. **Objectives:** The aim of this study is to compare ultrasound, intra operative and histological finding in premenopausal women submitted to hysterectomy. **Patients and Methods:** This is a retrospective study that recruited a total of 86 premenopausal patients who underwent a hysterectomy procedure indicated after an ultrasound scan suggesting endometrial polyps or submucous fibroids. **Results:** A total of 28 patients presented US suggesting submucous fibroids (SF) and the remaining 58 had findings suggesting endometrial polyps (EP). Regarding patients with US suggesting SF, twenty-six (93%) presented hysteroscopic findings and histological results confirming the initial diagnosis; one (3.5%) presented a normal hysteroscopy with no structural lesions found and in one (3.5%), an endometrial polyp was found, confirmed by histological result. In other hand, regarding patients with US suggesting EP, forty-nine (84.5%) presented hysteroscopic findings and histological results confirming the initial diagnosis, four (8%) presented a normal hysteroscopy and 5 (10%) presented hysteroscopic findings and histological results confirming submucous fibroids. **Conclusions:** In general, ultrasound finding are confirmed by hysteroscopic findings and histological results. This correlation seems better when the initial diagnosis is submucous fibroids. In this particular study hysteroscopic findings were confirmed by histological results in all patients.

**P026**

HYSTEROSCOPIC MANAGEMENT OF CESAREAN SCAR ECTOPIcal PREGNANCY: A CASE REPORT

Vanessa Silva1,2, Beatriz Bettencourt Silva1, Ana Filipa Brás1

Pedro Oliveira1

1Department of Obstetrics and Gynecology, Hospital Senhora Da Oliveira, Braga, Portugal
2Escola De Medicina Da Universidade Do Minho, ICVS – Institute of Life and Health Sciences, Braga, Portugal

**Problem statement:** Cesarean scar pregnancy (CSP) is a rare iatrogenic entity, affecting 1/2000 pregnancies. It represents about 6% of ectopic pregnancies in women with a previous caesarean section. This situation must be distinguished from a spontaneous abortion in progress or a cervical pregnancy. The management of CSP is an unexplored clinical field and a standard protocol is still missing. The hysteroscopic removal of CSP is an option. **Methods:** Retrospective case report. In this case report, we describe a woman with CSP diagnosed by transvaginal ultrasound who was initially treated as spontaneous abortion in progress with vaginal misoprostol and underwent a hysteroscopic surgery after medical treatment failure. **Results:** A 41-year-old woman, gravida 5, with a past history of one cesarean section. She went to the emergency department of Hospital Senhora da Oliveira 10 days after she has been treated in another institution for spontaneous abortion in progress with vaginal misoprostol and underwent a hysteroscopic surgery after medical treatment failure. **Conclusions:** An early and prompt diagnosis of CSP is essential. Hysteroscopic removal of CSP provides good prognosis and should be an option for CSP management.
**P027**

**COMPARISON BETWEEN OPERATIVE HYSTEROSCOPY AND HISTOPATHOLOGICAL FINDINGS**

Matilde Martins, Sara Cunha, Inês Reis, Mak Foo, António Lanhaso, Cristina Costa, Teresa Teles

Department of Gynaecology and Obstetrics, Entre o Douro e Vouga Hospital Centre, Santa Maria da Feira, Portugal

**Problem statement:** Operative hysteroscopy is a minimally invasive gynaecological procedure in which an endoscopic optical lens is inserted through the cervix into the endometrial cavity to directly treat various types of intrauterine pathology, such as endometrial polyps and uterine fibroids. The accuracy of diagnosis based on hysteroscopic visualization is high for endometrial cancer, but only moderate for other endometrial diseases.

**Methods:** A retrospective data analysis from all cases of operative hysteroscopy in our ambulatory surgery unit from July 2014 to July 2019 was conducted. The percentage agreement between hysteroscopic and histopathological findings was assessed.

**Results:** 2015 gynaecological ambulatory surgeries were performed, of which 880 (43.7%) were operative hysteroscopy with bipolar resectoscope under general anesthesia. 42 cases were excluded (complications that made the surgical procedure impossible or other procedures besides polypectomy, myomectomy or endometrial resection). The mean age was 50.94 +/- 8.6 years (minimum 23 and maximum 80). The majority of hysteroscopic findings were: polyp (73%, n=612), fibroid (12.4%, n=104) and endometrial hypertrophy (11%). The major histopathological findings were: endometrial polyp (60.9%, being the most frequent hyperplastic (n=314) and atrophic (n=117)), leiomyoma (14.7%), non-atypical simple endometrial hyperplasia (4.4%), and adenomyoma, atypical endometrial hyperplasia (simple and complex) in less than 1% of the cases. Normal histopathological findings were present in 12.6% of cases, with the most frequent being secretory endometrium (n=68). The majority of the histological diagnosis confirmed hysteroscopic findings: fibroid (94.2%), polyp (82.2%) and endometrial hypertrophy/hyperplasia (38.7%). 10% of polyps and 47% of endometrial hyperplasia diagnosed in hysteroscopy were actually normal histopathological types of endometrium, being the most frequent secretory endometrium (7.5% and 23.7% respectively).

**Conclusion:** The accuracy of diagnosis based on hysteroscopic visualization is very high for benign lesions such as uterine fibroid (94%) and endometrial polyp (92%). Tortuous and crowded glands of a late secretory endometrium can mimic a variety of intrauterine pathology, which makes it difficult the differential hysteroscopic diagnosis and increases the risk of an unnecessary operative hysteroscopy. No conflicts of interest to declare.

---

**P028**

**UTERINE BLEEDING IN POSTMENOPAUSAL WOMEN – THE ROLE OF HYSTEROSCOPY**

Diana Natacha Sousa1, Ana Rita Sarabando1, Ana Catarina Borges1, Cátia Correia1, Álvaro Rocha1, Cristina Nogueira-Silva1,2,3, Isabel Reis1

1Gynecology/Obstetrics, Braga’s Hospital, Portugal
2School of Medicine, Minho University, Portugal
3Life and Health and Science Research Institute, Minho University, Portugal

**Problem statement:** Uterine bleeding (UB) is one of the most common symptoms in gynaecological practice. Hysteroscopy is commonly considered the gold standard technique for the endometrial evaluation, allowing a direct view of the uterine cavity as well as diagnostic and therapeutic procedures. The aim of this study was to evaluate the role of hysteroscopy in the diagnosis of endometrial pathology and its relation to postmenopausal UB.

**Methods:** Retrospective study, including postmenopausal women with thickened endometrium (4mm) diagnosed by transvaginal ultrasound, who were submitted to hysteroscopy in Braga’s Hospital, between January and December 2018. The sample was divided into two groups: without UB (G1); with UB (G2). Sensitivity, specificity and accuracy of hysteroscopy were evaluated. Histological findings were classified as normal if they were atrophic or lightly proliferative; benign in cases of endometrial polyps, myomas, endometritis, adenomyosis or endometrial hyperplasia; and malignant if endometrial cancer. Descriptive and analytic evaluation was performed with SPSS and sensitivity, specificity and concordance coefficient (k) was calculated (p<0.05 level of significance).

**Results:** A total of 139 patients were included in the study. Mean age was 62.7±7 years in G1 and 64.1±10.2 in G2(p<0.05). Hypertensive disorders were more common in G2 (33.3% vs. 50.7%; p=0.04). No differences were found between the groups regarding age of menopause, body mass index, parity, hormonal replacement therapy or tamoxifen use. In hysteroscopy evaluation, polyps were the most common pathology in both groups but significantly more frequent in G1 (58.7% vs 34.4%, p<0.01). Overall rate of malignancy was 7.9%, but all cases had UB (0 vs. 18.6%, p<0.001). Malignancy was also significantly associated with a greater endometrial thickness when compared to benign pathology (12.3mm vs 26.2mm; p=0.01). For benign pathology, global hysteroscopy sensitivity was 97.9% and specificity 80.0%. For malignancy sensitivity was 91.6% and specificity was 99.5%. kappa concordance coefficient for benign pathology was 0.78 for G1 and 0.88 in G2, and for malignancy was, respectively, 0.76 and 0.87. Conclusions: Uterine bleeding is strongly associated with endometrial malignancy. Hysteroscopy is a valuable and minimally invasive procedure that can improve diagnostic accuracy of endometrial pathology.

---

**FETOMATERNAL MEDICINE**

**P029**

**DO CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION PREDISPOSE TO UTERINE TACHYSYSTOLE WHEN DOUBLE BALLOON CATHETER (DBC) IS CONSIDERED FOR CERVICAL RIPENING? CASE REPORT**

Shady Abd ElMoneim, Denise Morgan

Obstetrics and Gynecology, Doncaster and Bassetlaw Teaching Hospitals, NHS Foundation Trust, UK

**Problem statement and Background:** Induction of Labour occurs in up to 20% of pregnancies in UK1 and Double Balloon Catheter (DBC) is used commonly in this setting. DBC is associated with lower risk of uterine tachysystole when compared with prostaglandins2,3. Certain conditions increase the likelihood of uterine tachysystole, such as hypertension4, but are there risk factors that make tachysystole more likely to happen when DBC is used? We couldn’t find an answer for this question in the literature. **Case Presentation:** We are presenting the case of a 31-year-old primigravida woman, who had a history of CIN1 and HPV in 2014 and was conservatively managed. She got pregnant in 2018 and had an uneventful pregnancy until gestational age 38 weeks+5 days, when she developed mild preeclampsia, and had induction for labour using DBC. She developed uterine tachysystole four hours after DBC insertion, and so it was removed. Subsequently, she had two different preparations of dinoprostone, artificial rupture of membranes and oxytocin infusion without uterine overactivity and delivered vaginally thereafter. **Discussion and Conclusions:** The patient had uterine overactivity with DBC, and such tachysystole didn’t happen when prostaglandin E2 and oxytocin infusion were used. This is interesting, because in one study oxytocin was found to increase risk of tachysystole by 2- to 3-fold4. We believe this should prompt further research into the risk factors of uterine tachysystole in women receiving DBC. Patient has given her informed consent to publish her case.No conflicts of interest have been identified. References: 1. National Institute for Health and Care Excellence Interventional procedures guidance (IPG528). Insertion of a double balloon catheter for induction of labour in pregnant women without previous caesarean section. July
In relation to this, a daily dose of 0.4mg folic acid, 3 months before conception and in the first trimester of pregnancy, greatly reduces the incidence of this anomaly. Usually the anomaly is diagnosed in the 2nd trimester of the pregnancy. The struggle for even earlier diagnosing still remains. Anencephaly statistically is present in 1:1000 - 1:10,000 livebirths depending on the perinatal screening of different countries in the world. Methods: We are presenting a case of anencephaly diagnosed in the first trimester. First ultrasound results were of an embryo of CRL 6.79 mm which translates to a 6W 4D old embryo. Second ultrasound after two weeks with CRL 15.5 mm corresponding to 8W 0D old with positive impulse action. The age of the embryo is actually 8W 4D and CRL should be about 19.4mm. Measurement errors are inside the range of 2.1 mm and even taking this into consideration the CRL is inadequate. Besides this discrepancy, the embryo has an “odd” cranial shape which appears to be “jagged” (photo) unlike a normal embryo of the same age. Next ultrasound in the 11th week furthermore increases the already set doubts of anencephaly. The patient is sent to a tertiary health institution for consulting. A decision was made for the patient to be evaluated with ultrasound every two weeks and during the 13th week the pregnancy was spontaneously terminated. Results: When suspecting a possible anomaly in a pregnancy, permanent monitoring is done. In our case, after the termination of the pregnancy the 80mm embryo is sent for histopathological analysis. The diagnosis is confirmed, anencephalus with rachischisis. Conclusion: Anencephaly is a major congenital anomaly which today can be detected early in the first trimester of the pregnancy. Early termination is in favor of the physical and mental health of the mother.
stress. Based on our findings, we suggest that an abnormal uterine artery Doppler examination at 20–23 weeks of gestation may predict an increased cardiovascular risk in women whether or not they develop pre-eclampsia. Results require verification in large-scale trials. Identifying pregnant women at risk of developing future cardiovascular events will allow the early implementation of preventive measures.

P033
WHY 40 IS NOT THE NEW 20? PREGNANCY AND OBSTETRICAL OUTCOMES IN WOMEN OF ADVANCED MATERNAL AGE
Anita Barišić¹, Aleks Finderle²
¹Department of Medical Biology and Genetics, Faculty of medicine, University of Rijeka, Rijeka, Croatia
²Department of Obstetrics and Gynaecology, Clinical Hospital Center Rijeka, Rijeka, Croatia

Problem statement: There has been a notable shift to pregnancy at older maternal ages, which is generally agreed upon as age over 40 years. It is well recognized that women who delay childbearing are at increased risk of pregnancy complications. Our study aimed to compare the incidence of births to older women from 1 January 1995 to 31 December 1997 and from 1 January 2014 to 31 December 2016 and to evaluate the effects of advanced maternal age on pregnancy outcomes in Clinical Hospital Center Rijeka.

Methods: Maternal and obstetrical data were collected from the Register of Clinical Hospital Center Rijeka. We compared the outcomes for women aged ≥40 years with those of younger subgroups stratified by maternal age (20 years; 20–29 years; 30–39 years; control group); 30–39 years). Statistical analyses were performed using Stata 13.3.0. and MedCalc for Windows. In all analyses, P-values less than 0.05 were considered statistically significant.

Results: Over the last two decades, the percentage of mothers aged ≥40 years has increased from 2.1% to 3.8% (X²=46.25;P=0.001). A similar change has taken place in the rates of first-time mothers over 40, showing an increase of 64.1% compared to the 1990s. Moreover, our data revealed a notable rise in the frequency of both autosomal (61.1%) and sex chromosomal aneuploidies (68.2%), as a woman ages. Besides, we found a statistically significant association between pregnancy losses (ectopic pregnancies and abortions) and advanced maternal age. This association might reflect a decline in oocyte quality and/or changes in uterine and hormonal function. Finally, women ≥40 years of age are more likely in the diagnosis of hypertensive disorders (OR=1.86;P=0.009), gestational diabetes mellitus (OR=3.81;P=0.001) and preterm birth (OR=2.09;P=0.001). Compared to the control group, both elective (OR=5.83;P=0.001) and emergency (OR=1.67;P=0.001) Caesarean section, as well as instrumental vaginal delivery (OR=3.19;P=0.002), occur more often in older women. However, their neonates do not show higher odds for Apgar ≤7 and/or perinatal mortality.

Conclusion: In conclusion, the results of our retrospective analysis indicate a significant increase in delayed childbearing and propose advanced maternal age as a risk factor for pregnancy and obstetrical complications.

Conflicts of interest: none

P034
THE CHILDBIRTH EXPERIENCE QUESTIONNAIRE (CEQ) - VALIDATION OF ITS USE IN A DANISH-SPEAKING POPULATION OF NEW MOTHERS STIMULATED WITH OXYTOCIN DURING LABOUR
Sidse Boie¹, Henrik Hein Lauridsen², Julie Glavind², Mette Kiel Småe³, Niels Uldbjerg², Pinar Bor¹
¹Department of Obstetrics and Gynecology, Regional Hospital of Randers, Denmark
²Department of Sports Science and Clinical Biomechanics, University of Southern Denmark, Denmark
³Department of Obstetrics and Gynaecology, Aarhus University Hospital, Denmark

Problem statement: When determining optimal treatment regimens, patient reported outcomes including satisfaction are increasingly appreciated. Furthermore, it is well established that the birth experience may affect the postnatal attachment to the newborn and on the management of subsequent pregnancies and deliveries. As no robust validated Danish tool to evaluate the childbirth experience exists, we aimed to perform a transcultural adaptation of the Childbirth Experience Questionnaire (CEQ) to a Danish context. Methods: In accordance with the COSMIN-based Standards for the selection of health Measurement Instruments (COSMIN), we translated the CEQ from Swedish to Danish. The Danish CEQ was tested for content validity among 10 new mothers. In a population of women who have had their labour induced with oxytocin, we then assessed the electronic questionnaire for validity and reliability using factor analytical design, hypothesis testing, and internal consistency. Based on these data, we determined criterion and construct responsiveness in addition to floor and ceiling effects. Results: The content validation resulted in minor adjustments in two items. This improved the comprehensibility. The electronic questionnaire was completed by 377 of 495 women (76.2%). The original Swedish CEQ was four-dimensional, however an exploratory factor analysis revealed a three-dimensional structure in our Danish population (Own capacity, Participation, and Professional support). Parous women, women who delivered vaginally, and women with a labour duration 12 hours had a higher score in each domain. The internal consistency (Cronbach’s alpha) ranged between 0.75 and 0.89 and the ICC between 0.68-0.93. We found ceiling effects of 57.6% in the domain Professional support and of 25.5% in the domain Participation. Conclusion: This study offers a transcultural adaptation of the CEQ to a Danish context. The 3-dimensional Danish version of the CEQ demonstrates construct validity and reliability. Our results revealed a significant ceiling effect especially in the domain Professional support, which needs to be acknowledged when considering implementing the CEQ into trials and clinical practice.

P035
FACTORS ASSOCIATED WITH SUCCESSFUL VAGINAL BIRTH AFTER INDUCTION OF LABOR IN WOMEN WITH A PREVIOUS CESAREAN SECTION
Ana Catarina Borges, Natacha Sousa, Rita Sarabando, Belisá Vides, Isabel Reis
Department of Gynecology and Obstetrics, Braga Hospital, Braga, Portugal

Problem statement: The success rate of vaginal birth after cesarean section (VBAC) diverge between studies and controversy remains about the safety of induction of labor (IOL) in women with previous cesarean section (CS). Different scoring tools have been developed to help predict whether a woman will have a successful spontaneous VBAC. However, there are few scoring systems predicting the success VBAC after IOL. The purpose of this study is to identify maternal, fetal, and pregnancy characteristics that independently predict the success of IOL, defined as a vaginal delivery (VD) in women with previous CS. Methods: A retrospective cohort study was conducted including all women with singleton pregnancies and a previous single CS who attempted IOL at Braga’s Hospital (tertiary center) from January 2016 until December 2018. Prenatal determinants of women with vaginal birth after IOL were compared to those who failed VD. Pregnancies with non-cephalic presentation and with any ontraindications for VD were excluded. The induction methods used were: vaginal insert of dinoprostone 10mg if Bishop score (BS)= to 6 and oxytocin infusion if BS<6. To evaluate factors predicting VD after IOL, a binary logistic regression was performed. Results: A total of 202 women were enrolled, and 99(49.0%) delivered vaginally. The main indications for IOL were post-date pregnancy (36.6%) and premature rupture of membranes (PROM) (25.2%). Body mass index (p=0.03), favorable BS (p=0.03), IOL for PROM (p=0.02),
previous VD (p=0.04) and previous VD after CS (p=0.03) were associated with VBAC. Otherwise, maternal obesity (p=0.04) and newborn birth weight 4000g (p=0.05) appeared to be associated with failure of IOL. Uterine rupture during labor occurred in one case (0.5%). After performing a binary logistic regression BS, previous VD after CS and IOL for PROM significantly predict the occurrence of VBAC. \( X^2(3)=28.8, p=0.001, R^2=0.19 \). Conclusion: In this study, favorable BS, previous VD after CS and IOL for PROM were associated with successful VBAC, while obesity was associated with failure. These determinants may be useful for development of an admission scoring system predictor of successful VBAC after IOL. It could be valuable in counseling women with previous CS for the option of IOL or repeat CS.

P036
CONSERVATIVE MANAGEMENT OF EARLY-ONSET PREECLAMPSIA WITH SEVERE FEATURES: MATERNAL AND PERINATAL RESULTS AND ASSESSMENT OF CAUSES FOR EARLY DELIVERY
Augusto Brandao, Henrique Vitor Leite, Larissa Volpini, Antônio Carlos Cabral, Gabriela Luiza Sevidanes
Fetal Medicine, Universidade Federal De Minas Gerais, Belo Horizonte, Brazil

Problem statement: Hypertensive disorders in pregnancy, such as preeclampsia (PE) remains as an important cause of maternal and perinatal morbidity and mortality. In most cases of PE with severe features immediately delivery must be required and frequently, this condition happens before 34 weeks of pregnancy, carrying out the risk of perinatal complications linked to prematurity. Conservative management in these conditions aims to allow more time for fetal development and growth but meanwhile maternal stability must be constantly assessed, in order to prevent complications such as HELLP syndrome, eclampsia, eclampsia or death. Any signs of maternal instability or organ failure must indicate immediate delivery despite gestational age or fetal condition. Objectives: The aim of this study is to evaluate maternal and perinatal results and the reasons for delivery in patients with the diagnosis of PE with severe features, admitted for conservative management, who required delivery before 34 weeks of pregnancy. Patients and Methods: This is a retrospective study that recruited all patients with the diagnosis of PE with severe features who required delivery before 34 weeks of pregnancy. The reasons for the premature delivery were categorized and the medians of hospital stay and intensive care period were calculated for the mother and newborn. Results: A total of 72 patients matched the criteria during the period between January of 2016 and December of 2018. The most common reason for premature delivery was the impossibility of controlling the arterial pressure even with the use of combined antihypertensive drugs (2 or more). This reason alone was responsible for the premature delivery of 24 patients (33.3%). Plaquetopenia was responsible for 16 cases (22.2%), followed by prematurity placental abruption (8 cases, 11.1%) and eclampsia (7 cases; 9.7%). Conclusions: Conservative management of early-onset preeclampsia with severe features remains a challenge for obstetric care. A considerable number of cases will develop clinical conditions that won’t allow enough time for the administration of corticoids and adequate fetal development. This study showed that difficulties to control arterial pressure and plaquetopenia are the two most common reasons for these situations.

P038
AN UNUSUAL CAUSE OF ACUTE ABDOMINAL PAIN IN A PREGNANT DIDELPHIC UTERUS - A CASE REPORT
Olivia Anne Cassar1, Stephanie Attard2, Stephanie Attard, Kieran Chircop, Kieran Chircop2, K. Spiteri, K. Spiteri, Karl Spiteri2
1Obstetrics and Gynaecology, Mater Dei Hospital, Malta
2Radiology, Mater Dei Hospital, Malta

Problem statement: Acute abdominal pain is an uncommon complaint during pregnancy and can have a variety of causes some of which might not be suspected due to the gravid state of the uterus. The patient we present is a 30 year old primigravida with a previously diagnosed didelphic uterus who presented to the obstetric emergency area at 23+3 weeks of gestation with severe abdominal pain. She had an uneventful pregnancy till then and on admission was complaining of left sided flank pain of a colicky nature. An MRI performed while she was trying to conceive, had revealed a didelphic system with two uterine cavities, two cervixes and a vaginal septum. Methods: A physical examination performed on admission was remarkable and both cervixes were closed on vaginal assessment. Routine blood and urine investigations were normal and the pain initially settled with simple analgesics. Renal sonography at this stage showed marked hydrouretonephrosis on the left but no evidence of stones. Twenty four hours later the pain increased in severity and frequency leading to the suspicion of preterm labour and hence the neonatal team was alerted and the couple counselled about the probable poor outcome of delivery at this gestation. Results: Since the pain did not settle even when opiates were administered, an urgent MRI was organised and this finally revealed the diagnosis. Left sided...
P039
CHROMOSOMAL ASSOCIATIONS AND GENOMIC INSTABILITY IN IDIOPATHIC RECURRENT PREGNANCY LOSS (RPL)
Abhik Chakraborty, Birendranath Banerjee
School of Biotechnology, Kalinga Institute of Industrial Technology (KIIT) Deemed to Be University, Bhubaneswar, India

Problem statement: Death of infants in uterus or at birth has always been a devastating experience for mothers. The emotional issues surrounding pregnancy loss become magnified exponentially when miscarriage occurs on repetitive basis. Stress plays a very important role in this unexplained RPL cases. Stress is being linked with many life-style related disorders such as diabetes, hypertension, cardiovascular diseases etc, but very few studies have been done to explore the role of stress on RPL.

Methods: Studies have been done to explore the role of stress on RPL. It is being linked with many life-style related disorders such as diabetes, hypertension, cardiovascular diseases etc, but very few studies have been done to explore the role of stress on RPL. Stress plays a very important role in this unexplained RPL cases. Stress is being linked with many life-style related disorders such as diabetes, hypertension, cardiovascular diseases etc, but very few studies have been done to explore the role of stress on RPL.

Results: By performing basic GTG karyotyping analysis, we identified various structural or numerical chromosomal anomalies in the RPL patients. We have screened a couple of novel translocations responsible for RPL, which were not reported earlier. We have observed that a huge number of individuals with RPL in our cohort are reported normal in karyotype, and additionally the reason for their recurrent miscarriage is unknown. We further checked these individuals for their background genomic instability and we found that few of these individuals have high background of genomic instability as compared with the control samples. Further we checked the telomeric integrity of the patients with high genomic instability, few of them showed loss of telomeres (T/S ratio, by RT-PCR), we performed Q-FISH analysis on the same samples and have found loss in telomeric signals, also we have performed western blot analysis of some of the key players of the telomycin components and found low level of expression of these proteins in the RPL patients. From the above studies we observed that loss of telomeres were very evident in some of the patients which we have confirmed on various platforms. Conclusion: We have shown that apart from numerical or structural chromosomal anomalies, loss of telomeres also may play a critical role in promoting RPL. This work will lead to identification of few biomarkers for unexplained RPL. This will help in better management of the couple experiencing repeated trauma of RPL and will aid them towards better possibility of conception.

Disclosure of interest: No conflicts of interest. Abbreviations: RPL – Recurrent pregnancy losses; GTG – G-banding by trypsin and giemsa; PNA-FISH – Peptide nucleic acid-fluorescent in-situ hybridization.

P040
INCIDENCE OF ASYMPTOMATIC BACTERIURIA IN A LOCAL PREGNANT POPULATION
Cassandra Cheong1, Shu Qi Tan1, How Chuan Han2
1Division of Obstetrics and Gynaecology, KK Women’s and Children’s Hospital, Singapore
2Department of Urogynaecology, KK Women’s and Children’s Hospital, Singapore

Problem statement: Asymptomatic bacteriuria occurs in 2 to 10% of pregnancies. Clinical guidelines recommend routine antenatal screening of asymptomatic bacteriuria due to its association with increased risk of pyelonephritis, preterm labor and low birth weight. Routine screening of asymptomatic bacteriuria is not practiced in our institution. There is no local study on the prevalence of asymptomatic bacteriuria. This is a pilot study that aims to define the local incidence of asymptomatic bacteriuria and its associated adverse outcomes in our population.

Methods: This is a retrospective study in a tertiary obstetrics and gynaecology center in Singapore between October 2017 and August 2018. Urine dipstick for albumin, urine microscopy and urine culture with sensitivity were performed. A positive urine culture was defined when more than 10^5 bacteria per milliliters is present in a single voided midstream urine. Outcomes of interest were low birth weight, preterm delivery and admission for pyelonephritis. Results: Fifty patients had antenatal urine studies performed during this period. Asymptomatic bacteriuria was detected in 6% (n = 3). None of these cases had complications of low birth weight, preterm delivery or admission for pyelonephritis. Conclusion: Fifty patients had antenatal urine studies performed during this period. Asymptomatic bacteriuria was detected in 6% (n = 3). None of these cases had complications of low birth weight, preterm delivery or admission for pyelonephritis.

P041
FETAL PULMONARY VENOUS FLOW IMPEDANCE IN PREGNANCIES WITH PLACENTAL INSUFFICIENCY-RELATED OLIGOHYDRAMNIOSES
Hyunjin Cho, Yong-Il Ji, Chul-hoi Jeong, Sung-wook Chun, Gyun-ho Jeon, Eun-hyeon Lee
Obstetrics and Gynecology, Haeundae Paik Hospital, Inje University, Busan, South Korea

Problem statement: In placental insufficiency, alteration of left heart function is expected to occur, as a consequence increased placental vascular impedance. Pulmonary vein flow patterns could reflect

Figure 1: Schematic diagram showing work flow of the study.

Results: By performing basic GTG karyotyping analysis, we identified various structural or numerical chromosomal anomalies in the RPL patients. We have screened a couple of novel translocations responsible for RPL, which were not reported earlier. We have observed that a huge number of individuals with RPL in our cohort are reported normal in karyotype, and additionally the reason for their recurrent miscarriage is unknown. We further checked these individuals for their background genomic instability and we found that few of these individuals have high background of genomic instability as compared with the control samples. Further we checked the telomeric integrity of the patients with high genomic instability, few of them showed loss of telomeres (T/S ratio, by RT-PCR), we performed Q-FISH analysis on the same samples and have found loss in telomeric signals, also we have performed western blot analysis of some of the key players of the telomycin components and found low level of expression of these proteins in the RPL patients. From the above studies we observed that loss of telomeres were very evident in some of the patients which we have confirmed on various platforms. Conclusion: We have shown that apart from numerical or structural chromosomal anomalies, loss of telomeres also may play a critical role in promoting RPL. This work will lead to identification of few biomarkers for unexplained RPL. This will help in better management of the couple experiencing repeated trauma of RPL and will aid them towards better possibility of conception.

Disclosure of interest: No conflicts of interest. Abbreviations: RPL – Recurrent pregnancy losses; GTG – G-banding by trypsin and giemsa; PNA-FISH – Peptide nucleic acid-fluorescent in-situ hybridization.

P040
INCIDENCE OF ASYMPTOMATIC BACTERIURIA IN A LOCAL PREGNANT POPULATION
Cassandra Cheong1, Shu Qi Tan1, How Chuan Han2
1Division of Obstetrics and Gynaecology, KK Women’s and Children’s Hospital, Singapore
2Department of Urogynaecology, KK Women’s and Children’s Hospital, Singapore

Problem statement: Asymptomatic bacteriuria occurs in 2 to 10% of pregnancies. Clinical guidelines recommend routine antenatal screening of asymptomatic bacteriuria due to its association with increased risk of pyelonephritis, preterm labor and low birth weight. Routine screening of asymptomatic bacteriuria is not practiced in our institution. There is no local study on the prevalence of asymptomatic bacteriuria. This is a pilot study that aims to define the local incidence of asymptomatic bacteriuria and its associated adverse outcomes in our population.

Methods: This is a retrospective study in a tertiary obstetrics and gynaecology center in Singapore between October 2017 and August 2018. Urine dipstick for albumin, urine microscopy and urine culture with sensitivity were performed. A positive urine culture was defined when more than 10^5 bacteria per milliliters is present in a single voided midstream urine. Outcomes of interest were low birth weight, preterm delivery and admission for pyelonephritis. Results: Fifty patients had antenatal urine studies performed during this period. Asymptomatic bacteriuria was detected in 6% (n = 3). None of these cases had complications of low birth weight, preterm delivery or admission for pyelonephritis. Conclusion: Fifty patients had antenatal urine studies performed during this period. Asymptomatic bacteriuria was detected in 6% (n = 3). None of these cases had complications of low birth weight, preterm delivery or admission for pyelonephritis.

P041
FETAL PULMONARY VENOUS FLOW IMPEDANCE IN PREGNANCIES WITH PLACENTAL INSUFFICIENCY-RELATED OLIGOHYDRAMNIOSES
Hyunjin Cho, Yong-Il Ji, Chul-hoi Jeong, Sung-wook Chun, Gyun-ho Jeon, Eun-hyeon Lee
Obstetrics and Gynecology, Haeundae Paik Hospital, Inje University, Busan, South Korea

Problem statement: In placental insufficiency, alteration of left heart function is expected to occur, as a consequence increased placental vascular impedance. Pulmonary vein flow patterns could reflect
altered left atrial pressure. It is known that fetal pulmonary venous flow impedance was higher in women with placental insufficiency-related intrauterine insufficiency. The aim of this study was to determine whether fetal pulmonary venous pulsatility index (PVPI) was greater in women with placental insufficiency-related oligohydramnios than in women with adequate amounts of amniotic fluid during the third trimester. **Methods:** PVPI and the umbilical arterial systolic/diastolic (S/D) ratio were measured using Doppler echocardiography in 130 pregnant women between 28 and 39 gestational weeks. Two measurements were obtained for each fetus. The average value of two measurements was used. Two measurements were obtained for each fetus by single expert obstetrician. The average value of two measurements was used. Pregnant women were divided into two groups according to the amount of amniotic fluid. PVPI and umbilical arterial S/D ratio were compared between 19 pregnancies with oligohydramnios and 111 with adequate amniotic fluid. **Results:** The mean gestational age and estimated fetal weight were not significantly different between the two groups. The maternal age was older in the oligohydramnios group (36.89 ± 5.88 versus 34.06 ± 4.79; P = 0.23). But it was statistically insignificant. Intraclass correlation coefficient of PVPI was 0.982. The mean PVPI was significantly higher in the oligohydramnios group than in the control group (1.13 ± 0.22 versus 0.89 ± 0.31; P 0.001). There was no significant difference in umbilical arterial S/D ratio between the groups (p = 0.142).

**Conclusions:** This result suggests that PVPI could be used as an early diagnostic marker of fetal deterioration in placental insufficiency-related oligohydramnios. Figure 1. (A) Doppler tracing of a pulmonary vein flow obtained in a fetus with adequate amniotic fluid. Pulsatility index (PI) is 0.76. (B) fetus with oligohydramnios. PI is 1.21. S, systolic; D, diastolic; A, end-diastolic.

Correlation of maternal age, parity, gestational weeks and percentile of estimated fetal weight (per-EFW) at the time of PVPI measurement, PVPI, maternal HTN and DM, gestational weeks of delivery and percentile of fetal birth weight (per-FBW) was analyzed. Univariate and multivariate regression analysis were performed. In addition, the receiver operating characteristic (ROC) curve was performed to assess the sensitivity and specificity for low birth weight (LBW) infants. All statistical analyses were carried out using SPSS 24.0 and MedCalc 11.6.0 and p values less than 0.05 was considered statistically significant. **Results:** A total of 129 people were included in the study. The mean maternal age was 34.6 year old ± 5.0 (22.0–45.0), the mean gestational age of PVPI measurement was 32.5 weeks ± 3.4 (250–38.0). The mean gestational weeks of delivery was 37.2 weeks ± 2.0 (27.0–40.0). The number of LBW infants was 37 (28.7%) at birth. Statistically related factors to per-FBW were per-EFW (p=0.001) and PVPI (p=0.004) in multivariate regression analysis. Area under the ROC curves of per-EFW and PVPI to predict LBW were not significant different (0.911 versus 0.890, P=0.624). The cutoff of PVPI to predict LBW was 1.13 and it has 70.27% of sensitivity, 92.39% of specificity, 78.79% positive predictive value and 88.54% of negative predictive value. **Conclusion:** PVPI, measured after 25 weeks of gestation, can predict LBW infant at birth. There is no disclosure of interest.

**P043 ANAEMIA DURING PREGNANCY IN SOUTH AFRICA: ESTABLISHING THE CAUSE**

Vino Dorasamy1, Melissa Bengu2, Chauntelle Bagwandeen3, Jagadesa Moodley4

1School of Laboratory Medicine and Medical Sciences, University of Kwazulu-Natal, Durban, South Africa
2School of Clinical Medicine, University of Kwazulu-Natal, Durban, South Africa
3School of Nursing and Public Health, University of Kwazulu-Natal, Durban, South Africa

**Problem Statement:** A significant cause of morbidity and mortality during pregnancy is maternal anaemia. The causes of anaemia are varied, but in resource limited settings and certain geographic locations, its effects and sequelae are public health challenges. South Africa, a low to middle income country, is plagued by a quadruple burden of disease, with high maternal mortality ratios influenced by an epidemic of hypertensive disorders of pregnancy, HIV, tuberculosis and neglected tropical diseases. This is most prevalent in the Black population whose majority have low socio-economic status. Poor nutrition, chronic infections, lack of access to health care facilities and poor compliance with micronutrient supplementation all contribute to maternal anaemia. The aim of this study was to establish the prevalence, and type of anaemia affecting a pregnant South African population. **Method:** Six hundred pregnant women were recruited into the study. Haematological (full blood count and iron studies) and demographic data was collected from participants and hospital records. Stool and urine samples were collected and analysed for soil transmitted helminths and schistosomiasis. A Hb cutpoint of 10.5 g/dl was used to define anaemia in any stage of pregnancy. **Results:** The prevalence of anaemia in the study was 41%. All participants reported taking standard issued iron supplementation. The majority of cases were normocytic and normochromic suggestive of an infective cause or chronic condition. Most participants were mildly anaemic (84%) while 14% was moderately anaemic and 2% were severely anaemic. Participants living with HIV were at greater risk of being anaemic. Four percent of the study population were infected with soil transmitted parasites and 7% had schistosomiasis (S. haematobium). **Conclusion:** Anaemia is very common in the South African pregnant population. While iron supplementation may improve anaemia in pregnant women, universal prophylactic treatment for anaemia may not be appropriate without first establishing the type and cause of anaemia in this vulnerable population. Furthermore, indiscriminate
iron supplementation may have adverse pregnancy outcomes by counteracting normal physiological sequestration of iron in the face of infection. Health care providers should establish the cause of anaemia to reduce maternal and fetal morbidity and mortality.

P044
ANTENATAL DIAGNOSIS OF ABSENCE OF SEPTUM PELLUCIDUM
Imane Ben M'Barek-Jauvvin1, Michael Tassin1, Agnès Guéit2, Isabelle Simon3, Valérie Mairivotz1, Laurent Mandelbrot1, Olivier Picone1, Charles Egloff4
1Unité De Diagnostic Anténatal, Hôpital Louis Mourier, Colombes, Hopitaux Universitaires Paris Nord Val De Seine, Assistance Publique Des Hopitaux De Paris, Colombes, France
2Service De Pédiatrie, Hôpital Louis Mourier, Colombes, Hopitaux Universitaires Paris Nord Val De Seine, Assistance Publique Des Hopitaux De Paris, Colombes, France
3Service De Radiologie, Hôpital Louis Mourier, Colombes, Hopitaux Universitaires Paris Nord Val De Seine, Assistance Publique Des Hopitaux De Paris, Colombes, France
4Service de Gynécologie-obstétrique, Hôpital Louis Mourier, Colombes, France

Problem statement: The absence of septum pellucidum (ASP) is a rare cerebral disease. The prenatal counseling can be difficult because of unknown neurological outcome. Methods: Description of 4 cases of septal absence diagnosed antenatally between 2013 and 2016 and confirmed after birth. Results: Of the 4 cases, 2 were diagnosed during the morphological ultrasound examination, at 22 and 22+5 Weeks of Gestation (WG) and 2 were detected later in pregnancy, at 27+5WG and 32WG, due to technical problems (uterine fibroids and maternal obesity, respectively). All patients had an amniocentesis and a cerebral fetal MRI at 32WG. In case 1 (see Table) the MRI showed a hypointense signal on the pituitary, in case 4 there was a callosal agenesis and perisylvian polymicrogyria and in the two other cases the ASP appeared isolated. None of the patients received a termination of pregnancy, and all delivered at full term. After birth, the children were followed-up with neurologic and endocrine evaluations. Of the 4 cases of ASP, one was diagnosed with septo-optic dysplasia (SOD) after birth (case 1), one with bilateral opercular dysplasia (case 4) and the other 2 were confirmed to be isolated (cases 2 and 3). At the last evaluation, the child with SOD has a dyslexic executive syndrome, and the child with bilateral opercular dysplasia has a left monoparesis and language delay. Both children are receiving an adapted academic education. The children with isolated ASP have a normal neurological development. Conclusion: ASP can be diagnosed during routine second trimester morphological ultrasound screening. The prenatal work-up should include an amniocentesis for cytotyping and CGH array and a fetal cerebral MRI in order to access whether the ASP is isolated or not. The antenatal diagnosis is reassuring when the ASP is isolated, but still carries a 20% risk of SOD which may be isolated or not. The antenatal diagnosis is reassuring when the second trimester morphological ultrasound screening. The prenatal complications, leading to significant morbidity and mortality. This P044

P045
CURRARINO SYNDROME - A PRE AND POST NATAL DIAGNOSIS CORRELATION: CASE REPORT AND LITERATURE REVIEW
Catarina Ferreira2, Margarida Carvalho1, Sara Abrantes1, Manuel Gonçalves1, Catarina Luís2, Joaquim Fonseca1, Ana Paula Santos3, Ana Cristina Costa1, Antónia Nazaré1
1Department of Obstetrics, Hospital Professor Doutor Fernando Fonseca, Portugal
2Department of Pediatrics, Hospital Professor Doutor Fernando Fonseca, Portugal

Problem statement: Currarino syndrome is a rare autosomal dominant disorder and affected subjects are at-risk of serious complications, leading to significant morbidity and mortality. This disease is formed by a Currarino triad: sacral anomalies, presacral mass and an anorectal malformation; it exhibits variable expressivity and many heterozygotes are asymptomatic. Prenatal ultrasonography may identify the presence of a presacral mass, although it is not an accurate or complete investigation for someone at 50% risk. Methods: We discuss a case report of Currarino Syndrome with an early diagnosis through imagological study during pregnancy for prenatal diagnostic purposes. Results: First appointment of 24 years-old healthy primigravida with a suspicion of spina bifida occulta at 21 weeks. Obstetrical ultrasounds and the first fetal magnetic resonances presented first a closed sacrococcygeal dysraphism without meningocele and cerebral alterations like Arnold-Chiari malformations; at 29 weeks, a small meningocele with lowered medullary cone appeared during second fetal magnetic resonance. She had a term vaginal delivery, with a female newborn, 3315gr, Apgar score 9/9/10 and a perianal and endorectal polyoid mass. A magnetic resonance was performed which illustrated: a partial sacral agenesis; anterior myeloctraphic; rectosacral mass; anchored medulla (cone in L4). After these results, the newborn was diagnosed with the differential diagnosis of neural tube defects in the asymptomatic mother: sacral agenesis and anterior meningocele. Afterwards, we had an early Currarino Syndrome diagnosis and performed a neurosurgery to allow the medullar distal release and hents terminal section. The child has 1 year and a normal physical and psychomotor development, with symmetric leg movement and a normal intestinal transit. She will be monitored by a multidisciplinary team to evaluate her evolution, specifically locomotion and sphincter control. Conclusion: Despite the difficulty of doing a prenatal diagnosis of this syndrome, whenever we detect a presacral mass during the obstetric ultrasounds, we advise the inclusion of Currarino syndrome in the differential diagnosis of neural tube defects. We should also expand genetic counselling and promote screenings, allowing identification of asymptomatic heterozygotes. The recognition of at-risk subjects should lead to better planning of pregnancies and appropriate management of affected children at birth.

P046
IODINE SUPPLEMENTATION DURING PREGNANCY AND NEONATAL OUTCOMES
Maria Flores Casteleiro, Rita Vasconcelos, Fedra Rodrigues, Diogo Cunha, Belisa Vides, Isabel Reis
Serviço de Ginecologia E Obstetrícia, Hospital De Braga, EPE, Braga, Portugal

Problem statement: Iodine is essential for healthy thyroid function. An increase in its requirement during pregnancy puts women with low preconception iodine reserves at risk of pathological thyroid dysfunction and the child at risk of neurodevelopmental defects. Global guidelines recommend considering iodine supplementation during pregnancy and lactation. However, the effect of iodine supplementation or fortification on prenatal and postnatal growth is unclear and the existing literature suggests that successful salt iodization programmes can meet the needs of population groups susceptible to iodine deficiency, specifically pregnant women. The aim of this study is to assess the effects of iodine supplementation during pregnancy compared to a diet with iodised salt on prenatal and postnatal somatic growth of the fetus or newborns. Methods: Online search of PubMed, DARE and Cochrane Library databases. We used MeSH terms for search in PubMed: “iodine,” “pregnancy” and “newborn”. Selection criteria: guidelines, randomised controlled trials (RCT) and systematic reviews that assessed the benefits on children’s outcome of supplementation with iodine or iodized salt in the preconception period or during pregnancy. The articles’ date of publication was restricted to the past 10 years and only studies in Humans were selected. No language restrictions were used. Results: 138 records were examined. After screening the titles and abstracts of all the records and removing the
duplicates, we excluded 127 search results, as they were ineligible according to the pre-defined criteria. Finally, we included three systematic reviews and two randomised controlled trials. A Cochrane review suggests that there were no clear effects of supplementation on maternal or child outcomes and the RCTs demonstrated that iodine supplement does not have a statistical significance impact on adverse neonatal outcomes compared to no-supplement. However, these results must be interpreted with caution due to various limitations in study design and analysis including small sample size. Conclusion: Iodine supplementation improves some maternal thyroid indexes and may benefit the cognitive function in children. However, these findings, with low-quality evidence, suggest that pregnancy iodine supplementation usage needs to be evaluated and updated to clarify and quantify the risk/benefits of iodine supplementation in regions previously believed to be iodine sufficient.

PO47
CHORIONICITY IN TWIN PREGNANCIES – OBSTETRIC AND NEONATAL IMPACTS AT THE MOMENT OF DELIVERY
Maria Flores Casteleiro, Rita Vasconcelos, Ana Catarina Borges, Bárbara Ribeiro, Leonor Bivar, Fedra Rodrigues, Diogo Cunha, Belandinha Gil, Belisa Vides, Isabel Reis
Serviço De Ginecologia E Obstetricia, Hospital De Braga, EPE, Braga, Portugal

Problem statement: Multiple pregnancies represent about 3% of all pregnancies. Twin pregnancies are the most frequent and can be classified as monozygotic (1/3) or dizygotic (2/3). Morbidity and mortality in multifetal pregnancy is higher than unifetal and change according to chorionicity. Compared with dichorionic twins, monochorionic twins have a higher frequency of fetal and neonatal mortality, as well as morbidities, such as fetal and congenital anomalies, prematurity and fetal growth restriction. This study aims to assess the differences in maternal and neonatal outcomes based on chorionicity. Methods: Retrospective analysis of all twin pregnancies delivered at Hospital de Braga between January 2004 and June 2019. Triplets and stillbirths were excluded. 621 cases were analysed for demographic data, chorionicity, gestational age at delivery, pregnancy complications, delivery route and perinatal morbidity. Using SPSS Statistics version 23.0, a comparative analysis between groups was done, evaluating possible associations. Results: 456 (73.4%) were dichorionic and 165 (26.6%) were monochorionic pregnancies. From the data analysis, mean maternal age proved to be significantly higher at the dichorionic pregnancy group: 31.86 vs 31.44 years (p value = 0.040). Difference was observed between monochorionic and dichorionic pregnancies, respectively: regarding mean gestational age at delivery 34.63 vs 35.21 weeks (p value = 0.001); weight of first fetus 2187.23 vs 2300.93g (p value = 0.001); and weight of second fetus 2121.39 vs 2226.22g (p value = 0.005). Concerning the route of delivery, 69.1% of monochorionic and 61.0% of dichorionic were caesarean section (p value = 0.117). Regarding APGAR score and birth weight discordance (12.90% in monochorionic vs 12.16% in dichoronic; p value = 0.799) the results obtained weren’t statistically significant. Conclusion: Despite the literature associating monochorionic pregnancies with worse neonatal outcomes, APGAR did not show worse results in newborns who shared the same placenta. However, this investigation also found decreased weights in these newborns, which may be explained by the lower gestational age. In this study, monochorionic recorded the highest caesarean section rates, which may suggest greater maternal and fetal morbidity in this type of pregnancy, however, comparing with dichorionic pregnancies, the difference in the mode of delivery was not statistically significant.

PO48
MICRORNA ANALYSIS OF DESIDUA DERIVED MESENCHYMAL STEM CELLS FROM PREECLAMPSIA PATIENT
Tuba Guneli1, Nilufer Kamali1, Ali Beniam2, Kubra Sarı3, Yagmur Ergun3, Hale Goksever Celik4, Sercin Karahuseyinoglu1
1Department of Molecular Biology and Genetics, Faculty of Science, Istanbul University, Istanbul, Turkey
2Department of Obstetrics and Gynecology, Cerrahpasa Medical Faculty, Istanbul University - Cerrahpasa, Istanbul, Turkey
3Koc University Research Center for Translational Medicine, Medical Faculty, Koc University, Istanbul, Turkey
4Department of Obstetrics and Gynecology, Kanuni Sultan Süleyman Research and Training Hospital, Istanbul, Turkey

Disclosure of Interest: All authors declare that they have no conflict of interest.

PO49
DETERMINING PRETERM LABOUR THROUGH CERVICAL BIOMETRICS AND FETAL FIBRONECTIN
Elitsa Gyokova1,2, Yordan Popov1,2, Yoana Ivanova-Yoncheva1,3, Polina Vasileva1,2, Sarah Wilson4
1Department of Obstetrics and Gynecology, Medical University - Pleven, Pleven, Bulgaria
2Department of Obstetrics and Gynecology, University Multi-profile Hospital for Active Treatment “Dr. Georgi Stranski”, Pleven, Bulgaria
3Department of Obstetrics and Gynecology, University Multi-profile Hospital for Active Treatment “Saint Marina”, Pleven, Bulgaria
4Faculty of Medicine, Medical University - Pleven, Pleven, Bulgaria

Disclosure of Interest: All authors declare that they have no conflict of interest.

Problem statement: The main problem for fetal morbidity and mortality in twenty first century is still the premature delivery. It’s very highly searched how to predict which women will give preterm labour. The most widely used method of ultrasound cervical length measurement can determine the patients at highest risks, but there
is no stable cutoff. Therefore, were found some clinical biomarkers in the cervico-vaginal fluid – one of them is the fetal fibronectin (fFN). The aim of the study was to evaluate the predictive value of measuring the cervical length plus a quality test of fFN. **Methods:** A prospective, cross-sectional study was designed, dividing pregnant women between 24 and 32 weeks. Group A patients with clinical symptoms of preterm birth and Group B patients without symptoms. All patients that were included had a test of fFN performed followed by a transvaginal measurement of the cervix. The results from the fFN were blinded, all patients received same management, respectively, the patients from Group A were administrated tocolytic and steroid therapy. The pregnancy outcome was collected to be analyzed. **Results:** 63 patients took part in the research. All patients from group A that were positive on fFN and had shortening of the cervix, delivered in 2 weeks no matter the strong tocolytic. The results from Group B show false positive predictable value. The test showed high predictive value when negative result. When applying the used biochemical test in combination with cervical biometrics, the risk of preterm can be determined by more than 95% of the cases. **Conclusion:** The modern obstetrics cannot afford to skip the problem of the premature. Even so, the currently used methods for prediction are showing unsatisfactory predictive efficacy if used one by only. What we really need is to either find new methods for screening or improve those we have. The results from many studies are proving that the more markers are combined in one protocol, the better prognosis, the bigger the sensitivity and specificity, the best pregnancy outcomes. **Acknowledgements:** This research was funded by Medical University – Pleven through research project D1/2018.

**P050**

**IMPLICATIONS OF EXTREME WEIGHT LOSS DUE TO HYPEREMESIS IN PREGNANCY**

Nandini Halder1, Samir Ray2, Talar Amin3
1Obstetrics and Gynaecology, Glanuwil General Hospital, Carmarthen, UK
2Obstetrics and Gynaecology, Withybush General Hospital, Carmarthen, UK

**Introduction:** Hyperemesis causes poor weight gain in pregnancy sometimes causing gestational weight loss (GWL) in extreme cases. A GWL of 15% of booking weight is exceptionally rare and is classed as extreme weight loss. We present a lady who lost 20.5% of her booking weight. **Case Summary:** A 29-years-old G6P3 lady with previous vaginal deliveries, gestational hypertension and SGA babies was treated for pulmonary tuberculosis in childhood. Her booking weight was 90.5Kgs and BMI 30.5 and she was started on daily aspirin. She vomited although her pregnancy and developed gestational diabetes that was diet-controlled. She was hospitalised at 31+weeks and 33+ weeks gestation for excessive vomiting when her ALT was elevated, and abdominal ultrasound showed thickening of gall bladder wall with no obstructive features. She was managed conservatively with fluids, antiemetics, IV Pabrinex and dietician started her on Fresubin energy drinks. She lost 18.6Kg of her body weight by 32+weeks gestation. She was given 2 doses of betamethasone as her fetal growth was on 10% centile that dropped to 5th centile at 35+ weeks. Her membranes ruptured at 35+6 weeks and she was induced to labour at 37 weeks and quickly laboured delivering a baby boy weighing 2440gm in good condition. Both were discharged on D2 postnatal. **Discussion:** Meta-analysis of case reports suggests that GWL is associated with high odds of SGA, preterm births and fetal anomalies. RCOG Green-top recommends inpatient management for mothers with 5% GWL due to hyperemesis. Mums may develop a variety of complications. **Conclusions:** There is no nutritional guidelines available for hyperemesis. Referral to dietician and early consideration of parenteral supplement needs to be explored. MDT input including psychological support is essential, and caregivers in this case needed to address her diabetes alongside chronic starvation with ketosis to avoid diabetic ketoacidosis. There is role of pulsed steroid therapy in intractable hyperemesis however her co-existing gestational diabetes made that treatment decision difficult. This case highlights the need for regular maternal weight monitoring at every antenatal visit for mums suffering from hyperemesis. Such cases of significant GWL should be followed-up to study long term effects on mum and baby.

**P051**

**EFFICIENCY OF EXOGRAPHIC EXAMINATION OF FETOPLASENTAL SYSTEM OF WOMEN WITH UTERINE SCAR AFTER MYOMECTOMY**

Yashar Hasanov1, Nigar Kamilova2
1Obstetrics and Gynaecology, Central oil workers hospital, Baku, Azerbaijan
2Obstetrics-gynecology, Azerbaijan Medical University, Baku, Azerbaijan

The goal was study of informativeness exographic examination of fetoplacental system in women with uterine scar after myomectomy. **Materials and methods of research:** In order to study the frequency of myomectomy, operating instructions, intra- and postoperative complications during the period 2008–2014, in gynecological departments of the Central Oil Workers Hospital, birth center of the Nakhchivan Autonomous Republic and several private clinics (Real ST Center, Baku Medical Plaza, and so) it was analyzed 119 hospitalized women after myomectomy. The analysis and survey of these women was performed 2-3 years after reconstructive plastic surgery to analyze the long-term results. The following research methods were used: Nationwide examination; Clinical and laboratory diagnostic methods; Exographic examination of the fetoplacenar system, including ultrasound examination, dopplerometric examination and fetal anesthesia; Statistical analysis. **Results and their discussion:** Premature aging of 8 (26.7±2.4) pregnant women with chronic pyleonphritis complications (III degree of maturity before 37th week of pregnancy). This is manifested by the presence of irregularly shaped, non-homogeneous exogenous zones on the hollow plate. In addition, in the third trimester of pregnancy in 3 women (10±1.6) with severe acute pyleonphritis, placenta I was diagnosed with late pregnancy, indicating that the placenta was late. The placenta thickness was 2.4±0.05 sm in women from I group and 2.7±0.02 sm, from II group (p<0.001). In most cases, low placental (17 (36.2±7.01%), 16 (55.2%), in both groups 1 (2.12±2.1%) and 5 (17±0.5), respectively. Prevalence of placenta in the pregnant woman was 7 (0.01%). The prevalence of uterine-placental and I or fetal blood flow was found in all women in both groups; 14±5.19% in group I, 6 in group II, 9→7.1%, grade II disorder was 31.9±6.8% in Group I, 27.6±3.3% in Group II, Critical violations (III degree) were reported in I group 25 (53.2±7), 28%) and 19 (65.5±8.3%) in the II group. **Findings:** Using dopplerometry allows USM to predict the growth rate of the node and the risk of developing a stroke.

**P052**

**PREGNANCY OF UNCERTAIN VIABILITY: IS PREDICTION BETTER THAN STRATEGY?**

Helga Consiglio1,2, Karen Borg Grima1, Mark Formosa1,2, Stephen Wolstenhulme3
1Radiography, University of Malta, Msida, Malta
2Obstetrics and Gynaecology, Mater Dei Hospital, Msida, Malta
3Radiography, University of Leeds, Leeds, UK

**Problem statement:** Pregnancy of Uncertain Viability (PUV) is an intra-uterine pregnancy that does not present the ultrasonographic features to confirm viability or miscarriage. Making the correct diagnosis is non-negotiable. This necessitates follow-up which results in anxiety specific to uncertainty. The aim of the study was to investigate PUV prediction and ultrasound follow-up strategies to optimize PUV management. **Methods:** A prospective quantitative design was adopted. Women diagnosed with PUV were followed until a definitive diagnosis was reached. The predictive aspect analysed a bleeding score, ultrasonic parameters
and Human Chorionic Gonadotropin as well as progesterone levels in relation to PUV outcome. The predictive factors were analysed individually and in combination to devise a predictive model. The strategic aspect compared findings at weekly intervals to identify the ideal follow-up strategy. Results: 43 women diagnosed with PUV were recruited, of whom 41.9% miscarried. Pregnancy loss was found to be statistically associated with vaginal bleeding (p=0.003), presentation at a later gestational age (p=0.000) and lower progesterone levels (p=0.000). Viable gestation sacs were found to grow at a daily rate of 1.161mm while the non-viable mean sac growth was 0.769mm/day. A predictive model using progesterone, bleeding and Mean Sac Diameter had a sensitivity of 72.2% and a specificity of 88% (AUC 0.81). The strategic arm of progesterone, bleeding and Mean Sac Diameter had a sensitivity of 72.2% and a specificity of 88% (AUC 0.81). The strategic arm of the study showed that 78% of cases had a definitive diagnosis by day 7. Conclusions: A predictive model for PUV although suitable does not provide a definitive diagnosis. The 7 day waiting strategy provides a definitive diagnosis in 79% of PUV obviating the need to wait longer. This strategy may be evaluated further with potential for optimizing PUV management.

P054
INCIDENTAL MYOMECTOMY AT TIME OF VAGINAL DELIVERY CONTRIBUTING TO POSTPARTUM HEMORRHAGE: A CASE REPORT
Payam Katebi Kashfi1, Annette D. Palons2, Rhiana D. Saunders3, Erin N. McMullen4, Katherine L. Dengler5
1Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Inova Fairfax Women’s Hospital, Falls Church, USA
2Department of Obstetrics and Gynecology, Blanchfield Army Community Hospital, Fort Campbell, USA

Problem statement: Uterine leiomyomas are known to cause complications in pregnancy, including malpresentation, intrauterine growth restriction, preterm labor, and postpartum hemorrhage. Large submucosal leiomyomas may have higher complication rates. In the postpartum period, leiomyoma have been associated with postpartum hemorrhage due to uterine atony. The proposed mechanism of atony is the limited contractile ability of the uterus around the intrauterine mass. Hemorrhage from uterine atony can increase the use of uterotonic agents, blood transfusion rates, and surgical procedures including hysterectomy. Methods: A 44-year-old gravida 4 para 2-0-1-2 was admitted with premature rupture of membranes at 40 2/7 weeks. Her medical history was significant for advanced maternal age and a known large posterior leiomyoma, measuring nine centimeters on ultrasound (Figure 1). Her labor was induced with oxytocin and she delivered a viable female infant approximately 24 hours after admission. The third stage of labor was completed in eight minutes with the spontaneous delivery of an intact placenta. The uterine fundus was firm and 60 units of intravenous oxytocin was routinely administered. A thorough evaluation revealed no vaginal or cervical lacerations, however, active bleeding continued from the lower uterine segment. Results: Vaginal delivery in this patient was complicated by lower uterine segment atony leading to postpartum hemorrhage caused by her large submucosal fibroid. The patient was given multiple uterotonic medications without improvement. During a manual uterine sweep for suspected retained products of conception, a submucosal leiomyoma was incidentally extracted. Phenytoine was administered while intravenous fluid and blood product administration continued. Hemostasis was achieved with placement of a Bakri balloon. Her hematocrit was 40.0% on admission and decreased to 26.0% on post-partum day one following her blood product transfusions. She was discharged to home on postpartum day three in stable condition after a short intensive care unit admission. Histopathologic evaluation confirmed an epithelioid leiomyoma weighing 119 grams and measuring 7.0 x 7.0 x 5.0 centimeters. Conclusion: This case reaffirms the association of large (greater than five centimeters) submucosal leiomyomas with severe postpartum hemorrhage. The use of balloon tamponade in such situations may contribute to hemostasis and avoidance of postpartum hysterectomy. Financial Disclosure: none.
Uterine inversion is an abnormal protrusion of internal surface of relaxed uterus through the vaginal orifice. Acute inversions occurring immediately, or within 24 hours post-partum are the most common type. Chronic Uterine Inversions (CUI) occurring more than four weeks after the delivery are rare identities. Chronic nature of these inversions makes the restoration of the normal position of the uterus per vaginal difficult contrary to acute inversions which can be reposited more easily. A 34-year-old lady was initially admitted to our hospital with postpartum bleeding caused by uterine inversion. Obstetricians explained that her uterus had inverted when attached placenta manually removed and then reduct, but placenta might be remained approximately 70–80%. An abdomen CT ruled out active bleeding and uterus inversion, and confirmed that there were no abnormalities on uterus. There was 6.12 cm depth mass in endo-metrium considered retained placenta by transvaginal ultrasound. Although she received transfusion, the words: uterine inversion, postpartum spotting at postpartum: a case report

Hye-Sun Kim, Haew Won Choi, Haew Won Choi, Kyong-Chul Chun
Department of Obstetrics and Gynecology, Ilan-Pak Hospital, Inje University College of Medicine, Goyang, South Korea

Uterine inversion is abnormal protrusion of internal surface of relaxed uterus through the vaginal orifice. Acute inversions occurring immediately, or within 24 hours post-partum are the most common type. Chronic Uterine Inversions (CUI) occurring more than four weeks after the delivery are rare identities. Chronic nature of these inversions makes the restoration of the normal position of the uterus per vaginal difficult contrary to acute inversions which can be reposited more easily. A 34-year-old lady was initially admitted to our hospital with postpartum bleeding caused by uterine inversion. Obstetricians explained that her uterus had inverted when attached placenta manually removed and then reduct, but placenta might be remained approximately 70–80%. An abdomen CT ruled out active bleeding and uterus inversion, and confirmed that there were no abnormalities on uterus. There was 6.12 cm depth mass in endo-metrium considered retained placenta by transvaginal ultrasound. Although she received transfusion, the mother was discharged without any particular sequelae. She revisited after 4 weeks and said that there was a vaginal spotting continuously. We decided to remove retained placental materials by dilatation and curettage of endometrium. During operation, on vaginal examination, a 3 cm x 4 cm mass, occupying the cervix and extending in the vagina was felt. Cervix was thinned out behind the mass. Uterine Inversion was made and patient was planned for surgical repair. After the operation, the patient was discharged without complications. Differential diagnosis of chronic uterine inversion should always be kept in mind even if patient present with asymptomatic or symptomatic vaginal mass in postpartum. Key words: uterine inversion, postpartum spotting at postpartum:

P055
UTERINE INVERSION PRESENTING AS A VAGINAL SPOTTING AT POSTPARTUM: A CASE REPORT

Hye-Sun Kim, Haew Won Choi, Haew Won Choi, Kyong-Chul Chun
Department of Obstetrics and Gynecology, Ilan-Pak Hospital, Inje University College of Medicine, Goyang, South Korea

The purpose of this study is to compare neonatal outcomes and oxidative stress markers of preterm premature rupture membranes (PPROM) treated with generation cephalosporin plus metronidazole (regimen A) generation cephalosporin plus clarithromycin (regimen B). Methods: The present study included patient with singleton pregnancies with PPROM at earlier than 34 gestational weeks who admitted to the Chonnam National University Medical School, Gwangju, South Korea

P056
THE EFFICACY OF THIRD-GENERATION CEPHALOSPORIN PLUS METRONIDAZOLE VERSUS THIRD-GENERATION CEPHALOSPORIN PLUS CLARITHROMYCIN IN NEONATAL OUTCOMES AND OXIDATIVE STRESS MARKERS FOR WOMEN WITH PRETERM PREMATURITY RUPTURE OF MEMBRANES

Jong Woon Kim, Yoon Ha Kim
Department of Obstetrics and Gynecology, Chonnam National University Medical School, Gwangju, South Korea

The purpose of this study is to compare neonatal outcomes and oxidative stress markers of preterm premature rupture membranes (PPROM) treated with generation cephalosporin plus metronidazole (regimen A) generation cephalosporin plus clarithromycin (regimen B). Methods: The present study included patient with singleton pregnancies with PPROM at earlier than 34 gestational weeks who admitted to the Chonnam National University Medical School, Gwangju, South Korea

P057
CHALLENGES IN THE DIAGNOSIS AND SCREENING FOR TOXOPLASMA GONDII DURING PREGNANCY: RESULTS FROM A REFERENCE CENTER IN BRAZIL

Larissa Cynthia Cesar Rodrigues², Carolina Araujo Damasio Santos³, Carolina Resende Teixeira Barreto², Ana Claudine Pontes², Taynara Vieira Carneiro², Kenio Costa de Lima², Manoella do Monte Alves¹,²
¹Infectious Diseases Department, Universidade Federal do Rio Grande do Norte, Brazil
²Center for Education and Research in Health Anita Garibaldi, Santos Dumont Institute, Brazil
³Medical Student, Universidade Federal do Rio Grande do Norte, Brazil
⁴Department of Dentistry, Universidade Federal do Rio Grande do Norte, Natal, Brazil

Problem statement: In Brazil there is high prevalence of toxoplasmosis. The serological screening in the first trimester of pregnancy is recommended by the Brazilian Ministry of Health. Prenatal diagnosis of congenital toxoplasmosis (CT) influences follow up and therapeutic management in pregnant women. As maternal infection is usually asymptomatic, serological tests for toxoplasma-specific immunoglobulin M (IgM) and IgG are used to identify women infected during pregnancy, together with other serological results such as IgA avidity. No consensus exists about the most effective screening strategy. This study aimed to discuss the variability and persistence of positive toxoplasma-IgM results from the women followed during the pregnancy and after birth at a reference center in Rio Grande do Norte state, Brazil. Methods: Sixty-four women were included in the cohort between 2016 and 2018. They were referred to the center if they had tested positive for toxoplasma-specific immunoglobulin M (IgM) during the prenatal consultations. Only the patients with 2 or more serological results for IgM were included in the study. All the tests were performed by the state reference laboratory with an immunosorbent agglutination assay. We compared IgM results over time to see if they had alteration along the months and even years. Results: Sixty-four women were included in the cohort between 2016 and 2018. The median age was 29 years old. The Spearman correlation showed that the first IgM toxoplasma test during pregnancy did not vary compared to IgM dosed after 4 and 8 weeks. Furthermore, IgM levels during pregnancy did not change even after delivery, with a median of 246 days between IgM dosages. Conclusion: Variability in the duration of the IgM response limit their use for predicting the timing of infection (e.g. during the pregnancy or before), and the decision to refer for additional follow up and treatment should not be based on a single IgM- and IgG-positive test, while we have seen a lot of positive low level IgM results and persistence of those IgM low level even after years. Efforts to improve the current diagnostic strategies to reduce unnecessary follow up and treatment is necessary.

P058
ASSOCIATION OF THE DEVELOPMENT OF SURGICAL SITE INFECTION AND POST-OPERATIVE ORAL ANTIBIOTICS IN LOW RISK TERM PREGNANCIES WHO UNDERWENT CESAREAN SECTION IN A LOW RESOURCE COUNTRY HOSPITAL

Carla Lenice Lee, Ma. Cecilia Cruz-Reyes
Obstetrics and Gynecology, The Medical City, Pasig City, Philippines

Cesarean sections are one of the most commonly performed surgeries worldwide. In our institution, for example, 930 cesarean sections have been performed in the past year alone, comprising 61.26% of total deliveries. Of worldwide cesarean sections, 3% to

P056
THE EFFICACY OF THIRD-GENERATION CEPHALOSPORIN PLUS METRONIDAZOLE VERSUS THIRD-GENERATION CEPHALOSPORIN PLUS CLARITHROMYCIN IN NEONATAL OUTCOMES AND OXIDATIVE STRESS MARKERS FOR WOMEN WITH PRETERM PREMATURITY RUPTURE OF MEMBRANES

Jong Woon Kim, Yoon Ha Kim
Department of Obstetrics and Gynecology, Chonnam National University Medical School, Gwangju, South Korea

The purpose of this study is to compare neonatal outcomes and oxidative stress markers of preterm premature rupture membranes (PPROM) treated with generation cephalosporin plus metronidazole (regimen A) generation cephalosporin plus clarithromycin (regimen B). Methods: The present study included patient with singleton pregnancies with PPROM at earlier than 34 gestational weeks who admitted to the Chonnam National University Medical School, Gwangju, South Korea

P057
CHALLENGES IN THE DIAGNOSIS AND SCREENING FOR TOXOPLASMA GONDII DURING PREGNANCY: RESULTS FROM A REFERENCE CENTER IN BRAZIL

Larissa Cynthia Cesar Rodrigues², Carolina Araujo Damasio Santos³, Carolina Resende Teixeira Barreto², Ana Claudine Pontes², Taynara Vieira Carneiro², Kenio Costa de Lima², Manoella do Monte Alves¹,²
¹Infectious Diseases Department, Universidade Federal do Rio Grande do Norte, Brazil
²Center for Education and Research in Health Anita Garibaldi, Santos Dumont Institute, Brazil
³Medical Student, Universidade Federal do Rio Grande do Norte, Brazil
⁴Department of Dentistry, Universidade Federal do Rio Grande do Norte, Natal, Brazil

Problem statement: In Brazil there is high prevalence of toxoplasmosis. The serological screening in the first trimester of pregnancy is recommended by the Brazilian Ministry of Health. Prenatal diagnosis of congenital toxoplasmosis (CT) influences follow up and therapeutic management in pregnant women. As maternal infection is usually asymptomatic, serological tests for toxoplasma-specific immunoglobulin M (IgM) and IgG are used to identify women infected during pregnancy, together with other serological results such as IgA avidity. No consensus exists about the most effective screening strategy. This study aimed to discuss the variability and persistence of positive toxoplasma-IgM results from the women followed during the pregnancy and after birth at a reference center in Rio Grande do Norte state, Brazil. Methods: Sixty-four women were included in the cohort between 2016 and 2018. They were referred to the center if they had tested positive for toxoplasma-specific immunoglobulin M (IgM) during the prenatal consultations. Only the patients with 2 or more serological results for IgM were included in the study. All the tests were performed by the state reference laboratory with an immunosorbent agglutination assay. We compared IgM results over time to see if they had alteration along the months and even years. Results: Sixty-four women were included in the cohort between 2016 and 2018. The median age was 29 years old. The Spearman correlation showed that the first IgM toxoplasma test during pregnancy did not vary compared to IgM dosed after 4 and 8 weeks. Furthermore, IgM levels during pregnancy did not change even after delivery, with a median of 246 days between IgM dosages. Conclusion: Variability in the duration of the IgM response limit their use for predicting the timing of infection (e.g. during the pregnancy or before), and the decision to refer for additional follow up and treatment should not be based on a single IgM- and IgG-positive test, while we have seen a lot of positive low level IgM results and persistence of those IgM low level even after years. Efforts to improve the current diagnostic strategies to reduce unnecessary follow up and treatment is necessary.

P058
ASSOCIATION OF THE DEVELOPMENT OF SURGICAL SITE INFECTION AND POST-OPERATIVE ORAL ANTIBIOTICS IN LOW RISK TERM PREGNANCIES WHO UNDERWENT CESAREAN SECTION IN A LOW RESOURCE COUNTRY HOSPITAL

Carla Lenice Lee, Ma. Cecilia Cruz-Reyes
Obstetrics and Gynecology, The Medical City, Pasig City, Philippines

Cesarean sections are one of the most commonly performed surgeries worldwide. In our institution, for example, 930 cesarean sections have been performed in the past year alone, comprising 61.26% of total deliveries. Of worldwide cesarean sections, 3% to
15% develop surgical site infection as a complication. Much resource has been directed to decrease the incidence of such infection, from pre-operative, intra-operative and post-operative practices. The aim of this study was to determine the association of the use of post-operative oral antibiotics and the development of surgical site infection in a Philippine private tertiary hospital in low risk term pregnant patients who underwent cesarean section in the same institution. A purely observational prospective study was then employed and qualified patients were assessed, comparing and studying those who were given post-operative oral antibiotics versus those who were not, and the rate each arm (n ≥ 142) developed surgical site infection and its severity. A chi-squared test was then used with a 0.05 level of significance to analyze the collected data, which revealed no significant difference between the two arms. The study now provides local data of the incidence of surgical site infection after cesarean section and may be used as evidence to increase compliance of good antibiotic stewardship within the practices of obstetricians. The study also further solidifies the current inclusions of the cesarean section package available in the institution where the study was conducted.

P059
HIGH PLACENTAL GROWTH FACTOR LEVELS IN WOMEN WITH SUSPECTED OR WITH CONFIRMED PRECLAMPSIA DO NOT ASSOCIATE WITH BRONCHOPULMONARY DYSPLASIA DEVELOPMENT IN PRETERM NEONATES
Vanessa Marcha,1, Langeza Saleh1,2, Mona Mahjou2, Jan Danser2, Irwin Reiss3, Jasper Been1, Ton Van Den Meiracker2
1Department of Obstetrics and Gynecology, Maasstad Ziekenhuis, Rotterdam, Netherlands
2Department of Internal Medicine, Division of Vascular Medicine and Pharmacology, Erasmus MC University Medical Center, Rotterdam, Netherlands
3Department of Pediatrics, Division of Neonatology, Erasmus MC University Medical Center, Rotterdam, Netherlands

Problem statement: Studies have reported an association between umbilical cord blood levels of PI GF (placental growth factor), soluble fms-tyrosine kinase-1 (sFlt-1) and neonatal complications such as bronchopulmonary dysplasia (BPD). In this study we determine whether maternal serum levels of sFlt-1, PI GF and their ratio in women with suspected or with confirmed preeclampsia are associated with the development of BPD and other neonatal complications, independent of gestational age in preterm neonates. Methods: In patients submitted with suspected or clinically confirmed preeclampsia maternal blood was sampled for determination of serum levels of sFlt-1, PI GF and their ratio. Women with singleton pregnancies, delivering before 34 weeks of gestation were included. Fetal/neonatal outcomes were death, SGA (birthweight 10th percentile), Apgar score below 7 (after 5 minutes), length of stay at the neonatal intensive care unit (NICU), respiratory distress syndrome (RDS), BPD, and sepsis. Odds Ratios between values of sFlt-1, PI GF and sFlt-1/PI GF ratio and outcomes were evaluated using logistic regression analysis without and with adjustment of gestational age. Results: A total of 143 singleton deliveries were analyzed. The median GA was 28.2 weeks (interquartile range 20.3-33.6) at study entry and 29.2 weeks (20.6 – 34.0) at delivery. Fetal/neonatal death occurred in 17, birthweight 10% in 18, Apgar score 7 in 12, RDS in 80 BPD in 138. – 16.3 (3.0 – 89.1), 4.8 (1.2 – 19.1), 2.2 (0.8 – 5.8) and 3.0 (0.7 – 12.9). However, significant association were no longer found after correcting for gestational age at delivery. Conclusion: There is no direct connection between the biomarkers and adverse neonatal outcomes. Maternal PI GF and sFlt-1/PI GF-ratio are predictors of prematurity, and therefore indirectly related complications such as BPD, RDS and SGA. Disclosure of interests: None Declared

P060
UNRUPTURED THIRD TRIMESTER OVARIAN PREGNANCY: A CASE REPORT
Alexies Martinez, Glaiza de Guzman, Joselito Santiago
Department of Obstetrics and Gynecology, Philippine General Hospital, Manila, Philippines

Problem statement: Ovarian pregnancy is a type of ectopic pregnancy where the fertilized ovum is implanted in the ovary. It is a rare entity and preoperative diagnosis remains problematic due to its nonspecific clinical presentation and sonographic findings. Methods: Here, we present a case of an advanced ovarian pregnancy at 28 weeks’ age of gestation initially managed as a case of fetal death in-utero and subsequently as a suspected abdominal pregnancy. Preoperative aortogram and embolization was done to minimize intraoperative blood loss. Results: Upon exploration of the abdomen, the products of conception were contained within an intact right ovary. Our patient underwent right salpingo-oophorectomy. Conclusion: We obtained a stillborn baby girl weighing 1410 grams with no gross deformities. Histopathology confirmed the diagnosis of an ovarian pregnancy.

P061
CLAUDE-BERNARD-HORNER’S SYNDROME DURING LABOUR
Ana Maria Muñoz Ledesma, Almudena Lera Ramirez, Luisa Gil Guillen, Cristina Redondo Llorente, Marta Garcia-Yuste González, Claudia FiorellaMontoya Garcia, Katia Maria Pavon Saenz, Adriana Carolina Acha Salazar, Juan Martin Viteri Esteevez, Andrea Sole Mayoral, Daniela Carolina Mendez Guevara Obstetrics and Gynecology, University Hospital Rio Hortega, Valladolid, Spain

Problem statement: Claude-Bernard-Horner’s syndrome, or oculosympathetic palsy, is a neurological syndrome compound of the classic triad of ptosis, miosis and anhydrosis. It results from interruption, at any level, of the three neuron sympathetic pathway that originates in the hypothalamus. It is usually an acquired condition caused by tumors, trauma or cardiovascular disease. It has also been described as a complication of Epidural analgesia/analgesia, especially associated to obstetric procedures. Methods: This is a case report. Results-case report: A 34-year-old patient presented at 40 weeks and 1 day of gestation with active labour. She had a previous vacuum-assisted vaginal delivery 5 years before, without complications. Intravenous Oxytocin was started to stimulate uterine contractions due to meconium stained amniotic fluid. Half an hour later, the patient requested Epidural analgesia, which was started without incidents and with adequate pain control. One hour later, the patient presented miosis and reddening of her left eye, as well as paresthesias and distal weakness in her left upper limb. Her vital signs remain stable and the neurological examination was normal in addition to the transcranial doppler ultrasound. Epidural perfusion was discontinued. Labour continued without any other complications. Five hours later, the patient had an eutocic delivery of a 3470g female with Apgar test 9/10. The symptoms of miosis, ptosis and conjunctival reddening remained during immediate puerperium. A few hours after delivery, the patient had complete and spontaneous recovery. Conclusion: Horner’s syndrome is a rare complication of Epidural analgesia. It is more frequent in obstetric patients due to the anatomical and physiological changes during pregnancy that facilitate spreading of the anesthetics. Incidence of this syndrome is unknown because many cases are not diagnosed nor reported. It is a benign, self-limited condition so it is important for obstetric care providers to identify it and hereby avoid unnecessary diagnostic and therapeutic procedures. Nevertheless, Horner’s syndrome may be sign of severe underlying conditions which must keep us alert if it persists after a few hours.
P062

KNOWLEDGE, ATTITUDE AND PRACTICES OF OBSTETRICIANS AND GYNECOLOGISTS ON NON-INVASIVE PRENATAL TESTING IN A PRIVATE TERTIARY HOSPITAL IN A LOW RESOURCE INCOME COUNTRY

Kristel Danica Panes, Kristel Danica Panes, Gumersinda Cruz Javier
Obstetrics and Gynecology, The Medical City Ortigas, Obstetrics and Gynecology, Pasig, Pasig City, National Capital Region, Philippines, Pasig, Philippines

Chromosomal abnormalities are common. The American College of Obstetrics and Gynecologists (ACOG) and American College of Medical Genetics recommend invasive and non-invasive prenatal testing (NIPT). The invasive testing, however, carries risk for procedure-related miscarriage. This favors NIPT which avoids the risk. The current state of NIPT in the Philippines, it is only in January 2018, was a NIPT workshop was conducted by the Society of Maternal Fetal Medicine, Because little is known about NIPT locally, hence the conduct of study. Problem statement: The study aimed to investigate on the obstetrician and gynecologists' (OB-GYNs) knowledge, attitude towards and practices (KAP) about NIPT. Majority of the OB-GYNs were knowledgeable, had positive attitude and were practicing NIPT. Methods: The study was conducted at the following areas at two tertiary hospitals (pre-testing and actual conduct of study). The research protocol and the questionnaire were approved by the Institutional Review Board (IRB) of the two institutions. The survey was adapted from 2 previously constructed questionnaires (composed of 5-point Likert scale and multiple choices) used in studies of (Verweij, 2014; Tamminga et al., 2015; Van Schendel et al. 2015, 2016 and Davis, 2013). The questionnaire was further subjected for content validity (including face validity) and field content expert review.

Results: Majority of the OB-GYNs were knowledgeable, had positive attitude and were practicing NIPT. Strikingly, a fourth of the respondents were not comfortable in explaining NIPT. The researcher recommends that there is a need to conduct this study on a larger scale cross-sectional survey (national level) and multiple studies due to the paucity of data.

P063

ANTIBODY MICROARRAY ANALYSIS OF AMNIOTIC FLUID PROTEINS ASSOCIATED WITH SUBSEQUENT RUPTURED MEMBRANES AFTER CLINICALLY INDICATED AMNIOCENTESIS IN WOMEN WITH PRETERM LABOR

Ye Hyon Park1, Kyo Hoon Park1,2, SuBeong Hong1,2, Jee Yoon Park1, Young Eun Lee1, Yu Mi Kim1
1Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam, South Korea
2Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, South Korea

Problem statement: We aimed to identify proteins associated with subsequent ruptured membranes in the amniotic fluid (AF) of women with threatened preterm labor and intact membranes (PTL) who had a clinically indicated amniocentesis, to validate selected candidate proteins in a total cohort of PTL, and to examine the association between these proteins in AF and the onset of membrane rupture. Method: This retrospective cohort study included the consecutive collection of AF samples from 201 women with PTL (24-33.6 weeks) who underwent amniocentesis. A nested case-control study was conducted on 20 women with PTL with subsequent ruptured membranes within 7 days after amniocentesis, and 20 gestational age-matched women with PTL with term delivery (control subjects), using protein-antibody microarray analysis. The validation of 9 candidate proteins of interest was performed by ELISA in the total cohort (n = 201). Results: Seventeen proteins studied displayed intergroup differences. Validation by ELISA confirmed significantly increased AF levels of FAS, EN-RAGE,IGFBP-3, IL-6, IL-8, lipocalin-2, MMP-8, MMP-9, and S100 A8/A9 in women with rupture within 7 days of amniocentesis (n=39) than in women without rupture with term delivery (n=146). Similarly, AF levels of these proteins were significantly higher in women with rupture within 7 days of amniocentesis than in women with rupture who occurred more than 7 days, but less than 37.0 weeks (n=16). Moreover, time interval from amniocentesis to membrane rupture was inversely correlated with the AF levels of these proteins, except for the positive correlation of AF IGFBP-3 with time interval. Conclusion: In this study, we found a couple of inflammatory, angiogenic, matrix degradation, and apoptosis-related proteins in AF associated with subsequent ruptured membranes in women with threatened PTL, using an antibody microarray. These findings provide insight into mechanisms, which is chronic, underlying membrane rupture occurring in threatened PTL.

P064

PESSARY INSERTION IN PRETERM TWIN GESTATION IN THE PHILIPPINES: A CASE REPORT

Koleen Pasamba, Regina Rosario Panillio
Department of Obstetrics and Gynecology, Philippine General Hospital, Manila, Philippines

Problem statement: Preterm birth accounts to 35% of deaths in a year. Twin gestation, around 7.2 per 1000 births in the Philippines, is a known risk factor that increases likelihood of preterm birth compared to singletons. Most studies that addresses preterm births are focused on singleton pregnancies. The only established recommendation to control preterm labor in twin pregnancies in the Philippines is to give progesterone. Pessary insertion is one of the modalities that have shown benefits for preterm twin gestation among the western countries. There are no reported cases of pessary insertion to control preterm birth among twin pregnancies in the Philippines. Methods: This study presents a case of a 26 year old with twin gestation in preterm labor. She initially presented with irregular uterine contractions and vulvovaginal candidiasis at 27 weeks and 3 days age of gestation. On transvaginal ultrasound, she had no functional cervix. Her vulvovaginal candidiasis was treated with miconazole. She was given progesterone for her preterm labor, nifedipine to control her uterine contractions and dexamethasone for fetal lung maturity.
After treatment of candidiasis and control of uterine contractions, Hodge pessary was inserted at 28 weeks age of gestation. Her cervical length after pessary insertion was measured to be 2.38 cm. Prenatal consultations were advised for continuation throughout pregnancy. Results: She delivered by spontaneous vaginal delivery to live baby girls. Both newborns were 36 weeks by pediatric aging, 2.000 grams, appropriate for gestational age and directly roomed-in with their mother. Conclusion: Further studies are recommended to establish stronger evidence supporting pessary use in multiple gestation to improve outcome of neonates in the Philippines.

P065
MATERNAL MORTALITY IN MEXICO 2010-2018
Francisco Javier Posadas Robledo
National Center for The Prevention and Control Of HIV And Aids., Operative Research Director, Mexico City, Mexico

Problem statement: Between 2001 and 2010, Mexico managed to reduce the maternal mortality ratio (MMR) by 36%, from 68.9 to 44.1. Insufficient to reach the goal of 57%: 22.2 maternal deaths per 100 thousand births, committed to 2015, in the Millennium Development Goals (MDGs). The quality of obstetric care and social determinants complicated the achievement of the goal. Method: Observational study, descriptive evolution of 8 years of the MMR in Mexico from 2010 to 2017. Mexico has a total population of 123.5 million inhabitants, for the year 2017. There are 2.2 million births each year. We analyze the main causes of maternal mortality and consider possible scenarios and solutions to reduce it and the expectation of having a universal, free and quality health system to accelerate the impact. Results: Mexico registered 992 maternal deaths in 2010, with an MMR of 44.1. In 2017, there were 758 deaths, with an MMR of 34.0 maternal deaths per 100 thousand births. The age group with the highest mortality was the group of 45-49 years old with an MMR of 120 deaths and the youngest was 15-19 years old with an MMR of less than 10 deaths per 100 thousand births. The main causes of maternal death: hypertensive disease, obstetric hemorrhage, abortion, respiratory system disease and puerperal sepsis. These five causes concentrate 53.3%. The 64% of women, who died, did not have social security. * In 2018, with preliminary data, country registered a maternal mortality ratio of 29.8 deaths per 100,000 live births. Conclusions: In Mexico, maternal mortality continues to be a public health problem. The advances achieved are insufficient. In 8 years analyzed, there is a 30% decrease in MMR. The 84% of the causes of death are preventable. The evidence indicates that it is necessary to intensify actions to reverse social determinants, such as the lack of social security and to promote a universal, free and quality health system. The most affected states have unresolved social determinants, such as poverty and low educational level. The route to achieve reducing maternal death includes better quality of obstetric care and resolving social determinants.

P066
CONGENITAL X-LINKED INTESTINAL PSEUDO-OBSTRUCTION
Carolina Rueda, Berta Fabrego, Ariadna Salvador, Sonia Gayete, Eloy Cabello, Marta Baucells, Ana Galindo, M Teresa Castillo, Ana B Robles, Maria Prat, Mauricio Agüero, Alba Berguerio, Maite Lopez-Yarto, Paula Diaz, Julia Castellá
Obstetrics and Gynecology Department and Gynecology, Hospital Del Mar De Barcelona, Parc De Salut Mar, Barcelona, Spain

Problem statement: Intestinal pseudo-obstruction is a rare condition characterized by an impairment of the muscle contractions that move food through the digestive tract. Works as a bowel obstruction but no fisical bowel obstruction is found. This condition can cause abdominal swelling, nausea, pain and vomiting. Case report: We report a 39-year-old woman on her second pregnancy in which no anomalies were found on first and second trimester ultrasound scans. At 29.4 week gestation a 13 mm dilatation of the umbilical vein at the abdominal entry of the umbilical cord (aneurism), intestinal dilatation of 10mm, heart axis of 56º with normal fetal echocardiography were found associated to an estimated fetal weight on the 8th centile. Amniocentesis was performed and karyotyping resulted 46XY with normal ARRAY, also DiGeorge and Cystic fibrosis were ruled out. Maternal TORCH serologies were negative. Further ultrasound scans showed diffuse dilated bowel loops, estimated fetal weight between 4th and 12th centile and cardiomegaly with heart axis of 75º. Amniotic fluid volume and Doppler assessment were normal. Due to suspicion of bowel obstruction, labour was induced at 38 weeks ending on a vaginal birth of a 2810 gr male newborn. Newborn required surgery at 12 days due to an intestinal malrotation and an intestinal motility disorder was suspected. At age 3-month a gastrostomy and an exploratory laparotomy were performed, identifying normal jejunum and ileum. Biopsies were taken and Filamin A Immunohistochemistry Technique showed absence of expression in smooth muscle, supporting the diagnose of X-linked intestinal pseudo-obstruction (XPOI). Conclusion: FLNA gene is located at Xq28 and encodes Filamin A protein. Filamin A is an actin cross-linking protein involved in cytoskeleton formation and structure. Gene defects are associated to different disorders, such as congenital X-linked intestinal pseudo-obstruction. The congenital forms are rare but severe, diagnosis is often made in the early month of life.

P067
DANDY-WALKER MALFORMATION: THE IMPORTANCE OF PRENATAL DIAGNOSIS. A CASE REPORT
Carolina Rueda, Berta Fabrego, Ariadna Salvador, Sonia Gayete, Eloy Cabello, Marta Baucells, Ana Galindo, M Teresa Castillo, Ana B Robles, Maria Prat, Mauricio Agüero, Alba Berguerio, Maite Lopez-Yarto, Paula Diaz, Julia Castellá
Obstetrics and Gynecology Department and Gynecology, Hospital Del Mar De Barcelona, Parc De Salut Mar, Barcelona, Spain

Problem statement: Dandy-Walker malformation and its spectrum is a condition due to be suspected at second trimester ultrasound. It contemplates different levels of cerebellar vermis absence/atrophy and/or malrotation, expansion of the 4th ventricle and increased posterior fossa. Clinical manifestations may include mental retardation and impaired neurological development, the length of disability can’t be totally know prenatally. It contemplates different levels of cerebellar vermis absence/atrophy and/or malrotation, expansion of the 4th ventricle and increased posterior fossa. Clinical manifestations may include mental retardation and impaired neurological development, the length of disability can’t be totally know prenatally. Problem statement: Dandy-Walker malformation and its spectrum is a condition due to be suspected at second trimester ultrasound. It contemplates different levels of cerebellar vermis absence/atrophy and/or malrotation, expansion of the 4th ventricle and increased posterior fossa. Clinical manifestations may include mental retardation and impaired neurological development, the length of disability can’t be totally know prenatally. Further ultrasound scans showed diffuse dilated bowel loops, estimated fetal weight between 4th and 12th centile and cardiomegaly with heart axis of 75º. Amniotic fluid volume and Doppler assessment were normal. Due to suspicion of bowel obstruction, labour was induced at 38 weeks ending on a vaginal birth of a 2810 gr male newborn. Newborn required surgery at 12 days due to an intestinal malrotation and an intestinal motility disorder was suspected. At age 3-month a gastrostomy and an exploratory laparotomy were performed, identifying normal jejunum and ileum. Biopsies were taken and Filamin A Immunohistochemistry Technique showed absence of expression in smooth muscle, supporting the diagnose of X-linked intestinal pseudo-obstruction (XPOI). Conclusion: FLNA gene is located at Xq28 and encodes Filamin A protein. Filamin A is an actin cross-linking protein involved in cytoskeleton formation and structure. Gene defects are associated to different disorders, such as congenital X-linked intestinal pseudo-obstruction. The congenital forms are rare but severe, diagnosis is often made in the early month of life.
Currently ongoing. **Conclusion:** Second trimester ultrasound screening is the main technique to suspect/diagnose Dandy-Walker. MRI can add some information. Prognosis is variable. Half of affected individuals will present intellectual disability, delayed development of motor skills and coordinating movements. Parents should be carefully informed about the prognosis due to decide further steps.

**P068**

**PREGNANT AND NEWBORN WITH RESTRICTED FETAL GROWTH - 5-YEAR EXPERIENCE IN A TERTIARY HOSPITAL**

Rita Salgueiro Neto, Ana Calhau, Rita Leiria Gomes, Carlos Macedo, Cristina Pestana, Patricia Silva, Manuela Silva, Marta Ledo, Edite Costa, Henrique Leitão, Cremilda Barros, Joaquim Vieira

**Department of Obstetrics and Gynecology, Hospital Central do Funchal, Funchal, Portugal**

**Problem statement:** Fetal growth restriction is the pathological limitation of fetal growth, genetically determined for gestational age. It is a major cause of severe perinatal morbidity and mortality and long-term sequelae. Its diversified presentation makes it one of the most variable obstetric entities in the clinical approach, which is difficult to protocol. **Methods:** Retrospective descriptive study of all parturients admitted to our Service with p3 NB, between January/2014 and December/2018 (5 years). p0.05 was considered significant. SPSS version 25.0. We aim to characterize the parturient and the newborn with weight inferior to percentile 3 (P3 NB) in the only obstetric service of the Autonomous Region of Madeira, representative of its obstetric population. **Results:** There were 8934 deliveries during the study period, of which 16.09% (1442) corresponded to newborns weighing 10th percentile or 4.61% (412) to newborns p3. The average maternal age was 31.92 years. 63.05% were nulliparous and the average parity was 0.56. 50.22% of P3 newborn pregnancies were monitored under private medicine. 16.58% of P3 NB have smoking mothers. Regarding the mode of delivery, 48.23% of the p3 newborns were born by cesarean and 7.67% of the total number of cesarean were performed in P3 NB. 39.35% o P3 NB were born by elective cesarean section and 64.72% by urgent cesarean section. 59.94% of cesarean sections occurred in the absence of labour; non-reassuring fetal status (38.11%) and pregnancy-specific pathology (11.4%) were the most frequent reasons. 27.56% of the women belonged to Robson’s group 2. The average gestational age at birth was 37.87 weeks, with 5.57% of newborns p3 born before 32 weeks and 80.06% after 37 weeks. There were 84 cases of prematurity, 77 hospitalizations in the Neonatal Intensive Care Unit, 13 neonatal deaths and 9 cases of neonatal sepsis. **Conclusion:** Significant advances in neonatal intensive care decreased morbidity and mortality associated with prematurity. However, there are still significant differences in the morbidity of newborns with obstetric diagnosis of Fetal Growth Restriction. The growing collaboration between obstetricians and neonatologists will allow the early diagnosis and surveillance of these fetuses, with consequent impact on the short and long term prognosis.

**P069**

**THE ROLE OF TNF-α GENE POLYMORPHISMS IN PRETERM DELIVERY**

Aleksandra Mrozikiewicz1, Hubert Wolski2, Magdalena Barlik2, Krzysztof Drews2

1Division of Infertility and Reproductive Endocrinology, Poznan University of Medical Sciences, Poznań, Poland

2Division of Perinatology and Women’s Diseases, Poznan University of Medical Sciences, Poznań, Poland

**Division of Gynecology and Obstetrics, Podhale Multidisciplinary Hospital, Nowy Targ, Poland**

**Problem statement:** Nowadays the strong genetic background of preterm delivery (PTD) in connection with immune answer has been indicated. The purpose of the study was the assessment of frequency of TNF-α -238GA, -308GA, -376GA gene polymorphisms in the etiology of preterm delivery. **Material and methods:** The study group consisted of 150 women with PTD (22-0 – 36-6 gw.), the controls of 150 women who delivered at term (37 gw.). PTD group was divided into subgroups: a/ delivery between 22-28 gw., b/ 28-32 gw., and c/ 32-36+6 gw. Genetic analysis was performed by PCR/RFLP method. **Results:** Overrepresentation of -238GA genotype (12.7 vs. 4.7%, p=0.011) and -238A allele (7.7 vs. 2.3%, p=0.002) in PTD group has been observed. In PTD 28-32 gw. subgroup, higher frequency of -238GA genotype (31.6 vs. 4.7%, p=0.00095), and mutated -238A allele (21.1 vs. 2.3%, p=0.00004) was noted. Moreover in PTD 28-32 gw. subgroup we have noted higher presence of heterozygous -376GA genotype (10.5 vs. 1.3%, p=0.063) and mutated -376A allele (5.3 vs. 0.7%, p=0.064). Analysis of TNF-α polymorphisms co-occurrence showed statistically significant overrepresentation of genotypes containing mutated -238A allele in PTD group (-238GA/-308BG/-376GG: 8.0 vs. 2.7%, p=0.035). Haplotype analysis revealed statistically significant difference between PTD and controls in the incidence of -376G/-308G/-238A haplotype containing mutated -238A allele (0.063067 vs. 0.016634, p=0.030).

**Conclusion:** The study indicated the strong association of mutated -238A allele of TNF-α gene with increased risk of PTD. Analysis of genotypes and alleles prevalence in PTD women divided according to gestational age suggests the possible role of mutated variants of -238A and -376G TNF-α polymorphisms in Polish women delivering between 28 and 32 gw.

**P070**

**THE ESTABLISHMENT OF A SCORE SYSTEM FOR VAGINAL DELIVERY OF TWIN PREGNANCY**

Nan Shen

Obstetrics, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, China

**Problem statement:** To establish a score system for vaginal delivery of twin pregnancy. **Methods:** The study subjects are the twin pregnant women (uncomplicated twin pregnancy with head downward position of the first fetus, not MCMA twins) who were under systematic antenatal care and delivered at the Beijing Obstetrics and Gynecology Hospital from January 2017 to March 2019. The ones with successful vaginal delivery were classified into the study group and the ones who were transferred to Caesarean sections during trial delivery into the comparison group. The studying targets include: the chorionicity, position of the second fetus, weights and the difference of the two fetuses; the maternal age, delivery pregnancy weeks, parity, BMI, reasonability of weight gain during pregnancy, complications during pregnancy (including GDM, PIH, etc.), IVF-ET, the technical title of the doctor, modes of labour (spontaneous labor or induced labour and its mode), the application of labor analgesia, etc. **Results:** There were 114 women of twin pregnancy with 96 in the study group and 18 in the comparison group. Through the single-factor and multiple-factor logistic regression statistical analysis, there are five variables (P < 0.05) were included in the model. Models were developed and scores for each variable were given according to the multiple-factor regression analysis index and nomogram. The scores are: the age of the mother < 35 years old: 64; no GDM: 100, no insulin application in GDM: 47, and application of insulin: 0; reasonability of weight gain during pregnancy: 82; parities: 2; 58, and the weight of the second fetus is less than the first: 57. The ROC curve was plotted and the AUC is 0.8561. The maximum value of the Youden index is 0.5647 and the corresponding score is 168. **Conclusion:** The age of the mother, reasonability of weight gain, GDM, parity, and the weight difference of the twins should be included in the score system for vaginal delivery of twin pregnancy. The total score of the model is 361 and when the score is larger than 168, the success rate of the vaginal delivery increases significantly.
THE 27th World Congress on Controversies in Obstetrics, Gynecology & Infertility (COGI)  
Paris, France • November 21-23, 2019  

P072  
THE USE OF LEVOBUPIVACAINE WITH OR WITHOUT KETOROLAC IN POST CESAREAN PAIN MANAGEMENT: A RANDOMIZED DOUBLE-BLINDED CONTROL TRIAL  
Aritaya Singwongsa1, Rungrueedeen Wongrees1, Komsun Suwannarurk1, Densak Pongjojswip1, Athita Chanthasananont1, Junya Pattararchai2, Kornkarn Bhamarapravatana3  
1Obstetrics and Gynecology, Faculty of Medicine, Thammasat University, Klong Luang, Thailand  
2Chulabhorn International College of Medicine, Thammasat University, Klong Luang, Thailand  
3Preclinical Science, Faculty of Medicine, Thammasat University, Klong Luang, Thailand  

Background: Cesarean delivery is the most common operative procedure among reproductive age women. An effective analgesia is required for adequate postoperative pain control. Objective: To determine the effectiveness in pain reduction of levobupivacaine usage compared to its combination with ketorolac via local infiltration postoperatively in participants who underwent cesarean delivery under spinal anesthesia. Materials and methods: Pregnant women between 18 and 40 years of age, who underwent cesarean delivery, were enrolled. The participants were randomly allocated into two groups. The study and control group received local surgical wound infiltration of 50 mg of levobupivacaine (0.5%) with or without 30 mg of ketorolac at the end of surgical wound closure, respectively. After the operation, the visual analog scale (VAS) was recorded at 1, 2, 4, 8, 12, 18 and 24 hours. Demographic data, additional opioid requirement and adverse effects such as nausea, vomiting and postpartum hemorrhage were also recorded. Results: A total of 160 parturient were recruited and consist of 80 cases in each group. Both groups showed no statistical significance in demographic data. Postoperative pain in the study group was significantly lower than the control group within the first 24 hours after surgery. The p-value at 1, 2, 4, 6, 12, 18 and 24 hours were 0.038, 0.000, 0.000, 0.000, 0.010, 0.014 and 0.045, respectively. Overall meperidine requirement and side effects during the first 24 hours in the study and control group were comparable. Conclusion: Combined ketorolac with levobupivacaine significantly decreased postoperative pain after cesarean delivery compared to the use of only levobupivacaine. Keywords: Ketorolac, levobupivacaine, cesarean delivery, pain  

P073  
DELAYED DIAGNOSIS OF GESTATIONAL DIABETES MELLITUS IN PREGNANT WOMEN WITH MACROSOMIA AT LATE PREGNANCY  
Jeenah Sohn1,2, Byoung Jae Kim1,2, Sun Min Kim1,2  
1Department of Obstetrics and Gynecology, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, South Korea  
2Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, South Korea  

Problem statement: Gestational diabetes mellitus (GDM) is a leading cause of fetal excessive growth in utero. However, macrosomia is sometimes suspected on ultrasound at late pregnancy in women with normal blood glucose test at 24-28 weeks of gestation. This study was performed to evaluate the incidence of newly diagnosed GDM at late pregnancy and their perinatal outcome in these women. Methods: Retrospective cohort study was performed. Among the singleton pregnant women delivered from January 2010 to December 2018, women who were retested for an oral glucose tolerance test because of suspected fetal macrosomia on ultrasound in the 3rd trimester were enrolled. Their results of GDM screening at 24-28 weeks of gestations had been normal. Results: Of 169 pregnant women who were retested for 100-g OGTT, 13% (23/169) was newly diagnosed of GDM. There were no significant differences in the maternal age, parity, gestational age at OGTT, and fetal sex.
between GDM and non-GDM group. The women in GDM group had higher level of HbA1c (5.8 vs 5.3, p=0.01) and earlier gestational age at delivery than women in non-GDM group (38+1 vs 38+5 weeks of gestation, p=0.003). Cesarean delivery (CD) rate in GDM group was significantly higher than that of non GDM group (73.9%, vs 49.3%, p=0.028). When we analyzed the reason of CD, the proportions of reasons were similar in both groups except CD on maternal request (CDMR). The rate of CDMR without any obstetrical indication was higher in GDM group than that of non-GDM group (41.2% vs 23.6%), but it could not reach the statistical significance. There were no significant differences in incidence of obstetrical complications (gestational hypertensive disease, preterm birth, and shoulder dystocia) and neonatal complications (NICU admission and neonatal hypoglycemia) between the two groups. **Conclusion:** Showing normal results in routine blood glucose test, 13% of pregnant women with suspected macrosomia on ultrasound in the 3rd trimester of pregnancy were newly diagnosed of GDM. Nonetheless, there were no differences in perinatal outcomes between newly diagnosed GDM group and non-GDM group. However, concerns over complications of GDM, such as shoulder dystocia, appear to increase cesarean delivery.

**Problem statement:** Preterm premature rupture of membrane (PPROM) defined as a non-iatrogenic rupture of membranes before the onset of labor without effective contractions. PPROM is responsible for one-third of all preterm births and affecting 5-10% of pregnancies in Indonesia each year. PPROM is associated with significant maternal and neonatal morbidity and mortality from infection, umbilical cord compression, and preterm birth. The purpose of this research is to determine the pattern of bacteria and antibiotic susceptibility testing and to know the effectiveness of antibiotics used as a prophylaxis procedure in PPROM. **Methods:** This descriptive observational study was carried out in the department of Obstetrics and Gynaecology Hasan Sadikin General Hospital, Bandung, Indonesia.

The contamination pattern of bacteria to antibiotics does not indicate suitability of antibiotics used as a prophylaxis procedure in PPROM. Cefadroxil, Cefotaxime or Ceftriaxone as current prophylaxis. Erythromycin remains the antibiotic choice for PPROM prophylaxis.

**Problem statement:** The use of prenatal cf-DNA-testing brings changes in decline of numbers of invasive procedures in women with high or low risk. The average age of women with cf-DNA-testing decreases, numbers of tests increase, invasive procedures decrease. **Methods:** We present the characteristics of pregnant woman, who opted for cf-DNA-testing in one private clinic in the period from 1.1. 2013 until 31.12.2018. In our study, 11137 pregnant women were screened by combined NT assessment as first step. 639 women opted for cf-DNA-testing. Samples were analyzed in clinical laboratory BGI-Shenzhen, China. **Results:** 48.04 % of women with cf-DNA-testing were of advanced maternal age (37 years or more), 18.78 % were at high risk for T21, based on prior screening, 38.14 % had low risk regarding age and prior screening. The average age of women with cf-DNA-testing was similar in the last 5 years (2013: 36.1, 2014: 36.2, 2015: 36.4, 2016: 36.3, 2017: 36.2), but declined in 2018: (34.9 years). The proportion of women with cf-DNA-testing after NT screening increased over the last 6 years (2013: 1.4 %, 2016: 9.13 % and 2018: 18.11 %). The numbers of all invasive procedures in Slovenia decreased from 5.71 % to 4.74 % from 2013 to 2017. The prominent fall we find in the age 37 years or more: from 37.24 % in 2013 to 24.12 % in 2017 and in women aged 35-37 years: from 9.66 % in 2013 to 6.07 % in 2018. The use of prenatal cf-DNA-testing in one private clinic, who opted for cf-DNA-testing after NT screening increased over the last 6 years (2013: 1.4 %, 2016: 9.13 % and 2018: 18.11 %). The numbers of all invasive procedures in Slovenia decreased from 5.71 % to 4.74 % from 2013 to 2017. The prominent fall we find in the age 37 years or more: from 37.24 % in 2013 to 24.12 % in 2017 and in women aged 35-37 years: from 9.66 % in 2013 to 6.07 % in 2017. In general, cf-DNA-testing had 100 % (95% CI: 66.4 %-100 %) sensitivity and 99.82 % (95% CI: 98.97 %-100 %) specificity. PPV turned out to be 90 % (95% CI: 55.5 % -99.75 %) for all procedures decli nes as well, particularly in the group of women using cf-DNA-testing after NT screening. The average age of women with cf-DNA-testing was 36.3, 2017: 36.2), but declined in 2018: 34.9 years). The proportion of women with cf-DNA-testing after NT screening increased over the last 6 years (2013: 1.4 %, 2016: 9.13 % and 2018: 18.11 %). The numbers of all invasive procedures in Slovenia decreased from 5.71 % to 4.74 % from 2013 to 2017. The prominent fall we find in the age 37 years or more: from 37.24 % in 2013 to 24.12 % in 2017 and in women aged 35-37 years: from 9.66 % in 2013 to 6.07 % in 2017. In general, cf-DNA-testing had 100 % (95% CI: 66.4 %-100 %) sensitivity and 99.82 % (95% CI: 98.97 %-100 %) specificity. PPV turned out to be 90 % (95% CI: 55.5 %-99.75 %) for all aneuploidies. Regarding only T21, sensitivity and specificity were 100 %. **Conclusions:** Our results confirm that prenatal cf-DNA-testing represents highly accurate approach for advanced screening of most common aneuploidies. The numbers of tests in high and low risk pregnant women are increasing. The average age of women using cf-DNA-testing declines. The numbers of invasive procedures declines as well, particularly in the group of women aged 35 years or more.
TOTAL ANTIOXIDANT CAPACITY LEVEL COMPARISON BETWEEN SPONTANEOUS ABORTION AND NORMAL PREGNANCY

Alfonsus Zeus Suryawan1, Alfonsus Zeus Suryawan, Aloysius Suryawan1, Teresia Liliana Wargastetia1
1Obstetric and Gynecology Department, Maranatha Christian University, Bandung, Indonesia
2Biological Department, Maranatha Christian University, Bandung, Indonesia

Problem statement: Abortion is an obstetric problem that is one of the causes of maternal and fetal death. Bleeding or miscarriage threat in the first trimester compromises 20% to 25% of all pregnancy and 50% of them will end as spontaneous abortion. Some recent studies have indicated oxidative stress in spontaneous abortion. Oxidative stress usually happens if there's imbalance between oxidant and antioxidant. Human ability to counter oxidant is measured as total antioxidant capacity (SAT). These data indicate the importance of further research the difference of spontaneous abortion and normal pregnancy significantly and risk suffering spontaneous abortion. This study purpose is to examine the difference of spontaneous abortion and normal pregnancy SAT level and it's correlation with spontaneous abortion. This study

Methods: This was a cross sectional study, included 60 pregnant women with gestational age between 8-20 weeks. Composed by 2 group, 30 women with spontaneous abortion and 30 women with normal pregnancy. The blood samples gathered from all participants will be tested by spectrophotometer and RANDOX® Total Antioxidant Status kit. All observed data were analysed using Mann-Whitney test, continued with Chi Square and Odds Ratio calculation (c=0.05). Result: SAT level in spontaneous abortion is lower rather than in normal pregnancy and proved very significant. There is a connection between SAT with spontaneous abortion and normal pregnancy significantly and risk suffering spontaneous abortion 10.5times greater in women with low SAT rather the women with normal level of SAT. Conclusion: There’s difference of spontaneous abortion and normal pregnancy SAT level and there’s correlation between SAT with spontaneous abortion and normal pregnancy. Keywords Total antioxidant capacity (SAT), spontaneous abortion, normal pregnancy

THREE CASES OF RECURRENT PREGNANCY LOSS COMPLICATED BY COMPLEX CHROMOSOMAL REARRANGEMENTS

Koichi Takakuwa1, Taro Nonaka2
1Center for Perinatal, Maternal and Neonatal Medicine, Niigata University Medical and Dental Hospital, Niigata, Japan
2Department of Obstetrics and Gynecology, Niigata University Medical and Dental Hospital, Niigata, Japan

Problem statement: Complex chromosomal rearrangements (CCR) are defined as reciprocal exchanges between three or more chromosomes, and the frequency of CCR is extremely low, even in the patients with recurrent pregnancy loss (RPL). In this study, we analyzed the clinical courses of three patients of RPL complicated by CCR in order to elucidate the condition and pregnancy prognosis in such patients. Methods: We analyzed the clinical courses of the three patients of RPL complicated by CCR using medical records of the patients under informed consent. Results: Case 1: The patient (25 yo) experienced twice of spontaneous abortion. Autoimmune examinations revealed positive anti-cardiolipin antibody. The chromosome examination revealed that the patient had a reciprocal translocation among three chromosomes with the karyotype; 46, XX, t (4;12;8)(q33; q22; q21.2), while the husband had normal karyotype. After genetic consultation was performed, she was conceived as the third pregnancy. And this pregnancy continued uneventfully, and she delivered a baby girl. The infant's neonatal course was uneventful. For the positive anti-cardiolipin antibody, appropriate treatments were performed. Case 2: The patient (32 yo) experienced twice of spontaneous abortion. The routine examinations for RPL were done, and the chromosome examination revealed that the patient had a reciprocal translocation among three chromosomes with the karyotype; 46, XX, t (4;8;16) (q27; q11; q22), while the husband had normal karyotype. After genetic consultation was performed, she was conceived as the fourth pregnancy. This pregnancy continued uneventfully, and she delivered a baby girl, whose neonatal course was uneventful. Case 3: The patient (38 yo) experienced twice of spontaneous abortion. The routine examinations for recurrent abortion were done, and the chromosome examination revealed that the patient had a CCR with the karyotype; 46, XX, der(6)(6pter→6q11::12p11.2→12pter), der(12) (6pter→6q11::12p11.2→12q12::14p13→14pter), der(14)(12pter→12q12::14p13→14qter). While, the husband had normal karyotype. After genetic consultation was performed, she is now trying to become pregnant. Conclusion: There is possibility that patients of RPL complicated by CCR can obtain good pregnancy outcome with the appropriate treatment based on the close examinations. There is no conflict of interest.

MANAGEMENT OF A RARE CASE OF NON-IMMUNE HYDROPS AND CONGENITAL CHYLOTHORAX WITH DIFFUSE LUNG DISEASE

Yin Ru Tan1, Alvin JH Ngowe2, SK Samamandra3, OH Teoh2, MY Chan4, Daisy KL Chan2, Hah Koon Tan1
1Department of Obstetrics and Gynecology, Singapore General Hospital, Singapore
2Department of Neonatal and Developmental Medicine, Singapore General Hospital, Singapore
3Division of Paediatric Medicine, KK Women’s and Children’s Hospital, Singapore
4Department of Diagnostic Radiology, Singapore General Hospital, Singapore

Introduction: We report the management of a case of non-immune hydrops fetalis and chylothorax in a 35-week gestation baby found to have diffuse interstitial lung disease and possible congenital pulmonary lymphangiectasia. Methods: The patient was a 42-year-old gravida 2 para 2, who conceived via in-vitro fertilization and delivered via caesarean section at 35+4 weeks gestation. Non-invasive Prenatal Testing(NIPT) was low risk but no aneuploidy was performed. Fetal anomaly scan at 19 weeks was normal. Gross hydrops fetalis, pleural effusion and polyhydramnios was noted since 28-weeks gestation and patient was referred to a tertiary centre for management. Antenatal investigations ruled out immune hydrops. Screening for intrauterine infections was negative. There was no evidence of fetal anemia as Middle Cerebral Artery(MCA) doppler was normal. Baby was hydropic at birth with significant swelling of his head and neck, but only mild lower limb oedema. After being intubated at 3 minutes of life, he was admitted to the neonatal intensive care unit(NICU) for ventilation. Apgar scores were 3 at 1 minute, 7 at 5 minutes, 9 at 10 minutes. Chest X-Ray confirmed significant right pleural effusion and was drained with a chest tube. Diagnosis of congenital chylothorax was confirmed with pleural fluid analysis. Investigations for other causes of hydrops were negative, including a normal karyotype, negative screen for intrauterine infections, 2D-Echocardiography showing a structurally normal heart and abdominal ultrasound that was normal apart from ascites. High-resolution CT Thorax showed diffuse ground-glass opacity in both lungs. The baby was intubated for 14 days before he was weaned to high flow nasal cannula. He was fed exclusively with Monogen, a medium chain triglyceride-based formula from day 14 and achieved significant improvement, due most likely to improvement in pulmonary lymphatic drainage. He stayed in NICU for 45 days and high dependency unit for another 43 days before being discharged on day 87 with home oxygen. Results/Conclusion: The baby presented with both chylothorax and diffuse lung disease, due most likely to congenital pulmonary lymphangiectasia. All foetuses diagnosed antenatally with features of hydrops must be referred to and managed in a tertiary obstetrics and neonatal centre.
P079 CAFFEINE CONTENT IN NEWBORN HAIR CORRELATES WITH MATERNAL DIETARY INTAKE

Lauri Uusitalo1, Anni Lehtonen2, Sampo Auriola3,4, Katri Backman1,5, Seppo Heinonen1, Leea Keski-Nisula1,7, Markku Pasanen1, Juha Pekkalanen6, Tomi-Pekka Tuomainen1, Raimo Voutilainen1,5, Sari Voutilainen1, Marko Lehtonen1,4

1School of Medicine, Institute of Clinical Medicine, University of Eastern Finland, Finland
2Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Finland
3School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, Finland
4Biocenter Kuopio, LC-MS Metabolomics Center, Kuopio, Finland
5Department of Pediatrics, Kuopio University Hospital, Kuopio, Finland
6Department of Obstetrics and Gynecology, Helsinki University Hospital, Helsinki
7Department of Obstetrics and Gynecology, Kuopio University Hospital, Kuopio
8Department of Public Health, University of Helsinki, Finland
9Environmental Health Unit, National Institute for Health and Welfare, Finland

Problem statement: High maternal caffeine intake during pregnancy may be harmful for perinatal outcomes and future child health, but the level of fetal cumulative exposure has been difficult to measure thus far. Here, we present maternal dietary caffeine intake during the last trimester and its correlation to caffeine content in newborn hair after birth. Methods: Maternal third trimester diets and dietary caffeine intake were prospectively collected in Kuopio Birth Cohort (KuBiCo) using a 160-item food frequency questionnaire (n=2840). Newborn hair was collected within 48 hours after birth and analyzed by high-resolution mass spectrometry (HRMS) for caffeine (n=316). Correlation between dietary caffeine intake and neonatal hair caffeine content was evaluated from 203 mother-child pairs. Results: Mean dietary caffeine intake was 167 mg/day (95% CI 162-172 mg/day), of which coffee comprised 81%. Caffeine in the maternal diet and caffeine content in newborn hair correlated significantly (r=0.50; p<0.001). Older, multiparous, overweight women and smokers had the highest caffeine levels in the maternal diet, as well as similar levels in newborn hair. Conclusions: Caffeine exposure, estimated from newborn hair samples, reflects maternal third trimester dietary caffeine intake and introduces a new method to assess fetal cumulative caffeine exposure. Further studies to evaluate the effects of caffeine exposure on both perinatal and postnatal outcomes are warranted, since over 40% of pregnant women consume caffeine despite the current recommendations (European Food Safety Association, EFSA recommendations).

P081 ANTICOAGULANT TREATMENT IN WOMEN WITH RECURRENT MISCARRIAGES WITH INHERITED THROMBOPHILIA

Rita Vasconcelos, Maria Flores Casteleiro, Diogo Cunha, Femida Rodrigues, Belissa Vides, Isabel Reis

Serviço De Ginecologia E Obstetrícia, Hospital de Braga, EPE, Braga, Portugal

Problem statement: Recurrent miscarriage is a major women’s health problem, occurs in approximately 1% of couples, with no cause identified in half of cases. The role of inherited thrombophilia(IT) in recurrent early pregnancy loss is uncertain at present and test for thrombophilia are not required as part of the assessment. However, since hypercoagulability might result in recurrent miscarriage, anticoagulant agents could potentially increase the odds of live birth in subsequent pregnancies. The aim of this study is to assess the effect of anticoagulant treatment on preventing future pregnancy loss in women with recurrent miscarriages and IT. Methods: Online searches of Pubmed, DARE and the Cochrane Library databases. We used MeSH terms for search in PubMed: “recurrent miscarriage” and “thrombophilia”. Selection criteria: guidelines, randomised controlled trials(RCT) and systematic review that assessed the benefits of anticoagulant treatment on the live birth (LBR) in women with recurrent miscarriages and inherited thrombophilia. Interventions included aspirin and low molecular weight heparin (LMWH). The articles date of publication was restricted to the past 10 years and only studies in Humans were selected. No language restrictions were used. Results: 130 records were evaluated. After screening the titles and abstracts of all the records and removing the duplicates, we excluded 122 search results, as they were ineligible according to the predefined criteria. Finally, we included 3 systematic reviews and 2 RCT. Most of the studies were established as having a moderate methodological quality. The results suggest that anticoagulants did not have a beneficial effect on LBR, regardless of which anticoagulant was evaluated. Only one RCT demonstrates the benefit of LMWH on improving LBR by compared to control. However, this is to be considered with caution, since the overall numbers of participants in the studies were small. Conclusion: Despite the lack of benefit of LMWH preventing future pregnancy loss, anticoagulant therapy is commonly prescribed for women with a history of recurrent miscarriage. This research suggests that the treatment of women with recurrent miscarriage and IT has not been adequately studied and remains to be validated with large prospective randomised trials. So, no recommendations concerning treatment efficacy can be made.
Problem statement: Twin pregnancies have a variable incidence throughout the world, but it has globally increased due to the advancing maternal age and the use of fertility treatments and assisted reproductive technology (ART). Some studies demonstrated that twins born after ART pregnancies are at a higher risk of perinatal morbidity and mortality, such as birth defects and low birth weight. The research aim is to compare maternal and neonatal complications between spontaneous and ART pregnancies. Methods: The retrospective analysis of all twin pregnancies delivered at the Hospital de Braga between January 2004 and June 2019. Triplets and stillbirths were excluded. 616 cases were analysed for demographic data, type of conception, chioronicity, gestational age at birth, delivery route and perinatal morbidity. Using SPSS Statistics version 23.0, a comparative analysis between groups was done, evaluating possible associations. Results: 517 (83.93%) were spontaneous and 99 (16.07%) were ART pregnancies. From the data analysis, mean maternal age proved to be significantly higher at the ART pregnancy group: 31.28 vs 34.16 years (p value 0.001). No difference was observed between spontaneous and ART pregnancies, respectively, regarding mean gestational age 35.03 vs 35.20 weeks (p value = 0.972), weight of first fetus 2269,24 vs 2303,35g (p value = 0.739), weight of second fetus 2205,69 vs 2054.34g (p value = 0.209) and birth weight discordance 11,69 vs 14.15% (p value = 0.148 ). About the route of delivery, 66.7 % of ART pregnancies and 62.3% of spontaneous were caesarean (p value = 0.627). Regarding APGAR score the results obtained were not statistically different, except at 5th minute on second fetus (p value = 0.016); means of 9,65 e 9,77 in spontaneous and ART pregnancies, respectively. Conclusion: With the advancing maternal age the physiological reduction in fertility leads more women to use ART, as verified in our research. Although some studies suggest that worse neonatal outcomes are associated with ART pregnancies, in our investigation, this difference was not verified. Greater figures of caesarean section in ART pregnancies, which can be explained by the increased maternal age and morbidity of women that use ART, although it was not statically significant.

Problem statement: Vitamin D deficiency is associated with an increased risk of pregnancy complications related to placental function like Intrauterine Growth Retardation (IUGR), Pre-eclampsia (PE) and gestational diabetes, although the underlying mechanisms are far from elucidated. Pregnancy complications increase the risk of preterm delivery, perinatal morbidity and mortality. In worst case, especially PE can be fatal for the pregnant women. Accumulating evidence links exposure to pregnancy complications and vitamin D deficiency itself to long-term health problems. Among other, affected children have a higher risk of asthma, cardiovascular disease, diabetes, obesity, schizophrenia, neurodevelopmental problems and multiple sclerosis. This underlines the need for sufficient vitamin D supply during pregnancy where the fetus is highly dependent of maternal vitamin D supply. The aim of this study was to investigate prevalence of vitamin D deficiency and relationship with maternal lifestyle and pregnancy outcomes. Methods: A total of 223 pregnant women were included in a prospective cohort, when attending the national prenatal screenings program (week 10-13, 94% participation). June-December 2016. Plasma 25(OH)D level was determined and lifestyle information obtained upon inclusion and correlated to pregnancy outcomes. Placental samples were collected to assess vitamin D metabolism by qPCR. Results: Though the majority (92%) followed official recommendations i.e. a 10μg daily vitamin D supplementation, 43.8% was vitamin D deficient (25(OH)D75 nmol/L). 12.1% and 1.8% respectively were severely (25(OH)D50 nmol/L) or very severely deficient (25(OH)D25 nmol/L). Deficiency (25(OH)D75 nmol/L) was more common (51.8%) among women with BMI≥30. Maternal 25(OH)D was 45.6% and 13.3% below average in IUGR and PE pregnancies, albeit only significant for IUGR (p=0.007). Increasing maternal Body-Mass-Index (BMI) was correlated with increased mRNA expression of the vitamin D degrading enzyme CYP24A1 (p=0.003, n=30), but expression of the activating enzyme CYP27B1 was not significantly affected. Conclusion: Vitamin D deficiency is common in Danish pregnant women despite high adherence to official guidelines indicating that current guidelines might be insufficient. Women with high BMI are especially affected, and may have an altered placental vitamin D metabolism. Future studies should investigate the benefits of increased vitamin D supplements with regard to obstetric outcomes and underlying changes in placental vitamin D metabolism.
Fetal growth curves in the second trimester: are there differences in the different regions? Flávia Vicente, Diana Almeida, Joana Simões, CHUA, Portugal

Problem statement: Intrauterine growth reference curves - known as percentiles - are now often used as reference for clinical evaluation and decision attending to their correlation with fetal and neonatal outcomes. The aim of this work is to obtain a normal growth curve between 19th and 24th weeks of gestation and compare the values obtained with other published reference values. Methods: Analysis of all ultrasounds performed between 19th and 24th weeks of gestation at the Center for Diagnosis and Prenatal Therapy of Centro Hospitalar Universitário do Algarve, Hospital de Faro, Portugal between 1 January 2017 and 31 December 2018. Biometric data selected were: biparietal diameter (BP), head circumference (HC), abdominal circumference (AC), femur length (FL), weight (HADLOCK formula) and gestational age. Results: All parameters are being analyzed to create the growth curves of the study population. Conclusion: Intrauterine growth reference curves play an important role in complex clinical decisions, therefore they must be representative of the population in which they are being applied. It is essential the measures we use as reference reflect the distribution of the population we are working with in order to avoid over diagnosis and under diagnosis of some pathologies that lead to changes in fetal growth.

Labor patterns in women undergoing vaginal birth after cesarean delivery in Shanghai, China Li Wenxian, Du Li, Zhu Liping
1Department of Research and Education, Shanghai Center for Women and Children's Health, China 2Department of Director, Shanghai Center for Women and Children's Health, China

Problem statement: The universal two-child policy has been introduced in China since 2016. The demand for having a second child has been increasing recently. The high cesarean delivery rate in earlier years had made a high proportion of pregnant women with a previous cesarean section. Some of those multiparous women want to attempt a vaginal birth after cesarean delivery (VBAC). Exploring labor characteristics of women undergoing VBAC may be clinically useful for intrapartum management as well as prenatal counselling. Methods: In a cross-sectional survey of 16 hospitals in Shanghai from January to June, 2016, we compared labor duration of first and second stage among 54 women undergoing VBAC, 3203 nulliparous women and 1390 multiparous women with one previous vaginal birth. We included pregnant women with singleton gestations and vertex presentation, and who delivered at or after 28 completed weeks of gestation or with a newborn’s birth weight of at least 500g. Intrapartum stillbirths were excluded from the study. Results: Overall and first-stage labor duration for VBAC were comparable to multiparae undergoing a second vaginal birth (overall labor duration: 254min vs 256min, P=0.909; first stage: 225min vs 240min, P=0.510), but significantly shorter than nulliparous women (overall labor duration: 254min vs 450min, P<0.001; first stage: 225min vs 405min, P<0.001). The median second-stage of labor duration was significantly shorter for that of primiparae (17min vs 10min, P<0.001). Conclusions: Labor duration for VBAC was shorter compared to nulliparous labor. The labor pattern of second stage in women undergoing VBAC was longer than that of multiparous (17min vs 10min, P<0.001), but longer than that of multiparous (17min vs 10min, P<0.001). P085

Pregnancy outcomes in women with asymptomatic bacteriuria Tatiana Zefirova, Eugeny Yupatov, Maria Zhelzezova Obstetrics and Gynecology, Kazan State Medical Academy – Branch Campus of the Federal State Budgetary Educational Institution of Further Professional Education «Russian Medical Academy of Continuing Professional Education» of the Ministry of Healthcare of the Russian Federation, Kazan, Russia

Problem statement: Early form of intrauterine fetus growth restriction (IFGR) needs fetus state clinical-CTG-USG-Doppler monitoring, respiratory distress syndrome prophylaxis, pregnancy prolongation till fetus distress, which leads to iatrogenic preterm delivery. Pathomorphological explanation of clinical pathology is important for IFGR prevention. Materials of research: were 35 case records of women with early form of IFGR without preeclampsia and their afterbirths. Pregnancies have finished by cesarean section in 30-32 weeks with live births. The methods of research: were clinical, CTG, USG, Doppler, morphological, statistical methods. Results: Nulliparous women formed 80,0+6,86 %. Primary infertility, STI, inflammatory genital diseases, spontaneous or missed abortions were in anamnesis in 77,14+7,2 % of women. IFGR <3rd percentile was in 14,29+6,0 %, IFGR <10th percentile correspondingly in 85,71+5,0 %. Absent or reversed end diastolic flow in both umbilical cord arteries were accordingly in 22,86+7,2 % and 77,14+7,2 %. Acute inflammatory changes in fetal membranes have been found out in 88,57+5,46 %: acute parietal decidualitis in 54,29+6,54 %, acute chorioamnionitis in 8,57+4,8 %, membranes infiltration in 17,14+6,46 %. Acute inflammatory changes of umbilical cord have discovered in 22,86+7,2 % (the hallmark for fetal inflammatory response syndrome): phlebitis/periphlebitis in 8,57+4,8 %, arteritis in 5,71+3,98 %, purulent funisitis in 8,57+4,8 % (also cord edema in 14,29+6,0 %, vein dilatation in 25,71+7,5 %), perivascular hemorrhages in 25,71+7,5 %. In placenta acute placental chorioamnionitis in 34,29+8,14 %, basal deciduitis in 34,29+8,14 %, subchorial and/or central leukocyte-fibrin intervillitis in 40,0+8,4 %, intervillosic space thrombosis in 37,14+6,29 %, subchorial hemorrhages in 5,71+3,98 %, acute villitis in 8,57+4,8 %, acute placitis in 5,71+3,98 %, villi dyschronosis in 91,43+4,8 %, hypo/avascularization with villi fibrosis in 85,71+6,0 %, true villi infarctions in 54,29+8,54 %, pseudoinfarctions in 45,71+8,54 %, placenta petrification in 22,86+7,2 % of cases have been found out. Conclusion: Morphological signs of acute ascendant intrauterine infection, chronic placental insufficiency and fetus hypoxia in IFGR afterbirths were discovered. One of the directions of IFGR prevention is preparation to pregnancy of women with IFGR risk factors, preconceptional research of vaginal/cervical microbiota with correction of disturbances, treatment of STI and probiotics prescription. Conflict is absent.
Problem statement: Asymmetric bacteriuria (AB) is a common complication of pregnancy, described in 6-10% of the patients. One of the common opinions that AB can increase the likelihood of urinary tract infection and have a negative impact both on the mother and the fetus. Therefore AB is being treated [1]. Still, those recommendations have a low level of evidence. Also there are data that AB is not associated with increased incidence of premature labor and low birth weight [2]. Methods: We performed a chart review of 1600 pregnant patient and identified 132 (9,2%) women with a diagnosis of AB. Two urine cultures were performed in 3% of women, in other cases diagnosis was not performed correctly. 79% of patients received treatment. 21% did not receive therapy for various reasons. 25% of treated patient received antibiotics and 75% phytotherapy. Results: 100% of patient had some complications of pregnancy. Anemia diagnosed in 48% of patients, recurrent anaerobic vaginitis in 27%. In 36% of the cases premature rupture of membranes was noted, further complicated with hypotonic uterine dysfunction in 27%. Acute intrauterine hypoxia was noted in 17% of cases and C-section was performed in 20% of the patients. Perinatal complications were described in 42% of the newborns. Conclusion: Any patient with a suspected AB should be closely monitored, given risk of various perinatal complications. References: 1 Grabe M. (chairman), Bjerkund-Johansen E., et. al. Guidelines on Urological Infections. European Association of Urology. – 2013 – P.106 2. Kazemier BM., Koningstein FN., et al. Maternal and neonatal consequences of AB should be closely monitored, given risk of various perinatal complications. 25% of treated patient received antibiotics and 2% blood cultures were performed in 3% of the patients. Perinatal complications were described in 42% of the newborns. Conclusion: Any patient with a suspected AB should be closely monitored, given risk of various perinatal complications.

P090 DISTRIBUTION OF NATURALLY-OCcurring IGG ISOTYPES TO HCG AND ITS SUBUNITS IN PATIEnTS WITH OVARIAN CYST

Nino Chikadze1, Mariam Tevzadze2, Tamar Tsertsvadze1, Nino Gachechiladze1, Maia Janelidze4, Nina Porakishvili1,3
1Division of Immunology and Microbiology, Ivane Javakhishvili Tbilisi State University, Tbilisi, Georgia
2Department of Immunology, Tbilisi Medical Academy, Tbilisi, Georgia
3School of Life Sciences, University of Westminster, London, UK
4Department of Obstetrics and Gynaecology, Iq Clinic, Tbilisi, Georgia

Problem statement: Among the gynecological cancers, ovarian cancer is characterized by the highest rate of fatality, mainly due to late stage diagnosis. We have recently proposed that autoantibodies to human chorionic gonadotropin (hCG) are characteristic for the benign ovarian cyst, but not an ovarian cancer and could play a role of a diagnostic and prognostic biomarker. In this study we have investigated the subclass usage of naturally occurring autoantibodies to hCG and its subunits in patients with ovarian cysts. Methods: Blood sera was collected from 12 female patients diagnosed with ovarian cyst, aged 22-61, after ethical permission and informed consent. Using enzyme-linked immunosorbent assay (ELISA) it was confirmed that the sera contained appreciable levels of IgG autoantibodies to any of following antigens – hCGβ, hCGα, hCGα C-terminal peptide (hCGβCTP) and hCGα core fragment (hCGβCF). The sera was then tested for the IgG subclass distribution by indirect ELISA. Results: We have established the overwhelming prevalence of IgG2 subclass in the pool of autoantibodies to all tested antigens The optical density (OD) of binding of serum IgG2 autoantibodies to hCG was 0.25298±0.009656, to hCGα 0.293045±0.187829, to hCGβ 0.236625±0.079578, to hCGβCTP 0.31470±0.154222, to hCGβCF 0.152583±0.032702. Low levels of autoantibodies of IgG3 isotype to hCGβ were detected in 7 out of 12 samples (OD= 0.1256±0.0031, p<0.0001), to hCGβCF in 4 samples (OD= 0.137386±0.0001). Anti- hCGα autoantibodies of IgG3 isotype were not detected. Very low levels of autoantibodies of IgG4 isotype were found in some sera. Interestingly, no autoantibodies of IgG1 isotype to any of the tested hCG subunits were found in the sera of patients with ovarian cyst. Conclusion: Our data demonstrated that the overwhelming majority of autoantibodies in the sera of patients with ovarian cyst, binding to hCG and its subunits belong to the IgG2 isotype thus indicating that they might be directed against carbohydrate antigens within highly glycosylated hCG. Further investigation of the protective role of anti-carbohydrate autoantibodies against ovarian cancer may lead to the development of novel tumour prevention strategies.

P089 EXPRESSION OF GENETIC MARKERS OF ENDOTHELIAL PATHOLOGY IN PREGNANT WOMEN

Eugeny Yupatov1, Larisa Maltsava1, Olga Kravtsova2, Tatiana Zefirova3
1Obstetrics and Gynecology, Kazan State Medical Academy – Branch Campus of the Federal State Budgetary Educational Institution of Further Professional Education «Russian Medical Academy of Continuing Professional Education» of the Ministry of Healthcare of the Russian Federation, Kazan, Russia
2Institute of Fundamental Medicine, Kazan Federal University, Kazan, Russia

Problem statement: Pregnancy considers to be well-established risk factor for venous system disorders. The compound of cardiovascular changes during pregnancy provides significant load on veins, which increases with gestational age and may be accompanied by venous endothelial damage. This in turn can lead to the development of perinatal complications associated with endothelial dysfunction. The detection of biochemical markers of venous endothelial disfunction may help early diagnosis of pregnancy complications and expand the possibilities of preventive therapy. The goal: to study the features of expression of markers of endothelial vein dysfunction in women depending on pregnancy outcomes. Methods: There were 100 pregnant women in whom the expression of adhesion molecules ICAM-1, VCAM-1 and hypoxia gene HIF 1 were determined in the dynamics of pregnancy. Analysis of gene expression was performed by real-time PCR using commercial probes and primers (Applied Biosystems, Hs00234077_m1) on a CFX96 thermocycler (BioRad, USA). The reference gene used gene ACTB (Hs01060665_g1). At the end of pregnancy, women who gave birth to children with pathology of the early neonatal period were identified. The analysis of ICAM-1, VCAM-1 and hypoxia gene HIF 1 was carried out depending on pregnancy outcomes for the fetus. Results: In women who gave birth to children with complications of the early neonatal period the expression of the cell adhesion molecule ICAM1 is 6.1 times higher than in women who gave birth without complications. Such dynamics is observed in the expression of Hif1α gene – its expression is higher by 9.7 times in women who gave birth to children with pathology. VCAM 1 gene activity was not detected in any study group. Conclusion: The study of the expression of adhesion molecules ICAM-1, VCAM-1 and hypoxia gene HIF 1 demonstrated promising value for predicting complications of the neonatal period.

P091 ROUTINE FOLLOW-UP IN WOMEN CONSERVATIVELY TREATED FOR ENDOMETRIAL HYPERPLASIA MUST BE RECOMMENDED

Clara Maarup1, Maria Stentebjerg1, Lone Petersen2, Pinar Bor1
1Department of Obstetrics and Gynecology, Regional Hospital of Randers, Randers, Denmark
2Department of Gynecology, Odense University Hospital, Odense, Denmark

Problem statement: Endometrial hyperplasia characterized by excessive proliferation of the endometrium is strongly related to the
P092
INHIBITORY EFFECT OF TRADITIONAL KOREAN MEDICINE ON THE RECURRENT ENDOMETRIOSIS AFTER LAPAROSCOPIC ASSOCIATION OF CYP19A1 GENE RS2414098 SINGLE NUCLEOTIDE POLYMORPHISM WITH THE RISK OF ENDOMETRIAL CANCER
Rushania Gabidullina, Fikret Nuhbala, Elena Valeeva
Department of Obstetrics and Gynecology, Kazan State Medical University, Kazan, Russia

Aim: Determination of the frequency of polymorphism of the CYP19A1 gene (rs2414098) in patients with endometrial cancer and healthy women living in the Republic of Tatarstan (Russia).

Methods: The study included 60 patients with endometrial cancer and 101 women without endometrial pathology. The age of the subjects ranged from 41 to 91 years. The SNP of the CYP19A1 gene (rs2414098) was determined by real-time polymerase chain reaction. We ran the χ2 test and evaluated the odds ratio. Results: It was found that the level of endometrial cancer was higher in the group of people with the C allele of rs2414098 (OR = 2.11, 95% CI 1.10 - 4.05, p = 0.04) and the C/C genotype (OR = 1.88, 95% CI 1.15 - 3.06, p = 0.01) and the C/C genotype and the C/C SNP genotype of the CYP19A1 molecule is a significant factor that increases the risk of endometrial cancer of women living in the Republic of Tatarstan (Russia). Key words: endometrial cancer, genetic polymorphism, hereditary predisposition.

P093
IS THERE ANY RELATION BETWEEN miRNAs AND OVARIAN CYST TO BECOME OVARIAN CARCINOMA?
Ece Gumusoglu1, Tuba Gunes1, Mohammad Kazem Hosseini1, Nogayhan Seymen2, Taylan Senol3, Ugur Sezerman1, Samet Topuz2, Kiliç Aydını1
1Molecular Biology and Genetics Department, Istanbul University, Turkey
2Department of Obstetrics and Gynecology, Medicus Healthcare Center, Turkey

Aim: Several miRNAs might be evaluated to significant for malignant ovarian cyst to enable diagnosis and disease surveillance. In this study, we studied three different samples: serums of EOC patients, healthy individuals (HI) and benign ovarian cysts (BOC). Their miRNA expressions have been compared by microarray. Microarray data were analyzed according to miRNA expressions the relation between miRNAs target genes and EOC were examined by bioinformatic tools. 75 and 66 significantly dysregulated miRNAs were identified by microarray in BOC vs. EOC and BOC vs. HI comparison, respectively. Results: We focused on common miRNAs that found in both comparison and finally, 46 important miRNAs were detected which can represent the only common sample group. BOC. After these findings, we also considered miRNA profiling in EOC and HI, and surprisingly any common miRNAs were found with these 46 miRNAs. Thus, we analyzed them depending on their potential importance on BOC pathogenesis. After bioinformatics analysis, our findings indicated that there are several biological processes and pathways which can be considered to be related to BOC development. Conclusion: Several miRNAs might be evaluated to significant for malignant transformation from BOC to EOC depending on their targets genes and pathways. Thus, our study can lead further studies to investigate malignant potential of the ovarian cyst to enable prediction, diagnosis and disease surveillance.

P094
REDUCTION OF BONE MINERAL DENSITY AND RISK OF OSTEOPOROSIS IN GYNECOLOGIC CANCER PATIENTS
Yong il Ji1, Min Hyung Jung2
1gynecology, Haeundae Paik hospital, Busan, South Korea
2gynecology, Kyung-hee university Hospital, Seoul, South Korea

Aim: Endometrial and ovarian cancer on bone mineral density (BMD). Methods: From March 2010 to December 2016, study retrospectively reviewed the medical records of women who were treated at Haeundae Paik Hospital. We compared the lumbar spine and femur neck BMD of 243 women with gynecological cancer and 240 controls. Patients with cervical cancer (n=105), endometrial cancer (n=63) and ovarian cancer (n=75) among gynecological patients with cancer (n = 243) were treated with surgery, chemotherapy and/or radiotherapy. As a control group, women with postmenopausal, who did not diagnosed with gynecologic malignancy were selected. BMD was measured by dual energy X-ray absorptiometry (DXA) in the lumbar spine and femur neck. According to the criteria of the WHO, osteopenia was diagnosed as T-score of -1.0 to -2.5, and osteoporosis as T-score below -2.5.
Results: As a result of the research, the mean T-score of lumbar spine was -0.7 (SD = 1.5) in the gynecologic cancer group and -0.3 (SD = 1.5) in the control group (P = 0.001). Compared the each level of the lumbar spine, only the 1st lumbar spine (L1) show a significantly lower bone density in the gynecologic cancer group than control (P = 0.019). Also, T-score of the femur neck was -0.9 (SD = 1.2) in the gynecologic cancer group and -0.6 (SD = 1.1) in the control group (P = 0.01). Compared with according to the cancer type, the BMD of cervical cancer patients was significantly lower at first and second lumbar spine (L1, L2) and femur neck compared to the control group. In ovarian cancer patients, BMD of each level of lumbar spines and the mean of lumbar spines were significantly lower than the control group. The changes in BMD after surgical treatment, chemotherapy, or radiotherapy were
significantly lower in endometrial cancer patients than in cervical and ovarian patients. **Conclusion:** The prevalence of osteopenia and osteoporosis in the gynecologic cancer was 60.5% and 50.8%, respectively. The risk of osteoporosis is high in the gynecologic cancer. **Discourse:** None declared

**P095**

**CDK12 REGULATES GENE EXPRESSION OF DNMT1 & ERBB3 BY ALTERING TRANSCRIPTION OF mIR-152**

Jaroslav Klat1, Marta Dzimkóvá2, Hana Paculová2, Jiří Kohoutek2

1Ob/Gyn. Department, University Hospital Ostrava, Ostrava, Czech Republic
2Department of Chemistry and Toxicology, Veterinary Research Institute, Brno, Czech Republic

**Objective:** The DNA-damage-response (DDR) pathway is a cellular mechanism which has evolved to protect cellular integrity by detection and repair of DNA lesions. It was demonstrated that the cyclin-dependent kinase 12 (CDK12) maintains genome stability via regulation of transcription of DDR genes, specifically, BRCA1, RAD51 and others. Importantly, down-regulation of the CDK12 caused induction of the 53BP1 and γH2AX foci and acetylation of the H2A.Z histone of the cell cycle. We confirmed that upregulated expression of miR-152 leads to decreased expression of DNMT1 (DNA methyl transferase 1), RICTOR and MET proteins, which are often found deregulated in cancers. Defects in methylation of miR-152 has been observed in several cancers and studies have proven an on/off loop between expressions of DNMT1 and miR-152. In addition, the protein level of ERBB3 was also affected by downregulation of CDK12 in various ovarian cancer, as well as PEO1, COV362 and OVCAR5. **Conclusion:** We speculate that CDK12 participates in DDR machinery by two distinct mechanisms, either by orchestrating transcription of DDR genes or by stabilization of DNMT1 protein by blocking expression of miR-152 targeting DNMT1. The project is supported by the grant of the Ministry of Health AZV16-34152A.

**P096**

**OUTCOMES OF SURGICAL MANAGEMENT OF ENDOMETRIAL HYPERPLASIA WITHOUT ATYPIA**

Shi Hui Lee1, Hui Men Selina Chin1, Charissa Goh Shu Ying2, Manisha Mathur1, Yong Kuei Timothy Lim1, Felicia Chin Hui Xian1

1Department of Obstetrics and Gynaecology, KK Women's and Children's Hospital, Singapore
2Department of Gynaecological Oncology, KK Women's and Children's Hospital, Singapore

**Introduction:** First line treatment of endometrial hyperplasia without atypia is medical therapy with progesterone. However, there remains a group of patients who choose surgical management due to reasons such as contraindications to progestrone, other indications for surgery, and patients’ preferences. **Methodology:** Women diagnosed with endometrial hyperplasia without atypia who underwent surgical management at first line treatment, in KK Women's and Children's Hospital, between April 2015 to March 2016 were included in this study. **Results:** 262 patients were diagnosed with endometrial hyperplasia, 18.3% (n=48) underwent hysterectomy as first line management, with the average time to surgery being 85.3 days. The mean age was 51 years old, with 16 patients (33.3%) who were post-menopausal. The mean body mass index was 26.8. 9 patients (18.7%) had diabetes mellitus, 3 patients (6.25%) were on tamoxifen for breast cancer, 1 (2.1%) had polycystic ovarian syndrome, and 1 (2.1%) was diagnosed with granulosa cell tumor at the same time. Majority presented with abnormal uterine bleeding or postmenopausal bleeding (72.9%) with the remaining presenting with thickened endometrium, endometrial poly, or endometrial cells on pap smear. 18 patients (37.5%) chose surgical management in view of other indications. Surgery was uncomplicated except for 1 patient (2.1%) who had bladder injury during the surgery. 23 patients (47.9%) received progesterone therapy while awaiting surgery. Final pathology showed grade I adenocarcinoma in 2 patients (4.1%) had hyperplasia without atypia on final pathology, and the remaining 16 patients (33.3%) were found to have no hyperplasia. **Conclusion:** Surgical management for hyperplasia without atypia can be considered an option for high risk patients, as our current study shows up to 20% of patients harboring high grade final histology. Disclosures – NIL

**P097**

**MANAGEMENT OF OVARIAN TERATOMAS ASSOCIATED WITH AUTOIMMUNE ENCEPHALITIS: A CASE REPORT AND REVIEW OF THE LITERATURE**

Christopher Michael Mayer1, Humberto Leal Bailey2, David Kim2

1Alberty Medical College, Albany Medical Center, Albany, USA
2Department of Neurology, University of Texas Health Science Center at San Antonio, San Antonio, USA
3Department of Pathology, University of Texas Health Science Center at San Antonio, San Antonio, USA

**Problem statement:** NMDA encephalitis (NMDAE) is an autoimmune condition characterized by rapidly progressive psychiatric symptoms, cognitive impairment, seizures, abnormal movements, coma, and dysautonomia, sometimes requiring intensive care. Young females are mostly affected, with ovarian teratomas (OT) found in 18-50% of cases. Treatment includes OT resection, however, there is still insufficient evidence of the best management for NMDAE. **Methods:** Case report and literature review. **Results:** Case A healthy 34-year-old female presented with bizarre behavior, emotional lability, disorganized speech and auditory/visual hallucinations for 48 hours. She was treated with plasma exchange and Cyclophosphamide. She slowly recovered and was ultimately discharged, 94 days after admission. She received azathioprine and prednisolone. At the recent follow-up, she was asymptomatic. **Discussion:** Even though OTs are frequent, studies have found no role of screening for NMDA antibodies in patients with OT, and diagnosis requires high clinical suspicion. Some cases of NMDAE without OT might suggest a role for screening for OT development, as some patients might ultimately develop OTs. OT resection is an integral part of treatment. As in this case, it might be appropriate to perform resection in suspected cases, before diagnostic confirmation. There is controversy surrounding performing bilateral oophorectomy despite negative imaging for OT, as some cases subsequently identified OT microscopically. There might not be a specific time window for OT resection, as a case showed improvement even after 11 months since symptom onset. Anesthesiologists should avoid NMDA antagonists such as ketamine to avoid clinical worsening in suspected NMDAE. **Conclusion:** OTs are relatively frequent and mostly benign, however, they can cause significant neurological disease through autoimmune mediators, possibly reducing the role of screening for OT development.
THE INVESTIGATION OF POST-MENOPAUSAL BLEEDING;
Michele Montanaro Gauci
Obst and Gyneae Department, Mater Dei Hospital, Malta
Faculty of Health Sciences., University of Malta, Malta

Problem statement: There is no consensus regarding the ideal investigative pathway for post-menopausal bleeding (PMB). Outpatient endometrial sampling (ES) is often one of the tests used but the exact role of this test has not been clearly defined. The literature has shown that ES can be unsuccessful, can provide an insufficient sample or can miss focal intra-uterine cavity lesions altogether. ES does however detect around 90% of endometrial cancers (EC), in cases of PMB. Objective: To assess the value of ES in the investigative pathway of PMB. Methods: 69 consecutive women who presented with PMB underwent transvaginal ultrasound including measurement of endometrial thickness (ET). 47 of these had ET=4mm and were included in this prospective study and underwent gel-infusion sonohysterography (GIS). All 47 women had ES at the initial consultation. Some had subsequent hysteroscopic procedures (HY). Results: ES detected EC in 4 women. No other EC cases were diagnosed at subsequent HY. ES detected polyp fragments or polyps in 13/47 (27.6%) women. Focal intracavity lesions were seen in 30/47 (63.4%) women during GIS. Sessile intracavity lesions were more common than pedunculated lesions. ES diagnosed a higher proportion of the sessile lesions (38%) than of the pedunculated lesions (20%). ES failed to provide any diagnosis for the intracavity lesion in 60% of focal lesions. Conclusions: This study confirms that ES misses a high proportion of focal intracavity lesions and should not be used as the reference test in the investigation of PMB. ES can be easily performed at the initial consultation and can achieve high detection rates of EC early in the investigative pathway. Additionally; in women who have no focal intracavity lesions; a benign ES result may be one of a series of tests which contribute to achieving reassurance of the absence of EC.

NMDAE is treatable if promptly diagnosed, but potentially fatal if missed. Authors have no disclosures.

P098 WHICH ULTRASOUND FEATURES OF THE ENDOMETRIUM ARE PREDICTIVE OF MALIGNANCY IN POST-MENOPAUSAL BLEEDING?
Michele Montanaro Gauci
Obst and Gyneae Department, Mater Dei Hospital, Malta
Faculty of Health Sciences., University of Malta, Malta

Problem: The aim of this study was to find which ultrasound features of the endometrium could be predictive of endometrial cancer (EC) in women presenting with post-menopausal bleeding (PMB). Methods: A prospective study was performed on 47 women with PMB and endometrial thickness (ET) =4mm. The endometrium was evaluated at transvaginal ultrasound (TVUS) with Doppler imaging and gel-infusion sonohysterography (GIS), and the findings (defined as per terminology of International Endometrial Tumour Analysis [IETA] group) were correlated with histological diagnosis obtained at out-patient endometrial sampling (ES) or at hysteroscopy. Univariate and multivariate analysis by logistic regression were performed. Results: EC was diagnosed in 5.8% (4/69) of all women presenting with PMB. ET was found to be significantly predictive of EC (p=0.004). The endometrial outline (endometrial folds pattern) as seen after GIS was also found to be a significant predictor of EC (p=0.008). These two variables together with a multiple vessel vascular pattern of the endometrium on Doppler imaging (p=0.055), and a raised body-mass-index (BMI) (p=0.078) were incorporated into a logistic regression model to assess prediction of EC. Logistic regression modelling revealed only endometrial outline (p=0.003) and ET (p=0.032) to be significantly predictive of EC, when the 4 variables were assessed collectively in multivariate analysis. GIS revealed the presence of focal intra-cavity lesions in 63.8% of the women with ET=4mm. Out-patient ES missed 60% of these focal intra-cavity lesions. Conclusion: All US features identified as predictive, could be used in combination to estimate EC risk. GIS is a very useful addition to the TVUS investigation as it allows assessment of endometrial outline which is a strong predictor of EC. Statistically derived risk-scores for EC, based on predictive US features, should be one of a series of tests incorporated into clinical algorithms for management of women with PMB. Keywords: post-menopausal bleeding, endometrial cancer, transvaginal ultrasound, endometrial thickness, endometrial outline, gel-infusion sonohysterography.

P099 OUT-PATIENT ENDOMETRIAL SAMPLING IN THE INVESTIGATION OF POST-MENOPAUSAL BLEEDING; HOW USEFUL IS IT?
Michele Montanaro Gauci
University of Malta, Mater Dei Hospital, Malta

Problem statement: Endometrial polyps are common in women of all ages, especially in post-menopausal women. They are often asymptomatic. They are present in around 15% of women with post-menopausal bleeding (PMB) and in at least a third of the women with PMB who have an endometrial thickness of 4mm or 5mm. Most endometrial polyps are benign; but approximately 5% of them have malignant or pre-malignant disease within. The risk of malignancy within an endometrial polyp increases with age, menopausal status, symptoms of abnormal vaginal bleeding such as PMB, as well as polyp size. Women with PMB who are found to have endometrial polyps therefore appear to require polyp removal. The high prevalence of this focal lesion within the uterus cavity of post-menopausal women has huge implications for the investigative pathway of PMB. Intra-cavity lesions can alternatively be submucous fibroids or focal endometrial cancers. Methods of diagnosis: Endometrial polyps can be identified by means of certain suggestive features on transvaginal ultrasound. These include the presence of a bright edge around the polyp where it lies in contact with the endometrial lining; the appearance of small intralesional cystic areas within the polyp; the presence of a pedicle artery or feeding vessel extending from the endometrium into the polyp, and the elicitation of the sliding sign on movement of the ultrasound probe. In addition; intra-cavity lesions can be identified and delineated during sonohysterography when fluid instilled within the uterine cavity provides a negative contrast medium which outlines the intra-cavity lesion. Endometrial polyps can also be directly visualised during hysteroscopy. Outpatient endometrial sampling devices may detach fragments from an endometrial polyp thus allowing histological identification, but often the sampling devices miss the focal lesion entirely. Conclusions: The aim of investigating PMB is not primarily to diagnose and treat benign lesions, however, suspected endometrial polyps should undergo complete hysteroscopic removal, to achieve a representative histological diagnosis. Removal of an intra-cavity lesion should be performed hysteroscopically to ensure complete removal of the polyp from its base, including any stalk when present. If there is no suspicion of endometrial malignancy, the hysteroscopic procedure need not be fast-tracked.
P101

CLINICAL ALGORITHM FOR INVESTIGATION OF POST MENOPAUSAL BLEEDING

Michele Montanaro-Gauci
Mater Dei Hospital & University of Malta, Malta

Problem statement: There is no consensus regarding the ideal clinical pathway for investigation of post-menopausal bleeding (PMB). Many centres use an endometrial thickness (ET) measurement 4mm, taken during transvaginal ultrasound (TVUS), as the initial test to identify PMB patients who can be reassured about the absence of endometrial cancer (EC). For the remaining PMB patients, further testing is required. The exact nature and sequence of subsequent tests varies. Methods: The literature pertaining to investigation of PMB was reviewed and a clinical algorithm was devised. The algorithm applies to the clinical scenario where initial investigation of PMB is by TVUS +/- sonohysterography (SHG), which can be followed immediately by out-patient endometrial sampling (ES). A hysteroscopic procedure (HY) which allows polypectomy, targeted endometrial biopsies and/or endometrial curettage would be the next step in the investigative pathway. Results: In the investigation of PMB, women with ET15mm are classified as high-risk and fast-tracked for HY. The remaining women with ET 4 -15mm undergo detailed TVUS of the endometrial cavity with Doppler imaging and SHG, and the Risk of Endometrial Cancer (REC) score is applied; out-patient ES is also performed. Subsequent management will depend upon the REC score, the presence or absence of a focal intra-cavity lesion and the result of the out-patient ES. Women with a high risk of EC according to REC score will be fast-tracked for HY. For women with no focal intra-cavity lesion, the final negative likelihood ratio (LR) of a REC score of zero and/or with intermediate risk according to REC score, whose ES result is additionally benign, will undergo non-intra-cavity lesion and/or endometrial curettage; would be the next step in the investigative pathway. Conclusion: The tests used in this clinical algorithm include: ET4mm, ET15mm, REC score=0, REC score=4, out-patient ES, HY with representative endometrial cavity samples. By means of the algorithm, the fast-tracked, gold-standard HY test is reserved for women at highest risk of EC. Reassurance of absence of EC may be achieved in some, by a low REC score, together with a non-malignant out-patient ES result.

P102

INCIDENCE OF HIGH GRADE CERVICAL INTRAEPITHELIAL NEOPLASIA IN WOMEN WITH NORMAL AND ABNORMAL PAP SMEARS: A 3-YEAR FOLLOW UP IN THAMMASAT UNIVERSITY HOSPITAL

Awassada Punyashthira1, Kanokwan Promchit1, Nattapat Kanjanawlai1, Junya Pattaraarchachai1, Kornkarn Bhamarapravatana2, Komsun Suwannaruk1

1Obstetrics and Gynecology, Faculty of Medicine, Thammasat University, Klong Luang, Thailand
2Chulabhorn International College of Medicine, Thammasat University, Klong Luang, Thailand

Background: Cervical cancer is the third most malignancy among Thai women. Cervical intraepithelial neoplasia (CIN)2/3 was precancerous of cervical cancer that could be conservative treatment. Precise recurrent investigation tool was an important method. Objective: The aim of this retrospective study was to investigate the regression rate of CIN2/3 after three years of treatment. Materials and methods: Ninety cases of CIN2/3 from participants who underwent cervical cancer screening by co-testing method and treated between July 2013 and June 2016 at Gynecologic Clinic, Thammasat University Hospital, Pathum Thani, Thailand and affiliated clinics were recruited. Demographic data, method of treatment and co-testing report of participants were recorded for three consecutive years. Results: A total of 2,144 women during the period were recruited. After exclusion criteria, 1,505 cases were enrolled in the study. Cases who had abnormal co-testing had lesser mean age, more sexual partner and sexual transmitted diseases than those who had normal co-testing. Ninety-nine percent of the negative testing group had negative co-testing at the end of three years period. Ninety cases were diagnosed with CIN2/3. The regression rate of CIN2/3 at two and three years follow up after treatment were 97.8% (86/90) and 95.6% (85/90), respectively. Additional four cases who had negative co-testing at first and second year were diagnosed of CIN2/3 at third year of follow up period. Conclusion: The regression rate at two and three years follow up were 97.8 and 95.6 percent, respectively. Overextending by three consecutives co-testing follow up of CIN2/3 after treatment should be concerned. Keywords: CIN, Pap smear, high grade, follow up, exclusion procedure, ablation

P103

RADIOFREQUENCY ABLATION (RFA) LIMITS IN THE EMERGENCY HAEMOSTASIS IN BLEEDING TUMOURS OF THE UTERINE CERVIX

Maria-Manuela Ravas1,2, Augustin Marian Marinca1,2, Virgiliu Mihail Prunoiu1,2, Eugen Bratucu1,2

1Oncological Surgery, Bucharest Oncological Institute, Bucharest, Romania
2Surgery, Carol Davila University, Bucharest, Romania

Problem statement: Cervical cancer benefits from standard treatment such as: surgery and radio/chemotherapy. Recently, for the aggressive cancer forms which are resistant to radio/chemotherapy forms, IB-IV stages, thermally ablative treatments are used to destroy tumours using various sources of energy. The study aims to establish the place that radiofrequency ablation (RFA) holds in the current treatment protocols of cancers of the uterine cervix. Methods: We performed a 10-year retrospective study (2008-2018) in which we analysed the use of RFA, with selective criteria for aggressive tumors of the uterine cervix which bled and were associated with acute secondary anaemia (Hb=7-11g/dl). 96 patients with ages between 39 and 73 were evaluated with stages from IB to IV and 78 applications were done. Results: The results obtained underlined the haemostatic qualities of the procedure, RFA being the only non-surgical method which can achieve quicker bleeding control, in comparison with either external irradiation, or brachytherapy, which obtain the same effects, but no sooner than 12/48 hours). In 92 patients, haemostasis was obtained by the first RFA, but in 2 patients the procedure had to be repeated and in other 2 patients ligation of vascular pedicles was needed. Conclusions: RFA is useful in the treatment of cancers of the uterine cervix in achieving emergency haemostasis, and it can be considered a minimally invasive technique in neo-adjuvant complementary treatment of tumour palliation. The method can be associated with surgery and / or radio / chemotherapy, although it might be limited by the advanced stage of the disease when other methods of haemostasis may be used. We consider that RFA will be able to have an important place in oncology treatment protocols. Therefore, we suggest: Adding to the current treatment protocol a simple and quick haemostatic technique (RFA) in bleeding tumors of the uterine cervix which associate acute anaemia, Establishing clinical and paraclinical criteria as indicators of tumor aggression and responsiveness to treatment. There are no conflicts of interest Key words: cervical cancer, radiofrequency, haemostasis, hyperthermia

P104

CASE REPORT – ANAPLASTIC LARGE CELL LYMPHOMA IN WOMEN WITH BREAST IMPLANTS

Anna Salvador, Gabriela Sevidanes, Camila Cinquetti, Renata Saliba, Enaldo De Lima, Marco Antônio Dias Filho, Gnaana De Araujo, Maria Luisa Vieira, Henrique Silva

Mastology, Rede Mater Dei de Saúde, Belo Horizonte, Brazil
**Problem statement:** A 54 years old female patient presenting unilateral breast prosthesis seroma with related pain after 8 years of prosthesis insertion. **Methods:** Breast puncture was performed in March 2019 with the presence of hallmark cell suggestive of Anaplastic Large T-Cell Lymphoma associated with breast implant (BIA – ALCL). Patient was submitted to the removal of bilateral peri-prosthesis capsules and immunohistochemistry confirmed Anaplastic Large T-Cell Lymphoma associated with breast implant (BIA – ALCL) restricted to prosthesis surface (in situ). **Results:** BIA – ALCL is a tumor that develops in the capsule that surrounds breast implants. This condition is rare, occurring in 1 in each one million patients. Most patients present seroma with breast edema. A total of 10 to 35% of patients presents limited breast nodule or axillary lymphadenopathy. In general, cases are detected 3 to 19 years after implant insertion. If identified in its “in situ” stage, surgery with the complete removal of the implant and capsule deliveries a good prognosis; therefore, in advanced cases, chemotherapy should be recommended. **Conclusion:** BIA – ALCL is a rare condition but the early identification of the cases allows better prognosis with less spoliation to the patient once chemotherapy might be avoided.

**P105**

**THE EFFECT OF OCTEROTIDE IN POSTOPERATIVE LYMPHOCELE IN GYNECOLOGIC CANCER PATIENTS**

Seunghyuk Shim, Seung-Hyuk Shim
Department of Obstetrics and Gynecology, Konkuk University Medical Center, South Korea

**Objective:** Gynecologic cancer is usually treated surgically and lymphocele is an effective and safe treatment for the lymphocele did not recur. **Methods:** Retrospective chart review were done and patients with lymphocele after surgery who diagnosed from January 2008 to March 2019 were included. Using and not using octreotide were divided in two groups. Octreotide was injected 100 mcg per day and stopped when PCD decreased, lymphocele decreased on CT, and when patient’s symptoms has improved. The amount of PCD was checked daily and CT was followed up after 1-2 weeks of initiating octreotide. **Results:** A total of six patients with lymphocele treated with octreotide were included. Median age was 51 (39-67), with 5 endometrial cancer patients and 1 cervical cancer patients. The median total hospital stay for treatment was 32 days (19-68) and median treatment duration time was 17 days (3-30). The median number of lymph node dissection in primary surgery was 33 (17-54) and one patient underwent para-aortic lymph node dissection. All patients with octreotide, lymphocele did not recur. **Conclusion:** Treatment with octreotide in lymphocele is an effective and safe treatment for the management of lymphocele after lymphadenectomy, but further research is needed to establish optimal dosage and treatment regimens.

**GYNECOLOGY**

**P106**

**EMERGENCY CONTRACEPTION AMONG YOUTH POPULATION**

Natalia Aganezova, Sergey Aganezov, Anastasia Morotskaya
Department of Obstetrics and Gynecology, I.I. Mechnikov North-Western State Medical University, Ministry of Health of Russia, Saint-Petersburg, Russia

**Problem statement:** Every forth young woman in Russia has had sexual intercourse by the age of 17, around 40% of them did not use any method of contraception. Emergency contraception (EC) among young people in most cases can prevent unplanned pregnancy. **Objective:** To determine of frequency of EC use and awareness of EC among young people. **Methods:** The method of questioning was used (36 items). There were questions about gynecological anamnesis, experience in EC usage (female respondents only) and theoretical knowledge of EC (all participants). The questionnaire was presented in social networks and on paper carriers. The questionnaire was filled by 952 young persons (female – 802 (84.2%), male –150 (15.8%)) from various educational institutions, young doctors of different specialities, others. Mean age was 20.7±1.6 years (from 15 to 24 years). The group was a simple random sample. **Results:** Almost 10% of young women had pregnancy in the past, half of them were unplanned. Two thirds of unplanned pregnancies ended with medical abortions. One third of female respondents (32.9%) has used EC at least once, in all the cases they preferred levonorgestrel pills. The prevalence of EC usage grew with the increase of the respondents age. The majority of participants think that administration of EC is justifiable if unprotected sexual intercourse has taken place. Up to 65% of respondents know the right regimen of EC administration, a quarter of the participants have incorrect information, others were unable to answer. The greater part of all participants (63%) have incorrectly assume that repeated use of EC leads to infertility and reduction of effectiveness of EC methods. No one was aware of the possibility of an emergency intrauterine contraceptive introduction after unprotected intercourse. Knowledge of EC among schoolchildren and students of non-medical institutions was the lowest. **Conclusions:** Young people in Russia are highly aware of the existence of EC as such, but they have insufficient knowledge of it. It is highly important to give special lectures on family planning and contraception in schools and universities as it helps young people to maintain their reproductive health by using safe and effective methods of contraception.

**P107**

**ENDOMETRIAL LEUKEMIA INHIBITORY FACTOR EXPRESSION IN WOMEN WITH REPRODUCTIVE DYSFUNCTIONS**

Sergey Aganezov, Anastasia Morotskaya, Olga Ryndina, Natalia Aganezova
Obstetrics and Gynecology, I.I. Mechnikov North-Western State Medical University, Ministry of Health of Russia, Saint-Petersburg, Russia

**Problem statement:** To analyze the endometrial expression of leukemia inhibitory factor (LIF) in women with a history of reproductive dysfunctions. **Methods:** The main group (I) – 121 patients with infertility (n=81) and miscarriage (n=40); the control group (II) – 16 healthy fertile women; all subjects were 18-40 y.o. On 6-8th day after ovulation we performed endometrial biopsy and obtained peripheral blood to assess levels of estradiol (E2) and progesterone (P). We conducted histological and immunohistochemical (estrogen (ER), progesterone (PR) receptors, LIF expression) analysis of endometrium samples. **Results:** All women had a histological endometrium, the serum levels of E2 (pmol/l) were 692.2±29.1 (I) and 707.4±66.1 (II); P (nmol/l) – 45.12±0.9 (I) and 39.14±7.9 (II). Mid-secretory endometrium was determined in all healthy women and in 42% (n=51) of the main group. All healthy women showed low glandular ER, PR expression, reduced stromal ER expression, high PR stromal expression in endometrium. Only 44% (n=53) in the main group had the same characteristics of sex steroid receptors expression as the healthy women; 56% (n=88) of cases a disturbed hormone-receptor endometrial “response” was observed. We evaluated LIF expression in the endometrium in the main (I) and healthy (II) groups: in the luminal epithelium (I – 88, II – 16), in glands and stroma (I – 121, II – 16). The frequency of reduced LIF expression in the endometrial glands and stroma was significantly higher (p<0.05) in the main group (I) than in healthy women (II): in the glands – 31%, n=37 (I) vs 6%, n=11 (II); in stroma – 56%, n=68 (I) vs 13%, n=2 (II). Endometrial LIF expression levels were similar across the reproductive dysfunction types. In women with disturbed
The 27th World Congress on Controversies in Obstetrics, Gynecology & Infertility (COGI)
Paris, France • November 21-23, 2019  COGI

small cystic areas and well-defined echogenic foci suspicious for heterogenous left ovarian lesion measuring 21x12x19mm with underwent laparoscopic salpingo-oophorectomy. Histopathology ovarian teratoma as the cause of her symptoms. She subsequently course was complicated by worsening behavioural symptoms NMDA -receptor encephalitis was confirmed with the presence of lymphocytic pleocytosis with mononuclear cells. A diagnosis of Cerebrospinal fluid (CSF) from lumbar puncture demonstrated change. She also experienced déjà vu and odd smells, consistent with partial seizures. She had an abnormal electroencephalogram. Cerebrospinal fluid (CSF) from lumbar puncture demonstrated lymphocytic pleocytosis with mononuclear cells. A diagnosis of NMDA-receptor encephalitis was confirmed with the presence of serum and CSF antibodies. Pelvic ultrasound revealed a heterogeneous left ovarian lesion measuring 21x12x19mm with small cystic areas and well-defined echogenic foci suspicious for ovarian teratoma as the cause of her symptoms. She subsequently underwent laparoscopic salpingo-oophorectomy. Histopathology demonstrated a mature teratoma. Tumour markers were normal. She required intensive care admission and treatment with intravenous immunoglobulin and steroids. Her post-operative course was complicated by worsening behavioural symptoms requiring second-line treatment with Rituximab. She remained admitted for six weeks until her behavioural symptoms improved with anti-psychotic and anti-epileptic therapy. Discussion: This unusual presentation of anti-NMDA-receptor encephalitis prompted by ovarian teratoma is the first reported case with recurrent syncope as the primary presenting symptom. Furthermore, this case demonstrated refractory symptoms despite treatment, highlighting the importance of early identification and management, which have been associated with prompt improvement and good outcome (Acién et al. 2014). Note: Full list of references to be provided on request

P108 OVARIAN TERATOMA CAUSING RECURRENT SYNCOPE AND ANTI-N-METHYL-D-ASPARTATE RECEPTOR ENCEPHALITIS
Marrwah Ahmadzai1, Rebecca Li1, Sonia Hossain2
1Obstetrics and Gynaecology, The Canberra Hospital, Australia
2Obstetrics and Gynaecology, The Calvary Hospital, Australia

Background: Anti-N-Methyl-D-aspartic acid (NMDA) receptor encephalitis is a rare and potentially fatal form of encephalitis (Chiu et al. 2019). Several case reports describe the condition in association with ovarian teratomas, as neural tissue in the teratoma can secrete anti-NMDA-receptor antibodies (Iemura et al. 2018). The condition causes significant morbidity due to complex neuropsychiatric symptoms (Li et al. 2017). It is managed with tumour resection, immunotherapy and supportive measures (Acién et al. 2014). Case: A 37-year-old otherwise healthy multiparous female presented with a four-day history of recurrent syncope and postural hypotension. She had two previous normal vaginal deliveries. She was taking the combined oral contraceptive pill for contraception. Cardiac and neurological examinations, laboratory investigations, electrocardiogram and intracranial imaging were unremarkable. She was admitted under the medical team for further investigation and empirically commenced on Ceftiraxone, Ayclovir and Fludrocortisone. Despite this treatment, she had ongoing postural hypotension and within forty-eight hours of admission developed acute confusion, agitation and behavioural change. She also experienced déjà vu and odd smells, consistent with partial seizures. She had an abnormal electroencephalogram. Cerebrospinal fluid (CSF) from lumbar puncture demonstrated lymphocytic pleocytosis with mononuclear cells. A diagnosis of NMDA-receptor encephalitis was confirmed with the presence of serum and CSF antibodies. Pelvic ultrasound revealed a heterogeneous left ovarian lesion measuring 21x12x19mm with small cystic areas and well-defined echogenic foci suspicious for ovarian teratoma as the cause of her symptoms. She subsequently underwent laparoscopic salpingo-oophorectomy. Histopathology demonstrated a mature teratoma. Tumour markers were normal. She required intensive care admission and treatment with intravenous immunoglobulin and steroids. Her post-operative course was complicated by worsening behavioural symptoms requiring second-line treatment with Rituximab. She remained admitted for six weeks until her behavioural symptoms improved with anti-psychotic and anti-epileptic therapy. Discussion: This unusual presentation of anti-NMDA-receptor encephalitis prompted by ovarian teratoma is the first reported case with recurrent syncope as the primary presenting symptom. Furthermore, this case demonstrated refractory symptoms despite treatment, highlighting the importance of early identification and management, which have been associated with prompt improvement and good outcome (Acién et al. 2014). Note: Full list of references to be provided on request

Problem statement: To focus on recent developments in the definition, diagnosis, prevention, screening and treatment of preeclampsia. Method: Data was obtained by scanning evidence-based guides, consensus reports (Cochrane Preeclampsia, World Health Organization, American College of Obstetricians and Gynecologists, Agency for Healthcare Research and Quality, Centers for Disease Control and Prevention, National Heart, Lung, and Blood Institute) and related literature Results: Preeclampsia is a complication of pregnancy that affects all systems. Worldwide, this complication remains one of the leading causes of maternal-perinatal morbidity and mortality. Preeclampsia was formerly defined as a disorder characterized by new onset of hypertension and proteinuria typically arising after 20 weeks of gestation in a normotensive woman. Recently, proteinuria is no longer required for the diagnosis of preeclampsia. Preeclampsia is diagnosed by hypertension and either proteinuria or hypertension in association with thrombocytopenia, impairment liver dysfunction, new onset of renal impairment, pulmonary edema or cerebral/visual symptoms. Although there are some maternal clinical factors, biophysical and biomarkers to predict preeclampsia in early pregnancy, they are not yet ready for clinical use. Term “mild preeclampsia” is no longer used to describe preeclampsia, since preeclampsia is a dynamic and progressive disease process that can change rapidly. In addition, the term “severe preeclampsia” is replaced with preeclampsia with severe features. The administration of low-dose aspirin has a slight effect to reduce preeclampsia. There is not enough evidence to support bed rest or salt restriction to reduce preeclampsia risk. The only effective treatment of preeclampsia is to deliver the fetus and the placenta. Termination of pregnancy and the decision to deliver depend on gestational age, severity of preeclampsia, maternal and fetal conditions and severity of preeclampsia. Delivery is suggested for preeclampsia without severe features after 37 weeks of gestation and in case of preeclampsia with severe features after 34 weeks of gestation. Therapy is essentially based on antihypertensive treatment and magnesium sulfate. To promote fetal lung maturity, a single corticosteroids administration is recommended to preeclamptic women between 24-34 weeks. Also, preeclampsia increase risk of future cardiovascular disease Conclusion: New evidence over the past few decades have contributed to a better understanding of the preeclampsia.

P110 THE RELATIONSHIP OF OVARIAN RESERVE AND AUTOIMMUNE THYROID DISEASE IN WOMEN OF REPRODUCTIVE AGE
Yulia Absatarova1, Olga Grigoryan1, Natalia Krasnovskaya2, Robert Mikhail3, Elena Andreeva1, Ivan Dedov2
1Endocrinology, Professor, Moscow, Russia
2Gynecology, Dr., Moscow, Russia
3Endocrinology, Professor, Moscow, Russia

Problem statement: Several studies have shown a likely relationship between autoimmune thyroid diseases and reproductive disorders in women, but the results are contradictory, and the pathogenic mechanisms are not clear. Objective: To compare the ovarian reserve in healthy women of reproductive age with antithyroid antibodies (ATA) and in healthy women of reproductive age without ATA. Methods: The following markers of the ovarian reserve were determined on the 2nd-4th days of the menstrual cycle: serum levels of anti-Müllerian hormone (AMH), inhibin B, FSH, LH, estradiol, testosterone and progesterone. The number of antral follicles and the volume of the ovaries were examined by ultrasound. Patients. 70 healthy women of reproductive age in the state of euthyroidism (from 18 to 38 years old). Interventions. Participants were divided into equal groups (n = 35) depending on the status of the presence of antithyroid antibodies (AT-TPO, AT-TG). To determine the predisposition to premature ovarian failure, an analysis of the number of CGG repeats in the FMR1 gene was performed. Results: The levels of
PCOS. associated with a lower effectiveness of pathogenetic therapy for longer treatment and rehabilitation periods are required, which is PCOS and impaired thyroid function metabolic profile is worse, with combined oral contraceptives. hypothyroidism have higher levels of ovarian volume and the however, the therapy was less effective. Patients with PCOS and combination with Levothyroxine preparations if indicated), as well as in patients with PCOS and thyroid pathology (in metabolic and hormonal disorders in patients only with PCOS, as other groups. Combined therapy effectively compensates the PCOS and hypothyroidism is significantly higher than in women of hypothyroidism. The average level of cholesterol in patients with metabolic profile (higher levels of androgens, severe hyperinsulinemia and dyslipidemia, carbohydrate metabolism disorders), more often suffer from cardiovascular diseases. Primary infertility is more common in patients with PCOS and hypothyroidism. The average level of cholesterol in patients with PCOS and hypothyroidism is significantly higher than in women of other groups. Combined therapy effectively compensates the metabolic and hormonal disorders in patients only with PCOS, as well as in patients with PCOS and thyroid pathology (in combination with Levothyroxine preparations if indicated), however, the therapy was less effective. Patients with PCOS and hypothyroidism have higher levels of ovarian volume and the number of antral follicles, which requires a longer course of therapy with combined oral contraceptives. Conclusion: In patients with PCOS and impaired thyroid function metabolic profile is worse, longer treatment and rehabilitation periods are required, which is associated with a lower effectiveness of pathogenetic therapy for PCOS.

METABOLIC DISORDERS AND THERAPEUTIC OPTIONS FOR POLYCYSTIC OVARY SYNDROME WITH CONCOMITANT THYROID PATHOLOGY

Ashot Mkrtumyan1, Ekaterina Azizova1, Elena Andreeva2
1Endocrinology, Dr., Moscow, Russia
2Gynecology, Professor, Moscow, Russia

Problem statement: Autoimmune thyroiditis, hypothyroidism are 5 times more common in PCOS, and the presence of antibodies to the thyroid gland is associated with infertility. Aim: to evaluate the hormonal, metabolic and reproductive status in patients with PCOS and concomitant thyroid pathology: hypothyroidism, diffuse endemic goiter (DEG).

Methods: 154 women aged 18–40 years with PCOS who did not have thyroid pathology at the time of diagnosis of PCOS: group 1 (51 women did not have concomitant thyroid diseases), group 2 (51 women with DEG, 3 group (52 women with hypothyroidism). PCOS was diagnosed based on the Rotterdam 2003 criteria (ESRHE / ASRM). At the time of inclusion in the study, the duration of PCOS in group 1 was 4.0 ± 0.8 years, in group 2 - 5.8 ± 1.6 years, in group 3 - 4.2 ± 0.3 years. Hormonal and biochemical analysis: FSH, LH, TSH, testosterone, DHEAS, SHBG, TSH, free T3 and T4 in blood serum for 2-3 days of the menstrual cycle, cholesterol, LDL, HDL, triglycerides, glucose tolerance test, insulin. Therapy: combined oral contraceptives with drospirenone, metformin, statins, levothyroxine, potassium iodide. Ultrasound of the thyroid gland, ovaries and uterus. Results: Patients with thyroid pathology (group 2 and 3) have a worse metabolic profile (higher levels of androgens, severe hyperinsulinemia and dyslipidemia, carbohydrate metabolism disorders), more often suffer from cardiovascular diseases. Primary infertility is more common in patients with PCOS and hypothyroidism. The average level of cholesterol in patients with PCOS and hypothyroidism is significantly higher than in women of other groups. Combined therapy effectively compensates the metabolic and hormonal disorders in patients only with PCOS, as well as in patients with PCOS and thyroid pathology (in combination with Levothyroxine preparations if indicated), however, the therapy was less effective. Patients with PCOS and hypothyroidism have higher levels of ovarian volume and the number of antral follicles, which requires a longer course of therapy with combined oral contraceptives. Conclusion: In patients with PCOS and impaired thyroid function metabolic profile is worse, longer treatment and rehabilitation periods are required, which is associated with a lower effectiveness of pathogenetic therapy for PCOS.

MOLECULAR CHANGES IN UTERINE LEIOMYOMAS IN MYOMECTOMY PATIENTS

Anna Ayravaainen1,2, Tuomas Heikkinen1, Terhi Ahvenainen2, Annukka Pasanen1, Päivi Häärki1, Pia Vahteristo2
1Department of Obstetrics and Gynecology, Helsinki University Hospital, Finland
2Department of Pathology, Helsinki University Hospital, Finland

Problem statement: Uterine leiomyomas (ULM) are benign smooth muscle tumors, occurring in up to 70% of women by the age of 50 years. Myomectomy is a surgical treatment option where the uterus and thereby reproductive potential are preserved. The most important known genetic changes in ULM are mutations in mediator complex subunit 12 (MED12), changes leading to high mobility group AT-hook (HMG2) overexpression, and heterozygous germline mutations in fumarate hydratase (FH), resulting in hereditary leiomyomatosis and renal cell cancer (HLRCC) syndrome. The earlier studies on molecular background of ULM are mostly based on hysterectomy samples from middle aged women. Therefore, we wanted to know whether the pathogenesis of ULM is similar in younger women. Methods: The research material comprises of women up to 45 years old, who have undergone myomectomy at Helsinki University Central Hospital. We have collected formalin fixed paraffin embedded samples from patients operated during 2009—2014. MED12 mutation frequency was determined by direct sequencing of exons 1 and 2, and HMG2 expression levels were assessed by immunohistochemistry. Biallelic FH inactivation was detected with 2SC staining. Patients’ medical records were reviewed. Results: We analyzed 238 patients with 361 leiomyomas. The median age of patients at operation was 33 years. 6.3% of the patients had a prior myomectomy. The majority of patients (58%) were operated for a single leiomyoma. The frequency of MED12 inactivation was 71%, as reported in tumors obtained through hysterectomy. 9% of leiomyomas showed HMG2 overexpression, 3% were FH deficient, and 17% were wildtype for all of the studied alterations. Interestingly, in solitary leiomyomas, the MED12 frequency was significantly lower.
only 49%, and 27% of the solitary tumors were wildtype. Leiomyomas with MED12 mutation were smaller in size compared to tumors with HMG2 overexpression, and more often subserosal compared to tumors with other drivers. **Conclusion:** This study is a comprehensive sample series of young ULM patients. Our findings emphasize the meaning of solitary leiomyomas in clinical practice. Molecular changes behind the notable proportion of wildtype leiomyomas need more research. The authors declare that they have no conflict of interest.

**P114**

**THE CURIOUS CASE OF A DEVIANT MOLE: A CASE OF AN INVASIVE MOLECULAR METASTATIC TO THE OVARY**

Julienne Katrina Beltran, Marcella Cabatu, Anne Marie Trinidad, Maria Corazon Zaida Gamilla
Obstetrics & Gynecology, University of Santo Tomas Hospital, Metro Manila, Philippines

**Problem statement and Methods:** This report emphasizes the rarity of the case and how it can present differently, posing diagnostic dilemma. A high index of suspicion in cases of previous molar pregnancy will direct to the right diagnosis and appropriate management of metastatic Invasive Mole. **Results:** This is a case of 33 year old, G3P1 (1021), presenting with left lower quadrant pain. The positive pregnancy test and previous complete mole lead to the impression, Gestational Trophoblastic Neoplasia, probably ruptured vs. Ectopic pregnancy, probably ruptured. On laparotomy, a right ovarian mass exuding vesicular tissues and a bluish-black discoloration at the right postero-lateral aspect of the uterus was noted. With these findings, total abdominal hysterectomy with right salpingo-oophorectomy was performed. Histopathologic examination revealed an invasive mole metastatic to the ovary.

**Conclusion:** Though the possibility of invasive mole metastasizing to the ovary is not an impossibility, simply because of the adjacency of both organs, this case is still of great interest. This is the very first time that such occurrence is being accounted and reported, not only here, but globally, as well. This is a manifestation that truly, invasive mole, as its name implies, can invade or overrun any organ for that matter, far or near, as the latter in our case, the neighboring ovary. The impression of GTN at any given time and place, should tweak the curiosity in us, “What and where it is this time?” And this time, it is the ovary!

**P116**

**MYO-INOSITOL EFFECTS ON METABOLIC AND HORMONAL PARAMETERS AND BODY COMPOSITION IN WOMEN WITH POLYCYSTIC OVARY SYNDROME**

Galina Chernukha, Gyuzyal Tabeeva, Maria Udovichenko, Sergey Kuznetsov
Department of Gynecological Endocrinology, The National Medical Research Center of Obstetrics, Gynecology and Perinatology Named of Academic Kulakov V.I., Moscow, Russia

**Problem statement:** To evaluate the effects of a myo-inositol (MI) therapy on the hormonal and metabolic parameters and body composition outcomes of women with polycystic ovary syndrome (PCOS). **Methods:** Seventy-eight patients (26.4±4.6 years) diagnosed with PCOS according to the Rotterdam criteria were enrolled in this study. Patients were treated for 6 months with MI 4g + folic acid (FA) 400µg daily. Menstrual cycles, body mass index (BMI) and serum levels of the anti-mullerian hormone (AMH), free testosterone (tT), index of free androgens (FAI), androstendione (A), dihydrotestosterone (DHT), 17-OH-progesterone (17-OH), sex hormone-binding globulin (SHBG), luteinizing hormone (LH), follicle-stimulating hormone (FSH), progesterone were measured at baseline and 6 months. The serum levels of glucose and insulin during the standard oral glucose tolerance test (OGTT), body composition measurements, including total body fat (%), visceral adipose tissue (VAT) mass and volume by dual-energy X-ray absorptiometry scan (DXA). **Results:** Findings showed that MI use for 6 months was 2Life and Health Sciences Research Institute ‘3b’s Research Group, University of Minho, Braga, Portugal

**Problem statement:** Pregnancy and labor are known risk factors for pelvic floor dysfunction (PFD). Operative vaginal delivery (OVD) is one important risk factor and its impact in early PFD symptoms is controversy. The purpose of this study is to compare postpartum PFD symptoms between spontaneous vaginal delivery (SVD) and OVD. **Methods:** An observational prospective study (MOODS: Maternal-neonatal Outcomes in Operative-vaginal Delivery Study) was enrolled at Braga’s Hospital (tertiary center) from February to August 2018 (included all OVD (vacuum, forceps and spatulas) and random SVD sample, in a 2:1 ratio). To access PFD symptoms the Pelvic Floor Distress Inventory-20 (PFDI-20) was applied 3-months, 6-months and 1-year postpartum. The questionnaire has 20 questions and is divided into three subscales: Urinary (UDI), Colorectal-Anal (CRADI) and Pelvic Organ Prolapse Distress Inventory (POPDI). The answers were converted to a numerical scale. A partial score (0-100 in each subscale) and a global score (0-300, sum of 3 subscales scores) were calculated. Women that answer at least one of the questionnaires were included. **Results:** Of 271 women recruited, 193 were included, 69(35.8%) had a SVD and 124(64.2%) an OVD. Thierry spatulas were used in 50% of OVD. The response rate was 81.2% for SVD, 79.0% for OVD; at 6-months 44.0% for SVD, 43.5% for OVD; at 1-year 52.2% for SVD, 54.8% for OVD. No difference was found regarding age, body mass index, maternal-obstetric history, type of labor, perineal lacerations and birth weight. The frequency of nulliparous (p=0.001), episiotomy (p=0.001), loco-regional anesthesia (p=0.001), postpartum pain (p=0.002) and postpartum complications (p=0.026) was significantly higher in OVD. The second stage of labor duration was longer on OVD (p=0.001). At 3-months OVD had higher UDI-score (p=0.038), POPDI-score (p=0.004) and global score (38.8±39.9 vs. 24.3±29.4, p=0.010). At 6-months OVD had higher POPDI-score (p=0.020) and global score (35.2±41.8 vs. 19.8±25.3, p=0.037). There was no difference at 1-year evaluation and between the instruments used. **Conclusion:** OVD seems to be associated with higher prevalence of early PFD symptoms especially urinary and pelvic organ prolapse symptoms, and this is independent of the instrument used. However, overall low scores reflect a modest impact on patients’ quality of life.
significant associated with a decrease of the mean level of AMH by 27.7%, LH – 22%, FSH – 29%, T – 15%, 17-OH – 36.6%, FAI – 40.5%, leptin – 38.5% and a increase the mean level of SHBG by 25% (p=0.001). MI supplementation significantly reduced frequency of hyperinsulinemia (HI) from 48.7% to 22.8% (p=0.004) and of impaired glucose tolerance (IGT) – from 19.2% to 3.5% (p=0.001). The mean of BMI was reduced by 8.6% after treatment (p=0.001). The frequency of women with normal BMI (18.5-24.9%) was increased from 75.6% to 89.5% (p=0.001). However the BF in women with normal BMI was reduced from 64.7% to 39% (p=0.001). The average meanings of BF, VAT mass and volume reduced by 11.5%, 38.4% and 33.2 (p=0.001). The menstrual function restoration was observed in 38.6%. Conclusion: This study shows that MI significantly reduces hyperandrogeasinism, HI, IGT and body fat, mainly due to VAT, that leads to the regulation of menstrual function in every third woman with PCOS.

P117
WHY ARE WE ADMITTING WOMEN WITH ACUTE ABNORMAL BLEEDING? – ONE-YEAR EXPERIENCE
Carolina Da Costa Gomes, Joana Simões, Gonçalves Elisabete, Maria do Carmo Cruz, Ana Casquinho, Eunice Capela
Departamento De Ginecologia, Obstetrícia E Reprodução Humana, Centro Hospitalar Universitário Do Algarve, Faro, Portugal

Problem statement: Abnormal uterine bleeding (AUB) is a frequent complaint in pre-menopausal women. However rarely will

WHY ARE WE ADMITTING WOMEN WITH ACUTE

abnormal bleeding be severe enough justifying inward admission. Urgent admission, revealing ill-controlled AUB, may endorse additional risk for adverse outcome. Aim: to analyse urgent admissions for AUB, identifying causes, treatment and outcome. Methods: All cases of reproductive-aged women over 18 years old who underwent urgent inward admission for AUB at CHUA – Faro were included (01/06/2018 to 31/05/2019). AUB classification was based on the FIGO classification system (PALM-COEIN). Statistical analysis was performed with SPSS version 24.0. Results: A total of 18 women and 21 urgent admissions were included. Mean age was 44.1 years; 52.9% had co-morbidities, including 12.5% under anti-coagulants. Low compliance for gynaecological screening was noted. At admission, mean haemoglobin levels were 6.3 g/dL, haemodynamic stability was categorised as class III in 29.5%. Intravenous iron and transfusion support were required in 56 and 89%, respectively (average 2.66 units). Mean duration of inward admission was 5.44 days. One woman underwent Intensive Care Unit admission. Gynaecological ultrasound was performed in all cases, endometrial biopsy in 44.4%, hysteroscopy in 11.1 and pelvic resonance in 5.6%. Etiological investigation revealed ≥ 2 causes in 50% of women: Poly=22.3%, Adenomyosis=22.2%, Leiomyoma=36.5%, Malignant and precursor lesions=27.6% (1 sarcoma, 2 hyperplasia), Coagulopathy=11.2, Ovulatory dysfunction=5.6%, Iatrogenic=11.2. Not classified=5.6 (uterine arterious-venous malformation). Medical treatment included progestatives, antifibrinolitics and ulipristal acetate in 55.5%, haematuria, rectal bleeding, shoulder pain) increases the likelihood of having endometriosis or the thoracic component taking a longer time to reveal as the diaphragm undergoes cyclical necrosis and subsequent cycles may lead to the production of fenestrations, as in this particular case. Conclusion: The diagnosis of diaphragmatic endometriosis is challenging and requires a high index of suspicion. Due to the complexity and rarity of this condition, the diagnosis is often delayed or missed and can have a major impact and a detrimental effect on the patient’s overall health and fertility.

P118
A RARE CASE OF THORACIC DIAPHRAGMATIC ENDOMETRIOSIS INVADING THE LIVER AND LOWER LOBE OF LUNGS
Azal EL Adwan, Harjit Dhalliwal
Department of Obstetrics and Gynaecology, Royal Bournemouth Hospital, Bournemouth, UK

Introduction: Thoracic endometriosis is a rare manifestation of extra genital endometriosis with important clinical ramifications. Despite growing awareness of thoracic endometriosis, it remains an enigmatic condition with various theories proposed to explain its pathogenesis. Case history: A 47 year old presented to the Fast Track chest clinic with a cough of 10 months duration. She also reported having had right upper quadrant pain and ipsilateral shoulder and arm pain for approximately 15 years. All of the above coincided with her menstruation. She was found to have a 6.5 cm ill-defined lobulated mass invading the right hemi diaphragm, lower lobe of lung and protruding into the right lobe of the liver based on an MRI scan. The differential diagnosis was that of endometriosis or a primary pleural malignancy. A liver biopsy was taken which confirmed hepatic endometriosis. Given the benign nature of the disease, a multidisciplinary team review suggested that a medical therapy approach with GnRH (Gonadotropin- releasing hormone) analogues rather than resectional surgery would be more appropriate in view of her perimenopausal status. Being fully compliant with her medical therapy, there was a complete resolution of symptoms with confirmatory changes on a CT scan.

Discussion: Thoracic endometriosis often presents as a delayed diagnosis. The reasons could be partly due to the lack of proper history taking, as multiple symptoms being both cyclical gynaecological and non gynaecological (dyschezia, dysuria, haematuria, rectal bleeding, shoulder pain) increases the likelihood of having endometriosis or the thoracic component taking a longer time to reveal as the diaphragm undergoes cyclical necrosis and subsequent cycles may lead to the production of fenestrations, as in this particular case. Conclusion: The diagnosis of diaphragmatic endometriosis is challenging and requires a high index of suspicion. Due to the complexity and rarity of this condition, the diagnosis is often delayed or missed and can have a major impact and a detrimental effect on the patient’s overall health and fertility.

P119
EFFECTS OF FLEXIBLE EXTENDED REGIMENS OF ORAL CONTRACEPTIVES ON THE VAGINAL ENVIRONMENT
Rushania Gabidullina, Rufat Bagirli, Elmira Mingaleva
Department of obstetrics and gynaecology, Kazan State Medical University, Kazan, Russia

Objective: to study the effect of flexible extended regimens of oral contraceptives (COC) on the condition of the vaginal environment and the level of sex hormones in women of reproductive age. The study involved 54 women who need contraception aged from 18 to 45 years. The average age was 27.5±6.8 years. Before and after 6
months of using the COC the state of the vagina was determined by the degree of purity of the vaginal smear, moisture, and acidity (pH), the condition of the vaginal microbiota, as well as the level of sex hormones in blood. After 6 months of use of COC in flexible extended regimens normal microflora with a predominance of lactobacilli was determined; there was a significant in vaginal acidity without change of moisture. Against the background of the use of COC, a significant decrease in the level of estradiol, free testosterone and the index of free androgens, an increase in the level of sex hormone-binding globulin (SHBG) was revealed. A statistically significant correlation between vaginal acidity, the level of estradiol, free testosterone and the index of free androgens, a negative correlation between the level of SHBG were revealed. On the moisture content of the vagina the level of estradiol influenced significantly. **Conclusion:** The use of flexible extended regimens of oral contraceptives for 6 months contributes to the dominance of lactobacilli in the vagotype, increasing the acidity of the vagina against the background of a decrease in the level of estradiol and testosterone. **Keywords:** combined oral contraceptives, vaginal environment, vaginal microbiota, lactobacilli

P120

**PELVIC INFLAMMATORY DISEASE AS ATYPICAL PRESENTATION OF RECTAL CANCER**

Rita Leiria Gomes1, Cláudia Freitas1, Carlos Macedo1, Ana Calhau1, Rita Salgueiro Neto1, Kathleen Brazão1, Carmo Sousa1, Hugo Gaspar1, Manuel Pontes1, José Pinto da Cruz2

1 Obstetrics and Gynecology, Hospital Dr. Nélio Mendonça, Funchal, Portugal
2 General Surgery, Hospital Dr. Nélio Mendonça, Funchal, Portugal

**Problem statement:** Pelvic inflammatory disease (PID) is an infectious and inflammatory disorder of the upper female genital tract. Signs and symptoms associated with acute PID can include lower abdominal pain, abnormal vaginal discharge, fever and intermenstrual or postcoital bleeding. Colorectal cancer can have unusual presentations caused by local invasion and contained perforation of colon cancer, causing fever and abdominal pain.

**Methods:** We present a case of colorectal cancer in a female patient with PID as initial presentation. **Results:** A 49-year-old woman, with no relevant personal history, was admitted in the emergency department of Gynecology with acute abdomen, presenting pelvic pain and fever with 4 days of evolution. The diagnosis of PID was attributed due to salpingitis/tube-ovarian abscesses documented by abdominal-pelvic CT and ultrasound. The patient underwent urgent laparoscopy, finding a tube-ovarian abscess and a pelvic inflammatory process with multiple adhesions and obliteration of posterior cul-de-sacs. Bilateral salpingectomy and peritoneal lavage were performed. Due to clinical worsening and persistent faecal peritonitis, iatrogenic perforated hollow viscous was suspected and the patient underwent exploratory surgery twice. In the second intervention, a punctiform perforation at the anterior region of the recto-sigmoid transition was identified. Rafia of the defect and derivative ileostomy were performed. Postoperative complications include surgical wound infection and rehospitalization for dehydration and suspected residual pelvic abscess, with good response to antimicrobial treatment. Histological result of the first surgery revealed the presence of invasive epithelial malignant neoplasia, suggestive of high-grade serous carcinoma of the uterine tube. Surgery was proposed for oncological staging, having performed posterior pelvic exenteration, with colorectal anastomosis, lymphadenectomy and omentectomy. After started chemotherapy presented right hallux ischemia as a complication and was submitted to finger amputation. The definitive histological result was adenocarcinoma of the rectum with invasion of the parametrium. **Conclusion:** It is important to question the initial diagnosis if a patient continues to exhibit persistent symptoms after adequate therapy for the initial diagnosis. Sometimes colorectal cancer can have atypical presentations due to local invasion, or a contained perforation causing malignant fistula formation into adjacent organs, most commonly in cecal or sigmoid carcinomas.

P121

**PRESERVING THE UTERUS IN AN INFERTILE WOMAN WITH COMPLEX ATYPICAL ENDOMETRIAL HYPERPLASIA**

Rita Leiria Gomes, Cláudia Freitas, Carlos Macedo, Ana Calhau, Rita Salgueiro Neto, Hugo Gaspar, Joaquim Vieira

Obstetrics and Gynecology, Hospital Dr. Nélio Mendonça, Funchal, Portugal

**Problem statement:** Endometrial hyperplasia (EH) with atypia, also referred as endometrial intraepithelial neoplasia, has a high risk of progression to endometrial carcinoma. Hysterectomy is the treatment of choice for most women, but progestin therapy is a reasonable option for women who wish to preserve fertility or cannot tolerate surgery. **Methods:** We present a case of successful treatment of complex atypical EH with megestrol acetate in an infertile woman. **Results:** A 38-year-old woman, nulliparous, with obesity (BMI 36 kg/m²) and history of thrombophilia of the left lower limb, was followed for 5 years in Hospital Dr. Nélio Mendonça for primary infertility. During follow-up on Reproductive Medicine consultation, she performed induction of ovulation and intrauterine inseminations both unsuccessful. She underwent multiple hysteroscopic polypectomies and cyclic progesterin treatment for hypertrophic endometrium. During the hysteroscopic surveillance prior to infertility treatments, she presented endometrial biopsy with "endometrium with complex hyperplasia, with focal atypia" and endometrial polyp with "simple hyperplasia". Both Reproductive Medicine and Oncology teams agreed to perform fractional curettage with endometrial biopsy, which confirmed the diagnosis of complex EH with atypia. After that, ultrasound showed endometrium with 5,5mm thickness, with regular baseline and no vascularization. Therefore, was decided to treat with megestrol acetate, 80mg twice daily, due to the desire for fertility. In the hysteroscopic reevaluation after 3 months, 6 months and 1 year there was no endometrial hyperplasia. In the meanwhile, she was diagnosed with hypothyroidism and rheumatoid arthritis and started treatment with levothyroxine, hydroxychloroquine sulfate and prednisolone. In vitro fertilization (IVF) treatments were planned and she became pregnant after two years of the diagnosis of EH, although resulted in a first-trimester miscarriage. Later, she had an acute cholecystitis and was submitted to cholecystectomy. Currently she maintains follow-up with hysteroscopic surveillance every 6 months and infertility treatments. In vitro fertilization (IVF) treatments were planned and she became pregnant after two years of the diagnosis of EH, although resulted in a first-trimester miscarriage. Later, she had an acute cholecystitis and was submitted to cholecystectomy. Currently she maintains follow-up with hysteroscopic surveillance every 6 months and infertility treatments. **Conclusion:** The risk of progression of atypical EH to endometrial carcinoma is 15 to 28 percent. For premenopausal women who wish to preserve fertility is reasonable to treat with a progestin rather than hysterectomy, as we shown in this case of successful regression to endometrium with no hyperplasia, which allowed the woman to continue IVF treatments.

P122

**TREATMENT OF PATIENT WITH UTERINE FIBROID USING FOCUSED ULTRASOUND SURGERY - CLINICAL CASE**

Yoana Ivanova1, Elica Gyokova2, Dobromir Dimitrov2

1 University Hospital Saint Marina Pleven, Bulgaria, Department of Obstetrics and Gynecology, Medical University Pleven - Bulgaria, Pleven, Bulgaria
2 Department of Obstetrics and Gynecology, Umhat "Dr. Georgi Stranski", Medical University Pleven - Bulgaria, Pleven, Bulgaria

**Problem statement:** Focused ultrasound surgery (FUS) is taking part of the clinical gynecological practice over the last 10 years. It is non-invasive procedure, it does not use scalpels and is very gentle for the patients. Our aim is to present a clinical case about a patient with uterine fibroid who underwent FUS with High Intensity Focused Ultrasound (HIFU) therapy with very good therapeutic response, assessed with MRI and certified...
questionnaire about the Quality of life. **Methods:** 43 years old patient with clinical, ultrasound and MRI data for uterine fibroid, proving fibroid on the posterior uterine wall with size 73x71x74mm (125ml) was treated with FUS. After standart preparation, the patient was placed at the HIFU table. The uterine fibroid was found and then treated with HIFU beams. The maximum energy was 400W. Average energy output was 381W, total sonication time of the procedure was 526 seconds. The total energy was 200500J. The next day the patient was discharged in good general condition, without subjective complaints, afebrile, with antibiotic prophylaxis for 5 days. **Results:** At the control MRI of the pelvis after 45 days we found that the fibroid reduced its volume by 25% and had over 90% necrosis. The Quality of life of the patient was assessed by using Uterine Fibroid Symptom and Health Related Quality-of-Life Questionnaire and it was significantly improved. **Conclusion:** The presented clinical case is a good example for the therapeutic possibilities of FUS in patients with uterine fibroids. Future prospective investigations in this area are needed.

P123

**PSEUDOANEURYSM OF THE UTERINE ARTERY AFTER ABDOMINAL BILATERAL SALPINGO-OOPHORECTOMY CAUSED BY TUBO-OVARIAN ABOSSC**

Dahye Ju, Yoon-Kyung Shin
Department of Obst, Gangneung Asan Hospital, Gangneung, South Korea

Uterine artery pseudoaneurysms (UAPs) are rare vascular lesions and may be life threatening if not diagnosed and properly treated. Here, we describe the case of a woman with a UAP after abdominal bilateral salpingo-oophorectomy caused by a tubo-ovarian abscess. Six days later, she presented with sharp abdominal pain, and a Jackson-Pratt drain was filled with 70 cc per hour. Abdominal computed tomography angiography revealed a UAP on the left side. Selective uterine artery angiography demonstrated a pseudoaneurysm in the sidewall of the left uterine artery, and embolization was performed successfully. Patients usually leave the hospital two to six days after surgery. Most of the symptoms of a UAP occur after discharge and may occur after one month. Therefore, UAP suspicion is required in the event of initial symptoms such as vaginal spotting, abdominal discomfort/pain, fever, dizziness, etc. Additionally, patients should be informed that they must visit the emergency room in the case of such symptoms through warnings and education. In addition, if a pseudoaneurysm is suspected even slightly, an imaging work up should be conducted in a timely manner to quickly achieve diagnosis and treatment.

P124

**CLIMACTERIC SYNDROME WITH PSYCHOEMOTIONAL LOAD IN WOMEN**

Lamiya Guliyeva, Nigar Kamilova
Obstetrics and Gynaecology, Azerbaijan Medical University, Baku, Azerbaijan

The relevance of the study is determined by a high level of pathological variants of the course of menopausal syndrome in perimenopause in women, including due to an increase in psychoemotional loads. **Objective:** To study the characteristics of the formation and course of menopausal syndrome in women who have undergone a psychoemotional load. **Material and research methods:** 34 women were examined, the average age of which was 59.6 ± 3.69 years. Analysis of clinical and anamnestic data was carried out according to an individual examination map. The study was conducted using the scale for assessing the quality of life - "SF-36 Health Status Survey". Statistical data processing was carried out using the package of standard application programs Statistica for Windows (Ver. 10.0). **Results and discussion:** The reproductive health of women examined was presented as follows: the average number of pregnancies per woman was 9.60 ± 2.63, including childbirth - 5.83 ± 0.88, abortion - 4.58 ± 2.27, miscarriage - 1.19 ± 0.57. In the structure of gynecological pathology, the main diseases were cervical pathology 19 (55.9%), uterine fibroids 17 (50%). Pelvic inflammatory diseases accounted for 64.7%. The average age of menopause in all examined patients (34) was 49.11 ± 1.34 years. 18 (52.9%) patients had various metabolic and endocrine disorders (weight gain, arterial hypertension, headache, thyroid dysfunction, pain in muscles and bones, etc.). 20 women (58.8%) complained of the presence of psycho-emotional disorders (decreased performance, fatigue, memory impairment, irritability, tearfulness, depression) which is significantly more than the mean values of varying severity among all examined women was 73.5%, which exceeds the average statistical data in the population - 26% - 48%. The quality of life of women differs sharply from women of menopausal age of the general population. Physical activity and daily activities are significantly limited due to physical decline and deterioration of the emotional state. **Conclusion:** Women with a psycho-emotional load have a history of earlier detection of menopausal syndrome - 49.11 ± 1.34, while the frequency of MS of varying severity is 73.5%, which exceeds the average statistical data in the population - 26% - 48%.
**P126**

**VENOUS THROMBOEMBOLISMS FOLLOWING LAPAROSCOPIC HYSTERECTOMY FOR BENIGN DISEASE IN A DANISH COHORT**

Hanneh L Mengu¹, Margit Dueholm², Christine Bach³, Reem Al-Tai⁴, Vibeke Raaby⁵, Pinar Bor¹

¹Department of Obstetrics and Gynecology, Regional Hospital of Randers, Randers, Denmark
²Department of Obstetrics and Gynecology, Aarhus University Hospital, Aarhus, Denmark
³Department of Obstetrics and Gynecology, Regional Hospital of Horsens, Horsens, Denmark
⁴Department of Obstetrics and Gynecology, Regional Hospital of Viborg, Viborg, Denmark
⁵Department of Obstetrics and Gynecology, Regional Hospital of Herning, Herning, Denmark

**Problem statement:** Postoperative venous thromboembolism (VTE) is a common complication following gynaecologic procedures, particularly for women undergoing open surgery or with malignancy. However, there is limited knowledge about the risk of postoperative VTE after laparoscopic hysterectomy. Based on retrospective studies VTE risk appears to be present but low which has led authors to discuss whether thromboprophylaxis (TP) is indicated. Recommendations for TP in women undergoing minimally invasive gynaecologic surgery are not well established and to date there are no evidence-based guidelines that specifically provide recommendations to prevent VTE-events in this patient category. Consequently, gynaecologic departments in Denmark have different local guidelines. The aim of our project was to investigate the incidence of VTE and the current use of thromboprophylaxis in Danish women undergoing laparoscopic hysterectomy for benign disease. **Methods:** Women who underwent hysterectomy for benign indication between January 1st 2015 and December 31st 2017 were included. The Danish Hysterectomy and Hysteroscopy Database (DHHD) and the Danish National Patient Registry were used to collect relevant data concerning patient and operation characteristics, postoperative complications and thromboprophylaxis. Information about the current use of thromboprophylaxis in Denmark was retrieved through electronic surveys sent to all Gynaecologic departments in Denmark reporting data to DHHD. **Results:** Ongoing study, preliminary results are presented. Out of 11731 hysterectomized women, 81% (n=9507) underwent minimally invasive hysterectomy in which 66% (n=7739) were laparoscopic. Pharmacologic TP was used in 86% (n=6646) of laparoscopic hysterectomies. Data from the electronic survey were provided by 25 Gynecologic departments. The type and dosage vary between departments.

**P127**

**PREGNANCY AFTER HYSTERECTOMY: A CASE REPORT FROM HANOI OBSTETRICS AND GYNECOLOGY HOSPITAL AND LITERATURE REVIEW**

Toan Nguyen¹, Hai Nguyen¹, Nga Pham², Ha Nguyen², Anh Nguyen³

¹Department of Surgical Gynecology, Hanoi Obstetrics and Gynecology Hospital, Hanoi, Vietnam
²Department of Assisted Reproductive Technology and Andrology, Hanoi Obstetrics and Gynecology Hospital, Hanoi, Vietnam

**Problem statement:** Hysterectomy is one of the most common non-pregnancy-related major surgeries on women. With the uterus removed, it is obviously expected that the woman’s fertility would be terminated. However, in some very seldom cases, the woman somehow got pregnant post-operation. Late diagnosis and treatment may lead to catastrophic and life-threatening situations. **Case:** A case of a 40-year-old multigravida woman having a pregnancy in the left fallopian tube 3 years after a supra-cervical hysterectomy at Hanoi Obstetrics and Gynecology hospital was described. At first, the pregnancy diagnosis was not considered because of the history of hysterectomy. Nevertheless, after careful examination and consultation, ectopic pregnancy appeared to be the only possible explanation of the patient’s condition. The patient then underwent a successful laparoscopic intervention and was safely discharged after 3 days of post-operation. **Discussion:** With only 72 cases reported in English literature, pregnancies after hysterectomies is an extremely rare condition which might lead to misdiagnosing and belated treatment. Some cases were discussed to prove the point as well as two hypotheses of the condition. **Conclusions:** A successful intervention was performed on a patient who conceived pregnancy after hysterectomy. Preoperative βhCG level and careful ultrasonography screening play an important role in diagnosing.

**P128**

**RESULTS OF HORMONAL AND ULTRASOUND EXAMINATION IN CHRONIC SALPINGO-OOPHORITIS**

Ulker Aliyeva, Nigar Kamilova

Obstetrics-gynecology, Azerbaijani Medical University, Baku, Azerbaijan

Inflammatory diseases of pelvic organs in women occupy the first place in the structure of gynecological morbidity throughout the world. **The aim of the study** was to study the features of the menstrual cycle in patients with a chronic course of inflammatory diseases of the pelvic organs, taking into account the duration and severity of the disease. Materials and research methods. To identify the pathology of the upper reproductive tract, 100 women underwent pelvic ultrasound using the Voluson E8 apparatus, using transabdominal sensors of 11 Hz and 18 Hz and a transvaginal sensor with a frequency of 20 Hz and 31 Hz. During hormonal screening, the quantitative determination of serum concentrations sex steroid hormones hormones by the radio-immune method was determined. **Study results and discussion:** A study of the hormonal profile of patients of the first group showed that the average value of plasma hormones on the 14th day of the cycle was as follows: LH - 6.4 ± 0.6 IU / L (average norm 28.7 IU / L), FSH - 4.2 ± 0.3 IU / L (average norm 22.1 IU / L), prolactin - 24.1 ± 0.5 nmol / L (average norm 5.7 nmol / L), free testosterone - 4.6 ng / ml (the average norm is less than 1.0 ng / ml) (table. 2). Thus, in the first group of patients there were low values of the average values of LH, FSH against the background of hyperandrogenemia, hyperprolactinemia. The average levels of ACTH, TSH, free thyroxine, and cortisol were approaching the upper limit of normal. Folliculometry results showed a high
incidence of follicular persistence in 14 (14%), anovulatory disorders in 11 (11%) and follicular atresia in 12 (12%) women, hypo-ovulatory syndrome was in 29 (29%) women, hyperovulatory syndrome 22 (22%).

Findings: The main forms of menstrual irregularities are dysmenorrhea (27%), oligoovomororrhea (21%), hypo- and hyperpolyomorrhea (26.1%), as confirmed by ultrasound examination.

P129
CALCIUM AND VITAMIN D INTAKES FROM DIETARY SOURCES AND PHYSICAL ACTIVITY WOMEN IN PERI-AND POST-MENOPAUSE
Dragica Odalovic Markovic1, Dragica Odalovicmarkovic1,2
1Gynecology, Health Center, Belgrade, Serbia
2Gynecology, Health Center, Belgrade, Serbia

Background/aim: Calcium and vitamin D play a significant role in bone remodeling. Nutrition deficiency of calcium, vitamin D and insufficient physical activity are risk factor for development of osteoporosis. These can by modified and aim of this study is to identify those women at risk for bone thinning and fracture. Method: The study included 39 women in peri-menopause from 43 to 53 years of age and 46 women in post-menopause from 46 to 66 years of age. The selection criteria was that they had no other risk factors, not use HRT (Hormone Replacement Therapy) and calcium and vitamin D supplements, do not data of BMD (Bone Mineral Density) and the lactose intolerance. For women in both groups an approximate daily rate was determined calcium and vitamin D intakes, BMI (Body Mass Index) and the type of physical activity.

Results: Average age perimenopausal women is 48 and 56 years at postmenopausal. Women with BMI less than 20,0 had 38%perimenopausal and 4,3% postmenopausal women. Obese had 38,48% perimenopausal and 28.26% postmenopausal women. Women with body weight less than 58 kg had 15,38% perimenopausal and 6,52 % postmenopausal women. A daily intake of calcium less than 1000mg/d had 64,15% perimenopausal and 67,39% postmenopausal women and less than 700mg/d had 10,26% perimenopausal and 43,48% postmenopausal women. Only 12,82% perimenopausal and 19,57% postmenopausal women had daily intake of calcium 1000-1200mg/d. The recommended daily intake of vitamin D of 600 IU/d was not intake by any women in both groups(100%) as well as less than 400 IU/d only 1,2% perimenopausal and 0% postmenopausal women. A daily intake of vitamin D less than 200mg/d was not intake by any women in both groups(100%) as well as less than 400 IU/d 58,97% perimenopausal and 36,95% women in post-menopause physical activity was within the scope of their usual activities at home and at work. Weight-bearing exercise only at 10,85% postmenopausal and 0% perimenopausal women. Conclusion: These results are partly due to the socio-economic situation and insufficient preventive. Further examination of these women is required. Women in post-menopause avoid HRT, which would be the first line of treatment for younger postmenopausal women at risk of osteoporosis, Compliance with ethical standard, no conflict of interests. Key words: calcium and vitamin D intakes, physical activity, peri and post-menopause

P130
HYSTEROSCOPIC ISTHMOPLASTY AS TREATMENT FOR ABNORMAL UTERINE BLEEDING, PELVIC PAIN AND SECONDARY INFERTILITY - BRIEF REVIEW FROM A CASE REPORT
Sonia Gayete Lafuente, Mauricio Agüero Marфию, Ariadna Salvadó Salvadó, Silvia Agramunt Garcia, Mireia González Comadran, Ricardo Rubio Salazar, Berta Fabregó Capdevila, Júlia Castellá Cesari, Marta Baucells Nuri, Eloy Cabello Garcia, Carolina Rueda Garcia, Gemma Mancebo Moreno, Antonio Payà Panadés, Maria Prat OM
Hospital Del Mar (Barcelona), Obstetrics and Gynecology, Spain

Problem statement: An isthmocele is a myometrial discontinuity in the site of a previous caesarian section (CS) communicating to the uterine cavity, probably favored by a low incision, deficient hysterorraphy or other individual tissue-related factors. It is usually asymptomatic but can associate irregular spotting, dysmenorrhea, dyspareunia, chronic pelvic pain or infertility. In a consecutive pregnancy a scar ectopic implantation, placenta accreta or previa, scar dehiscence and uterine rupture may appear as complications. Nowadays the gold-standard treatment is the hysteroscopic isthmoplasty (p.i. mini-resectoscope or laser) in symptomatic women. It has demonstrated to safely and effectively control abnormal uterine bleeding and alleviate pain, considering that clinical persistence is reported in up to 18% of cases. Among published series, around 50% of the patients intervened for infertility achieved a consecutive pregnancy. Methods: Case report: We expose the case of a 39-year-old patient with history of hysteroscopic uterine septum resection at 32 and elective CS at 35, suffering from evolving intermenstral spotting and pelvic discomfort since then with secondary infertility. The initial approach including transvaginal-ultrasound showed a residual 16x7mm septum and a 3.6mm-wide isthmoecele with 1.7mm of minimum endometrial thickness at the sacular edge, also carefully examined by magnetic resonance imaging. A surgical hysteroscopy was performed to evaluate the cavity, resect the septum and mainly repair the isthmoecele through flattening of the surface crests using diode laser. Results: Evolution: After 2 weeks the patient was asymptomatic, and after 4 months presented with a 7.5-week ongoing pregnancy. Nowadays is being followed up in our High Risk Obstetric Unit and planned to undergo CS at term. Conclusion: As widely supported by current literature, hysteroscopic isthmoplasty is beneficial for patients with uterine bleeding abnormalities or painful conditions associated to a CS scar defect, with early and encouraging results. Given the favorable risk-benefit balance, also secondary infertile patients should be offered this minimally-invasive treatment, once explained the technique limitations and expected outcomes.

P131
PHYSIOTHERAPEUTIC APPROACH OF DYSpareunia IN WOMEN WITH CHRONIC PELVIC PAIN: COMPARISON BETWEEN TWO TECHNIQUES. A RANDOMIZED CLINICAL TRIAL
Ana Carolina Rosa-e-Silva, Ana Paula Moreira, Andreia Milidieri, Julio Rosa-e-Silva, Francisco Reis, Omero Poli-Neto, Antonio Nogueira
Department of Gynecology and Obstetrics, School of Medicine of Ribeirão Preto - University of São Paulo, Ribeirão Preto, Brazil

Problem statement: Dyspareunias an important sexual dysfunction commonly encountered in clinical practice, leading a negative impact in quality of life of women. Tenderness of pelvic floor muscles is frequently observed among women with dyspareunia. Most women regard dyspareunia as ordinary symptom and very often did not report the pain, what over the time can aggravate the symptom generating Chronic Pelvic Pain (CPP). Objectives: Evaluate the effectiveness of Thiele perineal massage and the effectiveness of intravaginal electrostimulation in treating women with CPP and dyspareunia caused by spasm of the pelvic muscles, to compare two techniques and their pain effects, anxiety and depression risks and sexual function. Methods: Was realized a clinical trial randomized with random allocation of people in parallel groups. Group A:14 women treated with perineal massage and group B:16 women treated with intravaginal electrostimulation. Inclusion criteria: Women with CPP and superficial dyspareunia caused by spasms of the pelvic muscles diagnosed and exclusion criteria: Dyspareunia without spasm in pelvic muscles, pregnant, menopause and with medical records of vasculopathies, neuropathies, diabetes, thyroid disease. These women were recruited in the Clinic of Chronic Pelvic Pain of the Hospital of Ribeirão Preto Medical School of the University of São Paulo. Evaluation with physical examination and application of VAS, McGill pain, HAD and SFIF and the collection of demographic data were performed. After end of treatment these women were re-
evaluated after 1, 4, 12 and 24 weeks follow-up by a foreign evaluator to the type of treatment. Results: No significant differences were found when comparing the effectiveness of one technique in relation to the other in any of the reevaluation times. However, significant results were found within each group between pre-treatment and post-treatment times (1, 4, 12, and 24 weeks post-treatment). In relation to the improvement of pain (EVA, McGill) and sexual function (FSFI), no significant differences were found regarding treatment techniques and the risk for anxiety and depression. Conclusion: The two treatment modalities were effective in improving pain, thus suggesting their use separately or in combination in cases of DPC associated with superficial dyspareunia secondary to pelvic muscle spasms. The authors declare that they have no competing interests.

P132 WOMEN WITH CHRONIC PELVIC PAIN HAVE WORSE PELVIC FLOOR MUSCLE PERFORMANCE
Ana Carolina Rosa-e-Silva, Carla Lopo, Omero Poli-Neto, Francisco Reis, Antonio Nogueira, Julio Rosa-e-Silva
Department of Gynecology and Obstetrics, School of Medicine of Ribeirão Preto - University of São Paulo, Ribeirão Preto, Brazil

Problem statement: Studies have increasingly demonstrated the importance of the musculoskeletal system in the formation and perpetuation of Chronic Pelvic Pain (CPP). There is evidence that approximately 85% of CPP patients may present musculoskeletal system dysfunction, including postural changes, pelvic floor muscle (PFM) spasm, and abdominal wall myofascial syndrome. The PFMs play an important role in the support of the abdominal and pelvic organs, and the control of urinary, fecal and sexual function. Objectives: This study evaluated the contractility of the muscles of the pelvic floor of women with chronic pelvic pain (CPP) compared to women without pelvic pain. Methods: Evaluation of pelvic floor muscles was performed by vaginal palpation and perineometry. During vaginal palpation, the muscle function was classified using the modified Oxford scale of 0 to 5. The contraction ability, coordination, and strength of the pelvic floor muscles were also evaluated. The contraction capacity was recorded as yes or no, the coordination was evaluated by the contraction capacity of the pelvic floor muscles without the use of accessory muscles, and the resistance was recorded as the time that the patient could sustain the contraction of the pelvic floor muscles. The evaluation of the floor muscles contraction pressure was conducted through the perineometer, consisting of an apparatus which records vaginal pressure generated by the contraction of PFM (Pelvic floor Muscle) in cm H2O measures. Results: We analyzed 78 women, with and without CPP. The comparative analysis between the groups showed that there is a difference in relation to the following: modified Oxford scale, muscle strength, urinary tract infection, abdominal surgery, vaginal birth, cesarean section, dyspareunia, BMI (Body Mass Index), and perineometry. There were no significant differences in the contraction capacity, muscle coordination, urinary incontinence, obstetric history, occurrence of births, and age. There was a strong correlation between the Oxford scale and perineometry, with a p-value of 0.0001. Conclusion: This study found that women with CPP have altered contractility of PFM in contrast to controls, demonstrated by the modified Oxford scale and perineometry. The authors declare that they have no competing interests.

P133 ASHI ACUPUNCTURE AND LOCAL ANESTHETIC INJECTION HAVE SIMILAR EFFICACY IN THE TREATMENT OF ABDOMINAL MYOFASCIAL PAIN SYNDROME IN WOMEN: A RANDOMIZED CLINICAL TRIAL
Julio Rosa-e-Silva, Andrea Mitidieri, Maria Carolina Vieira, Ana Paula Moreira, Ana Carolina Rosa-e-Silva, Omero Poli-Neto, Francisco Reis, Antonio Nogueira
Department of Gynecology and Obstetrics, School of Medicine of Ribeirão Preto - University of São Paulo, Ribeirão Preto, Brazil

Problem statement: Chronic pelvic pain (CPP) is defined as recurrent or continuous pain that occurs in the hypogastric region (lower abdomen or pelvis), is non-menstrual or non-cyclic, lasts at least six months, and is severe enough to interfere with the patient’s usual activities and affect the quality of life, necessitating surgical or pharmacological treatment. Among the musculoskeletal disorders related to CPP, abdominal myofascial pain syndrome (AMPS) appears to be a major condition. AMPS usually affect women more than men (54% and 45%, respectively) and is more frequent among women aged 30 to 40 years. Its estimated prevalence ranges from 30% in primary care centers to 85%-93% in specialized centers for the treatment of pain. Objective: This study aimed to compare the responses of ashi acupuncture treatment and local anesthetic injection in the treatment of chronic pelvic pain (CPP) secondary to abdominal myofascial pain syndrome (AMPS) in women. Methods: In this randomized controlled clinical trial, women with a clinical diagnosis of CPP secondary to AMPS were randomized and evaluated using instruments to assess clinical pain, namely, the visual analogue scale (VAS), numerical categorical scale (NCS), and the McGill Questionnaire, after receiving treatment with ashi acupuncture (group A, n = 16) or local anesthetic injections (group B, n = 19). They were reevaluated after one week and 1, 3, and 6 months after each treatment, in addition to assessments of pain and adverse events performed during the sessions. Results: Ashi acupuncture and local anesthetic injections were both effective in reducing clinical pain assessed through the analyzed variables among study participants. There was no difference between the groups and therefore there was a strong correlation between these pain assessment instruments. Conclusion: Treatment with ashi acupuncture and local anesthetic injections were effective in reducing clinical pain in women with abdominal myofascial pain syndrome. The authors declare that they have no competing interests.

P134 EFFECT OF DIAZEPAM ON FACILITATING THE PLACEMENT OF DEVICES DURING TUBAL STERILIZATION PROCEDURE BY HYSTEROSCOPY: A RANDOMIZED CONTROLLED TRIAL
Julio Rosa-e-Silva, Marina Ribas, Ana Carolina Zani, Ana Carolina Rosa-e-Silva, Francisco Reis, Omero Poli-Neto, Antonio Nogueira
Department of Gynecology and Obstetrics, School of Medicine of Ribeirão Preto - University of São Paulo, Ribeirão Preto, Brazil

Problem statement: Several factors are suggested to predict the success rate in the placement of tubal devices during tubal sterilization by hysteroscopy, one of these factors is the prescription of pre-procedure medications such as nonsteroidal anti-inflammatory drugs (NSAIDs), which are the more commonly tested drugs used to ease the device placement in the tubas. Also, diazepam, an anxiolytic, may reduce patient anxiety and the tubal motility. Both are recommended by the manufacturer, but there is no evaluation of diazepam used with the purpose of tubal relaxation in order to decrease its vasospasm, what would increase the success rate of the method. The objective of this study was to evaluate the effect of 10mg of oral diazepam prior to the hysteroscopically inserted tubal devices and their effect on the hysteroscopic tubal sterilization procedure, facilitating the insertion of the devices in the tubas. Methods: Randomized clinical trial with Eighty-two patients with indication/desire of tubal sterilization by hysteroscopic insertion of tubal device were randomized in 2 groups, 43 patients received 10 mg of diazepam thirty minutes prior to the procedure and 39 patients received placebo tabs. The procedure was classified by the physician who performed the device insertion in easy or difficult. Also, other quantitative and qualitative variables were analyzed, such as the duration time of the procedure (measured by a chronometer), the intensity of pain evaluated by pain scale immediately after the procedure, Analogic Visual Scale (AVS) and International Association for the Study of Pain (IASP) Face Scales. Results: Regarding the ease of insertion
of the device, the diazepam group presented an easier insertion compared to placebo, but only in the right tuba. There was no difference in pain complaint or in the procedure time duration between the two groups. **Conclusion:** The use of 10mg diazepam 30 minutes prior to hysteroscopic insertion of a tubal device for sterilization seems to facilitate its placement, mainly on the right side, however further studies should be performed for its routine recommendation. The authors declare that they have no competing interests.

P135
HYSTEROSCOPIC SURGERY FOR SUBMUCOSAL FIBROIDS PERFORMED IN CONSIDERATION OF THE MYOMA PSEUDOCAPSULE

Juichiro Saito, Kaoru Tejima, Yuko Ikemoto
Gynecology, Juntendo Tokyo Koto Geriatric Medical Center, 3-3-20 Shinjuku Koto-Ku, Japan

**Problem statement:** Hysteroscopic surgery for submucosal fibroids improves symptoms and fertility. This surgery is a minimally invasive procedure. Hysteroscopic surgery mainly performs incision, excision, hemostasis, cautery, using a high-frequency current generator to the hysteroscopescope. **Methods:** The myoma pseudocapsule (MP) is a structure formed surrounding the uterine fibroid, that in the uterus separates the myoma from normal tissue. MP has a proper vascular network surrounding myoma. MP cells have the features of smooth muscle cells similar to the myometrium. Because, MP are part of the myometrium which constitutes the leiomyoma. In this presentation, I will present this technique. **Results:** Recently, I have been performing hysteroscopic surgery for submucosal fibroids leaving pseudocapsules. **Conclusion:** When removing fibroids their MP should be preserved.

P136
THE MANAGEMENT OF PATIENTS WITH PREMATURE OVARIAN FAILURE

Zinaida Sarbu1,2
1Department of Obstetrics - Gynecology, State Medical University „Nicolae Testemiţanu”, Sarbu Zinaida, Chişinău, Moldova
2State Medical University „Nicolae Testemiţanu”, Sarbu Zinaida, Chişinău, Moldova

The patients with POF are young are most active in the social and economic aspects of their life. Goal of the study was to develop proper management for POF patients. Materials and methods: Case records were analyzed step by step for all patients: age at first visit; live anamnesis, somatic and gynaecological anamnesis, weight and body mass index; Kupperman index; serum testosterone, estradiol, LH, FSH, TSH, Prl;ultrasound examination; histological investigation; roentghenography of „selli turcica”; mammography. Results. The study were 121 patients with POF, aged 35 - 45 years, average age 38 ±1,3 years old. All evaluated patients had high education:in 43 cases - doctors, in 42 cases - teachers and in 36 cases – other specialists. The duration of amenorrhoea varied between 4,8 ± 3,4 years. Clinical symptoms of POF began, as follows: in group of 40–45 years old patients when climacteric like syndrome appeared after 9-12 months of amenorrhoea, in group of 32 -35 years old patients after the same period of amenorrhoea, in group of 36-39 years old patients besides climacteric like syndrom there were psychical disturbances. Treatment: In group of 32-35 years old patients cases and in group of 36-39 years old patients cases high level of testosterone was determined and therefore these patients were treated with Climen, in sequential regimen, until 48 – 50 years old and then switched to continuous postmenopausal regimen with Klimodien or Angeliq – during 3-4 years. In group of 40–45 years old patients cases the treatment started with Climen, in sequential regimen, until 48 – 50. After, they were switched to continuous postmenopausal regimen with Klimodien or Angeliq during 3-4 years. In the conclusion - HRT in the appropriate dose until the age of 50, the age of physiological menopause. After this women need continuous HRT with low hormonal doses. The HRT in POF women can continue 9-10 years in sequential regimen followed by 3-4 years of HRT in continuous regimen. I am not disclosure of Interest.

P137
PHOTODYNAMIC THERAPY OF CHRONIC ENDOMETRITIS IN INFERTILITY

Klara Serebrennikova1, Sergey Katsalap1, Igor Babichenko2, Aleksandr Alekhin1, Narina Arutyunyan1
1Scientific, Central Clinical Hospital of the Russian Academy of Sciences, Moscow, Russia
2Scientific, Peoples’ Friendship University of Russia, Moscow, Russia

Keywords: photodynamic therapy, infertility, chronic endometritis, estradiol, receptivity

**Problem statement:** Chronic endometritis (CE) can cause infertility, miscarriages, unsuccessful in vitro fertilization and embryo transfer. A modern and promising high-tech method of treating CE is photodynamic therapy (PDT).Objective: to determine the effectiveness of CE treatment by intracavitary PDT (IPDT) in patients with infertility. **Methods:** 125 CE patients of childbearing potential were examined, treated and divided into 2 groups: Group 1 – 85 patients treated by IPDT on Day 21-23 of the menstrual cycle (invention No. 2017129530 dated August 18, 2017) and low doses of transdermal 17-β-estradiol (Divigel 0.1%); Group 2 – 60 patients treated conventionally (antibacterial, anti-inflammatory, detoxification, immunomodulatory medication) and with medium doses of transdermal 17-β-estradiol (Divigel 0.1%). **Results:** sonography showed almost 2 times higher thickness of the endometrium after PDT vs the baseline in Group 1, and slight changes in the thickness of the endometrium in Group 2. On Day 12 of the menstrual cycle, the post-PDT thickness of the endometrium in Group 1 increased to 10.7 ±0.85 mm vs 6.1 ±0.74 mm in Group 2. An immunohistochemical test of the endometrium showed that the phases of the menstrual cycle correlate with the presence of steroid hormone receptors (SHRs), both in glandular epithelium nuclei and stromal cells (Fig. 1). CD138+ with high numerical density in endometrial stroma and diffuse distribution were found in 96.2% of CE patients. The abnormal SHR expression in the glands and stroma, as well as the Ki67 proliferative activity, significantly decreased in Group 1, and the distribution of progesterone receptors in the glands and endometrial stroma decreased in Group 2. **Conclusion:** IPDT is a minimally invasive, sparing and safe treatment that restores the morphofunctional state and estrogen/progesterone receptivity of the glands and endometrial stroma. Transdermal 17-β-estradiol (0.1%) causes adequate thickening of the endometrium. Comprehensive treatment in CE patients produces a persistent clinical effect, restores the fertility and reduces the pregnancy complication risk.
Perineal scar endometriosis is a rare condition with an incidence of about 0.03-0.15%. Early diagnosis and treatment is very important as delay in doing so not only prolongs the agony of the patient but also puts her at risk of disease extension. A 28 years old lady presented with a 2 years history of severe pain in the perineum which aggravates massively during menstruation. She gave a history of a small lump in the vagina. She also had a history of suprapubic pain radiating to the back down to her thighs. She also had history of dyspareunia and dyschezia. She was a Para 1 with a Spontaneous vaginal delivery with Episiotomy 3 years ago. She had a previous history of endometriosis diagnosed due to severe dysmenorrhea 7 years ago. She had tried Depot-Provera and COC in the past but with no relief. The abdomen was mildly tender. A 1cm firm nodule was palpated at the apex of episiotomy scar. Her pain intensity was reduced with Morphine. She was advised to take Troptorelin injections in the interim with a plan to be seen by Endometriosis specialist who decided to do a diagnostic laparoscopy and reasonable management of any endometriosis of peritoneal cavity and excision of perineal scar endometriosis. Per op: Endometriosis was found on pelvic side walls overlying the peritoneal cavity and excision of perineal scar endometriosis. Per: Endometriosis specialist who decided to do a diagnostic laparoscopy and reasonable management of any endometriosis of peritoneal cavity and excision of perineal scar endometriosis. Per: Endometriosis specialist who decided to do a diagnostic laparoscopy and reasonable management of any endometriosis of peritoneal cavity and excision of perineal scar endometriosis. Per: Endometriosis specialist who decided to do a diagnostic laparoscopy and reasonable management of any endometriosis of peritoneal cavity and excision of perineal scar endometriosis. Per: Endometriosis specialist who decided to do a diagnostic laparoscopy and reasonable management of any endometriosis of peritoneal cavity and excision of perineal scar endometriosis.

Results: Case 1 was diagnosed as total uterine necrosis and was hospitalized on 21/12/19 at 38+3 weeks. Intraoperatively, a 19cm subserosal fibroid was found with a significant size but shrunk post pregnancy; it is worth noting that in her previous pregnancy, the apparent same fibroid also grew to a significant size but shrunk post pregnancy; therefore, there was no initial suspicion of malignancy. Lower midline caesarean section for breech presentation was performed on 21/12/19 at 38+3 weeks. Intraoperatively, a 19cm subserosal fibroid was seen in the right lower uterine segment.

Keywords: Uterine necrosis; Uterine leiomyosarcoma; Pregnancy; Incidental finding of leiomyosarcoma during caesarean section.

Problem statement: Uterine leiomyosarcoma (LMS) is an uncommon malignancy. Majority of cases occur afterchildbearing age and incidence during pregnancy is even rarer, with only 8 cases reported thus far. Methods: We present a case report of an incidental finding of uterine LMS associated with pregnancy after myomectomy was done for a subserosal fibroid during caesarean section. Results: Patient is a 30 year old para 2, with a known history of fibroid on regular follow-up since 2015. Spontaneous pregnancy was achieved and the fibroid was closely monitored. It is worth noting that in her previous pregnancy, the apparent same fibroid also grew to a significant size but shrunk post pregnancy; therefore, there was no initial suspicion of malignancy. Lower midline caesarean section for breech presentation was performed on 21/12/19 at 38+3 weeks. Intraoperatively, a 19cm subserosal fibroid was seen in the right lower uterine segment.
Concurrent myomectomy was performed in view of easy access of fibroid. Histopathology of the fibroid showed high grade spindle cell leiomyosarcoma. Post operatively, staging scan revealed a stable fibroid corresponding to the one seen on ultrasound previously in 2015, with no radiological evidence of distant metastases. Completion surgery with total abdominal hysterectomy, bilateral salpingo-oophorectomy, bilateral pelvic lymph nodes dissection and omental biopsy was performed on 14/2/19. Histology showed small amount of focal residual leiomyosarcoma within its wall with no evidence of local or distant metastasis. Multidisciplinary team discussion confirmed Stage 1B high grade leiomyosarcoma. Systemic chemotherapy was recommended in view of high risk of recurrence and medical oncologist was referred. However, patient opted for close clinicoradiographic monitoring instead. 3 months post surgery, patient remained well and healthy, with no radiological signs of local recurrence. Conclusion: Although LMS diagnosis in pregnancy is uncommon, it is important to be aware of this possibility for better counselling of patients who have a known history of large fibroids. Physicians can include discussion of this rare possibility of malignancy during pre operative counselling so as to allow patients to make an informed decision regarding removal of large fibroids during caesarean section.

P142

METHOD OF SURGICAL TREATMENT OF PROLAPSE OF THE ANTERIOR PELVIC FLOOR WITH TITANIUM IMPLANT

Iuliia Tarasenko, Anatoliy Ischenko, Anton Ischenko, Oksana Gorbenko, Tatjana Gavriloa, Irina Khokhlova, Tea Dzhibladze, Leonid Aleksandrov
Clinic of Obstetrics and Gynecology named after V.F. Snegirev, Sechenov University

The aim: of the research is to evaluate the effectiveness of the method of surgical correction of cystocele II-III degree using titanium mesh implants. Materials and methods: 27 patients with cystocele II-III degree between the ages of 37 and 74 were under surveillance. All patients were given comprehensive clinical examination, surgical treatment with titanium mesh implants according to the developed method and outpatient observation in early and delayed postoperative periods. Patients were subjected to transvaginal and transperineal echographic examination (Toshiba Aplio, Japan) equipped with transvaginal and convex sensors. Magnetic resonance imaging was performed on a 1.5 T/L Simmonds Avanto tomograph (Germany). Surgical correction of degree II-III cystocele was performed with titanium mesh implants that have greater inertness to surrounding tissues than polypropylene framework systems. The results: For the formed group of patients we have developed a three-stage organ-saving surgical program within the framework of one transvaginal operation, 1 stage - measurement of two interobturator dimensions with subsequent cutting of trapezoidal flap from titanium mesh in accordance with obtained results. Stage 2 - surgical correction of cystocele of II-III degree (according to the developed method - transvaginal transobturant combined timesh - ligature cystopexia, anterior colporrhaphy, colpoperinealatoroplasty). Stage 3 - pelvic floor strengthening. The duration of the operation ranged from 60 to 85 minutes and averaged 72+12.3 minutes. The blood loss ranged from 100 to 200 ml (150+45.8 ml). Outpatient surveillance lasted 24 months. During the first month, 11 (44%) of them noted non-permanent pain in the lower abdomen and perineum, 4 (16%) - increased call to urination. The questionnaire of the patients showed satisfaction with the results of the surgical treatment, which positively affected the quality of life, mood, increased social and sexual activity of women. In the process of dynamic outpatient observation, gynaecological examination at rest and Valsalva sample, transvaginal and transperineal echography, MRI of significant pelvic organ displacement was not detected. Conclusion: The new original method of correction of cystocele with the help of titanium implants will optimize results of operative treatment, reduction of frequency of recurrence of disease, reduction of risk of development of mesh-associated complications. The results of the research make it necessary to continue scientific and practical work in this direction.

P143

TRANSVAGINAL SURGICAL PREVENTION FOR POSTHYSTERECTOMY PROLAPSE OF VAGINAL DOME IN PATIENTS WITH COMPLETE UTERINE PROLAPSE

Iuliia Tarasenko, Tatjana Gavriloa, Irina Khokhlova, Janet Akhkmedova, Dmitry Bruniun, Tea Dzhibladze, Irina Khokhlova, Anton Ischenko, Anatoliy Ischenko
Clinic of Obstetrics and Gynecology Named After V.F. Snegirev, Sechenov University
I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia

Due to the high frequency of prolapse of the vaginal dome after hysterectomies, the relevance of prevention of post hysterectomy prolapse is beyond doubt. Purpose: Evaluation of the effectiveness of a new surgical method for the prevention of post hysterectomy prolapse of the vaginal dome in patients with complete uterine prolapse. Material and methods: Between 2015 and 2019, 36 premenopausal and postmenopausal patients with complete uterine prolapse were examined and treated. Transvaginal and transperineal echography, and MRI were performed in all patients before and after surgery, along with the traditional examination. Surgical treatment included a developed three stage surgical program within one transvaginal operation performed under spinal anesthesia. - Stage I - performing a vaginal hysterectomy. - Stage II - a post hysterectomy prevention of prolapse of the vaginal dome using a combination of the patient’s tissue (cardinal and sacro-uterine ligaments) and synthetic mesh implants (sacro-spinal-shelf). - Stage III - pelvic floor strengthening. Duration of surgery ranged from 70 to 80 minutes. Blood loss ranged from 150 ml to 250 ml. Follow-up of patients was performed within 6 to 36 months. Subjectively, all women were satisfied with the results of the operation and felt healthy. Upon gynecological examination, transvaginal and transperineal sonography the dome of the vagina was high. When straining, significant displacement of the internal genitals was not registered. Conclusion: A new surgical method for prevention of post-hysterectomy prolapse of the vaginal dome slightly extends the duration of the operation, improves the operation’s effectiveness and the long-term positive results reduces the frequency of relapses.

P144

A RARE CASE OF GENITAL TUBERCULOSIS PRESENTING AS A VULVOVAGINAL ULCER IN A 12 YEAR OLD FEMALE

Kara Angelique Valles, Armida Cepedaoba
Obstetrics and Gynecology, Gov. Celestino Gallares Memorial Hospital, Tagbilaran, Philippines

Problem statement: Female genital tuberculosis (TB) specifically vulvovaginal TB is a rare form of extrapulmonary tuberculosis caused by Mycobacterium tuberculosis. Presentation and manifestations are varied depending on the affected area. Methods: This is a case of a 12 year old, female child who presented with a vulvo-vaginal ulcer for a year associated with dysuria and fever; which was preceded with a straddle injury that was left untreated. Histopathologic examination of the excised ulcer suspected for a neglected infected straddle injury wound revealed chronic granulomatous inflammation with Langhan’s type giant cells. Further work-up showed Miliary Pulmonary Tuberculosis on chest x-ray. Results: Patient was enrolled in the DOTS program and was prescribed 2 months of Isoniazid + Rifampin + Pyrazinamide + Ethambutol and 4 months of Isoniazide and Rifampin regimen. Conclusion: In a country where TB is endemic, there should be a high level of suspicion in female children who presents with vulvovaginal ulcers especially in those
who do not respond to common antibiotic or steroidal therapy. It is prudent to include AFB smear for gram stain and culture in patients with complaints of vaginal discharge, dyspareunia, infertility, and pelvic pain.

P145
UNICORNATE UTERUS WITH FUNCTIONAL RUDIMENTARY HORN: DIAGNOSTIC PROBLEMS
Nataliya Veresnyuk, Vira Pyrohova, Anzhela Misiura, Mariya Malachynska
Department of Obstetrics, Gynecology and Perinatology, Postgraduate Faculty, Danylo Halatsky Lviv National Medical University, Lviv, Ukraine

The prevalence of unicornuate uterus accounts for 2.4 to 13% of all Müllerian anomalies. It may be associated with gynecological and obstetric complications. Case report: We report a case of a successful pregnancy in rudimentary horn of unicorneuate uterus and postpartum clinical manifestations. The first time uterine anomaly was diagnosed by two-dimensional (2D) ultrasound seven years ago. It was classified as a uterus bicornis. The patient had undergone hysterolaparoscopy for evaluation of case of infertility in 2013. However, no information about rudimentary horn was reported in her surgical record. The pregnancy became two month later. At the first screening ultrasound, the pregnancy was diagnosed in the right horn. The patient was not said about the risk of a rudimentary horn rupture due to misdiagnosis of uterus anomaly. She was transferred to a tertiary referral hospital with the pregnancy-induced hypertension and intrauterine growth restriction and uterus duplex unicoil. At 37 weeks' pregnancy, the patient underwent an urgent cesarean section section because of fetal distress and she had a healthy baby girl. During the surgery, unexpectedly no communication with another horn was found. The volume of surgery was limited to caesarean section. After 4 years, the patient came to our hospital with complaints of dysmenorrhea and secondary infertility. An ultrasound examination of pelvis organs with the following three-dimensional transvaginal scan of uterus was performed. The investigation showed a left unicornuate uterus with a non-communicating rudimentary right horn with hematometra and postcesarean scar on it (Class U4a according to the ESHRE/ESGE classification 2013). In addition, hydrosalpinx and secondary infertility. An ultrasound examination of pelvis organs with the following three-dimensional transvaginal scan of uterus was performed. The investigation showed a left unicornuate uterus with a non-communicating rudimentary right horn with hematometra and postcesarean scar on it (Class U4a according to the ESHRE/ESGE classification 2013). In addition, hydrosalpinx and endometrioid cyst were diagnosed at the right side. Magnetic resonance imaging demonstrated the same images. Removal of right rudimentary horn, rightsided salpingectomy and resection of right ovary were performed. Conclusion: The diagnosis and the management of the rudimentary uterine horn are often a challenge. Patients affected by dysmenorhoea and chronic pelvic pain should always be screened with 2D and 3D ultrasound examinations by highexperienced specialist. Complete removal of a communicating or non-communicating functional rudimentary horn with or without pregnancy in it is always recommended to prevent menstrual and pregnancy complications.

P146
OUTCOMES OF TWO PATIENTS WITH STRUMAE OVARII IN DERMOID TUMOURS
Wanxuan Wang1, Chit Chong Khong1, Kazila Bhutia2
1Department of Obstetrics and Gynaecology, KK Women's and Children's Hospital, Singapore
2Department of Urogynaecology, KK Women's and Children's Hospital, Singapore

Problem statement: Struma ovarii is a rare ovarian tumour. The majority of cases are benign. One percent (1%) of all ovarian tumours and 2-5% of ovarian teratomas are struma ovarii. We present two patients with strumae ovarii following surgery for dermoid cysts. Methods: This is a case series on 2 cases of strumae ovarii and their management with varying outcomes. Records of these 2 patients were analysed. Results: Case 1 This Chinese patient is a 43-year-old nullipara with a history of Grave's disease. She had cystectomy for right ovarian endometrioma and left benign cystic teratoma containing a focus of non-neoplastic thyroid tissue. Nine years after surgery, she developed an abdomeno-pelvic mass. On ultrasound, it was a 13 centimeter left adnexal heterogeneous solid-cystic mass with internal septations and vascularity. Ovarian tumour markers were normal. She underwent left salpingo-oophorectomy for a left complex ovarian cyst measuring 12 centimeters in diameter. There were 200 millilitres of ascites and scattered small nodules which were less than 5 millimeters in size on the bowel and peritoneal surfaces. Frozen section of the ovarian cyst was reported to be benign struma ovarii. Paraffin sections of the left tube and ovary revealed highly differentiated thyroid follicular carcinoma, and the peritoneal and bowel nodules contained metastatic thyroid follicular carcinoma. The patient underwent total thyroidectomy. Histology of thyroid gland was benign. The patient also underwent pelvic surgery to clear residual disease. After this, the patient was staged to have stage 3A2 follicular thyroid carcinoma of the ovary and she underwent adjuvant therapy with radioactive iodine.

Case 2 This Chinese patient is a 40-year-old nullipara with previous laparoscopic ovarian cystectomy for right dermoid and left haemorrhagic cysts. Five years later, she presented with a six centimetre anechoic cyst in the right ovary with no intrinsic vascularity or soft tissue within the cyst. She underwent laparoscopic cystectomy, and the histology showed benign struma ovarii. Conclusion: Although rare, the first case shows that strumae ovarii have the potential to become malignant – a point to bear in mind when we counsel and follow up patients.

P147
POSSIBILITIES OF APPLICATION OF INTERFERON ALPHA-2B IN COMBINED TREATMENT OF PATIENTS WITH GENITAL ENDOMETRIOSIS
Maria Yarmolinskaya1, Elena Dumeva1, Dmitriy Sokolov2, Sergey Selkov
1Department of Gynaecology of Reproduction, Scientific Research Institute of Obstetrics, Gynaecology and Reproductology Named After D.O. Ott, Saint Petersburg, Russia
2Department of Immunology and Intercellular Interactions, Scientific Research Institute of Obstetrics, Gynaecology and Reproductology Named After D.O. Ott, Saint Petersburg, Russia

Problem statement: It is known that disorders in immune system play important role in occurrence and progression of genital endometriosis (GE), so the use of targeted immunomodulatory therapy is considered to be actual direction of treatment of this disease. The aim of the study was to evaluate effectiveness of human recombinant interferon alfa-2b (IFNα-2b) in combined treatment of patients with GE. Methods: 46 patients with laparoscopically and histologically confirmed diagnosis of GE I-II degree (according to R-AFS classification) were examined. The main group consisted of 21 patients with GE, who were appointed IFNα-2b (3 million Units per rectum 2 times a day for 10 days) together with 1st injection of gonadotropin releasing hormone agonist (aGnRH), after a 10-day interval, the second course of
immunomodulatory therapy was conducted. Comparison group included 25 patients with GE who received monotherapy with aGnRH for 6 months. Before surgery and 6 months after beginning of treatment severity of pain syndrome was assessed on the basis of visual-analog scale. **Results:** In the main group we found more pronounced decrease in severity of pelvic pain (by 90.5%) and dyspareunia (by 85.7%) compared to the second group (76% and 80% respectively). After treatment the level of IL-8 in the main group didn’t change, while in the comparison group its level increased by 31.64%. Level of RANTES decreased more significantly in patients who received immunomodulatory therapy (15% and 4.7%, respectively). Level of MCP-1 increased by 14.2% in the study group compared with its decrease by 17.6% in the group of monotherapy with aGnRH. TNF-α level did not change significantly; IP-10 level tended to increase in both groups. **Conclusion:** The use of IFNo-2b in combined therapy of GE showed good clinical effect, more over changes in cytokine profile indicated more evident suppression of inflammation and angiogenesis in comparison with standard regimens of treatment.

**P148**

**THE ROLE OF NEUROKININ B IN THE PATHOPHYSIOLOGICAL MECHANISMS OF VASOMOTOR SYMPTOMS AND SLEEP DISORDERS IN POSTMENOPAUSAL WOMEN**

Zukhra Ebzieva, Svetlana Yureneva, Tatiana Ivanets, Viktoriya Averkova

Federal State Budget Institution “Research Center for Obstetrics, Gynecology and Perinatology” Ministry of Healthcare and Social Development of the Russian Federation, Gynecology, Russia

**Problem statement:** Menopausal vasomotor symptoms (VS) and sleep disorders are a significant socio-economic and medical problem occurring in almost 65% postmenopausal women. Research of the pathophysiology of VS is vital for the development of target therapy. **Methods:** 80 women were divided into 3 groups: postmenopausal women with VS and sleep disorders (Group I, n=25) postmenopausal women without VS and sleep disorders (Group II, n=25), and 30 women of reproductive age with a regular menstrual cycle (Control group III). Group I received MHT 17-β estradiol transdermal gel 0.75 mg daily and micronized progesterone vaginally. Menopausal symptom frequency and intensity evaluated by the Greene Climacteric Scale. Determination of serum neurokinin B (NKB) levels was carried out by enzyme immunoassay (“Neurokinin B” cat. No. S-1271 Peninsula Laboratories International, Inc., USA.). **Results:** Patients of the I and II groups were comparable in age, postmenopausal duration and anthropometric indicators. NKB levels in Groups I and II were significantly higher compared to the control group (P1=0.0001, P2=0.003). NKB levels in Group I were 2.3 times higher than in Group II (P3=0.001). The results showed a clear and clinically relevant reduction of menopausal symptoms under MHT after 12 weeks of treatment in Group I. Hot flushes disappeared in 10 patients (40.0%) (p=0.0001), complete disappearance of night sweating was noted in 16 women (64.0%) (p=0.005). A relief or complete disappearance of sleep disorders was observed in 16 women (64.0%) (p=0.0001). After 12 weeks NKB levels in Group I decreased from 269.72±40.79 PG/ml to 83.56±26.07 PG/ml (p= 0.0003). **Conclusion:** The increase of NKB serum levels in postmenopausal women compared to women of reproductive age may be due to the activation of hypothalamic KNDy neurons in postmenopause. The increase in NKB levels in patients with menopausal symptoms compared to asymptomatic women and its MHT-associated decrease suggests the important role of NKB in the pathogenesis of VS and sleep disorders in postmenopausal women.

**P149**

**STUDY ON THE MECHANISM OF LYSYL OXIDASE FAMILY IN ENDOMETRIAL FIBROSIS AFTER INJURY**

Dong-dong WANG1, Lan-mei ZHANG2

1Department of Gynaecology and Obstetrics, Strategic Support Force Medical Centre of PLA, Beijing, China

2Department of Gynaecology and Obstetrics, The Sixth Medical Center of PLA General Hospital, Beijing, China

**Problem statement:** Lysyl oxidase (LOX) family, as we know, are involved in the formation of collagen fibers and elastic fibers, which play an important role in molecular crosslinking. So, we speculate that the LOX family may have great effects in the process of endometrial fibrosis. Studies have shown that with the increase of TGF-β1 expression in the endometrium, the severity of endometrial fibrosis increased synchronously. In our study we detected the expression of LOX family in rat fibrosis endometrium and explore the correlation between the expression of LOX family and TGF-β1/Smad signaling pathway in the process of endometrial fibrosis. **Methods:** 1. The fibrotic endometrial rat models were established by mechanical curettage. 2. Detecting the LOX activity and the expression of LOX family, TGF-β1, Smad2, Smad3, p-Smad2 and p-Smad3 at protein and RNA level in the normal rat endometrium, the fibrotic rat endometrium(the control group) and the endometrium of the rats (the experimental group) which were treated with 200mg/kg/d β-aminopropionitrile which can inhibit the LOX activity. **Results:** The expression of LOX and LOXL1 have a significant rise at protein and RNA level in fibrotic rat endometrium. 2. The expression of TGF-β1, Smad2, Smad3, p-Smad2 and p-Smad3 in the endometrium of experimental group is lower than those in the control group. **Conclusion:** LOX and LOXL1 are closely related to the formation of endometrial fibrosis which are closely related to TGF-β1/Smad signaling pathway during the formation of endometrial fibrosis. Declaration of Conflicting Interests: The authors declared no potential conflicts of interest with respect to the research.

**P150**

**Y – GRAFT APLICATION IN THE REPAIR OF PELVIC FLOOR FUNCTIONAL DISEASE OF DEPARTMENT OF GYNECOLOGY STUDY**

Yudi Zhang

Gynecology Section, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, China, China

**Problem statement:** This study reviews the clinical research and analysis of female pelvic floor reconstruction using Y-graft to repair function of clinical curative effect. **Methods:** This study included all the patients who received Y-graft to laparoscopic sacral vaginal suspension treatment. We recorded perioperative indicators (average operation time, blood loss, such confinement, complication rates), and regular follow-up was performed at different time points record POP - Q staging, and USES the PFIQ life scale subjective satisfaction survey. **Results:** All the patients were completed at least 1 years of follow-up, postoperative POP - Q (preoperative improved significantly (P
0.05). PFIQ - 7 life scale score also prompt improved obviously (P 0.05). All of the patients have no associated complications, treatment satisfaction as a whole. **Conclusions:** Using Y-graft in laparoscopic repair heavy female pelvic floor functional defects, suitable for human body biomechanical characteristics, are older women with minimally invasive, conform to one of the anatomical repair treatment of pelvic floor reconstruction.

**HVP**

**P151**

**P16/Ki67 EXPRESSION AND THE APLICABILITY THROUGH DIFFERENT AGES**

**Sara Bernardes da Cunha**1, Matilde Martins1, Inês Reis1, Cátia Rodrigues2, Vânia Ferreira3, Cátia Rasteiro1,2, Soledade Ferreira1, Teresa Paula Teles1

1Obstetrics and Gynecology, Centro Hospitalar De Entre Douro E Vouga, Portugal
2Faculdade De Ciências Da Saúde, Universidade Da Beira interior

**Problem statement:** Human papilloma virus (HPV) infection is one of the most common sexually transmitted diseases. The infection prevalence is higher in younger ages, as it's spontaneous resolution, making HR-HPV (high risk human papilloma virus) test less advantageous. CINtec PLUS is an histochemical immunoassay which evaluates the p16 and ki 67 tissue expression. Under normal physiological circumstances, they aren't simultaneous active, indicating cellular cycle deregulation. So, this test can be useful identifying cases with higher risk of bad outcomes. The goal is to evaluate the CINtec PLUS à test capability to predict HPV infection resolution along different life stages. **Methods:** Retrospective clinical information was collected, from cases from Cervical Cancer Screening consultation of our hospital. We selected cases with initial pap-smear negative for intraepithelial lesion and malignancy (NILM) (if HR-HPV positive), atypical squamous cells of undetermined significance (ASC-US) (HR-HPV positive) e low-grade squamous intraepithelial lesion (LSIL) in whom the p16/k67 was performed. Social-demographic information, initial and subsequent pap-smear result, and CINtec PLUS à test result were collected. The patients were divided in 2 groups (group1: age equal or under 30 years old; group2: age over 30 years old). The groups were compared. Results: 138 cases were selected (2017-2019) (34 cases in group 1 and 104 cases in group 2). HR-HPV became negative in 50% cases of group 1 and 47.8% of group 2. When CINtec PLUS results were compared with the infection resolution, there were no differences in group 1, however, there was a significant difference in the group of women over 30 years old. **Conclusion:** In our study, we did not verify a higher proportion of HPV infection resolution in group 1, in opposition to the study reports. The small number of cases in our sample is one limitation of the study. The follow-up (only 12 months) could be an important bias since it can be a short time to provide a complete HPV infection resolution in the younger group.

**P152**

**MEDICAL PROVIDERS` ATTITUDE TOWARD HPV VACCINATION, ISRAEL, 2017**

**Hanean Jeries-Ghantous**1,2, Marwan Odeh1,3, Rola Khamissy Farah1,2

1The Azrieli Faculty of Medicine, Bar Ilan University; Safed1, Clalit Medical Health Services2 Department of Obstetrics and Gynecology, Galilee Medical Center, Nahariyya, Israel

**Problem statement:** Investigating the awareness and attitude of physicians to HPV infection and vaccination among gynecologists, pediatricians and other physicians. **Methods:** Questionnaires were distributed to about 200 physicians, each questionnaire included 29 questions divided into three parts. The first part included 10 questions about demographics of the participants, the second part contained 8 knowledge-based questions on HPV and the vaccine. The third part included 11 questions that examine the approach to the HPV vaccine in terms of vaccination recommendation, the motives and the barriers to vaccination, and management with patients who hesitate to vaccinate their children. The questionnaires were distributed to physicians from different areas of specialty: gynecologists, pediatricians, internists, surgeons, interns, geriatricians, etc. **Results:** There were 139 responders, 26% of the participants were gynecologists, 10% were pediatricians, and the remaining 62% were doctors from various specialties. We thoroughly scanned and analyzed the questionnaires, and were able to deduce the following: In both parts containing knowledge-based questions and vaccine recommendation for girls, the results yielded no significant statistical difference between gynecologists and other physicians. Gynecologists and other physicians demonstrated no significant difference in recommendation for vaccination of teenage boys, however there was a difference between Gynecologists and Pediatricians although still statistically insignificant. Pediatricians are 4.73 times more likely to recommend vaccination to teenage boys. Doctors were more inclined to recommend vaccine to girls more than boys, while parental preference of vaccination between boys and girls was statistically insignificant. Pediatricians demonstrated more effort compared to other doctors, in an attempt to persuade parents to vaccinate their children. **Conclusion:** Doctors from all areas of specialty should generate more effort to spread awareness and reinforce the importance of the HPV vaccine, and convince the targeted group to be vaccinated.

**P153**

**PREVALENCE OF HIGH-RISK HPV AND ITS DISTRIBUTION IN CERVICAL PRECANCEROUS LESIONS AMONG 35-64 YEARS OLD WOMEN WHO RECEIVED CERVICAL CANCER SCREENING IN BEIJING**

**Wang Jiandong, Shen Jie, Han Lili**

Gynecological Oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, China

**Problem statement:** The prevalence of high-risk HPV (HR HPV) in women who accepted cervical cancer screening in Beijing and its distribution in cervical precancerous lesions is not known. **Methods:** From January 2014 to March 2015, all women aged 35-64 years old and received free screening in institutions of cervical cancer in Beijing were recruited. Stratified cluster random sampling method was used in selecting 31091 women for gynecological examination and genotyping of HR-HPV. Those positive for HR-HPV (exceptforHPV16/18) were examined for cervical cell. For those atypical squamous cells of uncertain significance (ASCUS) and above, who were positive for HPV16/18 and with uncertain results for cervical cell, were transferred for colposcopy examination. For those with abnormal or abnormal results for colposcopy, were transferred for histopathology. The prevalence of HR-HPV, cervical cancer and precancerous lesions among the participants were analyzed. **Results:** Totally 31091 women aged from 35-year-old to 64-year-old, with 44.3%(13780women) in the 35-49 age group and 55.7%(17311women) in the 50-64 age group,66.1%(20536women) were rural women. The infection rate of HR-HPV was 7.4%(2305cases) among the women. High-risk infection rates of HPV except HPV 16/18 were 5.7%(1758cases), and multi-infection rate was 1.5%(47cases). The highest infection rate was 7.9%(1044cases) among the 45-49 year-old and 50-54 year-old age groups (χ²=14.07, P=0.015). The rate in rural women was significantly higher than that of the urban women (6.2%,507cases;7.9%,1798cases) (χ²=25.75.P:0.001). The proportion of HPV16, HPV18, HPV52, HPV51, HPV58 was 17.0%(391cases),8.9%(16cases),8.6% (20cases),5.2%(12 cases) and 7.7%(18cases), respectively. The detection rate of cervical cancer and precancerous lesions in the population was 395.6/100000 (123 cases). In high-grade squamous intraepithelial lesions (HSIL), HPV16 and 18 infections accounted for 60.5%(72 cases) of all. HPV16 infection rate and detection rate of HSIL were
the highest in 50-54 year-old group which were 1.5% (107 cases) and 25.2% (30 cases); (χ²=11.54, P=0.042). Conclusion: Top five types of HR-HPV infection in women who accepted cervical cancer screening in Beijing were HPV16,18,52,51 and 58. The infection rate of HPV16 and 18 increased significantly in HSIL women. Disclosure of Interest: NO

OTHER

P154 SIGNIFICANT PUBIC SYMPHYSIS DIASTASIS FOLLOWING KIWI CUP DELIVERY: REPORT OF A SEvere CASE Marrwah Ahmadzai1, Jason Chinnappa2, Rebecca Li1, Paul Smith2
1Obstetrics and Gynaecology, The Canberra Hospital, Australia
2Orthopaedic Surgery, The Canberra Hospital, Australia

Background: Symphys pubis diastasis (SPD) refers to separation of the pubic symphysis joint without fracture (Shnaeckel et al. 2015). It is a serious maternal complication of delivery, resulting in significant pain and disability (Shnaeckel et al. 2015). Management options include conservative therapy or surgical fixation with no consensus on optimal treatment (Nayak and Panda 2017). Case: A 31-year-old female (G1P0) with a pre-pregnancy BMI of 19 and no antenatal complications or medical comorbidities presented at 39+3 weeks gestation presented in spontaneous early labour. She had a prolonged first stage lasting 17 hours and 10 minutes. Her labour was augmented with syntocinon infusion and prolonged variable decelerations, instrumental delivery was undertaken. She was placed in the lithotomy position; episiotomy was performed during the second stage with reduced variability and prolonged heart rate decelerations. The delivery was complicated by primary post-partum haemorrhage of 600ml managed with uterotonic. On the first postpartum day, she reported worsening severe pain in the mons pubis, lower abdomen and back, with inability to mobilise. X-ray demonstrated SPD, with diastasis of 53mm and bilateral sacroiliac joint (SIJ) widening was identified on Magnetic Resonance Imaging. Operative management was undertaken by anterior external-fixator frame that remained on for six weeks. Bilateral percutaneous SIJ screws were also inserted. She remained admitted for nine weeks, encompassing six weeks of bed rest. At the time of discharge, she was ambulant with a support frame and improving stiffness and pain. Discussion: The aetiology of SPD post-vaginal birth is poorly understood, with many possible risk factors including hyper-flexed legs during delivery, forceps delivery and epidural analgesia suggested but not substantiated by statistical evidence (Yoo et al. 2014). Traditionally, conservative management has been used to manage SPD, however recent literature suggests improved outcomes following surgical management (Nayak and Panda 2017). However, the management of SPD with external fixation postpartum, as in this case, has been rarely described in the literature. Reference list available on request

P155 EVALUATION OF THE UTILIZATION OF THROMBOPROPHYLAXIS IN OUT-PATIENT PREGNANT WOMEN AT SOUH Rahma Al-Haddabi
Obstetrics and Gynecology, Sultan Qaboos University Hospital, Al-Khodh, Oman

Objectives and rationale: To find the prevalence of Omani pregnant women with thrombophrophylaxis medication, to evaluate the adherence and non-adherence to the medication and to discuss the possible factors contributing to not adhering to the medication in Sultan Qaboos University Hospital (SQUH) in Oman. Materials and methods: A cross-sectional survey conducted in Obstetrics and Gynecology (OBGYN) clinic in SQUH between November 2018 and January 2019. With the help of the hospital electronic medical records, total number of pregnant women who visited OBGYN clinic at the study period were included in this study and the number of patients who were on thromboprophylaxis medication was obtained. Patients were grouped into adhering and non-adhering group according to WHO definition of non-adherence. Different parameters were collected from a question sheet which was distributed to the targeted patients and data were compared between the two groups by SPSS version 23. Results: Total number of pregnant women who visited OBGYN at the study period was 375 patients. Out of them, 75 patients were prescribed on thromboprophylaxis but 65 agreed to be part of the study. About 73.8% of patients were on anticoagulant drugs throughout pregnancy while the rest started the drug from week 28 onwards. It was found that 33.8% of pregnant women on anticoagulant drugs do not adhere to their medication. Forgetting was the main reason of non-adhering at 71.4% whereas 28.6% stated non-adherence due to other reasons. One significant factor that led to low adherence was in case of noticing any medication side effect and stopping the medication immediately. Other factors are discussed in the result section. Conclusion: Proportion of pregnant women who are prescribed thromboprophylaxis in the study period was 20%. Majority of pregnant women on thromboprophylaxis medication are highly adherent to their therapy. Minority that did not adhere to medication stated non-adherence due to forgetfulness. Front-line clinical staff should stress in informing the patient about adherence importance and may suggest medication reminder apps.
P157
PREIMPLANTATION GENETIC DIAGNOSIS (PGD) FOR DUCHENNE MUSCULAR DYSTROPHY (DMD) USING MULTIPLEX NESTED PCR: A SINGLE MEDICAL CENTER EXPERIENCE AND EVOLUTION ALONG SIXTEEN YEARS
Asaf Bilgory, Sagit Peleg, Tzvia Frumkin, Veronica Gold, Foad Azem, Mira Malcov
Wolf Pgd Stem Cell Lab, Racine IVF Unit, Lis Maternity Hospital, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

Problem statement: DMD is a progressive genetic disorder that can be prevented by applying PGD technology. Our aim was to evaluate our evolving performance along the years in the program of PGD for DMD families regarding the accuracy and reliability of diagnosis, and the reproductive outcomes. Materials and methods: A retrospective cohort study of all couples who underwent PGD in our unit between 5/2002-12/2018. Accuracy of diagnosis was evaluated by the rates of conclusive diagnosis, allele drop out (ADO) rate, amplification failure (AF) rate, misdiagnosis risk, and re-biopsy rate due to inconclusive results. Reliability was based on diagnosis of control isolated single leukocytes and on prenatal diagnosis. We stratified our data to three different chronological periods and compared our performances. Group A: 5-2002-9/2004, group B:10/2004-12/2011, and group C:1/2012-12/2018. Results: Thirty three patients underwent 152 PGD cycles, embryo transfer was done in 137 cycles, 30 women had a live birth (4 had twins), 7 had miscarriages, and 1 pregnancy is ongoing. As we advanced along the time periods, an increase in the total number of informative markers used per cycle was prominent with 4.35 (±1.3) in group B compared with 7.21 (±1.8) in group C (P=0.001), while AF rate decreased significantly from 5.89% in group B to 3.02% in group C (P=0.008). The ADO rate was not significantly different between group B with 0.52% and group C with 0.41% (P=0.768). However, the misdiagnosis risk decreased significantly from 0.82% in group B to 0.02% in group C (P=0.001). Conclusion: In 2005 we started using haplotypes which enabled us to discriminate between carrier and healthy female embryos. Due to the large diversity of the informative markers that we gained through the way, In 2012 we changed the policy of two blastomeres aspiration to a biopsy of one single blastomere. As for December 2018 we have more than 30 informative markers readily available for use in order to build the most informative haplotypes. Altogether we gave the opportunity for 33 couples, who finally gave birth to 26 children free of DMD disease and our work is still ongoing.

P158
A PILOT STUDY OF HCG POINT OF CARE TESTING: THINKING OUTSIDE THE LAB
Azal El Adwan, Alexander Taylor
Department of Obstetrics and Gynaecology, Royal Bournemouth Hospital, Bournemouth, UK

Problem statement: Point of care (POC) testing for human chorionic gonadotrophin (HCG) has the potential to shorten diagnostic pathways, improve patient experience and contribute to cost improvement plans. In the future we believe it is likely to be adopted the method of choice for diagnosis confirmation or exclusion of pregnancy in the acute hospital setting. However, in our opinion it should compliment rather than replace quantitative assays of HCG, as quantitative assays facilitate the monitoring of pregnancies in which a visible intrauterine sac hasn’t been seen yet, that is to say pregnancies of unknown location (PUL). The Abbott ISTAT POC device is the first approved device to provide quantitative HCG assays using whole blood. Our aim was to assess the validity of using the ISTAT point of care HCG assay by comparing it to a standard laboratory serum test. Method: We analysed data on 51 consecutive patients attending the early pregnancy unit at the Royal Bournemouth Hospital (UK) from 15/12/2018 to 30/01/2019. Blood samples with a wide range of HCG concentrations were analysed by both methods. Results were plotted and a percent difference was calculated for means of comparison. Results: Quantitative assays were available for 43 of the 51 samples, in the remainder samples the device reader displayed the result as (5) or (200). The ISTAT POC demonstrated acceptable performance for quantifying HCG in comparison to the standard laboratory method in the range 5 to 1500iu, however there was a relatively high percent difference for HCG levels approaching 2000 IU (maximum percentage:37.8%)

Conclusion: In our pilot study the Abbott ISTAT POC device produced comparative results to quantitative HCG testing up to 1500iu. Above this there were limits to it’s accuracy but this could well reflect our lack of data. Nonetheless this is well within the range and clinical utility to be a valuable tool in shortening diagnostic pathways and improving overall patient experience. Our data set is small and larger studies are required to determine the sensitivity and specificity before the device is more broadly adopted by early pregnancy assessment units.
P159
UNEXPECTED APPENDICULAR MALIGNANCY IN A TRANSGENDER MAN ON EXOGENOUS TESTOSTERONE SUPPLEMENTATION
Nandini Halder1, Hashim Samir1, Islam Abdelrahman1,
Haritharan Nageswaran2, Letchuman R Shankar1
1Obstetrics and Gynaecology, Glangwili General Hospital, Carmarthen, UK
2General Surgery, Glangwili General Hospital, Carmarthen, UK

Introduction: We present a transgender man who had an incidental finding of an appendicular mass on imaging that turned out to be an appendicular malignancy. Case: A 35-year-old transgender man with BMI 50, hypertension and sleep apnea was referred with heavy menstrual bleeding not improved by Mirena coil and endometrial ablation. The patient underwent transsection treatment with bilateral mammectomy and testosterone injections for last 5 years. Further gender-reassignment operation was postponed until the patient lost further weight. Pelvic ultrasound scan showed a fibroid uterus with right adnexal mass and mildly raised CA125 (48 kU/L) and CA19-9 (65kU/L). MRI scan suggested uterine adenomyosis with possible mucocele of the appendix. Colonoscopy was normal. Following gynae MDT, the patient underwent total laparoscopic hysterectomy with bilateral salpingo-oophorectomy (converted to an open due to an approximately 22 week-sized fibroid uterus) and appendicectomy, performed jointly by gynaecologists and general surgeons. The appendicular mucocele was resected without perforation. Histology confirmed an atrophic endometrium and low-grade mucinoid neoplasm of the appendix with involvement of the margins. The patient was discharged on the third postoperative day. Discussion at colorectal MDT determined that surveillance CT be performed at 6 months.

Discussion: Amenorrhoea is generally induced and maintained within 6 months of exogenous testosterone initiation unlike in this case. Testosterone induces a state of unopposed oestrogen due to aromatisation and anovulatory phase, posing a theoretical risk of endometrial cancer. However, half of such endometrium shows atrophy by biopsy like postmenopausal endometrium. Studies in mice and humans have shown testosterone to promote development of colorectal cancer (CRC) and may have a role as biomarker for CRC risk stratification in future. Imaging patient with such high BMI is challenging with all imaging modalities.

Conclusion: Further studies are needed on the effect of opposite-sex hormone on transgender physiology. The patient continued to have heavy periods despite conservative management possibly because the exogenous testosterone did not allow the uterine fibroids to shrink in size thereby increasing the endometrial surface. The unexpected appendicular malignancy may also be linked to the exogenous testosterone supplementation.

P160
APLASIA CUTIS CONGENITA HEREDITARY FORM - CASE REPORT
Yoana Ivanova1, Elitsa Gyokova1, Grigorioc Angelidis2
1University Hospital Saint Marina, Department of Obstetrics and Gynecology, Department of Obstetrics and Gynecology, Medical University - Pleven, Pleven, Bulgaria, Pleven, Bulgaria
2Faculty of Medicine, Medical University - Pleven, Pleven, Bulgaria, Medical University Pleven

Problem statement: Aplasia cutis congenita (ACC) is a rare disease characterized by congenital partial or complete absence of skin at birth, involving mostly the vertex. The pathogenesis of the condition is unclear and it may occur, either as an isolated defect, or in correlation with other fetal malformations. At this case report we describe an infant born with a 2 cm diameter lesion, localized on the scalp with clear rims and no signs of inflammation. Until the end of the hospital stay of the newborn patient, the wound demonstrated spontaneous granulation. Methods: At a planned Cesarean delivery in 39 week of gestation, a girl was born with weight 3460 grams, height 51 cm and APGAR score 7, 8, 9. During the delivery procedure a 2 cm round lesion was noticed on the head of the baby, specifically at the vertex part. The baby was otherwise healthy, in good condition with no signs of other malformations. The newborn was consulted with neurosurgeon and CT scan was performed with conclusion: Normal CT status. Small intradermal fibrosis occipitally in the left. No changes of the structure of the skull bone and the brain tissue. Later the grandmother of the newborn reported that she also had a Cesarean delivery and her baby (our patient who gave birth) was born with a similar lesion on the skin of the head. It healed spontaneously and nowadays, the mother has a small scar in the vertex part of her head. Results: After studying other clinical cases of ACC and consulting with the parents about their desire, conservative treatment was undertaken. At the 4th postnatal day, the lesion was healing well and fresh granulation tissue occurred. The mother and the baby were discharged at the 6th day with a visible improvement in the lesion’s condition. Conclusion: In this work we present a case with ACC group 1, that was diagnosed after rejecting other possible diseases. Considering all circumstances we decided to try conservative treatment that include local wound care, so the lesion healed spontaneously and surgical treatment was avoided.

P161
PERSISTENT RISE OF BHCG AFTER COMPLETE SURGICAL TREATMENT OF ECTOPIC PREGNANCY - CASE REPORT AND REVIEW OF LITERATURE.
Neeraja Jampana, Ali Nakash
Obstetrics and Gynaecology, Croydon University Hospitals, Croydon, UK

Problem statement: To gain knowledge of the various causes of persistent rise of HCG measurements after total surgical management of ectopic. Methods: A case study in our trust and reference search of various case reports published have been taken into account to draw results. Results: Omental and peritoneal secondary trophoblastic implantation are probably the result of disruption of the ectopic pregnancy or morcellation of the fallopian tube at salpingectomy. These implants present with persistent BHCG titre postoperatively and needs to be considered in cases of persistent disease following salpingectomy. Secondary pregnancy by an implant in laparoscopic trocar site has also been reported. The occurrence of simultaneous ectopic pregnancies in two extratubal locations although rare, particularly in spontaneous pregnancies; and heterotopic simultaneous ectopic and intrauterine pregnancy have been reported. Non pregnancy sources of BHCG like malignancy including gestational trophoblastic diseases, germ cell tumours, paraneoplastic syndrome; pituitary HCG and interfering antibodies remain the other causes. Conclusion: BHCG measurements after surgical treatment of ectopic pregnancy is justified to rule out persistent trophoblastic activity. Aim should be to exclude persistent ectopic and non pregnancy sources of BHCG and to minimise morbidity and mortality associated with it.

P162
SECONDARY POSTPARTUM HEMORRHAGE: INCIDENCE, ETIOLOGIES AND CLINICAL COURSES IN THE SETTING OF HIGH CESAREAN DELIVERY RATE
Kittiya Deevongkij, Chusana Pelpichetchian, Nathitcha Chainaronr
Department of Obstetrics and Gynecology, Faculty of Medicine, Prince of Songkla University

Background: Secondary postpartum hemorrhage(SPPH) is any significant vaginal bleeding occurring between 24 hours after ending of third stage of labor and following 6 to 12 weeks. The reported incidence was around 0.2-0.8%.Common causes include retention of placenta, endometritis and delayed involution of placental bed. To date, there has been limited number of studies
P163
THE PROGNOSIS OF PREGNANCY IN PATIENTS WITH RECURRENT ABORTION WHOSE CHROMOSOMES SHOW 46,XX/45,X MOSAICISM

Taro Nonaka1, Makiko Takahashi1, Koichi Takakuwa2, Takayuki Enomoto1

1Obstetrics and Gynecology, Niigata University, Niigata City, Japan
2Center for Perinatal, Maternal and Neonatal Medicine, Niigata University, Niigata City, Japan

Problem statement: As one of the major etiologies of recurrent abortion, chromosomal aberration is very important, and the major chromosomal aberration in patients with recurrent abortion is balanced translocation. On the other hand, some patients with recurrent abortion whose chromosomes show “46,XX/45,X mosaicism”. Although it is said that “46,XX/45,X mosaicism” is not harmful for the next pregnancy in patients with recurrent abortion, the detailed prognosis of pregnancy in such patients has not been reported. In this context, we analyzed the prognosis of the next pregnancy in patients with recurrent abortion whose chromosomes show “46,XX/45,X mosaicism”. Methods: Between January, 2012, and September, 2017, chromosomal karyotyping was performed in 469 couples with RPL (two or more consecutive spontaneous abortions), after obtaining their informed consent. The frequency of patients whose chromosomes showed 46,XX/45,X mosaicism was analyzed and the outcome of the next pregnancy in patients with 46,XX/45,X mosaicism was investigated. Results: Among 469 patients with recurrent abortion, 14 patients’ chromosomes showed 46,XX/45,X mosaicism. Thus, the frequency was 3.0%. Among the 14 patients who showed mosaicism, 10 patients have so far experienced 12 pregnancies. Eight of these pregnancies continued successfully, and the patients delivered normal mature infants. The rate of successful pregnancy was 66.7% (8 of 12), and the rate of successful pregnancy among individuals with mosaicism was 80.0% (8 of 10). Conclusion: Our study suggested that 46,XX/45,X mosaicism in patients with recurrent abortion does not have a bad effect on the subsequent pregnancies in these patients. However, it will be necessary to analyze an increased number of patients in order to obtain a more accurate conclusion. There is no conflict of interest.
women had their BMI checked in the last 12 months whilst 79.35% had their BP checked in last 6 months. A total of 70.32% had both their BMI and BP checked in the last 12 months. **Conclusion:** The main safety concerns for obese or hypertensive women using COCP are cardiovascular risks from exogenous oestrogen including VTE, acute MI and ischaemic stroke. To improve results towards 100%, an alert system could be put in place on EMIS for every consultation so that required checks are made. Additionally, a COCP-specific template that includes tick boxes could be used to ensure all questions are asked and measurements are recorded. Training sessions for GPs should be mandatory to ensure they know the importance of health checks in contraception reviews.

**P166 MEASURING THE CEREBELLUM – A GROWTH CURVE IN A SPECIFIC POPULATION**

Joana Simoes1, Flávia Vicente2, Diana Almeida1, Vera Mourinha1, Ângela Ferreira1, Amália Pacheco1

1Obstetrics, Centro Hospitalar E Universitário Do Algarve - Unidade De Faro, Faro, Portugal
2Obstetrics, Centro Hospitalar E Universitário Do Algarve - Unidade De Portimão, Portimão, Portugal

The cerebellum is derived from the dorsal portion of the mesencephalon, and is located in the posterior cranial fossa, beneath the occipital lobe and dorsal to the brainstem, delimiting part of the fourth ventricle. It’s one of the first structures in the brain to differentiate, initiating in the fifth week, but one of the last to mature. The mass of the cerebellum will double after the 19th week of gestation and continues to grow after birth. The cerebellum can be identified by ultrasonography at the end of the first trimester, however, the diagnosis of abnormalities should be avoided before the 18th week because the vermis is not totally formed yet. Goldstein was the first in 1987 to evaluate its growth and create a nomogram on the measurement of its transverse diameter. This measurement is considered a good parameter for dating gestations in cases of fetal growth restriction, as it is one of the last organs affected by placental insufficiency, and in late pregnancy discovery. It is known that for the same gestational age, the transverse cerebellar diameter varies between different ethnic groups. Although most women in our center are Caucasian, our population is composed by various ethnic groups and no normal reference curve has been determined for this parameter in our country. The aim of our study is to determine reference values for the fetal transverse cerebellar diameter from 19 to 25 weeks of gestation in a sample of our population. A retrospective cross-sectional study was carried out between January 2017 and December 2018, with evaluation of pregnant women referred for second-trimester ultrasound between 19 and 25 weeks. Multiple pregnancies and fetuses with malformations were excluded. Outliers were identified and excluded, percentiles were identified and a normal range curve for cerebellar diameter in our population was produced.

**P167 INTEROPERATOR VARIABILITY IN FETAL ULTRASOUND MEASUREMENTS IN A PORTUGUESE PRENATAL DIAGNOSIS CENTER**

Joana Simoes1, Flávia Vicente2, Diana Almeida1, Vera Mourinha1, Ângela Ferreira1, Ana Franco1, Amália Pacheco1

1Obstetrics, Centro Hospitalar E Universitário Do Algarve - Unidade De Faro, Faro, Portugal
2Obstetrics, Centro Hospitalar E Universitário Do Algarve - Unidade De Portimão, Portimão, Portugal

Ultrasound examination of the fetus is a vital tool necessary for the obstetric evaluation of fetal development and growth. Many clinical decisions depend upon an accurate and reproducible measurement of fetal biometry. The importance of ascertaining the reliability of sonographic measurements is necessary, not only to screen for anomalies, but also to improve the accuracy of gestational age prediction during pregnancy and monitoring fetal growth. In our hospital, sonographies of the same women often involve different operators. Inaccurate measurements can lead to erroneous detection of fetal growth restriction and macrosomia, and thus to unnecessary intervention, maternal anxiety and iatrogenic perinatal morbidity. It may also lead to inadvertently overlooking growth-restricted fetuses. There are relatively few studies assessing the variability of ultrasound measurements in fetal biometry by different operators. Our goal was to assess interoperator variability of fetal biometry measurements in the second trimester (between 19 and 25 weeks of gestation). A total of 490 scans of singleton pregnancies between 19 and 25 weeks of gestation performed between January 2017 and December 2018 by 5 different sonographers were analyzed. The measures taken in account were biparietal diameter, head circumference, abdominal circumference and femur length. We elaborated and compared measurement curves from the different sonographers to understand if they were significantly different and if the inter-operator variability should be considered when interpreting fetal growth rates. All parameters are being analyzed to create and compare measurement curves of each operator.

**P168 INHERITED THROMBOPHILIA IN PREGNANT PATIENTS: RELATIONSHIP BETWEEN THROMBOPHILIA AND EARLY PREGNANCY LOSS**

Diana Vraic1, Octavian Munteanul2, Luciana Arsene1, Monica Cirstoiu2

1 Department of Obstetrics and Gynecology, University Emergency Hospital Bucharest (Romania)
2 Carol Davila University of Medicine and Pharmacy, Bucharest (Romania)

**Problem statement:** Early pregnancy loss, also referred to as miscarriage or spontaneous abortion, is generally defined as a nonviable intrauterine pregnancy which occurs in the first trimester. Is the most common pregnancy complication and occur up to 12+6 weeks from the last menstrual period. Inherited maternal thrombophilia as a cause of early pregnancy loss is the cause of hypercoagulable state which leads to arterial and/or venous thrombosis at the site of implantation or in the placental blood vessels. **Methods:** A retrospective study was conducted in Bucharest Emergency University Hospital. Pregnant women were included in RO19.10 project "Improved healthcare for high-risk pregnancy, premature birth, and haematological diseases". Laboratory samples included protein C, protein S, antithrombin III and homocysteine. Genetic analysis collected during the study included mutations of factor V (G1691A, H1295R), gene MTHFR (C677T mutations; A1298C) and mutation of factor XIII (G103T, RS 5985). The study group included 100 randomly selected pregnant patients (4 weeks -12 weeks of pregnancy) for a period of 1 year between 2015 – 2016, with two or more consecutive miscarriages with the same partner in the first trimester of pregnancy. **Results:** Among all inherited thrombophilias, protein S deficiency is most common among women with early pregnancy loss. Also inherited thrombophilia is more common in women with two or more losses and also late pregnancy loss. In our study group there was an increased risk of late pregnancy loss in FV Leiden mutation heterozygotes(3.5%), prothrombin mutation heterozygotes (2%) and protein S deficiency (15%). **Conclusion:** This study highlighted that inherited thrombophilia in the case of early pregnancy loss plays an important role, in which cases FV Leiden mutation heterozygotes, prothrombin mutation heterozygotes and protein S deficiency most often involved. Preconceptual and prenatal counseling regarding modifiable etiologies and risk factors are the most important interventions for prevention of spontaneous abortion in women. The association between maternal inherited thrombophilia, recurrent spontaneous abortion and fetal loss is controversial. Latest evidences suggests that treatment with an anticoagulant can improve these outcomes. **Disclosure:** None of the authors have a conflict of interest. All authors have participated equally in developing this study. Keywords: Thrombophilia, Spontaneous Abortions, Heparin, Low-Molecular-Weight, Aspirin
CO₂ Laser System for Women’s Health

CO₂RE® Intima

Treats all 3 intimate areas: vagina, vulva and introitus.

Women report high satisfaction at 1-year follow-up¹:

• 100% showed significant improvement in vaginal health.
• 91% reported an improvement in dryness.
• 83% reported an improvement in sexual functioning.

Quick, non-surgical, in-office procedure.
Ask about CO₂RE Intima today!

www.candelamedical.com

Visit us at COGI 2019, Booth #15 | Level 0

¹ In a clinical study conducted at North Florida OB/GYN, Jacksonville, FL, USA & The Springs Medical Center, Louisville, KY, USA, 2017
VAGINAL ERBIUM LASER FOR WOMEN’S HEALTH

15:00-18:00  HALL B

Short Course Description: Course participants will learn the basic principles of using lasers in a variety of nonsurgical and surgical procedures within the fields of minimally invasive gynecology. The entire course is constituted of six topics covering the use of FotonaSmooth Erbium laser systems in indications of: Vaginal Relaxation Syndrome (or Vaginal laxity) (VRS), Genitourinary Syndrome of Menopause (GSM), Stress Urinary Incontinence (SUI), Pelvic Organ Prolapses (POP), Lichen Sclerosus, Condyloma and Labioplasty. Upon completing the End-of-Course Test the participants will receive the Course Certificate.

15:00–15:05  Introduction by program coordinator
  Zdenko Vizintin, Slovenia

15:05–15:25  Physical concepts of the application of the lasers in gynecology
  Zdenko Vizintin, Slovenia

15:25–16:05  Laser use in Stress Urinary Incontinence and Pelvic Organ Prolapses
  Urska Bizjak-Ogrinc, Slovenia

16:05–16:25  Laser use for treatment of Vaginal Laxity
  Ivan Fistonic, Croatia

16:25–16:45  Laser use in Genitourinary Syndrome of Menopause and vaginal laxity
  Marco Gambacciani, Italy

16:45–17:25  Laser treatment of Lichen Sclerosis et Atrophicus, Condyloma and Labioplasty
  Sabina Sencar, Slovenia

17:25–17:45  Safety and clinical evidence of non-ablative ErYAG
  Zdenko Vizintin, Slovenia

17:45–18:00  End-of-Course Test
INDUSTRY SUPPORTED SESSION
THURSDAY, NOVEMBER 21, 2019

SHINING LIGHT ON LUTEAL PHASE SUPPORT

<table>
<thead>
<tr>
<th>16:15-16:45</th>
<th>HALL A</th>
</tr>
</thead>
<tbody>
<tr>
<td>Capsule</td>
<td>Luteal phase support in ART is necessary and in search for the optimal protocol, recent evidence has emerged with possible implications for patient convenience</td>
</tr>
</tbody>
</table>
| Chairpersons| *Zion Ben Rafael, Israel*  
*Bart Fauser, Netherlands* |
| 16:15-16:45 | Luteal phase support: Time for a clinical paradigm shift  
*Herman Tournaye, Belgium* |

FRIDAY, NOVEMBER 22, 2019

CANDELA SYMPOSIUM

<table>
<thead>
<tr>
<th>10:20-11:50</th>
<th>HALL C</th>
</tr>
</thead>
<tbody>
<tr>
<td>Capsule</td>
<td>Leading physicians share experiences with the CO2RE® Intima system in gynecology, state of the art and future challenges</td>
</tr>
<tr>
<td>Chairperson</td>
<td><em>Santiago Palacios, Spain</em></td>
</tr>
</tbody>
</table>
| 10:20-10:40 | Use of laser in vulvo vaginal pathology  
*Santiago Palacios, Spain* |
| 10:40-11:00 | Vaginal wall relaxation  
*Abdulhassib Raslan, France* |
| 11:00-11:20 | Cosmetic gynecology vs regenerative gynecology  
*Santiago Palacios, Spain* |
| 11:20-11:40 | Stress urinary incontinence: Personal research  
*Abdulhassib Raslan, France* |
| 11:40-11:50 | Discussion |
### INDUSTRY SUPPORTED SESSION
FRIDAY, NOVEMBER 22, 2019

**FROM CONCEPTION TO BIRTH: HEALTHY BABIES AND HEALTHY MOTHERS FOLLOWING ART**

<table>
<thead>
<tr>
<th>Time</th>
<th>Capsule</th>
<th>Chairperson</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:20-11:50</td>
<td>Focusing on the specific aspects of ART pregnancies that impact on obstetrical care</td>
<td><strong>Chairperson</strong> Gian Carlo di Renzo, Italy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Reproductive medicine</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Scott Nelson, UK</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Michel De Vos, Belgium</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Maternal-fetal medicine</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Liona Poon, Hong Kong</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Yariv Yohev, Israel</td>
</tr>
</tbody>
</table>

### FRIDAY, NOVEMBER 22, 2019

**FIBROIDS: MEDICAL, SURGICAL, OR “NO TOUCH TECHNIQUE” TO TREAT SMALL FIBROIDS BEFORE IVF**

<table>
<thead>
<tr>
<th>Time</th>
<th>Capsule</th>
<th>Chairpersons</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:10-12:30</td>
<td>The association of fibroids and infertility is well established. However, the issue of if, when and how to treat needs clarification. Does medical option change the current paradigm?</td>
<td><strong>Chairpersons</strong> Jacques Donnez, Belgium</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Olivier Donnez, Belgium</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Eric Sedbon, France</td>
</tr>
<tr>
<td>12:30-12:55</td>
<td>Surgical or medical treatment before IVF?</td>
<td><strong>Jasper Verguts, Belgium</strong></td>
</tr>
<tr>
<td>12:55-13:15</td>
<td>No treatment before IVF is needed for intramural smaller than 3-cm fibroids</td>
<td><strong>Roberto Marci, Switzerland</strong></td>
</tr>
<tr>
<td>13:15-13:40</td>
<td>Fibroids and UPA: How to explain the good and bad responders</td>
<td><strong>Marie Madeleine Dolmans, Belgium</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Leiomyoma or leiomyosarcoma? How can we tell?</strong></td>
</tr>
</tbody>
</table>
INDUSTRY SUPPORTED SESSION
SATURDAY, NOVEMBER 23, 2019

LATEST INNOVATIONS IN PREIMPLANTATION GENETICS IN COLLABORATION WITH REPROCARE GENETICS SCANDINAVIA

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:20-11:50</td>
<td>Capsule&lt;br&gt;Gene editing of germline cells was recently used in clinical settings to manipulate human embryos, resulting in the birth of twins which will carry the new genes to future generations. Editing of somatic cells is not less controversial due to technical imperfection, unproven safety, cost that limits access to wealthy people only, and the possibility to treat a trait not important to general health.</td>
</tr>
<tr>
<td>Chairpersons</td>
<td>Attila Vereczkey, Hungary&lt;br&gt;Eero Varila, Finland&lt;br&gt;Simon Fishel, UK</td>
</tr>
<tr>
<td>10:20-10:45</td>
<td>The brave new world of ART: Genome editing, third-parent conceptions and transgenerational implications&lt;br&gt;Gerald Schatten, USA</td>
</tr>
<tr>
<td>10:45-11:10</td>
<td>Preimplantation gene editing&lt;br&gt;Dieter Egli, Switzerland</td>
</tr>
<tr>
<td>11:10-11:30</td>
<td>gSEQ for PGT-A (Preimplantation genetic testing for aneuploidies)&lt;br&gt;Noora Sirkkanen, Finland</td>
</tr>
<tr>
<td>11:30-11:50</td>
<td>Mosaicism is a gimmick&lt;br&gt;Nathan Treff, USA</td>
</tr>
</tbody>
</table>
The COGI Congress would like to thank the supporters and exhibitors. It is with the support of the industry that COGI can continue in its mission to promote research and education and to disseminate new knowledge.
At Abbott, we're committed to helping people live their best possible life through the power of health. For more than 125 years, we've brought new products and technologies to the world — in nutrition, diagnostics, medical devices and branded generic pharmaceuticals — that create more possibilities for more people at all stages of life. Today, 99,000 of us are working to help people live not just longer, but better, in the more than 150 countries we serve. Connect with us at www.abbott.com, on Facebook at www.facebook.com/abbott and on Twitter @FreeStyleDiabet, @AbbottNews and @AbbottGlobal

Besins Healthcare

Besins Healthcare is a privately held, global pharmaceutical company headquartered in Monaco. We are a world leader in novel therapies for gynecology and andrology. We have discovered groundbreaking technologies to improve patient well-being throughout our history. We developed several hormone therapies over the years including bioavailable natural progesterone by different routes of administration for pregnant women from conception until delivery and a natural testosterone transdermal gel for testosterone deficiency syndrome. We continue to be a leader in Estradiol Replacement Therapy with the first transdermal gel marketed in Europe. Our products are trusted and prescribed by healthcare professionals in more than 100 countries throughout the world.

BioGaia

BioGaia is a Swedish healthcare company and a world leader in probiotics with 30 years’ experience of developing, marketing and selling probiotic products. Our products are recommended by pediatricians and other healthcare professionals in more than 100 countries.

All BioGaia’s products contain Lactobacillus reuteri, one of few bacteria that has co-evolved with humans. To date L. reuteri has been tested in more than 200 clinical trials and proven effective and safe in children and adults. The effects have been proven in FGIDs, such as colic and constipation in children as well as in oral health for pregnant women. Moreover, L. reuteri has shown to modulate the early microbiota development in babies born by C-section.

Candela

Established in 1970, Candela is a leading US-based global medical aesthetic device company with headquarters in Wayland, Massachusetts. The company’s technologies enable physicians to provide advanced energy-based solutions for a broad range of medical-aesthetic applications including benign vascular and pigmented lesions, scars, hair removal, facial resurfacing, wrinkle reduction, women’s health treatments, tattoo removal, acne, leg veins, cellulite, and body shaping.
www.ccd-lab.com/en/

For more than fifty years, CCD, Laboratoire de la Femme®, has been producing innovations for women’s health, in France and abroad: Contraception, Assisted Reproductive Technology, Maternity, Menopause.

CCD – Laboratoire de la Femme® is reaffirming its ongoing commitment to offer you better products and services. Most of our products are manufactured in France, at our plant in Neuilly-en-Thelle (Oise, FRANCE). Our R&D team develops frenchmade products with the required expertise in all aspects of manufacturing and good practices.

Our daily mission: to provide care to women and accompany them through each phase of their lives.

www.coastscience.com

Coast Science®, a leader in physician approved, natural vitamin & antioxidant supplements since 2001. Our scientifically optimized Fertile One® formulas are the first choice of Fertility Specialists & Gynecologists around the world to increase fertility & pregnancy success. We make high quality products, including Fertile One® PC 600 with over 20 key ingredients to optimize egg quality & Fertile One® PCOS 600 reducing PCOS symptoms while improving egg quality. Our Preconception formulas for women have 600mg of Coenzyme Q10 and 999mcg of Quatrefolic®. New she-ology™ hormonal support supplements also include herbs to naturally ease symptoms of PMS, Peri-Menopause or Menopause.

www.medical.escoglobal.com

Esco Medical is the IVF business unit of Esco Group, a global life science tools provider. Esco Medical delivers innovative solutions for fertility clinics and laboratories. Esco Medical is the leading manufacturer and innovator of high-quality equipment such as long-term embryo incubators, ART workstations, anti-vibration table, time-lapse incubator and is continuously developing advanced technologies to meet the increasing demand of the IVF industry. Most of our products are designed in Denmark and manufactured in the EU. The primary focus of this division is to increase pregnancy success rates and patient satisfaction.

www.euroimmun.com

EUROIMMUN is an international provider of medical laboratory products with a growing portfolio for molecular genetic diagnostics. The company’s EUROArray platform includes microarrays for multiplex detection of human papillomaviruses, sexually transmitted infections and dermatophytes. The EUROArray HPV in particular allows sensitive detection of all thirty relevant high- and low-risk HPV in one reaction. Real-time PCR tests for Zika virus and HSV-1/2 are also available. Microarrays for genetic risk determination in different diseases complete the portfolio. All tests include fully automated data evaluation and documentation. EUROIMMUN’s molecular genetic diagnostics range complements its products for autoimmune, infection and allergy diagnostics.
www.ferring.com

**Ferring Pharmaceuticals** is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and women's health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years and has a portfolio covering treatments from conception to birth. Founded in 1950, privately-owned Ferring now employs approximately 6,500 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.

www.fotona.com

With more than 50 years of experience, **Fotona** is a world-leading medical laser manufacturer recognized for its innovative, award-winning laser systems for applications in gynecology, surgery, aesthetics & dermatology and dentistry. Fotona's combined Er:YAG and Nd:YAG laser systems are proven to be less invasive and highly effective for clinical and aesthetic gynecology treatments. We are proud to be the first manufacturer to introduce SMOOTH® mode technology for a range of non-invasive laser vaginal treatments. Our global distribution network spans across more than 60 countries, ensuring comprehensive support and service for Fotona laser users, including clinical training, workshops and hands-on demonstrations.

www.richter.hu

**Gedeon Richter Plc.**, headquartered in Budapest/Hungary, is a major pharmaceutical company in Central Eastern Europe, with an expanding direct presence in Western Europe, in China and in Latin America. Having reached a market capitalisation of EUR 4.1 billion (USD 4.9 billion) by the end of 2017, Richter’s consolidated sales were approximately EUR 1.4 billion (USD 1.6 billion) during the same year. The product portfolio of Richter covers many important therapeutic areas, including Women’s Healthcare, Central Nervous System, and Cardiovascular areas. Having the largest R&D unit in Central Eastern Europe, Richter’s original research activity focuses on CNS disorders. With its widely acknowledged steroid chemistry expertise, Richter is a significant player in the Women’s healthcare field worldwide. Richter is also active in biosimilar product development.

www.fertilovit.com

Austrian-based **Gonadosan Distribution GmbH** is dedicated to the development and ongoing research of state-of-the-art nutraceuticals meeting the specific nutritional needs of men and women planning for pregnancy. The Fertilovit® range of supplements is based on the latest scientific data, tested in cooperation with big European ART centers and has been proven to support fertility treatment effectively. A variety of patent-protected preparations offer highly specific solutions for different male and female fertility patients, ranging from mature patients to patients with thyroid autoimmunity, endometriosis, PCOS, and idiopathic OAT.
Guerbet

www.guerbet.com

Guerbet is a pioneer with more than 90 years’ experience in the field of contrast agents and a world leader in medical imaging. It offers a comprehensive range of pharmaceutical products, medical devices and services for diagnostic and interventional imaging, to improve the diagnosis and treatment of patients. Guerbet allocates 8% of its revenue to R&D and relies on over 200 employees in various work sites in France, Israel and the United States, making of the company a significant investor in research and innovation. Guerbet (GBT) is listed on Euronext Paris (segment B – mid caps) and generated €790 million in sales in 2018.

IBSA

Caring Innovation

www.ibsagroup.com

IBSA is an international pharmaceutical company with headquarters in Lugano, Switzerland. IBSA has developed an entirely new purification process in order to obtain a full range of highly purified, human gonadotrophins (hFSH, hMG and hCG). This patented process ensures both a high level of purity and the full respect of the natural glycosylation of these molecules. Recently IBSA has marketed a novel ingenious system to deliver progesterone subcutaneously in an aqueous solution. IBSA has managed to guarantee the highest quality of its products over the years due to the advantages of having a complete in-house manufacturing process in company-owned plants and thanks to a global quality system. The company’s other franchises include osteoarthritis, pain-management, dermatology and thyroid diseases.

KARL STORZ

www.karlstorz.com

KARL STORZ is a renowned manufacturer that is well established in all fields of endoscopy and can be considered as market leader in rigid endoscopy. The still family held company was founded in 1945 in Tuttlingen, Germany, and has grown to one with a worldwide presence and 7500 employees. KARL STORZ offers a range of both rigid and flexible endoscopes for a broad variety of applications. Today’s product range also includes fully integrated concepts for the OR and servicing.

LG Chem

www.lgchem.com

As one of strongly sponsored entrepreneurs from LG group, LG Chem is becoming the leader of pharmaceutical industry, especially specialized in development of highly qualified infertility treatment products (Follitrope™, IVF-M™, IVF-M HP™, IVF-C™) over 20 overseas countries by contributing to the better life quality of many infertile couples in globe.
Pantarhei Bioscience (PRB) and Pantarhei Oncology (PRO) focus on innovative drug development in Woman’s Health (WH) and Endocrine Cancers. PRB has developed a product pipeline based on its ability to identify, confirm and patent protect novel targets and medical uses of existing drugs, hormones, other endogenous human biologicals and combinations thereof. Pantarhei adheres to the highest scientific standards for preclinical and clinical drug development. The current pipeline of Pantarhei includes (i) Androgen Restored Contraception (ARC), adding dehydroepiandrosterone (DHEA) to oral contraceptives, (ii) the fetal estrogen Estetrol (E4) for the (co)-treatment of breast and prostate cancer and (iii) the use of the Zona Pellucida 3 (ZP3) antigen and biomarker for immunotherapy of ZP3 expressing tumors such as ovarian and prostate cancer.

Permanent International and European School in Perinatal, Neonatal and Reproductive Medicine. Founded in Florence (Italy) in 2012, the School, inspired by the values of scientific culture, ethics and bioethics of life sciences, pursues the aim of promoting and enhancing the fundamental ideals of maternal infant medicine in its entire course: reproductive, periconceptional, maternal and child health periods. The School run courses of reproductive, perinatal and neonatal medicine and related disciplines, training programs, national and international conferences, congresses, debates, and any other event or action consistent with its objectives.

Preimplantation Genetic Testing for Aneuploidy (PGT-A) has demonstrated clinical benefit in multiple randomized controlled trials. Contemporary methods of PGT-A involve next generation sequencing (NGS) with whole genome amplification (WGA). We have developed a new method of PGT-A that overcomes limitations of WGA based strategies. gSEQ not only evaluates chromosome copy number, including mosaicism, and segmental aneuploidy, but also provides genotype information through proprietary machine learning algorithms. The additional feature of genotyping data analyses improves PGT-A accuracy through allele-ratio assessment and allows for detection of contamination, triploidy, and relatedness, as well as independent confirmation of aneuploidy predictions. gSEQ provides increased sample processing throughput without compromising accuracy and at a cost significantly lower than WGA-based commercial PGT-A kits. ReproCare Genetics Scandinavia is now an exclusive provider of gSEQ based PGT-A clinical services in Europe.

Wisepress.com, Europe’s leading conference bookseller, has a complete range of books and journals relevant to the themes of the meeting. Books can be purchased at the stand or, if you would rather not carry them, posted to you – Wisepress will deliver worldwide. In addition to attending 200 conferences per year, Wisepress has a comprehensive medical and scientific bookshop online with great offers.
Were you in Vienna in 2017 or London in 2018?

The COGI Congress is proud to introduce the

LOYALTY MEMBER

program for returning participants

Loyalty members will enjoy varying special benefits from congress to congress

See you in Berlin in 2020!!

November 19-21, 2020

BERLIN, GERMANY

For more than fifty years, CCD, Laboratoire de la Femme**, has been producing innovations for women’s health, in France and abroad: Contraception, Assisted Reproductive Technology, Maternity, Menopause.

Our daily mission: to provide care to women and accompany them through each phase of their lives.

*Women’s Pharma Company
SAVE THE DATE

November 19-21, 2020
BERLIN, GERMANY

www.cogi-congress.org • cogi@congressmed.com